[
  {
    "nctId": "NCT03191786",
    "statement": "* Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC as per the American Joint Committee on Cancer (AJCC) 7th edition",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* No sensitizing epidermal growth factor receptor (EGFR) mutation (L858R or exon 19 deletions) or anaplastic lymphoma kinase (ALK) fusion oncogene detected",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* No prior systemic treatment for advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC as per the AJCC 7th edition",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Life expectancy greater than or equal to (\\>/=) 8 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Deemed unsuitable by the investigator for any platinum-doublet chemotherapy due to poor performance status (ECOG performance status of 2-3). However, participants \\>= 70 years of age who have an ECOG PS of 0 or 1 may be included due to: a) substantial comorbidities; b) contraindication(s) for any platinum-doublet chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Representative formalin-fixed paraffin-embedded (FPPE) tumor tissue block obtained during course of disease (archival tissue) or at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Participants with treated, asymptomatic central nervous system (CNS) metastases are eligible, provided they meet all of the following criteria: Measurable disease outside CNS; Only supratentorial and cerebellar metastases allowed; No ongoing requirement for corticosteroids as therapy for CNS disease; No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to randomization; No evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Adequate hematologic and end organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Female participants of childbearing potential randomized to the atezolizumab treatment arm agree to use protocol defined methods of contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "-Specific Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Participants younger than 70 years who have an ECOG performance status of 0 or 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation of the brain during screening and prior radiographic assessments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Uncontrolled tumor-related pain",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Uncontrolled or symptomatic hyerpcalcemia (ionized calcium \\> 1.5 mmol/L or calcium \\>12 mg/dL or corrected serum calcium \\>ULN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (v4.0) Grade 3 or higher toxicities due to any prior therapy (example \\[e.g.\\], radiotherapy) (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Participants who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from randomization since the last chemotherapy, radiotherapy, or chemoradiotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "General Medical Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* History of autoimmune disease except autoimmune-related hypothyroidism and controlled Type I diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* History of idiopathic pulmonary fibrosis (IPF), organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Known positivity for human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Known active hepatitis B or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Active tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Severe infections within 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomization, unstable arrhythmias, or unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Major surgical procedure other than for diagnosis within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Prior allogeneic bone marrow transplantation or solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Participants with an illness or condition that may interfere with capacity or compliance with the study protocol, as per investigator's judgment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "Exclusion Criteria Related to Atezolizumab:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Oral or IV antibiotic treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live attenuated vaccine will be required during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Treatment with systemic corticosteroids or other immunosuppressive medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Participants not willing to stop treatment with traditional herbal medicines",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "Exclusion Criteria Related to Chemotherapy:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03191786",
    "statement": "* Known sensitivity and contraindications to the 2 comparative chemotherapy agents (that is \\[i.e.\\] vinorelbine, oral or intravenous, and gemcitabine, intravenous)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Histologically or cytologically documented Stage IIIb or Stage IV NSCLC that has progressed following standard systemic chemotherapy (including if given in combination with anti-PD-1 therapy, after anti-PD-1 as monotherapy, or after TKI therapy). Participants with a previously detected sensitizing epidermal growth factor receptor (EGFR) mutation or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (ALK) fusion oncogene must have received targeted therapy (TKI) followed by at least one line of standard systemic chemotherapy prior to receiving atezolizumab. Overall, participants should not have received more than two lines of standard systemic chemotherapy. Participants who have discontinued first-line or second-line therapy due to intolerance are also eligible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* The last dose of prior systemic anticancer therapy or targeted therapy must have been administered more than or equal to (≥) 21 days prior to randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* The last dose of prior anti-PD-1 therapy must have been administered. Nivolumab must have been discontinued \\>= 14 days and pembrolizumab \\>= 21 days prior to study treatment initiation, providing that these treatments were not administered in a clinical trial setting.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Measurable disease, as defined by Response Evaluation Criteria for Solid Tumors, Version 1.1 (RECIST v1.1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Participants with asymptomatic central nervous system (CNS) metastases (treated or untreated), as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening and prior radiographic evaluation, are eligible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Life expectancy ≥ 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Adequate hematologic and end-organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (\\<) 1 percent (%) per year during the treatment period and for at least 5 months after the last dose of atezolizumab",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Participants must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and toxicities related to prior anti-PD-1-therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Symptomatic CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 2 weeks prior to study treatment initiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Uncontrolled pericardial effusion or ascites requiring recurrent drainage procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Pregnant or lactating, or intending to become pregnant during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Significant cardiovascular disease, such as New York Heart Association cardiac disease ≥ Class III, myocardial infarction within 3 months, unstable arrhythmias, or unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Significant renal disorder requiring dialysis or indication for renal transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to study treatment initiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Major surgical procedure within 4 weeks prior to study treatment initiation or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Inability to understand the local language(s) for which the EORTC QLQ-LC13 and EQ-5D-5L questionnaires are available",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* History of autoimmune disease are allowed if controlled and on stable treatment (i.e., same treatment, same dose) for the last 12 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Prior allogeneic stem cell or solid organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* History of idiopathic pulmonary fibrosis, including pneumonitis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Active tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Administration of a live, attenuated vaccine within 4 weeks prior to study treatment initiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies other than anti-PD-1 therapy, including anti-programmed death-ligand 1 therapeutic antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Treatment with systemic immunostimulatory agents (including, but not limited to, interferons or interleukin-2) within 4 weeks or five half-lives of the drug, whichever is longer, prior to initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03285763",
    "statement": "* Specifically for participants without autoimmune disease: treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to study treatment initiation, or anticipated requirement for systemic immunosuppressive medications during the trial. For participants with CNS metastases, use of prednisone at a stable dose (or dose equivalent) of \\<= 20 mg/day is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Provision of informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Female or male aged 18 years or above",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Histologic or cytologic confirmation of locally advanced or metastatic NSCLC (stage IIIB or IV) on entry into study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Failure of 1st line anti-cancer therapy (either radiological documentation of disease progression or due to toxicity) or subsequent relapse of disease following 1st line therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* WHO Performance status 0 - 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* One or more measurable lesions at least 10 mm in the longest diameter (LD) by spiral CT scan or 20 mm with conventional techniques according to RECIST criteria. Previously irradiated lesions will not be considered measurable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Life expectancy of 12 weeks or longer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Negative pregnancy test for women of childbearing potential only",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Mixed small cell and non-small cell lung cancer histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Patients have received 2nd-line or subsequent anti-cancer therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Prior treatment with pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Prior treatment with VEGFR TKIs (previous treatment with bevacizumab \\[Avastin\\] is permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Known or suspected brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable without steroid treatment for 10 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* The last radiation therapy within 4 weeks before the start of study therapy, not including local palliative radiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* The last dose of prior chemotherapy or other anti-cancer therapy is discontinued less than 3 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin, and suramin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Major surgery within 4 weeks before entry, or incompletely healed surgical incision",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Neutrophils \\<1.5 x 109/L or platelets \\<100 x 109/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Serum bilirubin \\>1.5 x the upper limit of reference range (ULRR)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Creatinine clearance \\<50 ml/min calculated by either Cockcroft -Gault, 24 hours urine collection, EDTA scan or other validated methods",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.5 x ULRR in the absence of liver metastases, or \\> 5 x ULRR in the presence of liver metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Alkaline phosphatase (ALP) \\>2.5 x ULRR in the absence of liver metastases, or \\>5 x ULRR in the presence of liver metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Current active gastrointestinal disease that may affect the ability of the patient to absorb ZD6474 or tolerate diarrhoea",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Any unresolved toxicity greater than CTCAE Grade 2 from previous anti-cancer therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Significant cardiovascular event (e.g., myocardial infarction, superior vena cava \\[SVC\\] syndrome), New York Heart Association \\[NYHA\\] classification of heart disease ≥2 within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* History of arrhythmia (multifocal premature ventricular contractions \\[PVCs\\], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* QT prolongation with other medications that required discontinuation of that medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Presence of left bundle branch block (LBBB)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG (Note: If a patient has QTc interval ≥480 msec on screening ECG, the screen ECG may be repeated twice \\[at least 24 hours apart\\]. The average QTc from the three screening ECGs must be \\<480 msec in order for the patient to be eligible for the study) Patients who are receiving a drug that has a risk of QTc prolongation are eligible if QTc is \\<460 msec.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Potassium \\<4.0 mmol/L despite supplementation; serum calcium (or ionized or adjusted for albumin), or magnesium out of normal range despite supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Women who are pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Any concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function. Drugs that have a risk of QTc prolongation, that in the investigator's opinion cannot be discontinued, are allowed, but only of the QTc is \\<460 msec",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 millimetre of mercury \\[mmHg\\] or diastolic blood pressure greater than 100 mmHg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix and adequately treated basal cell or squamous cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00418886",
    "statement": "* Concomitant use of yellow fever vaccine or any live attenuated vaccines",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Non-squamous cell Non Small Cell Lung Cancer (NSCLC) disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Clinical stage IIIB/IV or recurrent disease after surgery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* No prior systemic chemotherapy, immunotherapy, targeted therapy or biological therapy, including adjuvant therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Prior radiation therapy is allowed to less than 25% of the bone marrow",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Measurable disease as defined by response evaluation criteria in solid tumors (RECIST)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* The Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Estimated life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Clinically significant third-space fluid collections",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Central nervous system disease other than stable and treated brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* More than 3 weeks interval between the surgery and enrollment request date",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), for a 5 days period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Unable or unwilling to take folic acid or vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Unable to take corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Serious concomitant disorder that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01020786",
    "statement": "* Currently have and historically had interstitial pneumonitis (interstitial pneumonia) or pulmonary fibrosis manifested as opacity on Chest x-ray or Computed tomography (CT)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have a histological or cytological diagnosis of NSCLC defined as nonsquamous cell histology. Squamous cell and/or small cell histology is not permitted. Mixed NSCLC tumors will be categorized by the predominant cell type. NSCLC tumors that are not otherwise specified with regard to histology or cannot be subclassified as squamous, adenocarcinoma, or large cell histology will be categorized as nonsquamous",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have Stage IIIB (not amenable to curative treatment) or Stage IV NSCLC prior to induction therapy as defined by the American Joint Committee on Cancer (AJCC) Staging Criteria for Lung Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have completed 4 induction cycles of platinum-based doublet therapy (type at the discretion of the physician) for treatment of their advanced disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have not progressed after 4 cycles of induction therapy. Documented radiographic evidence of a tumor response must occur at the end of Cycle 4 of induction therapy within 3 weeks before receiving the first cycle of study drug \\[see Response Evaluation Criteria in Solid Tumors (RECIST), version (v) 1.1\\]",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Receive on-study treatment no earlier than 21 days and no later than 42 days from Cycle 4 Day 1 of induction therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have a Performance Status (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Meet the following guidelines if the participant has received prior radiation therapy:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Previous radiation therapy is allowed to \\<25% of the bone marrow, but should have been limited and must not have included whole pelvis radiation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Participants must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Participants who received palliative chest (in other words, thoracic skeleton including dorsal spine) or palliative extrathoracic radiotherapy to preexisting lesions are allowed to be enrolled in this trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have adequate organ function, including:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Adequate bone marrow reserve: absolute neutrophil count (ANC) (segmented and bands) \\>=1.5x109/Liter (L), platelets \\>=100x109/L, and hemoglobin \\>=9 grams per deciliter (g/dL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Hepatic: bilirubin \\<=1.5 x upper limit of normal (ULN) and alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) \\<=3.0 x ULN (ALP, AST, and ALT \\<=5.0 x ULN are acceptable if the liver has tumor involvement",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Renal: calculated creatinine clearance (CrCl) \\>=45 milliliters per minute (mL/min) based on the original weight-based Cockcroft and Gault formula",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Are willing to comply with the following contraceptive criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Females must be surgically sterile, postmenopausal or must have a negative serum or urine pregnancy test within 7 days prior to the first dose of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Males and females with reproductive potential: Must agree to use a reliable method of birth control during the study and for 6 months following the last dose of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have an estimated life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have given written informed consent/assent prior to any study-specific procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Are willing to comply with home delivery administration and have family or close environment support willing to comply with home delivery administration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or no approved use of a drug or device (other than pemetrexed used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have previously completed or withdrawn from this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have a serious concomitant systemic disorder (for example, active infection including human immunodeficiency virus)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required). Participants with treated CNS metastases are eligible for this study if they are not currently receiving corticosteroids and/or anticonvulsants for at least 1 week before starting study treatment and their disease is asymptomatic and radiographically stable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Are receiving concurrent administration of any other antitumor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than aspirin dose ≤1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Are unable or unwilling to take folic acid or vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Are unable or unwilling to take corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Are pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01473563",
    "statement": "* Have received a recent (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788163",
    "statement": "* Histological or cytological confirmed locally advanced NSCLC (stage IIIA/B) not suitable for curative treatment or metastatic (stage IV) NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788163",
    "statement": "* Newly diagnosed patients with locally advanced and/or metastatic NSCLC who are systemic treatment Naive (i.e. no chemotherapy or EGFR-TKI) or patients with recurrent disease who have previously received adjuvant chemotherapy (not including EGFR-TKI)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788163",
    "statement": "* Provision of diagnostic cancer tissue or cytology sample upon inclusion (surgical specimen, biopsy sample, or cytology sample is acceptable) and Provision of a routine blood (plasma) sample in China, Russia, Taiwan and Korea",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788163",
    "statement": "* Patients aged 18 years and older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788163",
    "statement": "* As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788163",
    "statement": "* Evidence of any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788163",
    "statement": "* Pregnancy or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Adequate contraception methods include: systemic contraceptives or IUD for 3 months prior to start of the study medication or diaphragm plus spermicide; for males, condom plus spermicide; or total abstinence from sexual intercourse during the course of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Women of childbearing potential and sexually active males must practice or use an accepted and effective form of contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Subjects who present with CNS metastases are eligible, provided the attending physician ascertains that the metastases are controlled before the start of chemotherapy, and the subject is asymptomatic on neurologic exam and is not receiving corticosteroid therapy to control symptoms. Continued use of other anti-seizure medication is permitted",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Free of active infection",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* At screening, a probable life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* No prior chemotherapy for SCLC or any chemotherapy within 5 years of the diagnosis of SCLC. Prior radiation to any symptomatic site is permitted provided that the indicator lesion site(s) are not irradiated, and radiation is completed before chemotherapy is started",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Performance status ECOG 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Adequate hematologic, renal and hepatic function •Hematologic: ANC 1500/mm3 \\[1.5 x 109/L\\], platelet count 100,000/L (100 x 109/L), hemoglobin 9.0 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Renal: Serum Creatinine ≤1.5mg/dL (133mol/L) and CrCl 60 ml/min (Cockroft-Gault) \\[Cockroft, 1976\\]",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "CrCl may be calculated using the Cockcroft-Gault formula:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "CrCl (ml/min) = Q x (140-age \\[yr\\]) x body wt \\[kg\\] 72 x serum creatinine \\[mg/dl\\] Q = 0.85 for females Q = 1.0 for males CrCl (ml/min) = K x (140-age \\[yr\\]) x body wt \\[kg\\] Serum creatinine \\[mol/L\\] K = 1.0 for females K = 1.23 for males",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Hepatic: Serum bilirubin (1.5 mg/dL), SGOT (AST), SGPT (ALT) and Alkaline Phosphatase 2 times the upper limit of normal (ULN) if liver metastases are absent by abdominal CT or MRI, or 5 times ULN if liver metastases are present",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* At least 18 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Written informed consent (subject's written understanding of and agreement to participate in this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Subject with histologically-confirmed extensive small cell lung cancer or unequivocally positive positive cytological evidence (sputum, at least two, or aspirate biopsy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Presence of measurable disease according to World Health Organization (WHO)\\* criteria, as determined by diagnostic tests, including CT scan of the chest and abdomen, or MRI scan of the brain, or CXR, or PET CT, MRI, and/or CXR are the preferred diagnostic methods to evaluate disease during the course of this study. Use of positron-emission tomography (PET) is not required, but is permitted if it is the standard diagnostic tool employed by the institution. Measurable disease - Presence of at least one bidimensionally measurable, non-CNS lesion (indicator lesion). If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology • Measurable disease, either on CT or MRI scan, requires one diameter 1 cm and one diameter 2 cm. • Measurable disease on CXR requires both diameters 2 cm. • Palpable tumor masses that could not be evaluated radiologically require two diameters 2 cm",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* At least 3 weeks since last major surgery (a lesser period is acceptable if decided to be in the best interest of the subject).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Subjects with central nervous system metastases are eligible as long as the attending doctor determines that the metastases are under control before the start of chemotherapy, and the subject has no symptoms of spreading of disease to the brain, and is not receiving drugs called steroids to control the symptoms.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Laboratory criteria: Subjects must have adequate bone marrow reserve and adequate kidney and liver function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Concurrent or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of SCLC. (Concurrent radiation for palliation of bone metastases and CNS lesions must be discussed with and approved by the GlaxoSmithKline Medical Monitor)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Concurrent severe medical problems other than the diagnosis of SCLC, which would significantly limit full compliance with the study or expose the patient to extreme risk",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Concomitant malignancies or previous malignancies other than SCLC within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or localized low grade prostate cancer (contact GlaxoSmithKline Medical Monitor to discuss enrolment of subjects with low grade prostate cancer)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Present clinical signs or symptoms of brain and/or leptomeningeal metastases confirmed by CT or MRI brain scan, or corticosteroid treatment to control symptoms of brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Uncontrolled infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Ongoing tumor or previous tumor other than lung cancer within the last 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Symptoms of spreading of the disease to the brain that requires treatment with drugs called steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Severe medical problems other than the diagnosis of SCLC that would limit the ability of the subject to follow study plan or that would expose the subject to extreme risk.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Ongoing or planned chemotherapy, immunotherapy, radiation treatment, or other experimental drug therapy for the treatment of SCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Use of investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Women who are pregnant or lactating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Women who can become pregnant who refuse to practice an adequate form of birth control.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Subjects with history of allergic reaction to chemicals related to HYCAMTIN and PARAPLATIN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316186",
    "statement": "* Subjects with pre-existing heart disease, such as congestive heart failure, irregular heartbeats that require treatment, and heart attack within the last 3-months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Confirmed diagnosis of stage IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Have progressed during or after platinum-based chemotherapy for advanced disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Have not received prior treatment with docetaxel.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Have availability of adequate formalin-fixed paraffin-embedded (FFPE) tumor derived material.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Have adequate organ function including hematology, renal, and liver.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Have good performance score (0-1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Have measurable disease per RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Agree to use a reliable medically approved method of birth control.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6 inhibitor or participated in a clinical trial with a CDK 4 and 6 inhibitor and the treatment administered is not known.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Are currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Have the presence of unstable central nervous system (CNS) metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450539",
    "statement": "* Have had major surgery (excluding biopsy) \\< 28 days of the initial dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must agree to have a tumor biopsy at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must have a diagnosis of advanced or metastatic non-squamous non-small cell lung cancer that has progressed after certain prior treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must be available for the duration of the study and willing to follow the study procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* If participant is a woman that is capable of having children, must have a negative pregnancy test within 7 days of taking first dose of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must have discontinued radiation therapy at least 4 weeks before entering this study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must not have taken an unapproved drug as treatment for any indication within the last 28 days before starting study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must not be pregnant or lactating, are considering becoming pregnant, or are considering fathering a child. Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial until the participant's physician considers it safe to become pregnant or father a child.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must not have known positive test in human immunodeficiency virus (HIV), hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must not have previously participated in a study involving LY2603618",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must not have previously taken pemetrexed for cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must not have a known allergy to LY2603618 or pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must not currently have an infection that may affect participant's ability to tolerate the therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* Must not have a serious medical condition or disorder that would make it unsafe for you to participate in the study such as uncontrolled diabetes or chest pain due to heart disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00988858",
    "statement": "* If taking certain medications called non-steroidal anti-inflammatory drugs (NSAIDS), such as ibuprofen, must be able to stop taking these medications according to certain guidelines",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": ". Provide signed and dated informed consent prior to study-specific screening procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "2. Male or female at least 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "3. Histologically or cytologically confirmed inoperable locally advanced or metastatic (stage IVA/IVB) NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "4. Documented KRAS mutation positive status (per Lung Cancer Mutation Consortium \\[LCMC\\] guidelines; see www.golcmc.com)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "5. At least one prior chemotherapy regimen for advanced NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "6. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, Version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "7. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "8. Male or female subjects of child-producing potential must agree to use double barrier contraception, oral contraceptives or avoidance of pregnancy measures during the study and for 90 days after the last day of treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "9. Females of childbearing potential must have a negative serum pregnancy test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "10. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 × ULN with metastatic liver disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "11. Total bilirubin ≤ 1.5 × ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "12. Serum creatinine ≤ 1.5 × ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "13. Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "14. Platelets ≥ 100 x 10\\^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "15. Hemoglobin ≥ 10 g/dL (transfusion is allowed at least 7 days prior to randomization)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "16. Subjects must agree to allow testing for c-Met status if archival and/or fresh tissue biopsy samples are available.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": ". Previous receipt of erlotinib or other epidermal growth factor receptor (EGFR) inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "2. Previous receipt of any c-MET inhibitor (a receptor tyrosine kinase) or other c-MET-targeted therapy, including ARQ 197, MetMab, crizotinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "3. Prior receipt of chemotherapy agent selected for administration in this study (e.g., if subject was treated with gemcitabine, he is not eligible to receive gemcitabine in this study but eligible to receive pemetrexed or docetaxel).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "4. Inability or unwillingness to receive ARQ 197, erlotinib, docetaxel, gemcitabine, and/or pemetrexed including contraindications, hypersensitivity, or prior administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "5. Receipt of any anti-tumor treatment for NSCLC within 3 weeks (2 weeks for radiotherapy) prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "6. Pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "7. Significant gastrointestinal disorder that could, in the opinion of the Investigator, interfere with the absorption of ARQ 197 and/or erlotinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "8. Any other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "9. Other malignancies within the last three years, with the exception of adequately treated intraepithelial carcinoma of the cervix uteri, prostate carcinoma with a prostate-specific antigen (PSA) value \\< 0.2 ng/mL or basal or squamous cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "10. Known human immunodeficiency virus (HIV), or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "11. Major surgical procedure within 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "12. History of cardiac disease: Congestive heart failure defined as Class II to IV per New York Heart Association classification; Active coronary artery disease; Previously diagnosed bradycardia or other cardiac arrhythmia defined as ≥ Grade 2 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, or uncontrolled hypertension; Myocardial infarction that occurred within 6 months prior to study entry (myocardial infarction that occurred \\> 6 months prior to study entry is permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "13. Clinically unstable central nervous system metastasis (to be enrolled in the study, subjects must have confirmation of stable disease by MRI or CT scan within 4 weeks of randomization and have central nervous system \\[CNS\\] metastases well controlled by steroids, anti-epileptics or other symptom-relieving medications)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395758",
    "statement": "14. Known EGFR-mutation positive status",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Diagnosis of unresectable stage IIIB or IV non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* No more than one prior chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Adequate hematologic, renal and hepatic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Measurable disease or evaluable disease on CAT scan or MRI",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Able to fast for 10 hrs twice during the study - Able to tolerate oral medications",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Symptomatic or untreated central nervous system metastases requiring current treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* History of arterial thrombosis within 1 year prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Anticoagulant therapy, except for warfarin of less than 2mg per day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Symptomatic peripheral neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* History of pulmonary hemorrhage or hemoptysis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Myocardial infarction within 1 year before enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Uncontrolled hypertension \\[diastolic greater than 85 mmHg; systolic greater than 145 mmHg\\]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* History of other cancer, unless treated with no known active disease for longer than 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Previous treatment with AMG 706 or panitumumab, previous treatment with inhibitors of VEGF or EGF",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* No antibody treatment for 6 weeks prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094835",
    "statement": "* Known HIV positive, hepatitis C positive or hepatitis B surface antigen positive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00415363",
    "statement": "* Having radiologically proven brain metastases of lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00415363",
    "statement": "* Having received whole brain radiotherapy with either 30 grays in 2 weeks or 20 grays in one week. Treatment with enzastaurin must start within 14 days after the last fraction of the whole brain radiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00415363",
    "statement": "* No other previous radiotherapy to the brain except for radiosurgery at one occasion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00415363",
    "statement": "* Adequate organ function as measured by appropriate laboratory tests.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00415363",
    "statement": "* Age 18 years or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00415363",
    "statement": "* Inability to swallow tablets or show conditions which could interfere with oral medication intake (e.g. vomiting, partial bowel obstruction).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00415363",
    "statement": "* Inability to discontinue use of certain anti-epileptic drugs such as, carbamazepine, phenobarbital or phenytoin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00415363",
    "statement": "* Concurrent administration of warfarin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00415363",
    "statement": "* Hemophilia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00415363",
    "statement": "* Having had any systemic anti-cancer treatment within the last 2 weeks prior to enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Adult participants, \\>/= 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Inoperable, locally advanced, recurrent or metastatic (Stage IIIB or IV) non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Presence of epidermal growth factor receptor (EGFR) mutations",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Previously untreated with any systemic anti-neoplastic therapy for advanced disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Last dose of a prior systemic anti-neoplastic therapy for early-stage disease \\>/= 4 weeks before study start, and patient recovered from acute toxicities of any previous therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* A life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Able to comply with the study and its follow-up procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Female participants had to be postmenopausal (24 months of amenorrhea), surgically sterile or agree to use a physical method of contraception. Male participants had to be surgically sterile or agree to use a barrier method of contraception. Women with an intact uterus (unless amenorrhoeic for the last 24 months) had to have a negative pregnancy test (urine or serum) within 3 days prior to erlotinib treatment initiation in the study. Male and female participants had to use effective contraception during the study and for a period of 90 days following the last administration of erlotinib. Acceptable methods of contraception included an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Pregnant or breast feeding women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Granulocyte count \\<1.5 x 109/L and platelet count \\<100\\*10\\^9/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Serum bilirubin \\>1.5 upper limit of normal (ULN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \\> 2 \\* ULN (or \\>5 \\* ULN if clearly attributable to liver metastasis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Serum creatinine \\>1.5 ULN or creatinine clearance \\<60 mL/min",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Known allergy or other adverse reaction to study drug or any other related compound",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Any significant unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, hepatic, renal or metabolic disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Prior systemic anti-neoplastic therapy with HER1/EGFR inhibitors (as small molecule or monoclonal antibody therapy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Newly diagnosed or not yet definitively treated (i.e. stable disease \\>/= 2 months) CNS metastases or spinal cord compression",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Any significant ophthalmological abnormality, especially those likely to increase the risk of corneal epithelial lesions (the use of contact lenses is not recommended during the study)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Participants who could not take oral medication, who required intravenous alimentation, had had prior surgical procedures affecting absorption, or had active peptic ulcer disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01174563",
    "statement": "* Active cancer other than NSCLC, except for basal cell or squamous cell carcinomas of the skin that have been excised and cured",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": ". Subjects must be at least 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "2. Subjects must have histologically and/or cytologically confirmed NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "3. Subjects must have incurable (advanced or metastatic) disease at the time of enrolment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "4. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "5. Subjects must provide signed informed consent prior to any study specific procedures that are not part of standard medical care.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "6. Subjects must have measurable neoplastic disease based on the iRECIST criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "7. Subjects must have received as least 1 and no more than 2 prior systemic regimens for the treatment of advanced/metastatic NSCLC. Patients are required to have progressed following treatment with both platinum-based chemotherapy and an anti-PD-(L)1 antibody administered either sequentially or concurrently. A prior PD-1/PD-L1 inhibitor is, however, not required if there was prior exposure to targeted therapies for a driver mutation positive tumors (e.g. EGFR or ALK inhibitors).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "Main",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": ". Subjects with active infection requiring treatment within 3 days of C1D1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "2. Subjects with other active neoplastic disease requiring concurrent anti-neoplastic treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "3. Subjects with known, suspected or documented parenchymal brain metastases unless treated with surgery and/or radiation, with the subject neurologically stable and off pharmacologic doses of systemic glucocorticoids; subjects with leptomeningeal metastases are not eligible. Patients should have completed brain radiation for at least 14 days and be off steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "4. Active or previously documented autoimmune or inflammatory disorders such as, but not limited to rheumatoid arthritis, systemic lupus erythematosus, uveitis, ulcerative colitis, Crohn's syndrome, Wegener's syndrome, multiple sclerosis, myasthenia gravis, scleroderma and sarcoidosis. The following are exceptions to this criterion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "* Vitiligo or psoriasis not requiring systemic treatment (within the last 2 years)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "* Subjects with endocrinopathies (e.g. following Hashimoto syndrome) stable on hormone replacement or do not require any therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "5. History of primary immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04880863",
    "statement": "6. Subjects with a history or prior allogeneic organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": ". Patients must sign an informed consent before assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "2. Patients with pathologically and/or clinically confirmed diagnosis of stage IV non-small (squamous or non-squamous) cell lung cancer (NSCLC) or stage III/IV adenocarcinoma of the pancreas.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "3. Patients with stage IV NSCLC will be receiving or completed or discontinued standard chemotherapy or be chemotherapy-naive by choice.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "4. Patients with stage III/IV pancreatic adenocarcinoma will be receiving standard chemotherapy or no chemotherapy. If patients are receiving chemotherapy, a change in chemotherapy is not expected.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "5. Greater than or equal to 5% unintentional weight loss over the previous 3-6 months, not explained by simple starvation. Simple starvation is considered to be excluded when weight loss is not ameliorated by standard nutritional counseling and oral supplementation over a 2 week period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "6. Body mass index (BMI) ≤ 30 kg/m2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "7. Life expectancy of at least 4 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "8. Able to communicate well and comply with the requirements of the study, including by phone and written logs.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": ". Patients who have received investigational anti-neoplastic therapy within 3 weeks of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "2. Evidence of inadequate organ or brain function, as defined by lab tests and imaging",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "3. Patients with severe and/or uncontrolled medical conditions that could interfere with the study (e.g. heart conditions, high blood pressure, diabetes, infection) uncontrolled pain or any other non-stable illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "4. Pregnant or lactating women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "5. Women capable of becoming pregnant must use highly effective contraception during the study and for 8 weeks after stopping treatment. All female patients must have negative pregnancy test results throughout the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "6. Patients unwilling or unable to follow instructions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01433263",
    "statement": "Other protocol-defined inclusion/exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": ". Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "2. Subject with histological or cytological confirmation of extensive stage Small Cell Lung Cancer (ES SCLC) or Stage IIIb or IV squamous Non-Small Cell Lung Cancer (sqNSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "3. Subject has received 1 or 2 prior lines of therapies, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   1. Cohort A (SCLC, Immune Checkpoint Inhibitor naïve):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* At least 1 prior treatment including a platinum-based chemotherapy doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* A minimum of 3 cycles of platinum-based chemotherapy in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   2. Cohort B (SCLC, ICI progressors):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* At least 1 prior first or second line treatment includes an ICI",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* If treatment includes an ICI as maintenance therapy, at least 1 cycle of ICI in maintenance should have been completed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* At least 1 prior treatment including a platinum-based chemotherapy doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* A minimum of 3 cycles of platinum-based chemotherapy, with or without ICI, in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* Subject must have progressed during ICI therapy, defined as unequivocal progression on or within 3 months of the last dose of ICI therapy (if no subsequent therapy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   3. Cohort C (sqNSCLC, ICI progressors):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* At least 1 prior first or second line treatment includes an ICI",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* If treatment includes an ICI as maintenance therapy, at least 1 cycle of ICI in maintenance should have been completed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* At least 1 prior treatment including a platinum-based chemotherapy doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* A minimum of 3 cycles of platinum-based chemotherapy, with or without an ICI, in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "* Subject must have progressed during ICI therapy, defined as unequivocal progression on or within 3 months of the last dose of ICI therapy (if no subsequent therapy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "4. Subject has progressed at the last line of therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "5. Subject has a measurable disease defined by RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "6. Subject agrees to provide a tumor biopsy from primary or metastatic site prior to first dose and at a pre-specified timepoint during treatment. Core biopsy is required however, in the event a core biopsy may not otherwise be feasible in the opinion of the treating physician, an endobronchial ultrasound-guided fine needle aspirate \\[EBUS-FNA\\]) biopsy, using the largest gauge needle, may be performed instead.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "7. Subject has ECOG Performance Status of 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "8. Subject must have the following laboratory values:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   2. Hemoglobin (Hgb) ≥ 9 g/dL (one-time blood transfusion is allowed)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   3. Platelet (Plt) Count ≥ 150 x 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   4. White blood cells (WBC) ≥ 2 x 109L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   5. Serum AST/serum glutamic oxaloacetic transaminase (SGOT) or ALT/serum glutamic pyruvic transaminase (SGPT) ≤ 3 x upper limit of normal (ULN) or ≤ 5 x ULN if presence of liver metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   6. Total serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN, if Gilbert's syndrome or if indirect bilirubin concentrations are suggestive of extrahepatic source of the elevation)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   7. Creatinine clearance (CrCl) ≥ 60 mL/minute based on Cockcroft-Gault or modification of diet in renal disease (MDRD) or ≥ 60 mL/min/1.73 m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": ". Subject has not recovered to Grade 2 or lower clinically significant toxicities related to the prior therapy (alopecia excluded).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "2. Subject has received prior LSD1 therapies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "3. Subject has a history of severe hypersensitivity reactions to other monoclonal antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "4. Subject with symptomatic and untreated or unstable central nervous system (CNS) metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   1. Subject has recently been treated with whole brain radiation or stereotactic radiosurgery for CNS metastases must have completed therapy at least 2 weeks prior to Cycle 1 Day 1 and has a follow-up brain computed tomography (CT) or magnetic resonance imaging (MRI) demonstrating either stable or improving metastases 2 or more weeks after completion of radiotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   2. Subject must be asymptomatic and off steroids or on stable dose of steroids for at least 2 weeks (≤ 10 mg daily prednisone or equivalent) prior to first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "5. Subject has persistent diarrhea due to a malabsorptive syndrome (such as celiac sprue or inflammatory bowel disease) ≥ NCI CTCAE Grade 2, despite medical management), or any other significant gastrointestinal (GI) disorder that could affect the absorption of the study treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "6. Subject with symptomatic or uncontrolled ulcers (gastric or duodenal), particularly those with a history of and/or risk of perforation and GI tract hemorrhages.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "7. Subject with any hemorrhage/bleeding event \\> NCI CTCAE Grade 2 or haemoptysis \\> 1 teaspoon within 4 weeks prior to the first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "8. Subject has any of the following cardiovascular criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   1. Evidence of acute or ongoing cardiac ischemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   2. Current symptomatic pulmonary embolism",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   3. Unstable angina pectoris or myocardial infarction ≤ 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   4. Heart failure of New York Heart Association Classification III or IV ≤ 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   5. Persistent or clinically meaningful ventricular arrhythmias prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   6. Cerebral vascular accident or transient ischemic attack ≤ 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   7. QT corrected based on Fridericia's equation (QTcF) ≥ 450 milliseconds (msec) on Screening ECG, a baseline prolongation of QTcF interval ≥ 450 msec (NCI CTCAE Grade ≥ 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   8. A history of additional risk factors for Torsades de pointes (TdP) (eg, heart failure, hypokalemia, family history of Long QT Syndrome)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "   9. Uncontrolled hypertension (blood pressure ≥ 160/95 mm Hg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "9. Subject has known human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "10. Subject has known chronic active hepatitis B or C virus (HBV, HCV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "    1. Subject who is seropositive due to HBV vaccination is eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "    2. Subject who has no active viral infection and is under adequate prophylaxis against HBV reactivation is eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "11. Subject has any other malignancy within 2 years prior to enrollment, with the exception of adequately treated in-situ bladder cancer, in-situ carcinoma of the cervix, uteri, nonmelanomatous skin cancer, ductal in situ breast carcinoma, thyroid cancer, or early stage prostate cancer (all treatment of which should have been completed 6 months prior to enrollment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "12. Subject has medical conditions requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "    1. A brief (≤ 7 days) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of nonautoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "    2. Adrenal replacement steroid doses \\> 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "    3. Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) are permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "13. Subject has active autoimmune diseases or history of autoimmune diseases that may relapse. Subjects with the following diseases are allowed to be enrolled after further screening: type I diabetes, hypothyroidism managed with hormone replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia), or diseases not expected to recur in the absence of external triggering factors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "14. Subject is pregnant or nursing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "15. Subject has a history of persistent skin rash ≥ NCI CTCAE Grade 2 related to prior ICI therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "16. Subject has organ transplant history, including allogeneic stem cell transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "17. Subject has interstitial lung disease history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "18. Subject has received a live/attenuated vaccine within 30 days of first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "19. Subject has previous SARS-CoV-2 infection either suspected or confirmed within 4 weeks prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "    1. Acute symptoms must have resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the subject at a higher risk of receiving investigational treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Clinical diagnosis of Systemic Lupus Erythematosus (SLE) confirmed by Systemic Lupus International Collaborating Clinics (SLICC) classification criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Moderate to severe SLE disease activity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Evidence for at least 1 of the following SLE markers:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Anti-dsDNA antibodies confirmed by central laboratory or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Low complement confirmed by central laboratory or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Antinuclear antibody (ANA) titer of \\>= 1:80 in combination with at least 1 of the following: Historical positivity for anti-dsDNA or Positivity for extractable nuclear antigen (anti-ENA) confirmed by central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* The subject is receiving stable SLE standard-of-care medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Mixed connective tissue disease, scleroderma, and/or overlap syndromes of SLE",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Subjects with severe neuropsychiatric SLE or other neurological symptoms that in the opinion of the Investigator, would prevent the subject from completing protocol required procedures and assessments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* New or worsening Class III or IV lupus nephritis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Chronic kidney failure stage 3b",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Evidence of human immunodeficiency virus (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection at any time prior to or during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Clinically significant active or latent infection (eg. chronic viral hepatitis B or C)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent TB (LTB) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Live/live attenuated vaccines within 6 weeks prior to the first study drug infusion (Visit 2) or who plan to receive these vaccines during the study or 12 weeks after the final dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* History of thromboembolic events within 12 months of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02804763",
    "statement": "* Subject has used protocol defined prohibited medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": ". Signed and dated informed consent form (by the patient or a legally acceptable representative as per the local regulations) obtained prior to initiation of any study-specific procedure and treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "2. Female or male of at least 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "3. Histologically or cytologically confirmed advanced solid tumor with no available standard approved treatment options in the opinion of the Investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "4. Eastern Cooperative Oncology Group (ECOG) Performance status (PS) ≤ 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "5. Expected life expectancy of ≥ 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "6. Able to swallow the study drug (no contra indication to oral agents).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "7. Renal function at screening and enrollment as defined by the Modification of Diet in Renal Disease (MDRD) equation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "8. Patient has had no clinically significant change in renal status within 3 months prior to screening, according to Investigator's review of clinical patient records.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "9. Patient is not currently on hemodialysis and/or peritoneal dialysis for management of chronic kidney disease or acute failure/conditions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "10. Patient has no unstable renal function, defined as a change in estimated glomerular filtration rate (eGFR) (calculated with the MDRD equation) of \\> 25% for patients with mild and moderate renal impaired or as a change in eGFR \\> 30% for patients with severe renal impaired, from screening to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "11. Adequate other organ function at screening and enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "12. Female patients of childbearing potential must have a negative serum pregnancy test at screening, and must agree to use a highly effective birth control method from the time of the first dose of study drug through 45 days after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "13. Male patients must agree to use a condom when having sex with a pregnant woman or with a non-pregnant female partner of childbearing potential, from 21 days before the first dose of study drug through 105 days after last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "14. Female patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "15. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": ". Treatment within 14 days or five half lives prior to enrollment with any type of systemic anticancer-therapy or any investigational drug, whichever is longer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "2. Have not recovered (recovery is defined as CTCAE grade ≤ 1) from the acute toxicities of previous anticancer standard or investigational therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "3. Major surgery within 28 days prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "4. Serious accompanying cardiac disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "5. Active known or suspected brain metastasis or active leptomeningeal disease undergoing or requiring treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "6. Symptomatic or impending spinal cord compression or cauda equina syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "7. Has undergone a liver transplant, kidney transplant or nephrectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "8. Prior allergic reaction or severe intolerance (meeting the criteria for a serious adverse event, a grade 3 or 4 AE, or permanent treatment discontinuation) to a poly ADP ribose polymerase (PARP) inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "9. Known myelodysplastic syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "10. Seropositive for human immunodeficiency virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "11. Any serious or unstable medical condition that interferes with ability to tolerate treatment or assessments associated with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "12. Gastrointestinal disorder affecting absorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "13. Known or suspected hypersensitivity to any of the talazoparib capsule components.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02997163",
    "statement": "14. Any condition or reason that interferes with ability to participate in the study, tolerate treatment or assessments associated with the protocol, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator or Medical Monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": ". Sign written informed consent before any trial-related processes are implemented;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "2. Age ≥ 18 years and \\<75 years;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "3. Life expectancy exceeds 3 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "4. The investigator confirmed at least one measurable lesion according to RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "   A measurable lesion located in the field of previous radiation therapy or after local treatment may be selected as a target lesion if it is confirmed to have progressed;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "5. According to the International Lung Cancer Research Association and the American Association for the Classification of Cancer Classification, the 8th edition of the TNM (Tumor Node Metastasis) staging of lung cancer, a histologically or cytologically confirmed locally advanced (IIIB/IIIC phase) that cannot be treated surgically and cannot undergo radical concurrent chemoradiotherapy, Patients with metastatic or recurrent (stage IV) non-squamous NSCLC;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "6. Confirmed for patients with EGFR (Epidermal growth factor receptor) or ALK (Anaplastic lymphoma kinase) targeted therapy (documentary evidence of no tumor EGFR-sensitive mutations and no ALK gene rearrangement)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "7. The Eastern Cancer Cooperative Group (ECOG) has a performance score of 0 or 1;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "8. Have not received any systematic anti-tumor treatment for advanced disease; The patient may have received adjuvant chemotherapy as long as the disease relapses at least 6 months after the last dose of chemotherapy is completed;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "9. Adequate hematologic function, defined as absolute neutrophil count ≥1.5×10\\^9 /L, platelet count ≥100 ×10\\^9 /L, hemoglobin ≥9g/dL (no blood transfusion or erythropoietin (EPO) within 7 days) Dependency);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "10. Adequate liver function, defined as total bilirubin levels ≤ 1.5 times normal upper limit (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times ULN in all patients, or for recorded liver Patients with metastasis, AST and ALT levels ≤ 5 times ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "11. Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN or measured or calculated creatinine clearance ≥ 60 ml / min (Cockcroft-Gault formula);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "12. Coagulation function is adequate, defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times normal upper limit (ULN); if the subject is receiving anticoagulant therapy, as long as the PT is used in anticoagulant drugs Within the scope;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "13. Female subjects of childbearing age should be negative for urine or serum pregnancy test within 72 hours prior to the first study drug administration (Day 1, Day 1). If the urine pregnancy test results are positive or cannot be confirmed as negative, a blood pregnancy test is required.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "14. If there is a risk of conception, male and female patients are required to use high-efficiency contraception (ie, an annual failure rate of less than 1%) and continue until at least 180 days after stopping the trial treatment; Note: If abstinence is the usual lifestyle of the subject and the preferred method of contraception, abstinence can be accepted as a method of contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": ". Histological squamous cell-dominated NSCLC; Mixed cell types must distinguish between dominant cell morphology, and if small cell types are present, the subject is not eligible for inclusion;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "2. Currently participating in interventional clinical research or treatment, or receiving other research drugs or using research equipment within 4 weeks before the first dose;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "3. Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or against another stimulatory or synergistic inhibition of T cell receptors \\[eg CTLA-4 (Cytotoxic T lymphocyte antigen-4), OX-40 (also called CD134, cluster of differentiation134), CD137\\] agent;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "4. Received a traditional Chinese medicine with anti-tumor effect, or an immunomodulatory drug (thymosin, interferon, interleukin) within 2 weeks before the first dose, or received major surgery within 3 weeks before the first dose;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "5. Pulmonary radiation therapy of \\>30 Gy within 6 months prior to the first dose;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "6. Completed palliative radiotherapy within 7 days prior to the first dose;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "7. Clinical active diverticulitis, abdominal abscess, gastrointestinal obstruction and peritoneal metastasis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "8. Have received a physical organ or blood system transplant;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "9. There is clinically uncontrollable pleural effusion/peritoneal effusion;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "10. known to have severe allergic reactions (≥3 grade) to the active ingredients of Sintilimab, pemetrexed, cisplatin, carboplatin and or any excipients;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "11. Active autoimmune diseases requiring systemic treatment (eg, using a disease-modifying drug, corticosteroid or immunosuppressant) within 2 years prior to the first dose. Alternative therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatments;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "12. Diagnosis of immunodeficiency or study of systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "    Physiological doses of corticosteroids (≤10 mg/day of prednisone or equivalent) are permitted;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "13. Has not fully recovered from the toxicity and/or complications caused by any intervention before starting treatment (ie, ≤1 or reaching baseline, excluding fatigue or alopecia);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "14. Other malignant tumors were diagnosed within 5 years prior to the first dose, with the exception of radical cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and/or radically resected carcinoma in situ;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "15. Active central nervous system (CNS) metastasis and / or cancerous meningitis. Patients with treated brain metastases who have remained clinically stable for at least 2 weeks and have no new or advanced brain metastases may be enrolled and discontinued hormone therapy 3 days prior to the first study drug. Patients with known untreated, asymptomatic brain metastases can be enrolled, but regular imaging assessments of the brain must be performed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "16. There is a history of (non-infectious) pneumonia requiring steroid therapy or the presence of interstitial lung disease 1 year before the first dose;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "17. There are active infections that require systemic treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "18. Subjects who are unable or unwilling to receive folic acid or vitamin B12 supplementation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "19. There are known cases of mental illness or substance abuse that may have an impact on compliance with the test requirements;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "20. A history of human immunodeficiency virus (HIV) infection (ie, HIV 1/2 antibody positive) is known.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "21. Untreated active hepatitis B;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "    Note: Controlled (treated) hepatitis B subjects also meet the inclusion criteria if the following criteria are met:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "    At least 4 weeks of HBV (Hepatitis B virus) antiviral therapy must have been received prior to the first dose of study drug, and the HBV viral load is \\<1000 copies/ml (200 IU/ml). Subjects who are receiving HBV therapy and have a viral load of \\<1000 copies/ml (200 IU/ml) should receive antiviral therapy throughout the study treatment period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "    For subjects with anti-HBc (hepatitis B core antigen)(+), HBsAg(-), anti-HBs(-), and HBV viral load (-), prophylactic anti-HBV therapy is not required, but viral reactivation is closely monitored;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "22. Active HCV (Hepatitis C virus)-infected subjects (HCV antibody positive and HCV-RNA levels above the lower limit of detection);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "23. Vaccination of live vaccine within 30 days before the first dose (1st cycle, 1st day); Note: Inactivated virus vaccines for seasonal influenza, injectable drugs are permitted; however, live attenuated influenza vaccines (such as FluMist®) are not allowed for intranasal administration;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03607539",
    "statement": "24. There may be a history of illness or disease evidence, treatment or laboratory abnormalities that may interfere with the subject's full participation in the study, or the investigator believes that participating in the study is not in the best interests of the subject, including dialysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Subjects must have mCRPC,RCC, MEL, Non-small-cell lung cancer (NSCLC), or Colorectal Cancer (CRC), that is advanced (non-resectable), or recurrent and for which no alternative, curative standard exists",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Must have at least 1 measurable lesion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Subjects with mCRPC and with only non-measurable bone lesions must have either progression new lesions or have Prostate-specific antigen (PSA) progression within the 6-week period before study administration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* At least 1 and up to 5 prior systemic therapies for advanced/recurrent disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Prior treated brain or meningeal metastases must be without Magnetic resonance imaging (MRI) evidence of progression for at least 8 weeks and off immunosuppressive doses of systemic steroids for at least 2 weeks before study drug administration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Prior systemic radiation therapy must have been completed at least 4 weeks before study drug administration. Prior focal radiotherapy completed at least 2 weeks prior to study drug administration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids must be discontinued at least 2 weeks before study drug administration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Prior surgery that required general anesthesia must be completed at least 2 weeks before study drug administration. Surgery requiring local/epidural anesthesia must be completed at least 72 hours before study drug administration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* History of severe hypersensitivity reactions to other Monoclonal antibody (mAb)s",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Prior therapy with an anti-Programmed death-1 (PD-1), anti-PD-L1, anti-PD-L2, or anti- Cytotoxic t-lymphocyte antigen-4 (CTLA-4) antibody (or any other antibody targeting T cell co-stimulation pathways)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Known history of Human Immunodeficiency Virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Active infection requiring therapy, positive tests for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Underlying medical conditions that will make the administration of study drug hazardous",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730639",
    "statement": "* Use of other investigational drugs (drugs not marketed for any indication) within 28 days or at least 5 half-lives (whichever is longer) before study drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806286",
    "statement": "* Histologically or cytologically confirmed metastatic (stage IV) NSCLC with no significant pleural effusion or pleural involvement from the tumor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806286",
    "statement": "* Age greater than or equal to 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806286",
    "statement": "* Adequate organ and bone marrow function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806286",
    "statement": "* Any prior systemic therapy for NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806286",
    "statement": "* Major surgical procedure or other investigational agents within 4 weeks before study enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806286",
    "statement": "* Need for concomitant use of other thiazolidinediones during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806286",
    "statement": "* History of any of the following conditions within 6 months prior to initiating study treatment: Diabetes mellitus requiring treatment with insulin or sulfonylureas or thiazolidinediones (TZDs) agents; Myocardia infarction with significant impairment of cardia function; Malabsorption syndrome, chronic diarrhea, inflammatory bowel disease or partial bowel obstruction;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806286",
    "statement": "* Clinically active brain metastases, uncontrolled seizure disorder; spinal cord compression or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": ". Participants must sign written ICF prior tothe implementation of any procedures related to the study;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "2. Aged ≥ 18 years and ≤ 75 years;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "3. With a life expectancy of more than 3 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "4. With at least one measurable lesion confirmed by the investigator according to RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "   Measurable lesions locatedin the field of previous radiotherapy or locoregional therapy canbe selected as target lesions if PD is confirmed;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "5. Participants with histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) who are ineligible for radical surgery or concurrent chemoradiotherapy, metastatic (stage IV)or recurrent squamous NSCLC based on the \"8th Edition of the TNM Classification for LungCancer\" issued by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "6. With an ECOG PS score of 0 or 1;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "7. Have not received any prior systemic anti-tumor therapy for advanced/metastatic disease; for participants who have received prior platinum-based adjuvant chemotherapy/radiotherapy,neoadjuvant chemotherapy/radiotherapy, or radical chemoradiotherapy, they are eligible for the study if PD occurs at \\> 6 months after the last treatment;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "8. With adequate hematologic function, defined as ANC ≥ 1.5 × 10\\^9/L, platelet count ≥ 100 × 10\\^9/L, and hemoglobin ≥ 90 g/L (noblood transfusion history within 7 days);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "9. Adequate hepatic function, defined as TBIL ≤ 1.5 × ULN and AST as well as ALT ≤ 2.5 × ULN for all participants, or AST and ALT ≤ 5 × ULN for participants with liver metastasis;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "10. Adequate renal function, defined as CCr ≥ 50 mL/min (Cockcroft-Gault formula);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "11. Adequate coagulation function, defined as INR or PT ≤ 1.5 × ULN; for the participant who is receiving anticoagulant therapy, INR or PT within the proposed scope of the anticoagulantmedication is acceptable;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "12. Female participants of childbearing age should be tested negative for urine or serum pregnancy within 3 days before the first dose of the study treatments. A blood pregnancy testis required if the urine pregnancy test is inconclusive;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "13. For male and female participants with conception potential, highly effective contraception measures (failure rate \\< 1% per year) should be taken until at least 180 days afterdiscontinuation of the study treatment;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "Note: Abstinence is acceptable as a method of contraception if it is the usual lifestyle and preferred method of contraception for the participant.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": ". Histological type of nonsquamousNSCLC. The dominant cell morphology must be identified for mixed cell type (participants with squamous cell carcinoma components \\> 50% can beenrolled); participants with small cell carcinoma, neuroendocrine carcinoma, and sarcoma components cannot be included;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "2. Participants with known EGFR-sensitive mutations or ALK rearrangement;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "3. Currently participating in an interventional clinical study, or treated with another study drug therapy or investigational device therapy within 4 weeks before the first dose;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "4. Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 agents or agents targeting another stimulation or synergistically inhibiting TCR (e.g., CTLA-4, OX-40,and CD137);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "5. Received proprietary Chinese medicines with anti-tumor indications or immunomodulators (thymosin, interferon, interleukin, etc.) within 2 weeks prior to the first dose, or received a major surgery within 3 weeks prior to the first dose;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "6. With active hemoptysis, active diverticulitis, abdominal abscess, gastrointestinal obstruction, and peritoneal metastases requiring clinical intervention;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "7. Have undergone solid organ transplantation or hematologic transplantation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "8. With clinically uncontrolled pleural effusion/ascites (participants who do not need effusion drainage or have no significant increase in effusion within 3 days after stopping drainage canbe enrolled);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "9. With a tumor compressing the surrounding important organs (such as esophagus) with relevant symptoms, compressing the superior vena cava, or invading the mediastinal great vessels,heart, etc.;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "10. With Class III-IV congestive cardiac failure (based on New York Heart Association Classification) or poorly controlled and clinically significant arrhythmia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "11. With any arterial thrombosis, embolism, or ischemia within 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, and transient ischemicattack. With a history of deep venous thrombosis, pulmonary embolism, or any other seriousthromboembolic events within 3 months priorto enrollment (implantable port or catheter-related thrombosis, or superficial venous thrombosis is not considered as \"serious\"thromboembolism);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "12. With known allergy to the active ingredients and/or any excipient of sintilimab , gemcitabine, cisplatin, orcarboplatin;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "13. With active autoimmune disease requiring systemic treatment (e.g., use of disease-modifying drugs, corticosteroids, or immunosuppressive agents) within 2 years before the first dose.Replacement therapy (e.g., thyroxine, insulin, or physiologic doses of corticosteroids foradrenal or pituitary insufficiency) is not considered systemic;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "14. Participants requiring long-term systemic use of corticosteroids. Participants requiring intermittent use of bronchodilators, inhaled corticosteroids, or localinjection ofcorticosteroids for COPD or asthma can be included in the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "15. Full recovery (i.e., ≤ Grade 1 or reaching the baseline, excluding asthenia or alopecia) from toxicity and/or complications caused by any intervention has not achieved before thestart oftreatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "16. Diagnosed with other malignant tumors within 5 years before the first dose, excluding radically cured cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and/orradically resected carcinoma in situ. For other malignant tumors or lung cancer diagnosedmore than 5 years before the first dose, pathological or cytological diagnosis should beperformed for recurrent and metastatic lesions;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "17. Symptomatic CNS metastasis. Participants with asymptomatic brain metastases or with stable symptoms after treatment of brain metastases are allowed to participate in this study as longas meeting all of the following criteria: presence of measurable lesions outside the CNS;absence of metastases in midbrain, pons, cerebellum, meninges, medulla oblongata, or spinalcord; maintain clinical stable condition for at least 2 weeks; discontinue hormone therapy 14 days prior to the first dose of the study treatments;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "18. With a history of non-infectious pneumonia requiring corticosteroid therapy within 1year prior to the first dose or with non-infectious pneumonia at present;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "19. With an active infection requiring treatment or have used systemic anti-infective drugs within one week prior to the first dose;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "20. With known psychiatric disorder or substance abuse that could affect the compliance with study requirements;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "21. Known history of HIV infection (i.e. HIV 1/2 antibody positive), known syphilis infection (syphilis antibody positive), or active tuberculosis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "22. With untreated active hepatitis B;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "    Note: Participants with hepatitis B who meet the following criteria are also eligible forinclusion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "    HBV viral load must be less than 1000 copies/mL (200 IU/mL) or below LLD prior to thefirst dose, and participants should receive anti-HBV treatment to avoid virus reactivation throughout the therapeutic phase of the study; For participants with HBcAb (+), HBsAg (-), HBsAb (-), and HBV load (-), close monitoring is required instead of prophylactic anti-HBV treatment to avoid virus reactivation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "23. Participants with active HCV infection (HCV antibody positive and HCV-RNA level above the LLD);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "24. Have received live vaccines within 30 days prior to the first dose; Note: Seasonal inactivated influenza virus vaccines for injection are allowed, while liveattenuated influenza vaccines forintranasal use are not acceptable;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "25. With any medical history, disease, treatment, or laboratory abnormal finding that would interfere with the study results or prevent the participant from participating in the whole study,or the investigator believes that participation in this study is not in the best interest of theparticipant;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03629925",
    "statement": "26. With local or systemic diseases not attributing to malignancy, or with cancer-related secondary diseases, which would result in a high medical risk and/or uncertainty in survivalevaluation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Histologically or cytologically confirmed stage IV non-small cell lung carcinoma (NSCLC), according to 7th Tumor/Node/Metastasis (TNM) classification (cytological specimens obtained by bronchial washing or brushing, or fine-needle aspiration are acceptable)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Subject has available and has provided consent to release to the sponsor (or designee) a tumor block with confirmed tumor content (or approximately 20 unstained charged slides \\[a minimum of 7 slides is mandatory\\]) and the corresponding pathology report",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Planned to receive 4 to 6 cycles of pemetrexed or gemcitabine in combination with cisplatin or carboplatin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* For subjects to receive pemetrexed, planned to receive vitamin B12 and folate per pemetrexed approved labeling",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Radiographically evaluable (measurable or non-measurable) disease (according to modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Other inclusion criteria may apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Known presence of documented sensitizing epidermal growth factor receptor (EGFR) activating mutation or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation (screening following local standards, but strongly encouraged in non-squamous histology)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Known brain metastases (systematic screening of patients not mandatory)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Any prior systemic therapy (before randomization) for the treatment of NSCLC (including chemoradiation), except if for non-metastatic disease and was completed at least 6 months prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Planned to receive bevacizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Significant dental/oral disease, including prior history or current evidence of osteonecrosis/ osteomyelitis of the jaw, or with the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Active dental or jaw condition which requires oral surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Non-healed dental/oral surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951586",
    "statement": "* Planned invasive dental procedures for the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has a histologically or cytologically confirmed diagnosis of Stage IV metastatic non-small cell lung cancer (NSCLC) (American Joint Committee on Cancer version 8)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as determined by investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has a life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Female participants of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Female participants of reproductive potential must agree to use contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has received prior systemic chemotherapy/other targeted or biological antineoplastic therapy treatment for their Stage IV metastatic NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has a tumor that harbors an epidermal growth factor receptor (EGFR)-sensitizing (activating) mutation or an anaplastic lymphoma kinase (ALK) translocation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has received prior therapy with an anti-Programmed Cell Death Receptor 1 (PD-1), anti-Programmed Cell Death Receptor Ligand 1 (anti-PD-L1), or anti- Programmed Cell Death Receptor Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 \\[CTLA-4\\], OX-40, CD137)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has received prior radiotherapy within 2 weeks of start of study therapy or received lung radiation therapy of \\>30 Gray (Gy) within 6 months of the first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has recovered from all radiation-related toxicities, does not require corticosteroids, and has not had radiation pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Is receiving systemic steroid therapy ≤7 days prior to the first dose of study therapy or receiving any other form of immunosuppressive medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (i.e., doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has a history of (non-infectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has had an allogeneic tissue/solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has received a live vaccine within 30 days prior to the first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has an active infection requiring systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has a known history of human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has a known history of hepatitis B or known active hepatitis C virus infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has a known history of active tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Is a regular user of any illicit drugs or had a recent history of substance abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Is pregnant or breast feeding or expecting to conceive starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has severe hypersensitivity to pembrolizumab and/or any of its excipients and/or to ipilimumab and/or any of its excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03302234",
    "statement": "* Has a c-ros oncogene 1 (ROS1) mutation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Stage IIIB (not eligible for definitive chemoradiotherapy), Stage IV, or recurrent NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* PDL1-positive status as determined by an immunohistochemistry assay performed by a central laboratory. A positive result in chemotherapy, chemoradiation of the tumor sample biopsy will satisfy the eligibility criterion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Eastern Cooperative Oncology group Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Life expectancy greater than or equal to 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors Version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Adequate hematologic and end organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exceptions are allowed. Hormone-replacement therapy or oral contraceptives, and tyrosine kinase inhibitors approved for treatment of NSCLC discontinued greater than 7 days prior to Cycle 1 Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Known central nervous system disease, including treated brain metastases in the following participants:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "  1. who will not receive prior chemotherapy for advanced disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "  2. who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (referred as 2L+ participants)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Participants with a history of treated asymptomatic brain metastases are allowed in the 2L+ participants and previously treated for brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Uncontrolled tumor-related pain",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "* Uncontrolled hypercalcemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Histologically or cytologically documented nonsmall-cell lung cancer (NSCLC) presenting as stage IIIB disease without indications for definitive radiotherapy, stage IV disease, or recurrent disease following radiation therapy or surgical resection",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* No prior chemotherapy, hormonal therapy, immunotherapy, or targeted-therapy-containing regimens for the treatment of NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Eastern Cooperative Oncology Group performance score of 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Adequate bone marrow function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Hemoglobin ≥9.0 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Absolute neutrophil count ≥1,500/mm\\^3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Platelet count ≥100,000/mm\\^3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Adequate liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Total bilirubin level ≤2.0\\*the upper limit of normal (ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Asparate aminotransferase level ≤2.5\\*ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Alanine aminotransferase level ≤2.5\\*ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Adequate renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Calculated creatinine clearance based on Cockcroft and Gault formula ≥50 mL/min.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Symptomatic central nervous system (CNS) metastasis or active CNS metastasis requiring medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Malignant body cavity fluid (eg, pleural effusion, cardiac effusion, ascites) that recurred despite appropriate supportive care",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Prior radiation of ≥30% of major bone-marrow containing areas (pelvis, lumbar spine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Documented history of severe autoimmune or immune-mediated symptomatic disease that required prolonged (longer than 2 months) systemic immunosuppressant treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Documented history of motor neuropathy considered of autoimmune origin (eg, Guillain Barré syndrome)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Any concurrent malignancy other than nonmelanoma skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, carcinoma of the mucous membrane of the gastrointestinal tract, or superficial bladder cancer treated with systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* ≥Grade 2 diarrhea",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* History of or concurrent disease of gastrointestinal tract perforations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* ≥Grade 2 peripheral neuropathy (motor or sensory)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Uncontrolled intercurrent illness including infection requiring systemic therapy, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled angina pectoris, uncontrolled peptic ulcer, and cardiac arrhythmia requiring medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165216",
    "statement": "* Positive finding for human immunodeficiency virus antibody, hepatitis B surface antigen, or hepatitis C virus antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Histologically or cytologically confirmed stage IIIB or IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Recurrent disease (either no response to treatment or subsequent relapse after an objective response) that has progressed after first line therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* ≥ 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Adequate organ and bone marrow function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0 grade ≤ 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Agreement to use effective contraception while on treatment and for at least 3 months after end of treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Treatment with anticancer therapy within 3 weeks before study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Therapeutic or palliative radiation therapy within 2 weeks or major surgery within 4 weeks before study treatment (except for radiotherapy for brain metastases).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Administration of other thiazolidinediones (TZDs) within 4 weeks before study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Current need for concomitant use of other TZDs during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection at time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* History of any of the following conditions within 6 months before initiating study treatment: diabetes mellitus requiring treatment with insulin or TZD agents; myocardial infarction with significant impairment of cardiac function; severe/unstable angina pectoris; coronary/peripheral artery bypass graft; New York Heart Association (NYHA) class III or IV congestive heart failure; malabsorption syndrome, chronic diarrhea (lasting \\> 4 weeks), inflammatory bowel disease, or partial bowel obstruction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Pericardial or pleural effusion (eg, requiring drainage) or pericardial involvement with the tumor. Participants with minimal pleural effusion may be eligible upon request by Investigator and approval by Sponsor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Pregnant or breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01101334",
    "statement": "* Prior treatment with epidermal growth factor receptor (EGFR) inhibitors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Have received at least 1 but no more than 4 prior systemic therapies",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Have adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Have estimated life expectancy greater than or equal to (≥)12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Have fully recovered from radiation therapy or surgery, and are recovering from any acute adverse effects of other cancer therapies",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Have discontinued all chemotherapy, investigational therapy, molecularly-targeted therapy, and cancer-related hormonal therapy at least 14 days prior, biologic or immunotherapeutic therapy at least 21 days prior, or mitomycin-C or nitrosoureas at least 6 weeks prior",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Female participants with reproductive potential agree to use 2 forms of highly effective contraception during the study and for the following 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Male participants must use a barrier method of contraception during the study and for the following 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "Phase 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Have evidence of a solid tumor that is locally advanced and/or metastatic (excluding primary brain tumor)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "Phase 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Have disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Have evidence of a solid tumor that is locally advanced and/or metastatic, and in:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Small Cell Lung Cancer (SCLC), must have failed platinum-containing therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Breast Cancer, be Estrogen Receptor positive and/or Progesterone Receptor positive, but Human Epidermal Growth Factor Receptor 2 (HER2) negative, and must have failed a hormone therapy and a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Triple negative breast cancer (TNBC) and failed standard therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Squamous cell cancers of the head neck associated with the human papilloma virus (HPV), and have failed standard therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Other solid tumor type that has been approved by the sponsor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Have symptomatic central nervous system (CNS) metastasis (unless asymptomatic and not current receiving corticosteroids) or a primary tumor of the CNS",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03092934",
    "statement": "* Have a medical condition that precludes participation (swallowing disorder, organ transplant, pregnant or nursing, HIV, active Hepatitis B or C, cardiac disease, history of major surgery in upper gastrointestinal (GI) tract or GI disease, hypokalemia, hypomagnesaemia or hypocalcaemia that cannot be controlled)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with histologic or cytologic confirmation of unresectable locally advanced or metastatic NSCLC (stage IIIB with pleural effusion only / stage IV) documented before first line therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Prior treatment with a platinum-containing regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Age ≥18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Performance status of 0-1 on the WHO scale.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Life expectancy of ≥3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* NSCLC patients should have at least one measurable lesion as defined by modified RECIST criteria. If the patient has had previous radiation to the marker lesion(s), the lesion must have demonstrated progression since the radiation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* NSCLC patients with controlled brain metastases are eligible to be enrolled in the brain metastases cohort at the MTD. \"Controlled brain metastases\" patients are defined as patients who are neurologically stable, i.e. have not experienced an increase in dose of steroidal or anticonvulsive therapy for at least 14 days prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with brain metastases must be verified to have metastases secondary to NSCLC based on histology of primary and by temporal sequence of events (note: these patients are eligible even if lung disease is quiescent).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with brain metastases must show evidence of residual disease or progression of disease since prior radiological or surgical therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with brain metastases should have at least one bidimensionally measurable intracranial lesion of minimum diameter 2 cm. Multifocal disease is permitted, but the eligibility of BM patients presenting with more than 6 intracranial lesions should be discussed with Novartis prior to enrolling the patient.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with adequate hematologic parameters:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* ANC ≥1.5 x 10\\^9/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Hb ≥9.0 g/dL,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Platelet count ≥100 x 10\\^9/L (untransfused).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Demonstrate the following blood chemistry laboratory values:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* total bilirubin ≤ 1.5 x ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* AST/ALT ≤ 2.5 X ULN; (≤ 5 x ULN if hepatic metastasis is present)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* alkaline phosphatase ≤ 2.5 x ULN; (≤ 5 x ULN if hepatic and/or bone metastasis are present)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* serum creatinine \\< 2 x ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* All patients of reproductive potential must agree to use an effective method of contraception during the study and three months following termination of treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* All patients must use a barrier method for contraception for sexual intercourse or avoid this for the first 5 days after patupilone infusion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Written informed consent must be obtained.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients who have received more than one prior chemotherapy regimen or any other systemic antineoplastic treatment including immunotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients who have received any investigational compound within the past 28 days or who are planning to receive other investigational drugs while participating in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with brain metastases who have received any prior chemotherapy regimen or any other systemic antineoplastic treatment for brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with brain metastases who have experienced a dose increase of 25% or more above previous dose, in concomitant steroidal or anticonvulsive therapy within 14 days prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with brain metastases receiving steroidal or anticonvulsive therapy for whom a dose increase has been required within 14 days prior to start of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with brain metastases who have leptomeningeal disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with brain metastases who have extracranial metastases in more than two organs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with any peripheral polyneuropathy \\> Grade 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with unresolved diarrhea \\> Grade 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients receiving hematopoietic growth factors except erythropoietin (refer Section 3.4.4).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Severe cardiac insufficiency (NYHA III or IV), with uncontrolled and/or unstable cardiac or coronary artery disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients taking warfarin or other agents containing warfarin, with the exception of low dose warfarin (1 mg or less daily) administered prophylactically for maintenance of in-dwelling lines or ports.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients who have not recovered fully from surgery for any cause, including brain metastases patients who have had a biopsy or surgical resection of the brain tumor within 2 weeks prior to starting study drug or who are not fully recovered from any prior biopsy or surgical resection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients who have received radiation therapy or chemotherapy within the last four weeks. Palliative radiotherapy of metastasis in extremities is allowed but such lesions cannot be used as tumor markers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients with the presence of active or suspected acute or chronic uncontrolled infection, including abscess or fistulae.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Patients known to be HIV positive.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* History of another malignancy within 3 years prior to study entry, except curatively treated non-melanotic skin cancer or cervical cancer in situ.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* For patients enrolling in the brain metastases cohort, any of the following exclusions to MRI imaging:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "Cardiac pacemaker Ferromagnetic metal implants other than those approved as safe for use in MRI scanners Claustrophobia Obesity (exceeding the limits of scanning equipment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* Pregnant or lactating females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "* A history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00171834",
    "statement": "Other protocol-dependent inclusion / exclusion criteria may apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* Histologically or cytologically confirmed diagnosis of SCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* First recurrence of SCLC after therapy with one prior chemotherapy regimen at initial diagnosis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* Relapsed SCLC of any duration (both sensitive and resistant relapse).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* ECOG performance status of \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "150/100.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* Prior h/o hypertensive crisis or encephalopathy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* NYHA Grade II or greater congestive heart failure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* H/O myocardial infarction within 6 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* H/O stroke or TIA within 6 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* H/O thrombotic or hemorrhagic disorders.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* Clinically significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* Anticipation of need for major surgical procedure during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* Minor surgical procedures within 7 days prior to treatment start (placement of vascular access devices is permitted).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* H/O abdominal fistula, GI perforation, or intra-abdominal abscess within prior 6 months. Serious, non-healing wound, active ulcer, or untreated bone fracture. - H/O hemoptysis within prior 1 month.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* Concurrent radiotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* H/O whole lung radiation within 90 days prior to start of treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* Presence or h/o central nervous system or brain metastases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* H/o another malignancy other than SCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "* Concurrent chemotherapy, immunotherapy, or investigational therapy for the treatment of small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00698516",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454934",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454934",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01720524",
    "statement": "* Neonates with persistent pulmonary hypertension of the newborn",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01720524",
    "statement": "* Age \\<=96 hours and \\>=34 weeks gestational age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01720524",
    "statement": "* Oxygenation Index \\>15 and \\<60",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01720524",
    "statement": "* Concurrent treatment with inhaled nitric oxide and \\>=50% oxygen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01720524",
    "statement": "* Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01720524",
    "statement": "* Expected duration of mechanical ventilation \\<48 hours",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01720524",
    "statement": "* Profound hypoxemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01720524",
    "statement": "* Life-threatening or lethal congenital anomaly",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": ". Males and female subjects aged ≤ 18 years to ≤ 80 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "2. Signed informed consent must be obtained before initiation of any study-specific procedures or treatment as confirmation of the subject's awareness and willingness to comply with the study requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "3. Subjects should have newly diagnosed or recurrent Stage IIIB/IV (defined by seventh edition of the Tumor, Node and Metastasis (TNM) classification for Lung Cancer, 2010) non-squamous NSCLC not amenable to curative intent surgery, and not have received any systemic therapy for advanced disease (",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "). For subjects with recurrent disease, at least 6 months must have elapsed before randomization from previous adjuvant treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "4. Previous radiation therapy if completed \\>4 weeks before randomization. Palliative radiotherapy to bone lesions is allowed if completed \\>2 weeks of randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "5. Subjects must have at least 1 unidimensional measurable lesion per RECIST version 1.1 (assessed locally).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "6. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤1 at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "7. Subjects must have adequate hepatic, renal and hematologic function defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "* Hepatic function: bilirubin level \\<1.5 the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels\\<2.5×ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "* Renal function: serum creatinine level \\<1.5×ULN, calculated creatinine clearance (CrCl) \\>50 mL/min (Cockcroft-Gault formula), urine protein to creatinine ratio \\<1. Subjects with urine protein-to-creatinine ratio \\>1 may be enrolled if they have \\<1 g of protein in 24-hour urine collection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "* Hematological function: Absolute neutrophil count \\>1.5×109 /L; platelets \\>100×109 /L, hemoglobin (Hb) \\>9 g/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "* Adequate coagulation parameters such as: INR ≤ 2.0 and aPTT ≤ 1.5 x ULN within 7 days prior to randomization for patients not receiving anticoagulation therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "8. Eligible subjects must have a systolic blood pressure of ≤ 140 mm Hg and a diastolic blood pressure of ≤90 mm Hg at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "9. Women of childbearing potential, and their partners, must agree to adhere to pregnancy prevention methods throughout the duration of the study (including the Follow-up visits, where applicable). Women of childbearing potential are defined as those who are not surgically sterile (did not underwent bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) and not postmenopausal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "Subjects and their partners must agree to use a highly effective method of contraception, to avoid women becoming pregnant throughout the course of the study. Medically acceptable forms of birth control can include the following, with approval of the treating physician:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "* Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "  10. Non fertile women can be included, that is, those who are physiologically incapable of becoming pregnant, because of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "* Hysterectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "* Bilateral oophorectomy (ovariectomy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "* Bilateral tubal ligation or,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "* Postmenopausal women defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "Subjects not using hormone replacement therapy (HRT) and have experienced total cessation of menses for ≥ 1 year and be greater than 45 years of age, OR, in questionable cases, have a follicle stimulating hormone \\>40 mIU/mL and an estradiol value \\<40 pg/mL (\\<140 pmol/L).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "Subjects must discontinue HRT before study enrolment because of the potential for inhibition of cytochrome enzymes that metabolize estrogens and progestins. For most forms of HRT, at least 2 to 4 weeks must elapse between the cessation of HRT and determination of menopausal status; the length of this interval depends on the type and dosage of HRT.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "If a female subject is determined not to be postmenopausal, that subject must use adequate contraception, as defined immediately above (inclusion 8).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "1. Inability to comply with protocol procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "2. Participation in another clinical trial or treatment with another investigational agent within 4 weeks or 5 half-lives of investigational agent before randomization, whichever is longer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "3. Subjects previously treated with monoclonal antibodies or small molecule inhibitors against Vascular Endothelial Growth Factor (VEGF) or VEGF receptors, including Avastin®.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "4. Subjects who have received previous chemotherapy, immunotherapy, targeted therapy, or biological therapy for their lung cancer. Note: Adjuvant and neo- adjuvant therapy are permitted (see: inclusion criterion 3).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "5. Subjects who have known central nervous system disease, with the exception of subjects with treated brain metastases who have completed treatment (radiation, surgery or stereotactic surgery) and have not received steroids for at least 4 weeks before randomization. Subjects with central nervous system metastases treated by neurosurgical resection or brain biopsy performed within 8 weeks before randomization will be excluded. Subjects with known or history of brain metastases must undergo brain imaging during screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "6. Current or recent (within 10 days of the first dose of study treatment) use of aspirin (at least 325 mg/day) or other nonsteroidal anti-inflammatory drugs with antiplatelet activity or treatment with dipyridamole (Persantine®), ticlopidine (Ticlid®), clopidogrel (Plavix®), or cilostazol (Pletal®).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "7. Current or recent (within 5 days) use of therapeutic anticoagulation or use of thrombolytic agent. Prophylactic use of low molecular weight heparin is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "8. Subjects with an INR \\>2, unless receiving active anticoagulation treatment, will be excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "9. Subjects who have a diagnosis of small cell carcinoma of the lung or squamous cell carcinoma of the lung. Mixed tumors should be categorized according to the predominant histology. If small cell elements are present, the subject will be excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "10. Subjects with known tumors that harbor activating epidermal growth factor receptor and anaplastic lymphoma receptor tyrosine kinase (assessed locally).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "11. Subjects who have a history of hypersensitivity to the active substance (bevacizumab, carboplatin, and/or paclitaxel) or any of the excipients (such as trehalose dehydrate, sodium phosphate, or polysorbate 20).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "12. Subjects with known active viral infection, including but not limited to: hepatitis B, hepatitis C, or HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "13. Subjects who are pregnant or breastfeeding. Women of child-bearing potential must have a negative pregnancy test at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "14. Subjects with previous major surgery, open biopsy, open pleurodesis, or significant traumatic injury within 4 weeks before randomization or those anticipated to require major surgery during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "15. Subjects who have had a core biopsy taken or have had another minor surgical procedure, excluding placement of vascular access device, closed pleurodesis, thoracentesis, and mediastinoscopy, within 1 week of randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "16. Subjects with a history of abdominal fistula, GI perforation, intra-abdominal abscess within 6 months of randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "17. Subjects with a nonhealing wound, active ulcer, or untreated bone fracture.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "18. Subjects with previous history of hypertensive crisis or hypertensive encephalopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "19. Subjects with New York Heart Association Grade II or greater congestive heart failure, or angina, myocardial infarction within 6 months before randomization; symptomatic arrhythmia or serious cardiac arrhythmia requiring medication; abnormal left ventricular ejection fraction \\< 50% assessed by ultrasound or multigated acquisition scan.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "20. Subjects with a previous malignancy within 3 years of randomization (other than superficial basal cell and superficial squamous (skin) cell carcinoma, or carcinoma in situ of the uterine cervix, bladder, or prostate).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "21. Subjects with history of a significant vascular event within 6 months before randomization (including, but not limited to myocardial infarction and stroke or transient ischemic attack).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "22. Subjects with known bleeding diathesis or significant coagulopathy defined as a bleeding event grade ≥ 2 within 3 months before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "23. Subjects with history of grade ≥2 hemoptysis within 6 months before randomization (≥0.5 teaspoons of bright red blood per event).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03296163",
    "statement": "24. Subjects with a tumor(s) invading or compressing major blood vessels.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Histologically or cytologically confirmed lung cancer (Stage IIIb/IV nonsmall-cell lung cancer or extensive stage small-cell lung cancer \\[SCLC\\])",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Measurable tumor lesion (as long as it is not located in a previously irradiated area) as defined by modified World Health Organization criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Eastern Cooperative Oncology Group performance status of ≤1 at study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Accessible for treatment and follow-up",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Malignant pleural effusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Motor neuropathy of autoimmune origin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* SCLC-related paraneoplastic syndromes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Any concurrent malignancy other than nonmelanoma skin cancer; carcinoma in situ of the cervix or breast; or prostate cancer treated with systemic therapy (participants with a previous malignancy but without evidence of disease for 5 years were allowed to enter the study)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Prior systemic therapy for lung cancer. Prior radiation therapy or locoregional surgeries performed later than at least 3 weeks prior to randomization date were allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Grade 2 peripheral neuropathy (motor or sensory)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Known HIV or hepatitis B or C infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or noncancer-related illnesses). However, use of corticosteroids was allowed if used as premedication for paclitaxel infusion or for treating immune-related adverse events or adrenal insufficiencies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Inadequate hematologic function defined by an absolute neutrophil count \\<1,500/mm\\^3, a platelet count \\<100,000/mm\\^3, or hemoglobin level \\<9 g/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Inadequate hepatic function defined by a total bilirubin level \\>2.0 times the upper limit of normal (ULN), or ≥2.5 times the ULN if liver metastases are present, aspartate aminotransferase and alanine aminotransferase levels ≥2.5 times the ULN or ≥5 times the ULN if liver metastases are present.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Inadequate renal function defined by a serum creatinine level ≥2.5 times the ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "* Inadequate creatinine clearance defined as less than 50 mL/min.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* The subject has a confirmed and established diagnosis of COPD, as defined by the Global Initiative for Chronic Obstructive lung Disease (GOLD) guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Male or female of non-child bearing potential between 40 and 75 years of age inclusive, at the time of signing the informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* The subject has a post-bronchodilator \\[400 microgram (mcg) salbutamol\\] Maximal amount of air FEV1/FVC \\<0.7 and FEV1 \\>=40% to \\<=80% of predicted (Predictions should be according to the European Community of Coal and Steel (ECCS) equations).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Subject is a smoker or an ex-smoker with a smoking history of at least 10 pack years (pack years = (cigarettes per day smoked/20) x number of years smoked)).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* The subject is able to produce \\>100 milligram (mg) of sputum at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Body weight \\>=45 kilogram (kg) and body mass index (BMI) within the range 17 - 32 kg/square meter (m\\^2) (inclusive).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy, salpingo-oophrectomy or oophrectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \\[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \\> 40 milli-International units (MIU)/millilitre (mL) and estradiol \\< 40 picogram (pg)/mL (\\<147 picomole(pmol)/Liter \\[L\\]) is confirmatory\\]. \\[Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods, if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.\\]; or has only same-sex partners, when this is her preferred and usual lifestyle.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods. This criterion must be followed from the time of the first dose of study medication until the follow-up visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Based on averaged QTcF values of triplicate ECGs obtained over a brief recording period (e.g. 5 minutes): QTcF \\<450 millisecond (msec); or QTcF\\<480 msec in subjects with right bundle branch block.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": ", outside the reference range for the population being studied may be included if the investigator \\[in consultation with the Glaxosmithkline (GSK) medical monitor if required\\] documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones and cholecystectomy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Subjects who have a past or current medical condition or diseases that are not well controlled and, which as judged by the Investigator, may affect subject safety or influence the outcome of the study. (Note: Patients with adequately treated and well controlled concurrent medical conditions (e.g. hypertension) are permitted to be entered into the study).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Subject has a diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis, pulmonary fibrosis, asthma or any other respiratory condition that might, in the opinion of the Investigator, compromise the safety of the subject or affect the interpretation of the results.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of \\>28 units for males or \\>21 units for females. One unit is equivalent to 8 gram of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* History of sensitivity to any of the study medications, or components (such as lactose) thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* A positive test for Human immunodeficiency virus (HIV) antibody - tested according to local policies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include cannabinoids, amphetamines, barbiturates, cocaine and opiates. The detection of drugs (e.g. benzodiazepines, opiates) taken for a legitimate medical purpose would not necessarily be an exclusion to study participation. The detection of alcohol would not be an exclusion at screening but would need to be negative pre-dose and during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* A positive pre-study Hepatitis B surface antigen (HBs-Ag) or positive total hepatitis B core antibody (anti-HBc IgM) or positive Hepatitis C antibody result within 3 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Pregnant females as determined by positive urine human chorionic gonadotropin (hCG) test at screening or prior to dosing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Lactating females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Exposure to more than four new chemical entities within 12 months prior to the first dosing day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Subject has poorly controlled or unstable COPD, defined as the occurrence of any of the following: Either: acute worsening of COPD (an exacerbation) that is managed by the subject at home requiring treatment with corticosteroids and/or antibiotics in the 4 weeks prior to the screening visit; or more than two exacerbations in the previous 2 months prior to the screening visit that required a course of oral corticosteroids and/or antibiotics, or for which the subject was hospitalised.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Subject has had a respiratory tract infection treated with antibiotics in the 4 weeks prior to first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Subject requires regular treatment with oral corticosteroids or has received oral or parenteral corticosteroids within 4 weeks of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* Vulnerable subject (e.g., person kept in detention).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130635",
    "statement": "* The subject is not able to understand and communicate in German or native language.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00085839",
    "statement": "* Stage IIIB or IV Nonsmall cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00085839",
    "statement": "* No prior chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00085839",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00085839",
    "statement": "* Clinically or radiologically measurable disease per RECIST criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00085839",
    "statement": "* Gastro-intestinal abnormalities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00085839",
    "statement": "* Any concurrent anticancer therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00085839",
    "statement": "* Prior treatment with epidermal growth factor receptor (EGFR) inhibitors of any kind",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00085839",
    "statement": "* Other active malignancies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00085839",
    "statement": "* Uncontrolled brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00085839",
    "statement": "* Severe abnormalities of the cornea",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00085839",
    "statement": "* Significant cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You must sign an informed consent document for clinical research.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You must have Stage IIIB or Stage IV nonsquamous non-small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You must not have received any prior treatment for your disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* Prior radiation therapy is allowed to \\< 25% of the bone marrow; however, prior radiation to the whole pelvis is not allowed. If you have had radiation therapy to the chest, you are not eligible to participate.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You must be at least 18 years of age or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You must have measureable tumor lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) or disease can be evaluated on computed tomography (CT) scan.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* Your test results assessing the function of blood forming tissue, kidneys and liver must be satisfactory.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* Women must be sterile, postmenopausal or on contraception and men must be sterile (for example post-vasectomy) or on contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have clinically significant third-space fluid collections (e.g. ascites or pleural effusions that cannot be controlled by drainage or other procedures).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have Non-small Cell Lung Carcinoma (NSCLC) of predominantly squamous cell histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have known central nervous system (CNS) disease, other than stable, treated brain metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have undergone a surgical procedure, open biopsy, open pleurodesis, or significant traumatic injury within 28 days of starting the study treatment, or have an anticipated need for major surgery during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have a history of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You are currently receiving ongoing treatment with full-dose warfarin or equivalent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have significant vascular disease, serious cardiac conditions (such as heart attack), stroke or transient ischemic attack within 6 months of the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have inadequately controlled hypertension, or a history of hypertensive crisis or hypertensive encephalopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have a serious, nonhealing wound, active ulcer, or untreated bone fracture.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have another form of cancer, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within the last 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have received an investigational treatment within 30 days prior to the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have previously received treatment with paclitaxel, carboplatin, pemetrexed, or bevacizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot be pregnant or breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have a known sensitivity to any component of paclitaxel, carboplatin, pemetrexed, or bevacizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You cannot have a history of hemoptysis (coughing blood) within 3 months prior to the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You are unable to stop taking aspirin more than 1.3 grams per day or other nonsteroidal anti-inflammatory drugs (NSAIDs).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You are unable or unwilling to take folic acid or vitamin B12 supplementation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You are unable to take corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00762034",
    "statement": "* You have any other on-going illnesses including active infections that may not allow you to adhere to the requirements of the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "Phase II part:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have had disease progression following their last prior therapy and fit into one of the following groups:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Group 1: NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Group 2: Melanoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Group 3: Renal cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Group 4: Mesothelioma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Group 5: TNBC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* History of severe hypersensitivity reactions to study treatment ingredients or other mAbs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Active, known or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Active infection requiring systemic antibiotic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* HIV infection. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Patients receiving chronic treatment with systemic steroid therapy, other than replacement-dose corticosteroids in the setting of adrenal insufficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Patients receiving systemic treatment with any immunosuppressive medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Use of live vaccines against infectious disease within 4 weeks of initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02460224",
    "statement": "* History of drug-induced pneumonitis or current pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Subjects with histopathologically confirmed diagnosis of advanced breast, gastric, head and neck, liver and non-small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* For subjects with non-small cell lung cancer only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Most recent treatment must be erlotinib and subjects must have had a radiographic partial or complete response to treatment as defined by RECIST criteria and should be currently progressing after the documented response.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* A documented mutation in EGFR exons 19 or 21",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Subjects must have no further standard of care options or have refused standard therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Measurable or evaluable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Age ≥ 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* ECOG performance \\< 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Life expectancy ≥ 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* If female, neither pregnant or lactating",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* If of child bearing potential, must use adequate birth control",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Absolute neutrophil count ≥ 1,500/µL; platelets ≥ 100,000/µL;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Creatinine ≤ 1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60mL/min/1.73m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN. In subjects with documented liver metastases, the AST/ALT may be ≤ 5x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Prothrombin time ≤1.5x ULN, unless receiving therapeutic anticoagulation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Serum magnesium and potassium within normal limits (may use supplements to achieve normal values)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Subjects with brain metastases are eligible if controlled on a stable dose ≤ 10mg prednisone/day or its equivalent dose of steroids",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Able to render informed consent and to follow protocol requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Anticancer therapy within 4 weeks of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Use of investigational agent(s) within 30 days of study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* History of cardiac disease with a New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF), myocardial infarction (MI) or unstable angina in the past 6 months prior to Day 1 of treatment, serious arrhythmias requiring medication for treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01171924",
    "statement": "* Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Subjects with liver cancer and hepatitis may be eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has a histologically-confirmed or cytologically-confirmed diagnosis of stage IV (M1a, M1b, or M1c \\[AJCC 8th edition\\]) nonsquamous NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Have confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), c-ros oncogene 1 (ROS1), or B isoform of rapidly accelerated fibrosarcoma (BRAF) directed therapy is not indicated as primary therapy. Documentation of the absence of tumor activating EGFR mutations, BRAF mutations, ALK gene rearrangements, and ROS1 gene rearrangements is required.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has not received prior systemic treatment for their advanced/metastatic NSCLC. Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Have provided sufficient evaluable Stage IV, archival, solid tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion (that was not previously irradiated) for biomarker analysis (Fine Needle Aspiration \\[FNA\\] samples will not be accepted). Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 10 days prior to the first dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* A male participant must agree to use contraception through the end of treatment and for at least 120 days, and refrain from donating sperm during this period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and if participant is a woman of childbearing potential (WOCBP), agrees to follow the contraceptive guidance as provided in the protocol through the end of treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has provided blood for cell-free ctDNA analysis that has been received and determined to be of sufficient quality and quantity by the designated laboratory for the primary endpoint.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has predominantly squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has small cell elements present in NSCLC tumor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment allocation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, peritoneal carcinomatosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has a known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 2 years since initiation of that therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has received prior therapy with a multiple programmed cell death 1 (PD-1)/ (PD-1) receptor/programmed cell death ligand 1 (PD-L1) receptor inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Is expected to require any other form of antineoplastic therapy while on study (including maintenance therapy with another agent for NSCLC, radiation therapy, and/or surgical resection).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has received a live vaccine within 30 days prior to treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients or to another monoclonal antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has a known sensitivity to any component of cisplatin, carboplatin or pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Is on chronic systemic steroids. Participants with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Is unable or unwilling to take folic acid or vitamin B12 supplementation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has an active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV ribonucleic acid (RNA) \\[qualitative\\] is detected) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has a known psychiatric or substance abuse disorder that would interfere with cooperating with the requirements of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03664024",
    "statement": "* Has had an allogenic tissue/solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Histologically or cytologically confirmed, Stage IV non-squamous NSCLC. Participants with tumors of mixed non-small cell histology (i.e., squamous and non-squamous) are eligible if the major histological component appears to be non-squamous",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* No prior treatment for Stage IV non-squamous NSCLC. Participants with a sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or with an anaplastic lymphoma kinase (ALK) fusion oncogene are excluded. Participants with unknown EGFR and ALK status require test results at screening from a local or central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Participants who have received prior neo-adjuvant, radiotherapy, adjuvant chemotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from randomization since the last dose of chemotherapy and/or radiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Participants should submit a pre-treatment tumor tissue sample if available before or within 4 weeks after enrollment. If tumor tissue is not available, participants are still eligible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* For participants enrolled in the extended China enrollment phase: current resident of mainland China, Hong Kong, or Taiwan and of Chinese ancestry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Measurable disease, as defined by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Adequate hematologic and end organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* For women of childbearing potential: agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than (\\<) 1 percent (%) per year during the treatment period and for at least 5 months after the last dose of atezolizumab or 6 months after the last dose of cisplatin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "-Specific Exclusions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Participants with a sensitizing mutation in the EGFR gene or an ALK fusion oncogene",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for greater than or equal to (\\>= 2) weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Uncontrolled tumor-related pain",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Uncontrolled or symptomatic hypercalcemia (greater than \\[\\>\\] 1.5 millimole/Liter ionized calcium or calcium \\>12 milligrams/deciliter or corrected serum calcium \\>upper limit of normal)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Malignancies other than NSCLC within 5 years prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Known tumor programmed death-ligand 1 (PD-L1) expression status from other clinical studies (e.g., participants whose PD-L1 expression status was determined during screening for entry into a study with anti-PD-1 or anti-PD L1 antibodies but were not eligible are excluded)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "General Medical Exclusions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* History of certain autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* All participants will be tested for human immunodeficiency virus (HIV) prior to the inclusion into the study and HIV-positive participants will be excluded from the clinical study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Severe infections within 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Illness or condition that may interfere with a participant's capacity to understand, follow, and/or comply with study procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "Exclusion Criteria Related to Medications and Chemotherapy:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Prior treatment with EGFR inhibitors or ALK inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Any approved anti-cancer therapy, including hormonal therapy within 21 days prior to initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-PD-1, and anti-PD-L1 therapeutic antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Treatment with systemic immunostimulatory agents within 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Treatment with systemic immunosuppressive medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "Exclusion Criteria Related to Chemotherapy:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* History of allergic reactions to cisplatin, carboplatin, or other platinum-containing compounds",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Participants with hearing impairment (cisplatin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Grade \\>=2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria (cisplatin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02657434",
    "statement": "* Creatinine clearance (CRCL) \\<60 milliliters/minute (mL/min) for cisplatin or \\<45 mL/min for carboplatin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Histologically documented unresectable stage III NSCLC. Mediastinal (N2) involvement must be confirmed by biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Stable disease or clinical response after primary therapy of chemo-radiation treatment for unresectable stage III disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Primary therapy should be a minimum of 2 cycles of Platinum-based first-line chemotherapy, given concurrent with thoracic radiation. The combined modality should consist of either:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* induction (2 cycles) chemotherapy followed by concurrent chemo-radiation therapy; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* concurrent chemo-radiation therapy followed by 2 cycles of consolidation chemotherapy; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* concurrent chemoradiation therapy alone",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* A minimum radiation dose of greater than or equal to (\\>=) 6,000 centigray (cGy) should be administered. Subjects must have completed the primary therapy at least 4 weeks and no later than 6 months prior to study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (\\<=) 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Ability to understand and willingness to sign a written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Other protocol defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Undergone lung cancer specific therapy (including surgery) prior to primary chemo-radiation therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Received immunotherapy/systemic immunosuppressive drugs/investigational systemic drugs within 4 weeks prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Subjects with brain metastases, pleural effusion, unless cytologically confirmed to be non-malignant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Autoimmune disease or immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Clinically significant hepatic, renal dysfunction or cardiac diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Clinically significant active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Pregnant or lactating, women of childbearing potential, unless using effective contraception as determined by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157196",
    "statement": "* Other protocol defined inclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": ". Age ≥ 20 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "2. Diagnosed stage III/IV NSCLC. The grading is determined according to the Tumor-Node-Metastasis (TNM) staging system for lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "3. Patients with histologically or cytologically proven primary NSCLC with adenocarcinoma or mixed cell type with adenocarcinoma, who have failed on standard treatments.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "4. With progressive tumor after two lines of chemotherapy (including one platinum-based) and 1 EGFR-targeted therapy if patient is identified with EGFR mutation or his/her EGFR mutation status is unknown OR having refused further currently approved treatment modalities.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "5. Life expectancy ≥ 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "6. Within 1 week of planned first study treatment day, adequate hematopoietic functions are presented: Total white blood cell (WBC) ≥ 3500 cells/mm3 Hemoglobin (Hb) ≥ 9.0 g/dL Platelets ≥ 100,000 cells/mm3 Absolute neutrophil count (ANC) ≥ 1500 /mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "7. Within 1 week of planned first study treatment day, adequate hepatic and renal functions are presented: Total bilirubin ≤2.0 mg/dLGOLANTA20090911, Amendment 4/v. 1.0/ 13 October 2010 AST ≤ 3 × upper limit of normal (ULN); patients with liver metastasis: AST ≤ 5 × ULN ALT ≤ 3 × ULN; patients with liver metastasis: ALT ≤ 5 × ULN Creatinine ≤ 1.5 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "8. Must have recovered from toxicities of previous anti-cancer treatments to grade 1 NCI-CTC or better, except for alopecia.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "9. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "10. Female patient with childbearing potential confirmed of not being pregnant at the screening; and informed that effective contraception must be used during the entire treatment period of this study and for 6 months after exiting from the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "11. Given signed and dated written informed consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": ". Primary major surgery \\< 4 weeks prior to the planned first study treatment day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "2. Lactating, pregnant or plans to be become pregnant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "3. Except for alopecia, recovered from any previous treatments to a grade 1 or less prior to the planned first study treatment day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "4. With active systemic infections, active and clinically significant cardiac diseases, active gastrointestinal ulcers, or medical conditions that may significantly affect adequate absorption of investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "5. Within 5 years, prior history of malignancy other than NSCLC, except cervical carcinoma in situ and basal or squamous cell skin carcinoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "6. Known allergic to antroquinonol or its formulation excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "7. Within 14 days of planned first study treatment day, exposed to any drug(s) known to be significant CYP2C19, 3A4, 2C8, and 2E1, inhibitor or activator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01134016",
    "statement": "8. With conditions judged by the investigator as unsuitable for the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00113516",
    "statement": "* Histologically proven NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00113516",
    "statement": "* Stage IIIB (locally advanced with malignant effusion) or Stage IV disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00113516",
    "statement": "* No prior therapy for NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00113516",
    "statement": "* Evidence of unidimensionally measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00113516",
    "statement": "* Previous treatment with systemic chemotherapy for lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00113516",
    "statement": "* History of or known brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00113516",
    "statement": "* NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00113516",
    "statement": "* Evidence of hemoptysis within 4 weeks of starting study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00113516",
    "statement": "* Serious acute or chronic illness or recent history of significant cardiac abnormality",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00113516",
    "statement": "* Previous treatment with anti-angiogenesis agents including thalidomide, or inhibitors of EGFR and PDGFR",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "(Part 1 and 2):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "1. Have histologically confirmed metastatic pancreatic adenocarcinoma. Recurrent unresectable pancreatic cancer is acceptable as long as the treatment is first-line.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "2. Have not received any approved chemotherapy, except in the adjuvant setting.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "3. Life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "4. Male subjects must agree to use contraception as per protocol during the treatment period and for at least 90 days after the last study treatment administration and refrain from donating sperm during this period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "5. Provision of an archival tumor sample (within 5 years). If an archival sample is unavailable, a fresh biopsy can be obtained during Screening. If archival tissue or biopsy sample is unavailable, the subject is ineligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "Inclusion Criteria (Part 3 Prostate Cancer):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "1. Metastatic, castrate resistance, histologically confirmed prostate cancer; continuous medical castration for ≥8 weeks prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "2. Effective castration with serum testosterone levels \\<0.5 ng/mL (50 ng/dL; 1.7 nmol/L).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "3. Have serum GDF15 levels ≥1300 pg/mL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "4. Have experienced PSA progression under 1 or more lines of ADT in the absence or presence of radiographic and/or clinical progression, who decline or are not eligible to receive chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "5. Have had PSA doubling time of \\>3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "(All parts):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "1. Subject was using immunosuppressive medications within 14 days before Screening with the exception of topical (intranasal, inhaled, and local injection), systemic (prednisone equivalent 10 mg/day or less), or as needed for hypersensitivity reactions such as computed tomography (CT) scan premedication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "2. Subject has active infections or other serious underlying significant medical illness, abnormal and clinically significant laboratory findings or psychiatric illness/social situation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "3. Subject is using a pacemaker, implantable cardiac defibrillator, neurostimulator, cochlear implants, cochlear implants, or other electronic medical equipment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "4. Subject has documented immunodeficiency or organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "5. Subject has an untreated central nervous system disease, leptomeningeal disease or cord compression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "6. Subject has a history, or presence, of significant cardiovascular diseases; including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months before randomization, congestive heart failure \\> New York Heart Association Class II, severe peripheral vascular disease, corrected QT (QTc) prolongation \\>470 msec, clinically significant pericardial effusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "7. Subject has a history or presence of documented inflammatory bowel disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068896",
    "statement": "8. Subject is known to be positive for human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Non-Small Cell Lung Cancer (NSCLC), Stage IV (per the American Joint Committee on Cancer (AJCC) Staging Manual, Seventh Edition) or recurrent disease following surgery and/or radiation therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Evaluable or measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Uncontrolled Central Nervous System (CNS) metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Previous exposure to monoclonal antibodies, signal transduction inhibitors or Epidermal growth factor receptor (EGFR) targeting therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Concurrent malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Prior chemotherapy for NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Pre-existing ascites grade ≥ 2 or pericardial effusion grade ≥ 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Superior vena cava syndrome contra-indicating hydration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* White Blood Cells (WBC) \\< 3,000/mm³",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Absolute neutrophile count (ANC) \\< 1,500/mm³",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Platelet \\< 100,000/mm³",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Hemoglobin (Hgb) \\< 9.0 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Total bilirubin \\> 1.5 x Upper limit of normal (ULN).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Aspartate aminotransferase (AST) or Alanine-aminotransferase (ALT) \\> 5.0 x ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01109524",
    "statement": "* Serum creatinine \\>1.25 x ULN and calculated creatinine clearance \\<60mL/min",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01017874",
    "statement": "* Histological diagnosis of NSCLC with locally advanced or metastatic disease that is of non-squamous histology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01017874",
    "statement": "* Participants must be \"light ex-smokers\" or \"never-smokers\".",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01017874",
    "statement": "* \"Light ex-smokers\" defined as having ceased smoking for greater than or equal to 5 years and not to have exceeded 10 pack-years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01017874",
    "statement": "* \"Never-smokers\" are defined as having smoked \\<100 cigarettes or equivalent during his/her lifetime.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01017874",
    "statement": "* Participants must be of East Asian ethnicity.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01017874",
    "statement": "* No prior systemic therapy for lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01017874",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01017874",
    "statement": "* Presence of clinically significant (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01017874",
    "statement": "* Any evidence of clinically active interstitial lung disease. Asymptomatic participants with chronic, stable, radiographic changes are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01017874",
    "statement": "* Participants whose Epidermal Growth Factor Receptor (EGFR) mutation status is known prior to study entry will be excluded. Participants in which EGFR mutation testing has not been performed, or whose EGFR mutation status is unknown or inconclusive at study entry are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Histologically or cytologically confirmed unresectable NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Patients must have failed one prior line of CT-based therapy for unresectable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Age between 18 and 75 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Eastern Cooperative Oncology Group (ECOG)performance status (PS) ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Adequate hematological, renal, metabolic and hepatic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* At least three weeks since the last prior therapy, at least four weeks since completion of any prior radiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Negative pregnancy test for pre-menopausal women",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Concomitant diseases/conditions as unstable angina, myocardial infarction, symptomatic congestive heart failure or asymptomatic with left ventricular ejection fraction (LVEF) ≤ 50%, dyspnea, infection by human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active uncontrolled infection, pleural or pericardial effusions, myopathy, limitation of the patient's ability to comply with the treatment or to follow-up the protocol, any other major illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Histological features of neuroendocrine or bronchioalveolar differentiation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Unknown epidermal growth factor receptor (EGFR)mutation status or previously known EGFR mutated status in patients with adenocarcinoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Prior or concurrent invasive malignant disease, unless in complete remission for more than three years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Significant cancer-related weight loss (≥10%)within four weeks prior to treatment start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Prior treatment with docetaxel-containing therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Symptomatic, steroid-requiring or progressive central nervous system (CNS) involvement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01951157",
    "statement": "* Paraneoplastic syndromes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Histologically- or cytologically-confirmed diagnosis of NSCLC that is anti-programmed cell death ligand 1 (PD-L1) positive per central laboratory review",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* At least one bi-dimensional measurable lesion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Radiographic progression after treatment with at least 2 cycles of a platinum-containing doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Prior therapy with docetaxel for NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Receiving systemic steroid therapy within 3 days prior to the first dose of study treatment or receiving any other form of immunosuppressive medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Currently participating or has participated in a study using an investigational antineoplastic agent or device within 30 days of first dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Expected to require any other form of systemic or localized antineoplastic therapy while on trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* History of allogeneic tissue/solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g., cetuximab), major surgery within 3 weeks of the first dose of study drug; received thoracic radiation therapy of \\>30 Gy within 6 months of the first dose of study drug; received prior tyrosine kinase inhibitor therapy or completed palliative radiotherapy within 7 days of the first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways), or took part in another pembrolizumab trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Known history of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cervical cancer, and has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Active autoimmune disease, or a documented history of autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Known history or active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01905657",
    "statement": "* Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after last dose of pembrolizumab or 180 days after last dose of docetaxel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": ". Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with pleural effusion) adenocarcinoma or Stage IV adenocarcinoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "2. Presence of activating mutation(s) in exon 18 to exon 21 of the EGFR-receptor confirmed by direct DNA sequencing of NSCLC tumor tissue.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "3. Progressive disease following a first line cytotoxic chemotherapy regimen or have recurrent disease after prior neoadjuvant or adjuvant chemotherapy. Patients who have not received first-line cytotoxic chemotherapy can be enrolled in stage 2 of the trial, if the criteria for entering stage 2 are met.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "4. Patients with at least one tumor lesion that can accurately be measured by computed tomography (CT) or magnetic resonance imaging (MRI) in at least one dimension with longest diameter to be recorded as 20 mm using conventional techniques or 10 mm with spiral CT scan.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "5. Male or female patient aged 18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "6. Life expectancy of at least three (3) months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "7. Written informed consents that is consistent with ICH-GCP guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "8. Eastern Cooperative Oncology Group (ECOG) performance score 0, 1 or 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": ". More than one (1) prior cytotoxic chemotherapy treatment regimen for relapsed or metastatic NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "2. Chemo-, hormone- (other than Megace®) or immunotherapy within the past 4 weeks or within less than four half-lives of the previous drug prior to treatment with the trial drug and/or persistence of toxicities of prior anticancer therapies which are deemed to be clinically relevant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "3. Previous treatment with erlotinib (Tarceva®), gefitinib (Iressa®) or any other EGFR inhibiting small molecule or antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "4. Brain metastases, which are symptomatic; patients with treated, asymptomatic brain metastases are eligible with stable brain disease for at least four (4) weeks without the requirement for steroids or anti-epileptic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "5. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohns disease, malabsorption, or CTCAE Grade \\>2 diarrhea of any etiology at baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "6. Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "7. Other malignancies diagnosed within the past five (5) years (other than non-melanomatous skin cancer and in situ cervical cancer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "8. Radiotherapy within the past 2 weeks prior to treatment with the trial drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "9. Patients with any serious active infection (i.e., requiring an IV antibiotic, antifungal, or antiviral agents).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "10. Patients with known HIV, active hepatitis B or active hepatitis C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "11. Known or suspected active drug or alcohol abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "12. Women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "13. Pregnancy or breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "14. Patient unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "15. History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA) functional classification of 3.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "16. Cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "17. QTc interval greater than 0.47 second.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "18. Prior treatment with anthracyclines with a cumulative dose of doxorubicin (or equivalent) greater than 400 mg/m2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "19. Absolute neutrophil count (ANC) less than 1500/mm3.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "20. Platelet count less than 100 000 /mm3.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "21. Bilirubin greater than 1.5 mg / dl (greater than 26 micromol / L, SI unit equivalent).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "22. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "23. Serum creatinine greater than 1.5 times of the upper normal limit or calculated/measured creatinine clearance equal or less than 45 ml / min.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00525148",
    "statement": "24. Patients with known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Age ≥ 18 years (≥20 years for Japan only) at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Signed and dated written informed consent in accordance with GCP (Good Clinical Practice ) and local legislation prior to admission to the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* WHO/ECOG (World Health Organization / Eastern Cooperative Oncology Group) performance status 0-1 assessed at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Patient must be able to swallow oral capsules or tablets",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "Cohort A (Solid Tumours) \\& Cohort E (NSCLC):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Male or female patients ready and able to use highly effective methods of birth control during the study and for 3 weeks following the last dose of abemaciclib per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. Women of childbearing potential must have a negative serum pregnancy test at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "Cohort A (Solid Tumours)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Patients with histologically or cytologically confirmed diagnosis of advanced and/or metastatic, measurable or evaluable, non-resectable solid tumours",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Patients must have received and failed, or have been intolerant to, all treatment known to confer clinical benefit or have no therapeutic options available as deemed appropriate by their treating physician",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Life expectancy ≥ 3 months in the opinion of the investigator assessed at screening;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "Cohorts B, C, D (dose finding, Breast Cancer) \\& Cohort D1 and Cohort D2 (Breast Cancer):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Women who have postmenopausal status due to either surgical/natural menopause or chemical ovarian suppression (initiated at least 28 days prior to Day 1 of Cycle 1) with a gonadotropin-releasing hormone (GnRH) agonist such as goserelin or radiation-induced ovarian suppression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "*- postmenopausal status due to surgical/natural menopause requires at least one of the following conditions:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* prior bilateral oophorectomy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* age ≥ 60 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* age \\< 60 years and amenorrheic (in the absence of tamoxifen, toremifene, ovarian suppression, or chemotherapy) for at least 12 months; and follicle-stimulating hormone (FSH) and estradiol within the postmenopausal range as per institutional reference ranges.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Postmenopausal status due to radiation-induced ovarian suppression must be confirmed by FSH and estradiol level in the postmenopausal range.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Histologically or cytologically proven diagnosis of breast cancer with evidence of locally advanced disease not amenable to curative resection or metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* HR+ (local lab results at screening or, if not available, at the time of diagnosis) To fulfil the requirement of HR+ disease, the primary tumour or metastatic lesion of the breast cancer must express at least one of the hormone receptors (estrogen receptor \\[ER\\] or progesterone receptor \\[PgR\\]) by immunohistochemistry (IHC). Estrogen receptor and PgR assays are considered positive if there are at least 1% positive tumour nuclei in the sample as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* HER2 negative (local lab results at screening or, if not available, at the time of diagnosis) as defined by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "Cohorts B, C, D (dose finding), F (Breast Cancer):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Previous adjuvant and neoadjuvant chemotherapy is permitted. 0-2 prior lines of chemotherapy for the metastatic setting are allowed (except Cohorts D1, D2 and F).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* At least 1 lesion (measurable or non-measurable) that can be accurately assessed at baseline with CT or MRI or PET-CT (CT portion of diagnostic quality) and which is suitable for accurate repeated measurement.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Cohort B, C, D: Must be eligible for the corresponding hormonal therapy (letrozole, anastrozole or fulvestrant). For Cohorts B and C previous treatment with fulvestrant or exemestane is allowed. For For Cohort D, prior therapy with non steroidal aromatase inhibitors (anastrozole, letrozole) or exemestane are permitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "Cohort E (NSCLC (Non-Small Cell Lung Cancer)):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Histologically or cytologically confirmed diagnosis of stage IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* The participant must have progressed after platinum-based chemotherapy AND immunotherapy (unless deemed inappropriate candidates for immunotherapy by their treating physician) AND have received 1 or a maximum of 2 other prior chemotherapy for advanced and/or metastatic disease OR must be judged by the physician as ineligible for further standard second-line chemotherapy. Prior treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and anaplastic lymphoma kinase (ALK) inhibitors is mandatory in participants whose tumour has EGFR-activating mutations or ALK translocations. Prior targeting agents and neoadjuvant/adjuvant therapies are permitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Have adequate organ function including haematology, renal, and liver.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Have measureable disease per RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "Cohort D1, Cohort D2 and Cohort F (Breast Cancer):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Have a negative serum pregnancy test at baseline (within 14 days prior to randomization) and agree to use medically approved precautions to prevent pregnancy during the study and for 3 weeks following the last dose of abemaciclib and for at least 6 months after last dose of xentuzumab if postmenopausal status is due to ovarian suppression with a GnRH agonist.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Have either measurable disease or non-measurable bone only disease. Measurable and non-measurable diseases are defined according to the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1 \\[v1.1\\]. Non-measurable bone only disease may include any of the following: blastic bone lesions, lytic bone lesions without a measurable soft tissue component, or mixed lytic-blastic bone lesions without a measurable soft tissue component.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "Cohort D1 and D2 only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Patients must fulfil 1 of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "*- Relapsed with radiologic evidence of progression while receiving neoadjuvant or adjuvant endocrine therapy, with no subsequent endocrine therapy received following progression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Relapsed with radiologic evidence of progression within 1 year from completion of adjuvant endocrine therapy, with no subsequent endocrine therapy received following progression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Relapsed with radiologic evidence of progression more than 1 year from completion of adjuvant endocrine therapy and then subsequently relapsed with radiologic evidence of progression after receiving treatment with either an anti-estrogen or an aromatase inhibitor as first-line endocrine therapy for metastatic disease. Patients may not have received more than 1 line of endocrine therapy or any prior chemotherapy for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Presented de novo with metastatic disease and then relapsed with radiologic evidence of progression after receiving treatment with either an anti-estrogen or an aromatase inhibitor as first-line endocrine therapy for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "Patients may not have received more than 1 line of endocrine therapy or any prior chemotherapy for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* For cohort D1 (visceral disease) patient must have at least one documented visceral metastasis; for cohort D2 (non-visceral disease), patient must not have any visceral metastasis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "Cohort F only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Patients with resistance to prior therapy with an aromatase inhibitor (AI) and CDK4/6 inhibitor (excluding abemaciclib) for locally advanced or metastatic breast cancer, defined as radiologic evidence of disease progression while on, or within 30 days after last dose of AI and/or CDK4/6 inhibitor (excl. abemaciclib) administered as first-line therapy for locally advanced or metastatic disease. Patients may not have received more than 1 line of prior endocrine based therapy or any prior chemotherapy for advanced/metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Patient must not have any visceral metastasis (example of allowed lesions are in breast, lymph nodes, soft tissue, bone).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "- Cohorts A, B, C, D (dose finding), E and F \\& Cohort D1 and Cohort D2 (Breast Cancer):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Previous treatment in this trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Currently enrolled in another investigational device or drug study, or less than 21 days since ending another investigational device or drug study(s), or receiving other investigational treatment(s).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable study subject or unlikely to complete the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Prior anti-cancer chemotherapy, biological or radiation therapy, androgens, thalidomide, other anticancer agents, or any investigational drug within 21 days (14 days for non-myelosuppressive agents); and/or 4 weeks for immunotherapy, before starting any of the trial drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Prior radiotherapy to ≥ 25% of bone marrow regardless of when it was received",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Unresolved treatment related toxicity from previous therapy of \\> CTCAE grade 1 at study entry (except for stable sensory neuropathy ≤ CTCAE grade 2 and alopecia)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Previous treatment with IGF-1R targeting compounds",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* The patient has serious and/or uncontrolled pre-existing medical condition(s) that, in the judgement of the Investigator, would preclude participation in this study, including interstitial lung disease, severe dyspnoea at rest or requiring oxygen therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Inadequate bone marrow reserve or organ function as demonstrated by any of the following: ANC \\< 1.5 x 10\\^9/L, platelets \\< 100 x 10\\^9/L, haemoglobin \\<90g/L, ALT \\> 2.5 x ULN or \\> 5 x ULN in the presence of liver metastases, total bilirubin \\>1.5 x ULN or \\>3 x ULN in patients with Gilbert's syndrome, serum creatinine \\> 1.5 x ULN concurrent with creatinine clearance ≤ 50 mL/min.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Refractory nausea and vomiting, chronic GI diseases, inability to swallow the product, or previous significant bowel resection that would preclude adequate absorption of abemaciclib or resulting in baseline Grade 2 or higher diarrhoea",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Patients with Diabetes Type I or uncontrolled Type II (defined by HgBA1C \\> 8%).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Patients with advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term including patients with massive uncontrolled effusions (pleural, pericardial, peritoneal), pulmonary lymphangitis, and over 50% of liver involvement in metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Prior hematopoietic stem cell or bone marrow transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Have a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Subjects with controlled atrial fibrillation for \\>30 days prior to study treatment are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Erythropoietin, G-CSF, and GM-CSF are not allowed within 2 weeks prior to study. The primary prophylactic use of G-CSF is not permitted but it may be used to treat treatment emergent neutropenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Have had major surgery (excluding biopsy) \\< 28 days of the initial dose of any of the study drugs or planned major surgery during study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Have active bacterial or fungal infection (that is, requiring IV antibiotics or therapy at time of initiating study treatment), and/or known viral infection (for example, human immunodeficiency virus \\[HIV\\] antibodies, hepatitis B surface antigen, or hepatitis C antibodies). Screening is not required for enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Patients with baseline Grade ≥2 hyperglycaemia or patients with baseline Grade ≥ 2 diarrhoea",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Patients needing treatment with CYP3A4 inhibitors/inducers cannot be included in the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "Cohorts A, B, C, D (dose finding), E and F",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Any documented active or suspected malignancy or history of malignancy, other than the disease under study, within 3 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix or ductal carcinoma in situ (DCIS) if properly treated in opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Women who are pregnant, nursing, or who plan to become pregnant while in the trial. Men who plan to father a child while in the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Prior anti CDK agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease, as indicated by clinical symptoms, cerebral oedema, and/or progressive growth. History of CNS metastases or cord compression are eligible if they have been definitively treated (e.g. radiotherapy, stereotactic surgery) and are clinically stable, off anticonvulsants and steroids for at least 4 weeks. Patients with brain metastases are eligible if they are asymptomatic, completed radiotherapy for at least 4 weeks or are on a stable dose of steroids for at least 4 weeks. Patients are not eligible if they have spinal cord compression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* History of hypersensitivity to active or inactive excipients of xentuzumab, abemaciclib or letrozole/anastrozole/fulvestrant, or loperamide hydrochloride, or drugs with similar chemical structures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "Cohort D1, Cohort D2 and Cohort F (Breast Cancer):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Any documented active or suspected malignancy or history of malignancy (including inflammatory breast cancer), other than the disease under study, within 3 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix or ductal carcinoma in situ (DCIS) if properly treated in opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Women who are pregnant, nursing, or who plan to become pregnant while in the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Have received prior treatment with chemotherapy (except for neoadjuvant/adjuvant chemotherapy), fulvestrant, everolimus, alpelisib or abemaciclib. For cohorts D1 and D2 only: prior treatment with palbociclib or ribociclib is also excluded)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Have clinical evidence or history of central nervous system metastasis. Screening is not required for enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* History of hypersensitivity to active or inactive excipients of xentuzumab, abemaciclib or fulvestrant, or loperamide hydrochloride, or drugs with similar chemical structures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Have initiated bisphosphonates or approved RANK ligand (RANK-L) targeted agents (for example, denosumab) \\<7 days prior to initiation of any study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03099174",
    "statement": "* Further exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Pathologically or cytologically confirmed NSCLC Stage IV Cancer (includes cytologically proven pleural effusion or pericardial effusion) or recurrent disease. Staging is based on American Joint Committee on Cancer (AJCC) Staging for NSCLC 7th edition (R12-4710)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Evidence of common EGFR mutation (Del 19 and/or L858R)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Age \\>= 70 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (R01-0787)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Further inclusion criteria apply.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Prior participation in an afatinib clinical study, even if not assigned to afatinib treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Prior systemic therapy for metastatic or recurrent NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Concurrent investigational therapy or investigational therapy within 4 weeks of start of afatinib therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Radiotherapy within 4 weeks prior to start of study treatment, except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to study treatment, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Systemic chemotherapy, biological therapy, immunotherapy or investigational agents within 5 half-life of the drug or within four weeks prior to the start of afatinib treatment (if the half-life of the drug is unknown).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Men, capable of fathering a child, who are unwilling to use adequate contraception prior to study entry, for the duration of study participation, and for at least 28 days after treatment has ended.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02514174",
    "statement": "* Further exclusion criteria apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* Male or female subjects aged greater than or equal to (\\>=) 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* With Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* At least 1 measurable tumor lesion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* With histologically confirmed metastatic or recurrent (Stage IV) non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* With availability of a recently-obtained, formalin-fixed, paraffin-embedded (FFPE) tissue sample containing tumor (biopsy from a non-irradiated area preferably within 6 months) or a minimum number of 10 (preferably 25) unstained tumor slides cut within 1 week, and suitable for PD-L1 expression assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* Subjects must not have received any treatment for systemic lung cancer, and have an estimated life expectancy of more than 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* Other protocol defined criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* Subjects whose disease harbors a EGFR mutation, or anaplastic lymphoma kinase (ALK) rearrangement are not eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* Other exclusion criteria include prior therapy with any antibody or drug targeting T cell coregulatory proteins, concurrent anticancer treatment, or immunosuppressive agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* Known severe hypersensitivity reactions to monoclonal antibodies (Grade \\>= 3 NCI CTCAE v 4.03), history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma), and persisting toxicity related to prior therapy of Grade \\> 1 NCI-CTCAE v 4.03.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* Subjects with brain metastases are excluded, except those meeting the following criteria: brain metastases that have been treated locally and are clinically stable for at least 2 weeks prior to randomization, subjects must be either off steroids or on a stable or decreasing dose of \\<= 10 mg daily prednisone (or equivalent), and do not have ongoing neurological symptoms that are related to the brain localization of the disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02576574",
    "statement": "* Other protocol defined criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects (male or non-pregnant female) must be ≥ 18 years of age on the day of signing the informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects with a histologically or cytologically confirmed diagnosis of (Stage III-IV) non-small cell lung cancer (NSCLC) and with at least one measurable lesion defined by RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects must have experienced a disease progression following treatment with an anti-PD1 or PD-L1 immune checkpoint antibody and a platinum-containing doublet treatment, administered simultaneously or sequentially.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects with a targetable driver mutation in EGFR or ALK gene will be allowed on trial after failing all available targeted therapies and having experienced a disease progression following treatment with an anti-PD1 or PD-L1 immune checkpoint antibody and a platinum-containing doublet treatment, administered simultaneously or sequentially.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects must have adequate organ and immune function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects must have a tumor lesion amenable for biopsies with no contraindication for biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects must have a life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects must have recovered from the toxic effects resulting from the most recent cancer treatment to Grade 1 or less. If the subjects underwent major surgery or received radiation therapy, they must have recovered from the complications and/or toxicity.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects (both male and female) of reproductive potential must be willing to practice highly effective methods of contraception throughout the study and for up to 90 days after the last dose of study medication. Abstinence is acceptable if this is the subject's usual lifestyle.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Female subjects are not considered of childbearing potential if they have a history of surgical sterility or evidence of post-menopausal status defined as any of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* ≥ 45 years of age and has not had menses for more than 2 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Amenorrhoeic for less than 2 years without hysterectomy and oophorectomy and a follicle stimulating hormone (FSH) value in the postmenopausal range at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Post hysterectomy, oophorectomy or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or by ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects must understand and be able and willing and likely to fully comply with the study procedures, including scheduled follow-up, and restrictions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects must have given written personally signed and dated informed consent to participate in the study in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines, before completing any study related procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who have received prior therapy with AB-16B5.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who have received prior therapy with docetaxel for the treatment of NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who are currently participating or has participated in a study of an investigational agent or using an investigational device within 21 days prior to the first dose of study treatment. The 21-day window should be calculated using the last dose of an antineoplastic investigational agent or last use of an investigational device with antineoplastic intent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who have received any anti-cancer treatment within 3 weeks or radiation therapy within 2 weeks prior to receiving the first dose of study treatment or who have not recovered from adverse events to Grade 1 or less. Subjects with alopecia are eligible to participate.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who are expected to require any other form of systemic or localized antineoplastic therapy while on the trial. This includes maintenance therapy with another agent or radiation therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who are receiving a dose \\> 10 mg/day of prednisone (or equivalent) within 7 days prior to the first dose of study treatment or any other form of immunosuppressive medication (corticosteroid pre-treatment and/or post-treatment of docetaxel is allowed).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who require treatment with a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole). Subjects may be included if there is an alternate treatment with a weak CYP3A4 inhibitor and they are willing to change at least 7 days prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who have another malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin or in situ cervical cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who have known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate if they have been clinically stable for at least 2 weeks prior to the first dose of study treatment, if they have no evidence of new or enlarging brain metastases and if they are not receiving a dose \\> 10 mg/day of prednisone (or equivalent) within 7 days prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects with clinically significant ECG abnormalities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who have received or will receive a live vaccine within 30 days prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects with a known history of human immunodeficiency (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects with an active Hepatitis B or C infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects with an active infection requiring antibiotic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects with a known history of alcohol or other substance abuse within the last year.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects with known hypersensitivity to docetaxel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who have a history or current evidence of any condition, therapy or laboratory abnormalities that may confound the results of the trial, interfere with the subject's participation for the full duration of the trial or if it is not in the best interest of the subject to participate in the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects with medical, social or psychosocial factors that, in the opinion of the treating Investigator, could impact the safety or compliance with study procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04364620",
    "statement": "* Subjects who are pregnant or lactating or who are expecting to conceive or father children within the projected duration of the trial through 90 days after the last dose of AB-16B5 or the last dose of docetaxel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": ".Age ≥ 18 years the time of signing the Informed Consent Form (ICF).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "2. Understand and voluntarily provide written informed consent prior to the conduct of any study related assessments/procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "3. Able to adhere to the study visit schedule and other protocol requirements. 4. Histologically or cytologically confirmed advanced NSCLC who will receive study therapy as second- or third-line of treatment for advanced disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "5. No other current active malignancy requiring anticancer therapy. 6. Radiographically documented measurable disease (defined by the presence of ≥ 1 radiographically documented measurable lesion).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "7. One prior platinum-containing chemotherapy for metastatic or recurrent NSCLC unless patients are ineligible to receive it. Patients may have received no more than one line of chemotherapy; immunotherapy in prior line of treatment (first or second line) is allowed. Absolute neutrophil count (ANC) ≥ 1500 cells/mm3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "8. Platelets ≥ 100,000 cells/mm3. 9. Hemoglobin (Hgb) ≥ 9 g/dL. 10. Aspartate transaminase (AST/serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine transaminase (ALT/serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 2.5 × upper limit of normal range (ULN) or ≤ 5.0 × ULN if liver metastases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "11. Total bilirubin ≤ 1.5 ULN (unless there is a known history of Gilberts Syndrome).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "12. Serum creatinine ≤ 1.5 x ULN, or calculated creatinine clearance ≥ 60 mL/min (if renal impairment is suspected 24-hour urine collection for measurement is required).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "13. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 14. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 15. Females of childbearing potential \\[defined as a sexually mature woman who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months)\\] must:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "1. Have a negative pregnancy test (ß-hCG) as verified by the study doctor within 72 hours prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the subject practices true abstinence\\* from heterosexual contact.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "2. Either commit to true abstinence\\* from heterosexual contact (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting investigational product (IP), during the study therapy (including dose interruptions), and for 3 months after discontinuation of study therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "Male subjects must:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "1. Practice true abstinence\\* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 6 months following IP discontinuation, even if he has undergone a successful vasectomy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "2. Refrain from semen or sperm donation while taking durvalumab and for at least 3 months after the last dose of durvalumab.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "   16. Females must abstain from breastfeeding during study participation and 3 months after IP discontinuation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "* The presence of any of the following will exclude a subject from enrollment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     1. Refractory to prior taxane therapy for advanced disease. Prior taxane used in the adjuvant setting does not exclude eligibility, provided there is no disease recurrence within 12 months upon completion of chemotherapy in that setting.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     2. Evidence of active brain metastases, including leptomeningeal involvement (prior evidence of brain metastasis are permitted only if asymptomatic and clinically stable for at least 8 weeks following completion of therapy). MRI of the brain (or CT scan w/contrast) is preferred.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     3. Only evidence of disease is non-measurable at study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     4. Known activating EGFR mutations (such as exon 19 deletions or L858R).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     5. Known activating EML4-ALK mutations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     6. Preexisting peripheral neuropathy of Grade \\> 2 (per NCI CTCAE v4.0).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     7. Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     8. Venous thromboembolism within 1 month prior to Cycle 1 Day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     9. Current congestive heart failure (New York Heart Association Class II-IV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     10. History of the following within 6 months prior to Cycle 1 Day 1: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant electrocardiogram (ECG) abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     11. Known hepatitis B or C virus (HBV/HCV) infection, known history of human immunodeficiency virus (HIV) infection, or receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications, history of active primary immunodeficiency, active tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     12. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     13. History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or pulmonary hypersensitivity pneumonitis or multiple allergies. Any lung disease that may interfere with the detection or management of suspected drug-related pulmonary toxicity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     14. Subject has a clinically significant malabsorption syndrome, persistent diarrhea, or known sub-acute bowel obstruction \\> NCI CTCAE Grade 2, despite medical management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     15. Treatment with any chemotherapy, investigational product, biologic or hormonal therapy for cancer treatment within 28 days prior to signing the ICF. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g. hormone replacement therapy) is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     16. History of or suspected allergy to any IP or their excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     17. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     18. Currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     19. Any other clinically significant medical condition, psychiatric illness, and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol or which, in the views of investigator, preclude combination chemotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     20. Any other malignancy within 5 years prior to randomization/treatment assignement, or advanced malignant hepatic tumors, with the exception of adequately treated squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (TNM Classification of Malignant Tumours (TNM) stage of T1a or T1b). (All treatment of which should have been completed 6 months prior to signing ICF).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     21. Radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting IP, and/or from whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     22. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     23. Any medical condition that confounds the ability to interpret data from the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     24. Female patients who are pregnant or breastfeeding or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     25. Male patients of reproductive potential who are not willing to employ effective birth control from screenin to 90 days after the last dose of durvalumab and from screening to 6 months after the last dose of of nab-paclitaxel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     26. History of allogenic organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     27. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "* Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "* Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) 28. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "     29. Prior enrollment and treatment in a previous durvalumab clinical study. 30. Patients who have received prior anti-PD-1 or anti PD-L1:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "* Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "* All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "* Must not have experienced a ≥ Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE: Subjects with endocrine AE of ≤ Grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02250326",
    "statement": "* Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of \\> 10 mg prednisone or equivalent per day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": ". Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "2. Have histologically or cytologically confirmed stage IIIB (locally advanced or recurrent) or stage IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "3. Must meet one of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Have documentation of ALK rearrangement by a positive result from the Vysis ALK Break-Apart fluorescence in situ hybridization (FISH) Probe Kit or the Ventana ALK (D5F3) CDx Assay or Foundation Medicine's FoundationOne CDx.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Have documented ALK rearrangement by a different test and be able to provide tumor sample to the central laboratory. (Note: central laboratory ALK rearrangement testing results are not required to be obtained before randomization).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "4. Had PD while on crizotinib, as assessed by the investigator or treating physician except for participants previously participating in the Brigatinib-2002 study (Note: crizotinib does not need to be the last therapy a participant received. The participant may have received chemotherapy as his/her last therapy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "5. Treatment with crizotinib for at least 4 weeks before progression except for participants previously participating in the Brigatinib-2002 study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "6. Have had no other ALK inhibitor other than crizotinib except for participants previously participating in the Brigatinib-2002 study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "7. Have had no more than 2 prior regimens of systemic anticancer therapy (other than crizotinib) in the locally advanced or metastatic setting. Note: a systemic anticancer therapy regimen will be counted if it is administered for at least 1 complete cycle. A new anticancer agent used as maintenance therapy will be counted as a new regimen. Neoadjuvant or adjuvant systemic anticancer therapy will be counted as a prior regimen if disease progression/recurrence occurred within 12 months upon completion of this neoadjuvant or adjuvant therapy. (Systemic therapy followed by maintenance therapy will be considered as one regimen if the maintenance therapy consists of a drug or drugs that were used in the regimen that immediately preceded maintenance).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "8. Have at least 1 measurable (that is, target) lesion per RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "9. Have recovered from toxicities related to prior anticancer therapy to national cancer institute common terminology criteria for adverse events (NCI CTCAE) version 4.03 grade less than or equal to (\\<=)1. (Note: treatment-related alopecia or peripheral neuropathy that are grade greater than (\\>) 1 are allowed, if deemed irreversible).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "10. Have adequate organ function, at the time of initial screening, except for participants previously participating in the Brigatinib-2002 study as determined by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Total bilirubin \\<=1.5 times the upper limit of normal (ULN).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Estimated glomerular filtration rate greater than equal to (\\>=) 30 milliliter per minute (mL/min)/1.73 square meter \\[m\\^2\\], using the modification of diet in renal disease equation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \\<=2.5\\*ULN; \\<=5\\*ULN is acceptable if liver metastases are present.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Serum lipase \\<=1.5\\*ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Platelet count \\>=75\\*10\\^9 per liter \\[/L\\].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Hemoglobin \\>=9 gram per deciliter (g/dL).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Absolute neutrophil count \\>=1.5\\*10\\^9 / L.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "11. Suitable venous access for study-required blood sampling (that is, including pharmacokinetic \\[PK\\] and laboratory safety tests).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": ". Had participated in the control (crizotinib) arm of Study AP26113-13-301 (ALTA 1L) \\[NCT02737501\\].",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "2. Had received crizotinib within 7 days before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "3. Have a history or presence at baseline of pulmonary interstitial disease, drug related pneumonitis, or radiation pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "4. Have uncontrolled hypertension. Participants with hypertension should be under treatment for control of blood pressure upon study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "5. Had received systemic treatment with strong cytochrome P-450 (CYP) 3A inhibitors, moderate CYP3A inhibitors, strong CYP3A inducers, or moderate CYP3A inducers within 14 days before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "6. Treatment with any investigational systemic anticancer agents within 14 days or 5 half-lives, whichever is longer, before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "7. Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated nonmelanoma skin cancer or cervical cancer in situ; definitively treated nonmetastatic prostate cancer; or participants with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "8. Had received chemotherapy or radiation therapy within 14 days before randomization except for stereotactic radiosurgery (SRS) or stereotactic body radiation therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "9. Had received antineoplastic monoclonal antibodies within 30 days of randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "10. Had major surgery within 30 days of randomization. Minor surgical procedures, such as catheter placement or minimally invasive biopsies, are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "11. Have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening (participants with asymptomatic brain metastases or participants who have stable symptoms and did not require an increased dose of corticosteroids to control symptoms within 7 days before randomization will be enrolled). Note: If a participant has worsening neurological symptoms or signs due to CNS metastasis, the participant needs to complete local therapy and be neurologically stable (with no requirement for an increasing dose of corticosteroids or use of anticonvulsants) for 7 days before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "12. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Participants with leptomeningeal disease and without cord compression are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "13. Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Myocardial infarction within 6 months before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Unstable angina within 6 months before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* New York Heart Association Class III or IV heart failure within 6 months before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "* Any history of clinically significant ventricular arrhythmia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "14. Had cerebrovascular accident or transient ischemic attack within 6 months before first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "15. Have malabsorption syndrome or other gastrointestinal illness or condition that could affect oral absorption of the study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "16. Have an ongoing or active infection, including but not limited to, the requirement for intravenous antibiotics.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "17. Have a known history of human immunodeficiency virus (HIV) infection. Testing is not required in the absence of history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "18. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection. Testing is not required in the absence of history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "19. Any serious medical condition or psychiatric illness that could, in the investigator's opinion, potentially compromise participant safety or interfere with the completion of treatment according to this protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "20. Have a known or suspected hypersensitivity to brigatinib or alectinib or their excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "21. Life-threatening illness unrelated to cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "22. Female participants who are lactating and breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03596866",
    "statement": "23. Admission or evidence of illicit drug use, drug abuse, or alcohol abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Histologically confirmed non-small cell lung cancer (NSCLC)(squamous cell, adenocarcinoma, large cell, or bronchoalveolar carcinoma)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Stage IIIB NSCLC with pleural effusion, Stage IV NSCLC, or recurrent disease following surgery with or without radiation therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Available paraffin-embedded tissue to measure the expression levels of βIII tubulin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Disease measurable by Response Evaluation Criteria in Solid Tumors, with at least 1 target lesion situated outside any previous radiotherapy field",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Karnofsky performance status of 70-100",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Men and women, ages 18 years and older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Uncontrolled brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Peripheral neuropathy greater than Grade 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Fewer than 4 weeks from prior radiation therapy or locoregional surgeries to randomization date (less than 1 week from focal/palliative radiotherapy or minor surgery)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Any concurrent malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Known HIV-positive status",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Absolute neutrophil count lower than 1500 cells mm\\^3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Total bilirubin level higher than upper limit of normal (ULN) as defined by the institution (with the exception of elevation due to Gilbert's syndrome)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Aspartate transaminase or alanine transaminase level higher than 2.5\\*ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Serum creatine level of 1.5 mg/dL or higher",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Renal function with a creatinine clearance of less than 50 mL/min (as calculated with the Cockcroft and Gault equation)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00723957",
    "statement": "* Any prior antineoplastic systemic regimens.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00447057",
    "statement": "* Histological or cytological diagnosis of locally advanced or metastatic NSCLC that is of nonsquamous histology and not amenable to curative therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00447057",
    "statement": "* Failure of previous treatment with one prior platinum-based chemotherapy regimen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00447057",
    "statement": "* Good performance status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00447057",
    "statement": "* Adequate bone marrow reserve, renal and hepatic functions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00447057",
    "statement": "* Serious concomitant systemic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00447057",
    "statement": "* Inability to take oral medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00447057",
    "statement": "* Inability or unwillingness to take vitamin supplementation and corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00447057",
    "statement": "* Pregnancy / Breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00447057",
    "statement": "* Treatment with certain medicines that prevent blood from clotting.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "* locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "* Epidermal Growth Factor Receptor (EGFR) mutation-positive result per the institution's testing methodology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "* Adequate organ function, defined as all of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "  1. Absolute Neutrophil Count (ANC) \\> 1500/mm3. (ANC \\>1000/mm3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the sponsor).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "  2. Platelet count \\>75,000/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "  3. Serum creatinine \\< 1.5 times of the upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "  4. Total Bilirubin \\< 1.5 times upper limit of (institutional) normal (Patients with Gilbert's syndrome total bilirubin must be \\<4 times institutional upper limit of normal).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "  5. Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) \\< three times the upper limit of (institutional) normal (ULN) (if related to liver metastases \\< five times ULN).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) score between 0 - 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "* written informed consent by patient or guardian prior to admission into the trial that is consistent with International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP) guidelines and local law.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "* prior treatment with an EGFR tyrosine kinase inhibitor (TKI)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "* anti-cancer treatment within 2 weeks prior to start of trial treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "* radiotherapy within 14 days prior to drug administration, except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "  1. Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "  2. Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "* previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "* known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853826",
    "statement": "* meningeal carcinomatosis and symptomatic brain metastases (patients with asymptomatic brain metastases, who were previously treated, are eligible provided they have had Stable Disease (SD) for at least 4 weeks on stable doses of medication)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Patients aged 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Newly diagnosed advanced (stage IV) /recurrent non-squamous NSCLC for which they had not received any systemic anti-cancer therapy for metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Histologically or cytologically confirmed diagnosis of predominantly non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Existence of at least 1 measurable lesion by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Adequate hematological, renal and liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Eastern Collaborative Oncology Group Performance Status (ECOG PS) 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Life expectancy longer than 6 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Any unresolved toxicities from prior systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Known sensitizing epidermal growth factor receptor (EGFR) mutations or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation positive mutations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Previous dosing with vascular endothelial growth factor (VEGF) inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Known hypersensitivity to any excipients of the Investigational Products (IPs) and combination chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Use of prohibited concomitant medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Known Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "* Fertile men or women of childbearing potential not using adequate contraception.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02810457",
    "statement": "Other inclusion/exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* For Part A: Has a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* For Part B: Has a histologically-confirmed or cytologically confirmed diagnosis of non-small cell lung carcinoma (NSCLC) stage IIIB/IV, be naïve to systemic therapy, and have confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated. Cohort 1 and 2 must have a histological or cytological diagnosis of non-squamous cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has at least one measurable lesion by computed tomography or magnetic resonance imaging per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has a life expectancy of ≥3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Women of childbearing potential and male participants must agree to use adequate contraception during the study through 120 days after the last dose of study medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* For Part A: Has provided tissue for programmed cell death ligand 1 (PD-L1)/ Indoleamine 2,3-dioxygenase 1 (IDO1) expression evaluation from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. For Part B submission of tissue is optional.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has received prior therapy with an anti-Programmed cell death protein (PD)-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agents (including ipilimumab or any other antibody/drug specifically targeting T-cell co-stimulation or checkpoint pathways), or IDO1 inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Is currently participating or has participated in a study with an investigational compound or device within 4 weeks, or 5 times half-life of the investigational compound, whichever is longer, of initial dosing on this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* For Part A: Has had chemotherapy, targeted small molecule therapy, radiotherapy, major surgery, or biological cancer therapy (including monoclonal antibodies) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the first dose of study medication, or who has not recovered (≤ Grade 1 or baseline) from adverse events due to a previously administered treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* For Part B: Has received radiotherapy within 7 days of the first dose of trial treatment or radiation therapy to the lung that is \\>30 Gray (Gy) within 6 months of the first dose of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Is expected to require any other form of systemic or localized anti-neoplastic therapy while in study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has active central nervous system (CNS) metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has symptomatic ascites or pleural effusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has an active autoimmune disease that has required systemic treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 1 week prior to the first dose of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has an active infection requiring systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has received a live vaccine within 4 weeks prior to the first dose of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has a known hypersensitivity to the components of the trial treatment or another monoclonal antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* For Part B: Has a known sensitivity to any component of cisplatin, carboplatin, paclitaxel, or pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* For Part B: Is on chronic systemic steroids with the exception of use of bronchodilators, inhaled steroids, or local steroid injections",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* For Part B cohort 1 and 2: Is unable to interrupt aspirin or other nonsteroidal ant-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* For Part B cohort 1 and 2: Is unable or unwilling to take folic acid or vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Is Human Immunodeficiency Virus (HIV)-positive (HIV 1/2 antibodies)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has known history of or is positive for active Hepatitis B (Hepatitis B surface antigen reactive) or has active Hepatitis C (Hepatitis C virus ribonucleic acid)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Is pregnant or breastfeeding, or expecting to conceive or father children during the study through 120 days after the last dose of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has received monoamine oxidase inhibitors (MAOIs) within the 3 weeks before the first dose of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has any history of Serotonin Syndrome after receiving serotonergic drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02862457",
    "statement": "* Has presence of a gastrointestinal condition that may affect drug absorption",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Aged at least 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Documented evidence of NSCLC (Stage IIIB/ IV disease)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Disease progression or recurrence after both a platinum-based chemotherapy regimen and at least 1 additional regimen for treatment of NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* World Health Organization (WHO) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Estimated life expectancy more than 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody or anti-CTLA4",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Active or prior documented autoimmune disease within the past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Evidence of severe or uncontrolled systemic disease, including active bleeding diatheses or active infections including hepatitis B, C and HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Any unresolved toxicity CTCAE (Common Terminology Criteria of Adverse Events) \\>Grade 2 from previous anti-cancer therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Known EGFR TK activating mutations or ALK rearrangements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \\>Grade 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02352948",
    "statement": "* Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Provide signed, written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Male and female participants, age \\>=18 years (at the time consent is obtained).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Histological documentation of locally advanced, recurrent or metastatic solid malignancy that has progressed after standard therapy appropriate for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate. Participants should not have received more than 5 prior lines of therapy for advanced disease including both standards of care and investigational therapies. Participants whose cancers harbor molecular alterations for which targeted therapy is standard of care should have received health authority approved appropriate targeted therapy for their tumor types before enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Participants with the following solid tumors are eligible for screening: Non-small cell lung cancer (NSCLC), Squamous cell carcinoma of the head and neck (SCCHN), Renal cell carcinoma (RCC), melanoma, bladder, Soft Tissue Sarcoma (STS), Triple-negative breast cancer (TNBC), and Colorectal carcinoma displaying high microsatellite instability (MSI CRC). In Part 2B (Cohort Expansion), specific subgroups of the above solid tumors will be studied. These subgroups may be defined by specific lines of treatment, types of prior treatment, histological subtypes, and may be enriched for selected biomarkers or participant characteristics. Populations to be studied in Amendment 3 include but are not limited to the following. Enrolment of additional populations will be communicated in writing: Participants with dedifferentiated liposarcoma who have not received prior treatment with a Programmed death ligand 1 (PD-L1) inhibitor; Participants with melanoma who have received a prior PD-L1 inhibitor, had a CR, PR or SD and subsequently progressed while on PD-L1 therapy. Participants who have received prior treatment with a PD-L1 inhibitor must have documented disease progression as defined by meeting all of the following criteria: Has received at least 2 doses of an approved PD-L1 inhibitor; has demonstrated disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The initial evidence of disease progression is to be confirmed by a second assessment no less than four weeks from the date of the first documented PD , in the absence of rapid clinical progression; Progressive disease has been documented within 18 weeks from the last dose of the PD-L1 inhibitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* In Parts 1A and 2A, a biopsy of the tumor tissue obtained at anytime from the initial diagnosis to study entry. Although a fresh biopsy obtained during screening is preferred, archival tumor specimen is acceptable if it is not feasible to obtain a fresh biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "Participants enrolled in Part 1A or Part 2A Pharmacodynamic Cohorts or in Part 2B of the study must provide a fresh biopsy of a tumor lesion not previously irradiated during the screening period and must agree to provide at least one additional on-treatment biopsy. In addition, an archived tumor tissue should be submitted for Participants in Part 2B, if available. The criterion for collection of fresh biopsies may be waived once GlaxoSmithKline (GSK)has determined an appropriate number of viable tissue samples have been analyzed For Part 1B and Part 2B, any archival tumor specimen must have been obtained within 3 months of starting study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Measurable disease as per RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Palpable lesions that are not measurable by radiologic or photographic evaluations may not be utilized as the only measurable lesion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Life expectancy of at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Adequate organ function as defined by System Laboratory Values; Hematologic (Absolute neutrophil count \\[ANC\\] \\>=1.5x10\\^9/ liter \\[L\\], Lymphocyte count \\>=800/cubic millimeter \\[mm\\^3\\], Hemoglobin \\>=9 grams/deciliter \\[g/dL\\], Platelets \\>=100x10\\^9/L), Hepatic (Total bilirubin \\<=1.5x upper limit of normal \\[ULN\\] \\[For participants with Gilbert's Syndrome, only if direct bilirubin \\<=35 percent (%), \\<=3.0xULN\\], for Part 1A and 2A: alanine aminotransferase \\[ALT\\] \\<=1.5xULN), Part 2B: ALT \\<=2.5xULN; Renal (Serum Creatinine \\<=1.5xULN OR Calculated creatinine clearance \\[CrCl \\>50 mL/min ) and Endocrine (Thyroid stimulating hormone \\[TSH\\]) within normal limits. If TSH is not within normal limits at baseline, the participant may still be eligible if total triiodothyronine (T3) or free T3 and free thyroxine (T4) are within the normal limits.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* QT duration corrected for heart rate by Fridericia's formula (QTcF) \\<450 milliseconds (msec) or \\<480 msec for participants with bundle branch block.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* In France, a participant will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Female participant: is eligible to participate if she is not pregnant (as confirmed by a negative serum beta-human chorionic gonadotrophin \\[beta-hCG\\] test), not lactating, and at least one of the following conditions applies: Non-reproductive potential defined as: Pre-menopausal females with one of the following: Documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion ; Hysterectomy; Documented Bilateral Oophorectomy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Reproductive potential and agrees to follow one of the options listed below in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication and until 120 days after the last dose of study medication and completion of the follow-up visit. GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "This list does not apply to FRP with same sex partners, when this is their preferred and usual lifestyle or for participants who are and will continue to be abstinent from penile-vaginal intercourse on a long term and persistent basis: Contraceptive subdermal implant with a \\<1% rate of failure per year, as stated in the product label; Intrauterine device or intrauterine system with a \\<1% rate of failure per year, as stated in the product label; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen; Contraceptive vaginal ring; Percutaneous contraceptive patches; Male partner sterilization with documentation of azoospermia prior to the female participant's entry into the study, and this male is the sole partner for that participant. These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that participants understand how to properly use these methods of contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Male Participants with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until 120 days after the last dose of study medication: Vasectomy with documentation of azoospermia; Male condom plus partner use of one of the contraceptive options below; Contraceptive subdermal implant with a \\<1% rate of failure per year, as stated in the product label; Intrauterine device or intrauterine system with a \\<1% rate of failure per year, as stated in the product label; Oral Contraceptive, either combined or progestogen alone Injectable progestogen; Contraceptive vaginal ring; Percutaneous contraceptive patches.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that participants understand how to properly use these methods of contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Prior treatment with the following agents (from last dose of prior treatment to first dose of GSK3174998): Tumor necrosis factor receptor (TNFR) agonists, including OX40, CD27, CD137 (4-1BB), CD357 (GITR): at any time; Checkpoint inhibitors, including Programmed death receptor-1 (PD-1),",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "  1, and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors: within 4 weeks; other anticancer therapy, including chemotherapy, targeted therapy, and biological therapy: within 4 weeks or 5 half lives of the drug, whichever is shorter. Prior radiation therapy is permissible if at least one unirradiated measurable lesion is available for assessment via RECIST version 1.1. A wash out of at least two weeks before start of study drug for palliative radiation to the extremities for osseous bone metastases and 4 weeks for radiation to the chest, brain, or visceral organs is required; Investigational therapy: if the participant has participated in a clinical trial and has received an investigational product: within 30 days or 5 half-lives of the investigational product (whichever is shorter). At least 14 days must have passed between the last dose of prior investigational agent and the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Prior allogeneic or autologous bone marrow transplantation or other solid organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Toxicity from previous treatment: Participants with \\>=Grade 3 toxicity related to prior immunotherapy leading to study treatment discontinuation are not eligible; participants whose toxicity related to prior treatment has not resolved to \\<=Grade 1 (except alopecia, hearing loss, grade \\<=2 neuropathy or endocrinopathy managed with replacement therapy) are not eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Malignancy other than disease under study, except as noted below: any other malignancy from which the participant has been disease-free for more than 2 years and, in the opinion of the principal investigators and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on currently targeted malignancy, can be included in this clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Central nervous system (CNS) metastases, with the following exception: Participants who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids for 2 weeks prior to first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Has received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte colony stimulating factor \\[G-CSF\\], granulocyte-macrophage colony-stimulating factor \\[GMCSF\\], recombinant erythropoietin) within 2 weeks before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Major surgery \\<=4 weeks before the first dose of study treatment. Participants must have also fully recovered from any surgery (major or minor) and/or its complications before initiating study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Active autoimmune disease that has required systemic treatment within the last 2 years (that is with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (example \\[e.g.\\], thyroxine or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Concurrent medical condition requiring the use of systemic immunosuppressive medications within 28 days before the first dose of study treatment. Physiologic doses of corticosteroids for treatment of endocrinopathies or steroids with minimal systemic absorption, including topical, inhaled, or intranasal corticosteroids may be continued if the participant is on a stable dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Active infection, known human immunodeficiency virus infection, or positive test for hepatitis B surface antigen or hepatitis C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease per investigator assessment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Known, current drug or alcohol abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel disease, intra-abdominal abscess, or gastrointestinal obstruction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Receipt of any live vaccine within 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Recent history of allergen desensitization therapy within 4 weeks of starting study Treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* History of severe hypersensitivity to other mAbs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* History or evidence of cardiovascular risk including any of the following: Recent (within the past 6 months) history of serious uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities including second degree (Type II) or third degree atrioventricular block; Documented cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting, or bypass grafting within the past 6 months before enrollment; documented congestive heart failure (Class II, III, or IV) as defined by the New York Heart Association functional classification system; recent (within the past 6 months) history of symptomatic pericarditis Current or history of idiopathic pulmonary fibrosis, interstitial lung disease, or organizing pneumonia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* History of (non-infectious) pneumonitis that required steroids or current pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Any serious and/or unstable pre-existing medical, psychiatric disorder, or other condition that could interfere with the participant's safety, obtaining informed consent, or compliance to the study procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific participant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02528357",
    "statement": "* History of severe hypersensitivity (\\>=Grade 3) to pembrolizumab and/or any of its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* Adult participants, ≥ 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* Locally advanced or recurrent (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* Presence of epidermal growth factor receptor (EGFR) mutations in tumours.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* European Cooperative Oncology Group (ECOG) performance status ≤ 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* Prior exposure to agents directed at the human epidermal receptor (HER) axis (eg, but not limited to erlotinib, gefitinib, cetuximab, or trastuzumab).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* Prior chemotherapy or systemic anti-neoplastic therapy for advanced disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or active gastroduodenal ulcer disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* Any inflammatory changes of the surface of the eye.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* ≥ Grade 2 peripheral neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* History of any other malignancies within 5 years, except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* Brain metastasis or spinal cord compression that has not yet been definitely treated with surgery and/or radiation, or treated but without evidence of stable disease for at least 2 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* Human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01342965",
    "statement": "* Pregnant, nursing, or lactating women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Stage IIIb/IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Disease progression \\>1 year after completing adjuvant therapy for Stage I-IIIA disease and no systemic therapy for the recurrent disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Resolution of any toxic effects (excepting alopecia) of the most recent therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* At least one radiographically measurable lesion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Female participants of reproductive potential must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Female and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to 120 days after the last dose of study therapy and for up to 180 days after the last dose of chemotherapeutic agents or tyrosine kinase inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of administration of pembrolizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Expected to require any other form of antineoplastic therapy while on study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Is on chronic systemic steroid therapy or on any other form of immunosuppressive medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Has received a live-virus vaccination within 30 days of planned treatment start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, or abdominal carcinomatosis (known risks factors for bowel perforation)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* History of a hematologic malignancy, primary brain tumor or sarcoma, or of another primary solid tumor, unless the participant has undergone potentially curative therapy with no evidence of that disease for 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Active central nervous system (CNS) metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapies for hormone deficiencies are allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Prior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or PD Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2) agent or an antibody targeting other immuno-regulatory receptors or mechanisms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within 3 weeks of the first dose of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Radiation therapy to lung \\>30 Gy within 6 months of first dose of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Prior tyrosine kinase inhibitor therapy or palliative radiation within 7 days of first dose of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Active infection requiring therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* History of Human Immunodeficiency Virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Active Hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Symptomatic ascites or pleural effusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Interstitial lung disease or pneumonitis requiring oral or IV glucocorticoids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02039674",
    "statement": "* Psychiatric disorders and substance (drug/alcohol) abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": ". Multiple myeloma with relapsing or progressing disease at study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "2. Patients must have evaluable multiple myeloma with, at least one of the following (assessed within 21 days prior to randomization):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "* Serum M-protein ≥ 0.5 g/dL, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "* Urine M-protein ≥ 200 mg/24 hour, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "* In patients without detectable serum or urine M-protein, serum free light chain (SFLC) \\> 100 mg/L (involved light chain) and an abnormal serum kappa/lamda ratio, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "* For immunoglobulin (Ig) A patients whose disease can only be reliably measured by serum quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "3. Patients must have documented at least partial response (PR) to at least 1 line of prior therapy. PR documentation can be based on Investigator assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "4. Received 1, but no more than 3 prior treatment regimens or lines of therapy for multiple myeloma. (Induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as one line of therapy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "5. Prior therapy with Velcade is allowed as long as the patient had at least a PR to prior Velcade therapy, was not removed from Velcade therapy due to toxicity, and will have at least a 6 month Velcade treatment-free interval from last dose received until first study treatment. (Patients may receive maintenance therapy with drugs that are not in the proteasome inhibitor class during this 6 month Velcade treatment-free interval).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "6. Prior therapy with carfilzomib is allowed as long as the patient had at least a PR to prior carfilzomib therapy, was not removed from carfilzomib therapy due to toxicity, and had at least a 6-month carfilzomib treatment-free interval from last dose received until first study treatment. (Patients may receive maintenance therapy with drugs that are not in the proteasome inhibitor class during this 6 month carfilzomib treatment-free interval). The exception to this is patients randomized or previously randomized in any other Onyx-Sponsored Phase 3 trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "7. Males and females ≥ 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "9. Adequate hepatic function within 21 days prior to randomization, with bilirubin \\< 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\< 3 times the ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "10. Left ventricular ejection fraction (LVEF) ≥ 40%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "11. Absolute neutrophil count (ANC) ≥ 1000/mm³ within 21 days prior to randomization. Screening ANC should be independent of growth factor support for ≥ 1 week.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "12. Hemoglobin ≥ 8.0 g/dL within 21 days prior to randomization. Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed, however most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "13. Platelet count ≥ 50,000/mm³ (≥ 30,000/mm³ if myeloma involvement in the bone marrow is \\> 50%) within 21 days prior to randomization. Patients should not have received platelet transfusions for at least 1 week prior to obtaining the screening platelet count.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "14. Calculated or measured creatinine clearance (CrCl) of ≥ 15 mL/min within 21 days prior to randomization. Calculation should be based on standard formula such as the Cockcroft and Gault:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "    \\[(140 - Age) x Mass (kg) / (72 x Creatinine mg/dL)\\]; multiply result by 0.85 if female.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "15. Written informed consent in accordance with federal, local, and institutional guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "16. Female patients of child-bearing potential (FCBP) must have a negative serum pregnancy test within 21 days prior to randomization and agree to use an effective method of contraception during and for 3 months following last dose of drug (more frequent pregnancy tests may be conducted if required per local regulations). FCBP is defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "17. Male patients must use an effective barrier method of contraception during study and for 3 months following the last dose if sexually active with a FCBP.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": ". Multiple Myeloma of IgM subtype.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "2. Glucocorticoid therapy (prednisone \\> 30 mg/day or equivalent) within 14 days prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "3. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "4. Plasma cell leukemia or circulating plasma cells ≥ 2 × 10\\^9/L.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "5. Waldenstrom's Macroglobulinemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "6. Patients with known amyloidosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "7. Chemotherapy with approved or investigational anticancer therapeutics within 21 days prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "8. Patients randomized or previously randomized in any other Onyx-Sponsored Phase 3 trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "9. Focal radiation therapy within 7 days prior to randomization. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to randomization (i.e., prior radiation must have been to less than 30% of the bone marrow).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "10. Immunotherapy within 21 days prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "11. Major surgery (excluding kyphoplasty) within 28 days prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "12. Active congestive heart failure (New York Heart Association \\[NYHA\\] Class III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within four months prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "13. Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed at hepatitis B) or antifungal agents within 14 days prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "14. Known human immunodeficiency (HIV) seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen \\[SAg\\] or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "15. Patients with known cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "16. Second malignancy within the past 3 years except:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "* adequately treated basal cell or squamous cell skin cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "* carcinoma in situ of the cervix",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "* prostate cancer \\< Gleason score 6 with stable prostate-specific antigen (PSA) over 12 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "* breast carcinoma in situ with full surgical resection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "* treated medullary or papillary thyroid cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "17. Patients with myelodysplastic syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "18. Significant neuropathy (Grades 3 to 4, or Grade 2 with pain) within 14 days prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "19. Female patients who are pregnant or lactating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "20. Known history of allergy to Captisol(a cyclodextrin derivative used to solubilize carfilzomib).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "21. Patients with hypersensitivity to carfilzomib, Velcade, boron, or mannitol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "22. Patients with contraindication to dexamethasone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "23. Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "24. Ongoing graft-vs-host disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01568866",
    "statement": "25. Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00391274",
    "statement": "* Histologic or cytologic diagnosis NSCLC (Stage IIIA, IIIB, or IV), not amenable to curative surgery or radiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00391274",
    "statement": "* At least one prior chemotherapy for palliative therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00391274",
    "statement": "* Response Evaluation Criteria In Solid Tumors (RECIST) criteria for disease status assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00391274",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00391274",
    "statement": "* Concurrent administration of any other tumor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00391274",
    "statement": "* Pregnant or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00391274",
    "statement": "* Serious concomitant disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00391274",
    "statement": "* Inability or unwillingness to take folic acid or vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363766",
    "statement": "* Diagnosis of metastatic non-small-cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363766",
    "statement": "* At least 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363766",
    "statement": "* Have received 2 previous treatment regimens for metastatic non-small-cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363766",
    "statement": "* Serious pre-existing medical conditions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363766",
    "statement": "* Previous cancer (except skin cancer, excluding melanoma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363766",
    "statement": "* Have received 3 or more previous treatment regimens for metastatic non- small-cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363766",
    "statement": "* Active treatment with Coumadin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02538666",
    "statement": "* Subjects with histologically or cytologically confirmed extensive stage disease SCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02538666",
    "statement": "* Ongoing response of stable disease or better following 4 cycles of platinum-based first line chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02538666",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02538666",
    "statement": "* Subjects with symptomatic Central Nervous System (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02538666",
    "statement": "* Subjects receiving consolidative chest radiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02538666",
    "statement": "* Subjects with active, known, or suspected autoimmune disease are excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02538666",
    "statement": "* All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02538666",
    "statement": "Other protocol-defined inclusion/exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444766",
    "statement": "* Locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy OR advanced renal cell carcinoma (RCC) after prior therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444766",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444766",
    "statement": "* Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444766",
    "statement": "* Participants with untreated, symptomatic central nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444766",
    "statement": "* Participants with carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444766",
    "statement": "* Participants with active, known or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444766",
    "statement": "* Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444766",
    "statement": "* Other active malignancy requiring concurrent intervention",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444766",
    "statement": "Other protocol defined inclusion/exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685060",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685060",
    "statement": "* Patients with known hypersensitivity to any of the excipients of LDK378.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685060",
    "statement": "* Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685060",
    "statement": "* History of carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685060",
    "statement": "* Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685060",
    "statement": "* Clinically significant, uncontrolled heart disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685060",
    "statement": "* Systemic anti-cancer therapy given after the last dose of crizotinib and prior to starting study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Histologically- or cytologically-confirmed diagnosis of advanced or metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* PD-L1 positive tumor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Measureable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* No prior systemic chemotherapy for the treatment of the participant's advanced or metastatic disease (treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior to diagnosis of advanced or metastatic disease)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* No prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cancer, or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Submission of formalin-fixed diagnostic tumor tissue (in the case of participants having received adjuvant systemic therapy, the tissue should be taken after completion of this therapy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Female participants of childbearing potential must have a negative urine or serum pregnancy test and must be willing to use two adequate barrier methods of contraception or a barrier method plus a hormonal method starting with the screening visit through 120 days after the last dose of pembrolizumab or 180 days after the last dose of chemotherapeutic agents used in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Male participants with a female partner(s) of child-bearing potential must be willing to use two adequate barrier methods of contraception from screening through 120 days after the last dose of pembrolizumab or 180 days after the last dose of chemotherapeutic agents used in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or is echinoderm microtubule-associated protein-like 4(EML4) gene/anaplastic lymphoma kinase (ALK) gene fusion positive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* No tumor specimen evaluable for PD-L1 expression by the central study laboratory",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Squamous histology and received carboplatin in combination with paclitaxel in the adjuvant setting",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Is receiving systemic steroid therapy ≤3 days prior to the first dose of study therapy or receiving any other form of immunosuppressive medication with the exception of daily steroid replacement therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* The NSCLC can be treated with curative intent with either surgical resection and/or chemoradiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Expected to require any other form of systemic or localized antineoplastic therapy while on study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Any prior systemic cytotoxic chemotherapy, biological therapy or major surgery within 3 weeks of the first dose of study therapy; received lung radiation therapy \\>30 Gy within 6 months of the first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Known central nervous system metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Active autoimmune disease that has required systemic treatment in the past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Had allogeneic tissue/solid organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Interstitial lung disease or history of pneumonitis that has required oral or IV steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Has received or will receive a live vaccine within 30 days prior to the first study therapy (seasonal flu vaccines that do not contain live vaccine are permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Active infection requiring intravenous systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Known history of human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Known active Hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02220894",
    "statement": "* Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": ". Had the informed consent in writing for all prior to registration into the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "2. Had histologic or cytologic confirmation of locally advanced or metastatic (stage IIIb/IV) NSCLC (non-squamous histology). Participants with mixed tumor types could have been enrolled, unless small cell elements were discovered",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "3. Had measurable disease, defined as at least 1 lesion that could be accurately measured in at least 1 dimension (longest diameter) as ≥ 2.0 cm with conventional computerized tomography (CT) or magnetic resonance imaging (MRI) scans, or as ≥ 1.0 cm with spiral CT scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "4. Had no prior systemic chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "5. Was male or female ≥ 18 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "6. Had an estimated life expectance of ≥ 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "7. Had an ECOG performance status (PS) of 0, 1, or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "8. Was a nonpregnant, nonlactating female Was a male or female of childbearing potential who was willing to use an effective form of contraception while on therapy and for 90 days thereafter.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "9. Had adequate renal function as determined by the following within 2 weeks prior to study registration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* A calculated creatinine clearance greater than 45 mL/min using the Cockcroft-Gault formula",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* A urine dipstick or urinalysis for protein \\<2+ (Participants discovered to have ≥ 2+ proteinuria on dipstick or urinalysis at baseline had to undergo a 24 hour urine collection and had to have ≤ 1 gm of protein over 24 hours to be eligible).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "10. Had a hematologic evaluation within 2 weeks prior to study registration (and met the minimum values):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Had absolute neutrophil count (ANC) ≥ 1,500 cells/microL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Had platelet count ≥ 100,000 cells/microL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Had hemoglobin ≥ 9.9 gm/deciL (erythropoietin \\[e.g., Epogen®\\] could have been used to maintain or exceed this level)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Had a partial thromboplastin time (PTT) ≤ upper limit of normal (ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "11. Had a hepatic function evaluation within 2 weeks prior to study registration met the eligibility criteria for bilirubin, Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": ". Had received prior systemic chemotherapy or vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) inhibitor therapy at any time; or had received recent or current radiation therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "2. Had intrathoracic lung carcinoma of squamous cell histology. (Participants with extrathoracic-only squamous cell NSCLC were eligible. Participants with only peripheral lung lesions (of any NSCLC histology) were also eligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "3. Had cardiovascular diseases and related treatment, including the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* New York Heart Association Class ≥ 2 congestive heart failure; participants with a history of serious cardiac disease not adequately controlled; or a history of myocardial infarction or unstable angina pectoris within 6 months prior to study registration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* History of stroke or transient ischemic attack within 6 months of study registration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* History of hypertensive crisis or hypertensive encephalopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* History of thrombotic or hemorrhagic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Clinically meaningful peripheral vascular disease, or arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Inadequately controlled blood pressure (defined as systolic blood pressure \\>150 mm Hg and/or diastolic blood pressure \\>100 mm Hg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Significant vascular disease (e.g., aortic aneurysm, aortic dissection) within 6 months prior to study registration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Therapeutic anticoagulation (Participants receiving prophylactic anticoagulation for venous access devices were allowed providing they met certain criteria)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Chronic daily treatment with aspirin (≥ 325 mg/day) or nonsteroidal anti-inflammatory agents known to inhibit platelet function; treatment with dipyridamole, ticlopidine, clopidogrel, or cilostazol was not allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "4. Had a surgical procedure in anamnesis (medical history):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to study registration, or anticipation of need for major surgical procedure during the course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* In the case of high-risk procedures, such as liver resection, thoracotomy, or neurosurgery, within 8 weeks prior to study registration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Minor surgical procedures (e.g., fine needle aspirations, core biopsies) within 7 days prior to registration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "5. Had a serious nonhealing wound, active ulcer, or untreated bone fracture",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "6. Had a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study registration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "7. Had a history of gross hemoptysis (defined as bright red blood of ≥ 0.5 teaspoon) within 4 weeks prior to study registration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "8. Had a history of hypersensitivity reaction to drugs formulated with polysorbate 80 or platinum containing compounds",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "9. Had peripheral neuropathy ≥ Grade 2 (based on CTCAE v3.0)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "10. Had known central nervous system (CNS) disease, except for treated brain metastasis. However, participants with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to study registration were excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "11. Had a history of a malignancy other than NSCLC; exceptions to this included:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* Curatively treated basal cell carcinoma, cervical intraepithelial neoplasia, or localized prostate cancer with a current prostate-specific antigen (PSA) of less than 1.0 ng/dL on 2 successive evaluations at least 3 months apart, and the most recent evaluation being within 4 weeks of study registration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "* History of another malignancy that was curatively treated and no evidence of disease for a minimum of 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "12. Had symptoms of a clinically meaningful illness in the 90 days before study registration, or had history of other disease, (such as human immunodeficiency virus \\[HIV\\] positive, chronic infection \\[e.g., pulmonary tuberculosis\\], or hepatitis A, B, or C \\[active or previously treated\\]), had an active infection with fever, had metabolic dysfunction, had physical examination finding, or had clinical a laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug, that might affect the interpretation of the results of the study, or render the participant at high risk from treatment complications; (testing for these conditions was at investigator discretion)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "13. Had a mental condition rendering the participant unable to understand the nature, scope, and possible consequences of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00356122",
    "statement": "The above information is not intended to contain all considerations relevant to a patients potential participation in a clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04402060",
    "statement": "* Be at least 18 years of age at time of informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04402060",
    "statement": "* Diagnosis of active SARS CoV 2 infection using viral RNA or viral antigen within 7 days of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04402060",
    "statement": "* Respiratory failure requiring oxygen supplementation or either invasive or noninvasive mechanical ventilation with PaO2/FiO2 ratio \\>100 mm Hg. Respiratory failure cannot be fully explained by cardiac failure or fluid overload.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04402060",
    "statement": "* Treatment with immune checkpoint inhibitors, or other immunomodulators within 3 months prior to study enrollment (however, treatment with convalescent plasma, steroids, IL-6 inhibitors, and antiviral agents is NOT excluded)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04402060",
    "statement": "* Active bacterial, fungal, or parasitic infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04402060",
    "statement": "* History of neuromuscular degenerative disease (eg, amyotrophic lateral sclerosis, Duchenne muscular dystrophy, or multiple sclerosis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04402060",
    "statement": "* Current participation in an interventional clincial trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04402060",
    "statement": "* Subjects who have, at screening, been on mechanical ventilation for \\>7 days Have evidence of kidney and liver failure at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04402060",
    "statement": "* Have a hereditary complement deficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04402060",
    "statement": "* Pregnancy or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531960",
    "statement": "* adult patients, \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531960",
    "statement": "* advanced (stage IIIb and IV) non-small cell lung cancer;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531960",
    "statement": "* measurable disease;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531960",
    "statement": "* ECOG PS 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531960",
    "statement": "* prior chemotherapy or treatment with another systemic anti-cancer agent;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531960",
    "statement": "* radiotherapy within 4 weeks prior to first dose of study treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531960",
    "statement": "* CNS metastases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531960",
    "statement": "* other malignancies in past 5 years, except for adequately treated cancer in situ of the cervix, basal or squamous cell skin cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828112",
    "statement": ". Patient has a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as assessed by the FDA approved Abbott FISH Test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828112",
    "statement": "2. Patient has stage IIIB or IV diagnosis and must have received one or two prior regimens (including platinum- doublet) of cytotoxic chemotherapy for the treatment of locally advanced or metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828112",
    "statement": "3. Patient has at least one measurable lesion as defined by RECIST 1.1. A previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the irradiation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828112",
    "statement": "4. Patients must have received previous treatment with crizotinib for the treatment of locally advanced or metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828112",
    "statement": ". Patient with known hypersensitivity to any of the excipients of LDK378 (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828112",
    "statement": "2. Patient with a history of severe hypersensitivity reaction to pemetrexed or docetaxel or any known excipients of these drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828112",
    "statement": "3. Patient with symptomatic central nervous system (CNS) metastases who is neurologically unstable or has required increasing doses of steroids within the 2 weeks prior to screening to manage CNS symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Capable of giving signed informed consent/assent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Male or female, aged 18 years or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Body weight \\>=30 kilograms (kg).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Histological or cytological documentation of an invasive malignancy that was diagnosed as locally advanced/metastatic or relapsed/refractory and is of one of the following tumor types: a) Part 1: cutaneous melanoma; HNSCC (oral cavity, larynx, oropharynx, hypopharynx, nasal cavity/paranasal sinuses); non-small cell lung cancer (squamous and non-squamous); urothelial carcinoma of the upper and lower urinary tract; clear cell renal carcinoma; castrate resistant prostate adenocarcinoma. b) Part 2: HNSCC (oral cavity, larynx, pharynx, paranasal sinuses).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Part 1 only: Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists, or where standard therapy is refused. May be anti-PD-1/anti-PD-L1 experienced or naïve.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Part 2 only: Disease that has progressed after receiving platinum-based chemotherapy (unless medically contraindicated or discontinued due to toxicity) and anti-PD-1/anti-PD-L1 therapy (in combination or as separate lines of therapy in either sequence).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Measurable disease per RECIST version 1.1 guidelines. Palpable lesions that are not measurable by radiographic or photographic evaluations may not be utilized as the only measurable lesion. Any measurable lesion biopsied at Screening cannot be followed as a target/index lesion unless agreed upon by GlaxoSmithKline (GSK).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions apply: a) Not a woman of childbearing potential (WOCBP); or, b) A WOCBP who agrees to follow the contraceptive while receiving study intervention and for at least 180 days after the last dose of study intervention.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* A male subject must agree to use a highly effective contraception while receiving study intervention and for at least 180 days after the last dose of study intervention and refrain from donating sperm during this period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Agree to collection of tumor tissue: a) Part 1 and Part 2: Archival tumor tissue collected any time from the initial diagnosis of invasive malignancy; a fresh tumor biopsy will be required if archival specimen is unavailable prior to first dose. b) Part 1 pharmacokinetic/pharmacodynamic cohort(s): Archival tissue as noted in point (a) above. Paired tumor biopsies: tumor tissue collected any time after completion of dosing of the last therapy and prior to first dose and an on-treatment biopsy. c) Part 2: A minimum of 15 subjects from each arm will be required to provide paired tumor biopsies (in addition to the archival tissues as noted in point (a) above): tumor tissue collected any time after completion of dosing of the last therapy and prior to first dose and an on-treatment biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Received prior treatment with the following therapies; calculation is based on date of last therapy to date of first dose of study intervention or SOC: a) Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4 \\[including tremelimumab\\] or Inducible T Cell Co-Stimulator (ICOS)-directed therapies at any time; b) \\>=4 lines of prior anticancer treatment: In subjects that relapse or progress within 1 year from the beginning of adjuvant or concurrent therapy, the adjuvant/concurrent therapy is considered first line therapy; c) Systemic anticancer therapy or investigational therapy within 30 days, or 5 half-lives, whichever is shorter; at least 14 days must have elapsed between the date of the last prior therapy to the date of first dose of study intervention or SOC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Prior radiation therapy: permissible if at least one non-irradiated measurable lesion is available for assessment per RECIST v1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. At least 14 days must have elapsed between the date of the last dosage of radiation and the first dose of study intervention/SOC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Invasive malignancy or history of invasive malignancy other than disease under study within the last two years, except: a) Any other invasive malignancy for which the subject was definitively treated, has been disease-free for \\<=2 years and in the opinion of the Investigator and Medical Monitor will not affect the evaluation of the effects of the study intervention or SOC on the currently targeted malignancy, may be included in this clinical study; Curatively treated non-melanoma skin cancer or successfully treated in-situ carcinoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Toxicity from previous anticancer treatment that includes: a) \\>=Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation; b) Toxicity related to prior treatment that has not resolved to \\<=Grade 1 (except alopecia, vitiligo, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \\<=Grade 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Central nervous system (CNS) metastases, with the following exception: Subjects with previously treated CNS metastases who are clinically stable and had no requirement for steroids during at least 14 days prior to first dose of study intervention or SOC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Major surgery \\<=28 days of first dose of study intervention or SOC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Autoimmune disease (current or history) or syndrome that required systemic treatment within the past 2 years. Replacement therapies which include physiological doses of corticosteroids for treatment of endocrinopathies (i.e., adrenal insufficiency) are not considered systemic treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Recent history (within 24 weeks) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Receiving systemic steroids (\\>=10 milligrams \\[mg\\] oral prednisone or equivalent) or other immunosuppressive agents within 7 days prior to first dose of study intervention or SOC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Prior allogeneic/autologous bone marrow or solid organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Received live-virus vaccine within 30 days from start of study intervention or SOC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Current or history of idiopathic pulmonary fibrosis, pneumonitis (for past, subject is excluded if steroids were required), interstitial lung disease or organizing pneumonia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Recent history (within 24 weeks) of uncontrolled, symptomatic ascites, pleural or pericardial effusions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* History or evidence of cardiac abnormalities within the 24 weeks prior to enrollment which include: a) Serious uncontrolled cardiac arrhythmia or clinically significant electrocardiogram abnormalities including second degree (Type II) or third degree atrioventricular block. b) Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting, or bypass grafting. c) Symptomatic pericarditis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Known human immunodeficiency virus infection; positive test for hepatitis B active infection (presence of hepatitis B surface antigen) or hepatitis C active infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* History of severe hypersensitivity to monoclonal antibodies, the Standard of Care agents, including any ingredient used in the formulation, based on which treatment the subject is to receive.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* For subjects receiving SOC: Requires therapy with a medication that may alter the PK of the SOC agent (e.g., strong inducers or inhibitors of cytochrome P (CYP)3A4 for subjects receiving docetaxel or paclitaxel) during the study treatment period. Please refer to the package insert for the agent the subject is to receive.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693612",
    "statement": "* For subjects receiving SOC: Any contraindication, per the package insert and/or Institutional guidelines, to the treatment the subject is to receive.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Patients with Histologically or cytologically confirmed diagnosis of stage IIIb/IV NSCLC (AJCC 7.0), who had failed one or two systemic chemotherapy regimens, one of which must be platinum-based .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Tumor tissue with HER2 mutations as confirmed by AmoyDx® HER2 Mutation Detection Kit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Patients with at least one measurable tumor lesion that can accurately be measured by CT scan or MRI according to RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Age\\>=18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Recovered from any previous therapy related toxicity to \\<=Grade 1 at study entry (except for stable sensory neuropathy \\<=Grade 2 and alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Written informed consents that is consistent with International Conference on Harmonisation (ICH) - Good Clinical Practice (GCP) and local GCP guidelines Inclusion criterion for Part B",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Adequate organ function, as inclusion criteria No.6",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* ECOG performance score 0\\~2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* More than 12 weeks clinical benefit (PR, Complete Response (CR), SD) in part A Further inclusion criteria apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Prior treatment with Epidermal Growth Factor Receptor (EGFR) or HER2 targeting small molecules or antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Any chemo-, or immune anticancer therapy within 4 weeks prior to start of study treatment, Hormonal treatment within 2 weeks prior to start of study treatment, Radiotherapy within 4 weeks prior to start of treatment, except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "  i.) Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to enter, and ii.) Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Known hypersensitivity to afatinib or the excipients of any of the trial drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of \\>= 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to randomisation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Requiring treatment with any of the prohibited concomitant medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Known pre-existing interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Active hepatitis B infection and/or active hepatitis C infection and/or known HIV carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Leptomeningeal carcinomatosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Symptomatic brain metastases; To be eligible patients must be asymptomatic from brain metastases at least 4 weeks without requirement for steroids or anti-epileptic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use highly effective methods of birth control for the duration of study participation and for at least 2 weeks after treatment has ended.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02597946",
    "statement": "* Women who are pregnant, nursing, or who plan to become pregnant while in the trial Exclusion criterion for Part B Any known contraindication for paclitaxel treatment. Not able to tolerate lowest dose of afatinib. Peripheral polyneuropathy \\>Grade 2 Further exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Ability to understand and willingness to sign a written Informed Consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Advanced relapsed or refractory predominantly non squamous NSCLC. The diagnosis must have been confirmed cyto-/ histologically",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Patients must have measurable or non-measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* At least two but not more than three prior standard treatment regimens for NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Male or female subjects \\>/= 18 years of age (\\>/=20 for Japan) at the time of Informed Consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Ability to swallow oral medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Both men and women using adequate barrier birth control measures during the course of the trial and 4 weeks after the completion of trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of the study drug:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Haemoglobin \\> 9.0 g/dl",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Absolute neutrophil count (ANC) \\>1,500/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Platelet count \\>/= 100,000/µl",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Total bilirubin \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "/= 50 mL/min",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* NSCLC patients with predominantly squamous cell carcinoma histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "Excluded medical conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* History of cardiac disease: Congestive heart failure, Active coronary artery disease (CAD), Cardiac arrhythmias (\\>Grade 2 NCI-CTCAE \\[National Cancer Institute-Common Terminology Criteria for Adverse Events\\] vers. 3.0)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Uncontrolled hypertension despite two anti-hypertensive medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* History of Human immunodeficiency virus (HIV) infection or chronic hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* History of organ allograft",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Active clinically serious infections (\\> grade 2 NCI-CTCAE vers. 3.0)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Patients with seizure disorder requiring medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Patients with evidence or history of bleeding diathesis or coagulopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Patients undergoing renal dialysis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Pulmonary hemorrhage/ bleeding event \\>/= CTCAE grade 2 within four weeks prior to the first dose of the study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Any other hemorrhage/ bleeding event \\>/= CTCAE grade 3 within four weeks prior to the first dose of the study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Thrombotic or embolic venous or arterial events such as cerebrovascular accident",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Pregnant or breast-feeding women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Any condition which could affect the absorption or pharmacokinetics of the study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00863746",
    "statement": "* Prior treatment with other Vascular Endothelial Growth Factor (VEGF) (R) inhibitors, including compounds that impact vascularity (i.e. sunitinib, thalidomide, vandetanib, vascular disrupting agents \\[VDA\\], VEGF-trap and other experimental agents of this class). Only bevacizumab (Avastin) is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00138658",
    "statement": ". Patients must have a histologically or cytologically confirmed diagnosis of NSCLC and must not have had chemotherapy or biological therapy for their disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00138658",
    "statement": "2. Stage IIIB (N3 and/or pleural or pericardial effusion) or IV disease that is not amenable to either surgery or radiation therapy of curative intent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00138658",
    "statement": "3. Life expectancy of ≥ 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00138658",
    "statement": "4. If patient has had prior radiation therapy: lesion(s) used for determination of response was not previously irradiated or has increased in size since the completion of radiotherapy; and patient has recovered from any toxicity from the radiotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00138658",
    "statement": "5. Radiotherapy to lesion(s) used for determination of response was completed at least 6 weeks prior to treatment; radiotherapy to other sites was completed at least 2 weeks prior to treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00138658",
    "statement": "6. At least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors \\[RECIST\\] (at least 10 mm in longest diameter by spiral computed tomography \\[CT\\] scan, or at least 20 mm by standard techniques).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00138658",
    "statement": "7. ECOG status must be ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00138658",
    "statement": ". Prior chemotherapy or biological therapy (approved or experimental) for NSCLC, including adjuvant and neoadjuvant treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00138658",
    "statement": "2. Presence of central nervous system (CNS) metastases, unless the patient has completed successful local therapy for CNS metastases, with the exception of leptomeningeal disease for which patients will be excluded. Patients must be off corticosteroids for at least 21 days prior to starting treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00138658",
    "statement": "3. Second primary malignancy (except in situ carcinoma of the cervix, adequately treated non-melanomatous skin cancers, clinically localized prostate cancer, superficial bladder cancer or other malignancy treated at least 3 years previously with no evidence of recurrence).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00138658",
    "statement": "4. Patients eligible for combined modality therapy with curative intent as defined by the combination of chemotherapy, radiation therapy and/or surgery. (This criteria is intended to exclude patients with stage IIIB disease, as defined by the presence of N3 nodal status, who have been reported to have cure rates as high as 10% when treated with combined modality therapy.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* Adult participants greater than or equal to 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* PD-L1-positive tumor status as determined by an immunohistochemistry (IHC) assay based on PD-L1 expression on tumor infiltrating immune cells and/or tumor cells performed by a central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* Measurable disease, as defined by RECIST version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exception are allowed:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "Hormone-replacement therapy or oral contraceptives tyrosine-kinase inhibitors (TKIs) approved for treatment of NSCLC discontinued \\>7 days prior to Cycle 1, Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* Central nervous system (CNS) disease, including treated brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with negligible risk of metastases or death and treated with expected curative outcome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* History of autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* History of idiopathic pulmonary fibrosis (including pneumonia), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening CT scan. History of radiation pneumonitis in the radiation field (fibrosis) id permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* Active hepatitis B or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* Human Immunodeficiency virus (HIV) positive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02031458",
    "statement": "* Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Evidence of histologically or cytologically confirmed diagnosis of metastatic NSCLC (Stage IV, AJCC v7.0) that carries an ALK rearrangement, as determined by the Food and Drug Administration (FDA) approved FISH assay (Abbott Molecular Inc) or by Immunohistochemistry (IHC) (Ventana Inc), or a ROS1 rearrangement as determined by FISH or RT PCR or Next Generation Sequencing (NGS) via a local diagnostic test (LDT). All patients (ALK positive and ROS1 positive) must have archival tissue sample available and collected prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Disease Status Requirements:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "Phase 1: ALK-positive NSCLC and ROS1-positive patients must either be treatment naïve in the advanced setting or have had disease progression after at least 1 previous ALK/ROS1 inhibitor therapy(ies).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "Phase 2:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "ALK-positive NSCLC patients must either be or have had:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Treatment naïve (ie, no prior chemotherapy in the metastatic disease setting and no prior ALK inhibitor therapy allowed).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Disease progression after crizotinib only. No prior chemotherapy is allowed in the metastatic disease setting.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Disease progression after crizotinib and 1 or 2 prior regimens of chemotherapy in the metastatic disease setting.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Disease progression after 1 prior ALK inhibitor therapy other than crizotinib. Patients may have had any number of prior chemotherapy regimens in any disease setting.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Disease progression after 2 prior ALK inhibitor therapies. Patients may have had any number of prior chemotherapy regimens in any disease setting.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Disease progression after 3 prior ALK inhibitor therapies. Patients may have had any number of prior chemotherapy regimens in any disease setting.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "ROS1-positive NSCLC patients may be:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Treatment naïve (ie, no prior chemotherapy in the metastatic disease setting and no prior ROS inhibitor therapy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Any number of prior therapies (ie, chemotherapy and/or ROS inhibitor therapies).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Tumor Requirements:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "All Patients must have at least one measurable target extracranial lesion according to RECIST v1.1. In addition patients with asymptomatic CNS metastases (including patients asymptomatic by means of stable or decreasing doses of steroids within the last 2 weeks prior to study entry) will be eligible. Patients who have leptomeningeal disease (LM) or carcinomatous meningitis (CM) are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Adequate Bone Marrow, Pancreatic Function, Renal Function and Liver Function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Negative Serum pregnancy test for females of childbearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Whole brain radiation must have completed at least 4 weeks prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Systemic anti cancer therapy completed within a minimum of 5 half lives of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including, but not limited to, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4 (anti-CTLA-4) antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Clinically significant cardiovascular disease (that is, active or \\<3 months prior to enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association Classification Class ≥ II), second-degree or third-degree AV block (unless paced) or any AV block with PR \\>220 msec. Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as \\<50 bpm (unless patient is otherwise healthy such as long-distance runners, etc.), machine-read ECG with QTc \\>470 msec, or congenital long QT syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970865",
    "statement": "* Current use or anticipated need for food or drugs that are known strong or moderate CYP3A4 inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs that are sensitive CYP2B6 substrates; drugs that are strong CYP2C19 inhibitors; drugs that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* Primary tissue from patient's surgery must be epidermal growth factor receptor (EGFR)-positive by certain tests",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* Patients may have up to 4 cycles of chemotherapy after surgery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* Complete removal of the tumor by surgery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* Able to start drug under the following timelines:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* 6 months from the day of surgery for patients who get chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* 3 months from the day of surgery for those who do not get chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* Confirmed diagnosis of Stage IB-IIIA NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* Patients must be accessible for follow-up visits",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* History of prior radiotherapy for NSCLC either before or after surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* History of heart disease or uncontrolled heart arrhythmias within the previous year",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* History of poorly controlled gastrointestinal (GI) disorders that could affect the absorption of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* History of other cancer except certain skin or cervical cancers, patients who have had other cancer are eligible if they have remained disease free for at least 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* Patients who have received chemotherapy for NSCLC before surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "* Tumors with mixed histology of NSCLC and Small Cell Lung Cancer (SCLC). Patients with carcinoid tumors are not eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316225",
    "statement": "* Diagnosis of locally advanced or metastatic (Stage III or IV at entry) non-small cell lung cancer (NSCLC) or mesothelioma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316225",
    "statement": "* Presence of third-space fluid (fluid around the lungs or abdomen).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316225",
    "statement": "* Eastern Cooperative Oncology Group Performance Status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316225",
    "statement": "* Prior anticancer treatment (except radiation) must be completed at least 3 weeks prior to study enrollment, and the patient must have recovered from the sharp toxic effects the anticancer treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316225",
    "statement": "* Estimated life expectancy of at least 8 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316225",
    "statement": "* Have received treatment within the last 30 days with a drug that was not a marketed product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316225",
    "statement": "* Active infection that, in the opinion of the investigator, would not allow the patient to tolerate therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316225",
    "statement": "* Pregnancy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316225",
    "statement": "* Breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316225",
    "statement": "* Significant weight loss (that is, greater than or equal to 10% of body weight) over the 6 weeks before study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00316225",
    "statement": "* Brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has a cytologically or histologically and radiologically confirmed, advanced, recurrent, or metastatic solid tumor of the nine types listed below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Pancreatic Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Castration-Resistant Prostate Cancer (CRPC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Hepatocellular Carcinoma (HCC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Gastric or Gastroesophageal Junction Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Melanoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Small Cell Lung Cancer (SCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Ovarian cancer, primary peritoneal or fallopian tube carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Breast cancer that is one of the following subtypes: estrogen receptor positive breast cancer, estrogen receptor/progesterone receptor/HER2-negative (triple-negative), or inflammatory (regardless of receptor status) disease histology",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Non-Small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Certain requirements for prior therapies may apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has documented progressive disease at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Subjects having any tumor type of other than CRPC must have at least one lesion that is not within a previously irradiated field and is measurable on CT or MRI scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has recovered to baseline or CTCAE ≤ Grade 1 from toxicities related to prior treatment (some exceptions apply)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject is ≥ 18 years old on the day of consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Tissue samples from archival or fresh tissue, or a tissue block of the subject's tumor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Sexually active fertile subjects (male and female), and their partners, must agree to use medically accepted methods of contraception during the course of the study and for 3 months after the last dose of the study drug(s)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Female subjects of childbearing potential must have a negative pregnancy test at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has experienced clinically-significant hematemesis or hemoptysis of \\>0.5 teaspoon of red blood, or other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has a cavitating pulmonary lesion(s) or a pulmonary lesion abutting or encasing a major blood vessel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* Certain restrictions on prior treatments apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has known symptomatic or uncontrolled brain metastases or epidural disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has prothrombin time/International Normalized Ratio (PT/INR) or partial thromboplastin time (PTT) test results that are above (1.3x)the laboratory upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or Coumadin-related agents, heparin, thrombin or FXa inhibitors, and antiplatelet agents (low-dose aspirin (≤81 mg/day), low-dose warfarin (≤1mg/day, and prophylactic low molecular weight heparin (LMWH) are permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has a corrected QT interval(QTcF)\\>500 ms at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has uncontrolled, significant intercurrent illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject is unable to swallow capsules",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject is pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00940225",
    "statement": "* The subject has had another diagnosis of malignancy requiring systemic treatment within the last two years, unless non-melanoma skin cancer, in-situ carcinoma of the cervix, or superficial bladder cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00818441",
    "statement": "* Advanced adenocarcinoma of lung, measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00818441",
    "statement": "* Non-smoker, or former light (less than 10 pack years and stopped at least 15 years); OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00818441",
    "statement": "* patients with known EGFR activating mutation regardless of smoking status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00818441",
    "statement": "* ECOG(Eastern Cooperative Oncology Group) 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00818441",
    "statement": "Cohort B (select sites only): patients with HER2 amplified or HER2 mutation-positive NSCLC; may have had prior therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00818441",
    "statement": "* Active brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00818441",
    "statement": "* Prior systemic therapy for advanced disease in Cohort A only. Cohort B can have had any number of prior lines of systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00818441",
    "statement": "* known EGFR wild type NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Histologically or cytologically confirmed diagnosis of Stage IV (American Joint Committee on Cancer \\[AJCC\\], version 8 or current version), nonsquamous NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Confirmation that Epidermal Growth Factor Receptor (EGFR), ALK Receptor Tyrosine Kinase (ALK), or ROS1 Receptor Tyrosine Kinase (ROS1)-directed therapy is not indicated as primary treatment (documentation of absence of tumor-activating EGFR mutations AND absence of ALK and ROS1 gene rearrangements OR presence of a Kirsten Rat Sarcoma (KRAS) gene mutation).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Have measurable disease based on RECIST 1.1. Note: Lesions that appear measurable, but are situated in a previously irradiated area, can be considered measurable (eligible for selection as target lesions) if they have shown documented growth since the completion of radiation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion (not previously irradiated).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study intervention but before randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Male participants must agree for at least 7 days after the last dose of lenvatinib/matching placebo and up to 180 days after the last dose of chemotherapeutic agents to:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "  1. Refrain from donating sperm PLUS either:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "  2. Be abstinence from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "  3. Must agree to use contraception unless confirmed to be azoopsermic (vasectomized or secondary to medical cause) as detailed below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "     1. Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "Note: 7 days after lenvatinib/matching placebo is stopped, if the participant is on pembrolizumab only and is greater than 180 days post chemotherapy, no male contraception measures are needed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "  1. Is not a WOCBP OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "  2. Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days post pembrolizumab and/or 30 days post-lenvatinib/matching placebo, and up to 180 days post last dose of chemotherapeutic agents, whichever occurs last.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week prior to randomization. Note: Participants must not have a history of uncontrolled or poorly-controlled hypertension, defined as \\>150/90 mm Hg for \\>4 weeks despite standard medical management.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, clinically stable, and have not required steroids for at least 14 days prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel. Additionally, the degree of proximity to major blood vessels should be considered for exclusion because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis after lenvatinib-therapy. (In the chest, major blood vessels include the main pulmonary artery, the left and right pulmonary arteries, the 4 major pulmonary veins, the superior or inferior vena cava, and the aorta).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy. Note: The time requirement also does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Has had allogeneic tissue/solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Known history of Hepatitis B or active Hepatitis C. No testing for Hepatitis B or Hepatitis C is required unless mandated by the local health authority.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* History of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral drug absorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Active hemoptysis (at least 0.5 teaspoon of bright red blood) within 2 weeks prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Significant cardiovascular impairment within 12 months prior to the first dose of study intervention, including history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction, cerebrovascular accident (CVA)/stroke, or cardiac arrhythmia associated with hemodynamic instability.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Known history of active tuberculosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Has not recovered adequately from any toxicity and/or complication from major surgery prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Previously had a severe hypersensitivity reaction to treatment with a monoclonal antibody or has a known sensitivity to any component of lenvatinib or pembrolizumab, or as applicable, carboplatin, cisplatin, or pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* A WOCBP who has a positive urine pregnancy test within 24 hours prior to randomization or treatment allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Received prior treatment with pembrolizumab or any other anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent, with lenvatinib or any other receptor tyrosine kinase inhibitor (RTKi), or with an agent directed to another stimulatory or co-inhibitory T cell receptor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Received radiotherapy within 14 days prior to the first dose of study intervention or received lung radiation therapy of \\>30 Gy within 6 months prior to the first dose of study intervention. Note: Participants must have recovered from all radiation-related toxicities to Grade ≤1, not required corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Received systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention. Note: killed vaccines are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Has a prolongation of QTc interval (calculated using Fridericia's formula) of \\>480 msecl.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Left ventricular ejection fraction (LVEF) below the institutional (or local laboratory) normal range as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829319",
    "statement": "* Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00701558",
    "statement": "* adult patients, \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00701558",
    "statement": "* advanced and/or metastatic (stage IIIB/IV) unresectable non-small cell lung cancer;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00701558",
    "statement": "* no previous systemic chemotherapy, radiation therapy or immunotherapy;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00701558",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) \\>=2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00701558",
    "statement": "* prior systemic anti-tumor therapy with human epidermal growth factor receptor 1 (HER1/EGFR) inhibitors;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00701558",
    "statement": "* active, non-controlled systemic disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00701558",
    "statement": "* any other malignancies within 5 years (except for adequately treated cancer in situ of cervix, or basal or squamous cell skin cancer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": ". Pathologically or cytologically confirmed diagnosis of Stage IIIB or Stage IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "2. Patients who have failed conventional treatment (at least 1 prior treatment line), or for whom no therapy of proven efficacy exists",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "3. Patients whose tumors:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "* are EGFR mutation-positive or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "* are EGFR mutation-negative or unknown provided they had disease progression after achieving either response or stable disease for at least 6 months from a previous treatment with erlotinib (Tarceva®) or gefitinib (Iressa®)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "4. Patients aged 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "5. Life expectancy of at least three (3) months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "6. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "7. Written informed consent that is consistent with ICH-GCP guidelines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": ". Prior major surgery, chemotherapy or radiation therapy within 4 weeks before start of therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "2. Prior treatment with an mTOR inhibitor within the past 4 weeks before start of therapy or concomitantly with this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "3. Use of erlotinib (Tarceva®) or gefitinib (Iressa®) within 14 days of run-in treatment with Sirolimus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "4. Active CNS metastases (defined as stable for \\<4 weeks and/or symptomatic and/or requiring treatment with anticonvulsants or steroids)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "5. Severe alteration in serum fasting cholesterol (equal or more than 350 mg/dL) or triglycerides (equal or more than 400 mg/dL). Patients may be allowed to enrol on the trial after initiation of lipid lowering agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "6. Requirement for treatment with any of the prohibited concomitant medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "* Concomitant CYP3A4 inhibitors within the past 7 days before start of therapy or concomitantly with this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "* Concomitant CYP3A4 inducers within the past 14 days before start of therapy or concomitantly with this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "7. Any contraindications for therapy with Sirolimus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "8. Known hypersensitivity to BIBW 2992, Sirolimus or other rapamycin analogues (everolimus, temsirolimus, deforolimus, etc.) or the excipients of any of the trial drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "9. Use of any investigational drug within 4 weeks before start of therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03215706",
    "statement": "* Participants with histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03215706",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03215706",
    "statement": "* Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03215706",
    "statement": "* Participants must have PD-L1 IHC testing with results performed by a central laboratory during the screening period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03215706",
    "statement": "* Participants with known epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapy (including, but not limited to, deletions in exon 19 and exon 21 \\[L858R\\] substitution mutations) are excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03215706",
    "statement": "* Participants with known anaplastic lymphoma kinase (ALK) translocations which are sensitive to available targeted inhibitor therapy are excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03215706",
    "statement": "* Participants with untreated CNS metastases are excluded. Participants are eligible if CNS metastases are adequately treated and participants are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to first treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03215706",
    "statement": "Other protocol inclusion/exclusion criteria may apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": ". Evidence of histologically or cytologically confirmed diagnosis of unresectable advanced and/or recurrent NSCLC that carries an ALK rearrangement, as detected by an appropriate test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "2. Disease progression or intolerance to 1 previous treatment with ALK TKI. Participants may have also had prior chemotherapy for their advanced and/or recurrent disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "3. Participants with asymptomatic CNS metastases (including participants controlled with stable or decreasing steroid use within the last 2 weeks prior to study enrollment) will be eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "4. Age ≥18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "6. Adequate hematologic and renal function as defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   1. Absolute neutrophil count (ANC) ≥1,000/mm3;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   2. Platelets ≥50,000/mm3;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   3. Hemoglobin ≥8 g/dL;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   4. Estimated creatinine clearance ≥30 mL/min as calculated using the method standard for the institution.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "7. Adequate liver function, including:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   1. Total serum bilirubin ≤1.5 × upper limit of normal (ULN);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5.0 × ULN in case of liver metastases).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "8. Adequate pancreatic function, including:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   1. Serum total amylase ≤1.5 × ULN.\\*",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   2. Serum lipase \\<1.5 × ULN. \\*if total amylase \\>1.5 × ULN, but pancreatic amylase is within the ULN, the participant may be enrolled.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "9. Acute effects of any prior therapy resolved to baseline severity or to CTCAE Grade \\<1 except for AEs that in the Investigator's judgment do not constitute a safety risk for the participant.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "10. Systemic anticancer therapy completed within a minimum of 5 half-lives of study enrollment (unless clinically meaningful tumor flare per discretion of the Investigator, in which discussion with the Sponsor is warranted).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "11. Evidence of a personally signed and dated informed consent document indicating that the participant (or a legally acceptable representative) has been informed of all pertinent aspects of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "12. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "13. Pregnancy test for females of childbearing potential negative at Screening or female participants who are not of childbearing potential. Male and female participants of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception from the time of Screening, throughout the study and for 3 months after the last dose of assigned treatment, 6 months if female participants.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": ". Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study enrollment. Palliative radiation (\\<10 fractions) must have been completed at least 48 hours prior to study enrollment. Stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study enrollment. Whole brain radiation must have completed at least 4 weeks prior to study enrollment. Prior irradiation to \\>25% of the bone marrow.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "2. Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "3. Known prior or suspected severe hypersensitivity to study drug or any component in its formulation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "4. Active and clinically significant bacterial, fungal, or viral infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "5. Clinically significant vascular (both arterial and venous) and non-vascular cardiac conditions (active or within 3 months prior to enrollment), which may include, but are not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   1. Arterial disease such as cerebral vascular accident/stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction, unstable angina;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   2. Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary embolism;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   3. Non-vascular cardiac disease such as congestive heart failure (New York Heart Association Classification Class ≥II), second degree or third degree atrioventricular (AV) block (unless paced) or any AV block with PR interval \\>220 msec; or ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as \\<50 beats per minute (bpm) (unless participant is otherwise healthy such as long distance runners, etc.), machine read ECG with QT interval corrected for heart rate (QTc) \\>470 msec, or congenital long QT syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "6. History or known presence of interstitial fibrosis, interstitial lung disease (ILD), pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and pulmonary fibrosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "7. Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the participant inappropriate for enrollment in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "8. Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, ductal carcinoma in situ \\[DCIS\\] of the breast or localized and presumed cured prostate cancer) within the last 3 years prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "9. Concurrent use of any of the following food or drugs (consult the Sponsor if in doubt whether a food or a drug falls into any of the categories described below) within 12 days prior to the first dose of lorlatinib:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   1. Known strong cytochrome (CYP)3A inducers (eg, carbamazepine, enzalutamide, mitotane, rifampin, St. John's Wort).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   2. Known strong CYP3A inhibitors (eg, grapefruit juice or grapefruit/grapefruit related citrus fruits \\[eg, Seville oranges, pomelos\\], boceprevir, cobicistat, clarithromycin, conivaptan, diltiazem, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nelfinavir, paritaprevir, posaconazole, ritonavir alone and with elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir and voriconazole). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   3. Known CYP3A substrates with narrow therapeutic index, such as pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "   4. Known permeability glycoprotein (P-gp) substrates with a narrow therapeutic index (eg, digoxin).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "10. Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or participants who are Pfizer employees directly involved in the conduct of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "11. Participation in other studies involving investigational drug(s) (Phases 1-4) during study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "12. Breastfeeding female participants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828099",
    "statement": ". The patient had a histologically or cytologically confirmed diagnosis of non-squamous Non-small cell lung cancer (NSCLC) that was Anaplastic lymphoma kinase (ALK) positive as assessed by the Ventana Immunohistochemistry (IHC) test. The test was performed at Novartis designated central laboratories.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828099",
    "statement": "2. The patient had a newly diagnosed stage IIIB (who was not a candidate for definitive multimodality therapy) or stage IV NSCLC or relapsed locally advanced or metastatic NSCLC not previously treated with any systemic anti-cancer therapy (e.g. cytotoxic drugs, monoclonal antibody therapy, crizotinib or other ALK inhibitors, or other targeted therapies, either experimental or not), with the exception of neo-adjuvant or adjuvant therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828099",
    "statement": "3. The patient had at least one measurable lesion as defined by RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828099",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828099",
    "statement": ". The patient had known hypersensitivity to any of the excipients of LDK378 (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide, and magnesium stearate).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828099",
    "statement": "2. The patient had a history of severe hypersensitivity reaction to platinum-containing drugs, pemetrexed, or any known excipients of these drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01828099",
    "statement": "3. The patient had symptomatic central nervous system (CNS) metastases and was neurologically unstable or had required increasing doses of steroids within the 2 weeks prior to screening to manage CNS symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": ". Male and female patients aged \\>18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "2. Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with pleural effusion) or Stage IV and histopathological classification of adeno- or bronchoalveolar carcinoma (BAC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "3. Increased EGFR gene copy number assessed by FISH analysis. After signed informed consent, positive result to EGFR FISH determination is mandatory to proceed to other screening assessments.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "4. At least one tumour lesion that can accurately be measured by computed tomography (CT) or magnetic resonance imaging (MRI) in at least one dimension with longest diameter to be recorded as more or same 20 mm using conventional techniques or moro or same 10 mm with spiral CT scan.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "5. Patients not previously exposed to chemotherapy for NSCLC (1st line patients, 40 in total; for these subjects adjuvant chemotherapy is allowed if at least 12 months elapsed since last course of treatment), or patients with relapse after one systemic treatment (2nd line patients, 30 in total; if less than 12 months elapsed since adjuvant chemotherapy, patients are 2nd line ones, as adjuvant chemotherapy must be considered a line of treatment).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "6. Life expectancy of at least three (3) months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "7. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0, 1 or 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "8. Written informed consent that is consistent with ICH-GCP guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": ". More than two (2) prior cytotoxic chemotherapy treatment regimens for relapsed or metastatic NSCLC, included adjuvant chemotherapy if relapse occurred less than 12 months before",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "2. Previous treatment with erlotinib (Tarceva®), gefitinib (Iressa®) or any other EGFR inhibiting small molecule or antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "3. Active brain metastases (stable \\<4 weeks, symptomatic, requiring treatment with anticonvulsants, or leptomeningeal disease). Dexamethasone therapy will be allowed if administered as a stable dose for at least one month before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "4. Chemo-, hormone- (other than megestrol acetate or steroids required for maintenance non-cancer therapy) or immunotherapy within the past 4 weeks before first drug administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "5. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn disease, malabsorption, or CTCAE Grade \\>2 diarrhea of any etiology at baseline",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "6. Patients who have any other life-threatening illness or organ system dysfunction which, in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "7. Other malignancies diagnosed within the past five (5) years (other than non melanomatous skin cancer and in situ cervical cancer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "8. Radiotherapy within the past 2 weeks prior to treatment with the trial drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "9. Patients with any serious active infection (i.e., requiring an IV antibiotic, antifungal, or antiviral agents).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "10. Patients with known HIV, active hepatitis B or active hepatitis C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "11. Known or suspected active drug or alcohol abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "12. Women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "13. Pregnancy or breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00796549",
    "statement": "14. Patients unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02013206",
    "statement": "* adult patients, \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02013206",
    "statement": "* histologically documented advanced non-small cell lung cancer (stage IIIB/IV);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02013206",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02013206",
    "statement": "* no previous chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02013206",
    "statement": "* previous therapy which acts on Epidermal Growth Factor Receptor (EGFR) axis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02013206",
    "statement": "* clinical evidence of brain metastasis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02013206",
    "statement": "* any unstable systemic disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02013206",
    "statement": "* unable to take oral medication;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02013206",
    "statement": "* any significant ophthalmological abnormality.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": ". Patient's age was ≥ 18 years of age at the time of signing informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "2. Patient had a confirmed diagnosis of a selected solid tumor (except for primary diagnosis of urothelial tumors, hepatocellular carcinoma (HCC), endometrial carcinoma, metastatic breast cancer (mBC), squamous NSCLC, and renal cell carcinoma (RCC)) or hematologic malignancies (except for primary diagnosis of FLT3 AML and multiple myeloma). Additional tumor types could be excluded during the course of the study in the case of early futility or success based upon an interim analysis or at the discretion of Novartis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "3. Patient was in need of treatment because of progression or relapse defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "* radiological progression for solid tumor and lymphoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "* for hematologic malignancies, measureable progression or relapse by appropriate criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "4. Patients had pre-identified tumor with a mutation and/or translocation of one of the known kinase targets of dovitinib. The qualifying alteration were assessed and reported by a CLIA-certified laboratory. The mutations included:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "   1. FGFR 1-3 (amplifications were also allowed)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "   2. PDGFRα or PDGFRβ",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "   3. VEGFR1-2 (KDR)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "   4. FLT3, cKIT (amplifications are also allowed),",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "   5. RET, TrkA (NTRK1), or CSF-1R",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "5. Patient had archival tissue available for submission to allow for molecular testing related to pathway activation. If the tissue was not available or not of sufficient quantity the patient was willing to undergo a fresh tumor biopsy to allow for this analysis. The sample was submitted prior to first study dose unless agreed upon between Novartis and the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "6. Patient received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options were anticipated to result in a durable remission.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "7. Diffuse large B cell lymphoma only: Patient received or was ineligible for autologous or allogeneic stem cell transplant. This did not apply to patients with Mantle cell lymphoma or follicular lymphoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "8. Patients with measurable disease as per appropriate guidelines:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "   a. Solid Tumors: by RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "9. Lymphoma: Patient had at least one measurable nodal lesion (≥2 cm) according to Cheson criteria (Cheson 2007). In case where the patient had no measurable nodal lesions ≥ 2 cm in the long axis at screening, then the patient had at least one measurable extra-nodal lesion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "10. Leukemia only: Relapsed/refractory leukemia for which no standard therapy options were anticipated to result in a durable remission:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    1. Acute myelogenous leukemia (AML) by World Health Organization (WHO) classification (except FLT3) or acute lymphoblastic leukemia (ALL) relapsed or refractory to standard chemotherapy; unsuitable for standard chemotherapy or unwilling to undergo standard chemotherapy. Philadelphia chromosome (Ph) positive ALL eligible if failed prior tyrosine-kinase inhibitor therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    2. Age \\> 60 years with AML (except FLT3) not candidates for or have refused standard chemotherapy, excluding patients with acute promyelocytic leukemia (APL) or with favorable cytogenetic abnormalities.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    3. For patients with Chronic Myeloid Leukemia (CML) only accelerated and blast phase CML were allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "11. Patient with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "12. Patient with a life expectancy of at least 16 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "13. All Patients were having adequate bone marrow as described below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L (not applicable for leukemia patients).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    2. Platelets (PLT) ≥ 75 x 109/L (no platelet transfusion within past 14 days) (not applicable for leukemia patients).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    3. Hemoglobin (Hgb) ≥ 9 g/dl (not applicable for leukemia patients).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    4. International Normalized Ratio (INR) ≤ 1.5.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    5. Serum amylase and lipase ≤ upper limit of normal (ULN).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "14. All patients had adequate organ function defined as described below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    1. Potassium, calcium (corrected for serum albumin) and magnesium within normal limits (WNL). Supplementation was allowed to meet eligibility requirements. Bisphosphonates to treat malignant hypercalcemia WERE NOT allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    2. Serum creatinine ≤ 1.5 x ULN or Serum creatinine \\>1.5 - 3 x ULN if",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "* creatinine clearance by 24-hr urine was ≥ 30 mL/min/1.73m2 (≥50 mL/min/1.73m2 in the presence of proteinuria as defined by inclusion criterion #16 or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "* calculated creatinine clearance (CrCl) was ≥ 30 mL/min using the Cockroft- Gault equation CrCl = (140 - age in years) x (weight in kg) / (72 x serum creatinine in mg/dL) (if female, multiply the number by 0.85)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    3. Alanine aminotransferase (AST) and/or aspartate aminotransferase (ALT) ≤ 3.0 x upper limit of normal range (ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    4. Total serum bilirubin within normal range (or ≤ 1.5 x ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "15. Urine dipstick reading: Negative for proteinuria or, if documentation of +1 results for protein on dipstick reading, then total urinary protein ≤ 500 mg and measured creatinine clearance ≥ 50 mL/min/1.73m2 from a 24 hour urine collection.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "16. For Leukemia patients, peripheral blast counts \\< 50,000 blasts/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": ". Patients who received prior treatment with dovitinib (TKI258).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "2. Patients with a known hypersensitivity to dovitinib (TKI258) or to its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "3. Patients with brain metastasis or history of brain metastasis or leptomeningeal carcinomatosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "4. Patients with diarrhea ≥ CTCAE grade 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "5. Patients with neuropathy ≥ CTCAE grade 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "6. Patients with acute or chronic pancreatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "7. Patients with external biliary drains.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "8. Patients with a history of pulmonary embolism (PE), or untreated deep venous thrombosis (DVT) ≤ 6 months prior to starting study drug. Note: Patients with recent DVT who were treated with therapeutic anti-coagulant agents for at least 6 weeks are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "9. Patients with impaired cardiac function or clinically significant cardiac diseases, including any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "   1. History or presence of serious uncontrolled ventricular arrhythmias.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "   2. Clinically significant resting bradycardia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "   3. LVEF assessed by either 2-D echocardiogram (ECHO) \\< 50% or lower limit of normal (whichever was the higher), or 2-D multiple gated acquisition scan (MUGA) \\< 45% or lower limit of normal (whichever was the higher).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "   4. Any of the following within 6 months prior to starting study drug: myocardial infarction (MI), severe/unstable angina, coronary artery bypass graft (CABG), congestive heart failure (CHF), cerebrovascular accident (CVA), transient ischemic Attack (TIA).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "   5. Uncontrolled hypertension defined by a SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg, with or without anti-hypertensive medication(s). Initiation or adjustment of antihypertensive medication(s) was allowed prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "10. Patients with uncontrolled diabetes mellitus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "11. Patients with clinical evidence of active CNS leukemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "12. Patient who received Allogeneic stem cell transplant and/or had active has graft-versus host disease (GVHD).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "13. Patient received Autologous stem cell transplant within last 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "14. Impairment of GI function or GI disease that could significantly alter the absorption of dovitinib (e.g. severe ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "15. Any other condition that was, in the Investigator's judgment, contraindicate patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g. infection/inflammation, intestinal obstruction, unable to swallow oral medication, social/psychological complications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "16. Patients who were treated with any hematopoietic colony-stimulating growth factors (e.g.,G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin or darbepoetin therapy, if initiated at least 2 weeks prior to enrollment, could be continued. Restriction was not applicable for patients with Leukemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "17. Patient who received chemotherapy or other anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, monoclonal antibodies or mitomycin-C) prior to starting study drug or who had not recovered to a grade 1 from side effects of such therapy (except for alopecia and neuropathy). Patients with leukemia could receive therapy with hydroxyurea and/or steroids for the purpose of cytoreduction but must discontinue use prior to first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "18. Patients who received the last administration of an anticancer small molecule therapy (e.g. sunitinib, sorafenib, pazopanib, axitinib, everolimus, temsirolimus, ridaforolimus) ≤ 2 weeks prior to starting study drug, or who had not recovered from the side effects of such therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "19. Patients not able to discontinue their current anti-cancer therapy prior to first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "20. Patients who received radiotherapy ≤ 4 weeks prior to starting the study drug or who had not recovered from radiotherapy-related toxicities (note: palliative radiotherapy for bone lesions ≤ 2 weeks prior to starting study drug is allowed).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "21. Patients who had undergone major surgery (e.g., intra-thoracic, intra-abdominal, intrapelvic) ≤ 4 weeks prior to starting study treatment or who had not recovered from side effects of such surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "22. Patient was currently receiving antiplatelet therapy of prasugrel or clopidogrel, or full dose anticoagulation treatment with therapeutic doses of warfarin. However, treatment with low doses of warfarin (e.g., ≤ 2 mg/day) or locally accepted low doses of acetylsalicylic acid (up to 100 mg daily) to prevent cardiovascular events or strokes was allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "23. Patients with another primary malignancy within 3 years prior to starting study treatment, with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "24. Cirrhosis of the liver or known hepatitis B or C infection that was either acute or was considered chronic because the virus did not become undetectable:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    1. Hepatitis C Virus (HCV) infection: acute or chronic infection as depicted by a positive HCV RNA testing (note: in a patient with known anti-HCV but with a negative test for HCV RNA, re-testing for HCV RNA 4-6 months later was requested to confirm the resolution of HCV infection).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    2. Hepatitis B Virus (HBV) infection: acute infection (HBsAg+ with or without HBeAg+ or detectable serum HBV DNA), HBV carriers as evidence by ongoing presence of HBsAg and detectable serum HBV DNA levels.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "25. Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing was not mandatory).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "26. Patients who received investigational agents within ≤ 5t1/2 of the agent (or ≤ 4 weeks when half-life was unknown) prior to starting study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "27. Patient with history of non-compliance to medical regimen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "28. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "29. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they were using highly effective methods of contraception (defined below). Highly effective contraception had to be used by both sexes (female patients and their male partners) during study treatment and for 30 days after the last doseof study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    Highly effective contraception methods included:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "* Total abstinence (when this was in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post- ovulation methods) and withdrawal were not acceptable methods of contraception",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "* Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "    In case of oophorectomy alone, only when the reproductive status of the woman was confirmed by follow up hormone level assessment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "* Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner was the sole partner for that subject.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "* Combination of the following (a+b):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "      1. Placement of an intrauterine device (IUD) or intrauterine system (IUS)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "      2. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "30. Oral, implantable, or injectable hormone contraceptives might be affected by cytochrome P450 interactions, and were therefore not considered effective for this study Women of child-bearing potential (sexually mature women) who had not undergone a hysterectomy or who were not naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months), were required to have a negative serum pregnancy test ≤ 14 days prior to starting study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "31. Post-menopausal women were allowed to participate in this study. Women were considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels \\> 40 mIU/mL or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks prior to entry in the study. In the case of oophorectomy alone, only when the reproductive status of the woman was confirmed by follow up hormone level assessment, then she was considered not of child bearing potential.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831726",
    "statement": "32. Fertile males not willing to use contraception. Fertile males must use condom with spermicide. Highly effective contraception, as defined above, was to be used by both sexes (male patients and their female partners) during study treatment and for 90 days after the last dose of study medication and was not to father a child in this period. A condom was required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Patients with histologically or cytologically confirmed, -sensitive-relapse- SCLC defined by a relapse 60 days or more after cessation of prior first-line chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Patients with at least one measurable lesion, with longest diameter to be recorded as 20 mm or greater.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Life expectancy of at least three months and ECOG performance score of 2 or less and written informed consent that must be consistent with ICH-GCP Guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* More than one prior regimen of chemotherapy, mixed small cell/large cell or combined small cell histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Symptomatic brain metastases or leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Patients with ascites, patients who have any other life-threatening illness or organ system dysfunction, or other malignancies diagnosed within the past five (5) years (other than non melanomatous skin cancer)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Absolute neutrophil count (ANC) \\<1,500/µl, platelet count \\<100,000/µl, or hemoglobin \\<9 mg/dl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Total bilirubin \\>1.5 x ULN, aspartame amino transferase (AST) and/or alanine amino transferase (ALT) \\>2.5 x ULN, or aspartate amino transferase (AST) and/or alanine amino transferase (ALT) \\>5 x ULN in case of known liver metastases, serum creatinine \\>2.0 mg/dl (\\>176 µmol/L, SI Unit equivalent)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Chemo-, hormone- (other than Megace®) or immunotherapy within the past 4 weeks or within less than 4 half-life times of the previous drug prior to treatment with the trial drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Radiation therapy within the past 2 weeks prior to or during treatment with the trial drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Patients with any serious active infection (i.e., requiring an IV antibiotic, antifungal, or antiviral agents), patients with known HIV, hepatitis-B or -C infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Known or suspected active drug or alcohol abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Treatment with any other investigational drug within the past 4 weeks or within less than 4 half-life times of the investigational drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Patients with a known pre-existing coagulopathy or requiring therapeutic anticoagulation with warfarin (Coumadin ®)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00412880",
    "statement": "* Patients with neuropathy (sensory or motor) CTCAE 3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02735980",
    "statement": "* Have ED-SCLC and have received a prior platinum-based regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02735980",
    "statement": "* Participants in Cohort 1 and in the addendum must have had an objective response to prior platinum-based therapy with subsequent progression ≥90 days after the last dose of platinum",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02735980",
    "statement": "* Participants in Cohort 2 must have either not had an objective response to prior platinum based therapy or had progression \\<90 days after the last dose of platinum",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02735980",
    "statement": "* Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02735980",
    "statement": "* Have received more than 2 prior therapies for ED-SCLC (including immunotherapy, targeted therapies, or chemotherapy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02735980",
    "statement": "* Have symptomatic central nervous system (CNS) malignancy or metastasis. Asymptomatic participants with treated CNS metastases are eligible for this study if they are not currently receiving corticosteroids to treat CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02735980",
    "statement": "* Have previously completed or withdrawn from this study or any other study investigating prexasertib or a checkpoint kinase I (CHK1) inhibitor or have shown hypersensitivity to any of the components of the prexasertib formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02735980",
    "statement": "* Have a serious cardiac condition",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03195491",
    "statement": "* Advanced metastatic stage IIIB/IV NSCLC (Nonsquamous and squamous)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03195491",
    "statement": "* 1 to 2 prior systemic therapies",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03195491",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03195491",
    "statement": "* Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03195491",
    "statement": "* Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to starting study treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03195491",
    "statement": "* Women with a positive pregnancy test at enrollment or prior to administration of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03195491",
    "statement": "* Participants with active central nervous system metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03195491",
    "statement": "* Participants with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03195491",
    "statement": "* Participants with previous malignancies are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required or anticipated to be required during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03195491",
    "statement": "* Participants with carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03195491",
    "statement": "Other protocol defined inclusion/exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Histologic or cytologic diagnosis of unresectable nonsquamous Stage IIIA or Stage IIIB (without malignant pleural/pericardial effusions) NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have an ECOG performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Previous radiation therapy should have been limited and must not have included thoracic radiation, whole pelvis radiation, or radiation to \\>25% of the participant's bone marrow, participants must have recovered from the toxic effects of radiation treatment prior to study enrollment (except for alopecia). Prior radiotherapy must be completed 30 days before study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have at least 1 unidimensionally measurable lesion meeting RECIST guidelines, version 1.0.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Estimated life expectancy of at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Participant compliance and geographic proximity that allow adequate follow-up.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Adequate bone marrow reserve, hepatic-, renal- and pulmonary function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Participants must sign an Informed Consent Document.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Participants must have a total lung V20 less than or equal to 35%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* For women: Must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen, during and for 6 months after the treatment period; must have a negative serum pregnancy test within 7 days before study enrollment and must not be breast-feeding. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have not received prior systemic anticancer therapy for NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have received treatment within the last 30 days of enrollment with a drug that has not received regulatory approval for any indication at the time of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have previously completed or withdrawn from this study or any other study investigating pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have a serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the participant's ability to adhere to the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have had a prior malignancy other than NSCLC, carcinoma in situ of the cervix, or non-melanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. Participants with a history of low-grade (Gleason score less than or equal to 6) localized prostate cancer will be eligible even if diagnosed less than 5 years previously.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Are receiving concurrent administration of any other antitumor therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have had weight loss of more than 10% over the previous 3 months before study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Are unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose less than or equal to 1.3 grams per day, for at least 2 days before (5 days for long-acting agents), the day of, and for at least 2 days after administration of pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Are unable or unwilling to take folic acid or vitamin B12 supplementation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Are unable or unwilling to take corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have received a recent yellow fever vaccination (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have known hypersensitivity to pemetrexed, cisplatin, or any of the excipients in these medicinal products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have evidence of clinical hearing loss.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01000480",
    "statement": "* Have clinically significant third-space fluid collections, that cannot be controlled by drainage or other procedures prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00700180",
    "statement": "* adult patients, \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00700180",
    "statement": "* locally advanced metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00700180",
    "statement": "* \\>=1 measurable tumor lesion;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00700180",
    "statement": "* ECOG performance status 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00700180",
    "statement": "* prior chemotherapy or treatment with another systemic anti-cancer agent;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00700180",
    "statement": "* evidence of CNS metastases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00700180",
    "statement": "* history of grade 2 or higher hemoptysis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00700180",
    "statement": "* evidence of tumor invading or abutting major blood vessels;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00700180",
    "statement": "* malignancies other than NSCLC within 5 years prior to randomization, other than adequately treated cancer in situ of cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00700180",
    "statement": "* clinically significant cardiovascular disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00700180",
    "statement": "* current or recent use of aspirin (\\>325mg/day) or full dose anticoagulants or thrombolytic agents for therapeutic purposes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Signed Informed Consent Form(s)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Histologically confirmed NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Recurrent or progressive disease after receiving at least one chemotherapy regimen for advanced or metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Age ≥ 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Recovery from reversible acute effects of prior anti-cancer therapy (chemotherapy, radiotherapy, or investigational treatment) to NCI Common Toxicity Criteria for Adverse Events (NCI CTCAE) Grade ≤ 1 (excluding alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Ability to comply with the study and follow-up procedures, including all specified imaging studies",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Ability to take oral medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Availability of archival diagnostic paraffin-embedded tumor tissue and willingness to provide sufficient tissue for testing for EGFR levels in tumor by both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Life expectancy ≥ 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Measurable disease on computed tomography (CT)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* At least one detectable lesion on FDG-PET scan and/or FLT-PET scan that is measurable on CT",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Use of an acceptable means of contraception (men and women of childbearing potential) or documentation of infertility",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Prior treatment with an investigational or marketed agent for the purpose of inhibiting epidermal growth factor receptor (EGFR) (including, but not limited to, erlotinib and gefitinib)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Chemotherapy, radiotherapy, or investigational treatment within 14 days or within 5 half-lives of the active molecules in the chemotherapy or investigational treatment, whichever is longer, prior to study entry or from which patients have not yet recovered",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Inability to take oral medications, disease affecting gastrointestinal absorption, or prior surgical procedure affecting gastrointestinal absorption",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Uncontrolled diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Any unstable systemic disease (including active infection, unstable angina, congestive heart failure, myocardial infarction within 1 month prior to study entry, hepatic, renal, or metabolic disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Pregnancy or lactation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* History of another malignancy in the past 2 years, unless the malignancy has been adequately treated, is currently not detectable, and is associated with a 5-year survival \\> 90%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Claustrophobia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00453362",
    "statement": "* Any other disease, condition, physical examination finding, or clinical laboratory finding which, in the opinion of the investigator, makes the patient inappropriate for the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01769391",
    "statement": "* Histologically or cytologically confirmed squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01769391",
    "statement": "* Stage IV disease at time of study entry based on American Joint Committee on Cancer (AJCC) 7th edition",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01769391",
    "statement": "* Measurable disease at time of study entry as defined by Response Evaluation Criteria in Solid Tumors, (RECIST) Version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01769391",
    "statement": "* Archived or recent tumor tissue (minimum of 5 unstained tissue slides or a paraffin-embedded tissue block) available for analysis of epidermal growth factor receptor (EGFR) protein expression by immunohistochemistry (IHC) and other biomarker assessments",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01769391",
    "statement": "* Nonsquamous NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01769391",
    "statement": "* Prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01769391",
    "statement": "* Previous chemotherapy for NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01769391",
    "statement": "* Major surgery or received any investigational therapy in the 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01769391",
    "statement": "* Chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01769391",
    "statement": "* Brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants (Participants who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Part A: histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of standard therapy or for which no standard therapy is available",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Part B: Pancreatic Adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Presence of histologically confirmed inoperable locally advanced or metastatic pancreatic adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Part B: NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Stage IIIB with malignant pleural effusion/pleural seeding or stage IV histologically confirmed NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Absence of known epidermal growth factor receptor (EGFR) mutation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Absence of known translocation or inversion events involving the ALK gene locus (resulting in EML4-ALK fusion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Part B: Esophagogastric Adenocarcinoma:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Histologically confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapsed gastric adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Human epidermal growth factor receptor 2 (HER2)-negative tumor (primary tumor or metastatic lesion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Part B: First-Line Colorectal Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Radiographically measureable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* No prior cytotoxic chemotherapy to treat their metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Part B: Second-Line Colorectal Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Radiographically measureable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Received first-line combination therapy containing oxaliplatin and fluoropyrimidine with or without bevacizumab for metastatic disease with documented evidence of disease progression during or after treatment completion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Part B: Breast Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Histologically or cytologically confirmed metastatic breast cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Radiographically measureable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Previous hormonal therapy for metastatic breast cancer or cytotoxic adjuvant chemotherapy is allowed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* HER-2 negative tumor (primary tumor or metastatic lesion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Individuals with known central nervous system (CNS) metastases, unless metastases are treated and stable and the individual does not require systemic steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Myocardial infarction, symptomatic congestive heart failure, unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "* Anti-tumor therapy within 28 days of study drug dosing; concurrent use of hormone therapy for breast or prostate cancer is permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Note: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Histological/cytological proven locally advanced or metastatic small cell lung cancer with progressive disease during or after first line platinum based chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Male or female greater than or equal to (\\>=) 18 years (or country's legal age of majority if greater than \\[\\>\\]18 years)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Participants with measurable disease, Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\\<=) 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Absence of signed and dated Institutional Review Board (IRB)-approved participant informed consent form prior to enrollment into the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* More than one prior chemotherapy regimen. Prior treatment with topotecan or taxanes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Less than 28 days elapsed from prior treatment with chemotherapy, radiotherapy or surgery to the time of randomization (Radiotherapy for bone pain palliation is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Adverse events (excluding alopecia) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common Terminology Criteria \\[NCI CTCAE\\] v4.03) at the time of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Uncontrolled Central Nervous System (CNS) metastases: participants with CNS metastases may have previous irradiation, only participants with stable disease or response to irradiation who are without CNS symptoms and on a maximum steroid dose of dexamethasone 8 mg daily or equivalent could be included",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Participants with known leptomeningeal metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* History of other, invasive neoplasm requiring ongoing therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association class III or IV congestive heart failure, stroke or transient ischemic attack",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Any severe acute or chronic medical condition, which could impair the ability of the participant to participate in the study or interfere with interpretation of study results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Known Human Immunodeficiency Virus (HIV) disease, or active hepatitis B or C (systematic testing was not required)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Pregnant or breast-feeding woman. Positive serum or urine pregnancy test prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Participant with reproductive potential (M/F) who did not agree to use an accepted and effective method of contraception during the study treatment period and for at least 6 months after the completion of the study treatment. The definition of \"effective method of contraception\" was based on the investigator's judgment. Effective method of contraception should also be adapted to local regulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* History of hypersensitivity to polysorbate 80",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Inadequate organ and bone marrow function as evidenced by:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Hemoglobin less than \\[\\<\\] 9.0 gram per deciliter (g/dL)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Absolute neutrophil count \\<1.5 x 10\\^9 per liter",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Platelet count \\<100 x 10\\^9 per liter",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) and/or alanine aminotransferase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) \\>2.5 x Upper Limit of Normal (ULN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Alkaline Phosphatase (AP) \\>2.5 x ULN. In case of liver metastases AP \\>5 x ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Total bilirubin \\>1.0 x ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "* Serum Creatinine \\>1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to Chronic Kidney Disease Epidemiology Collaboration formula, and creatinine clearance \\<60 milliliter per minute (mL/min) was exclude the participant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01500720",
    "statement": "The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00965731",
    "statement": "* histologically proven diagnosis of Non-Small Cell Lung Cancer (NSCLC) that is locally advanced or metastatic and of the adenocarcinoma subtype (including mixed adenosquamous histology)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00965731",
    "statement": "* evident disease progression by Response Evaluation Criterion in Solid Tumors (RECIST) after at least one but no more than 2 chemotherapy regimens for advanced disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00965731",
    "statement": "* tumors must have measurable disease as per RECIST",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00965731",
    "statement": "* known interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00965731",
    "statement": "* prior treatment with an agent that is known or proposed to be active by action on EGFR tyrosine kinase or c-Met/HGF (Phase 2 Portion)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Phase 1: Subjects with advanced or metastatic solid tumors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Phase 1: Subjects who have disease progression after treatment with available therapies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Phase 2: Subjects with advanced or metastatic gastric cancer, SCCHN, NSCLC, or RCC and are considered refractory to prior PD-1/L1 therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Presence of measurable disease based on RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Laboratory and medical history parameters not within the Protocol-defined range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Has not recovered to ≤ Grade 1 from toxic effects of prior therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Active autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Known active central nervous system metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03241173",
    "statement": "* Known history of human immunodeficiency virus (HIV); HIV 1/2 antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": ". Signed Informed Consent Form",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "2. Histologically or cytologically confirmed Stage IV non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "3. Availability of FFPE (formalin-fixed paraffin-embedded) tumor tissue, either fresh core-needle-biopsied or archived",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "4. Age \\> or = to 21 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "5. ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "6. Disease that is measurable per RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "7. Adequate organ and marrow function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "8. For women of childbearing potential, agreement to use two effective forms of contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "Main",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": ". Histologically or cytologically documented, advanced, mixed non-small cell and small cell tumors or mixed adenosquamous carcinomas",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "2. NSCLC with known EGFR (epidermal growth factor receptor ) mutation or anaplastic lymphoma kinase (ALK) gene translocation (such as EML4 \\[echinoderm microtubule-associated protein-like 4\\]-ALK \\[anaplastic lymphoma kinase\\])",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "3. Prior or ongoing therapy (including chemotherapy, antibody therapy, tyrosine kinase inhibitors, radiotherapy, immunotherapy, hormonal therapy, or investigational therapy) for the treatment of Stage IV non-squamous NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "4. Evidence of tumor invading major blood vessels, cavitation of one or more pulmonary tumor mass(es) or tracheo-esophageal fistula",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "5. Brain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active neurologic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "6. Malignancies other than non-squamous NSCLC successfully treated within 3 years prior to randomization (with the exception of certain early-stage cancers)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "7. History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "8. Significant intercurrent illness defined as an illness that may result in the subject's death prior to their death from non-squamous NSCLC and/or significantly limit their ability to comply with the requirements of this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "9. Recent hemoptysis \\>2.5 mL or serious bleeding from another site, known bleeding disorder or coagulopathy or therapeutic anti-coagulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259582",
    "statement": "10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipation of need for major surgical procedure during the course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant has locally advanced or metastatic stage IIIB/IV NSCLC that has relapsed after hemotherapy/chemoratiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant has had at least one chemotherapy regimen for recurrent or metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant is 18 years of age or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant has a performance status of 0-2 on Eastern Cooperative Group (ECOG) scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Women of childbearing potential have a negative pregnancy test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant has had chemotherapy within 2 weeks or biological therapy (e.g. bevacizumab) within 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant has not recovered from adverse events from previous therapy within 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant has received EGFR-Tyrosine Kinase Inhibitor (TKI) inhibitor/anti-EGFR mAb therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant has received IGF1R-TKI inhibitor/anti-IGF1R mAB therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant has had more than 2 systemic chemotherapies for metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant has not completed radiotherapy with complete resolution of toxicities at least 2 weeks before starting in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant is taking part in another clinical study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant has a primary central nervous system tumor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant abuses drugs or alcohol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant is pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant is Human Immunodeficiency Virus (HIV) positive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant has a history of hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00654420",
    "statement": "* Participant is using growth hormone or growth hormone inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has a histologically-confirmed or cytologically confirmed diagnosis of stage IV nonsquamous NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has measurable disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has not received prior systemic treatment for their advanced/metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Can provide tumor tissue.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has a life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* If female of childbearing potential, is willing to use adequate contraception for the course of the study through 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* If male with a female partner(s) of child-bearing potential, must agree to use adequate contraception starting with the first dose of study medication through 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has predominantly squamous cell histology NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Before the first dose of study medication: a) Has received prior systemic cytotoxic chemotherapy for metastatic disease, b) Has received antineoplastic biological therapy (e.g. erlotinib, crizotinib, cetuximab), c) Had major surgery (\\<3 weeks prior to first dose)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Received radiation therapy to the lung that is \\>30 Gray (Gy) within 6 months of the first dose of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Completed palliative radiotherapy within 7 days of the first dose of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Is expected to require any other form of antineoplastic therapy while on study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Received a live-virus vaccination within 30 days of planned start of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has clinically active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, peritoneal carcinomatosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Known history of prior malignancy except if participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy, except for successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Known sensitivity to any component of cisplatin, carboplatin or pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has active autoimmune disease that has required systemic treatment in past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Is on chronic systemic steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Is unable or unwilling to take folic acid or vitamin B12 supplementation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Had prior treatment with any other anti-programmed cell death-1 (PD-1), or PD-ligand 1 (PD-L1) or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms. Has participated in any other pembrolizumab study and has been treated with pembrolizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has an active infection requiring therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has known history of Human Immunodeficiency Virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has known active Hepatitis B or C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Is a regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has symptomatic ascites or pleural effusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03950674",
    "statement": "* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* At least 18 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Confirmed advanced non-small cell lung carcinoma (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Received one prior chemotherapy for metastatic NSCLC excluding TAXOTERE or HYCAMTIN. In addition, subjects are allowed to have previously received a non-cytotoxic therapy, such as an endothelial growth factor receptor (EGFR) or angiogenesis inhibitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Presence of either measurable or non-measurable disease by radiologic study or physical examination.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Full recovery and at least 21 days from prior treatment for NSCLC; 42 days from treatment with mitomycin or nitrosureas and 30 days from prior non-cytotoxic therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* At least 3 weeks since last major surgery (a lesser period is acceptable if deemed in the best interest of the patient).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* At least 7 days since prior radiotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* A probable life expectance of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Adequate bone marrow reserve, CBC/Platelet, kidney and liver function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Concomitant malignancies or other malignancies within the last five years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Symptoms of brain metastases requiring treatment with steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Active infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Severe medical problems other than the diagnosis of NSCLC that would limit the ability of the subject to follow study guidelines or expose the subject to extreme risk.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Ongoing or planned chemotherapy (other than treatment during this study), immunotherapy, radiotherapy, or investigational therapy for the treatment of NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Use of investigational drug within 30 days or 5 half-lives prior to the first dose of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Women who are pregnant or lactating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Subjects of child-bearing potential refusing to practice adequate contraception.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Prior treatment with or history of allergic reaction to either HYCAMTIN or TAXOTERE.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065182",
    "statement": "* Subjects who cannot receive steroid premedication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00428220",
    "statement": "* Must have ended treatment from one of the following sunitinib studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00428220",
    "statement": "* See inclusion criteria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Able to understand and willing to sign a written informed consent document",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Patients who have recurrent or metastatic NSCLC, who have failed initial therapy with a platinum-containing regimen and have not received any second-line therapy (adjuvant therapy is acceptable if it was completed greater than or equal to 12 months before the cancer recurrence)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Laboratory Values within the normal or reasonable reference range as specified by the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Prior exposure to SNS-595",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Women of childbearing potential or male partners of women of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Other active malignancies or other malignancies within the past 12 months except non-melanoma skin cancer, cervical intraepithelial neoplasia or prostatic intraepithelial neoplasia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Brain metastases, if present, without radiologic evidence of progressive disease for at least 3 months after completion of therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Myocardial infarction, cerebrovascular accident/transient ischemic attack (TIA) or thromboembolic event (deep vein thrombosis or pulmonary embolus) within 6 months before the first SNS-595 dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Requires kidney dialysis (hemodialysis or peritoneal)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Prior chemotherapy, investigational agents, or radiation therapy within 28 days before Cycle 1 Day 0; however, nitrosoureas and mitomycin are not permitted for at least 42 days before Cycle 1 Day 0",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* In patients with toxicities caused by prior cancer therapy, those toxicities must have returned to less than or equal to Grade 1, with the exception of alopecia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Prior pelvic radiation therapy or radiation to greater than or equal to 25% of bone marrow reserve (prior palliative radiation is permitted as long as it does not exceed 25% of bone marrow reserve)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00252382",
    "statement": "* Any other medical, psychological, or social condition that, in the opinion of the Principal Investigator, would contraindicate the patient's participation in the clinical trial due to safety concerns or compliance with study procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Documented diagnosis of unresectable Stage III or Stage IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Patients may be receiving maintenance chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Patients planning to initiate a new chemotherapy and/or radiation therapy regimen may do so only within ± 14 days of randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Patients may have completed a chemotherapy and/or radiation therapy and/or have no plan to initiate a new regimen within 12 weeks from randomization; at least 14 days must elapse from the completion of the chemotherapy and/or radiation therapy prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Involuntary weight loss of ≥5% body weight within 6 months prior to screening or a screening body mass index (BMI) \\<20 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Body mass index ≤30 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Life expectancy of \\>4 months at time of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* ECOG performance status ≤2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Adequate hepatic function, defined as AST and ALT levels ≤5 x upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Adequate renal function, defined as creatinine ≤2 x upper limit of normal, or calculated creatinine clearance \\>30 ml/minute",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Ability to understand and comply with the procedures for the HGS evaluation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* If a woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for 30 days following the last dose of study drug (an effective form of contraception is abstinence, a hormonal contraceptive, or a double-barrier method)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Must be willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Other forms of lung cancer (e.g., small cell, mesothelioma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Women who are pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Known HIV, hepatitis (B\\&C), or active tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Had major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization; patients must be well recovered from acute effects of surgery prior to screening; patients should not have plans to undergo major surgical procedures during the treatment period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Currently taking prescription medications intended to increase appetite or treat weight loss; these include, but are not limited to, testosterone, androgenic compounds, megestrol acetate, methylphenidate, and dronabinol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Inability to readily swallow oral tablets; patients with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption, or obstructive symptoms) or intractable or frequent vomiting are excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Has an active, uncontrolled infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Has uncontrolled diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Has untreated clinically relevant hypothyroidism",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Has known or symptomatic brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Receiving strong CYP3A4 inhibitors within 14 days of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Receiving tube feedings or parenteral nutrition (either total or partial); patients must have discontinued these treatments for at least 6 weeks prior to Day 1, and throughout the study duration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Other clinical diagnosis, ongoing or intercurrent illness that in the Investigator's opinion would prevent the patient's participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Has had previous exposure to Anamorelin HCl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387282",
    "statement": "* Patients actively receiving a concurrent investigational agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00642473",
    "statement": "* non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00642473",
    "statement": "* eligible to start treatment with erlotinib",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00642473",
    "statement": "* hypersensitivity to metronidazole",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02276027",
    "statement": "* Advanced (stage IIIB or stage IV) NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02276027",
    "statement": "* Must have specific molecular alterations",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02276027",
    "statement": "* Symptomatic central nervous system (CNS) metastases which are neurologically unstable or requiring increasing doses of steroids within the 4 weeks prior to study entry to control their CNS disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02276027",
    "statement": "* Radiation therapy within ≤ 4 weeks prior to study entry, with the exception of limited field palliative radiotherapy for bone pain relief.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02276027",
    "statement": "* Any other malignancies within the last 5 years before study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02276027",
    "statement": "* Major surgery ≤ 2 weeks prior to study entry or who have not recovered from side effects of such therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* In Part A: Histological or cytological diagnosis of MEL or any type of carcinoma, progressive metastatic disease, or progressive locally advanced disease not amenable to local therapy. In Parts B and D of the study, histological or cytological diagnoses of metastatic MEL with progressive locally advanced or metastatic disease. In Parts C and F, histological or cytological diagnosis of NSCLC. In Part F1, participants with Stage IV NSCLC without prior systemic therapy may be eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Failure of established standard medical anti-cancer therapies for a given tumor type or intolerance to such therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* In Parts B, C, D, or F of the study, MEL or NSCLC must be measurable by imaging.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* In Part F of the study, NSCLC with PD-L1 gene expression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Female participants of childbearing potential should have a negative urine or serum pregnancy test prior to receiving study medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Female participants of childbearing potential must be willing to use adequate contraception from study start, through the course of the study, and for 120 days after the last dose of study medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Male participants of childbearing potential must agree to use adequate contraception from the first dose of study medication through 120 days after the last dose of study medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Chemotherapy, radioactive, or biological cancer therapy within 4 weeks prior to the first dose of study therapy, or not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from the adverse events caused by therapy administered more than 4 weeks prior to first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Participation in a study of an investigational agent or using an investigational device within 30 days of administration of pembrolizumab, with the exception of participants in the follow-up phase.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Other form(s) of antineoplastic therapy anticipated during the period of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* History of non-infectious pneumonitis requiring treatment with steroids, or has a history of interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Medical condition that requires chronic systemic steroid therapy, or on any other form of immunosuppressive medication, excepting use of inhaled steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Risk factors for bowel obstruction or bowel perforation (including a history of acute diverticulitis, intra-abdominal abscess, abdominal carcinomatosis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* History of a hematologic malignancy, malignant primary brain tumor, malignant sarcoma, or another malignant primary solid tumor, unless no evidence of that disease for 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Previous severe hypersensitivity reaction to another monoclonal antibody (mAb).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents, except vitiligo or resolved childhood asthma/atopy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Prior therapy with another anti-programmed cell death (PD)-1 agent or previously enrolled in any pembrolizumab trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Active infection requiring therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Positive for Human Immunodeficiency Virus (HIV), Hepatitis B (Hepatitis B Surface Antigen \\[HBsAg\\] reactive), or Hepatitis C virus (Hepatitis C Virus Ribonucleic Acid \\[HCV RNA\\] (qualitative) is detected).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Regular use of illicit drugs or a recent history (within the last year) of substance abuse (including alcohol).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Symptomatic ascites or pleural effusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01295827",
    "statement": "* Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Age criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* High dose TBI regimen: 6 months to =\\< 45 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Middle intensity TBI regimen: 6 months to =\\< 65 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Conditioning regimen selection should be based on the underlying disease, presence of minimal residual disease (MRD), age, co-morbidities, attending physician, and site preference; conditioning regimen will not require stratification of the randomization due to heterogeneity in the cohort of eligible patients.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Acute myeloid leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* All patients must have acute myeloid leukemia (AML) that is considered best treated by stem cell transplant by the referring physician and the attending transplant physician",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* All patients must be in complete remission (CR) as defined by \\< 5% blasts by morphology/flow cytometry in a representative bone marrow sample with cellularity \\>= 15% for age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Patients in which adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the principal investigator prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Acute lymphoblastic leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* High risk first complete remission (CR1) (for example, but not limited to: t(9;22), t(1;19), t(4;11) or other mixed-lineage leukemia \\[MLL\\] rearrangements, hypodiploid); or high risk (HR) as defined by referring institution treatment protocol greater than 1 cycle to obtain CR; second complete remission (CR2) or greater",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* All patients must be in CR as defined by \\< 5% blasts by morphology/flow cytometry in a representative bone marrow sample with cellularity \\>= 15% for age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Patients in which adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the principal investigator prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Chronic myelogenous leukemia excluding refractory blast crisis; to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to tyrosine kinase inhibitor therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Myelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate (Int)-2 or high risk (i.e., refractory anemia with excess blasts \\[RAEB\\], refractory anemia with excess blasts in transformation \\[RAEBt\\]) or refractory anemia with severe pancytopenia or high risk cytogenetics; blasts must be \\< 10% by a representative bone marrow aspirate morphology",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Karnofsky (\\>= 16 years old) \\>= 70 or Eastern Cooperative Oncology Group (ECOG) 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Lansky (\\< 16 years old) \\>= 60",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Adults: calculated creatinine clearance must be \\> 60 mL and serum creatinine =\\< 2 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Children (\\< 18 years old): calculated creatinine clearance must be \\> 60 mL/min",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Total serum bilirubin must be \\< 3 mg/dL unless the elevation is thought to be due to Gilbert's disease or hemolysis",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Transaminases must be \\< 3 x the upper limit of normal per reference values of referring institution",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Diffusing capacity of the lung for carbon monoxide (DLCO) corrected \\> 60% normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* For pediatric patients unable to perform pulmonary function tests, oxygen (O2) saturation \\> 92% on room air",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* May not be on supplemental oxygen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Left ventricular ejection fraction \\> 45% OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Shortening fraction \\> 26%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Ability to understand and the willingness to sign a written informed consent document",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Uncontrolled viral or bacterial infection at the time of study enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Active or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* History of human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Prior myeloablative transplant containing full dose TBI (greater than 8 Gy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy and/or cranial radiation prior to initiation of conditioning; diagnostic lumbar puncture is to be performed per protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01690520",
    "statement": "* Patients \\>= 45 years: comorbidity score of 5 or higher",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02754882",
    "statement": ". Aged ≥ 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02754882",
    "statement": "2. ECOG performance status of 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02754882",
    "statement": "3. Histologically-confirmed metastatic or recurrent non-squamous non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02754882",
    "statement": "4. At least one measurable lesion according to RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02754882",
    "statement": "5. Able to receive bevacizumab, carboplatin and paclitaxel based on adequate laboratory and clinical parameters",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02754882",
    "statement": ". Diagnosis of small cell carcinoma of the lung or squamous cell carcinoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02754882",
    "statement": "2. Sensitizing EGFR mutations or ALK rearrangements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02754882",
    "statement": "3. Increased risk of bleeding determined by investigator based on radiographic / clinical findings",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02754882",
    "statement": "4. History of systemic chemotherapy administered in the first-line setting for metastatic or recurrent disease of NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03001882",
    "statement": "* Histologically confirmed, stage IV or recurrent non-small cell lung cancer with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03001882",
    "statement": "* Measurable disease by CT or MRI",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03001882",
    "statement": "* Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03001882",
    "statement": "* Participants with untreated central nervous system metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03001882",
    "statement": "* Participants with active, known or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03001882",
    "statement": "* Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03001882",
    "statement": "Other protocol defined inclusion/exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Have brain metastases secondary to hormone receptor positive breast cancer, NSCLC, or melanoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Have either human epidermal growth factor receptor 2 positive (HER2+) (Study Part A) or negative HER2- (Study Part B) breast cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Participants in Study Part C must have HR+ breast cancer, NSCLC, or melanoma with brain lesions clinically indicated for surgical resection as well as consent to provide tissue for drug concentration determination after 5 to 14 days of study drug dosing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Participants in Part D must have NSCLC of any subtype.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Participants in Part E must have melanoma of any subtype.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Participants in Part F must have HR+ breast cancer, NSCLC, or melanoma with leptomeningeal metastases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* For Parts A, B, D, and E: Must have at least 1 measurable brain lesion ≥10 millimeters (mm) in the longest diameter (LD).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* For Part C (surgical): Have metastatic brain lesion(s) for which surgical resection is clinically indicated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Have completed local therapy (surgical resection, whole-breast radiotherapy (WBRT), or SRS) ≥14 days prior to initiating abemaciclib and recovered from all acute effects.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* If receiving concomitant corticosteroids, must be on a stable or decreasing dose for at least 7 days prior to the baseline Gd-MRI.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Have a Karnofsky performance status of ≥70.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Have a life expectancy ≥12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* For HR+ breast cancer participants in part A, B, C, and F: If currently receiving endocrine therapy, a participant may continue to receive the same endocrine therapy provided that extracranial disease is stable for at least 3 months and central nervous system (CNS) disease progression has occurred while on this endocrine therapy. If these conditions are not met, participants must discontinue endocrine therapy prior to initiation of abemaciclib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* For HER2+ breast cancer participants in parts A, C, and F: participants may receive concurrent treatment (ongoing or initiated simultaneously with abemaciclib) with IV trastuzumab.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* For NSCLC participants in parts C, D, and F: if currently receiving gemcitabine or pemetrexed (single-agent or in combination with another therapy), a participant may continue to receive 1 of these 2 therapies provided that extracranial disease is stable for at least 6 weeks and CNS disease progression has occurred while on this therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Have adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Require immediate local therapy, including but not limited to WBRT, SRS, or surgical resection, for treatment of brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Are taking concurrent enzyme-inducing antiepileptic drugs (EIAED).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Have evidence of significant (ie, symptomatic) intracranial hemorrhage.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* For Parts A, B, C, D, E: Have evidence of leptomeningeal metastases. Note: discrete dural metastases are permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Have experienced \\>2 seizures within 4 weeks prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* For Parts A, B, D, E, and F: Have previously received treatment with any cyclin dependent kinase 6 (CDK6) inhibitor. For Part C participants may have received prior palbociclib or ribociclib, but not abemaciclib treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Have known contraindication to Gd-MRI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02308020",
    "statement": "* Have a preexisting chronic condition resulting in persistent diarrhea.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen or combined modality (e.g., chemoradiation) regimen with curative intent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* Known active or untreated central nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* History of autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* Active hepatitis B or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* Prior treatment with docetaxel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02008227",
    "statement": "* Prior treatment with cluster of differentiation 137 (CD137) agonists, anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA4), anti-programmed death-1 (anti-PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Histologically confirmed metastatic 1L Stage IV non-small cell lung cancer (NSCLC) of squamous or nonsquamous histology",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* No prior systemic anti-cancer treatment given as primary therapy for advanced or metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 20 unstained slides of tumor tissue obtained during screening or prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Life expectancy of at least 3 months at the time of first dose",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or c-ros oncogene 1 (ROS-1) mutations which are sensitive to available targeted inhibitor therapy. Participants with nonsquamous histology and unknown EGFR, ALK, or ROS-1 status are also excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Participants with known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF) V600E mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown or indeterminate BRAF mutation status are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Untreated central nervous system metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Leptomeningeal metastases (carcinomatous meningitis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Concurrent malignancy requiring treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Active, known, or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "* Uncontrolled or significant cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05005273",
    "statement": "Other protocol-defined inclusion/exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Histologically or cytologically confirmed Stage IIIB or IV advanced or metastatic NSCLC with measurable neoplastic disease. Sputum cytology alone is not considered an acceptable method of diagnosis;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Prior therapy must meet all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  1. Subject has experienced disease progression or unacceptable toxicity/intolerance after receiving at least 1 systemic platinum-containing regimen;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  2. Subject with a tumor of non-squamous histology must be tested for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement. Subject with EGFR activating mutation or ALK rearrangement must have experienced disease progression or unacceptable toxicity/intolerance after receiving at least one EGFR tyrosine kinase inhibitor or ALK inhibitor;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  3. Subject has received PD-1/PD-L1 blockade or has been informed of the results of relevant positive Phase 3 trials with these agents.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 at baseline;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Minimum life expectancy of 3 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Agrees to use a medically effective method of contraception. Male subjects and women of child-bearing potential (WOCBP) must agree to use effective contraception, e.g., oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide), or practice true abstinence from sexual intercourse during the study and for 3 months after the last dose. Women of child-bearing potential include female subjects who have experienced menarche and have not undergone surgical sterilization or are not postmenopausal (defined as amenorrhea ≥ 12 consecutive months without an alternative medical cause);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* WOCBP must have a negative serum pregnancy test within 7 days prior to receiving investigational product and a negative urine pregnancy test on Day 1 of each Cycle;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Recovered (i.e., Grade ≤ 1 or to a baseline level) from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other therapies for cancer (with the exception of alopecia for which no resolution is required and peripheral neuropathy which must have resolved to Grade ≤ 1 for subjects receiving prior taxane-based chemotherapy);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Adequate organ function defined as below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  1. Total bilirubin ≤ upper limit of normal (ULN);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  2. Hemoglobin (Hgb) ≥ 9.0 g/dL;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  3. Serum creatinine (sCr) ≤ 1.5 x ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  4. Absolute neutrophil count (ANC) ≥ 1500 cells/mm3;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  5. Platelets ≥ 100 × 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Sufficient archived tumor samples (if taken within 6 months prior to treatment may be submitted) available for PD assessments, or willingness to undergo a pre-treatment core needle biopsy, preferably of the primary tumor, in order to obtain such tissue;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Willing and able to undergo a post-dose core needle biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Prior treatment with docetaxel or mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Requires administration of a prohibited medication or treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Has a significant uncontrolled intercurrent illness including, but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  1. Ongoing or active infection requiring antibiotics;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  2. Clinically significant cardiac disease (class III, or IV of the New York Heart Association classification; unstable angina pectoris, myocardial infarction within 6 months or is post angioplasty or stenting within 6 months; clinically significant cardiac arrhythmia, or uncontrolled hypertension (i.e., systolic blood pressure \\> 150 mm Hg, diastolic blood pressure \\> 90 mmHg) despite anti-hypertensive medication;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  3. Uncontrolled diabetes, active liver disease, poorly controlled chronic obstructive pulmonary disease, serious or non-healing wound, ulcer, or fracture;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  4. Known or tests positive for human immunodeficiency virus, hepatitis B, or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  5. Active known auto-immune disease with the exception of autoimmune thyroiditis, vitiligo, and alopecia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  6. Pleural effusion requiring repetitive drainage, i.e., an indwelling catheter or 2 thoracenteses with 6 weeks of the first dose of mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Received monoclonal antibodies (for any reason), chemotherapy, surgery, investigational therapy, or radiotherapy within 14 days of the first dose of mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Received live, attenuated vaccine within 28 days prior to the first dose of mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Use of immunosuppressive medication within 14 days before the first dose of mogamulizumab. Note: Inhaled, intranasal, intra-articular, or topical corticosteroids are allowed. Non-immunosuppresive doses of systemic steroids for adrenal replacement or for contrast allergy are allowed;;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Any history or signs of central nervous system metastases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Any history or signs of pulmonary lymphangitic spread;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* Experienced a Grade 3 or higher hypersensitivity reaction to monoclonal antibodies or other therapeutic proteins, and the reaction could not be controlled or prevented on subsequent infusion with standard therapies such as antihistamines, 5-hydroxytryptamine (5-HT3) receptor antagonists, or corticosteroids;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* The subject has a history of severe hypersensitivity reactions to drugs formulated with polysorbate 80;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* History of second primary cancer within the past 5 years, with the exception of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  1. Curatively resected non-melanomatous skin cancer;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  2. Curatively treated cervical intraepithelial neoplasia or prostate carcinoma with current prostate specific antigen (PSA) \\< 0.01 ng/mL; or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "  3. Curatively treated ductal carcinoma in situ of the breast;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* The subject is pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "* The subject has aspartate aminotransferase and/or alanine aminotransferase \\> 1.5 × ULN, with concomitant alkaline phosphatase \\> 2.5 × ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00560573",
    "statement": "* Histologically or cytologically proven diagnosis of Stage IIIB (N3 and/or T4) or Stage IV Non-Small Cell Lung Cancer in patients 18-year-old or older, with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 not amenable to curative surgery or radiation therapy and an adequate organ function (bone marrow, hepatic, renal, and cardiac) within 14 days prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00560573",
    "statement": "* Any prior treatment for Non-Small Cell Lung Cancer including chemotherapy, biologic response modifiers or therapy with any investigational agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00560573",
    "statement": "* Patients with known brain metastases, spinal cord compression, uncontrolled superior vein cava syndrome or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00560573",
    "statement": "* Patients with gastrointestinal abnormalities including active gastrointestinal bleeding, pre-diabetes (pre-fasting glycemia \\> 120 g/dL and/or glycosylate haemoglobin level \\> 7.5%), known HIV or AIDS-related illness, significant active cardiac disease or receiving chronic steroid therapy or concurrent use of growth hormones or growth hormone inhibitors or aminoglycoside antibiotics should be excluded from the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": ". Histologically or cytologically confirmed locally advanced NSCLC in which the participant is not a candidate for definitive therapy; or, the participant has recurrent or metastatic (Stage IV) disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "2. Refractory or intolerant to standard available therapies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "3. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "4. Minimum life expectancy of 3 months or more.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "5. Adequate organ function as defined by the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Total serum bilirubin less than or equal to (\\<=) 1.5\\*upper limit of normal (ULN) (\\<=3\\*ULN for participants with Gilbert syndrome or if liver function abnormalities are due to underlying malignancy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Alanine aminotransferase and aspartate aminotransferase \\<=2.5\\*ULN (or \\<=5\\*ULN if liver function abnormalities are due to underlying malignancy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Estimated creatinine clearance greater than or equal to (\\>=) 30 milliliter per minute (mL/min) (calculated by using the Cockcroft-Gault equation)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Serum albumin \\>= 2 gram/deciliter (g/dL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Serum lipase/amylase \\<=1.5\\*ULN; and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Serum amylase \\<=1.5\\*ULN unless the increased serum amylase is due to salivary isoenzymes.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "6. Adequate bone marrow function as defined by the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Absolute neutrophil count \\>=1.5\\*10\\^9 per liter (/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Platelet count \\>=75\\*10\\^9/L; and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Hemoglobin \\>=9.0 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "7. Normal QT interval on screening electrocardiogram (ECG), defined as QT interval with Fridericia's correction (QTcF) of \\<= 450 millisecond (msec) in males or \\<= 470 msec in females. (as conducted and interpreted in accordance to local institutional practices and confirmed by principal investigator \\[PI\\]).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "8. All toxicities from prior anticancer therapy must have resolved to \\<= Grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or have resolved to baseline, at the time of first dose of TAK-788. Note: treatment-related Grade 2 or 3 alopecia and treatment-related Grade 2 peripheral neuropathy are allowed if deemed irreversible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "9. Suitable venous access for study-required blood sampling (that is, including for PK, pharmacodynamics, and clinical laboratory tests).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": ". Received a strong or moderate cytochrome P450 3A (CYP3A) inhibitor or strong or moderate CYP3A inducer within 2 weeks prior to the first dose of TAK-788.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "2. Received small-molecule anticancer therapy (including but not limited to cytotoxic chemotherapy and investigational agents) within 2 weeks prior to the first dose of TAK-788.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "3. Received antineoplastic monoclonal antibodies including check point inhibitors within 28 days of the first dose of TAK-788.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "4. Received radiotherapy \\<=14 days prior to the first dose of TAK-788. However, participants are allowed to receive any of the following treatments up to 7 days prior to the first dose: (a) Stereotactic radiosurgery (SRS) (b) stereotactic body radiation therapy (SBRT) or (c) palliative radiation outside the chest and brain.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "5. Major surgery within 28 days prior to the first dose of TAK-788. Minor surgical procedures, such as catheter placement or minimally invasive biopsy, are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "6. Diagnosed with another primary malignancy other than NSCLC except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or another primary malignancy and is definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "7. Have known active brain metastases (have either previously untreated intracranial central nervous system (CNS) metastases or previously treated intracranial CNS metastases with radiologically documented new or progressing CNS lesions). Brain metastases are allowed if they have been treated with surgery and/or radiation and have been stable without requiring corticosteroids to control symptoms within 7 days before the first dose of TAK-788, and have no evidence of new or enlarging brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "8. Current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging) or leptomeningeal disease (symptomatic or asymptomatic).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "9. Have uncontrolled hypertension. Participants with hypertension should be under treatment on study entry to control blood pressure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "10. Significant, uncontrolled, or active cardiovascular disease, including, but not limited to the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Myocardial infarction within 6 months prior to the first dose of study drug;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Unstable angina within 6 months prior to the first dose of study drug;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Congestive heart failure within 6 months prior to the first dose of study drug. Cardiac ejection fraction \\<50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* History of clinically significant (as determined by the treating physician) atrial arrhythmia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Any history of ventricular arrhythmia; or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "* Cerebrovascular accident or transient ischemic attack within 6 months prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "11. Treatment with medications known to be associated with the development of torsades de pointes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04051827",
    "statement": "12. Gastrointestinal illness or disorder that could affect oral absorption of TAK-788 or midazolam.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Age 18 or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* In the dose-escalation phase: histologically- or cytologically- confirmed advanced solid tumor that is refractory to standard therapy and for which no standard therapy exists.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* In the dose-expansion phase: histologically- or cytologically- confirmed advanced solid tumor where if an approved first-line therapy is available, participants must have failed, be intolerant to, be ineligible for, or have refused",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Adequate organ and marrow function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Participants must have at least 1 measurable lesion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Available archived tumor tissue sample.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Willingness to provide consent for biopsy sample (dose-expansion only)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Any prior Grade ≥ 3 immune-mediated adverse event (imAE) while receiving immunotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Prior treatment with immunotherapy agents including, but not limited to, tumor necrosis factor receptor superfamily agonists or checkpoint inhibitors or natural killer (NK) cell inhibitors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Active or prior documented autoimmune disease within the past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* History of primary immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* History of organ transplant that requires use of immunosuppressives",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Other invasive malignancy within 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Women who are pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Uncontrolled intercurrent illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Known history of tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Known to be human immunodeficiency virus (HIV) positive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01693562",
    "statement": "* Known to be Hepatitis B or C positive (except HCC participants)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Histologically confirmed non-small cell lung cancer (NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Recurrent or progressive disease after receiving at least 1, but no more than two, chemotherapy regimens for advanced or metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Recovery from reversible acute effects of prior anti-cancer therapy (chemotherapy, radiotherapy, or investigational treatment) to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade ≤ 1 (excluding alopecia).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Ability to comply with the study and follow-up procedures, including all specified imaging studies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Ability to take oral medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Life expectancy ≥ 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Measurable disease on computed tomography (CT).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* At least 1 extracerebral lesion on 2-deoxy-2-\\[18F\\]fluoro-D-glucose-positron emission tomography (FDG-PET) scan that is suitable for response assessment, that is measurable, and ≥ 15 mm on CT.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Left ventricular ejection fraction (LVEF) ≥ 50%, as determined by echocardiogram or MUltiple Gated Acquisition (MUGA) scan.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by the patient and/or partner.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Availability and willingness to provide sufficient tumor tissue for testing for epidermal growth factor receptor (EGFR) mutations, and other human epidermal growth factor receptor (HER) pathway and NSCLC-related biomarkers.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Prior treatment with an investigational or marketed agent for the purpose of inhibiting HER family members (including HER1, HER2, HER3, and HER4). This includes, but is not limited to erlotinib, gefitinib, pertuzumab, cetuximab, and panitumumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Chemotherapy, radiotherapy, or investigational treatment within 28 days of start of study (ie, prior to Day 0) or from which patients have not yet recovered.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Inability to take oral medications, disease affecting gastrointestinal absorption, or prior surgical procedure affecting gastrointestinal absorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Uncontrolled diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Clinical or radiographic evidence of new or progression of pre-existing central nervous system (CNS) metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Current severe, uncontrolled systemic disease (eg, clinically significant cardiovascular, pulmonary, or metabolic disease; wound-healing disorders; ulcers; or bone fractures).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Current uncontrolled hypertension or unstable angina.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* History of congestive heart failure (CHF) of any New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* History of myocardial infarction within 6 months of enrollment or history of unstable angina.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Any evidence of an unstable infection as suggested by an infectious process, coupled with hypotension and/or tachycardia and/or fever and/or positive blood culture.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Known human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Uncontrolled hypercalcemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Pregnancy or lactation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* History of another malignancy in the past 2 years, unless the malignancy has been adequately treated, is currently not detectable, and is associated with a 5-year survival \\> 90%.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Claustrophobia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00855894",
    "statement": "* Any other disease, condition, physical examination finding, or clinical laboratory finding that, in the opinion of the investigator, makes the patient inappropriate for the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03365791",
    "statement": "* Patient must have had at least one prior line of therapy for their disease and must not be beyond 4th progression/relapse of disease (5 maximum prior lines).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03365791",
    "statement": "* Patient has a pathology confirmed diagnosis of a solid tumor or lymphoma listed in the section \"condition\". Patients must have measurable disease as per appropriate guidelines (Solid Tumors by RECIST 1.1 and Diffuse Large B-cell Lymphoma by Revised Response Criteria for Malignant Lymphoma - Cheson et al 2007).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03365791",
    "statement": "* History of severe hypersensitivity reactions to other monoclonal antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03365791",
    "statement": "* Impaired cardiac function or clinically significant cardiac disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03365791",
    "statement": "* Active, known or suspected autoimmune disease or a documented history of autoimmune disease within three years prior to screening with a few exceptions as per protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03365791",
    "statement": "* Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03365791",
    "statement": "* Patient with second primary malignancy within \\< 3 years of first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03365791",
    "statement": "* Prior immunotherapy treatment with PD-1, PD-L1, CTLA-4, or LAG-3 antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": ". Capable of giving signed informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "2. Age ≥ 18 years at study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "3. Histologically or cytologically documented NSCLC with locally-advanced, unresectable Stage III disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "4. Deemed ineligible for chemotherapy per Investigator assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "5. Receipt of radiation therapy that was completed within 42 days prior to first study drug administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "6. Must have received a total dose of radiation of 40 to 66 Gy (standard or hypofractionated BED).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "7. Must not have progressed following radiation therapy, as per Investigator assessed RECIST 1.1 criteria: a) Patients with measurable disease and/or nonmeasurable and/or no evidence of disease assessed at baseline by computed tomography /magnetic resonance imaging will be eligible for this study. b) Prior irradiated lesions may be considered measurable and selected as target lesions (TLs) providing they fulfill the other criteria for measurability.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "8. World Health Organization/ECOG performance status of ≤2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "9. No prior exposure to immune-mediated therapy including, but not limited to, anti-CTLA-4, anti-PD-1, anti-PD-L1, and antiprogrammed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "10. Patients must have adequate organ and marrow function as defined below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "* Hemoglobin ≥ 9.0 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "* Absolute neutrophil count ≥ 1.0 × 109 /L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "* Platelet count ≥ 75 × 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "* Serum bilirubin ≤ 1.5 × the upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "* Alanine aminotransferase and aspartate aminotransferase ≤ 2.5 × ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "* Measured creatinine clearance \\> 30 mL/min or calculated CL \\> 30 mL/min as determined by Cockcroft-Gault",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "11. Life expectancy of greater than 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "12. Body weight greater than 30 kg at study entry and at first study drug administration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": ". Patients with locally-advanced NSCLC whose disease has progressed following radiation therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "2. Mixed small cell lung cancer and NSCLC histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "3. History of allogeneic organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "4. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "5. Uncontrolled intercurrent illness (e.g., ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "6. History of another primary malignancy except for (a) malignancy treated with curative intent and with no known active disease ≥ 5 years before the first study drug administration, (b) adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease, and c) treated carcinoma in situ without evidence of disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "7. History of leptomeningeal carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "8. History of active primary immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "9. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "10. Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, lymphopenia, and the laboratory values defined in the inclusion criteria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "11. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "12. Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "13. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of durvalumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "14. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "15. Participation in another clinical study with an IP administered in the last 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "16. Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "17. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "18. Patients who refuse chemotherapy by their own decision.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "19. Involvement in the planning and/or conduct of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "20. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "21. Judgment by the Investigator that the patient should not participate in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "22. Genetics research study (optional):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04249362",
    "statement": "Exclusion criteria for participation in the optional genetics research component of the study include: a) Previous allogeneic bone marrow transplant b)Nonleukocyte-depleted whole blood transfusion within 120 days of genetic sample collection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Present with histologically proven or cytological diagnosis of non-squamous non-small cell lung cancer (NSCLC) Stage IIIB or IV.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Participants must agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Female participants must not be pregnant.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* No prior systemic chemotherapy for lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* At least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Prior radiation therapy allowed to \\<25% of the bone marrow.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Signed informed consent document on file.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Estimated life expectancy of greater than or equal to 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Participant compliance and geographic proximity that allow adequate follow up.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Peripheral neuropathy of great than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Inability to comply with protocol or study procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the participant's ability to complete the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Documented brain metastases unless the participant has completed successful local therapy for central nervous system metastases and has not taken corticosteroids for at least 4 weeks before enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Presence of clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Significant weight loss (that is, greater than or equal to 10%) over the previous 6 weeks before study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Concurrent administration of any other anti-tumor therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents, such as piroxicam).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Inability or unwillingness to take folic acid or vitamin B12 supplementation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Inability to take corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Pregnant or breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01005680",
    "statement": "* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Age \\> 18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Advanced cancer potentially sensitive to vinorelbine:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Breast cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Stage 3 or 4 non-small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Non-Hodgkins lymphoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Cancer of other histologic type, sensitive to vinca alkaloids.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Rare tumor type with no standard treatment, for which single agent vinorelbine is appropriate therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Failure of standard treatment(s) of the tumor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Life expectancy of at least three months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* ECOG performance level 0-2 or Karnofsky score 100-70.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Hematological and serum chemistry results with defined ranges.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Willingness and ability to provide written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Pregnancy or lactation. In a woman of childbearing potential, a positive pregnancy test result, no pregnancy test result, or no use of reliable contraception, at baseline. A postmenopausal woman will be considered to be of childbearing potential until there has been amenorrhea for at least 12 consecutive months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Previous treatment with vinorelbine or mitomycin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Any history suggesting or demonstrating resistance to, lack of response to, or intolerance of any prior vinca alkaloid treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Active infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Prior anticancer therapy completed within four weeks prior to the first day of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Failure to have recovered from any toxicity of previous cancer treatment (patients with alopecia will not be excluded).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Participation in another experimental drug study within four weeks prior to the first day of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Requirement for any concomitant chemotherapeutic agent other than the study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00432562",
    "statement": "* Any investigator judgment that the individual would not be an appropriate study subject.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01378962",
    "statement": "* Adult patients, \\>/=18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01378962",
    "statement": "* Locally advanced or metastatic non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01378962",
    "statement": "* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01378962",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01378962",
    "statement": "* Life expectancy over \\>/=12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01378962",
    "statement": "* Adequate hematological, liver, or kidney function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01378962",
    "statement": "* Previous therapy against epidermal growth factor receptor for metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01378962",
    "statement": "* Treatment with investigational drug during the 3 weeks before enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01378962",
    "statement": "* History of neoplasm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01378962",
    "statement": "* Patients with symptomatic cerebral metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01378962",
    "statement": "* Unstable systemic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has a histologically-confirmed or cytologically confirmed diagnosis of stage IV nonsquamous NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has measurable disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has not received prior systemic treatment for their advanced/metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Can provide tumor tissue.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has a life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* If female of childbearing potential, is willing to use adequate contraception for the course of the study through 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* If male with a female partner(s) of child-bearing potential, must agree to use adequate contraception starting with the first dose of study medication through 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has predominantly squamous cell histology NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Before the first dose of study medication: a) Has received prior systemic cytotoxic chemotherapy for metastatic disease, b) Has received antineoplastic biological therapy (e.g., erlotinib, crizotinib, cetuximab), c) Had major surgery (\\<3 weeks prior to first dose)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Received radiation therapy to the lung that is \\>30 Gray (Gy) within 6 months of the first dose of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Completed palliative radiotherapy within 7 days of the first dose of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Is expected to require any other form of antineoplastic therapy while on study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Received a live-virus vaccination within 30 days of planned start of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has clinically active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, peritoneal carcinomatosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Known history of prior malignancy except if participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy, except for successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Known sensitivity to any component of cisplatin, carboplatin or pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has active autoimmune disease that has required systemic treatment in past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Is on chronic systemic steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Is unable or unwilling to take folic acid or vitamin B12 supplementation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Had prior treatment with any other anti-programmed cell death-1 (PD-1), or PD-ligand 1 (PD-L1) or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms. Has participated in any other pembrolizumab study and has been treated with pembrolizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has an active infection requiring therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has known history of Human Immunodeficiency Virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has known active Hepatitis B or C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Is a regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has symptomatic ascites or pleural effusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Has interstitial lung disease or a history of pneumonitis that required oral of IV glucocorticoids to assist with management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02578680",
    "statement": "* Is pregnant or breastfeeding, or expecting to conceive or father children prior to 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040780",
    "statement": ". Confirmed NSCLC with Histology or cytology; advanced （IIIb/IV).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040780",
    "statement": "2. Must have received 1 or 2 chemotherapy (at least 1 is platin based)before, and prior chemotherapy must be completed at least 4 weeks before study enrollment; =.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040780",
    "statement": ". Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin, erbitux.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* Age \\>= 18",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* Histologically or cytologically documented non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* Eastern Cooperative Oncology Group (ECOG)performance status (PS)0, 1, 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* Radiologically measurable or evaluable disease No prior chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* 1 or 2 epithelial growth factor receptor (EGFR) pathway markers positive at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* Tumor tissue block or fine needle aspirate",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* Any concurrent anticancer therapy or radiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* Other active malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* Uncontrolled brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* GI abnormalities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* Severe abnormalities of the cornea",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* Significant cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00294762",
    "statement": "* Active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Pathologically documented, advanced colorectal, pancreatic or non-small cell lung cancer that is refractory to standard treatment, or the subjects have been intolerant to or refuse standard treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Measurable disease per RECIST 1.1 guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Adequate hematologic, renal, and hepatic function determined by laboratory blood and urine tests.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Availability of recent tumor tissue within 3 months prior to enrollment, when feasible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Has known active central nervous system metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* History of other malignancy with the past 2 years with some exceptions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Evidence of active non-infectious pneumonitis/interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Evidence of other active autoimmune disease that has required prolonged systemic treatment in past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Evidence of clinically significant immunosuppression such as organ or stem cell transplantation, any severe congenital or acquired cellular and/or humoral immune deficiency, concurrent opportunistic infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Receiving systemic immunostimulatory agents within 6 weeks or 5 half-lives, whichever is shorter, prior to first dose of study treatment (except ant PD-1/PD-L1 treatment if recruited into Group 4a or 4b).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Evidence of active infection within 2 weeks prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Prior chemotherapy, radiotherapy, biological cancer therapy or major surgery within 28 days prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Currently participating or has participated in a study (treatment period only) of an investigational agent or used an investigational device within 28 days of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Received live vaccine within 28 days prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Adverse event due to cancer therapy administered more than 28 days prior to enrollment that has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Positive for human immunodeficiency virus (HIV), Hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713529",
    "statement": "* Women planning to become pregnant or who are lactating/breastfeeding while on study through 4 months after receiving the last dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735680",
    "statement": "* Biopsy-confirmed diagnosis of primary or recurrent respective tumor type and scheduled to undergo surgical resection",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735680",
    "statement": "* Part 1: Biopsy-confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC) or breast cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735680",
    "statement": "* Part 2: Biopsy-confirmed diagnosis of HNSCC, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, urothelial carcinoma and non-small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735680",
    "statement": "* Part 3: Stage 2 to 4 HNSCC Including T0 or Tx unknown Primary cancers",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735680",
    "statement": "* Histologically diagnosed by an excisional biopsy procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735680",
    "statement": "* Tumors at sites of which the surgeon would assess that in vivo intraoperative imaging would not be feasible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735680",
    "statement": "* Life expectancy \\<12 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735680",
    "statement": "* Hepatic impairment (Child-Pugh score \\>5) or significant liver disease including active hepatitis or cirrhosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": ". Locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "2. Epidermal Growth Factor Receptor (EGFR) mutation-positive results per the institution's testing methodology",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "3. Male or female patients age \\>=18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "4. Adequate organ function, defined as all of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "   1. Absolute neutrophil count (ANC) \\>1500/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "   2. Platelet count\\>75,000/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "   3. Serum creatinine\\<1.5 times of the upper limit of (institutional) normal and/or creatinine clearance (measured or calculated)\\>45ml/min",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "   4. Total bilirubin \\<1.5 times upper limit of (institutional) normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "   5. Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) \\< three times the upper limit of (institutional) normal (if related to liver metastases \\< five times ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "5. Eastern Cooperative Oncology Group (ECOG) score between 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "6. Written informed consent by patient or guardian prior to admission into the trial that is consistent with International Conference on Harmonization (ICH)- Good Clinical Practice (GCP) guidelines and local law",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "7. Recovery from any previous therapy related toxicity to \\<=CTCAE Grade 1 at study entry (except for stable sensory neuropathy \\<=CTCAE Grade 2 and alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": ". Prior treatment with an EGFR tyrosine kinase inhibitor (TKI)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "2. Hormonal anti-cancer treatment within 2 weeks prior to start of trial treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "3. Radiotherapy within 28 days prior to drug administration, except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "   1. Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "   2. Single dose palliative treatment for symptomatic metastases outside above allowance to be discussed with sponsor prior to enrolling",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "4. Major surgery within 4 weeks before starting trial treatment or scheduled for surgery during the projected course of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "5. Known hypersensitivity to afatinib or any of its excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "6. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to starting trial treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "7. Women of Child-Bearing Potential (WOCBP) and men who are able to father a child, unwilling to use adequate contraception prior to trial entry, for the duration of trial participation and for at least 2 weeks after treatment has ended",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "8. Childbearing potential who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "   1. are nursing or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "   2. are pregnant or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "   3. are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "9. Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patients ability to comply with the trial or interfere with the evaluation of safety for the trial drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "10. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "11. Requiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "12. Known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "13. Presence of poorly controlled gastrointestinal disorders that could affect the absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis, malabsorption, or Common Terminology Criteria grade =2 diarrhea of any aetiology) based on investigator assessment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "14. Active hepatitis B infection (defined as presence of Hepatitis B (HepB) sAg and/or HepB DNA), active Hepatitis C (HEP C) infection (defined as presence of Hep C RNA) and/or known Human Immunodeficiency Virus (HIV) carrier",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "15. Meningeal carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02044380",
    "statement": "16. Symptomatic brain metastases (patients with asymptomatic brain metastases, who were previously treated, are eligible provided they have had Stable Disease (SD) for at least 4 weeks on stable doses of corticosteroid)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00533429",
    "statement": "* participants or their legal representative must have signed an informed consent document for clinical research",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00533429",
    "statement": "* have laboratory confirmed diagnosis of advanced, nonsquamous cell non-small cell lung cancer (NSCLC) (Stage IIIB or IV disease) which is not curable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00533429",
    "statement": "* have not received any prior systemic chemotherapy, immunotherapy, targeted therapy, or biological therapy for advanced NSCLC, prior radiation therapy is allowed to less than 25% of the bone marrow",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00533429",
    "statement": "* have measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00533429",
    "statement": "* have adequate organ function and estimated life expectancy of 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00533429",
    "statement": "* have known central nervous system (CNS) disease; major surgery within 28 days; minor surgery within 7 days; serious concomitant systemic disorder; serious cardiac condition; have a serious, nonhealing wound, ulcer, or bone fracture",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00533429",
    "statement": "* have received treatment within the last 30 days with any drug that has not received regulatory approval for any indication at the time of study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00533429",
    "statement": "* have previously received treatment with enzastaurin, pemetrexed, or bevacizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00533429",
    "statement": "* are pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00533429",
    "statement": "* are unable to swallow tablets",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03531762",
    "statement": "* Healthy participants of non-child bearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03531762",
    "statement": "* Body mass index (BMI) between 18.5 and 29.9 kilogram per meter square (kg/m\\^2)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03531762",
    "statement": "* Body weight between 50 to 100 kilogram (kg)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03531762",
    "statement": "* Other protocol defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03531762",
    "statement": "* Participation in a clinical study within 60 days prior to first drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03531762",
    "statement": "* Whole blood donation or loss of greater than (\\>) 450 milliliter (mL) within 60 days prior to first drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03531762",
    "statement": "* Any surgical or medical condition, or any other significant disease that could interfere with the study objectives, conduct, or evaluation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03531762",
    "statement": "* Other protocol defined exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Diagnosis of locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the EGFR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Measurable disease according to RECIST",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Life expectancy greater than or equal to (\\>/=) 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Adequate hematological, liver and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Participants with asymptomatic and stable cerebral metastases receiving medical treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Previous chemotherapy or treatment against EGFR for metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Treatment with an investigational agent less than 3 weeks before enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* History of neoplasm other than non-small cell lung cancer (except carcinoma in situ of the uterine cervix, basal cell skin carcinoma, or prostate carcinoma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Participants with symptomatic cerebral metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Any significant ophthalmologic abnormality",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Unstable systemic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Coumarins use",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding contraindicating the use of an investigational drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Participants with pre-existing parenchymal lung disease such as pulmonary fibrosis, lymphangiosis carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01667562",
    "statement": "* Participants with known infection with human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Non-Small Cell Lung Cancer disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Clinical stage IV or recurrent disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* One prior first-line platinum-based chemotherapy regimen with or without maintenance therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* For Non-Small Cell Lung Cancer (NSCLC) tumors other than squamous cell histology, the epidermal growth factor receptor (EGFR) mutation status is known prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* For participants with activating epidermal growth factor receptor (EGFR) mutation only, prior epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) monotherapy (only one regimen in the setting of single use) should be utilized",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version RECIST version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Estimated life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Have undergone major surgery within 28 days prior to randomization or have planned major surgery during study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Receiving concurrent treatment with other anticancer therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Central nervous system disease other than stable and treated brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Has major blood vessel invasion or encasement by cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Has intratumor cavitation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Has a history of uncontrolled thrombotic disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Is receiving therapeutic anticoagulation with drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Is receiving chronic therapy with nonsteroidal anti-inflammatory drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Has a history of hemoptysis within 2 months prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Has clinically relevant congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Has experienced any arterial thromboembolic event",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Has uncontrolled arterial hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Has had a serious or nonhealing wound or, ulcer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01703091",
    "statement": "* Has significant existing conditions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Chinese participants must be born, raised, and reside in China",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has a histologically or cytologically confirmed diagnosis of stage IIIB/IV or recurrent NSCLC and have at least one measurable lesion as defined by RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has a life expectancy of ≥3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has progression of disease (investigator determined) per RECIST 1.1 after treatment with at least two cycles of a platinum-containing doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has documentation of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Participants with an EGFR sensitizing mutation tumor will be excluded",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 within 10 days prior to study start",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has provided archival tumor tissue sample or newly obtained formalin fixed tumor tissue from a recent biopsy of a tumor lesion not previously irradiated",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has a PD-L1 positive tumor as determined by immunohistochemistry at a central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has recovered from the toxicity and/or complications of any recent major surgery or radiation therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours prior to receiving the first dose of study medication)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Female and male participants of reproductive potential must agree to use adequate contraception starting with the first dose of study therapy through 120 days after the last dose of pembrolizumab (MK-3475) or 180 days after the last dose of docetaxel",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has received prior therapy with docetaxel for NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Is receiving systemic steroid therapy within 3 days prior to the first dose of study treatment or receiving any other form of immunosuppressive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Is expected to require any other form of systemic or localized antineoplastic therapy while on study including maintenance therapy with another agent for NSCLC or radiation therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has received prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g., cetuximab), any other agents used as systemic treatment for cancer, or major surgery within 3 weeks of the first dose of study treatment; received thoracic radiation therapy of \\> 30 Gray Units (Gy) within 6 months of the first dose of study treatment; received prior ALK-directed tyrosine kinase inhibitor therapy or completed palliative radiotherapy of 30 Gy or less within 7 days of the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-PD-L1, anti-PD-L2, with an agent directed to an agonist or antagonist T-cell check point receptor, or if the participant has previously participated in Merck sponsored clinical trials evaluating pembrolizumab (MK-3475)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has a known additional malignancy that is progressing or requires active treatment, with the exception of early stage cancers, treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has known active central nervous system metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has active autoimmune disease that has required systemic treatment in past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has had an allogeneic tissue/solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has received or will receive a live vaccine within 30 days prior to the first administration of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has an active infection requiring intravenous systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has known history of Human Immunodeficiency Virus (HIV) (HIV ½ antibodies)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has known active Hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Is, at the time of signing informed consent, a regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Is pregnant or breastfeeding, or expecting to conceive or father children starting with the screening visit (Visit 1) through 120 days after the last dose of pembrolizumab (MK-3475) or 180 days after the last dose of docetaxel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864394",
    "statement": "* Requires treatment with a strong inhibitor of Cytochrome P450 3A4",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Aged 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Pathologically confirmed of advanced and/or metastatic stage IIIb/IV non-small cell carcinoma of lung",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Activating EGFR mutation (exon 19 deletion, L858R, G719X, L861X)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Presence of EGFR activating mutation and absence of EGFR T790M in the tumour associated with the latest disease progression. Only applicable in Part B",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Must have adequate fresh or archival tumour tissue at the late disease progression immediately prior to the study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Part A: Progression of disease (RECIST 1.1) while on continuous treatment with single EGFR TKI or for histology other than adenocarcinoma and without prior EGFR TKI treatment: progression of disease (RECIST v1.1) on platinum-based chemotherapy. Part B: Progression of disease (RECIST v1.1) while on continuous treatment with single agent of the second generation irreversible EGFR TKI (e.g. afatinib or dacomitinib)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* No intervening systemic therapy between cessation of EGFR TKI and study treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Patient must have measurable disease per RECIST 1.1 presented after tumour biopsy for the late disease progression",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Life expectancy of \\>= 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Fasting plasma glucose \\< 8.9 mmol/L (\\< 160mg/dL) and HbA1C \\< 8%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Recovered from any previous therapy related toxicity to \\<= Grade 1 at study entry (except for stable sensory neuropathy \\<= Grade 2 and alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Written informed consent that is consistent with ICH-GCP guidelines and local regulations",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* No known potentially targetable mutation other than IGF signaling pathway or EGFR or no available treatment for potentially targetable mutation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Part A only: For patient who has been treated with afatinib: last treatment at reduced dose below the assigned dose level",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Patient whose disease progressed on insufficient dose of EGFR TKI immediately prior to study in the opinion of the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* More than 2 prior EGFR TKI treatment regimens for Part B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Chemotherapy, biological therapy or investigational agents (except EGFR TKIs) within 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Use of previous EGFR TKIs except afatinib within 3 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Radiotherapy within 4 weeks prior to the start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Active brain or subdural metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Meningeal carcinomatosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Major surgery (as judged by the investigator) within 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Known hypersensitivity to afatinib, monoclonal antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Prior severe infusion-related reaction to a monoclonal antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* History or presence of clinically relevant cardiovascular abnormalities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Female patients of childbearing potential (see Section 4.2.2.3) and male who are able to father a child",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Any history of or concomitant condition that, in the opinion of the investigator not to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Disease that is considered by the investigator to be rapidly progressing or life threatening such as extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumour (subjects who are intended for urgent chemotherapy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Requiring treatment with any of the prohibited concomitant medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Known pre-existing interstitial lung disease (ILD)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Active hepatitis B infection active hepatitis C infection and/or known HIV carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Previous treatment with agents targeting the insulin like growth factor (IGF) signalling pathway.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Previous treatment with EGFR TKI which cannot be documented as either reversible or irreversible (Part B only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02191891",
    "statement": "* Part B only: Prior treatment with third generation irreversible EGFR TKI (e.g. AZD9291 or CO-1686)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Histologically confirmed NSCLC with activated PI3K pathway",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Progressive disease after prior systemic antineoplastic treatment(s) for advanced NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Archival or fresh tumor biopsy must be available for profiling",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Measurable and/or non-measurable disease as per RECIST 1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Adequate organ function as assessed by laboratory tests",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Patient has received previous treatment with PI3K inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Patient with squamous NSCLC has received more than one line of chemotherapy treatment for metastatic disease; patient with non-squamous NSCLC has received more than two lines of systemic antineoplastic treatment for metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Uncontrolled or symptomatic CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Concurrent use of any other approved or investigational antineoplastic agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Radiotherapy ≤ 28 days prior to starting study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Major surgery within 28 days prior to starting study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* History of clinically significant cardiac dysfunction, mood disorders, or poorly controlled diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Current treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Impairment of gastrointestinal (GI) function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Chronic treatment with steroids or another immunosuppressive agent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Concurrent severe and/or uncontrolled medical condition",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Currently receiving Warfarin or another coumarin derivative",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Known history of HIV infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Sensory neuropathy with functional impairment (CTC grade 2 neuropathy, regardless of causality)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Pregnancy, lactation, or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "* Woman of child-bearing potential",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01297491",
    "statement": "Other protocol-defined inclusion/exclusion criteria may apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00195260",
    "statement": "* Advanced or recurrent solid malignancy confirmed histologically or cytologically for which no effective therapy is available.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00195260",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00195260",
    "statement": "* Measurable disease as outlined by the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00195260",
    "statement": "* Other inclusion applies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00195260",
    "statement": "* Use of any systemic antitumor agents or any investigational agent within 28 days before the first dose of test article is administered.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00195260",
    "statement": "* Prior exposure to SKI-606 or any other Src-kinase inhibitor, major surgery or radiotherapy within 14 days before the first dose of test article (recovery from previous surgery should be complete before day 1).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00195260",
    "statement": "* Active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, requirement for corticosteroids and/or progressive growth (Treated CNS metastases must be stable for \\>= 2 weeks before day 1).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00195260",
    "statement": "* Other exclusion applies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00050960",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00050960",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "* Documented active diagnosis of non-small cell lung, pancreatic, colorectal cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "* Cachexia defined by Fearon criteria of weight loss",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "* Serum GDF-15 concentrations",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "* Signed informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "* ECOG PS ≤3 with life expectancy of at least 4 months to be able to complete Part A.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "* Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "* Current active reversible causes of decreased food intake.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "* Cachexia caused by other reasons.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "* History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "* inadequate liver function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05546476",
    "statement": "* renal disease requiring dialysis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": ". Histologically/cytologically confirmed, locally advanced/metastatic NSCLC of stage IIIB/IV or recurrent NSCLC (all histologies. Existence or nonexistence of measurable lesion according to RECIST is no object.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "2. Patients with one prior chemotherapy regimen including platinum-containing drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "   In case of recurrent disease, one additional prior regimen is allowed for adjuvant and/or neoadjuvant therapy. However monotherapy of EGFR-TKI (i.e. erlotinib/Tarceva® and gefitinib/Iressa®) is not counted as 'one regimen'.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "3. Male or female patients age \\>=20 years and =\\<74 years at the enrolment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "4. Life expectancy of at least three (3) months after the start of administration of the investigational drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "5. Eastern Cooperative Oncology Group (ECOG) \\[R01-0787\\] performance Score 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "6. Patients retaining a significant physiological compensatory function and patients with sufficient baseline organ function as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "* Haemoglobin count more than 9.0g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "* Absolute neutrophil count more than 1500/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "* Platelet count more than 100 000/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "* Serum creatinine less than or equal to1.5x upper limit of normal range at the investigator site",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "* Aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) less than or equal to 1.5x upper limit of normal range at the investigator site (It is the same if patients have liver metastases)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "* PaO2 or SpO2 more than 60torr or 92%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "7. Written informed consent that is consistent with ICH-GCP guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": ". Patients who have received chemotherapy (including other investigational drug), hormonal therapy and immune therapy =\\<4 weeks prior to registration or who have not recovered from side effects of such therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "2. Patients who have received radiotherapy =\\<4 weeks (limited field (e.g brain or bone metastasis) radiation =\\<2 weeks) prior to registration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "3. Patients who have active brain metastases. (Patients who have no symptoms and is not needed to receive therapy in the registration may participate in this trial)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "4. Patients with active double cancer. (Patients who have skin cancer that is not malignant melanoma and carcinoma in situ of uterine cervix may participate in this trial)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "5. Patients with distinct / suspected pulmonary fibrosis or interstitial lung disease by the chest radiographic findings, or patients with a previous history of.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "6. History of clinically significant haemoptysis within the past 3 months (more than one tea spoon of fresh blood per day)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "7. Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid =\\<325 mg per day)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "8. History of major thrombotic or clinically relevant major bleeding event in the past 6 months prior to registration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "9. Known inherited predisposition to bleeding or thrombosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "10. Significant cardiovascular diseases. (i.e. hypertension not controlled by medical therapy, unstable angina, history of myocardial infarction within the past 6 months, congestive heart failure \\> NYHA II, serious cardiac arrhythmia, pericardial effusion)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "11. Significant weight loss (\\> 10 %) within the past 6 weeks prior to registration in the this trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "12. Current peripheral neuropathy \\>= CTCAE grade 2 except due to trauma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "13. Accumulation of coelomic fluid (e.g. pleural effusion, ascites fluid, cardiac effusion) requiring treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "14. Major injuries and/or surgery within the past 10 days prior to registration with incomplete wound healing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "15. Serious infections requiring systemic antibiotic (e.g antiviral, antimicrobial, antifungal) therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "16. Decompensated diabetes mellitus or other contraindication to high dose corticosteroid therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "17. Gastrointestinal disorders or abnormalities (e.g Crohn's disease, Colitis ulcerosa and extensive gastrectomy) that would interfere with absorption of the study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "18. Patients with difficulty in swallowing study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "19. Patients with positive HBs antigen, HCV antibody, or HIV antibody test",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "20. Serious illness or concomitant non-oncological disease such as neurologic-, psychiatric-, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or investigational drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "21. Patients who are sexually active and unwilling to use a medically acceptable method of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females, condoms for participating males) during the trial and for at least 12 months after end of active therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "22. Female patients who are pregnant, breast feeding and may become pregnant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "23. Patients who have or is suspected of having active alcohol or drug abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "24. Patient with clinically meaningful drug hypersensitivities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "25. Patients with auto immune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "26. Patients unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00876460",
    "statement": "27. Other patients judged ineligible for enrolment in the study by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00520676",
    "statement": "* Patient with locally advanced or metastatic (Stage IIIB/IV) NCSLC with no prior chemotherapy for advanced disease or molecular target treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00520676",
    "statement": "* Easter Cooperative Oncology Group (ECOG) performance status 0 to 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00520676",
    "statement": "* Estimated life expectancy of at least 8 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00520676",
    "statement": "* Known or suspected brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00520676",
    "statement": "* Concurrent administration of any other tumor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00520676",
    "statement": "* Serious concomitant disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00520676",
    "statement": "* Pregnancy or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00520676",
    "statement": "* Inability or unwillingness to take folic acid or vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065429",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00065429",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Histologically- or cytologically-documented ES-SCLC (stage IV \\[T any, N any, M1 a/b\\], or with T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan (Brain metastases; must be asymptomatic or treated and stable off steroids and anticonvulsants for at least 1 month prior to study treatment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Participants must be considered suitable to receive a platinum-based chemotherapy regimen as 1st line treatment for the ES-SCLC. Chemotherapy must contain either cisplatin or carboplatin in combination with etoposide",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* World Health Organization/ Eastern Cooperative Oncology Group performance status of 0 to 2 at enrollment Baseline computed tomography/ magnetic resonance imaging results of the brain, chest and abdomen (including liver and adrenal glands) within 28 days prior to the treatment initiation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* No prior exposure to immune-mediated therapy including, but not limited to, other anti- CTLA-4, anti-Programmed cell death-1 (PD-1), anti- Programmed cell death ligand-1 (PD-L1), and anti-PD-L2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Adequate organ and marrow function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Body weight \\> 30 kg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal participants",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* History of allogeneic organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Active or prior documented autoimmune or inflammatory disorders, systemic lupus erythematosus, sarcoidosis syndrome, or wegener syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the participant to give written informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* History of another primary malignancy except for:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of Investigational medicinal product (IMP) and of low potential risk for recurrence",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Adequately treated carcinoma in situ without evidence of disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* History of leptomeningeal carcinomatosis and active primary immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Active infection including tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Any unresolved toxicity Common Terminology Criteria for Adverse Events Grade ≥ 2 from previous anticancer therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Received prior systemic therapy for ES-SCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Medical contraindication to platinum (cisplatin or carboplatin)-etoposide-based chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Any concurrent chemotherapy, IMP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions is acceptable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Planned consolidation chest radiation therapy. Radiation therapy outside of the chest for palliative care is allowed but must be completed before first dose of the study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Receipt of live attenuated vaccine within 30 days prior to the first dose of in IMP",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Major surgical procedure within 28 days prior to the first dose of IMP",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Participants who have received prior immunotherapy agents including anti-PD-1 or anti PD-L1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Participation in another clinical study with an investigational product administered in the last 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04774380",
    "statement": "* Female participants who are pregnant or breastfeeding or male or female participants of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab and 180 days after the last dose of etoposide",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191191",
    "statement": "* Clinical stage III or IV",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191191",
    "statement": "* Previously treated with one or two chemotherapeutic regimens",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191191",
    "statement": "* Performance status: 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191191",
    "statement": "* Inability or unwillingness to take folic acid or vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has histologically or cytologically confirmed non-small cell lung cancer (NSCLC), except squamous cell carcinoma. Mixed tumors will be categorized by the predominant cell type, but the presence of small cell lung cancer elements will make the patient ineligible. Cytologic or histologic elements can be established on metastatic tumor aspirates or biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has advanced NSCLC (Stage IIIB with malignant pleural effusion or Stage IV or recurrent disease).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient's Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has adequate hematologic function as defined by an Absolute Neutrophil Count greater than or equal to 1500/mm³,hemoglobin greater than or equal to 9 gm/dL, and a platelet count greater than or equal to 100,000/mm³ obtained within 2 weeks prior to the first dose of study medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has adequate hepatic function as defined by a total bilirubin greater than or equal to 1.5 mg/dL and transaminases and alkaline phosphatase less than or equal to 5 x the Upper Limit of Normal (ULN) obtained within 2 weeks prior to the first dose of study medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has adequate renal function as defined by serum creatinine less than or equal to 1.5 x ULN or calculated creatinine clearance (CrCl) \\>60 mL/minute, and urine dipstick for proteinuria \\<1+ (ie, either 0 or trace) obtained within 2 weeks prior to the first dose of study medication. If urine dipstick is greater than or equal to 1+, then a 24-hour urine for protein must demonstrate \\<500 mg of protein in 24 hours to allow participation in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has adequate coagulation function as defined by International Normalized Ratio less than or equal to 1.5 and a Prothrombin time and partial thromboplastin time less than or equal to ULN obtained within 2 weeks prior to the first dose of study medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient, if a woman of childbearing potential, agrees to use an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study. If a male and sexually active, the patient agrees to use effective contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has known Central Nervous System metastases. A head computed tomography (CT) is required within 4 weeks prior to the first dose of study medication (magnetic resonance imagines \\[MRIs\\] are also acceptable).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has received prior cetuximab therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has received prior bevacizumab therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has received prior systemic chemotherapy or radiation therapy at any time for lung cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* Any concurrent malignancy other than basal cell skin cancer, or carcinoma in situ of the cervix. Patients with adequately treated cancers of other histologies who have been disease-free for more than 3 years prior to the first treatment dose are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* Concurrent treatment with other anti-cancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has a history of thrombotic or hemorrhagic disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has uncontrolled hypertension (\\>150/100 mmHg) on a standard regimen of anti-hypertensive therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient is receiving chronic daily treatment with aspirin (\\>325 mg/day) or nonsteroidal anti-inflammatory agents known to inhibit platelet function.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient is receiving treatment with dipyridamole (Persantine®), ticlopidine (Ticlid®), clopidogrel (Plavix®) and /or cilostazol (Pletal®).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient is receiving anti-coagulation therapy. Prophylactic anti-coagulation of venous access devices is allowed. Caution should be taken on treating patients with low dose heparin or low molecular weight heparin for deep vein thrombosis (DVT) prophylaxis during treatment with bevacizumab as there may be an increased risk of bleeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* Patients with a history of gross hemoptysis (defined as bright red blood or greater than or equal to ½ teaspoon).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has a serious non-healing wound ulcer, bone fracture, or major surgical procedure within 30 days prior to first dose of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* Elective or planned major surgery to be performed during the course of the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient has a pre-existing neuropathy \\>grade 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00343291",
    "statement": "* The patient, if a woman, is pregnant or lactating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Must have advanced or metastatic non-small cell lung cancer that has not been previously treated with any chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Tumor/disease lesions that can be measured bidimensionally.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Must be able to carry-out work of light or sedentary nature (e.g. light house work, office work).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Adequate recovery from recent surgery or radiation therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Must be at least 4 weeks from last major surgery or prior treatment with an investigational agent. At least 12 weeks from any radiation therapy to chest.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Accessible for treatment, follow-up and required visits at a participating center(s).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Prior chemotherapy or adjuvant chemotherapy for the treatment of lung cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Prior treatment with cetuximab or other epidermal growth factor (EGFR)-targeted therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Prior severe infusion reaction to antibody therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Concurrent malignancy (previous malignancy without evidence of disease for 5 years will be allowed to enter trial).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Concurrent chemotherapy or therapy with another investigational agent not indicated in the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Serious uncontrolled medical disorders that would impair the ability to receive therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* History of myocardial infarction within prior 3 months, uncontrolled angina, uncontrolled arrhythmia, or uncontrolled congestive heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Symptomatic or uncontrolled metastases in the central nervous system. Subjects receiving a glucocorticoid for central nervous system (CNS) metastases are not eligible, but those receiving an anticonvulsant are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Peripheral neuropathy \\>= grade 2 (Common Toxicity Criteria Adverse Event \\[CTCAE\\] Version 3.0).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Inadequate hematologic and/or liver and/or kidney function.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Sexually active and fertile individuals or partners of these individuals who are unwilling or unable to use an acceptable method of birth control for entire trial and up to 4 weeks after the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Women who are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Women with a positive pregnancy test on enrollment prior to study drug administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00112294",
    "statement": "* Altered mental status or psychiatric condition that prohibits understanding or rendering of consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* male or female patient aged 18 years or older;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* histologically or cytologically confirmed, locally advanced and/or metastatic NSCLC of stage IIIB or IV or recurrent NSCLC;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* relapse or failure of one first line prior chemotherapy;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* at least one target tumour lesion that has not been irradiated within the past three months and that can accurately be measured ;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* life expectancy of at least three months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* Eastern Cooperative Oncology group (ECOG) score of 0 or 1;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* patient has given written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* more than one prior chemotherapy regimen for advanced and/or metastatic or recurrent NSCLC;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* more than one chemotherapy treatment regimen (either neoadjuvant or adjuvant or neoadjuvant plus adjuvant) prior to first line chemotherapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* previous therapy with other VEGFR inhibitors (other than bevacizumab) or docetaxel for treatment of NSCLC;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* persistence of clinically relevant therapy related toxicities from previous chemotherapy and/or radiotherapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* treatment with other investigational drugs or other anti-cancer therapy or treatment in another clinical trial within the past four weeks before start of - therapy or concomitantly with this trial ;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* radiotherapy (except extremities and brain) within the past three months prior to baseline imaging;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* active brain metastases or leptomeningeal disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* radiographic evidence of cavitary or necrotic tumours;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* centrally located tumours with radiographic evidence (CT or MRI) of local invasion of major blood vessels;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* history of clinically significant haemoptysis within the past 3 months;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* therapeutic anticoagulation (except low dose heparin) or antiplatelet therapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* history of major thrombotic or clinically relevant major bleeding event in the past 6 months;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* known inherited predisposition to bleeding or thrombosis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* significant cardiovascular diseases ;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* inadequate safety laboratory parameters;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* significant weight loss (\\> 10 %) within the past 6 weeks;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* current peripheral neuropathy greater than CTCAE grade 2 except due to trauma;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* preexisting ascites and/or clinically significant pleural effusion;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* major injuries and/or surgery within the past ten days prior to randomisation with incomplete wound healing;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* serious infections requiring systemic antibiotic therapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* decompensated diabetes mellitus or other contraindication to high dose corticosteroid therapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* active or chronic hepatitis C and/or B infection;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* serious illness or concomitant non-oncological disease or laboratory abnormality that may increase the risk associated with study participation or study drug administration;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial and for at least twelve months after end of active therapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* pregnancy or breast feeding;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* patients unable to comply with the protocol;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* active alcohol or drug abuse;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* other malignancy within the past three years other than basal cell skin cancer, or carcinoma in situ of the cervix;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* any contraindications for therapy with docetaxel;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* history of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80 (Tween 80);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* hypersensitivity to BIBF 1120 and/or the excipients of the trial drugs;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00805194",
    "statement": "* hypersensitivity to contrast media",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": ";",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "1. Patients with pathologic confirmation of NSCLC with tissue diagnosis or cytologic diagnosis, whose NSCLCs are locally advanced or metastatic Stage III-B / IV adenocarcinoma, and are inoperable and incurable with radiotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "2. Patients who have received the following pretreatments for the treatment of relapsed or metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "* Patients who have received at least one but not more than two lines of chemotherapy. (\"Chemotherapy\" means only the first line (doublet chemotherapies including a platinum) and/or the second line (single chemotherapy except for a platinum) of cytotoxic chemotherapy according to the standard chemotherapies, and erlotinib (Tarceva®) and gefitinib (Iressa®) should be excluded. One of the chemotherapy regimens must have been platinum-based. In addition, only one prior cytotoxic chemotherapy treatment regimen is allowed after adjuvant chemotherapy containing a platinum. More than two prior cytotoxic chemotherapy treatment regimens are not allowed.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "* After the above chemotherapies, patients who once got clinical benefits (i.e. complete response, partial response or stable disease) but progressed following at least 12 weeks of treatment with erlotinib (Tarceva®) or gefitinib (Iressa®) as the most recent treatment. (\"Clinical benefit\" and \"progression\" should be confirmed by computed tomography (CT) or magnetic resonance imaging (MRI). In addition, \"at least 12 weeks of treatment\" should be 9 weeks or more as the actual \"treatment period except for treatment pause due to adverse events and other reasons.) As long as the treatment is erlotinib or gefitinib monotherapy, patients can receive multiple regimens of either or both treatments, but one of the regimens should be for at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "3. Male or female patients age \\>=20 years at the enrolment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "4. Life expectancy of at least three (3) months after the start of administration of the investigational drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "5. Eastern Cooperative Oncology Group (ECOG) performance Score 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "6. Patients with at least one tumor lesion that can accurately be measured by CT or MRI in at least one dimension with longest diameter to be recorded as no less than double the slice thickness and \\>=10 mm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "7. Written informed consent that is consistent with ICH-GCP guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": ";",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "1. Use of erlotinib (Tarceva®) or gefitinib (Iressa®) within two weeks before starting the study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "2. Patients who have received definitive thoracic radiotherapy with curative intent. Patients who have received radiotherapy or other investigational drugs (non-oncological) within four weeks before enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "3. Significant gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's disease, mal-absorption, or CTCAE Grade \\>2 diarrhea of any etiology at the enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "4. Patients with distinct / suspected pulmonary fibrosis or interstitial lung disease by the chest radiographic findings, or patients with a previous history of.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "5. Brain tumor, and / or brain metastases, which are symptomatic or requiring treatment at the enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "6. Other malignancies diagnosed within the past five years (other than carcinoma in situ of gastric cancer, colon cancer and cervical cancer, and non melanomatous skin cancer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "7. History of uncontrolled cardiac disease such as angina or myocardial infarction within the past 6 months at the enrolment, congestive heart failure including New York Heart Association (NYHA) functional classification of 3, or arrhythmia requiring treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "8. Coelomic fluid retention (such as pleural effusion, ascites or pericardial effusion) requiring treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "9. Uncontrolled concomitant diseases (e.g. diabetes mellitus, hypertension etc).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "10. History of serious drug hypersensitivity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "11. Patients who do not have sufficient baseline organ function and whose laboratory data do not meet the following criteria at the enrolment.11",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "* Haemoglobin count \\>=9.0 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "* Absolute neutrophil count (ANC) \\>=1500 / mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "* Platelet count \\>=100 000 / mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "* Serum creatinine \\<=1.5 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "* Total bilirubin \\<=1.5 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "* Aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) \\<=2.5x upper limit of normal range (if related to liver metastases \\<=2.5x upper limit of normal also)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "* PaO2 \\>=60torr or SpO2 \\>=92%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "* LVEF as measured by echocardiography or multigated blood pool imaging of the heart (MUGA scan) \\>=50%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "* QTc interval \\<0.47 second",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "12. Patients who disagree with using a medically acceptable method of contraception during the administration of the investigational drug and for at least 6 months after the end of administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "13. Pregnant or breast-feeding women, or women suspected of being pregnant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "14. Known positive HBs antigen, HCV antibody, or HIV antibody test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "15. Known or suspected active drug or alcohol abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00711594",
    "statement": "16. Other patients judged ineligible for enrolment in the study by the investigator (sub-investigator).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Pathologically confirmed diagnosis of NSCLC considered to be of squamous histology, including mixed histology, in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Locally advanced (stage IIIb) or metastatic (stage IV) NSCLC not considered eligible for curative therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Documented disease progression or relapse (based on investigator's assessment) during or after completion of at least 2 cycles of platinum-based chemotherapy as first line treatment of Stage IIIB/IV SCC of the lung. This includes patients relapsing within 6 months of completing (neo)adjuvant/curative-intent chemotherapy or definitive chemoradiotherapy. Patients should be eligible to receive 2nd line therapy in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* At least one target lesion (outside the brain) that can be accurately measured per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. In patients who only have one target lesion and a biopsy of the lesion is required; the baseline imaging must be performed at least two weeks after the biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Availability and willingness to provide a fresh tumour tissue sample obtained after relapse or progression on or after prior therapy. In case a fresh biopsy cannot be obtained (e.g. inaccessible lesions or patient safety concern), an archived specimen may be submitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Adequate organ function (all screening labs should be performed within 10 days prior to treatment initiation).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Recovery from major surgery or any previous anti-cancer or radiation therapy-related toxicity to ≤ CTCAE Grade 1 at C1_V1 (except for alopecia; stable sensory neuropathy must be ≤ CTCAE Grade 2).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* At least 18 years of age or over the legal age of consent in countries where that is greater than 18 years at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, starting with the screening visit and through 120 days after the last dose of pembrolizumab treatment and 2 weeks after last afatinib treatment, respectively, as listed in the protocol. A list of contraception methods meeting these criteria is provided in the patient information.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Note: Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to taking study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the patient to be eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Prior therapy with any immune checkpoint inhibitor; however, prior (neo) adjuvant checkpoint inhibitor therapy is allowed if completed at least 12 months before relapse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Prior therapy with EGFR inhibiting drugs; however, prior EGFR-targeted (neo) adjuvant therapy is allowed if completed at least 12 months before relapse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Treatment with prior chemotherapy, non-EGFR targeted therapy, or anti-cancer hormonal treatment within 2 weeks prior to the first dose of trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Current or previous treatment with experimental therapy or use of an investigational device within 30 days prior to the first dose of trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to the first dose of trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Received a live vaccine within 30 days prior to the first dose of trial treatment. Seasonal flu vaccines that do not contain live virus are permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of the efficacy and safety of the test drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Radiotherapy within 4 weeks prior to start of treatment except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Palliative radiotherapy to regions other than the chest is allowed up to 2 weeks prior to start of treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Single dose palliative radiotherapy for symptomatic metastasis within 2 weeks prior to start of treatment may be allowed but must be agreed with the Sponsor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Major surgery (according to the investigator's assessment) performed within 4 weeks prior to start of treatment or planned during the projected course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Requirement or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Known history of hypersensitivity to afatinib or any of its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Known history of hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "*- Note: Patients with previously treated brain metastases may participate provided they are radiologically stable i.e. without evidence of progression for at least four weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable, and without requirement of steroids treatment for at least 14 days prior to first dose of study treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids or current ILD/pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Any history or presence of uncontrolled gastrointestinal disorders that could affect the intake and/or absorption of the study drug (e.g. nausea, vomiting, Crohn's disease, ulcerative colitis, chronic diarrhoea, malabsorption) in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Active infectious disease requiring systemic therapy or which puts the patient at increased risk in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Previous or concomitant malignancies at other sites than the lung, except:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Effectively treated non-melanoma skin cancers;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Effectively treated carcinoma in situ of the cervix;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Effectively treated ductal carcinoma in situ;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Other effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Known human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B (e.g. HBsAg reactive) or known active hepatitis C infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* History of active TB (Bacillus Tuberculosis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of ≥3, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator. Myocardial infarction within 6 months prior to start of treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Psychiatric, substance abuse disorders, or chronic alcohol abuse or any condition as per investigator's opinion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03157089",
    "statement": "* Further criteria apply, some were shortened.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* Confirmed EGFR mutation for non-small cell lung cancer associated with EGFR TKI sensitivity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* For Part 2, EGFR T790M mutation-positive tumor status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* Left ventricular ejection fraction (LVEF) ≥ institution's lower limit of the reference range",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* For Part 1, evaluable or measurable disease as defined by RECIST, Version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* For Part 2, measurable disease as defined by RECIST, Version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* ECOG performance status 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* Prior treatment with EGFR TKI within 9 days of first study dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* For Part 1, prior treatment with more than 2 prior lines of chemotherapy for advanced NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* For Part 2, prior treatment with osimertinib or other T790M active EGFR TKI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* For Part 2, prior chemotherapy for advanced NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* Active uncontrolled/symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* Investigational drug within 3 months or 5 half-lives, whichever is longer, of first study dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* Concurrent radiotherapy, radiotherapy within 28 days of first study dose, previous radiotherapy to the target lesion sites, or prior radiotherapy to \\> 25% of bone marrow",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03455829",
    "statement": "* Prior hematopoietic stem cell or bone marrow transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01858389",
    "statement": "* Evidence of histologically confirmed, advanced NSCLC (stage IIIB/IV).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01858389",
    "statement": "* Evidence of T790M mutation to enroll in Cohort A.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01858389",
    "statement": "* Evidence of measurable disease by radiographic technique.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01858389",
    "statement": "* Adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01858389",
    "statement": "* Patients with T790M mutation who stopped any prior EGFR-directed therapy without evidence of disease progression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01858389",
    "statement": "* Symptomatic brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01858389",
    "statement": "* Uncontrolled or significant cardiovascular disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01858389",
    "statement": "* Pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Part 1: Participants with advanced or metastatic solid tumors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Part 2: Participants with advanced or metastatic adenocarcinoma of endometrium, melanoma, non-small cell lung cancer, and renal cell carcinoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Participants who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or participants who refuse standard treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Presence of measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Laboratory and medical history parameters not within the protocol-defined range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Receipt of a live vaccine within 30 days of planned start of study therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Active autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Prior treatment with any tumor necrosis factor super family agonist.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Known active central nervous system metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Evidence of active, non-infectious pneumonitis or history of interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02697591",
    "statement": "* Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* Histologically or cytologically confirmed NSCLC Stage IV:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* Part A: NSCLC Stage IV (any type).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* Part B: NSCLC Stage IV (squamous and nonsquamous).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* Measurable disease at the time of study entry as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* The participant must have progressed after platinum-based chemotherapy AND have received a maximum of 1 other prior chemotherapy for advanced and/or metastatic disease OR must be judged by the physician as ineligible for further standard second-line chemotherapy. Prior treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and anaplastic lymphoma kinase (ALK) inhibitors is mandatory in participants whose tumor has EGFR-activating mutations or ALK translocations. Prior targeting agents and neoadjuvant/adjuvant therapies are permitted with the exception of cyclin-dependent kinase (CDK)4/6-targeting agents or necitumumab.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* The participant has tumor tissue available for biomarker analyses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* The participant has an Eastern Cooperative Oncology Group performance status score of 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* Have adequate organ functions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* The participant is currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device. Prior treatment with cyclin-dependent kinase 4 and 6 (CDK4/6) - targeting agents or necitumumab is not permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* Have a serious concomitant systemic disorder or significant cardiac disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* The participant has undergone major surgery or received any investigational therapy in the 30-days prior to study enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* The participant has undergone chest irradiation within 4 weeks prior to receiving study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* The participant has brain metastases that are symptomatic.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* History of arterial or venous thromboembolism within 3 months prior to study enrollment. Participants with a history of venous thromboembolism beyond 3 months prior to study enrollment can be enrolled if they are appropriately treated with low molecular weight heparin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* The participant has active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* The participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab or abemaciclib, or any other contraindication to one of the administered treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* The participant is pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* The participant has a concurrent active malignancy. Previous history of malignancy is permitted, provided that the participant has been free of disease for ≥3 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancers that in the judgment of the investigator and sponsor may not affect the interpretation of results (for example, prostate, bladder).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02411591",
    "statement": "* History of interstitial lung disease or an active non-infectious pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094094",
    "statement": "* Histologically documented non-small cell lung cancer with metastases (Stage IV or recurrent disease) or locally advanced (Stage IIIB) with malignant pleural effusion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094094",
    "statement": "* At least 1 prior systemic therapy for metastatic disease (Prior adjuvant therapy for localized disease does not count as a prior therapy for metastatic disease).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094094",
    "statement": "* Central lung lesions involving major blood vessels (arteries or veins). (Central lesions that maintain the structural integrity of vessels have the potential to bleed if the tumor lesion undergoes necrosis. MRI or CT angiography should be used in any case where there is any question as to whether blood vessels are involved.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094094",
    "statement": "* Patients with a history of Grade 2 or worse hemoptysis are not eligible. Patients with a history of Grade 1 hemoptysis within 30 days of entry are not eligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Male or female, ≥ 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Diagnosis of cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Opioid-tolerant. Subjects who were opioid tolerant were those taking ≥ 60 mg of oral morphine/day, at least 25 μg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer for cancer-related pain.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Experienced persistent pain related to the cancer or its treatment of moderate or lesser intensity in the 24 hours prior to assessment by a verbal rating scale at the Screening Visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Over the previous 7 days, subject experienced, on average, 1 to 4 breakthrough cancer pain episodes per day usually at least partially controlled by supplemental medication of at least 5 mg immediate-release morphine or an equivalent short-acting opioid (eg, oxycodone, hydrocodone, or codeine with acetaminophen).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Able to evaluate and record pain relief, assess medication performance at set times after dosing, record AEs, record each use of the study drug or supplemental medication in an electronic diary (a caregiver may have provided the subject the medication, help with the mechanics of handling the electronic diary but was not permitted to record any information in the electronic diary).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Able and willing to give informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Women of childbearing potential were to have a) a negative serum pregnancy test, b) not be breastfeeding and c) agree to practice a reliable form of contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Intolerance to opioids or fentanyl.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Current use of commercially available oral short-acting fentanyl for breakthrough pain. Subjects previously on Actiq or Fentora were permitted to be enrolled if they had a 7 day washout.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Rapidly increasing/uncontrolled pain.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* A history of major organ system impairment or disease, that in the Investigator's or his/her designee's opinion could increase the risk associated with the use of opioids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Uncontrolled hypertension (systolic blood pressure {SBP} \\> 180 mmHg or diastolic blood pressure \\[DBP\\] \\> 90 mmHg on 2 occasions ≥ 6 hours apart) despite antihypertensive therapy, or a history of hypertensive crisis within the past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* A recent history (≤ 2 years prior) of transient ischemic attacks, neural vascular disease, stroke, or cerebral aneurysms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Clinically uncontrolled sleep apnea.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Brain metastases with signs or symptoms of increased intracranial pressure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Inability to assess pain or response to pain medications for any reason, including psychiatric disorder, concurrent medical disorder, or concomitant therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Received investigational study product(s) ≤ 30 days prior to the Screening Visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Painful erythema, oedema or ulcers under the tongue.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00538850",
    "statement": "* Use of monoamine oxidase (MAO) inhibitors within 14 days of the Screening Visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Histological or cytological diagnosis of nonsquamous Stage IIIB or Stage IV NSCLC that is not amenable to curative therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* At least 1 unidimensionally measurable lesion meeting the Response Evaluation Criteria In Solid Tumors (RECIST) criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Adequate organ function, including the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) ≥1.5 x 10\\^9 per Liter (10\\^9/L), platelets ≥100 x 10\\^9/L, and hemoglobin ≥10 gram per deciliter (g/dL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Hepatic: bilirubin ≤1.5 times the upper limit of normal (ULN); alkaline phosphatase (AP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤3.0 x ULN (AP, AST, and ALT ≤5 x ULN is acceptable if liver has tumor involvement)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Renal: calculated creatinine clearance (CrCl) ≥45 milliliter per minute (mL/min) based on the original weight-based Cockcroft and Gault formula, and serum creatinine ≤1.5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* At the time of enrollment, if the urinalysis dipstick result is ≥2+ for protein, a 24-hour urine collection should be taken. In these cases, participants must have ≤1g protein/24 hours to be eligible for study participation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Participants must sign an Informed Consent Document (ICD)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Have received prior systemic anticancer therapy for lung cancer (including adjuvant early-stage treatment for NSCLC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Have a second primary malignancy that is clinically detectable at the time of consideration for study enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Have known central nervous system (CNS) disease, other than stable, treated brain metastasis. Stable, treated brain metastasis is defined as metastasis having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and post-treatment brain imaging (Computed Tomography \\[CT\\] scan or magnetic resonance imaging \\[MRI\\])",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Are receiving concurrent administration of any other antitumor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Have a history of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Have had significant weight loss (that is, ≥10%) over the previous 6 weeks before study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Have a history of gross hemoptysis (bright red blood of ≥½ teaspoon per episode of coughing) \\<3 months prior to enrollment or history or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Are taking or have recently taken (within 10 days of enrollment) full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes. Prophylactic use of anticoagulants is allowed; international normalized ratio (INR) should be \\<1.5 at study enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Have a history of hypertension, unless hypertension is well controlled upon study entry (≤150/90 millimeter of mercury \\[mm Hg\\]) and the participant is on a stable regimen of antihypertensive therapy. Participants should not have any prior history of hypertensive crisis or hypertensive encephalopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* Have had major surgery, open biopsy, or significant traumatic injury within 28 days prior to study enrollment, or anticipate the need for major surgical procedure during the course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01004250",
    "statement": "* History of thrombotic disorders within the last 6 months prior to entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03061812",
    "statement": "* Participant must have histologically or cytologically confirmed advanced or metastatic Small Cell Lung Cancer (SCLC) with documented first disease progression during or following front-line platinum-based systemic regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03061812",
    "statement": "* Tumor must have high Delta-like protein 3 (DLL3) expression defined as having ≥ 75% tumor cells staining positive according to the VENTANA DLL3 (SP347) IHC Assay.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03061812",
    "statement": "* Participant must have measurable disease, as defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03061812",
    "statement": "* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03061812",
    "statement": "* Participant must have recovery to Grade 0 or 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03061812",
    "statement": "* Participant has a documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association Class (NYHA) III - IV within 6 months prior to their first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03061812",
    "statement": "* Participant has known leptomeningeal metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03061812",
    "statement": "* Participant has received more than one prior systemic therapy regimen for SCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03061812",
    "statement": "* Participant had a serious infection within 2 weeks prior to randomization, including any Grade 3 or higher viral, bacterial, or fungal infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03061812",
    "statement": "* Participant has a history of active malignancies other than SCLC within the past 2 years prior to study entry, with the exception of in situ cancer which was curatively treated.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03061812",
    "statement": "* Participant had prior exposure to topotecan, irinotecan or any other topoisomerase I inhibitors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00102804",
    "statement": "* Histologic or cytologic diagnosis of NSCLC Stage IIIB (with pleural effusion and/or positive supraclavicular lymph nodes) or Stage IV prior to induction therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00102804",
    "statement": "* Participants must have had 1 of the following induction therapies for treatment for Stage IIIB (with pleural effusion and/or positive supraclavicular lymph nodes) or IV NSCLC: Gemcitabine plus carboplatin, paclitaxel plus carboplatin, or docetaxel plus carboplatin, gemcitabine plus cisplatin, paclitaxel plus cisplatin or docetaxel plus cisplatin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00102804",
    "statement": "* Participants must have received only 1 chemotherapeutic doublet lasting precisely 4 cycles.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00102804",
    "statement": "* Induction regimens must be based on 21-day cycles.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00102804",
    "statement": "* Documented evidence of a tumor response of complete response (CR), partial response (PR), or stable disease (SD). Tumor assessment must occur between Cycle 4 (Day 1) of induction therapy and the date of randomization. This response does not have to be confirmed in order for the participant to be randomized. Positron emission tomography (PET) scans and ultrasounds may not be used for lesion measurements for response determination.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00102804",
    "statement": "* With the exception of those chemotherapies listed as inclusion criterion, participants will not be included if they have received prior systemic anticancer therapy (including adjuvant early-stage treatment for NSCLC) or any systemic treatment for any other cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00102804",
    "statement": "* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00102804",
    "statement": "* Inability to comply with protocol or study procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00102804",
    "statement": "* A serious concomitant systemic disorder that would compromise the participant's ability to complete the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00102804",
    "statement": "* A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You must sign an informed consent document for clinical research.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You must have Stage IIIB or IV nonsquamous Non-Small Cell Lung Cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You must at least be able to be physically mobile, take care of yourself, and must be up and about and able to perform light activities such as light housework or office work.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You are allowed to have had prior radiation therapy as long as it was not to more than 25% of the bone marrow and did not include the whole pelvis. Thoracic radiation must be completed more than 30 days before the study. You must be recovered from the toxic effects (except hair loss).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You must have at least 1 measurable tumor lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines or disease that can be evaluated by computed tomography (CT) Scan.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* Your test results assessing the function of your blood forming tissue, kidneys, and liver must be satisfactory.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You must be 18 years of age or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* Women must be sterile, postmenopausal or on contraception and men must be on contraception or sterile (e.g. post-vasectomy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You cannot have squamous cell and/or mixed small cell, non-small cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You cannot have received other investigational drugs within the last 30 days of entering the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You cannot have previously completed or withdrawn from this study or any other study investigating pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You cannot have other serious on-going illnesses including active infections.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You cannot have a serious cardiac condition, such as a heart attack, angina, or heart disease within 6 months of entering the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You cannot have had another form of cancer other than superficial basal cell and superficial squamous (skin) cell cancer, or carcinoma in situ of the cervix within the last 5 years. Patients with a history of low-grade (Gleason score less than or equal to 6) localized prostate cancer will be eligible even if diagnosed less than 5 years ago.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You cannot have known central nervous system (CNS) metastases, other than treated, stable brain metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You cannot be receiving nor have received any prior systemic anticancer therapy for lung cancer (including chemotherapy given after surgery in early-stage treatment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You cannot have clinically significant third-space fluid collections (e.g. ascites or pleural effusions that cannot be controlled by drainage or other procedures).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You cannot have received a recent (within 30 days) or are receiving a yellow fever vaccination.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You are unable to stop taking more than 1.3 grams of aspirin on a daily basis or other non-steroidal anti-inflammatory drugs (NSAIDs).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You are unable or unwilling to take folic acid, injections of vitamin B12, or corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You cannot be pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "Inclusion criteria at Randomization for the Maintenance Phase:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You must at least be able to be physically mobile, take care of yourself, and must be up and about and able to perform light activities such as light housework or office work.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00789373",
    "statement": "* You must have documented radiographic evidence of a tumor response of complete response (CR), partial response (PR), or stable disease (SD) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. Tumor assessment must occur between Cycle 4 (Day 1) of induction therapy and the date of randomization. This response does not have to be confirmed in order for the patient to be randomized to the maintenance phase.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00550173",
    "statement": "* Patients with locally advanced or metastatic nonsquamous non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00550173",
    "statement": "* Patients must be non-smokers",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00550173",
    "statement": "* Patients must have at least one measurable lesion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00550173",
    "statement": "* Performance status of 0 to 2 on the Eastern Cooperative Oncology Group Scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00550173",
    "statement": "* Patients must have failed only one prior chemotherapy regimen and must be considered eligible for further chemotherapy following progression of their disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00550173",
    "statement": "* Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00550173",
    "statement": "* Patients who have previously received treatment with drugs against the human epidermal growth factor receptors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00550173",
    "statement": "* Patients who have previously received treatment with drugs which have similar targets as Pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00550173",
    "statement": "* Patients who have any known significant ophthalmologic abnormalities of the surface of the eye",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00550173",
    "statement": "* Patients who have a history of severe hypersensitivity reaction to erlotinib or pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Participants capable of giving signed informed consent/assent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Male or female, aged 18 years or older at the time consent is obtained.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Participants with histologically or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "  1. Documented disease progression based on radiographic imaging, during or after a maximum of 2 lines of systemic treatment for locally/regionally advanced recurrent, Stage IIIb/Stage IIIc/Stage IV or metastatic disease. Two components of treatment must have been received in the same line or as separate lines of therapy: i) No more than or less than 1 line of platinum-containing chemotherapy regimen, and ii) No more than or less than 1 line of Programmed cell death ligand 1 (PD\\[L\\]1) monoclonal antibody (mAb) containing regimen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "  2. Participants with known V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) molecular alterations must have had disease progression after receiving the locally available SoC treatment for the molecular alteration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "  3. Participants who received prior anti-PD(L)1 therapy must fulfill the following requirements: i) Have achieved a CR, PR or SD and subsequently had disease progression (per RECIST 1.1 criteria) either on or after completing PD(L)1 therapy ii) Have not progressed or recurred within the first 12 weeks of PD(L)1 therapy, either clinically or per RECIST 1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Measurable disease, presenting with at least 1 measurable lesion per RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* A tumor tissue sample obtained at any time from the initial diagnosis of NSCLC to time of study entry is mandatory. Although a fresh tumor tissue sample obtained during screening is preferred, archival tumor specimen is acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Adequate organ function as defined in the protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions apply:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "  i) Not a woman of childbearing potential (WOCBP) as defined in the protocol or ii) A WOCBP who agrees to follow the protocol defined contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Life expectancy of at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "(calculation is based on date of last therapy to date of first dose of study treatment):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "1. Docetaxel at any time.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "2. Any of the investigational agents being tested in the current study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "3. Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug administered.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "4. Prior radiation therapy: permissible if at least one non-irradiated measurable lesion is available for assessment per RECIST version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least 2 weeks before start of study drug for radiation of any intended use is required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Received greater than (\\>) 2 prior lines of therapy for NSCLC, including participants with BRAF molecular alternations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Invasive malignancy or history of invasive malignancy other than disease under study within the last 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Carcinomatous meningitis (regardless of clinical status) and uncontrolled or symptomatic Central nervous system (CNS) metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Major surgery less than or equal to (\\<=) 28 days of first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Autoimmune disease (current or history) or syndrome that required systemic treatment within the past 2 years. Replacement therapies which include physiological doses of corticosteroids for treatment of endocrinopathies (for example, adrenal insufficiency) are not considered systemic treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Receiving systemic steroids (\\>10 milligrams \\[mg\\]) oral prednisone or equivalent) or other immunosuppressive agents within 7 days prior to first dose of study treatment. Steroids as premedication for hypersensitivity reactions (e.g., computed tomography \\[CT\\] scan premedication) are permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Prior allogeneic/autologous bone marrow or solid organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Receipt of any live vaccine within 30 days prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Toxicity from previous anticancer treatment that includes:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "1. Greater than or equal to (\\>=) Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "2. History of myocarditis of any grade during a previous treatment with immunotherapy 3. Toxicity related to prior treatment that has not resolved to \\<= Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \\<= Grade 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* History (current and past) of idiopathic pulmonary fibrosis, pneumonitis (for pastpneumonitis exclusion only if steroids were required for treatment), interstitial lung disease, or organizing pneumonia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* History or evidence of cardiac abnormalities within the 6 months prior to enrollment which include",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "  1. Serious, uncontrolled cardiac arrhythmia or clinically significant electrocardiogram abnormalities including second degree (Type II) or third degree atrioventricular block.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "  2. Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting or bypass grafting.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "  3. Symptomatic pericarditis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypo-albuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Active infection requiring systemic therapy \\<=7 days prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Participants with known human immunodeficiency virus infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Participants with history of severe hypersensitivity to mAbs or hypersensitivity to any of the study treatment(s) or their excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Pregnant or lactating female participants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Participant who is currently participating in or has participated in a study of an investigational device within 4 weeks prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Participants with presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Participants with positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Participants with positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Receipt of transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony stimulating factor \\[G-CSF\\], granulocyte-macrophage colony-stimulating factor, and recombinant erythropoietin) within 14 days before the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Known hypersensitivity to components or excipients of dostarlimab, belrestotug, and/or nelistotug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06926673",
    "statement": "* Has received prior antibodies or drugs targeting TIGIT, CD96, PVRIG, or other therapies targeting the CD226 axis pathway",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": ". Have histologically or cytologically confirmed locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) that is anaplastic lymphoma kinase (ALK+).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "2. Must meet one of the following two criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   1. Have documented ALK rearrangement by a positive result from the Vysis® ALK Break-Apart fluorescence in situ hybridization (FISH) Probe Kit; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   2. Have documented ALK positivity by a different test and tissue available for the Vysis® FISH test. Tissue should be derived preferably from a biopsy taken after progression with crizotinib. If such a sample is not available, testing may be performed with archived tumor tissue.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "3. Had progressive disease while on crizotinib, as assessed by the investigator or treating physician.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "4. Have at least 1 measurable lesion per RECIST v1.1. Note: Previously irradiated lesions may not be used for target lesions, unless there is unambiguous radiological progression after radiotherapy. Brain lesions may not be used as target lesions if they were: 1) previously treated with whole brain radiation therapy (WBRT) within 3 months, or 2) previously treated by stereotactic radiosurgery (SRS) or surgical resection.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "5. Recovered from toxicities related to prior anticancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v4.0) grade ≤2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "6. Are a male or female participants ≥18 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "7. Have a life expectancy ≥3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "8. Have adequate organ and hematologic function, as determined by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   1. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 x upper limit of normal (ULN; ≤5 x ULN is acceptable if liver metastases are present)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   2. Total serum bilirubin ≤1.5 x ULN (\\<3.0 x ULN for participants with Gilbert syndrome)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   3. Serum creatinine ≤1.5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   4. Serum lipase/amylase ≤1.5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   5. Absolute neutrophil count (ANC) ≥1500/µL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   6. Platelets ≥75000/µL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   7. Hemoglobin ≥10 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "9. Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "10. Have normal QT interval on screening electrocardiogram (ECG) evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 ms in males or ≤470 ms in females.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "11. For female participants of childbearing potential, a negative pregnancy test must be documented prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "12. Female and male participants who are fertile must agree to use a highly effective form of contraception with their sexual partners throughout study participation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "13. Must provide a signed and dated informed consent indicating that the participants has been informed of all pertinent aspects of the study, including the potential risks, and is willingly participating.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "14. Have the willingness and ability to comply with scheduled visits and study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": ". Received any prior ALK-targeted TKI other than crizotinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "2. Received crizotinib within 3 days of the first dose of brigatinib (Day 1, Cycle 1).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "3. Received cytotoxic chemotherapy, investigational agents, or radiation within 14 days, except SRS or stereotactic body radiosurgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "4. Received monoclonal antibodies or had major surgery within 30 days of the first dose of brigatinib (Day 1, Cycle 1).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "5. Have been diagnosed with another primary malignancy within the past 3 years (except for adequately treated non-melanoma skin cancer, cervical cancer in situ, or prostate cancer, which are allowed within 3 years).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "6. Have symptomatic CNS metastases that are neurologically unstable or require an increasing dose of corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "7. Have current spinal cord compression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "8. Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   1. Myocardial infarction (MI) within 6 months prior to the first dose of brigatinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   2. Unstable angina within 6 months prior to first dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   3. Congestive heart failure (CHF) within 6 months prior to first dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   4. History of clinically significant (as determined by the treating physician) atrial arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   5. Any history of ventricular arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "   6. Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "9. Have a history or the presence of pulmonary interstitial disease or drug-related pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "10. Have an ongoing or active infection. The requirement for intravenous (IV) antibiotics is considered active infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "11. Have a known history of human immunodeficiency virus (HIV). Testing is not required in the absence of history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "12. Have a history of or active significant gastrointestinal (GI) bleeding within 3 months of the first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "13. Have a known or suspected hypersensitivity to brigatinib or its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "14. Have malabsorption syndrome or other GI illness that could affect oral absorption of the study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "15. Have any condition or illness that, in the opinion of the investigator, would compromise participants safety or interfere with evaluation of the drug study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094573",
    "statement": "16. Be pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Men and women ≥18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Subjects with histologically or cytologically-documented squamous cell NSCLC who present with Stage IIIB/IV disease or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection or definitive chemoradiation therapy for locally advanced disease)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Disease recurrence or progression during/after one prior platinum doublet-based chemotherapy regimen for advanced or metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Measurable disease by computed tomography (CT)/Magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Subjects with untreated central nervous system (CNS) metastases are excluded. Subjects are eligible if CNS metastases are treated and subjects are neurologically returned to baseline for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of ≤10 mg daily prednisone (or equivalent)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Subjects with carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Subjects with active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Prior therapy with anti-Programmed death-1 (PD-1), anti-Programmed cell death ligand 1 (PD-L1), anti-Programmed cell death ligand 2 (PD-L2), anti-CD137, or anti-Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Prior treatment on the first line study CA184104 first line NSCLC study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Prior treatment with Docetaxel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01642004",
    "statement": "* Treatment with any investigational agent within 14 days of first administration of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788566",
    "statement": "* Histologically or cytologically confirmed squamous Non-small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788566",
    "statement": "* Stage IV disease at time of study entry based on American Joint Committee on Cancer 7th edition",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788566",
    "statement": "* Measurable disease at time of study entry as defined by Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788566",
    "statement": "* Required to have a performance status (PS) 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788566",
    "statement": "* Nonsquamous NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788566",
    "statement": "* Prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), or VEGF receptor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788566",
    "statement": "* Previous chemotherapy for NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788566",
    "statement": "* Major surgery or received any investigational therapy in the 4 weeks prior to study enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788566",
    "statement": "* Chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01788566",
    "statement": "* Brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants (participants who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* Part A1 only: Patients with histological or cytological diagnosis of HNSCC, HCC, melanoma, or clear cell RCC who progressed on or are intolerant to standard therapy, for which no standard therapy is available or who decline standard therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* Part A2 only: Patients with histological or cytological diagnosis of advanced/metastatic HCC who are treatment naïve and have declined standard of care, or have had at least 1 prior line of systemic therapy. Prior anti PD L1/PD 1 therapy is allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* Part B1 only: Patients with histological or cytological diagnosis of NSCLC, HNSCC, melanoma, urothelial bladder carcinoma (including renal pelvis, ureters, urinary bladder, and urethra), gastric or squamous cell carcinoma of the uterine cervix who progressed on or are intolerant to standard therapy, for which no standard therapy is available, or who decline standard therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* Part B2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "Arm 1 only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "1. Ocular melanoma patients with advanced/metastatic disease, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "2. Cutaneous/acral melanoma patients with advanced/metastatic disease who have received checkpoint inhibitor (anti PD L1, anti PD 1, or anti CTLA4) based treatment on which disease progressed. \\[Note: Checkpoint inhibitor may have been part of a combination therapy, as long as the combination did not contain OX40 or 4 1BB agonist.\\] Any questions on prior treatment may be discussed with the Sponsor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "Arm 2 only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* Histological or cytological diagnosis of NSCLC with advanced/metastatic disease. Patients must have previously received prior anti PD L1 or anti PD 1 mAb on which disease progressed. \\[Note: Previous anti PD L1 or anti PD 1 mAb may have been part of a combination therapy, eg, in combination with chemotherapy, as long as the combination did not contain OX40 or 4 1BB agonist.\\]",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* Performance Status of 0 or 1 - Adequate bone marrow, kidney and liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* Brain metastases requiring steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* Major surgery, Radiation therapy within 4 weeks of starting study treatment (except: palliative radiotherapy to a limited field is allowed after consultation with sponsor's medical monitor at any time during study participation, including during screening), or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* Active and clinically significant bacterial, fungal, or viral infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* History of active autoimmune disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* History of immune-mediated adverse events requiring immunosuppressive therapy or were grade 3 or higher related to prior immune-modulatory therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* Prior treatment with an OX40 agonist and 4-1BB agonist (for Part B1/B2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02315066",
    "statement": "* Prior anthracycline treatment and at risk of cardiac failure (New York Heart Association Class 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Histologically or cytologically confirmed diagnosis of stage IV NSCLC without epidermal growth factor receptor (EGFR)-sensitizing mutation, ROS1 and/or anaplastic lymphoma kinase (ALK) translocation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Measurable disease based on RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Adequate organ function per protocol-defined criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Provide tumor tissue sample.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Known untreated central nervous system metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* History of (non-infectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Symptomatic ascites or pleural effusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Active autoimmune disease that has required systemic treatment in past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Has had an allogeneic tissue/solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Has known history of or is positive for active Hepatitis B (HBsAg reactive) or has active Hepatitis C (HCV RNA). Note: Testing must be performed to determine eligibility.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* History or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's opinion, is clinically meaningful.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322566",
    "statement": "* Use of protocol-defined prior/concomitant therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": ". Cytologically and/or histologically-documented NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "   1. Stage I (\\> 2 cm) to IIIA (for participants with N2 disease, only those with 1 single nodal station ≤ 3 cm are eligible) NSCLC according to the 8th edition of American Joint Committee on Cancer staging classification",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "   2. Amenable to complete surgical resection",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "   3. Have not received any other therapy for this condition",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "2. Predicted forced expiratory volume in one second (FEV1) ≥ 50%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "3. Predicted diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 50%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "4. ECOG 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "5. Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": ". Participants with small-cell lung cancer or mixed small-cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "2. Participants who require or may require pneumonectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "3. Prior treatment with programmed cell death ligand-1 (PD-L1), PD-L1, or cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "4. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "5. Active or prior documented autoimmune or inflammatory disorders. The following are exceptions to this criterion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "   1. Participants with vitiligo or alopecia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "   2. Participants with hypothyroidism on hormone replacement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "   3. Any chronic skin condition that does not require systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "   4. Participants without active disease in the last 5 years may be included but only after consultation with the study physician",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "   5. Participants with celiac disease controlled by diet alone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "6. Pregnant or breast-feeding female",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "7. Major surgical procedure within prior 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "8. History of active primary immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "9. Active infection including tuberculosis, hepatitis B, hepatitis C, or HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "10. QTc interval (QTc) ≥ 470 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "11. Uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the participant to give written informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "12. Receipt of live attenuated vaccination within 30 days prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "13. History of another primary malignancy except for:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "    1. Curative-treated malignancy with no known active disease \\> 2 years before enrollment on the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03794544",
    "statement": "    2. Curative-treated non-melanoma skin cancer and/or carcinoma in-situ",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Previously obtained archival tumor tissue or tissue obtained from biopsy at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Measurable disease as defined by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Adequate hematologic and end organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Active or untreated central nervous system (CNS) metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* History of autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan, History of radiation pneumonitis in the radiation field (fibrosis) is permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Positive test for Human Immunodeficiency Virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Active hepatitis B or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Severe infection within 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367794",
    "statement": "* Significant history of cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Dose Expansion: Histologically confirmed and documented, previously untreated or treated stage IIIB or IV NSCLC having failed no more than 1 previous platinum containing chemotherapy regimen for locally-advanced or metastatic disease or relapsed/refractory locally advanced or metastatic gastric adenocarcinoma having failed no more than 2 previous chemotherapy regimens for locally advanced or metastatic disease. Participants with NSCLC who are known to be epidermal growth factor receptor (EGFR)-mutation positive must have received an EGFR inhibitor and participants known to be anaplastic lymphoma kinase (ALK)-mutation positive must have received an ALK inhibitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "Prior to enrollment, confirmation of the following must be obtained:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* For participants in the dose expansion portion of the study, it is mandatory that available archived tumor tissue in formalin-fixed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "paraffin-embedded (FFPE) block or minimum 10-15 unstained consecutive core biopsy slides from 1 archival block that meet specific tissue requirements are available.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* For dose expansion: one or more tumors measurable on computed tomography (CT) scan/magnetic resonance imaging (MRI) scan per RECIST v 1.1., for dose escalation, participants need only have evaluable disease - Previously irradiated tumors may be eligible if they have clearly progressed in size.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Life expectancy greater than or equal to (≥) 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "Participants must also satisfy the following inclusion criterion to be enrolled in the dose expansion portion:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Participants (NSCLC and gastric adenocarcinoma) must be determined to have HA-high levels from their tumor biopsies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* NSCLC and gastric adenocarcinoma participants must have tissue available for HA-selection and programmed cell death-1 (PD-L1) testing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Previous treatment with pembrolizumab, nivolumab, or other antibody (anti-)-PD-1 or PD-1 ligand-antibody (anti-PD-L1) agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* New York Heart Association Class III or IV (Appendix D) cardiac disease or myocardial infarction within the past 12 months before screening, or preexisting atrial fibrillation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Prior history of cerebrovascular accident or transient ischemic attack.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* NSCLC participants with known brain metastases (certain exceptions allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Gastric adenocarcinoma participants with brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* History of active bleeding within the last 3 months requiring transfusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Anti-angiogenic therapy within the last month",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Participants with known interstitial fibrosis or interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Previous history of pulmonary embolism or pulmonary embolism found on screening exam.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* History of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "  1. Pneumonitis that requires oral or IV steroids;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "  2. Or known cases of hepatobiliary diseases (e.g., primary biliary cholangitis, primary sclerosing cholangitis, history of immune-mediated cholangitis);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Participants with cholangitis attributed to infectious etiology (e.g., ascending cholangitis, bacterial cholangitis) are eligible if the infection has been fully resolved prior to the screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "  3. Or known cases of drug-induced hepatobiliary toxicities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* Active autoimmune disease requiring systemic treatment within the past 3 months or documented history of clinically severe autoimmune disease, or syndrome that requires systemic steroids or immunosuppressive agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02563548",
    "statement": "* History of another primary cancer within the last 3 years that required treatment, with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in situ.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Cytologically or histologically confirmed NSCLC of stage IIIb or IV",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Received at least 1 but no more than 2 prior chemotherapy or chemoradiotherapy regimens for advanced NSCLC (that did not include erlotinib and valproic acid) and progressed based on radiologic evidence",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* At least 1 measurable lesion by conventional or spiral computed tomography (CT) scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1, or 2 and life expectancy of at least 6 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Paraffin-embedded tumor specimen available for correlative studies",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Male or female over 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x 10\\^9/L; absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9/L without the use of hematopoietic growth factors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Bilirubin and creatinine less than 2 times the upper limit of normal for the institution",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Albumin ≥ 2.5 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 times the upper limit of normal for the institution",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Prothrombin time less than 1.5 times the upper limit of normal for the institution",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Potassium, magnesium and phosphorus within the normal range for the institution (supplementation is permissible)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Willing to use accepted and effective methods of contraception during the study (both men and women as appropriate) and for 3 months after the last dose of SNDX-275",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Patient or legally acceptable representative has granted written informed consent before any study-specific procedure (including special screening tests) are performed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Prior stem cell transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Clinical evidence of central nervous system (CNS) involvement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Prior treatment with an histone deacetylase (HDAC) inhibitor or an epidermal growth factor receptor (EGFR) inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Currently taking known inhibitors of CYPA4, including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, ≥ 10 mg prednisone, and voriconazole",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Currently taking medication(s) on the prohibited medication list",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Prior exposure to SNDX-275",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Systemic chemotherapy, radiotherapy, or treatment with an investigational agent without recovery to at least grade 1 or baseline before study drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Daily treatment with ≥ 10 mg prednisone within 28 days before study drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Local or whole brain palliative radiotherapy within 14 days before study drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Currently active second malignancy, or any malignancy within the last 5 years other than cured basal or squamous cell skin carcinoma, cervical carcinoma in situ, carcinoma in situ of the bladder, or papillary thyroid cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Inability to swallow oral medications or a gastrointestinal malabsorption condition",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Acute infection requiring intravenous (IV) antibiotics, antivirals, or antifungals within 14 days before study drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Another serious or uncontrolled medical condition within 90 days before study drug administration such as acute myocardial infarction, angina, ventricular arrhythmias, hypertension, diabetes mellitus, or renal or hepatic insufficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Known hypersensitivity to benzamides",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Women who are currently pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Patient currently is enrolled in (or completed within 28 days before study drug administration) another investigational drug study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00602030",
    "statement": "* Patient has any kind of medical, psychiatric, or behavioral disorder that places the patient at increased risk for study participation or compromises the ability of the patient to give written informed consent and/or to comply with study procedures and requirements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have documented advanced or metastatic malignant solid tumors (except for colorectal tumors with KRAS mutation) that are resistant to standard therapy or for which no standard therapy is available",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* May have measurable or non-measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have resolution to Grade 0 or 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE 4.0) of all clinically significant toxic effects (other than alopecia) of prior chemotherapy, surgery, radiotherapy, or hormonal therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have adequate hepatic, hematologic and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* If female, are surgically sterile, postmenopausal, or agree to be compliant with a highly effective contraceptive method during and for 6 months after the treatment period. If male, are surgically sterile or agree to be compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Female participants of childbearing potential have a negative serum pregnancy test within 7 days prior to the first dose of study therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have received a systemic anticancer agent (including EGFR tyrosine kinase inhibitors) or device within 28 days prior to first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* The most recent anticancer therapy received by the participant included either gemcitabine or cisplatin (or both)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have received radiotherapy within 14 days prior to first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have received cytotoxic chemotherapy within 21 days prior to first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Are receiving concurrent treatment with another anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiation therapy, chemoembolization, or targeted therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Are considered surgical candidates (with resectable disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have narrowing of or blockage in large veins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have coronary artery disease or uncontrolled congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have uncontrolled angina pectoris, or experienced myocardial infarction within 6 months prior to first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have an ongoing or active infection (requiring treatment), including active tuberculosis or known infection with the human immunodeficiency virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have known drug or alcohol abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* If female, are pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Have had major surgery within 28 days prior to first dose of study medication or subcutaneous venous access device implantation within 7 days prior to first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01606748",
    "statement": "* Are currently enrolled in, or discontinued within the 30 days prior to first dose of study therapy from a clinical trial involving an investigational product or nonapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Documented histologic or cytologic diagnosis of advanced metastatic NSCLC, advanced/unresectable pancreatic cancer, or metastatic colorectal cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Cachexia, defined by BMI \\<20 kg/m2 with involuntary weight loss of \\>2% within 6 months prior to screening or Involuntary weight loss of \\>5% within 6 months prior to screening irrespective of BMI or If medical record documentation is unavailable, patient's report will suffice to estimate involuntary body weight loss.;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Will receive the following for non-small cell lung cancer:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* a platinum + pemetrexed ± pembrolizumab or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* a platinum + nab paclitaxel or paclitaxel ± pembrolizumab or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* pembrolizumab alone",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Will receive the following for pancreatic cancer:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* FOLFIRINOX or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Nab-Paclitaxel + Gemcitabine",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Gemcitabine",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Will receive the following for colorectal cancer:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* FOLFOX +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* FOLFIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* FOLFOXIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Pembrolizumab for MSI-H • Will be entering the study at the first or second cycle of their current course of anti-cancer treatment/ therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Adequate renal and liver function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Signed informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* All other forms of cancers not specified above unless currently considered cured (\\>5 years without evidence of recurrence).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Planned radiation therapy as part of the primary anti-tumor therapy regimen. However, localized radiation therapy for symptomatic relief is permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Cachexia caused by other reasons: Severe COPD requiring use of home O2, heart failure or AIDS.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* known symptomatic brain metastases requiring steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Active hepatitis B or C virus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Confirmed positive HIV test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Current active reversible causes of decreased food intake.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Receiving tube feedings or parenteral nutrition at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Elevated blood pressure that cannot be controlled by medications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04299048",
    "statement": "* Women who are pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": ". Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Ethics Committee (IRB/EC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "2. Is between the ages of 18 and 75 years old, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "3. Has histologically or cytologically confirmed stage IIIB (malignant pericardial or pleural effusion) or stage IV non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "4. Has measurable disease, defined as at least one tumor that fulfills the criteria for a target lesion according to RECIST",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "5. Has an ECOG performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "6. Has a life expectancy of \\> 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "7. Has adequate hematologic function as evidenced by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* ANC ≥ 1,500/μL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* PLT ≥ 100,000/μL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* HGB ≥ 9 g/dL obtained within 1 week prior to the first dose of study medication;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "8. Has adequate renal function as evidenced by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* Serum creatinine ≤ 1.5 X the upper limit of normal (ULN) for the reference lab",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* Urine dipstick for proteinuria of \\< 1+ (i.e., either 0 or trace) within 2 weeks of Day 1 If urine dipstick is ≥ 1+, then urine protein excretion must be ≤ 500 mg over a 24 hour collection obtained within 1 week prior to the first dose of study medication;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "9. Has adequate hepatic function as evidenced by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* Serum total bilirubin ≤ 1.0 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* AST ≤ 2.5X ULN for the reference lab (≤ 5X ULN for subjects with known hepatic metastases)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* ALT ≤ 2.5X ULN for the reference lab (≤ 5X ULN for subjects with known hepatic metastases) obtained within 1 week prior to the first dose of study medication;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "10. If a woman of childbearing potential or a fertile man (and his partners), must agree to use an effective form of contraception (hormonal contraceptive, double-barrier method or abstinence) during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": ". Has received prior systemic chemotherapy at any time for lung cancer;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "2. Has received previous radiation therapy to \\>30% of active bone marrow or any radiation therapy within 3 weeks of Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "3. Has a known hypersensitivity to baker's yeast, or has an active yeast infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "4. Has had previous exposure to Betafectin® or Imprime PGG",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "5. Has an active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "6. Presents with any of the following medical diagnoses/conditions at the time of screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* Central nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* Uncontrolled hypertension (\\>150/100 mmHg) or hypertension that requires \\> two agents for adequate control",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* Peripheral neuropathy ≥ grade 2 from any cause",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* Fever of \\>38.5° C within 3 days prior to screening or Day 1, initial dosing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* Known HIV/AIDs, Hepatitis B, Hepatitis C, connective tissue or autoimmune disease, or other clinical diagnosis, ongoing or intercurrent illness that in the physician's opinion could interfere with participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "7. Has a history of any of the following medical diagnoses/conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* Myocardial infarction or an unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure) within the previous 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "* Second malignancy within the previous 5 years, other than basal cell carcinoma, cervical intra-epithelial neoplasia or curatively treated prostate cancer with a PSA of \\<2.0 ng/mL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "8. Has a known hypersensitivity to cetuximab, murine proteins, or any component of cetuximab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "9. Has a know sensitivity to Cremophor EL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "10. Has previously received treatment with cetuximab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "11. If female, is pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "12. Is receiving concurrent investigational therapy or has received investigational therapy within a period of 30 days prior to the first scheduled day of dosing (investigational therapy is defined as treatment for which there is currently no regulatory-authority-approved indication)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00874848",
    "statement": "13. Has previously received an organ or progenitor/stem cell transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02481830",
    "statement": "* Histologically or cytologically confirmed small cell lung cancer (SCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02481830",
    "statement": "* Subjects with either limited or extensive disease stage at the initial diagnosis",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02481830",
    "statement": "* Must have recurrence or progression after platinum-based first-line chemotherapy or chemoradiation therapy for the treatment of limited or extensive disease stage SCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02481830",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02481830",
    "statement": "* Untreated or symptomatic central nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02481830",
    "statement": "* Prior therapy with anti-PD-1, anti-PDL1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02481830",
    "statement": "* Inadequate hematologic or hepatic function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has Stage IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* Part A: NSCLC Stage IV (any type)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* Part B: NSCLC Stage IV (squamous and nonsquamous)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* Part C: NSCLC Stage IV in Japanese participants (squamous and nonsquamous)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant must have progressed after 1 platinum-based chemotherapy regimen for Stage IV NSCLC. Prior therapy with VEGF/VEGFR targeting agents is permitted. Prior neoadjuvant/adjuvant therapy is permitted. Prior treatment with EGFR-TKI and ALK inhibitors is mandatory in participants with NSCLC whose tumor has EGFR-activating mutations or ALK translocations, respectively.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* Measurable disease at the time of study entry as defined by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has evaluable tumor tissue available for biomarker analyses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant is currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 monoclonal antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* Have a serious concomitant systemic disorder or significant cardiac disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has undergone major surgery or received anti-cancer monoclonal antibody therapy in the 30-days prior to study enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has undergone chest irradiation within 2 weeks prior to receiving study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has brain metastases that are symptomatic.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has a history of arterial thromboembolism event (ATE) or venous thromboembolism event (VTE) within 3 months prior to study enrollment. Participants with history of VTE beyond 3 months prior to study enrollment can be enrolled if they are appropriately treated with low molecular weight heparin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab or pembrolizumab, or any other contraindication to one of the administered treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has a concurrent active malignancy. Previous history of malignancy is permitted, provided that the participant has been free of disease for ≥3 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancers that in the judgment of the investigator and sponsor may not affect the interpretation of results (for example, prostate, bladder).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* History of interstitial lung disease, pneumonitis, autoimmune disease or syndrome that requires steroids or immunosuppressive agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has active infection requiring systemic therapy, including active tuberculosis or known history of infection with the human immunodeficiency virus (HIV 1/2 antibodies), or hepatitis B (e.g., HBsAg reactive) and/or C virus (e.g., HCV RNA \\[qualitative\\] is detected).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has an active autoimmune disease or a documented history of autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "* The participant has received a live vaccine within 30 days prior to the first dose of trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04122625",
    "statement": "* Have received at least one prior line of standard systemic chemotherapy in the advanced/unresectable cancer setting (standard adjuvant/neoadjuvant treatment is acceptable if relapse occurred within six months of treatment end)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04122625",
    "statement": "* Have progressed or relapsed during or after a prior anti-programmed cell death-1 (PD-1)/ programmed cell death-ligand 1 (PD-L1)-based treatment, given either as a single agent or in combination with standard/approved chemotherapy, tyrosine kinase inhibitors (TKIs), radiotherapy (RT) or other monoclonal antibodies (mAbs) that are not known to modulate/inhibit immune checkpoints (CPIs)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04122625",
    "statement": "* Measurable disease (Part B only) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or Gynecologic Cancer Intergroup (GCIG) criteria in Cohort #4 of Part B (if applicable) and documented PD during or after prior PD-1/PD-L1 based therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04122625",
    "statement": "* Thoracic or head and neck radiation \\>30 gray (Gy) within the 3 months prior to Cycle 1 Day 1 (C1D1)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04122625",
    "statement": "* Have received, in total, more than 3 (i.e., Cohorts 1 \\& 2) or 4 (i.e., Cohorts 3 \\& 4) lines of prior systemic treatments in Part B (including adjuvant or neoadjuvant regimens if relapse within six months prior to C1D1)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04122625",
    "statement": "* Liver cirrhosis Child-Pugh score B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": ". patients with pathologically confirmed diagnosis of NSCLC stage IIIB/IV adeno- or bronchoalveolar carcinoma (BAC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "2. non smokers patients or patients having smoked less than 15 pack years and who stopped smoking for at least one year before diagnosis (except for patients with her2-neu mutation)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "3. presence of activating mutation(s) in exon 18 to exon 21 of the EGFR or HER2-neu-receptor confirmed by direct DNA sequencing of NSCLC tumor tissue or increased copy number of the EGFR gene as determined by FISH analysis",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "4. prior treatment up to 3 lines of chemotherapy except for HER2-neu patients (no restrictions) no prior EGFR TKI therapy for EGFR mutation negative and FISCH positive patients",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "5. patients with at least one tumor lesion that can accurately be measured by CTscan or MRI in at least one dimension with long diameter to be recorded as \\> or equal to 20 mm using conventional techniques or \\> or equal to 10 mm with spiral CT scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "6. male or female patient aged above or equal to 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "7. life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "8. written informed consents that is consistent with ICH-GCP guidelines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "9. ECOG performance score 0, 1 or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": ". more than 3 prior cytotoxic chemotherapy treatment regimen for relapsed or metastatic NSCLC, except for patients with HER2-neu mutations who may have received any prior therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "2. Any chemo-, hormone- or immunotherapy within the past 4 weeks or within less than 4 half-lives of the previous drug prior to treatment with the trial drug and/or persistence of toxicities of prior anticancer therapies which are deemed to be clinically relevant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "3. brain metastases which are symptomatic; patients with treated asymptomatic brain metastases are eligible with stable brain disease for at least 4 weeks without requirement for steroids or anti-epileptic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "4. significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g. Crohn's disease, malabsorption or CTCAE Grade \\> 2 diarrhea of any etiology at baseline",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "5. patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "6. other malignancies diagnosed within the past 5 years (other than non melanomatous skin cancer and in situ cervical cancer)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "7. radiotherapy within the past 2 weeks prior to treatment with the trial drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "8. patients with any serious active infection (i.e., requiring an IV antibiotic, antifungal, or antiviral agents)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "9. patients with known HIV, active hepatitis B or active hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "10. known or suspected active drug or alcohol abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "11. women of childbearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "12. pregnancy or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "13. patient unable to comply with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "14. history of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA) functional classification of 3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "15. Cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or Echocardiogram.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "16. Absolute neutrophil count (ANC) less than 1500/mm³.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "17. Platelet count less than 100 000 / mm³.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "18. Bilirubin greater than 1.5 mg / dl (\\>26 µmol / L, SI unit equivalent).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "19. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00730925",
    "statement": "20. Serum creatinine greater than 1.5 times of the upper normal limit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00890825",
    "statement": "* Locally advanced or metastatic non small cell lung cancer (IIIB-IV)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00890825",
    "statement": "* Failure of first line anti-cancer therapy (either radiological documentation of disease progression or due to toxicity) in advanced disease or subsequent relapse of disease following first line therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00890825",
    "statement": "* Tumour sample confirmed as KRAS mutation positive (Note: Sample must be available upon enrolment to ship to AZ appointed central laboratory, or mutation status confirmed locally at AstraZeneca agreed local laboratory using agreed methodology, or mutation status confirmed by an accredited (eg CLIA certified) commercial laboratory (eg Genzyme or Lab 21).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00890825",
    "statement": "* Received \\>1 prior anti-cancer therapy for advanced or metastatic non small cell lung cancer (excluding radiotherapy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00890825",
    "statement": "* Prior treatment with a MEK inhibitor or any docetaxel containing regimen (prior treatment with paclitaxel is acceptable)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00890825",
    "statement": "* Having received an investigational drug within 30 days of starting treatment, or have not recovered from side effects of an investigational drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00890825",
    "statement": "* Brain metastases or spinal cord compression unless asymptomatic, treated and stable off steroids and anti-convulsants for at least 1 month",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": ". Have histologically or cytologically confirmed SCLC (undifferentiated small-cell carcinoma arising in or consistent with lung cancer origin).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "2. Documented relapse or disease progression during or after first-line platinum-based therapy (subjects refractory to initial platinum-based therapy are eligible).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "3. Have no curative therapy available.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "4. Have a life expectancy of at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "5. Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "6. Have adequate bone marrow and hepatic function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "7. Have calculated creatinine clearance (CrCL) ≥30 mL/minute or serum creatinine ≤1.5 times below the upper limit of normal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "8. Women of reproductive potential must not be pregnant or breastfeeding and have a negative urine or serum pregnancy test obtained within 7 days prior to the first dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "9. Subjects must agree to consistently use 2 forms of highly effective contraception/birth control between signing of the informed consent and 60 days after the last study drug administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": ". Candidate for re-treatment with original platinum-based regimen as second-line therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "2. Prior treatment with irinotecan, topotecan, or dinutuximab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "3. Have active brain metastases. Subjects with brain metastases are allowed if they completed definitive brain therapy, are asymptomatic and radiologically stable, and if they are not currently receiving corticosteroids or radiation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "4. Have mixed small cell and non-small cell histologic features.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "5. Have a previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis \\[carcinoma in situ\\]) or any previous cancer curatively treated \\<3 years ago.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "6. Have a history or current evidence of uncontrolled cardiovascular disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "7. Have not recovered from prior surgery, significant trauma, systemic anticancer therapy, radiation therapy or investigational therapy to Grade 1 or better toxicity prior to enrollment (Part 1) or randomization (Part 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "8. Have had organ allograft or hematopoietic transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "9. Known to be human immunodeficiency virus (HIV) positive.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "10. Have an active infection requiring treatment or one that is clinically serious in the Investigator's opinion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "11. Have received a live vaccine within 6 months of enrollment (Part 1) or randomization (Part 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "12. Exposure to strong CYP3A4 and/or UGT1A1 inhibitors and strong CYP3A4 inducers within 14 days of enrollment (Part 1) or randomization (Part 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098030",
    "statement": "13. Have any clinical condition that is considered unstable or might jeopardize the safety of the subject and/or influence the subject's compliance in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Signed informed consent obtained prior to initiation of any study-specific procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Histologically or cytologically confirmed diagnosis of non-squamous non small cell lung cancer (NSCLC), not amenable for radical resection, stage IIIB with pleural or pericardial effusion or stage IV, who has not received previous chemotherapy or other systemic treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* At least one unidimensionally measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Male or female patients aged at least 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* ECOG Performance Status (PS): 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Life expectancy \\> 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Prior local radiotherapy is allowed if it was completed ≥ 3 weeks prior to the first dose of the study medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Concomitant palliative radiotherapy to an existing bone lesion for pain control is allowed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Prior surgery is allowed if it is performed at least 4 weeks prior to the first dose of study medication and patient should be fully recovered",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Adequate organ function, including the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Bone marrow: white blood cell (WBC) count \\>= 4 x 109/L, absolute neutrophil count (ANC) \\>= 1.5 x 109/L, platelet count \\>= 100 x 109/L, hemoglobin \\>= 9 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Hepatic: Bilirubin ≤ 1.5 x the upper limit of normal (ULN), aspartate transaminases (AST/SGOT) and alanine transaminases (ALT/SGPT) ≤ 2.5 x ULN (or ≤ 5 x ULN if liver metastases are present), INR ≤ 1.5 x ULN, albumin \\>= 3.0 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Renal: Serum creatinine ≤ 1.5 mg/dL or creatinine clearance \\>= 45 mL/min (calculated according to the Cockroft and Gault formula)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Female patients of child-bearing potential must have a negative pregnancy test and be using at least one form of contraception as approved by the Investigator for 4 weeks prior to the study and 4 months after the last dose of study drug. For the purposes of this study, child-bearing potential is defined as: \"All female patients unless they are post-menopausal for at least one year or are surgically sterile\"",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Male patients must use a form of barrier contraception approved by the Investigator during the study and for 4 months after the last dose of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Ability to cooperate with the treatment and follow-up",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Radiation therapy to more than 30% of the bone marrow prior to entry into the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Histology of pure bronchioloalveolar carcinoma or neuroendocrine features in the tumor sample",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Previous treatment with chemotherapy, new biological therapies (small molecules, antibodies), immunotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Absence of measurable lesions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* An ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorders in the opinion of the Investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Any previous history of another malignancy within 5 years of study entry (other than cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Presence of any significant central nervous system (CNS) or psychiatric disorder(s) that would hamper the patient's compliance",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Evidence of peripheral neuropathy \\> grade 1 according to NCI-CTCAE Version 3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Known HIV, HBV, HCV infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Presence of symptomatic brain metastasis. Patients with brain metastases must:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Be without neurologic dysfunction that would confound the evaluation of neurologic and other AEs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Inability or unwillingness to take folic acid, vitamin B12 or corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than aspirin dose ≤ 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such piroxicam)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Significant weight loss (\\>= 10% body weight during preceding 6 weeks)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942825",
    "statement": "* Presence of clinically significant (by physical exam) third space fluid collections, e.g., ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Disease progression during or after one prior first-line platinum-based chemotherapy with or without maintenance therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Prior bevacizumab as first-line and/or maintenance therapy is allowed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02322281",
    "statement": "Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Histologically or cytologically confirmed NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Stage IV NSCLC disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Participants have measurable or nonmeasurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Adequate organ function, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Total bilirubin less than or equal to Upper Limit of Normal (ULN),",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Aspartate Aminotransferase (AST) and Alanine Aminotransaminase (ALT) less than or equal to 2.5 x ULN, or less than or equal to 5 x ULN if the transferase elevation is due to liver metastases,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Serum creatinine less than or equal to 1.5 x ULN or calculated creatinine clearance greater than or equal to 50 milliliters per minute (ml/min) (per the Cockcroft-Gault formula or equivalent and/or 24-hour urine collection),",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Absolute Neutrophil Count (ANC) greater than or equal to 1.5 x 10\\^3/microliters (µL), hemoglobin greater than or equal to 10.0 grams/deciliter (g/dL), and platelets greater than or equal to 100 x 10\\^3/µL,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Adequate coagulation function as defined by International Normalized Ratio (INR) less than or equal to 1.5, or prothrombin time and partial thromboplastin time less than or equal to 1.5 x ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* The participant does not have cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Urinary protein is less than or equal to 1+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria greater than or equal to 2+, a 24-hour urine must be collected and must demonstrate less than 1000 milligrams (mg) of protein.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Participants of reproductive potential (both sexes) must agree to use reliable method of birth control (hormonal or barrier methods) during the study period and at least 12 weeks after the last dose of study therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Life expectancy of greater than or equal to 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Prior radiation therapy is allowed if: In the case of chest radiotherapy at least 28 days have elapsed from the completion of radiation treatment prior to randomization; In the case of focal or palliative radiation treatment at least 7 days have elapsed from last radiation treatment prior to randomization (and provided that 25% or less of total bone marrow had been irradiated); In the case of Central Nervous System (CNS) radiation at least 14 days have elapsed from the completion of radiation treatment prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Disease progression on more than 1 prior chemotherapy regimens",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Participants whose only prior treatment was a tyrosine kinase inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* The participant's tumor wholly or partially contains small cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Major surgery within 28 days prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization. Postoperative bleeding complications or wound complications from a surgical procedure performed in the last 2 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or targeted therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Last dose of bevacizumab must be at least 28 days from time of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Last dose of cytotoxic chemotherapy must be at least 14 days from time of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* The participant has untreated CNS metastases. Participants with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation ending at least 2 weeks prior to randomization, or after surgical resection performed at least 28 days prior to randomization. No evidence of Grade greater than or equal to 1 CNS hemorrhage based on pretreatment Magnetic Resonance Imaging (MRI) or IV contrast Computed Tomography (CT) scan.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Radiologically documented evidence of major blood vessel invasion or encasement by cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Radiographic evidence of intratumor cavitation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* History of uncontrolled hereditary or acquired thrombotic disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Chronic therapy with nonsteroidal anti-inflammatory drug (NSAIDs) or other antiplatelet agents; Aspirin use at doses up to 325 milligrams per day (mg/day) is permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* History of gross hemoptysis (defined as bright red blood or greater than or equal to 1/2 teaspoon) within 2 months prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Clinically relevant congestive heart failure \\[New York Heart Association (NYHA II-IV)\\] or symptomatic or poorly controlled cardiac arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Uncontrolled arterial hypertension greater than or equal to 150 / greater than or equal to 90 millimeters of mercury (mm Hg) despite standard medical management",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Significant bleeding disorders, vasculitis, or Grade 3/4 gastrointestinal bleeding within 3 months prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Gastrointestinal (GI) perforation and/or fistulae within 6 months prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection Crohn's disease, ulcerative colitis, or chronic diarrhea",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Peripheral neuropathy greater than or equal to Grade 2 \\[National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.02\\]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Serious illness or medical condition(s) including, but not limited to: Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness; Active or uncontrolled clinically serious infection; Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Known allergy or hypersensitivity reaction to any of the treatment components",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* The participant is pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Current or recent (within 28 days prior to randomization) treatment with an investigational drug or device that has not received regulatory approval for any indication at the time of randomization, or participation in another interventional clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01168973",
    "statement": "* Prior therapy with docetaxel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02000531",
    "statement": "* Participant in ENSURE trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02000531",
    "statement": "* Disease progression during first-line treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02000531",
    "statement": "* N/A",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": ". Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses. Procedures performed for routine clinical practice up to 2 weeks before the provision of written consent are acceptable if not intentionally done for study purposes.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "   If a patient declines to participate in any voluntary exploratory research and/or genetic component of the study, there will be no penalty or loss of benefit to the patient and he/she will not be excluded from other aspects of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "2. Male or female aged at least 18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "3. Histological or cytological confirmation of diagnosis of NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "4. Confirmation that the tumour harbours an EGFR mutation known to be associated with EGFR-TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) or T790M EGFR resistance mutation as assessed by local laboratory/or central laboratory via tissue/cytology or in plasma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "5. Mandatory provision (if available) of formalin fixed, paraffin embedded tissue and blood for central confirmation of EGFR mutation status. Please refer to the Laboratory Manual for details.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "6. In all patients enrolled, confirmed BM as having at least one non-measurable and/or measurable brain lesion at baseline as per CNS RECIST 1.1 via MRI imaging.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "7. World Health Organisation (WHO) performance status 0 to 2 and a minimum life expectancy of 4 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "8. Females should be using adequate contraceptive measures (up to 6 months after the last administration), should not be breastfeeding and must have a negative serum pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential by fulfilling 1 of the following criteria at screening:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Women under 50 years old would be consider postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with luteinising hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "9. Male subjects should be willing to use barrier contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "10. Have a body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 inclusive and weigh at least 40.0 kg and no more than 100.0 kg, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "11. Able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": ". Participation in another clinical study with an IP during the previous 14 days (or longer, depending on characteristics of agents used).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "2. Treatment with any of the following: EGFR-TKI (e.g. erlotinib, gefitinib or afatinib) within 10 days or at least 5x the half-life, whichever is the longer; any cytotoxic chemotherapy, investigational agents or other anticancer drugs within 14 days of start of IP; osimertinib in the present or other studies; major surgery (excluding placement of vascular access) within 4 weeks of start of IP; radiotherapy (including brain) with a limited field of radiation within 1 week of start of IP, except in patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation which must be completed within 4 weeks of the first administration of the IP; current receipt (or inability to stop at least 3 weeks before study start) medications or herbal supplements known to be potent inducers of CYP3A4.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "3. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting the IP with the exception of alopecia and grade 2, prior platinum therapy-related neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "4. History of brain surgery or major brain trauma in the last year (if the surgery is in the same hemisphere as the brain metastasis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses or active infection including hepatitis B, hepatitis C and HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "6. Any of the following cardiac criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Mean resting corrected QT interval (QTc) \\>470 msec obtained from 3 ECGs, using the screening clinic ECG machine derived QTc value.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third degree heart block, second degree heart block).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as electrolyte abnormalities including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Serum/plasma potassium \\",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "2.5x ULN or \\>5x ULN in the presence of liver metastases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Aspartate aminotransferase (AST) \\>2.5x ULN or \\>5x ULN in the presence of liver metastases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Total bilirubin \\>1.5x ULN or \\>3x ULN in the presence of liver metastases or Gilbert's Syndrome;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Creatinine \\>1.5xl ULN concurrent with creatinine clearance \\<50 mL/min (using Cockcroft-Gault formula).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "9. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the tablet or previous significant bowel resection that would preclude adequate absorption of osimertinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "10. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "11. In addition, the following is considered a criterion for exclusion from the exploratory genetic research:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Previous allogenic bone marrow transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "12. Patients on anticoagulant treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "13. Absence of collateral flow between ulnar and radial artery as assessed by the Allen´s test\".",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "14. Suffering from claustrophobia and/or having implanted metal devices or implants such as pacemaker, vascular or heart valves or metal deposits such as bullets, shells, metal grains in the eyes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "15. Previous participation in a research PET or PET/CT study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "16. The following are exclusion criteria for contrast enhanced MRIs:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Glomerular filtration rate \\<30 ml/min",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* History of renal insufficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "* Pregnancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "17. Women who are breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": ". Age ≥ 18 years old (≥ 20 years old in Japan);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "2. Histologically diagnosed or cytologically proven advanced or metastatic NSCLC patients, either Stage IIIB/Stage IV disease (according to Version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or recurrent disease following radiation therapy or surgical resection;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "3. Patients who had received at least 2 prior therapies for advanced or metastatic disease condition, including platinum doublet and pemetrexed, docetaxel, or immunotherapy, and were refractory to or unable to tolerate their last prior therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Version 1.1, 2009);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "6. Predicted life expectancy of at least 3 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "7. Able to take medications orally;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "8. Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "9. Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "10. Willing and able to comply with required scheduled visits and study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": ". Treatment with any of the following within the specified time frame prior to the study drug administration:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "* Major surgery within prior 4 weeks and minor surgery within 7 days;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "* Radiotherapy for extended field within prior 4 weeks or limited field within prior 2 weeks;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "* Any anticancer therapy or investigational agent within prior 3 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "2. A serious illness or medical condition",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "3. Concomitant treatment with the following drugs that may interact with S-1:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "   Sorivudine, brivudine, uracil, eniluracil, folinate/folinic acid, Cimetidine, dipyridamole, and nitroimidazoles, including metronidazole and misonidazoleMethotrexate, Clozapine,Allopurinol,Phenytoin,Flucytosine, a fluorinated pyrimidine antifungal agent,Coumarin-derivative anticoagulant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "4. Known hypersensitivity to S-1 or its metabolites (eg, 5-FU);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "5. Previous use of TAS-114, S-1, and 5-FU drugs;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "6. A pregnant or lactating female or possibly pregnant women, or men or women wishing to have children during the study period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02855125",
    "statement": "7. A judgment of the investigator that the patient is inappropriate for study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Life expectancy ≥ 10 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Histologically or cytologically confirmed stage IIIB, IIIC, or IV non-squamous NSCLC. Patients with tumors of mixed histology are eligible if the major histological component appears to be non-squamous.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* No prior treatment for Stage IIIB, IIIC, or IV non-squamous NSCLC, with the following exceptions:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "Patients with a sensitizing mutation in the EGFR gene must have experienced disease progression or were intolerant to treatment with one or more EGFR TKIs. Patients who have progressed on or were intolerant to first-line osimertinib or other thirdgeneration EGFR TKIs are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "Patients who have progressed on or were intolerant to first- or second-generation EGFR TKIs, and who have no evidence of the EGFR T790M mutation after TKI therapy are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "Patients who have progressed on or were intolerant to first- or second-generation EGFR TKIs and who have evidence of the T790M mutation must have also progressed on or were intolerant to osimertinib to be eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* TKIs approved for treatment of NSCLC discontinued \\>7 days prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Measurable disease per RECIST v1.1. PD-L1 expression of ≥1% as documented through central testing of a representative tumor tissue specimen either from previously obtained archival tumor tissue or tissue obtained from a biopsy at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* ECOG Performance Status of 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Adequate hematologic and end-organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Negative HIV test at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Negative hepatitis B surface antigen (HBsAg) test at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening. The HBV DNA test will be performed only for patients who have a positive total HBcAb test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases as determined by CT or MRI evaluation during screening and prior radiographic assessments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* History of leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Prior chemotherapy or other systemic therapy for stage IIIB, IIIC, or IV disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Active or history of autoimmune disease or immune deficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Active tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Prior allogeneic stem cell or solid organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Current treatment with anti-viral therapy for HBV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Treatment with investigational therapy within 28 days prior to initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab, 6 months after the final dose of bevacizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Prior history of hypertensive crisis or hypertensive encephalopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Significant vascular disease within 6 months prior to initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* History of Grade ≥ 2 hemoptysis within 1 month prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Evidence of bleeding diathesis or coagulopathy. Current or recent use of aspirin, clopidogrel or treatment with dipyramidole, ticlopidine, or cilostazol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes that has not been stable for \\> 2 weeks prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* History of stroke or transient ischemic attack within 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first dose of bevacizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* History of abdominal or tracheosphageal fistula or gastrointestinal perforation within 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* History of intra-abdominal inflammatory process within 6 months prior to initiation of study treatment, including but not limited to active peptic ulcer disease, diverticulitis,or colitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Clinical signs of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Evidence of abdominal free air not explained by paracentesis or recent surgical procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Proteinuria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Clear tumor infiltration into the thoracic great vessels is seen on imaging",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04426825",
    "statement": "* Clear cavitation of pulmonary lesions is seen on imaging",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556712",
    "statement": "* adult patients \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556712",
    "statement": "* histologically documented, locally advanced , recurrent or metastatic NSCLC;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556712",
    "statement": "* measurable disease;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556712",
    "statement": "* no disease progression after 4 cycles of platinum-based chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556712",
    "statement": "* unstable systemic disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556712",
    "statement": "* any other malignancies in the last 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has Stage IV NSCLC (American Joint Committee on Cancer \\[AJCC\\])",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has measurable disease based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has tumor tissue that demonstrates programmed cell death-ligand 1 (PD-L1) expression in ≥1% of tumor cells (Tumor Proportion Score \\[TPS\\] ≥1%) as assessed by immunohistochemistry (IHC) 22C3 pharmDx assay (Dako North America, Inc.) at a central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has a life expectancy of ≥3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study treatment but before randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Male participants must agree to the following during the treatment period and for ≥7 days after the last dose of lenvatinib/matching placebo: 1) Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR 2) Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Female participants are eligible to participate if not pregnant or breastfeeding, and ≥1 of the following applies: 1) Is not a woman of child-bearing potential (WOCBP), OR 2) Is a WOCBP and is using a highly effective contraceptive method that has a low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle during the treatment period and for ≥120 days post pembrolizumab or ≥30 days post lenvatinib/matching placebo, whichever occurs last",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week before randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has known untreated central nervous system metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for ≥3 years since initiation of that therapy (Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has an active autoimmune disease that has required systemic treatment in the past 2 years Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has had an allogeneic tissue/solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has a known history of human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has a history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has a known history of hepatitis B or known active hepatitis C virus infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has a history of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral study drug absorption",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has significant cardiovascular impairment within 12 months of the first dose of study treatment, such as a history of congestive heart failure greater than New York Heart Association Class II, unstable angina, myocardial infarction, cerebrovascular accident/stroke, or cardiac arrhythmia associated with hemodynamic instability",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has not recovered adequately from any toxicity and/or complications from major surgery before starting study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has a known history of active tuberculosis (TB)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has an active infection requiring systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has previously had a severe hypersensitivity reaction to treatment with a monoclonal antibody or has a known sensitivity or intolerance to any component of lenvatinib or pembrolizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 \\[CTLA-4\\], Tumor necrosis factor receptor superfamily, member 4 \\[OX 40\\], tumor necrosis factor receptor superfamily member 9 \\[CD137\\]) or has received lenvatinib as monotherapy or in combination with anti- programmed cell death protein (anti-PD-1) agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has received radiotherapy within 14 days before the first dose of study treatment or received lung radiation therapy of \\>30 Gray (Gy) within 6 months before the first dose of study treatment. (Note: Participants must have recovered from all radiation-related toxicities to ≤Grade 1, not require corticosteroids, and not have had radiation pneumonitis.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within 7 days before the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Is receiving systemic steroid therapy (doses \\>10 mg daily of prednisone equivalent) within 7 days before the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has received a live vaccine within 30 days before the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has had major surgery within 3 weeks prior to first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04676412",
    "statement": "* Has pre-existing ≥Grade 3 gastrointestinal or non-gastrointestinal fistula",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01809210",
    "statement": "* Provision of signed, written and dated consent prior to any study specific procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01809210",
    "statement": "* Male or female, aged 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01809210",
    "statement": "* Histological or cytological confirmation of locally advanced or metastatic NSCLC (IIIB-IV)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01809210",
    "statement": "* Female patients must not be breast-feeding and have a negative pregnancy test prior to start of dosing or must have evidence of non-child-bearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01809210",
    "statement": "* Patients must be eligible to receive treatment with the platinum doublet combination with which selumetinib is being combined and in accordance with the local product information",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01809210",
    "statement": "* Prior chemotherapy or other systemic anti-cancer treatment for advanced NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01809210",
    "statement": "* Prior surgery or radiotherapy within 6 months or palliative radiotherapy within 4 weeks of start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01809210",
    "statement": "* Female patients who are breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01809210",
    "statement": "* Another primary malignancy within 5 years of starting study treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01809210",
    "statement": "* As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, active bleeding diatheses, renal transplant, or active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01470612",
    "statement": "* Subjects who completed induction studies A3921094 or A3921095 and were classified as not meeting clinical response criteria; OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01470612",
    "statement": "* Subjects who completed maintenance study A3921096 or who discontinued treatment early in Study A3921096 due to treatment failure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01470612",
    "statement": "* Subjects who had a major protocol violation in Study A3921094, A3921095 or A3921096.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01470612",
    "statement": "* Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01470612",
    "statement": "* Subjects who have had surgery for ulcerative colitis or in the opinion of the investigator, are likely to require surgery for ulcerative colitis during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participant is \\>=18 years of age on the day of signing informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participant has a diagnosis of histologically or cytologically confirmed advanced non-small cell lung cancer (Stage IIIB or IV) or recurrent disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participants with known epidermal growth factor receptor (EGFR) mutations or Anaplastic lymphoma kinase receptor (ALK) or ROS1 gene rearrangements must have failed (disease progression \\[PD\\] or unacceptable toxicity) prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively (PD or unacceptable toxicity). There is no limit to lines of prior anti-cancer therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participant has measurable disease according RECIST v1.1 criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participant is HLA-A\\*02:01, HLA-A\\*02:05 and/or HLA-A\\*02:06 positive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participant's tumor is positive for NYESO and/or LAGE-1a expression by a designated central laboratory.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participant has Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participant has an anticipated life expectancy \\>3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participant has left ventricular ejection fraction \\>=50 percent(%).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participant is fit for leukapheresis and has adequate venous access for the cell collection.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Male or Female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participant must have adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per Investigator assessment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Washout periods for prior radiotherapy and chemotherapy and other systemic therapy must be followed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Experimental anti-cancer vaccine within 2 months prior to leukapheresis in the absence of response or in the opinion of the Investigator is responding to an experimental vaccine given within 6 months prior to leukapheresis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Any prior gene therapy using an integrating vector.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Toxicity from previous anti-cancer therapy that has not recovered to less than or equal to (\\<=)Grade 1 prior to enrollment (with exceptions).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, fludarabine, or other agents used in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Central nervous system (CNS) metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Active brain metastases or leptomeningeal metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* History of chronic or recurrent (within the last year prior to enrollment) severe autoimmune or active immune-mediated disease requiring steroids or other immunosuppressive treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Other active malignancies besides NSCLC within 3 years prior to Screening not in complete remission.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Unintended weight loss \\>10% in 6 months preceding study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Corrected QT interval (QTc) \\>450 milliseconds (msec) or QTc \\>480 msec for participants with Bundle Branch Block (BBB).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Uncontrolled intercurrent illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participants who in the opinion of the Investigator will be unlikely to fully comply with protocol requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or human T-cell lymphotropic virus (HTLV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Participant is pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02588612",
    "statement": "* Major surgery within 4 weeks prior to lymphodepleting chemotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* Histologically confirmed NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* Availability of a tumor specimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* Recurrent or progressive disease following at least one chemo containing regimen for Stage IIIB/IV disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* At least one measurable lesion on a pre-treatment 18-fluorodeoxyglcose-positron emission tomography (FDG-PET) scan that is also a target lesion on computed tomography (CT) according to RECIST",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* More than two prior treatments for Stage IIIB/IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known epidermal growth factor receptor (EGFR)-related toxicity resulting in dose modifications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* Chemotherapy, biologic therapy, radiotherapy or investigational drug within 28 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* Untreated and/or active (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) central nervous system (CNS) metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* History of serious systemic disease within the past 6 months prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* Uncontrolled diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* Major surgical procedure or significant traumatic injury within 28 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* Anticipation of need for a major surgical procedure during the course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* Local palliative radiotherapy within 7 days prior to randomization or persistent adverse effects from radiotherapy that have not been resolved to Grade II or less prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00854308",
    "statement": "* Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) (Stage IIIb or greater)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Tumor cell programmed death-ligand 1 (PD-L1) score of tumor cells (TC)1-3 and immune cell PD-L1 score of tumor-infiltrating immune cells (IC)0-3 as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained after the last line of therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin \\[beta- hCG\\]) at Screening within 14 days prior to study drug administration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Inclusion Criteria for Crossover:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over. If not clinically feasible, discussion with Sponsor is required",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* The first dose of atezolizumab in the crossover arm should be within 42 days of last dose but no less than 21 days from the last dose prior to crossing over",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Received any of the following prescribed medications or therapies in the past:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "  1. Anti-cluster of differentiation(CD)38 therapy, including daratumumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "  2. CD137 agonists, immune checkpoint inhibitors including but not limited to CTLA-4, anti-PD-1, and anti-PD-L1 therapies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Known to be seropositive for human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Prior allogeneic bone marrow transplantation or solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Active hepatitis B, defined by a positive test for hepatitis B surface antigen \\[HBsAg\\] or prior history of hepatitis B, defined by presence of antibodies to hepatitis B core antigen \\[anti-HBc\\], regardless of hepatitis B surface antibody \\[anti-HBs\\] status; active hepatitis C or prior history of hepatitis C (anti-HCV positive), except in the setting of a sustained virologic response (SVR), defined as aviremia 12 weeks after completion of antiviral therapy. If hepatitis C virus (HCV) antibodies are detected, an HCV RNA test for viral load by polymerase chain reaction (PCR) should be performed at least 12 weeks after completion of antiviral therapy to rule out active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Exclusion Criteria for Crossover:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Received any subsequent anti-cancer therapies from the time between the last dose of atezolizumab prior to the first administration of study drug after crossing over",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "* Whole brain radiation within 28 days or other radiotherapy within 14 days prior to first administration of study drug after crossing over",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": ". Histologically confirmed metastatic non-small cell lung cancer (NSCLC) with disease recurrence or progression during or after prior platinum-containing doublet chemotherapy regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "2. Histologically confirmed metastatic non-small cell lung cancer (NSCLC) that has relapsed following prior PD-1/PD-L1 checkpoint inhibitor therapy without Grade 3 immune-related toxicity, which may or may not have included concurrent chemotherapy. Relapse following prior PD-1 checkpoint therapy is defined as confirmed progressive disease following stable disease or better (e.g., iSD, iPR, iCR) on at least 1 tumor assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "3. Patients with an active oncogenic driver (e.g., epidermal growth factor \\[EGFR\\], activin-receptor-like kinase 1 \\[ALK1\\], or the proto-oncogene tyrosine-protein kinase ROS-1) must have progressed on or after a US Food and Drug Administration (FDA)-approved therapy for that aberration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "4. Patients who received adjuvant or neoadjuvant platinum-doublet chemotherapy (after surgery and/or radiation therapy) and developed recurrent or metastatic disease within 6 months of completing therapy are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "5. Patients with recurrent disease \\> 6 months after adjuvant or neoadjuvant platinum-based chemotherapy, who also subsequently progressed during or after a platinum- doublet regimen given to treat the recurrence, are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "6. Formalin fixed, paraffin-embedded (FFPE) tumor tissue block that permits the preparation of 20 unstained slides of tumor sample (archival) - Biopsy must be excisional, incisional, or core. Needle aspiration is insufficient. In cases where archival tumor tissue is unavailable, tumor biopsy will be required prior to treatment initiation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "7. Programmed death ligand 1 (PD-L1) determination by validated immunohistochemistry assay",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "8. Measurable disease by iRECIST",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "9. Age ≥ 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "10. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "11. Resolution of all acute adverse events resulting from prior cancer therapies to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1 or baseline (except alopecia or neuropathy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "12. Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "13. Willingness and ability to consent for self to participate in study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "14. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": ". Autoimmune disease requiring treatment within the past twelve months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "2. Condition requiring systemic treatment with either corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "3. History or active interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "4. Prior therapy with T-cell therapy, including an immune checkpoint inhibitor. Patients who received prior immune checkpoint inhibitor therapy are allowed in Expansion Cohort 2 in the absence of recurrent grade 2 (except skin, endocrine and constitutional symptoms), or ≥ 3 immune-related toxicity).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "5. Prior treatment with carotuximab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "6. Current treatment on another therapeutic clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "7. Receipt of systemic anticancer therapy, including investigational agents, within 28 days prior to study treatment (Note: If anticancer therapy was given within 28 days prior to starting study treatment, patients are not excluded if ≥ 5 times the elimination half-life of the drug has elapsed.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "8. Major surgical procedure or significant traumatic injury within 4 weeks prior to study treatment, and must have fully recovered from any such procedure; and no date of surgery (if applicable) or anticipated need for a major surgical procedure planned within the next 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "9. Chest radiotherapy ≤ 28 days, wide field radiotherapy ≤ 28 days (defined as \\> 50% of volume of pelvic bones or equivalent), or limited field radiation for palliation ≤ 14 days prior to study treatment - Such patients must have recovered adequately from any side effects of such therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "10. Hypertension defined as blood pressure (BP) systolic \\> 150 or diastolic \\> 90 mm Hg (Note: Initiation or adjustment of antihypertensive medication prior to study entry is allowed provided that the average of 3 BP readings prior to study treatment is ≤150/90 mm Hg.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "11. Ascites or pericardial effusion that required intervention within 3 months prior to study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "12. History of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "13. Angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within 6 months prior to study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "14. Deep venous thrombosis within 6 months prior to study treatment, unless the patient is anti-coagulated without the use of warfarin for ≥2 weeks prior to study treatment; in this situation, low molecular weight heparin is preferred",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "15. Active bleeding or pathologic condition that carries a high risk of bleeding (e.g., hereditary hemorrhagic telangiectasia)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "16. Thrombolytic use (except to maintain IV catheters) within 10 days prior study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "17. Known active viral or nonviral hepatitis or cirrhosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "18. Any active infection requiring systemic treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "19. History of hemorrhage or hemoptysis (\\> ½ teaspoon bright red blood) within 3 months prior to study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "20. History of peptic ulcer within the past 3 months prior to study treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days prior to study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "21. History of gastrointestinal perforation or fistula in the 6 months prior to study treatment, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g., through surgical resection or repair)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "22. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "23. Pregnancy or breastfeeding - Female patients must be surgically sterile (i.e., ≥6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) or be postmenopausal, or must agree to use effective contraception during the study and for 3 months following last dose of carotuximab. All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to study treatment. Male patients must be surgically sterile or must agree to use effective contraception during the study and for at least 180 days following last dose of study drug (carotuximab or nivolumab, whichever occurs later).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03181308",
    "statement": "24. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191308",
    "statement": "* pathologic documentation of non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191308",
    "statement": "* tumor must be accessible by bronchoscopy for tumor tissue sample collection",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191308",
    "statement": "* patients must have lung cancer with clinical stage IB, II, IIIA",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191308",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191308",
    "statement": "* patients must not have received prior systemic chemotherapy or radiation therapy for NSCLC (prior resection of lung is allowed provided at least 5 years have elapsed between prior surgery and enrolment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191308",
    "statement": "* bronchoalveolar carcinoma or stage IIIA tumor involving the superior sulcus (Pancoast tumors)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191308",
    "statement": "* pregnant or breast feeding patients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191308",
    "statement": "* patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191308",
    "statement": "* patients with history or presence of other malignancy except in situ carcinoma of the skin or prior malignancy treated more than 5 years before without recurrence (excluding melanoma, breast cancer and hypernephroma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191308",
    "statement": "* unwillingness to take folic acid or vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": ". Pathologic or cytologic confirmed diagnosis of NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "2. Recurrent, advanced or metastatic NSCLC that has progressed following one prior platinum based chemotherapy regimen (not counting adjuvant or neoadjuvant chemotherapy if completed more than 12 months prior to platinum based therapy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "3. Patients who are eligible for pemetrexed as second line chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "4. Measurable disease by one or more techniques (CT, MRI) according to RECIST",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "5. Patients aged 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "6. Life expectancy of at least three (3) months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "7. Eastern Cooperative Oncology Group (ECOG) performance Score 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "8. Written informed consent that is consistent with ICH-GCP guidelines and local legislation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": ". Treatment with an investigational drug in another clinical study within the past 28 days prior to the start of therapy or concomitantly with this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "2. Anti-cancer therapy for NSCLC (except radiotherapy for palliative reasons) within the past 28 days prior to Treatment Day 1 of Cycle 1 of this trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "3. Any persisting toxicities which are deemed to be clinically significant from the previous therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "4. Patients who have received more than one prior chemotherapy regimen for advanced disease (not including prior adjuvant therapy). Patients may have received prior epidermal growth factor receptor tyrosine kinase inhibitors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "5. Patients who are unwilling or unable to take folic acid and vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "6. Active brain metastases (stable for \\<28 days, symptomatic, or requiring concurrent steroids). Patients who have received prior whole brain irradiation and whose brain metastases are stable according to the criteria above will not be excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "7. Other active malignancy diagnosed within the past 3 years (other than non melanomatous skin cancer and cervical intraepithelial neoplasia)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "8. Concomitant intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situation that would limit compliance with trial requirement or which are considered relevant for the evaluation of the efficacy or safety of the trial drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "9. Patients unable or unwilling to interrupt concomitant administration of NSAIDS 5 days prior to, the day of and 2 days after the administration of pemetrexed, with the exception of lose dose aspirin 81mg daily",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "10. Patients who have received prior therapy with pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "11. Absolute neutrophil count (ANC) less than 1,500/mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "12. Platelet count less than 100,000/mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "13. Hemoglobin \\<90g/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "14. Total bilirubin \\>26µmol/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "15. Alanine amino transferase (ALT) and/or aspartate amino transferase (AST) less than 2.5 X ULN, except in case of known liver metastasis where maximum 5 X ULN is acceptable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "16. Serum creatinine level \\>133µmol/L and/or creatinine clearance (measured or calculated) \\<45 ml/min",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "17. Clinically relevant QTc prolongation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "18. Women and men who are sexually active and unwilling to use a medically acceptable method of contraception",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "19. Pregnancy or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "20. Known or suspected active alcohol or drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "21. Patients unable to comply with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "22. Any known hypersensitivity to the trial drugs or their excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00824408",
    "statement": "23. Patients with NSCLC of confirmed Squamous histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Histologically or cytologically confirmed unresectable locally advanced or metastatic (stage IIIb or IV) non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* No prior systemic therapy for NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Male or female ≥ 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Anticipation of more than 3 months survival",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Adequate organ and bone marrow function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Anticipation of need for a major surgical procedure or radiation therapy during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Remaining influence of previous therapies such as radiotherapy, surgery, immunotherapy within 4 weeks prior to start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* History of any of the following events within 6 months prior to start of study treatment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) class ≥I congestive heart failure (CHF), cerebrovascular accident or cerebral infarction, pulmonary embolism, deep vein thrombosis, or other clinically significant thromboembolic event; clinically significant pulmonary disease (eg, severe chronic-obstructive pulmonary disease (COPD) or asthma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Severe edema, ascites fluid, pericardial or pleural effusion or pericardial involvement with the tumor within 6 months prior to start of study treatment, or which require steroid therapy/ diuretic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Subjects with brain metastasis (defined as untreated, symptomatic or requiring steroids or anticonvulsant medications to control associated symptoms)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Subjects with clinically significant active infection which requires antibiotic therapy, or who are hepatitis B surface antigen (HBs)- or hepatitis C virus (HCV)- or human immunodeficiency virus (HIV)- positive and receiving antiretroviral therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Subjects with malabsorption syndrome, chronic diarrhea (lasting over 4 weeks), inflammatory bowel disease, or partial bowel obstruction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Diabetes mellitus requiring insulin, or a history of poor serum glucose control with the use of non-insulin diabetes medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Treatment with thiazolidinediones (TZDs) within 4 weeks prior to start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* History of a second malignancy, with the exception of in situ cervical cancer or adequately treated basal cell or squamous cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199055",
    "statement": "* Poorly-controlled blood pressure as judged by the Investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Subject has given written informed consent before any trial-related activities are carried out",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Male or female, greater than or equal to (\\>=)18 years of age at the time of informed consent, inpatient or outpatient",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Diagnosis of histologically or cytologically confirmed NSCLC, stage IIIB NSCLC with pleural effusion or stage IV",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Presence of at least 1 uni-dimensionally measurable index lesion, whereby index lesions must not lie in a previously irradiated area",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at inclusion in the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* White blood count\\>= 3 \\* 10\\^9 per liter (/L) with neutrophils \\>= 1.5 \\* 10\\^9 /L , platelet count \\>=100 \\* 10\\^9 /L , and hemoglobin \\>= 5.6 millimole per liter (mmol/L) (9 gram per deciliter \\[g/dL\\])",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Total bilirubin less than or equal to (=\\<)1.5 \\* upper limit of normal (ULN) range",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) =\\< 5 \\* ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Glomerular filtration rate (GFR) \\>=60 milliliter per minute (mL/min). The creatinine clearance (CrCl) estimated based on the Cockroft-Gault formula is used as a surrogate for the GFR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Effective contraception that is, barrier method (condoms, diaphragm), oral, injectable or implant birth control, for both male and female subjects during the whole trial period and for at least 6 months after the end of trial treatment, if the risk of conception exists",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Recovered from relevant toxicities prior to inclusion in the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Previous exposure to Epidermal Growth Factor Receptor (EGFR)-targeting therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Previous chemotherapy for NSCLC; neo-adjuvant or adjuvant (radio-)chemotherapy is allowed if it was finished 6 months prior to start of trial treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Major surgery within 30 days prior to inclusion in the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Prior chest irradiation within 90 days prior to inclusion in the trial (palliative radiation of bone lesions is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Participation in another clinical trial or treatment with any investigational agent(s) within 30 days prior to inclusion in the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Concurrent chronic systemic immune therapy, chemotherapy for disease other than cancer, or hormone therapy for the treatment of cancer not indicated in the trial protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Documented or symptomatic brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Pre-existing ascites Grade \\>= 2 and/or pericardial effusion Grade \\>= 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Superior vena cava syndrome contra-indicating hydration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Previous malignancy in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Active infection (infection requiring intravenous antibiotics), including active tuberculosis, known and declared human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Myocardial infarction within 6 months prior to inclusion into the trial, uncontrolled congestive heart failure; or any current Grade 3 or 4 cardio-vascular disorder despite treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Known hypersensitivity reaction to any of the components of trial treatments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria (NCI-CTC) Grade \\>= 2 and/or ototoxicity Grade \\>= 2, except if due to trauma or mechanical impairment due to tumor mass",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* History of significant neurologic or psychiatric disorders including dementia, seizures, bipolar disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Medical or psychological condition that would not permit the subject to complete the trial or sign informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Legal incapacity or limited legal capacity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Known drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00820755",
    "statement": "* Pregnancy (absence to be confirmed by serum beta-human chorionic gonadotropin \\[beta-HCG test\\]) or lactation period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00143455",
    "statement": "* Histologically or cytologically proven Small Cell Lung Cancer (SCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00143455",
    "statement": "* WHO performance status : 0, 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00143455",
    "statement": "* No previous radiotherapy is allowed except on bone metastases when newly diagnosed. Radiotherapy is not allowed for vena cava syndrome, a stent is recommended ;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00143455",
    "statement": "* No prior surgery on the primary tumor except for palliative purpose (stent for vena cava syndrome).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05246514",
    "statement": "* Pathologically documented metastatic non-squamous NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05246514",
    "statement": "* Has relapsed from or is refractory to at least one-line of anticancer treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05246514",
    "statement": "* Documented HER2 exon 19 or 20 mutation from central FFPE tumour tissue testing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05246514",
    "statement": "* WHO or ECOG performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05246514",
    "statement": "* Presence of at least one measurable lesion assessed by the investigator based on RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05246514",
    "statement": "* LVEF ≥ 50% within 28 days before enrolment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05246514",
    "statement": "* Mixed small cell lung cancer, squamous histology NSCLC, and sarcomatoid histology variant NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05246514",
    "statement": "* Corrected QT interval (QTcF) prolongation to \\> 470 ms (females) or \\> 450 ms (males), based on average of the screening triplicate 12-lead ECG.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05246514",
    "statement": "* History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05246514",
    "statement": "* Has unresolved toxicities from previous anticancer therapy, defined as toxicities (excluding alopecia) not yet resolved to Grade ≤1 or baseline. Participants with clinically stable chronic Grade 2 toxicity not reasonably expected to be exacerbated by study intervention may be included only after consultation with the AstraZeneca study physician or designee.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05246514",
    "statement": "* Has been previously treated with HER2-targeted therapies, except for pan-HER class TKIs or has received prior treatment with an ADC which consists of an exatecan derivative that is a topoisomerase I inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Signed Informed Consent Form",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Histologically or cytologically confirmed NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Advanced NSCLC or recurrent disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* INR no greater than 1.3 and aPTT no greater than upper limits of normal (ULN) within 28 days prior to enrollment for subjects not on low molecular weight heparin or fondaparinux. Subjects on low molecular weight heparin or fondaparinux are not required to meet INR or aPTT limits. Chronic full-dose anticoagulation with warfarin is not permitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* 18 years of age or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* For women of childbearing potential and sexually active men, use of an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to enrollment and for the duration of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Prior systemic chemotherapy in the metastatic setting",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Treatment with an investigational or marketed agent that acts by either EGFR inhibition or anti-angiogenesis mechanisms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Pregnancy or lactation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Any other medical condition, including mental illness or substance abuse, deemed by the clinician to be likely to interfere with a subject's ability to provide informed consent, cooperate, and participate in the study, or to interfere with the interpretation of the results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Active infection or a fever within 3 days of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Active malignancy other than lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Radiation therapy to sites other than whole brain within 14 days prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* History of gross hemoptysis within 3 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Known hypersensitivity to any of the components of cytotoxic chemotherapy combinations, bevacizumab, or tyrosine kinase inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Inadequately controlled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Unstable angina or New York Heart Association Grade II or greater CHF",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* History of myocardial infarction within 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* History of stroke within 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Symptomatic peripheral vascular disease within 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Evidence of bleeding diathesis or coagulopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Serious, non-healing wound, ulcer, or bone fracture",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment; anticipation of need for major surgical procedure during the course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Current, recent, or planned participation in an experimental drug study other than this Genentech-sponsored bevacizumab/erlotinib study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* Progressive neurologic symptoms in subjects with a history of brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00257608",
    "statement": "* History of significant vascular disease (e.g., aortic aneurysm)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Patients with advanced, histologically or cytologically confirmed solid tumors, malignant lymphomas, or multiple myeloma refractory to any standard therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Radiographical, hematological or clinically evaluable tumor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Signed informed consent must be obtained prior to any study specific procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* History of cardiac disease: congestive heart failure (CHF) \\> New York Heart Association (NYHA) Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset angina within 3 months or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Uncontrolled hypertension defined as systolic blood pressure \\> 150 mm Hg and/or diastolic blood pressure \\> 90 mmHg, despite optimal medical management",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* History of HIV infection or chronic hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Active clinically serious infections (\\> Grade 2 NCI Common Terminology Criteria for Adverse Events v3.0)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Symptomatic metastatic brain or meningeal tumors unless the patient is \\> 6 months from definitive therapy, has no evidence of tumor growth on an imaging study within 2 weeks prior to study entry and is clinically stable with respect to the tumor at the time of study entry. Patients with brain metastases must not be undergoing acute steroid therapy or steroid taper (chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Substance abuse, medical, psychological or social conditions that may interfere with the patient178s participation in the study or evaluation of the study results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Radiotherapy to the target lesions within 3 weeks prior to Day 1, Cycle 1 (first dose of study drug). (Palliative radiotherapy will be allowed). Radiotherapy to the target lesions during study will be regarded as progressive disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01117623",
    "statement": "* Previous or concurrent cancer which is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors \\[Ta, Tis and T1\\] or any cancer curatively treated \\> 3 years prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* (Part 1 only) Have a histologically or cytologically confirmed diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* (Part 2 only) Cohort 1: Have histologically or cytologically confirmed diagnosis of Stage IV squamous NSCLC and have not received prior chemotherapy or immunotherapy for metastatic disease and are not known to be PD-L1 positive (known high PD-L1 expression defined as Tumor Proportion Score \\[TPS\\] greater than or equal to 50%). Patients with known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) fusion oncogene must have received at least 1 and up to 2 targeted therapies prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* (Part 2 only) Cohort 2: Have histologically or cytologically confirmed diagnosis of nonresectable, recurrent, or metastatic biliary tract carcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma) and have not received prior systemic anticancer therapy for advanced or metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* (Part 2 only) Cohort 3: Have histologically or cytologically confirmed diagnosis of metastatic or locally advanced TCC of the urinary tract (bladder, urethra, ureter, renal pelvis) (T3b-T4 N0 M0, Tany N1-N3 M0, or Tany Nany M1) and are not candidates for surgery.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Have measurable disease per RECIST version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Have an ECOG PS of 0 to 1, with the exception of patients in Part 2 (Cohort 3, unfit bladder cancer patients) who may have an ECOG PS of 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Adequate bone marrow reserve, liver and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Have a negative pregnancy test result at Screening for females of childbearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Male patients must agree to use a condom during treatment and for 90 days after dosing and must agree not to donate sperm for 90 days after dosing",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Women of childbearing potential are willing to agree to use 1 of the study defined effective methods of birth control from the time of study entry to 6 months after the last day of treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Reasonably recovered from preceding major surgery as judged by the investigator or no major surgery within 4 weeks prior to the start of Day 1 treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Have received prior platinum therapy in the past 3 months (Part 1) or 6 months in the adjuvant or neoadjuvant setting (Part 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Have received prior cisplatin and gemcitabine concomitantly within the last 6 months or are refractory to cisplatin and gemcitabine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Have evidence suggesting pulmonary fibrosis or interstitial pneumonia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Have a history of thrombocytopenia with complications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Have known hypersensitivity to platinum compounds or gemcitabine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Have uncontrolled diabetes or have hypertension requiring more than 3 medications for control of hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Have pre-existing alcoholic liver injury or significant liver disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02240238",
    "statement": "* Pregnant or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Participants capable of giving signed informed consent/assent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Male or female, aged 18 years or older at the time consent is obtained. Participants in Korea must be age 19 years or older at the time consent is obtained.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Participants with histologically or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  a) Documented disease progression based on radiographic imaging, during or after a maximum of 2 lines of systemic treatment for locally/regionally advanced recurrent, Stage IIIb/Stage IIIc/Stage IV or metastatic disease. Two components of treatment must have been received in the same line or as separate lines of therapy: i) No more than or less than 1 line of platinum-containing chemotherapy regimen, and ii) No more than or less than 1 line of Programmed cell death ligand 1 (PD\\[L\\]1) monoclonal antibody (mAb) containing regimen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  b) Participants with known BRAF molecular alterations must have had disease progression after receiving the locally available SoC treatment for the molecular alteration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  c) Participants who received prior anti-PD(L)1 therapy must fulfill the following requirements: i) Have achieved a CR, PR or SD and subsequently had disease progression (per RECIST 1.1 criteria) either on or after completing PD(L)1 therapy ii) Have not progressed or recurred within the first 12 weeks of PD(L)1 therapy, either clinically or per RECIST 1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Measurable disease, presenting with at least 1 measurable lesion per RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* A tumor tissue sample obtained at any time from the initial diagnosis of NSCLC to time of study entry is mandatory. Although a fresh tumor tissue sample obtained during screening is preferred, archival tumor specimen is acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Adequate organ function as defined in the protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* A male participant must agree to use a highly effective contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions apply:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  i) Not a woman of childbearing potential (WOCBP) or ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Life expectancy of at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Participants who received prior treatment with the following therapies (calculation is based on date of last therapy to date of first dose of study treatment):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  1. Docetaxel at any time.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  2. Any of the investigational agents being tested in the current study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  3. Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  4. Prior radiation therapy: permissible if at least one non-irradiated measurable lesion is available for assessment per RECIST version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least 2 weeks before start of study drug for radiation of any intended use is required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Received greater than (\\>)2 prior lines of therapy for NSCLC, including participants with BRAF molecular alternations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Invasive malignancy or history of invasive malignancy other than disease under study within the last 2 years, except",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Any other invasive malignancy for which the participant was definitively treated, has been disease-free for at least 2 years and in the opinion of the principal investigator and GlaxoSmithKline Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Curatively treated non-melanoma skin cancer or successfully treated in situ carcinoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Carcinomatous meningitis (regardless of clinical status) and uncontrolled or symptomatic Central nervous system (CNS) metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Major surgery less than or equal to (\\<=) 28 days of first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Autoimmune disease (current or history) or syndrome that required systemic treatment within the past 2 years. Replacement therapies which include physiological doses of corticosteroids for treatment of endocrinopathies (for example, adrenal insufficiency) are not considered systemic treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Receiving systemic steroids (\\>10 milligrams \\[mg\\]) oral prednisone or equivalent) or other immunosuppressive agents within 7 days prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Prior allogeneic/autologous bone marrow or solid organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Receipt of any live vaccine within 30 days prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Toxicity from previous anticancer treatment that includes:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  1. Greater than or equal to (\\>=) Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  2. History of myocarditis of any grade during a previous treatment with immunotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  3. Toxicity related to prior treatment that has not resolved to \\<= Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \\<= Grade 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* History (current and past) of idiopathic pulmonary fibrosis, pneumonitis (for past- pneumonitis exclusion only if steroids were required for treatment), interstitial lung disease, or organizing pneumonia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* History or evidence of cardiac abnormalities within the 6 months prior to enrollment which include",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  1. Serious, uncontrolled cardiac arrhythmia or clinically significant electrocardiogram abnormalities including second degree (Type II) or third degree atrioventricular block.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  2. Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting or bypass grafting.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "  3. Symptomatic pericarditis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypo-albuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Active infection requiring systemic therapy \\<=7 days prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Participants with known human immunodeficiency virus infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Participants with history of severe hypersensitivity to mAb or hypersensitivity to any of the study treatment(s) or their excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Participants requiring ongoing therapy with a medication that is a strong inhibitor or inducer of the cytochrome P 3A4 (CYP3A4) enzymes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Pregnant or lactating female participants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Participant who is currently participating in or has participated in a study of an investigational device within 4 weeks prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Participants with presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Participants with positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Participants with positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03739710",
    "statement": "* Receipt of transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony stimulating factor \\[G-CSF\\], granulocyte-macrophage colony-stimulating factor, and recombinant erythropoietin) within 14 days before the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01260181",
    "statement": "* Locally advanced or metastatic NSCLC with EGFR mutations",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01260181",
    "statement": "* Measurable disease according to RECIST criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01260181",
    "statement": "* Adequate hematological, renal and liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01260181",
    "statement": "* Previous chemotherapy or therapy against EGFR for metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01260181",
    "statement": "* Symptomatic cerebral metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01260181",
    "statement": "* Pre-existing disease of the lung parenchyma such as lung fibrosis, lymphangitic carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01260181",
    "statement": "* History of another malignancy except for carcinoma in-situ of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01260181",
    "statement": "* Concomitant use of coumarins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01750281",
    "statement": "* Provision of signed, written and dated informed consent prior to any study specific procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01750281",
    "statement": "* Male or female, aged 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01750281",
    "statement": "* Histological or cytological confirmation of locally advanced or metastatic NSCLC (IIIB-IV)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01750281",
    "statement": "* Prospective confirmation of KRAS mutation negative status as determined via an AZ approved laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01750281",
    "statement": "* Failure of 1st line anti-cancer therapy due to radiological documentation of disease progression in advanced disease or subsequent relapse of disease following 1st line therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01750281",
    "statement": "* Mixed small cell and non-small cell lung cancer histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01750281",
    "statement": "* Received \\>1 prior anti-cancer drug regimen for advanced or metastatic NSCLC. Patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01750281",
    "statement": "* Other concomitant anti-cancer therapy agents except steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01750281",
    "statement": "* Prior treatment with a MEK (Mitogen-Activated Protein Kinase) inhibitor or any docetaxel-containing regimen (prior treatment with paclitaxel is acceptable)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01750281",
    "statement": "* The last radiation therapy within 4 weeks prior to starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": ". Age ≥18 years old with advanced or metastatic stage solid tumors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "2. Eastern Cooperative Oncology Group (ECOG) status ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "3. Have disease either evaluable (dose-escalation cohort) or measurable (dose-escalation and -expansion cohorts) per RECIST V1.1, except for prostate cancer participants",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "4. Agree to provide archival tumor tissue",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "5. Additional inclusion criteria for dose expansion cohorts:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "* Participants with homologous recombination deficiency (HRD+) or known BRCA mutant ovarian cancer Previously received at least one line of platinum-containing therapy in the advanced or metastatic setting and No progression or recurrent disease within 6 months from last platinum-containing regimen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "* Participants with HRD+ or known BRCA mutant triple-negative breast cancer Up to one prior platinum-containing treatment in any treatment setting and up to 3 prior lines of therapy in the advanced or metastatic setting",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "* Participants with HRD+ or known BRCA mutant prostate cancer Chemotherapy-naïve or previously received up to two taxane-based chemotherapy regimens, with documented prostate cancer progression",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "* Participants with small cell lung cancer and gastric cancer, previously received ≤ 2 prior lines of therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "* Other HRD+ solid tumors of multiple indications",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": ". Prior treatment with a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "2. Refractory to platinum-based therapy (dose-expansion cohort).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150810",
    "statement": "NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": ". Written informed consent obtained before undergoing any study-related activities.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "2. Male or female, at least 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "3. Histologically confirmed NSCLC, Stage IIIb with documented malignant pleural effusion or Stage IV (according to staging system 6th edition)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "4. EGFR expression greater than or equal to (\\>=) 200 on tumor tissue determined by local testing using the kit and testing procedures described in the study Manual of Operations (MOP)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "5. Archived tumor material sample for central histology and further biomarker research including mutational analysis of genes such as EGFR, k-ras, b-raf (material details described in the study MOP)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "6. At least 1 radiographically documented measurable lesion in a previously non-irradiated area according to evaluation criteria in solid tumors (RECIST), i.e. this lesion must be adequately measurable in at least 1 dimension (longest diameter \\[LD\\] to be recorded) as \\>=2 centimeter (cm) by conventional techniques or ≥1 cm by spiral CT scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "7. Eastern Cooperative Oncology Group (ECOG)-performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "8. Leukocyte count \\>=3.0 x 10\\^9 per liter (/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "9. Absolute neutrophil count (ANC) \\>=1.5 x 10\\^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "10. Platelets \\>=100 x 10\\^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "11. Hemoglobin \\>=9 gram per deciliter (g/dL) (without transfusions)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "12. Bilirubin less than or equal to (\\<=) 1.5 x upper limit of normality (ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "13. Aspartate Aminotransferase (AST) \\<=5 x ULN and Alanine Aminotransferase (ALT) \\<=5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "14. Serum creatinine \\<=1.25 x ULN and/or creatinine clearance \\>=60 milliliter per minute (mL/min)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "15. Prothrombin time (PT), international normalized ratio (INR) within normal limits and partial thromboplastin time (PTT) below upper limit of normal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "16. Sodium and potassium within normal limits or \\<=10% above or below (supplementation permitted).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "17. Effective contraception for both male and female subjects (if the risk of conception exists). If female, she must: be neither pregnant nor breast-feeding, nor attempting to conceive, use a highly effective method of contraception for at least 7 days before entry into the trial, throughout the entire duration of the trial and for 6 months following completion of the last dose of trial medication. A highly effective method of contraception is defined as those which result in a low failure rate (that is, \\<1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, intrauterine devices (IUDs) (hormonal or copper-based), sexual abstinence or vasectomized partner, or be post-menopausal or surgically sterilized. If male, he must be willing to use contraception to avoid pregnancies for at least 7 days before entry into the trial, throughout the entire duration of the trial and for 6 months following the last dose of trial medication. Two negative semen analyses post-vasectomy have to be available in order to be considered infertile",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": ". Prior treatment with an antibody or molecule targeting EGFR- and/or vascular endothelial growth factor receptor (VEGFR)-related signaling pathways",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "2. Previous chemotherapy for NSCLC including prior adjuvant therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "3. History of or current brain metastasis and/or leptomeningeal disease (known or suspected)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "4. Radiotherapy (except localized radiotherapy for pain relief), major surgery or any intake of investigational drug in the 30 days before the start of study treatment entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "5. Concurrent chronic immunosuppressive or hormone anti-cancer therapy (physiologic hormone replacement or corticosteroid treatment for chronic obstructive pulmonary disease \\[COPD\\] is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "6. Clinically relevant coronary artery disease (New York Heart Association \\[NYHA\\] functional angina classification III/IV), congestive heart failure (NYHA III/IV), clinically relevant cardiomyopathy, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "7. History of coagulation disorder associated with bleeding, recurrent or recent thrombotic events or history of hemoptysis related to bronchopulmonary cancer. Hemoptysis is defined as coughing more than a teaspoon of red blood per day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "8. Recent peptic ulcer disease (endoscopically proven gastric, duodenal or esophageal ulcer) within 6 months of study treatment start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "9. Presence of any contra-indication to treatment with cilengitide, cetuximab, cisplatin and vinorelbine or gemcitabine including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "* Known hypersensitivity to cilengitide, cetuximab, cisplatin, vinorelbine, or gemcitabine or to any of the excipients of these drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "* Superior vena cava syndrome contra-indicating hydration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "* Symptomatic peripheral neuropathy National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade \\>=2 and/or ototoxicity NCI CTC AE Grade \\>=2, except if due to trauma or mechanical impairment due to tumor mass",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "* Phenytoin (introduced to prevent the anticonvulsant effect of certain anticancer drugs) (contra-indication for cisplatin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "* Yellow Fever Vaccine, Live Attenuated Vaccines (contra-indications for cisplatin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "10. Pregnancy or lactation period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "11. Concurrent treatment with a non-permitted drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "12. Treatment with any other investigational product within the past 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "13. Previous malignancy other than NSCLC in the last 5 years except for basal cell cancer of the skin or pre-invasive cancer of the cervix",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "14. Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "15. Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "16. Patients with hepatitis, massive liver metastases (\\>75%), current alcoholism or liver cirrhosis (because of vinorelbine and gemcitabine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "17. Patients who have been therapeutically anticoagulated",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "18. Legal incapacity or limited legal capacity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00842712",
    "statement": "19. Significant disease (for example, interstitial lung disease) which, in the investigator's opinion, would exclude the subject from the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01327612",
    "statement": "* To be enrolled in this study, subjects must be currently enrolled in a prior Amgen-sponsored conatumumab or AMG 479 study and are eligible according to the parent study to receive their next dose of conatumumab (with or without co-therapy), or AMG 479 alone.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01327612",
    "statement": "Subjects must have their eligibility assessed for this study and be enrolled within 30 days of their last treatment on the parent protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01327612",
    "statement": "* Discontinued from a conatumumab study due to an adverse event considered by the investigator to be related to conatumumab treatment, including intolerance to conatumumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01327612",
    "statement": "* Subjects determined to have disease progression during their participation in the parent Amgen study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01327612",
    "statement": "* Woman or man with partner of childbearing potential not consenting to use adequate contraceptive precautions ie, double barrier contraceptive methods (eg, diaphragm plus condom), or abstinence during the course of the study and for 6 months after the last dose of protocol-specified therapy administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01327612",
    "statement": "* Subject is pregnant or breast feeding, or planning to become pregnant within 6 months after the last dose of protocol-specified therapy administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01327612",
    "statement": "* Male subject with a pregnant partner who is not willing to use a condom during treatment and for an additional 6 months after the last dose of protocol-specified therapy administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01327612",
    "statement": "* Subject has previously entered this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01327612",
    "statement": "* Subject will not be available for protocol required study visits, to the best of the subject and investigator's knowledge",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01327612",
    "statement": "* Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780010",
    "statement": "* Stage 4 Non-Squamous Cell Lung Cancer that has not been treated previously with systemic chemotherapy or bevacizumab, but may have received prior targeted treatment (e.g., alk1 inhibitor)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780010",
    "statement": "* ECOG performance status ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780010",
    "statement": "* Measurable disease by RECIST",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780010",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780010",
    "statement": "* Non-small cell lung cancer of squamous histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780010",
    "statement": "* Current treatment on another therapeutic clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780010",
    "statement": "* Patients who have received wide field radiotherapy ≤ 28 days (defined as \\> 50% of volume of pelvic bones or equivalent) or limited field radiation for palliation \\< 14 days prior to study registration or those patients who have not recovered adequately from side effects of such therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03780010",
    "statement": "* Active bleeding or pathologic condition that carries a high risk of bleeding (e.g. hereditary hemorrhagic telangiectasia). Patients who have been uneventfully anti-coagulated with low molecular weight heparin are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": ". Age greater than or equal to 18 years;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "2. Participants with histologically or cytologically confirmed non-squamous NSCLC with locally advanced or metastatic disease based on Tumor, Node, Metastasis (TNM) staging according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, Seventh Edition, who had failed at least two lines of systemic anticancer therapy for advanced or metastatic NSCLC (did not include adjuvant chemotherapy). In countries where erlotinib was approved and marketed for the treatment of NSCLC, participants must have received erlotinib treatment (or gefitinib for participants outside of the US) for their NSCLC if they had known EGFR-activating mutations. Participants of unknown EGFR status who had not received prior erlotinib (or gefitinib) should have been tested for EGFR-activating mutations prior to study entry. In countries where crizotinib was approved and marketed, participants must have received crizotinib treatment for NSCLC that was ALK-positive. Participants with ALK positive NCSLC or participants with KRAS mutations were not required to have prior treatment with erlotinib or gefitinib",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "3. Participants must have at least 1 site of measurable disease by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "4. ECOG PS of 0 to 2;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "5. Participants must have adequate renal function as evidenced by serum creatinine less than or equal to 1.5 x upper limit of normal (ULN) or calculated creatinine clearance greater than or equal to 30 mL/min per the Cockcroft and Gault formula;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "6. Blood pressure must be well-controlled (less than or equal to140/90 mm Hg at Screening) with or without antihypertensive medication. Participants must have no history of hypertensive crisis or hypertensive encephalopathy;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "7. Participants must have adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L, hemoglobin greater than or equal to 9.0 g/dL, and platelet count greater than or equal to 100 x 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "8. Participants must have adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the ULN, and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 x ULN (in the case of liver metastases, less than or equal to 5 x ULN).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "9. Participants must have adequate coagulation system function as defined by prothrombin time/International normalized ratio (INR) less than or equal to 1.5 x ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "10. Male or female participants of child-producing potential must agree to use double barrier contraception, oral contraceptives, or avoidance of pregnancy measures during the study and for 90 days after the last day of treatment;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "11. Females of childbearing potential must have a negative serum pregnancy test;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "12. Females may not be breastfeeding;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "13. Ability to understand and willingness to sign a written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": ". Prior therapy with E7080 or other small molecule vascular endothelial growth factor inhibitors;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "2. Presence of brain metastases, unless the participant has received adequate treatment at least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids for at least 4 weeks prior to randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "3. Meningeal carcinomatosis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "4. Received chemotherapy, targeted therapy, radiotherapy, surgery, or immunotherapy within the 21 days prior to commencing study treatment or have not recovered from all treatment-related toxicities to Grade less than or equal to 2, except for alopecia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "5. Received treatment with another investigational agent within the 30 days prior to commencing study treatment or participants who have not recovered from side effects of an investigational drug to Grade less than or equal to 2, except for alopecia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "6. Participants with proteinuria greater than 1+ on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with 24-hour urine protein greater than or equal to 1 g/24 hours will be ineligible;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "7. Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury within the 28 days prior to commencing study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "8. Major surgery scheduled during the projected course of the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "9. History of bleeding diathesis or coagulopathy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "10. Active hemoptysis (defined as bright red blood of a half teaspoon or more) within the 30 days prior to study entry;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "11. Refractory nausea and vomiting, malabsorption, significant bowel resection, or any other medical condition that would preclude adequate absorption or result in the inability to take oral medication;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "12. Other malignancy within 3 years of randomization, with the exception of adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer, with no subsequent evidence of recurrence and/or malignancies diagnosed at a stage where definitive therapy results in near certain cures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "13. Significant cardiovascular impairment (history of congestive heart failure New York Heart Association \\[NYHA\\] Class greater than II, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "14. Any history of cerebral vascular accident (CVA), transient ischemic attack (TIA), or Grade greater than or equal to 2 peripheral vascular disease unless they have had no evidence of active disease for at least 6 months prior to randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "15. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the 6 months prior to enrollment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "16. Participants with organ allografts requiring immunosuppression;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "17. Known positive human immunodeficiency virus (HIV), known hepatitis B surface antigen, or hepatitis C positive;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "18. Hypersensitivity to E7080 or any of the excipients;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01529112",
    "statement": "19. Any history of or concomitant medical condition that, in the opinion of the Investigator, would compromise the participant's ability to safely complete the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Epidermal Growth Factor Receptor mutation detected by central laboratory analysis of tumour biopsy material.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Measurable disease according to RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Eastern Cooperative Oncology Group score of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Age \\>/= 18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Life expectancy of at least three months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Written informed consent that is consistent with International Conference on Harmonisation-Good Clinical Practice guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Prior chemotherapy for relapsed and/or metastatic NSCLC. Neoadjuvant/adjuvant chemotherapy is permitted if at least 12 months has elapsed between the end of chemotherapy and randomisation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Prior treatment with Epidermal Growth Factor Receptor targeting small molecules or antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Radiotherapy or surgery (other than biopsy) within 4 weeks prior to randomisation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Active brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Any other current malignancy or malignancy diagnosed within the past five years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Known pre-existing interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* History or presence of clinically relevant cardiovascular abnormalities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Any other concomitant serious illness or organ system dysfunction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Adequate absolute neutrophil count and platelet count",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Adequate liver and kidney function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949650",
    "statement": "* Active hepatitis B infection, active hepatitis C infection or known HIV carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Histologically confirmed non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* At least one prior platinum-based doublet anti-cancer treatment for recurrent or advanced NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Disease progression during or after the last anti-cancer therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Serum creatinine less than or equal to 2.0 mg/dL or creatinine clearance 40 mL/min according to Cockcroft and Gault formula:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Absolute neutrophil count greater than or equal to 1.5 x 10\\^9/L, hemoglobin greater than or equal to 10 g/dL (can be corrected by growth factor or transfusion), and platelet count greater than or equal to 100 x 10\\^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Total bilirubin less than or equal to 1.5 times the upper limit of normal (ULN) and alkaline phosphatase (AP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 times ULN (in the case of liver metastases less than or equal to 5 times ULN). In case AP is greater than 3 times ULN (in absence of liver metastases) or greater than 5 times ULN (in presence of liver metastases) AND subject also is known to have bone metastases, the liver specific AP must be separated from the total and used to assess the liver function instead of the total AP.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* At least one lesion of greater than or equal to 1.5 cm in longest diameter for non-lymph nodes or greater than or equal to 1.5 cm in shortest diameter for lymph nodes which is serially measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.17",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Males and females, age greater than or equal to 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Provide written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Are willing and able to comply with all aspects of the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Females of childbearing potential must have a negative serum beta-human chorionic gonadotropin (Beta-hCG) at Visit 1 (Screening) and a negative urine pregnancy test prior to starting study drug (Visit 2). Female subjects of childbearing potential must agree to be abstinent or to use highly effective methods of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, intrauterine device (IUD), or have a vasectomised partner) having starting for at least one menstrual cycle prior to starting study drugs and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those women using hormonal contraceptives must also be using an additional approved method of contraception (as described previously). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Male subjects who are not abstinent or have not undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use a highly effective method of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, IUD) starting for at least one menstrual cycle prior to starting study drugs and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Prior therapy with eribulin or an tyrosine kinase inhibitor of the epidermal growth factor receptor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Subjects with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued steroids for this indication for greater than or equal to 4 weeks before starting study treatment. Symptoms attributed to brain metastases must be stable for greater than or equal to 4 weeks before starting study treatment; radiographic stability should be determined by comparing contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) brain scan performed during screening to a prior scan performed 4 weeks earlier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Existing anti-cancer therapy-related toxicities of grade greater than or equal to 2, other than any grade of alopecia or grade less than or equal to 2 neuropathy, which are acceptable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Current smokers who will not stop smoking one week prior to treatment and during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* History of congestive heart failure with New York Heart Association (NYHA) Grade greater than II, unstable angina, myocardial infarction within the past 6 months, serious cardiac arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Electrocardiogram with QTc interval greater than or equal to 500 msec based upon Bazett's formula (QTcB)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Females who are pregnant (positive Beta-hCG test) or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Subject with hypersensitivity to eribulin and /or erlotinib or any of the excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Presence of a progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Subjects who are known to be human immunodeficiency virus (HIV) positive, because the neutropenia caused by the study treatments may make such subjects particularly susceptible to infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Subjects with active viral hepatitis (A, B, or C) as demonstrated by positive serology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Radiotherapy, chemotherapy, biological therapy or investigational agents within 2 weeks prior to start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Meningeal carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* History of drug or alcohol dependency or abuse within approximately the last 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Medically unfit to receive the study drug or unsuitable for any other reason according to investigator judgment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Any history of or concomitant medical condition that, in the opinion of the Investigator, would compromise the subject's ability to safely complete the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01104155",
    "statement": "* Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098550",
    "statement": "-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098550",
    "statement": "* Patients with metastatic or advanced solid tumors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098550",
    "statement": "* Women with histologically or cytologically confirmed triple negative breast carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098550",
    "statement": "* Participants with histologically or cytologically confirmed pancreatic adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098550",
    "statement": "* Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098550",
    "statement": "* Active brain metastases or leptomeningeal metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098550",
    "statement": "* Any serious or uncontrolled medical disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098550",
    "statement": "* Prior malignancy active within the previous 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03098550",
    "statement": "Other protocol defined inclusion/exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* Phase 1: Histologically or cytologically confirmed advanced or metastatic solid malignancies that are known to express EGFR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* Phase 1: Previously treated with ≥ 1 lines of anticancer therapy and have documented disease progression during or after their most recent line of anticancer therapy. In addition, either there is no further SOC therapy for the patient or the remaining SOC therapies are deemed not appropriate for the patient by the Investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* Phase 1: Patients must have at least one tumor site that is accessible to biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* Phase 2a: Measurable disease per RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* Phase 2a: Histologically confirmed advanced or metastatic EGFR+ malignancies for each expansion cohorts:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* Colorectal Cancer (MSS), KRAS-wildtype: disease has progressed after ≥ 2 prior lines of therapy which must have included oxaliplatin, fluoropyrimidine, bevacizumab, and an anti-EGFR therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* ccRCC: disease has progressed after ≥ 2 prior lines of therapy which must have included a TKI and a checkpoint inhibitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* metastatic NSCLC, EGFRmut: disease has progressed on/after after ≥ 1 prior lines of therapy for advanced disease including ≥ 1 prior TKI approved for EGFR mut NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* Treatment with systemic anticancer therapy within 4 weeks of the first dose of study drug (6 weeks if therapy was mitomycin C and/or nitrosoureas), or within 5 half-lives of the agent if half-life is known and it is shorter, before first dose of study drug. Anticancer therapies include cytotoxic chemotherapy, targeted inhibitors, and immunotherapies, but do not include hormonal therapy or radiotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* Radiation therapy within 2 weeks before 1st dose of study drug or unresolved toxicity from previous radiotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* History of any other malignancy known to be active, with the exception of completely removed in situ cervical intra-epithelial neoplasia, non-melanoma skin cancer, DCIS, early stage prostate cancer that has been adequately treated, and other cancers from which the patient has been disease free for 3 years or longer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04259450",
    "statement": "* Currently participating in a study and receiving study therapy, or participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Written informed consent has been obtained prior to surgical tumour resection and prior to the performance of any other protocol-specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* At least 18 years of age at the time of resection.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Pathologically proven, surgically staged squamous or non-squamous IB, IIA or IIB NSCLC, and complete surgical resection.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* The operative technique for resection of the patient's tumour involves at least a lobectomy or a sleeve lobectomy, conforming to all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "  1. Removal of all gross disease with negative resection margins, by lobectomy, sleeve resection, bilobectomy or pneumonectomy, based on intra-operative findings.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "  2. The level of nodal sampling is at least as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "Levels 4, 7, 10 in both right upper and right middle lobes Levels 4, 7, 9, 10 in right lower lobe Levels 5, 6, 7 in left upper lobe Levels 7, 9, 10 in left lower lobe. or at the maximum defined as systematic radical mediastinal lymphadenectomy: all ipsilateral and easily accessible lymph-node levels must be removed, independently of the location of the primary tumour. The level of nodal sampling is as follows: Levels 2, 4, 7, 8, 9, 10 in right-sided tumours, Levels 5, 6, 7, 8, 9, 10 in left-sided tumours",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Tumour shows expression of MAGE-3 antigen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Recovered from surgery for at least 4 weeks and not more than 6 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* ECOG performance status of ≤ 1 at the time of randomisation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Laboratory criteria (all of the following must be fulfilled): adequate bone marrow reserve, adequate renal function, adequate hepatic function, serum bilirubin within normal range, negative HIV antibody test, negative HBV antigen test, negative HCV antibody test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* (For females): EITHER not of child-bearing potential OR sexually abstinent OR all of the following: negative urine/serum β-HCG pregnancy test, use of adequate contraceptive precautions for 30 days before first vaccination. Agree to continue such precautions for 2 months after completion of the course of vaccination.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Received any anti-cancer specific treatment including radiotherapy, prior to surgery, unless the treatment was for previous malignancies allowed by the protocol, i.e., basal and localised squamous-cell skin carcinoma that has been successfully treated, or carcinoma in situ of the cervix (see exclusion criterion no. 10).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Candidate for post-surgery radiation therapy or any kind of anti-cancer-specific treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Pregnant/lactating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* (For female patients of child-bearing potential): not agree to practice an effective method of contraception.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Uncontrolled bleeding disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* History of anaphylaxis or severe allergic reaction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Undergone splenectomy or radiation to the spleen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Received a major organ allograft.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Malignancies at other sites (except (i) basal and localised squamous-cell skin carcinoma that has been successfully treated, and (ii) carcinoma in situ of the cervix).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Uncontrolled congestive heart failure or hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Unstable heart disease or uncontrolled arrhythmia at the time of enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Psychiatric or addictive disorders that may compromise ability to give informed consent, or to comply with the trial procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Any evidence of residual tumour after surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Require concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Received chemotherapy, immunotherapy related to NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Need home oxygenation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00290355",
    "statement": "* Received any investigational or non-registered drug or vaccine other than the study vaccine within the 30 days preceding the first dose of study vaccine, or plans to receive such a drug during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Participants must have histological or cytological confirmed diagnosis of the following tumor types that is advanced and/or metastatic cancer and must be, in the judgment of the investigator, an appropriate participant for experimental therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Part A: Any type of solid tumor (\"all comer\")",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Part B1: Gastric or Gastroesophageal Junction (GEJ) adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Part B2: Hepatocellular cancer (excluding fibrolamellar carcinoma)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Part B3: Renal cell carcinoma (any histology)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Part B4: Non-small cell lung cancer (squamous or non-squamous)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have at least 1 measurable lesion outside of the central nervous system (CNS) whose presence is assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Availability of a tumor sample taken after progression on the most recent line of systemic tumor therapy or willing to undergo a tumor biopsy pre-study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have a performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale in Part A and ≤ 1 on the ECOG scale in Part B.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Routine urinalysis showing ≤1+ protein or protein/creatinine ratio \\<0.5. For proteinuria ≥2+ or urine protein/creatinine ratio ≥0.5, 24-hour urine must be collected and the level must be \\<1 gram of protein in 24 hours for subject enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have discontinued all previous cancer therapies and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 halflives prior to study enrollment, whichever is shorter, and recovered from the acute effects for therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have an estimated life expectancy, in the judgment of the investigator, that will permit the participant to complete 8 weeks (2 cycles) of treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for at least 3 months following the last dose of study drug. Females with childbearing potential must have had a negative serum pregnancy test 7 days before the first dose of study drug and must not be breast-feeding.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have serious pre-existing medical conditions (at the discretion of the investigator, such as severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have a history of hypertensive crisis or hypertensive encephalopathy or current poorly controlled hypertension despite standard medical management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Participant has experienced any arterial thromboembolic event (ATE), including myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack, within 6 months prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolic event during the 3 months prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Are receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents. Participants receiving prophylactic, low-dose anticoagulation therapy are eligible provided that they are on low-molecular weight heparin or oral factor Xa inhibitors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* The participant is receiving chronic therapy with nonsteroidal anti-inflammatory drugs or other antiplatelet agents. Aspirin use at doses up to 325 mg/day is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have a history of GI perforation and/or fistulae within 6 months prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have congestive heart failure (CHF) New York Heart Association class ≥3 or symptomatic or poorly controlled cardiac arrhythmia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have undergone major surgery within 28 days prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to receiving study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have a known active fungal, bacterial, and/or known viral infection. Hepatocellular cancer participants with chronic viral (B or C) hepatitis are eligible if they retain adequate liver function.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have liver cirrhosis with a Child-Pugh Stage of B or C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have symptomatic CNS malignancy (with the exception of medulloblastoma) or metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have corrected QT (QTc) interval of \\>470 milliseconds on screening electrocardiogram (ECG).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have received previous treatment with ramucirumab or Emibetuzumab, except for participants enrolled in cohort B1 (Gastric or GEJ adenocarcinoma) and B4 (non- small cell lung cancer) who may have received previous ramucirumab treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Known hypersensitivity to any of the treatment components of ramucirumab or Emibetuzumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* For Part B4 (non-small cell lung cancer) only:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* Participants with a history of gross hemoptysis within 2 months prior to study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02082210",
    "statement": "* The participant has radiographic evidence of intratumor cavitation, regardless of tumor histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Has completed the Day 85 Visit in the original trial (Study HT-ANAM-301 or HT-ANAM-302) and is considered appropriate to continue to receive additional study drug; must start dosing on the extension study within 5 days of completing dosing on the original trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* ECOG performance status ≤2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Life expectancy of \\>4 months at time of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* If woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for 30 days following the last dose of study drug (an effective form of contraception is abstinence, a hormonal contraceptive, or a double-barrier method)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Must be willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Women who are pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Had major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to enrollment into the extension study; patients must be well recovered from acute effects of surgery prior to screening; patients should not have plans to undergo major surgical procedures during the treatment period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Currently taking prescription medications intended to increase appetite or treat weight loss; these include, but are not limited to, testosterone, androgenic compounds, megestrol acetate, methylphenidate, and dronabinol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Inability to readily swallow oral tablets; patients with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption, or obstructive symptoms) or intractable or frequent vomiting are excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Has an active, uncontrolled infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Has known or symptomatic brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Receiving strong CYP3A4 inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Receiving tube feedings or parenteral nutrition (either total or partial); patients must have discontinued these treatments for at least 6 weeks prior to Day 1, and throughout the study duration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Other clinical diagnosis, ongoing or intercurrent illness that in the Investigator's opinion would prevent the patient's participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01395914",
    "statement": "* Patients actively receiving a concurrent investigational agent, other than Anamorelin HCl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Is willing and able to understand and provide signed informed consent for the study that fulfills IRB guidelines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Male or female patients \\>18 years of age on the day of signing informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Histologically or cytologically-confirmed advanced or metastatic solid tumors who have disease progression after treatment with available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment in the context of the particular line of treatment or, specifically for AML, demonstrate as their best response after 4 cycles of HMA therapy the status of \"partial response\" per European LeukemiaNet (ELN) criteria and meet the additional specified requirements for the cohort of the study they will enroll into.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* All patients in the solid tumor arms will be tested for WT1 expression via IHC in their initial primary tumor OR recent biopsy of metastatic disease at the time of screening for study entry. Specifically for AML, patients will be tested for WT1 expression via IHC in their leukemic blasts either in the BM or PB. Assessment of WT1 expression positivity will be performed via central review prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Patients may have received a specific maximum allowable number of prior lines of therapy for metastatic disease, as follows: CRC: 2 or 3 lines; OvC: 1 or 2 lines; SCLC: 1 line; TNBC: 1 line; and AML: 1 line (allo-SCT-eligible status not allowed)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* For solid tumor arms: patients must measurable disease based on RECIST v1.1 as determined by the local study team.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* For AML arm, eligibility is defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "  1. Prior frontline (1st line) with HMAs since initial AML diagnosis;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "  2. Prior cytoreductive therapy with hydroxyurea or leukapheresis at the time of initial diagnosis, with subsequent immediate seamless transitioning to HMA therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "  3. History of induction early failure after initial therapy with up to 2 cycles of standard chemotherapy (\"7+3\" or similar regimen), with subsequent immediate seamless transitioning to HMA therapy as long as patients have achieved PR as their best observable response after 4 cycles of HMA therapy; HMA therapy continues throughout the trial period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Resolution of toxicity effect(s) from most recent prior chemotherapy to Grade 1 or less (except alopecia). If the patient received major surgery or radiation therapy of \\> 30 Gy, they must have recovered from the toxicity and/or complications from the intervention.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* For women of child-bearing potential, agreement to use adequate birth control (abstinence, hysterectomy, bilateral oophorectomy, bilateral tubal ligation, oral contraception, IUD, or use of condoms or diaphragms)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Male patients of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 4 months following the last study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Have adequate organ function as defined:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Absolute neutrophil count (ANC) ≥1500/µL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Platelets ≥100,000/µL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Hemoglobin (Hb) ≥9.0 g/dL or ≥5.6 mmol/L (N.B.: Hb criterion must be met without erythropoietin dependency and without packed red blood cell transfusion within last 2 weeks)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Creatinine ≤1.5 × upper limit of normal (ULN) OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≥30 mL/min for subjects with creatinine levels \\>1.5 × institutional ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for subjects with total bilirubin levels \\>1.5 × ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* AST (SGOT) and ALT (SGPT) ≤2.5 × ULN OR ≤5 × ULN for subjects with liver metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* International normalized ratio (INR) OR prothrombin time (PT) and Activated partial thromboplastin time (aPTT) ≤1.5 × ULN, unless subjects are receiving anticoagulant therapy as long as PT or aPTT is within the therapeutic range of intended use of anticoagulants",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "(i).Colorectal Cancer (third/fourth line)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Histologically or cytologically documented adenocarcinoma of colon or rectum at the time of initial presentation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Metastatic CRC with documented disease progression (per standard criteria) after the last administration of standard therapies or intolerance to standard therapies (and approved therapies must have included all the following a fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and, if KRAS wild-type, cetuximab or panitumumab). Prior use of and failure after regorafenib or trifluridine/tipiracil is allowed but not mandated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "(ii). OvC (second/third line)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Histologically diagnosed ovarian, fallopian tube or primary peritoneal cancer at the time of initial presentation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Patients will have either relapsed or be disease resistant to their prior therapy. Interval surgery is permitted, but patients must have objective evidence of disease on computed tomography (CT)or magnetic resonance imaging (MRI), with concomitant CA-125 increase and/or biopsy showing OvC (only for recurrent disease).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Patients should have received platinum-containing chemotherapy and been designated as harboring platinum-refractory or -resistant disease. Additionally, all eligible subjects should have either received (or been offered) bevacizumab therapy, and those with BRCA germline mutations (gBRCA mut) should have been offered therapy with poly-ADP ribose polymerase (PARP) inhibitors (olaparib, rucaparib or niraparib).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "(iii). SCLC (second line)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Histologically or cytologically confirmed SCLC based on biopsy of the tumor at initial presentation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Asymptomatic or treated brain metastases are allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Patients must have measurable disease (by CT or MRI) after they progressed or were resistant to 1 prior systemic therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "(iv). TNBC (second line)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Histologically proven metastatic breast carcinoma with triple negative receptor status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* TNBC status is defined as estrogen and progesterone receptor negative by IHC, and human epidermal growth factor receptor 2 \\[HER2\\] negative by IHC AND HER2 gene non-amplified by fluorescence in situ hybridization \\[FISH\\], per standard criteria. Patients who are weakly positive for the estrogen or progesterone receptor (i.e., \\< 5%) are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Patients must have measurable disease(by CT or MRI) after they progressed or were resistant to 1 prior systemic therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Patients have undergone second-line therapy after residual or recurrent disease after first-line therapy. The latter may have included:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "  1. Neoadjuvant therapy if macroscopic disease was still present after surgery OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "  2. Adjuvant therapy, but only if the macroscopic relapse occurred \\> 6 months from the start of study treatment with pembrolizumab.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "  (v). AML",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Pathologically or morphologically confirmed de novo or secondary AML at the time of initial diagnosis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Achievement of no better than morphologic PR, as defined initially by the AML Working Group criteria (Cheson et al,2003), and also quoted in the more recent ELN criteria (Döhner et al, 2010),while on active treatment with HMAs.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* AML patients are eligible only if they received first-line therapy with HMAs (decitabine or azacytidine) for 4 cycles and achieved only PR at the end of cycle 4.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* AML patients must remain on HMA therapy throughout the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Presence of disease that is suitable for local or regional therapy administered with curative intent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* N.B.: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* N.B.: If the subject underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has received prior radiotherapy within 2 weeks of the start of study treatment. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Subject currently participates in a clinical trial with another investigational agent and is receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has undergone prior allogeneic hematopoietic stem cell transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor. Steroids taken as short-term therapy (≤ 7 days) for antiemesis are permissible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years, even if currently inactive or unapparent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* N.B.: Specifically, AML patients with prior history of myelodysplastic syndromes or myeloproliferative neoplasms are not excluded. Participants in any of the study arms (solid tumors or AML) with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy, as well as patients with prostate cancer managed clinically with \"watchful waiting\" are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has known hypersensitivity to Montanide or vaccine adjuvants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Had a previous clinically significant systemic allergic reaction to Montanide, sargramostim (GM-CSF), or filgrastim (G-CSF).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has an active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Subjects with known human immunodeficiency virus (HIV) and/or history of Hepatitis B or C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus (HBV) DNA or Hepatitis C Antibody or RNA are excluded. Active Hepatitis C is defined by a known positive Hep C Ab result and known quantitative HCV RNA results greater than the lower limits of detection of the assay.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator. This includes any serious, intercurrent, chronic, or acute illness, such as cardiac disease (New York Heart Association \\[NYHA\\] class III or IV), hepatic disease, or other illness considered by the investigator as an unwarranted high risk for investigational drug treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* For female subjects: Subject is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 30 days after the last dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has had an allogeneic tissue/solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* Has received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (excluding GM-CSF, but including G-CSF or recombinant erythropoietin) within 4 weeks prior to first study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "(i). CRC: None (ii). OvC: None (iii). SCLC: Mixed SCLC (iv). TNBC: None (v). AML:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "1. Planned/anticipated HSCT (autologous or allogeneic, with any degree of match donor); acute promyelocytic leukemia (APL; M3 or any morphologic and molecular variants, inclusive); history or current diagnosis of CNS leukemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "2. Relapsed (Second line) patients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03761914",
    "statement": "* N.B.: Patients who received any chemotherapy (\"3 + 7\" or similar chemotherapy regimen) for up to 2 cycles during initial induction therapy in the first-line setting and subsequently immediately seamlessly switched to HMAs are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00482014",
    "statement": "* Inoperable non small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00482014",
    "statement": "* No weight loss greater than 10% in 3 months prior to enrolling in trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00482014",
    "statement": "* Adequate kidney function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00482014",
    "statement": "* Adequate liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00482014",
    "statement": "* Adequate lung function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00482014",
    "statement": "* Previous surgery to remove lung tumor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00482014",
    "statement": "* Previous chemotherapy or radiation therapy or lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00482014",
    "statement": "* Inability to take vitamin supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00482014",
    "statement": "* Heart attack within past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00482014",
    "statement": "* Active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753714",
    "statement": "* Histologic or cytologic confirmation of advanced NSCLC (stage IIIB with supraclavicular lymph node metastases or pleural effusion or stage IV) on entry into study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753714",
    "statement": "* One or more measurable lesions at least 10 mm in the longest diameter (LD) by spiral CT scan or 20 mm with conventional techniques according to RECIST criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753714",
    "statement": "* Chemotherapy-naïve (prior chemotherapy in the adjuvant setting completed more than 3 months before the trial entry is accepted).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753714",
    "statement": "* Female or male aged 70 years or above",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753714",
    "statement": "* Patients must not have received prior anti-cancer therapy except in the adjuvant setting",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753714",
    "statement": "* Inadequate end-organ function or Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the Investigator's opinion makes it undesirable for the patient to participate in the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753714",
    "statement": "* Significant cardiovascular event (e.g. myocardial infarction, superior vena cava \\[SVC\\] syndrome, New York Heart Association \\[NYHA\\] classification of heart disease ³2) within 3 months before entry, or presence of cardiac disease that in the opinion of",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753714",
    "statement": "* History of arrhythmia or QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Histologically or cytologically confirmed stage IIIB or IV non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Male or non-pregnant and non-lactating female, and equal or greater than age 18",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* If a female patient is of child-bearing potential, as evidence by regular menstrual periods, she must have a negative serum pregnancy test (beta human chorionic gonadotropin \\[βhCG\\]) documented within 72 hours of the first administration of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* If sexually active, the patient must agree to utilize contraception considered adequate and appropriate by the investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* No other current active malignancy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Radiographically-documented measurable disease (defined by the presence of at least 1 radiographically documented measurable lesion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Patients must have received no prior chemotherapy for the treatment of metastatic disease. Adjuvant chemotherapy permitted providing cytotoxic chemotherapy was completed 12 months prior to starting the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Patient has the following blood counts at baseline:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Absolute neutrophil count (ANC) greater than or equal to 1.5x10\\^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Platelets greater than or equal to 100x10\\^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Hemoglobin (Hgb) greater than or equal to 9 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Patient has the following blood chemistry levels at baseline:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Aspartate aminotransferase (SGOT), alanine aminotransferase (SGPT) less than or equal to 2.5 x upper limit of normal range (ULN) or less than or equal to 5.0 x ULN if liver metastases;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Total bilirubin less than or equal to ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Creatinine less than or equal to 1.5 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Expected survival of greater than 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent form prior to participation in any study-related activities",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Evidence of active brain metastases, including leptomeningeal involvement. Prior evidence of brain metastasis permitted only if treated and stable and off therapy for greater than or equal to 1 month",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* The only evidence of disease is non-measurable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Patient has pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology Criteria for Adverse Events \\[CTCAE\\] Version 3).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Patient received radiotherapy in the last 4 weeks, except if to a non-target lesion only. Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Patient has a clinically significant concurrent illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Patient has received treatment with any investigational drug within the previous 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Patient has a history of allergy or hypersensitivity to any of the study drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "* Patient is enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": ", subjects must meet all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* have been diagnosed with Stage 2, 3 or 4 non-small cell lung cancer or Stage 2, 3 or 4 colorectal cancer or non-hodgkin's lymphoma or chronic lymphocytic leukemia or Stage 3 or 4 breast cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* be prior to initiation of or between cycles of chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* have experienced greater than or equal to 2% weight loss from the highest patient reported weight in the 6 months prior to screening for Protocol G200502 (Wt = body weight)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "  % weight loss = (Wt at screening - highest Wt in last 6 months) / highest Wt in last 6 months x 100%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* If surgery is part of the cancer treatment, screening for this study should be conducted at least 2 weeks (14 days) after surgery.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* have a life expectancy of \\>6 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* FEMALES - be clinically confirmed as postmenopausal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* MALES - over 45 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* ECOG score ≤1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* history of active/uncontrolled congestive heart failure, chronic hepatitis, hepatic cirrhosis, or HIV infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* Cardiovascular: No uncontrolled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* Positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen), anti-HCV (Hepatitis C Antibody), hepatitis A antibody IgM, or HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* Currently taking testosterone, OXANDRIN® (oxandrolone), testosterone-like agents (such as DHEA, androstenedione, and other androgenic compounds, including herbals), or antiandrogens (Please note that previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day wash-out. However, if the previous testosterone therapy was a long-term depot, within the past 6 months, the site should call the medical monitor for this study to determine appropriate washout period.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00467844",
    "statement": "* Currently taking megestrol acetate (MEGACE®), dronabinol (MARINOL®), or any prescription medication intended to increase appetite or treat unintentional weight loss",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has a histologically or cytologically confirmed diagnosis of stage IV (M1a or M1b-American Joint Committee on Cancer \\[AJCC\\]) squamous NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has not received prior systemic treatment for metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has provided tumor tissue from locations not radiated prior to biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has a life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* If female of childbearing potential, is willing to use an adequate method of contraception for the course of the study through 180 days after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* If male with a female partner(s) of child-bearing potential, must agree to use an adequate method of contraception starting with the first dose of study treatment through 95 days after the last dose of study treatment. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has non-squamous histology NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Before the first dose of study drug: a) Has received prior systemic cytotoxic chemotherapy for metastatic disease; b) Has received other targeted or biological antineoplastic therapy (e.g., erlotinib, crizotinib, cetuximab) for metastatic disease; c) Has had major surgery (\\<3 weeks prior to first dose).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Received radiation therapy to the lung that is \\>30 Gray (Gy) within 6 months of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Completed palliative radiotherapy within 7 days of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Is expected to require any other form of antineoplastic therapy while on study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has received a live-virus vaccination within 30 days of planned treatment start.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has a known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has pre-existing peripheral neuropathy that is ≥ Grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) Version 4 criteria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has a known sensitivity to any component of carboplatin or paclitaxel or nab-paclitaxel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has active autoimmune disease that has required systemic treatment in past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Is on chronic systemic steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Had prior treatment with any other anti-programmed cell death 1 (anti-PD-1), or programmed cell death ligand 1 (PD-L1) or PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors or mechanisms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has participated in any other pembrolizumab trial and has been treated with pembrolizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has an active infection requiring therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has known history of Human Immunodeficiency Virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has known active Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Is, at the time of providing documented informed consent, a regular user (including \"recreational use\") of any illicit drugs or has a recent history (within the last year) of substance abuse (including alcohol).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03875092",
    "statement": "* Has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Capable of given written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Male or female age 20 years or greater; able to swallow and retain oral medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* BRAF mutation positive advanced solid tumor ( Phase I part). BRAF mutation positive melanoma (Phase II part).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Measurable disease according to RECIST version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Eastern Cooperative Oncology Group Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Agree to contraception requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Adequate organ system function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Phase II part ONLY: Prior systemic anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) for Stage IIIC (unresectable) or Stage IV (metastatic) melanoma. Prior systemic treatment in the adjuvant setting is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 28 days prior to the study treatment (6 weeks for prior nitrosourea or mitomycin C), or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to the study treatment. Limited radiotherapy within the last 2 weeks. (Note: Ipilimumab treatment must end at least 8 weeks prior to the study treatment.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Taken an investigational drug within 28 days or 5 half-lives (minimum 14 days), whichever is shorter, prior to the study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Current use of a prohibited medication or requires any of these medications during treatment with the study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* A history of another malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that could interfere with the subject's safety, obtaining informed consent, or compliance with study procedures (e.g., uncontrolled diabetes).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* History of pneumonitis or interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Known HIV infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Certain cardiac abnormality",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* A history or current evidence/risk of retinal vein occlusion or central serous retinopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01928940",
    "statement": "* Pregnant or lactating female.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03676192",
    "statement": "* diagnosed as recurrent disease or stage IV",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03676192",
    "statement": "* has at least 1 measurable lesion by Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03676192",
    "statement": "* has predominantly squamous cell histology non-small cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03676192",
    "statement": "* had surgery for metastatic non-squamous non-small cell lung cancer (nsNSCLC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Cytologically or histologically confirmed non squamous NSCLC Stage IV (including pleural effusion).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Radiologically confirmed disease progression following two previous lines of anti-cancer therapy, one of which should be a platinum based regimen, OR the patient has refused treatment with approved treatment modalities",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* At least one radiologically measurable target lesion per RECIST version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Fresh or archival biopsy tissue available to determine tumor mutation status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Written informed consent that is consistent with International Conference on Harmonisation Tripartite Guideline on Good Clinical Practice guidelines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Patient or legally acceptable representative has granted written informed consent before any study specific procedures (including special Screening tests) are performed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x 109/L; absolute neutrophil count ≥ 1.5 x 109/L without the use of hematopoietic growth factors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Bilirubin and creatinine less than 2 × upper limit of normal (ULN) for the institution",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Albumin ≥ 2.5 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Aspartate aminotransferase and alanine aminotransferase less than 5 × ULN for the institution",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Prothrombin time less than 1.5 × ULN for the institution",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Potassium, magnesium and phosphorus within the normal range for the institution (supplementation is permissible)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Recovery to Grade 1 or baseline of any toxicities due to prior treatments, excluding alopecia",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Chemo-, hormone- or immunotherapy, within 4 weeks or within less than four half lives of the date of first administration of study drug and/or persistence of toxicities of prior anti-cancer therapies which are deemed to be clinically relevant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Radiotherapy within the past 2 weeks prior to date of first administration of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Previous treatment with an histone deacetylase inhibitor or an epidermal growth factor receptor inhibitor within at least 4 weeks of the date of first administration of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Treatment with any drug(s) known to be an inhibitor or inducer of cytochrome P450 (CYP)2C19, CYP3A4, CYP2C8, and CYP2E1, within 14 days of the date of first administration of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Brain metastases, which are symptomatic; patients with treated, brain metastases are eligible with stable brain disease for at least 4 weeks without the requirement for steroids or anti epileptic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Inability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea e.g., Cohn's disease, malabsorption, or Common Terminology Criteria for Adverse Event (CTCAE) Grade \\> 2 diarrhea of any etiology at baseline",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Other malignancies diagnosed within the past five years (other than curatively treated cervical cancer in situ), non melanoma skin cancer, superficial bladder tumors Ta (non invasive tumor) and TIS (carcinoma in situ)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Patients with any serious active infection (i.e., requiring an intravenous antibiotic, antifungal, or antiviral agent)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Patients with known human immunodeficiency virus, active hepatitis B or active hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Patients who have any other life threatening illness or organ system dysfunction, which in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Known or suspected substance abuse or alcohol abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* Pregnancy or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02047344",
    "statement": "* History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association functional classification of three",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457392",
    "statement": "* Patients with locally advanced/metastatic non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457392",
    "statement": "* Prior treatment with no more than 2 chemotherapy regimens including a platinum-based regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457392",
    "statement": "* Prior treatment with any receptor tyrosine kinase inhibitors, VEGF inhibitor (with the exception of bevacizumab) or other angiogenesis inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457392",
    "statement": "* History of or known brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Histologically or cytologically confirmed diagnosis of stage IV NSCLC without epidermal growth factor receptor (EGFR)-sensitizing mutation, ROS1 and/or anaplastic lymphoma kinase (ALK) translocation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Measurable disease based on RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Tumor tissue that demonstrates programmed cell death ligand 1 (PD-L1) expression in ≥ 50% of tumor cells (tumor proportion score \\[TPS\\] ≥ 50%) as assessed by immunohistochemistry at a central laboratory.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Adequate organ function per protocol-defined criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Known untreated central nervous system metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Symptomatic ascites or pleural effusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Active autoimmune disease that has required systemic treatment in past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Has had an allogeneic tissue/solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Has known history of or is positive for active Hepatitis B (HBsAg reactive) or has active Hepatitis C (HCV RNA). Note: Testing must be performed to determine eligibility.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* History or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's opinion, is clinically meaningful.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03322540",
    "statement": "* Use of protocol-defined prior/concomitant therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "-in Phase I",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "1. Histologically or cytologically confirmed diagnosis of stage IIIB/IV or recurrent Non Small Cell Lung Cancer (NSCLC) with squamous cell histology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "2. Measurable disease according to Response Evaluation Criteria in Solid Tumours ( RECIST 1.1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "3. Patient Eastern Cooperative Oncology Group (ECOG) score of 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "4. Male or female patients age = 18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "5. Life expectancy of at least three (3) months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "6. Written informed consent in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "   Phase II - in addition to the above criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "7. Radiologically-confirmed at least stable disease after 2 prior cycles of cisplatin / gemcitabine chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": ". Prior therapy for advanced or metastatic or recurrent Non Small Cell Lung Cancer (NSCLC). One prior adjuvant, neoadjuvant or adjuvant + neoadjuvant treatment is allowed if at least 12 months have elapsed between the end of the treatment and randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "2. Prior treatment with other Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors (other than bevacizumab)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "3. Any contraindications for treatment with gemcitabine and/or cisplatin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "4. Use of any investigational drug within 4 weeks of entering the 1199.82 study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "5. History of major thrombotic or clinically relevant bleeding event in the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "6. Significant cardiovascular diseases (i.e. hypertension not controlled by medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "7. Surgery within 4 weeks (except tumour biopsy) prior randomisation and incomplete wound healing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "8. Active brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "9. Radiotherapy (except extremities) within 3 months prior to baseline imaging and radiotherapy for brain metastasis \\< 4 weeks prior baseline imaging.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01346540",
    "statement": "10. Any other current malignancy or malignancy diagnosed within the past five (5) years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Participants with non-small cell lung cancer with locally or advanced metastatic disease(Stage IIIB or IV at entry) not amenable to curative therapy and who have progressed after 1 line of chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Measureable disease as defined by response evaluation criteria in solid tumors (RECIST) version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Must make available any existing tumor tissue from the primary biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Participants with prior radiation may be eligible if they meet certain criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Adequate bone marrow reserve and organ functioning",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Women must have a negative pregnancy test and must comply with a highly reliable contraceptive method during and for 6 months after the treatment period and must not be breastfeeding",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Men must comply with a contraceptive regimen during and for 6 months after the treatment period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Currently enrolled in or discontinued a clinical trial involving an investigational drug/device within the last 30 days. Participants may be permitted to enter treatment before the 30 day waiting period in special circumstances",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Serious concomitant systemic disorders that would compromise the safety of the participant or the participant's ability to complete the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Second primary malignancy that could affect compliance with the protocol or interpretation of the study results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Known allergy or hypersensitivity to docetaxel, taxanes, LY2181308, oligonucleotides, or any component of the formulations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Participants with documented central nervous system or brain metastasis at the time of study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01107444",
    "statement": "* Pre-existing neuropathy equivalent to a common terminology criteria for adverse events(CTCAE)code greater than or equal to 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00370292",
    "statement": "* Histologically or cytologically proven IIIB and IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00370292",
    "statement": "* No symptomatic uncontrolled brain metastasis",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00370292",
    "statement": "* Not suitable for platinum containing regimens if chemo-naive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00370292",
    "statement": "* Performance status less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) Scale.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00370292",
    "statement": "* Creatinine Clearance (CrCl) greater than or equal to 45 milliliters per min (mL/min)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00370292",
    "statement": "* Prior radiation to greater than 25% of bone marrow",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00370292",
    "statement": "* Inability to interrupt Aspirin at doses of greater than 1.3 grams/day or non-steroidal anti-inflammatory agents for a 5-day period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00370292",
    "statement": "* Presence of clinically relevant third-space fluid collections not controllable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00370292",
    "statement": "* Significant cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00350792",
    "statement": "* Pathologically confirmed Non Small Cell Lung Cancer Stage IIIb (not amenable to radiotherapy treatment) or Stage IV",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00350792",
    "statement": "* No previous chemotherapy for lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00350792",
    "statement": "* Men and women \\> or = 70 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00350792",
    "statement": "* At least one uni-dimensionally measurable lesion (Response Evaluation Criteria In Solid Tumors \\[RECIST\\]criteria)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00350792",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00350792",
    "statement": "* Treatment within the last 30 days with a drug that has not received regulatory approval",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00350792",
    "statement": "* Serious systemic disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00350792",
    "statement": "* Inability to discontinue administration of aspirin or anti-inflammatory non steroid",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00350792",
    "statement": "* Concurrent administration of any other antitumor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00350792",
    "statement": "* Brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Eastern cooperative oncology group performance status (ECOG PS) of 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Participants with no prior systemic treatment for advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Adequate renal, and hematologic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Measurable disease by response evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1) prior to the administration of study treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Negative pregnancy test for all females of child bearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Use of highly effective contraception as defined by the study protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Participants with a previous malignancy within the past 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Any gastrointestinal (GI) disorder or liver disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* National cancer institute common terminology criteria for adverse events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy (e.g., radiotherapy) (excluding alopecia)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* History of organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Co-administration of anti-cancer therapies other than those administered in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Participants with baseline QTc greater than (\\>) 470 milliseconds or symptomatic bradycardia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Recipient of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the first dose until the end of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Recipient of any drug with potential QT interval prolonging effects within 14 days prior to the first dose for all participants and while on treatment through the end of the study for crizotinib-treated participants only",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* History of hypersensitivity to any of the additives in the alectinib and crizotinib drug formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Pregnancy or lactation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Any clinically significant disease or condition (or history of) that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the principal investigator, pose an unacceptable risk to the participant in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02075840",
    "statement": "* Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the participant before trial entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Voluntarily written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Age: between 18 and 75 years (both inclusive).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1. Cohort of patients with SCLC and endometrial cáncer ECOG PS ≤ 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Life expectancy ≥ 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Patients with a histologically/cytologically confirmed diagnosis of advanced disease of any of the following tumors:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "  1. Breast cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "  2. Soft-tissue sarcoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "  3. Primary bone sarcomas.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "  4. Gynecologic tumors (endometrial adenocarcinomas, epithelial ovarian cancer...)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "  5. Hepatocellular carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "  6. Gastroenteropancreatic neuroendocrine tumors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "  7. Small cell lung cancer (SCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "  8. Gastric cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "  9. Bladder cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "  10. Adenocarcinoma of unknown primary site",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* At least three weeks since the last anticancer therapy, including radiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Adequate bone marrow, renal, hepatic, and metabolic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six weeks after discontinuation of treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Concomitant diseases/conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Symptomatic or any uncontrolled arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Ongoing chronic alcohol consumption, or cirrhosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Active uncontrolled infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Known human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Any other major illness that, in the Investigator's judgment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Brain metastases or leptomeningeal disease involvement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Men or women of childbearing potential who are not using an effective method of contraception",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* Patients who have had radiation therapy in more than 35% of the bone marrow. This criterion will not apply to cohort of patients with SCLC and endometrial cáncer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01970540",
    "statement": "* History of previous bone marrow and/or stem cell transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00769067",
    "statement": "* advanced measurable Non-Small Cell Lung Cancer (NSCLC);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00769067",
    "statement": "* progressed after 1-2 prior chemotherapy;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00769067",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) 0-2;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00769067",
    "statement": "* tissue available for future KRAS/ EGFR testing",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00769067",
    "statement": "* prior Epidermal Growth Factor Receptor (EGFR) targeted therapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00769067",
    "statement": "* active or untreated Central Nervous System (CNS) metastases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00643201",
    "statement": "* Men and women ≥ 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00643201",
    "statement": "* Clinical diagnosis of DVT or PE",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00643201",
    "statement": "* Contraindications for enoxaparin or warfarin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00643201",
    "statement": "* Active bleeding or high risk for serious bleeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00643201",
    "statement": "* Short life expectancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00643201",
    "statement": "* Uncontrolled high blood pressure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00643201",
    "statement": "* Significantly impaired kidney or liver function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Portion A: Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy or B cell lymphoma, for which no curative therapy is available. Portion A expansion includes patients who have documented disease progression on a checkpoint inhibitor (anti CTLA 4, anti PD1/PD L1 antibodies) per RECIST criteria. Tumor types include metastatic melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NCSLC) and squamous cell carcinoma of the head and neck (SCCHN). Patients in the dose expansion stage are required to provide archival or baseline (obtained during the screening period) tumor biopsies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Portion B: Histological confirmed relapsed or refractory CD20 positive NHL for which no curative therapy is available. Patients enrolled in the expansion cohort must have archival tissue available, sampled within 6 months of study entry. The Expansion cohort includes patients with FL or DLBCL with relapsed or refractory disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Measurable disease with at least one extranodal tumor mass \\>1.0 cm in the greatest transverse diameter (GTD) or in the case of malignant lymph nodes \\>1.5 cm in the GTD.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* ECOG performance status of ≤ 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Adequate bone marrow function, for Portion A: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥100 x 109/L, hemoglobin \\>9.0 g/dL. For Portion B: ANC ≥ 1.0 x 109/L, platelet count ≥ 75 x 109/L, and hemoglobin ≥ 8.0 g/dL. In both cases, patients must be transfusion independent at least 14 days prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Serum creatinine ≤ 2 x ULN or estimated creatinine clearance ≥ 50 ml/min.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Total serum bilirubin ≤ 1.5 x ULN unless the patient has documented Gilbert syndrome and AST and ALT ≤ 2.5 x ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Patients with known symptomatic brain metastases requiring steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Prior allogeneic hematopoietic stem cell transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Immunosuppressive regimens involving systemic corticosteroids within 14 days before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Therapeutic or experimental monoclonal antibodies within 28 day or prior radiation therapy within 14 days of the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Autoimmune disorders and other diseases that compromise or impair the immune system.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Unstable or serious concurrent medical conditions in the previous 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01307267",
    "statement": "* Prior therapy with any anti CD137 monoclonal antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": ". Have histologically or cytologically confirmed stage IIIB (and not a candidate for definitive multimodality therapy) or stage four (IV) NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "2. Must have documented ALK rearrangement.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "3. Have sufficient tumor tissue available for central analysis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "4. Have at least 1 measurable (that is, target) lesion per RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "5. Recovered from toxicities related to prior anticancer therapy to National Cancer Institute (of the United States) (NCI) Common Terminology Criteria for Adverse Events (version 4.0) (CTCAE v 4.0) grade be less than or equal to (\\<=) 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "6. Are a male or female participants greater than or equal to (\\>=)18 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "7. Have adequate organ function, as defined by the study protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "8. Have Eastern Cooperative Oncology Group (ECOG) performance status \\<=2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "9. Have normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of \\<= 450 millisecond (msec) in males or \\<=470 msec in females.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "10. For female participants of childbearing potential, have a negative pregnancy test documented prior to randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "11. For female and male participants who are fertile, agree to use a highly effective form of contraception, as defined by the study protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "12. Provide signed and dated informed consent indicating that the participants has been informed of all pertinent aspects of the study, including the potential risks, and is willingly participating.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "13. Have the willingness and ability to comply with scheduled visit and study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": ". Previously received an investigational antineoplastic agent for NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "2. Previously received any prior tyrosine kinase inhibitor (TKI), including ALK-targeted TKIs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "3. Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "4. Received chemotherapy or radiation within 14 days of first dose of study drug, except stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "5. Received anti-neoplastic monoclonal antibodies within 30 days of the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "6. Had major surgery within 30 days of the first dose of study drug, minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "7. Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or participants with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "8. Have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or asymptomatic disease requiring an increasing dose of corticosteroids to control symptoms within 7 days prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "9. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Participants with leptomeningeal disease and without cord compression are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "10. Be pregnant, planning a pregnancy, or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "11. Have significant, uncontrolled, or active cardiovascular disease, as defined by the study protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "12. Have uncontrolled hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "13. Have a history or the presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "14. Have an ongoing or active infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "15. Have a known history of human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "16. Have a known or suspected hypersensitivity to brigatinib or its excipients and/or crizotinib or its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "17. Have malabsorption syndrome or other gastrointestinal (GI) illness or condition.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02737501",
    "statement": "18. Have any condition or illness that, in the opinion of the investigator, would compromise participant's safety or interfere with the evaluation of the study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Confirmed diagnosis of one of the following: treatment-naïve metastatic non-small cell lung cancer with high PD-L1 expression (tumor proportion score ≥ 50%) and no epidermal growth factor receptor (EGFR), alkaline phosphatase (ALK), or ROS activating genomic tumor aberrations; locally advanced or metastatic urothelial carcinoma in participants who are not eligible for cisplatin therapy and whose tumors express PD-L1 with a combined positive score ≥ 10; unresectable or metastatic melanoma; locally advanced or metastatic renal cell carcinoma with clear cell component (with or without sarcomatoid features) and having received no prior systemic therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Measurable disease per RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Eastern Cooperative Oncology Group performance status 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Willingness to avoid pregnancy or fathering children.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Receipt of anticancer therapy or participation in another interventional clinical study within 21 days before the first administration of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Prior treatment with PD-1 or PD-L1 directed therapy (other immunotherapies may be acceptable with prior approval from the medical monitor).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Radiotherapy within 14 days of first dose of study treatment with the following caveats: 28 days for pelvic radiotherapy; 6 months for thoracic region radiotherapy that is \\> 30 Gy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of anemia not requiring transfusion support and any grade of alopecia). Endocrinopathy, if well-managed, is not exclusionary and should be discussed with sponsor medical monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Has not recovered adequately from toxicities and/or complications from surgical intervention before starting study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Laboratory values outside the protocol-defined range at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 3 years of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (\\> 10 mg of prednisone or equivalent).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Evidence of interstitial lung disease or active noninfectious pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Known active central nervous system metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Known active hepatitis B antigen, hepatitis B virus, or hepatitis C virus infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Active infections requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Known to be HIV-positive, unless all of the following criteria are met: CD4+ count ≥ 300/μL, undetectable viral load, receiving antiretroviral therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Impaired cardiac function or clinically significant cardiac disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Is pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03679767",
    "statement": "* Has received a live vaccine within 28 days of the planned start of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Positive for translocation or inversion events involving the ALK gene locus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* No prior systemic treatment for locally advanced or metastatic disease; Patients with brain metastases only if treated and neurologically stable with no ongoing requirement for corticosteroids",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome \\[PRO\\] measures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* 18 years of age or older with the exception of India which has an upper age limit of 65 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Current treatment on another therapeutic clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Prior therapy directly targeting ALK.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack. - - Appropriate treatment with anticoagulants is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Ongoing cardiac dysrhythmias of NCI CTCAE Grade \\>=2, uncontrolled atrial fibrillation of any grade, or QTc interval \\>470 msec.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Pregnancy or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Use of drugs or foods that are known potent CYP3A4 inducers/inhibitors Concurrent use of drugs that are CYP3A4 substrates with narrow therapeutic indices.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Known HIV infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Known interstitial lung disease or interstitial fibrosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01154140",
    "statement": "* Other severe acute or chronic medical conditions (including severe gastrointestinal conditions such as diarrhea or ulcer) or psychiatric conditions, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate for entry into this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": ". Signed dated, written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "2. Healthy male aged 18 to 65 yrs with suitable veins for blood sampling",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "3. BMI: 19 and 32 kg/m2 inclusive, weight at least 50 kg and no more than 100 kg, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "4. At screening, calculated creatinine clearance ≥50 mL/min using Cockcroft Gault formula.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "5. Willing to use defined methods of contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "6. Willing and able to comply with study procedures, restrictions and requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "7. Provision of informed consent for genetic research. Declining genetic research will not exclude subjects from other aspects of study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": ". Involvement in planning and/or conduct of study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "2. Subjects previously enrolled in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "3. History of clinically significant disease or disorder which, either puts subject at risk because of participation in study, or influences results or subject's ability to participate in study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "4. History or presence of condition known to interfere with ADME of drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "5. Any clinically significant abnormalities in physical examination, as judged by PI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "6. Acute illness, surgical procedures, or trauma from within 2 wks before screening until first admin of investigational product (IMP).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "7. Subjects who have received live or live-attenuated vaccine in 2 wks prior to IMP admin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "8. Subjects with active malignancy or neoplastic disease in previous 12 mths.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "9. A suspected/manifested infection according to IATA Categories A and B.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "10. Positive screening tests for serum hepatitis B surface antigen, hepatitis C antibody, or HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "11. Any clinically important abnormalities in rhythm, conduction, or morphology of resting 12-lead ECG, QT interval \\>470 ms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "12. Known or suspected history of significant drug abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "13. Positive screen for drugs of abuse or cotinine at screening or positive screen for alcohol, drugs of abuse, or cotinine on admission to centre prior to first admin of IMP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "14. History of alcohol abuse or excessive intake of alcohol, defined as regular weekly intake of more than 21 units of alcohol in men",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "15. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by PI, or history of hypersensitivity to AZD9291, its excipients, or drugs with a similar chemical structure or class.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "16. Use of any prescribed or non-prescribed medication, including drugs during the 4 wks (or longer depending on the medication's half-life) prior to admin of AZD9291 is not permitted. Occasional use of paracetamol and adrenergic nasal spray for relief of nasal congestion is permitted at the discretion of the PI. Exceptions as agreed by PI and sponsor's medical monitor if do not interfere with aims of study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "17. Use of drugs with enzyme inducing properties such as St John's Wort within 4 wks prior to IMP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "18. Any intake of grapefruit, grapefruit juice, Seville oranges or products containing these fruit within 7 days of first admin of IMP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "19. Blood donation within 1 mth of screening or any blood donation/blood loss greater than 500 mL during 3 mths prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "20. Subjects who received another NCE or participated in any other clinical study (including methodology studies where no drugs were given) within 3 mths of first admin of IMP",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "21. Judgment by PI that subject should not participate in study if subject is considered unlikely to comply with study procedures, restrictions, and requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "22. Ongoing or planned inpatient surgery, dental procedure, or hospitalisation during study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "23. Radiation exposure exceeding 5 mSv in last 12 mths or 10 mSv in last 5 yrs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "24. Admin of any amount of a \\[14C\\]-labelled compound within last 12 mths.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "25. Used of nicotine products (including cigarettes) within previous 3 mths.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "26. Judgment by PI that subject would not be able to understand or cooperate with requirements of study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "27. Previous bone marrow transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02491944",
    "statement": "28. Blood transfusion within 120 days of genetic sample collection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Men \\& women ≥18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Subjects with histologically or cytologically-documented non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemoradiation therapy for locally advanced disease) and who will receive study therapy as second or third line of treatment for advanced disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Disease recurrence or progression during/after one prior platinum doublet-based chemotherapy regimen for advanced or metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST 1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Subjects with untreated central nervous system (CNS) metastases are excluded. Subjects are eligible if CNS metastases are asymptomatic or treated and subjects are neurologically returned to baseline for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of ≤10mg daily prednisone (or equivalent)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Subjects with carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Subjects with active or recent history of known or suspected autoimmune disease. Subjects with Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Prior therapy with anti-programmed death-1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), anti-programmed cell death ligand 2 (anti-PD-L2), anti-cluster of differentiation 137 (anti-CD137), or anti-Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody (including Ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Prior treatment with Docetaxel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "* Treatment with any investigational agent within 14 days of first administration of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01673867",
    "statement": "Other protocol-defined inclusion/exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": ". Histologically or cytologically confirmed diagnosis of breast, colorectal, pancreas, or NSCLC (adenocarcinoma) that is metastatic or unresectable for which there is no effective therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "2. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 (see Appendix A).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "3. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "4. Subject has recovered (to Grade less than or equal to 1) from all clinically significant toxicities related to prior antineoplastic therapies with the exception of alopecia and bone marrow and organ functions (described separately below).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "5. Adequate organ system function less than or equal to 2 weeks prior to Day1, defined as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "* Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10\\^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "* Platelets greater than or equal to 100 x 10\\^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "* Hemoglobin greater than or equal to 9 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "* Prothrombin time/partial thromboplastin time (PT/PTT) within institutional limits of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "* Serum total bilirubin less than or equal to 1.5 times the upper limit of normal (ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 3.0 x ULN if no liver involvement or less than or equal to 5 x ULN with liver involvement.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "* Serum creatinine less than or equal to 1.5 x ULN or calculated creatinine clearance greater than or equal to 50 mL/min as calculated by the Cockcroft-Gault method, OR 24-hour measured urine creatinine clearance greater than or equal to 50 mL/min.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "6. Life expectancy of greater than or equal to 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "7. Female patients of child-bearing potential (see Appendix C), and all male patients must consent to use a medically acceptable method of contraception throughout the study period and for 30 days after their last MORAb-066 administration. A barrier method of contraception must be included.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "8. Patients must be greater than or equal to 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "9. Patients entering this study will be asked to provide archival tissue from a previous tumor biopsy (if available) for correlative testing. If tissue is not available, the subject will still be eligible for enrollment into the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "10. Ability to understand the nature of this study and give written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": ". Patients currently receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "2. Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of MORAb-066. For investigational drugs for which 5 half-lives is less than 21 days, a minimum of 10 days between termination of the investigational drug and administration of MORAb-066 is required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "3. Any major surgery, chemotherapy, radiotherapy, or immunotherapy within the last 21 days (limited palliative radiation is allowed greater than or equal to 2 weeks).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "4. Subject has received wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) less than or equal to 28 days or limited field radiation for palliation less than or equal to 14 days prior to starting study drug or has not recovered from side effects of such therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "5. Known intracranial involvement, leptomeningeal metastases or spinal cord compression due to disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "6. Known allergy or hypersensitivity to monoclonal antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "7. Known bleeding diathesis, such as factor deficiency, factor inhibitor, platelet disorder, or who are on active anticoagulation, or any dose of aspirin within 5 days prior to first dose of MORAb-066.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "8. Known prior significant bleeding history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "9. Patients with ureteral stents or 3+ blood in the urine at baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "10. Patients who are receiving chronic systemic anticoagulation therapy (warfarin sodium or heparin, etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "11. Patients who received a previous mAb therapy and have evidence of an immune or allergic reaction or previously documented HAHA reaction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "12. A serious non-healing wound, active ulcer, or untreated bone fracture. An abdominal fistula or gastrointestinal perforation less than 6 months prior to treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "13. History of hematemesis or hemoptysis (defined as having bright red blood of 1/2 teaspoon or more per episode) less than or equal to 1 month prior to study enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "14. Subject has cardiac dysfunction including any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "* Myocardial infarction within the last 6 months, documented by persistent elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular ejection fraction function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "* QTcF greater than 470 msec",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "* History of documented congestive heart failure (New York Heart Association functional classification III-IV \\[see Appendix B\\])",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "* Angina not well-controlled by medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "15. A serious active infection (bacterial or fungal) at the time of treatment, or another serious underlying medical condition that would impair the ability of the subject to receive protocol treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "16. Chronic inflammatory disorder(e.g., inflammatory bowel disease, active vasculitis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "17. Herbal preparations/medications must be discontinued 7 days prior to first dose of study drug (see Section 5.3.1).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "18. Known diagnosis of human immunodeficiency virus, Hepatitis B or Hepatitis C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "19. History or current diagnosis of glomerulonephritis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "20. History of clinically significant or current diagnosis of hematuria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "21. Women who are pregnant or lactating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "22. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "23. Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01761240",
    "statement": "24. Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Pathologically confirmed diagnosis of Stage IIIB or Stage IV adenocarcinoma of the lung. Patients with mixed histology will be eligible if adenocarcinoma is the predominant histology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Measurable disease according to RECIST version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Prior chemotherapy for relapsed or metastatic non small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Negative human chorionic gonadotropin (hCG) test in women of childbearing potential (defined as women ≤ 50 years of age or history of amenorrhea for ≤ 12 months prior to study screening). Sexually active male and female patients of childbearing potential must agree to use an effective method of birth control e.g. barrier methods with spermicides, oral or parenteral contraceptives and/or intrauterine devices, during the entire duration of the study and for 1 month after the final administration of VAL401. Note that female patients may be surgically sterile (with appropriate documentation in the patient's medical records).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Ability to give written, informed consent prior to any study-specific screening procedures with the understanding that the consent may be withdrawn by the patient at any time without prejudice.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Patient is capable of understanding the protocol requirements, is willing and able to comply with the study protocol procedures, and has signed the informed consent document.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Radiotherapy or surgery (other than biopsy) within 4 weeks prior to Cycle 1 Day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Any chemotherapy regimens (including investigational agents) with delayed toxicity with 6 weeks of Cycle 1 Day 1, or received any chemotherapy regimens given continuously or on a weekly basis which have limited potential for delayed toxicity within 2 weeks prior to Cycle 1 Day 1. Palliative treatment regimens, and other concomitant drugs regimens are permitted with stable toxicity, and recording of all concomitant medications (including herbal).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Pregnant or lactating female patients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Active hepatitis B or C or other active liver disease (other than malignancy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Any active, clinically significant, viral, bacterial, or systemic fungal infection within 2 weeks prior to Cycle 1 Day 1; other than cytomegalovirus which may be present providing any required concomitant anti-viral treatment is recorded appropriately.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Known human immunodeficiency virus positivity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* History of clinically significant cardiac condition, including ischemic cardiac event, myocardial infarction or unstable cardiac disease with 3 months prior to Cycle 1 Day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Active brain metastases (defined as stable for \\<4 weeks and/or symptomatic and/or requiring treatment with anticonvulsants or steroids and/or leptomeningeal disease).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Any known contraindications to Risperidone or patients who would not be eligible to receive the treatment as defined in the Special Warnings and Precautions section of the local label for Risperidone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02875340",
    "statement": "* Any medical history that in the Investigator's opinion would jeopardise compliance with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": ". Provision of informed consent prior",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "2. Patients aged 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "3. Patients with histological confirmation of locally advanced or metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "4. Patients with M1 stage according to the Tumor, Node and Metastasis Classification of Malignant Tumours (TNM)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "5. Patients with an EGFR deletion or mutation known (from tumour biopsy or plasma) to be associated with EGFR TKI sensitivity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "6. Existence of measurable or evaluable disease (as per RECIST 1.1 criteria).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "7. Possibility of obtaining sufficient tissue sample, via a biopsy or surgical resection of the primary tumour or metastatic tumour tissue",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "8. WHO performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "9. Life expectancy ≥12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "10. Capacity to swallow",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "11. Patients able to complete study and within geographical proximity allowing for adequate follow up",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "12. Resolution of all acute toxic effects of previous anticancer therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "13. Female patients must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "14. Male patients must be willing to use barrier contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": ". Locally advanced lung cancer candidate for curative treatment through radical surgery and/or radio(chemo)therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "2. Patients diagnosed with another lung cancer subtype",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "3. Patients with an EGFR exon 20 insertion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "4. Patients with just one measurable or evaluable tumour lesion that has been resected or irradiated prior to their enrolment in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "5. Second active neoplasia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "6. Treatment with an investigational drug within five half-lives of the compound",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "7. Participation in another clinical study with an investigational product (IP) during the last 3 weeks before the first day of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "8. Patients who have received prior immunotherapies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "9. Patients who have received prior EGFR treatments for lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "10. Patients who have received prior treatment with an EGFR TKI including in the adjuvant setting",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "11. Patients who have received previous treatment for metastatic or stage IV disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "12. Prior treatment with cytotoxic chemotherapy for advanced NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "13. Patients with a history of cancer that has been completely treated, with no evidence of malignant disease currently cannot be enrolled in the study if their chemotherapy was completed less than 6 months prior and/or have received a bone marrow transplant less than 2 years before the first day of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "14. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum-therapy related neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "15. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses or active infection (eg, patients receiving treatment for infection) including hepatitis C and human immunodeficiency virus (HIV), or active uncontrolled Hepatitis B virus (HBV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "16. Patients who have had a surgical procedure unrelated to the study within 14 days or major surgery within 1 month prior to the administration of the study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "17. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "18. Any of the following cardiac criteria: Mean resting QT interval corrected for heart rate (QTc) more than 470 msec, obtained from 3 ECGs, using the screening clinic ECG machine derived QTc value. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, hypomagnesaemia, hypocalcaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "19. Spinal cord compression, symptomatic and unstable brain metastases except for those patients who have completed definitive therapy, and have had a stable neurological status for at least 2 weeks after completion of definitive therapy. 20.Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "21.Inadequate bone marrow reserve or organ function 22.Female patients who are breastfeeding 23.Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome (CYP) 3A4.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03239340",
    "statement": "24.Patient unwilling to undergo a biopsy at the time of disease progression 25.History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib 26.Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements 27.Involvement in the planning and/or conduct of the study 28.Previous enrolment in the present study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Pathologically determined Stage IV NSCLC including Stage IIIb (pleural effusion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Failed at least one prior platinum-based chemotherapy for Stage IIIb or Stage IV NSCLC. Patients receiving platinum-based chemotherapy only given in an adjuvant setting are not eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Measurable disease by RECIST",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Greater than or equal to 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* ECOG PS of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Radiation therapy within 2 weeks; chemotherapy within 3 weeks; non-cytotoxic investigational agents within 4 weeks of initiating study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Evidence of NYHA class III or greater cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* History of MI, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 12 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Known HIV infection or AIDS",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Symptomatic CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Pregnant or nursing women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Hypersensitivity or intolerance to erlotinib, sulfonamides, aspirin, or other NSAIDs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* History of upper GI bleeding, ulceration, or perforation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Prior history of COX-2 inhibitor therapy for the treatment of metastatic NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00652340",
    "statement": "* Previous anti-EGFR kinase therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": ". Have histologically or cytologically confirmed stage IIIB (locally advanced or recurrent and not a participant for curative therapy) or stage IV non-small-cell lung cancer (NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "2. Must meet both of the following 2 criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "   1. Have documentation of anaplastic lymphoma kinase (ALK) rearrangement by a positive result from any laboratory test® approved by the food and drug administration (FDA) or Have documented ALK rearrangement by a different test (non-FDA-approved local lab tests) and have provided tumor sample to the central laboratory. (Note: Central laboratory ALK rearrangement testing results are not required to be obtained before randomization.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "   2. Had been on any one of the ALK tyrosine kinase inhibitor (TKIs) (alectinib, ceritinib, crizotinib) for at least 12 weeks before progression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "3. Had progressive disease (PD) while on alectinib or ceritinib",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "4. Had alectinib or ceritinib as the most recent ALK inhibitor therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "5. Have at least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) version 1.1 as assessed by the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "6. Had recovered from toxicities related to prior anticancer therapy to national cancer institute common terminology criteria for adverse events (NCI CTCAE), version 4.03, Grade \\<=1. (Note: Treatment-related alopecia or peripheral neuropathy that are Grade \\>1 are allowed if deemed irreversible.) and have adequate major organ functions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "7. Have a life expectancy of ≥3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": ". Had received any prior ALK-targeted TKI other than crizotinib, alectinib, or ceritinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "2. Had received both alectinib and ceritinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "3. Had previously received more than 3 regimens of systemic anticancer therapy for locally advanced or metastatic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "4. Had symptomatic brain metastasis (parenchymal or leptomeningeal). Participants with asymptomatic brain metastasis or who have stable symptoms that did not require an increased dose of corticosteroids to control symptoms in the past 7 days before the first dose of brigatinib may be enrolled.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "5. Had current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Participants with leptomeningeal disease and without cord compression are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "6. Had a cerebrovascular accident or transient ischemic attack within 6 months before first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "7. Had an ongoing or active infection, including, but not limited to, the requirement for intravenous antibiotics.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03535740",
    "statement": "8. Had malabsorption syndrome or other gastrointestinal (GI) illness that could affect oral absorption of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Confirmed NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Stage IV disease at the time of study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Measurable disease at the time of study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Resolution to Grade ≤ 1 Adverse Events, of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (except alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Adequate hematologic function, hepatic function, renal function and coagulation function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* If sexually active, must be post-menopausal, surgically sterile, or using effective contraception; and agrees to use adequate contraception during the study period and for up to 6 months after the last dose of study medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Female participants of childbearing potential must have a negative serum pregnancy test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Has cirrhosis at a level of Child-Pugh B (or worse), or cirrhosis and a history of hepatic encephalopathy, or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Tumor wholly or partially contains small cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Untreated central nervous system (CNS) metastases, eligible if they are clinically stable with regard to neurologic function, off all steroids after cranial irradiation at least 2 weeks prior or after surgical resection performed at least 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Concurrent active malignancy other than adequately treated basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix. A participant with previous history of malignancy other than NSCLC is eligible, provided that he/she has been free of disease for ≥ 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Received prior therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Receiving concurrent treatment with other anticancer therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Has received previous chemotherapy for Stage IV NSCLC (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 6 months prior to randomization)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Has radiologically documented evidence of major blood vessel invasion or encasement by cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Has undergone chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Ongoing or active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* History of significant neurological or psychiatric disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Experienced clinically relevant coronary artery disease, myocardial infarction within 6 months prior to randomization, uncontrolled congestive heart failure, or symptomatic poorly controlled arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Poorly-controlled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Experienced any serious Grade 3-4 gastrointestinal bleeding within 3 months prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Receiving chronic daily treatment with aspirin (\\> 325 mg/day) or other known inhibitors of platelet function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Serious nonhealing wound, ulcer, or bone fracture within 28 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Major surgery within 28 days prior the first dose of study medication, or subcutaneous venous access device placement within 7 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Elective or a planned major surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Any other serious uncontrolled medical disorders or psychological conditions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* Allergy / history of hypersensitivity reaction to any of the treatment components",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01160744",
    "statement": "* History of drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Histologically- or cytologically-confirmed diagnosis of advanced or metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* PD-L1 positive tumor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* No prior systemic chemotherapy for the treatment of the participant's advanced or metastatic disease (treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior to diagnosis of advanced or metastatic disease)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* No prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cancer, or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Submission of formalin-fixed diagnostic tumor tissue (in the case of participants having received adjuvant systemic therapy, the tissue should be taken after completion of this therapy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Female participants of childbearing potential must have a negative urine or serum pregnancy test and must be willing to use two adequate barrier methods of contraception or a barrier method plus a hormonal method starting with the screening visit through 120 days after the last dose of pembrolizumab or 180 days after the last dose of chemotherapeutic agents used in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Male participants with a female partner(s) of childbearing potential must be willing to use two adequate barrier methods of contraception from screening through 120 days after the last dose of pembrolizumab or 180 days after the last dose of chemotherapeutic agents used in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or is echinoderm microtubule-associated protein-like 4 (EML4) gene/anaplastic lymphoma kinase (ALK) gene fusion positive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* No tumor specimen evaluable for PD-L1 expression by the central study laboratory",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Squamous histology and received carboplatin in combination with paclitaxel in the adjuvant setting",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Is receiving systemic steroid therapy ≤3 days prior to the first dose of study therapy or receiving any other form of immunosuppressive medication with the exception of daily steroid replacement therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* The NSCLC can be treated with curative intent with either surgical resection and/or chemoradiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Expected to require any other form of systemic or localized antineoplastic therapy while on study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Any prior systemic cytotoxic chemotherapy, biological therapy or major surgery within 3 weeks of the first dose of study therapy; received lung radiation therapy \\>30 Gy within 6 months of the first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Known central nervous system metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Active autoimmune disease that has required systemic treatment in the past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Had allogeneic tissue/solid organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Interstitial lung disease or history of pneumonitis that has required oral or IV steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Has received or will receive a live vaccine within 30 days prior to the first study therapy (seasonal flu vaccines that do not contain live vaccine are permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Active infection requiring intravenous systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Known history of human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Known active Hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03850444",
    "statement": "* Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "* Histologically confirmed Stage 4 or recurrent non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out light housework or office work through to being fully active as you were before cancer)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "* No prior systemic anticancer therapy (including EGFR and ALK inhibitors)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "* Tissue or Programmed death-ligand 1 (PD-L1) results available",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "Cohort 1A Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) score 2 or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) score 0-1 and one disease specific criteria as listed in the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "Cohort C Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "* High Tumor Mutation Burden",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "* Untreated brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "* An active malignancy that requires concurrent intervention",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "* Active, known or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "* Carcinomatous meningitis, which means there is inflammation of the covering of the brain, caused by cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02869789",
    "statement": "Other protocol-defined inclusion/exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Voluntarily signed and dated written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Age between 18 and 75 years old (both inclusive)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Life expectancy ≥ 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "  1. Breast cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "  2. Epithelial ovarian cancer or gynecological cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "  3. Head and neck squamous cell carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "  4. Non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "  5. Small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "  6. Platinum-refractory germ-cell tumors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "  7. Adenocarcinoma or carcinoma of unknown primary site",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Adequate bone marrow, renal, hepatic, and metabolic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Recovery to grade ≤ 1 or to baseline from any Adverse Event (AE) derived from previous treatment (excluding alopecia of any grade).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Pre-menopausal women must have a negative pregnancy test before study entry and agree to use a medically acceptable method of contraception throughout the treatment period and for at least six weeks after treatment discontinuation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Prior treatment with PM01183 or weekly paclitaxel or nanoalbumin-paclitaxel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Patients who have previously discontinued paclitaxel-based regimes due to drug related toxicity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Known hypersensitivity to bevacizumab or any component of its formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Patients who have previously discontinued bevacizumab-containing regimes due to drug-related toxicity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* More than three prior lines of chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Less than three months since last taxane-containing therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Wash-out period:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "  1. Less than three weeks since the last chemotherapy-containing regimen",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "  2. Less than three weeks since the last radiotherapy dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "  3. Less than four weeks since last monoclonal antibody-containing therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Concomitant diseases/conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "Unstable angina, myocardial infarction, valvular heart disease, encephalopathy, ischemic attacks, hemorrhagic or ischemic cerebrovascular accident (CVA) or ongoing pulmonary embolism within last year, arrhythmia, hepatopathy, uncontrolled infection, hemoptysis or oxygen requiring dyspnea, known HIV infection, bleeding risk, muscular problems, peripheral neuropathy, Symptomatic or progressive brain metastases or leptomeningeal disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Men or pre-menopausal women who are not using an effective method of contraception as previously described; actively breast feeding women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Patients who have pelvic irradiation with doses ≥ 45 Grays (Gy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* History of previous bone marrow and/or stem cell transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01831089",
    "statement": "* Confirmed bone marrow involvement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00603538",
    "statement": "* Diagnosis of advanced non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00603538",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00603538",
    "statement": "* Any prior treatment for non-small cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00603538",
    "statement": "* Brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00603538",
    "statement": "* With diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": ". Aged ≥18 years at the time of signing the informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "2. Histologically confirmed diagnosis of NSCLC, advanced (stage IIIB) or metastatic (stage IV).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "3. Documented somatic ErbB2 (HER2) activating mutation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "4. Patients with anaplastic lymphoma kinase (ALK) translocations must have received crizotinib, except for cases of intolerable toxicity to crizotinib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "5. At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "6. Eastern Cooperative Oncology Group (ECOG) status \\<2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "7. Left ventricular ejection fraction (LVEF) ≥50% measured by multiple -gated acquisition scan (MUGA) or echocardiogram (ECHO).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "8. Negative β-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after menopause.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "9. Men and women of childbearing potential must agree and commit to the use of a highly effective method of contraception, as determined to be acceptable by the Investigator, from the time of informed consent until 3 months after the last dose of the investigational products.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "10. Provide written, informed consent to participate in the study and follow the study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": ". Previous treatment with any investigational agent ≤14 days prior to the initiation of investigational products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "2. Previous treatment with any strong inhibitor and/or inducer of CYP3A4 enzyme or sensitive P-glycoprotein (P-gp) substrates ≤30 days prior to the initiation of investigational products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "3. Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of ≥2), unstable angina, myocardial infarction within 12 months of enrollment, or ventricular arrhythmia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "4. Major surgery \\<30 days of starting treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "5. Chronic steroid use (prednisone \\>12.5 mg/day or dexamethasone \\>2 mg/day, excluding inhaled steroids).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "6. Currently breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "7. Symptomatic or unstable brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "8. QTc interval \\>0.450 seconds for men and \\>0.470 seconds for women, or known history of QTc prolongation or Torsades de Pointes (TdP).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "9. Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade ≥2 (National Cancer Institute \\[NCI\\] Common Terminology Criteria for Adverse Events Version 4.0 \\[CTCAE v.4.0\\] diarrhea of any etiology at baseline).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "10. Prior exposure to neratinib or mTOR inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "11. Active infection or unexplained fever \\>38.5°C (101.3°F).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "12. Unable or unwilling to swallow tablets.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "13. Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness/social situations that would, in the Investigator's judgment, make the patient inappropriate for this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "14. Known hypersensitivity to any component of the investigational products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "15. Unstable or uncontrolled diabetes mellitus (glycosylated hemoglobin \\[HbA1c\\] \\>6.5%).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01827267",
    "statement": "16. Screening laboratory assessments outside the following limits: ANC \\<1000/μL (\\<1.0 x 109/L), Platelet count \\<75,000/μL (\\<75 x 109/L), Hemoglobin \\<8 g/dL, transfusions allowed, must be at least 7 days prior to baseline, Total bilirubin \\>1.5 x institutional upper limit of normal (ULN), AST and/or ALT 5 minutes, Creatinine clearance \\<50 mL/min.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* Histologically or cytologically proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* Positive for translocation or inversion events involving the ALK gene locus.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* No prior systemic treatment for locally advanced or metastatic disease. Patients with brain metastases only if treated and neurologically stable for at least 2 weeks and are not taking any medications contraindicated in",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* Evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome \\[PRO\\] measures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* Current treatment on another therapeutic clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* Prior therapy directly targeting ALK.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* Any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack. Appropriate treatment with anticoagulants is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* Ongoing cardiac dysrhythmias of NCI CTCAE Grade \\>=2, uncontrolled atrial fibrillation of any grade, or QTc interval \\>470 msec.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* Pregnancy or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* Use of drugs or foods that are known potent CYP3A inducers/inhibitors Concurrent use of drugs that are CYP3A substrates with narrow therapeutic indices.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* Known HIV infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01639001",
    "statement": "* Other severe acute or chronic medical conditions (including severe gastrointestinal conditions such as diarrhea or ulcer) or psychiatric conditions, or end-stage renal disease on hemodialysis, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate for entry into this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02927301",
    "statement": "* Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02927301",
    "statement": "* Adequate pulmonary and cardiac function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02927301",
    "statement": "* Available biopsy of primary tumor with adequate samples",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02927301",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02927301",
    "statement": "* NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02927301",
    "statement": "* Any prior therapy for lung cancer within 3 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02927301",
    "statement": "* Prior treatment with anti-PD-1 or PD-L1 therapies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02927301",
    "statement": "* History or risk of autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713867",
    "statement": "* Histologically or cytologically documented Squamous or non-Squamous Non-small cell lung cancer (NSCLC) (Stage IIIB/IV), or recurrent or progressive disease following multimodal therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713867",
    "statement": "* Patients must have received pre-study nivolumab for up to 12 months and have 2 consecutive tumor assessments confirming Complete response (CR), Partial response (PR), or Stable disease (SD)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713867",
    "statement": "* Measurable disease before start of pre-study nivolumab treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713867",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713867",
    "statement": "* Carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713867",
    "statement": "* Untreated, symptomatic Central nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713867",
    "statement": "* Symptomatic interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02713867",
    "statement": "Other protocol defined inclusion/exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00608868",
    "statement": "* Pathological Diagnosis of local advanced/metastatic Non Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00608868",
    "statement": "* Previously failed the first-line chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00608868",
    "statement": "* Patient who can provide sample for EGFR mutation test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00608868",
    "statement": "* Central Nervous System metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00608868",
    "statement": "* Any evidence of clinically active interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": ", which includes a mandatory genetic informed consent and compliance with the requirements and restrictions listed in the informed consent forms (ICFs) and in this protocol. Provision of signed and dated, written ICFs must occur prior to any mandatory study-specific procedures, sampling, and analyses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "In addition to ICF1 and ICF2, patients will provide signed and dated written optional genetic informed consent prior to collection of a sample for optional genetic analysis at the time of second screening (Table 2). This is different from the genetic samples and testing covered by ICF1, which are mandatory for participation in this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "Criteria and procedures initiated with the signing of ICF1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "1. ICF1 must be signed and dated prior to any study procedures and prior to the planned surgical resection of the primary NSCLC, with the exceptions noted below. This consent will cover the study-specific first screening procedures outlined in Table 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   Exception: Patients will be permitted to sign ICF1 up to Week 3 (Day 21) postsurgery. Patients identified after Week 3 post-surgery but prior to Week 5 (Day 35) post-surgery may be allowed to sign ICF1 depending on the outcome of the discussion with the study physician. In these cases, a whole blood sample and resected tumor tissue must be collected and sent to the diagnostic lab as soon as possible after ICF1 is signed for development of the personalized panel. A plasma sample must still be collected at Week 3-5 (Day 21-35) post-surgery, even if creation of the personalized panel for MRD detection is delayed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   Age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "2. Age ≥18 years at the time of screening. Sex",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "3. Male and/or female. Type of patient and disease characteristics",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "4. Individuals who have diagnosis of histologically confirmed NSCLC (WHO 2015 classification) with resectable (stage II-III) disease (according to IASLC Staging Manual in Thoracic Oncology v8.0). Select (ie, T3N2 or T4N2) stage IIIB patients will be eligible, provided that they are upstaged to T3N2 or T4N2 based on confirmed pathology. Patients who are staged asT3N2 or T4N2 prior to surgery are not eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "5. A contrast-enhanced CT or MRI scan of the chest must have been done for surgical planning prior to surgery. It is recommended that patients undergo combined FDG-PET (18F-Fluoro-deoxyglucose positron emission tomography) and CT scan (contrastenhanced or low-dose CT component) in order to rule out detectable extrathoracic, extracranial metastasis and to assess for potential mediastinal lymph node involvement prior to surgery. In the absence of pre-operative FDG-PET CT imaging, pre-operative contrast-enhanced CT imaging or MRI scan must cover liver and adrenal glands. If only CT is available, or FDG-PET reveals suspicious lymph node mediastinal involvement, it is recommended that invasive pre-operative mediastinal staging is performed according to the algorithm of the European Society of Thoracic Surgeons guidelines (algorithm to follow for primary mediastinal staging if only pre-operative CT is available \\[De Leyn et al 2007\\], algorithm to follow for primary mediastinal staging when PET-CT is available \\[De Leyn et al 2014\\]). It is preferred that imaging occurs within 6 weeks prior to surgery. Brain MRI (preferred) or brain CT with IV contrast is required for complete staging of the tumor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "6. Complete resection of the primary NSCLC is mandatory. The primary tumor must be deemed resectable by a multidisciplinary evaluation that must include a thoracic surgeon certified or trained according to local standards and who performs lung cancer surgery as a significant part of their practice. Surgical resection of the primary NSCLC can occur by open thoracotomy or by video-assisted thoracic surgery (VATS) and resection can be achieved by segmentectomy, lobectomy, sleeve resection, bilobectomy, or pneumonectomy. Patients undergoing wedge resection are not eligible for this study. Note: Patients undergoing segmentectomy must have tumors less than 2 cm in maximum diameter. Where a resection has been extended by means of a wedge resection of an adjacent lobe to ensure complete resection of a tumor at or crossing a fissure between lobes, this is acceptable if surgical margins are clear of disease. Where the resection of a second tumor nodule (eg, a T4 lesion) is undertaken by means of a wedge resection of a separate lobe, then the patient is not eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   At a minimum, the following parameters should be met for a tumor to be declared completely resected:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   1. The surgeon performing the resection should remove all gross disease by the end of surgery. All surgical margins of resection must be macroscopically negative for tumor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   2. Pathology and/or operative reports must include the examination of at least 2 different mediastinal lymph node (N2) levels, one of which is the subcarinal node-group (level 7) and the second of which is lobe-specific (defined below).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "      Note: In the uncommon clinical situation where the surgeon thoroughly examines a mediastinal lymph node level and does not find any lymph nodes, that mediastinal lymph node level may be counted among the minimum 2 required levels. However, the surgeon must clearly document in the operative report or in a separate written statement that the lymph node level was explored and no lymph nodes were present. Normal appearing lymph nodes, if present, must be biopsied or removed. Exploration of nodes must clearly be documented in medical file if not recorded in operative report.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "      Note: Lobe-specific lymph node stations are classified based on the location of the primary tumor as follows (based on IASLC 2009 lymph node map terminology \\[Rusch et al 2009\\]): Stations 2R and 4R for right upper lobe or middle lobe tumors, stations 4L, 5, and 6 for left upper lobe tumors, stations 8 and 9 for lower lobe tumors of both sides (Adachi et al 2017, Rami-Porta et al 2005).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   3. No extracapsular nodal extension of the tumor is observed in resected mediastinal N2 lymph nodes.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   Note: Extracapsular nodal extension in resected N1 nodes is permitted. Note: The highest mediastinal node resected can be positive for malignancy. Note: Carcinoma-in-situ can be present at the bronchial margin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "7. All patients who enrol in the study prior to surgery must have a pre-surgical plasma sample collected for MRD evaluation. Patients will not be excluded from randomization based on the results of analysing the pre-surgical plasma samples.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   The following criteria must be met prior to signing ICF2:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "8. Confirmation of suitable samples of resected tumor tissue and whole blood for WES of tumor and germline DNA, respectively, and creation of Sponsor-approved personalized panel for MRD detection. Tumor tissue and whole blood samples must be provided to the diagnostic laboratory for development of the personalized panel as soon as possible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   Germline sequencing of whole blood is mandatory. Note: If a patient's tumor has less than the requisite 50 tumor-specific variants, a panel cannot be built and the patient will no longer be able to participate in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "9. Established MRD status (MRD+ or MRD-) based on Sponsor-approved personalized assay of a plasma sample collected at Week 3-5 (Day 21-35) post-surgery.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "10. Known tumor PD-L1 status determined at a central reference laboratory testing service using a validated Ventana SP263 PD-L1 immunohistochemistry (IHC) assay prior randomization. Patients with unknown PD-L1 status are not eligible for the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "    Criteria and procedures initiated with the signing of ICF2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "11. Post-operative CT scan of the chest (including liver and adrenal glands) performed within 28 days + 7 days prior to randomization. If clinically indicated, additional scans (such as brain MRI \\[preferred\\] or brain CT with IV contrast) should be performed to confirm no evidence of metastasis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "12. ICF2 must be signed and dated after MRD status is determined and prior to initiation of any study-specific procedures, sampling, and analyses outlined in SoAs in Table 2 and Table 3. Randomization must occur within the 12 weeks (+ 7 days) following surgery.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "13. WHO/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "14. Complete postoperative wound healing must have occurred prior to randomization; patients must have recovered from all acute, reversible toxic effects from prior treatments (excluding alopecia) that could potentially adversely impact further administration of durvalumab/placebo or chemotherapy according to the Investigator's judgment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "15. Eligible to tolerate 4 cycles of platinum-based adjuvant chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "16. Adequate organ and marrow function as described in the protocol. 17 Must have a life expectancy of at least 12 weeks Weight 18 Body weight \\>30 kg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": ". Post-operative imaging demonstrating unequivocal evidence of disease recurrence or tissue biopsy-proven disease recurrence. In the event of lymphadenopathy on imaging that would lead to exclusion, histopathological confirmation of lymph node metastasis should be obtained prior to excluding a patient from the study. If pathological confirmation of lymph-node metastasis is not technically feasible and imaging appearance are deemed unequivocal for relapse, the patient will be excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "2. EGFR-mutant and/or ALK-translocation-positive, as assessed either from a pre-surgical biopsy sample (preferred) or the resected tumor tissue (if biopsy was not evaluable or available). Any of the following scenarios are acceptable for this study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   Where EGFR/ALK results are obtained from a pre-surgical tissue biopsy as part of standard local practice, the patient must be confirmed EGFR/ALK wild-type prior to enrolling in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   Results obtained from testing the patient's primary tumor tissue during screening for another AstraZeneca study may be used in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "   Results from local testing of a pre-surgical biopsy. All local EGFR/ALK testing performed locally must be performed using a well-validated, local regulatory-approved test. EGFR/ALK may be tested centrally if local testing is unavailable. Patients will still be allowed to continue with first screening procedures while testing is ongoing but will not be able to continue into second screening if their tumor tests positive for EGFR mutations and/or ALK translocations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "3. Mixed small cell and NSCLC histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "4. Require re-resection or are deemed to have unresectable NSCLC by a multidisciplinary evaluation that must include a thoracic surgeon who performs lung cancer surgery as a significant part of their practice.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "5. Patients who are candidates to undergo only wedge resections. Medical conditions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "6. History of allogeneic organ or bone marrow transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "7. Non-leukocyte-depleted whole blood transfusion within 120 days of genetic sample collection. Note: This exclusion criterion only relates to whole blood and does not include other blood products (eg, packed red blood cells).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "8. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[eg, colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "* Patients with vitiligo or alopecia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "* Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "* Any chronic skin condition that does not require systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "* Patients without active disease in the last 5 years may be included but only after consultation with the Study Physician",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "* Patients with celiac disease controlled by diet alone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active ILD, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "10. History of another primary malignancy, except for",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "* Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "* Adequately treated carcinoma-in-situ without evidence of disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "11. History of active primary immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "12. Active infection, including tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (HBV; known positive HBV surface antigen \\[HBsAg\\] result), hepatitis C (HCV), or human immunodeficiency virus infection (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "13. Known allergy or hypersensitivity to any of the IPs or any of the IP excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "14. Any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the local labeling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "    Prior/concomitant therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "15. Received any prior adjuvant therapy for NSCLC or any prior exposure to durvalumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "16. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "17. Radiotherapy treatment for NSCLC in the neoadjuvant setting. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "18. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "19. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "20. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab/placebo. The following are exceptions to this criterion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "* Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "* Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) Prior/concurrent clinical study experience",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "21. Participation in another clinical study with an IP administered since completion of surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "22. Previous IP assignment in the present study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "23. Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study, or during the follow-up period of an interventional study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "24. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment group assignment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "    Other exclusions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "25. Patients who are never-smokers; defined as no more than 100 cigarettes or its equivalent in his/her lifetime.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "26. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab/placebo.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04385368",
    "statement": "27. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735904",
    "statement": "* Histologically- or cytologically-confirmed diagnosis of squamous NSCLC Stage IIIB with malignant effusion (fluid cytology demonstrating malignant cells required), Stage IV, or recurrent disease after definitive local therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735904",
    "statement": "* Candidate for primary treatment with cisplatin and gemcitabine",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735904",
    "statement": "* Presence of measurable disease by RECIST",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735904",
    "statement": "* Adequate organ function as defined by the following criteria: ECOG performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735904",
    "statement": "* Prior systemic treatment for Stage IIIB (with malignant effusion) or Stage IV NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735904",
    "statement": "* One or more lung lesions with cavitation, or any lesion invading or abutting a major blood vessel as assessed by CT or MRI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735904",
    "statement": "* History of hemoptysis \\> ½ tsp (2.5 ml) of blood per day for a day or more within 1 week of study treatment, or Grade 3 or 4 hemoptysis within 4 weeks of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735904",
    "statement": "* NCI CTCAE Grade 3 hemorrhage from any cause within 4 weeks of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735904",
    "statement": "* Preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735904",
    "statement": "* Untreated brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735904",
    "statement": "* Need for therapeutic anticoagulation, regular use of aspirin (\\> 325 mg/day), NSAID or other medications known to inhibit platelet function.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* ECOG Status: PS 0-1 \\& PS 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* Subjects with histologically or cytologically-documented SqNSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* Subjects must have experienced disease progression or recurrence during or after one prior platinum doublet-based chemotherapy regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* Subjects must have evaluable disease by CT or MRI per RECIST 1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* Subjects with treated or asymptomatic CNS metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* Prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* Prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy, immunotherapy, surgical resection of lesions, non-palliative radiation therapy, or standard or investigational agents for treatment of NSCLC, must be completed 28 days prior to the first dose of nivolumab",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* Males and Females, ages 18 or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* Subjects with untreated, symptomatic CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* Subjects with carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* Subjects with active, known or suspected autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409368",
    "statement": "* Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Signed written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Male or female participants aged greater than or equal to 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Participants must have histologically or cytologically proven metastatic or locally advanced solid tumors, for which no standard therapy exists or standard therapy has failed. Availability of tumor archival material or fresh biopsies is optional for participants in dose escalation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST 1.1, except for participants with metastatic castrate-resistant prostate cancer (mCRPC) or metastatic breast cancer (MBC) who may be enrolled with objective evidence of disease without a measureable lesion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Adequate hematological, hepatic and renal function as defined in the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Effective contraception for both male and female participants if the risk of conception exists",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Other protocol defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "Inclusion Criteria for expansion phase:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Participants must have relapsed, refractory, or progressive disease following last line of treatment (with the exception of the gastric and gastroesophageal junction (GEJ) cancer cohort, which does not require progression). Availability of tumor archival material or fresh biopsies (excluding bone biopsies) is mandatory for eligibility in the expansion cohorts. For participants in the MBC cohort, the biopsy or surgical specimen must have been collected within 90 days prior to the first investigational medicinal product (IMP) administration. Specifically, the following will be required:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* NSCLC post platinum doublet: Histologically or cytologically confirmed stage IIIB or stage IV NSCLC that has progressed after 1 line of platinum-containing doublet chemotherapy. Participants should have received only 1 line of platinum-containing treatment for metastatic disease (i.e., adjuvant treatment with a platinum-containing regimen is not sufficient for eligibility because not received in the context of a metastatic disease). Participants in the NSCLC cohort will only be enrolled in USA",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* NSCLC first line: Stage IV (per 7th International Association for the Study of Lung Cancer \\[IASLC\\] classification) or recurrent NSCLC that is histologically proven. Participants must not have received treatment for their metastatic or recurrent disease. No activating epidermal growth factor receptor (EGFR) mutation nor ALK translocation/re-arrangement",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Gastric and GEJ cancer: Histologically confirmed, unresectable locally advanced or metastatic adenocarcinoma of the gastric and gastro-esophageal junction, treated with first-line chemotherapy combination with or without disease progression. Participants should have received no more than 1 line of treatment for metastatic disease. Participants should not have been treated with trastuzumab (but can be Human Epidermal growth factor Receptor 2 \\[HER2\\] positive). Participants who received any platinum containing doublet or triplet as a neoadjuvant chemotherapy strategy, but are not ultimately candidates for surgery will also be eligible, as long as they did not have progressive disease after completion of the neoadjuvant chemotherapy. In addition, participants with gastric cancer can enter in the study if their white blood cell (WBC) and lymphocyte count is as defined in the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* MBC: Participants must have histologically confirmed locally advanced or MBC and have tumor that is refractory to or progressive after standard of care therapy. Participants must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. Participants must have received a taxane and an anthracycline, unless contra-indicated",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Secondary expansion cohorts: Metastatic colorectal cancer (mCRC), Metastatic castrate-resistant prostate cancer (mCRPC), melanoma, ovarian cancer, ACC, mesothelioma, urothelial carcinoma and renal cell carcinoma as defined in the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Efficacy expansion cohorts: Gastric and GEJ cancer (third line), ovarian cancer (platinum Refractory + liposomal doxorubicin), urothelial carcinoma, and HNSCC as defined in the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Other protocol defined inclusion criteria for expansion phase could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Concurrent treatment with a non-permitted drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Prior therapy with specific antibody/drug targeting T cell co-regulatory proteins (immune checkpoints)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Concurrent anticancer treatment, major surgery, or use of any investigational drug within 28 days before the start of trial treatment; or concurrent systemic therapy with immunosuppressive agents, use of hormonal agents within 7 days before the start of trial treatment as defined in the protocol. Note: Participants receiving bisphosphonate or denosumab are eligible provided treatment was initiated at least 14 days before the first dose of avelumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Previous malignant disease other than the target malignancy to be investigated in this trial within the last 5 years with the exception of basal or squamous cell carcinoma of the skin or cervical carcinoma in situ",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Rapidly progressive disease (for example, tumor lysis syndrome)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Active or history of central nervous system metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Receipt of any organ transplantation including allogeneic stem-cell transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Significant acute or chronic infections as defined in the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Active or history of any autoimmune disease (Participants with diabetes Type 1, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible) or immunodeficiencies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Persisting toxicity related to prior therapy greater than Grade 1 NCI-CTCAE v4.0, however sensory neuropathy less than or equal to Grade 2 is acceptable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Pregnancy or lactation period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Known alcohol or drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Clinically significant (that is, active) cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* All other significant diseases (for example, inflammatory bowel disease), which, in the opinion of the investigator, might impair the Participant's tolerance of trial treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Any psychiatric condition that would prohibit the understanding or rendering of informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Legal incapacity or limited legal capacity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01772004",
    "statement": "* Non-oncology vaccine therapies for prevention of infection disease (for example, seasonal flu vaccine, human papilloma virus vaccine) within 4 weeks of study drug administration. Vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Age ≥20 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Histologic or cytologic diagnosis of advanced non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Advanced NSCLC, defined as stage IIIB (without indications for radiotherapy), stage IV, or recurrent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* No prior chemotherapy-containing regimens for the treatment of NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Eastern Cooperative Oncology Group performance status of 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Accessible for treatment and follow up; patients who could be hospitalized for first 15 days of Cycle 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Adequate recovery from previous systemic therapy (at least 3 weeks for surgery or radiation therapy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Women of childbearing potential (WOCBP) unwilling or unable to use an acceptable method to avoid pregnancy for study period and for up to 4 weeks after last dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Women pregnant or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Women with a positive pregnancy test result on enrollment or prior to study drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Sexually active fertile men not using effective birth control for the entire study period and for up to 3 months after the last dose of study drug if their partners are WOCBP",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Patients with symptomatic or requiring treatment for brain metastases and/or leptomeningeal metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Prior radiation must not have included ≥30% of major bone-marrow-containing areas (pelvis, lumbar spine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Common Terminology Criteria (CTC) Grade 2 or greater neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Psychiatric or other disorders rendering the patient incapable of complying with protocol requirements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Any concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix (Patients with a history of malignancy but without evidence of disease for 5 years are eligible)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Serious uncontrolled medical disorder or active systemic infection that would impair the ability of the subject to receive protocol therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Myocardial infarction, unstable angina, or unstable congestive heart failure within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Known history of infection with human immunodeficiency virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Inadequate bone marrow function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Inadequate hepatic function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Inadequate renal function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Known prior severe hypersensitivity reaction (CTC Grade 2 or greater) to agents containing Cremophor®EL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Known severe hypersensitivity reaction to agents containing carboplatin and other platinum",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Prior treatment with an epothilone and/or with platinum",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* History of high-dose chemotherapy with bone marrow transplant or peripheral blood stem cell support within 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* On treatment with strong Cytochrome P450 3A4 inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Current imprisonment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00683904",
    "statement": "* Compulsorily detention for treatment of psychiatric or physical illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": ". signed inform consent form(ICF)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "2. Age ≥ 18 years and ≤ 75 years, male or female",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "3. Histologically or cytologically documented inoperable, local advanced (stage IIIB), metastatic (stage IV), or recurrent non-squamous NSCLC; Mixed tumors should be categorized according to the predominant cell type",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "4. Histologically confirmed epidermal growth factor receptor (EGFR) wild type or insensitive mutation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "5. At least one measurable lesion according to Response Evaluation Criteria In Solid Tumors（RECISIT） v 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "6. Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "7. Life expectancy ≥ 6 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "8. Laboratory results:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "   1. Adequate hematologic function, defined as absolute neutrophil count ≥1.5×10\\^9 /L, platelet count ≥100 ×10\\^9 /L, hemoglobin ≥90g/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "   2. Adequate liver function, defined as total bilirubin levels ≤ 1.5 times normal upper limit (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times ULN, or AST and ALT levels ≤ 5 times ULN for patients with hepatic metastasis;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "   3. Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 50 ml / min (Cockcroft-Gault formula) and proteinuria \\< 2+;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "   4. Coagulation function is adequate, defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times normal upper limit (ULN), PTT or aPTT ≤ 1.5 times ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "9. Expected protocol compliance",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "10. Patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for 6 months after receiving last study treatment (e.g. abstinence, sterilization surgery, oral contraceptives, contraception by progesterone injection or subcutaneous).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": ". Prior chemotherapy or target therapy with another systemic anti-cancer agent (e.g., monoclonal antibody, tyrosine kinase inhibitor) for the treatment of the patient's current stage of disease (Stage IIIB not amenable for combined modality treatment, stage IV or recurrent disease). Prior surgery and irradiation is permitted, provided that the criteria outlined in the protocol for both treatments are met. Disease progressed within 6 months after adjuvant therapy must be excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "2. Mixed non-small cell and small cell carcinoma, or mixed adenosquamous carcinomas with predominant squamous cell",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "3. Histologically or cytologically confirmed EGFR sensitive mutation type, unknown EGFR status for any reason is allowed in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "4. Known hemoptysis within 3 months prior to screening with blood volume more than 2.5 mL each time",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "5. Evidence of tumor invading major blood vessels on imaging. The investigator or the local radiologist must exclude evidence of tumor that is fully contiguous with, surrounding, or extending into the lumen of a major blood vessel (e.g., pulmonary artery or superior vena cava)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "6. Evidence of brain metastasis, spinal cord compression or carcinomatous meningitis history with clinical symptoms. For stable patients with no symptom, could be admitted if fulfill all below criteria: measurable lesion(s) out of CNS, no metastasis at mesocephalon, annular protuberance, medulla oblongata and spinal cord; no history of intracranial bleeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "7. Radical radiotherapy to the thorax with curative intent within 28 days prior to enrollment; palliative radiotherapy for bone lesions outside the thoracic region within 2 weeks prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "8. Serious, non-healing wound, active ulcer, or untreated bone fracture, or major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "9. Minor surgery (Including insertion of an indwelling catheter) within 48 hours prior to first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "10. Recent or current (within 10 days prior to first dose of study treatment) receive treatment of Aspirin (\\> 325 mg/day) or other non-steroidal anti-inflammatory drugs (NSAID) known to inhibit platelet function (within 10 days prior to first dose of study treatment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "11. Recent or current receive treatment of oral all doses of oral or parenteral anticoagulants or thrombolytic agent. Prophylactic use of anticoagulants is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "12. History or evidence of inherited bleeding diathesis or coagulopathy or thrombus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "13. Uncontrolled hypertension (SBP\\>140 mmHg and/or diastolic blood pressure\\>90 mmHg), prior history of hypertensive crisis and hypertensive encephalopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "14. Clinically significant cardiovascular disease but not limited to active infections; unstable angina; stroke or transient cerebral ischemia (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening) ; congestive heart-failure (New York Heart Association (NYHA) class≥ II) ; serious cardiac arrhythmia, hepatic, renal or metabolic disease requiring medication during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "15. History of peptic ulcer, gastrointestinal perforation, erosive esophagitis, erosive gastritis, inflammatory bowel disease or diverticulitis, abdominal fistula or intra-abdominal abscess within 6 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "16. Patient diagnosed with a tracheo-esophageal fistula",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "17. Clinically significant third space effusion (e.g., uncontrolled ascites or pleural effusion by extraction or other treatment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "18. Pulmonary fibrosis or active pneumonia showed by CT at baseline",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "19. Active malignancy other than non-small cell lung cancer (NSCLC), treated carcinoma in situ of the cervix, superficial basal cell or squamous cell carcinoma, radical surgery of localized prostate cancer, radical surgery of ductal carcinoma in situ within 5 years prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "20. Known autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "21. Known positive HbsAg and hepatitis B virus (HBV)-DNA drop test in peripheral blood ≥ 1 x 10\\^3 copy number/L or 200 IU/mL; If HBsAg positive and HBV-DNA drop test in peripheral blood \\< 1 x 10\\^3 copy number/L or 200 IU/mL, patient is considered to be eligible by investigator only when chronic hepatitis B in the plateau and do not increase the risk",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "22. Known positive HIV or hepatitis C virus (HCV) or syphilis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "23. Known allergic disease or allergic physique",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "24. Treatment with any other investigational agent or participation in another clinical trial within 30 days prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "25. Known alcoholism or drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "26. Pregnant or anticipation of pregnant during the study or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "27. Known hypersensitivity to bevacizumab or any of its excipients and/or any of the chemotherapy agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02954172",
    "statement": "28. Other conditions that the investigator thinks unsuitable in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": ". Male and female subjects, age greater than or equal to 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "2. Females should be either of non-childbearing potential as a result of surgery, radiation therapy, menopause (one year post onset), or of childbearing potential and willing to adhere to an acceptable method of pregnancy prevention.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "3. Subjects must be newly diagnosed, symptomatic proximal deep-vein thrombosis of the lower extremity, pulmonary embolism, or both.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "4. Subjects must have active malignancy defined as a diagnosis of cancer (excluding basal cell or squamous cell carcinoma of the skin) within six months before enrollment, having received any treatment for cancer within the previous six months, or having documented recurrent or metastatic cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "5. Prior to enrollment, subjects must not have received therapeutic doses of anticoagulant therapy (including low molecular weight heparin \\[LMWH\\]) for \\>48 hours (or \\>4 doses within 48 hours).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "7. Subjects must have a life expectancy of \\>6 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "8. Subjects must have a platelet count of \\>75,000 mm\\^3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "9. The subject must not be on any oral anticoagulant therapy for concomitant diseases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "10. Subjects must have no active or serious bleeding episodes within two weeks prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "11. Subjects must be able to comply with scheduled follow-ups.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": ". Subjects who have a high risk of serious bleeding (e.g., recent neurosurgery within 30 days, history of intracranial hemorrhage, acute gastroduodenal ulcer, etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "2. Subjects who are on hemodialysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "3. Subjects who have a prior placement of a Greenfield filter or other device to prevent embolization of deep vein thromboses.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "4. Subjects with a known contraindication to the use of heparin (e.g., heparin-induced thrombocytopenia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "5. Subjects with a known hypersensitivity to heparin, dalteparin sodium, other LMWHs or pork products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "6. Subjects who are currently participating in another clinical trial involving anticoagulation therapy (with the exception of acetylsalicylic acid (ASA) in the 30 days prior to study entry, or who are actively using any investigational drugs/treatments 30 days prior to study entry involving anticoagulation therapy (with the exception of ASA , t.i.d).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "7. Subject is pregnant or breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "8. Subjects with uncontrolled hypertension characterized by a sustained systolic pressure \\>170 mmHg and/or diastolic pressure \\>100 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "9. Subjects with a serious concomitant systemic disorder (for example, active infection including HIV or cardiac disease) that in the opinion of the investigator, would compromise the subject's ability to complete the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "10. Any condition that makes the subject unsuitable in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00942968",
    "statement": "11. Subjects with leukemia or myeloproliferative syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Participants must have evidence of histologically or cytologically confirmed diagnosis of metastatic NSCLC (Stage IV, American Joint Committee on Cancer \\[AJCC\\] v7.0) that carries an ALK rearrangement.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Disease Status Requirements: disease progression after alectinib or ceritinib as first line therapy (the study will limit enrollment of participants with best response of progression or indeterminate on prior alectinib to 8 participants). Participants may have had prior chemotherapy, but only if before starting treatment with alectinib or ceritinib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Tumor Requirements: All Participants must have at least one measurable target extracranial lesion according to RECIST v1.1. Participants with asymptomatic CNS metastases (including participants controlled with stable or decreasing steroid use within the last 2 weeks prior to study entry) will be eligible. Participants who have leptomeningeal disease (LM) or carcinomatous meningitis (CM) will be eligible if the LM/CM is visualized on magnetic resonance imaging (MRI) or if documented baseline cerebral spinal fluid (CSF) positive cytology is available.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Adequate bone marrow functioning, pancreatic function, renal function and liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Acute effects of any prior therapy resolved to baseline severity or to CTCAE Grade ≤1 except for adverse events (AEs) that in the investigator' judgment do not constitute a safety risk for the participant.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Systemic anti-cancer therapy with alectinib or ceritinib discontinued within a minimum of 5 half-lives prior to first dose of lorlatinib on the study (unless clinically meaningful tumor flare per discretion of the investigator, in which discussion with the sponsor is warranted).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Male participants are eligible to participate if they agree to use proper contraception during the intervention period and for at least 98 days after the last dose of study intervention",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Female participants are eligible to participate if they are not pregnant or breastfeeding, and agree to use proper contraception during the intervention period and for at least 35 days after the last dose of study intervention.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Capable of giving signed informed consent and willingness and ability to comply with the study scheduled visits and other procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Prior ALK TKI treatment or anti-cancer treatment other than first line alectinib or ceritinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Spinal cord compression unless the participant has good pain control attained through therapy, and there is stabilization or recovery of neurological function for the 4 weeks prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Gastrointestinal abnormalities, including inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection or lap band; active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer disease in the past 6 months; malabsorption syndromes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV) or hepatitis C virus (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Clinically significant vascular (both arterial and venous) and non-vascular cardiac conditions, (active or within 3 months prior to enrollment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Participants presenting with abnormal Left Ventricular Ejection Fraction (LVEF) by echocardiogram or Multi-Gated Acquisition Scan according to institutional lower limits.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Participants with predisposing characteristics for acute pancreatitis according to investigator judgment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* History or known presence of interstitial fibrosis, interstitial lung disease, pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and pulmonary fibrosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, ductal carcinoma in situ (DCIS) of the breast or localized and presumed cured prostate cancer) within the last 3 years prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation must have been completed at least 48 hours prior to study entry. Stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study entry. Whole brain radiation must have completed at least 4 weeks prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Prior irradiation to \\>25% of the bone marrow.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Concurrent use of any of the following food or drugs within 12 days prior to the first dose of lorlatinib: known strong CYP3A inducers, known strong CYP3A inhibitors, known CYP3A substrates with narrow therapeutic index, known permeability glycoprotein (P-gp) substrates with a narrow therapeutic index",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Major surgery within 4 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Known prior or suspected severe hypersensitivity to study interventions or any component in their formulations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04362072",
    "statement": "* Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01946789",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01946789",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* Able to provide informed consent and comply with requirements of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* Males ≥18 y.o. with confirmed diagnosis of hemophilia B (≤2 IU/dL or ≤2% endogenous factor IX)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* Received ≥50 exposure days to factor IX products",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* A minimum average of 4 bleeding events per year requiring episodic treatment of factor IX infusions or prophylactic factor IX infusions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* No measurable factor IX inhibitor as assessed by the central laboratory and have no prior history of inhibitors to factor IX protein",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* Agree to use reliable barrier contraception until 3 consecutive samples are negative for vector sequences",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* Evidence of active hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* Currently on antiviral therapy for hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* Have significant underlying liver disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* Have serological evidence\\* of HIV-1 or HIV-2 with CD4 counts ≤200/mm3 (\\* subjects who are HIV+ and stable with CD4 count \\>200/mm3 and undetectable viral load are eligible to enroll)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* Neutralizing antibodies reactive with AAV-Spark100 above and/or below a defined titre",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* Participated in a gene transfer trial within the last 52 weeks or in a clinical trial with an investigational drug within the last 12 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02484092",
    "statement": "* Unable or unwilling to comply with study assessments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Male or female patient with histologically proven, measurable metastatic cutaneous melanoma, and with documented progressive disease within the 12 weeks before the first administration of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Written informed consent for NY-ESO-1 expression screening and gene profiling on resected tumor tissue and for the complete study has been obtained from the patient prior to shipment of the sample for expression testing and prior to the performance of any other protocol-specific procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Patient is \\>= 18 years of age at the time of signature of the informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient's tumor shows expression of NY-ESO-1, as determined by real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis or any updated technique on fresh tissue sample(s).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Eastern Cooperative Oncology Group performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient has normal organ functions as shown by all of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Hemoglobin ≥ 12 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Absolute leukocytes count ≥ 3.0 x 1000000000/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Absolute lymphocytes count ≥ 1.0 x 1000000000/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Platelets ≥ 100 x 1000000000/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Serum creatinine ≤ Upper Limit of Normal (ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Serum total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert's syndrome for whom the limit is 2 x ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Lactate dehydrogenase ≤ ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Aspartate aminotransferase ≤ 2 × ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Alanine aminotransferase ≤ 2 × ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "These tests must be done no more than 3 weeks before the first ASCI administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Female patients of non-childbearing potential may be enrolled in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Female patient of childbearing potential may be enrolled in the study, if the patient:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* has practiced adequate contraception for 30 days prior to first ASCI administration, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* has a negative pregnancy test at the specified study visits, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the ASCI administration series.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* In the view of the investigator, the patient can and will comply with the requirements of this protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient has at any time received systemic chemotherapy, biochemotherapy, small molecules or nti-CTLA-4 monoclonal antibody for metastatic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient is scheduled to receive any other anticancer treatments than those specified in the protocol, including but not limited to (bio-) chemotherapeutic, immunomodulating agents and radiotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient received any cancer immunotherapy containing a NY-ESO-1 antigen or any cancer immunotherapy for his/her metastatic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient requires concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* Use of any investigational or non-registered product other than the ASCI within 30 days preceding the first ASCI administration, or planned use during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient has (had) previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers or carcinoma in situ of the cervix or effectively treated malignancy that has been in remission for over 5 years and is highly likely to have been cured.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient has an allergy to any component of the study investigational product or has a history of previous allergic reactions to vaccinations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient has an autoimmune disease such as, but not limited to, multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient has a family history of congenital or hereditary immunodeficiency.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient is known to be positive for the Human Immunodeficiency Virus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient has an uncontrolled bleeding disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient has a family history of congenital or hereditary immunodeficiency.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the trial procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01213472",
    "statement": "* For female patients: the patient is pregnant or lactating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Signed written informed consent before any trial related procedure",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Male or female participants aged greater than or equal to (\\>=) 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Availability of a formalin-fixed, paraffin-embedded block containing tumor tissue or 7 unstained tumor slides suitable for PD-L1 expression assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Tumor determined to be evaluable for PD-L1 expression per the evaluation of a central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Participants with histologically confirmed Stage IIIb/IV or recurrent NSCLC who have experienced disease progression",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Participants must have progressed after an acceptable therapy defined as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "  1. Participants must have progressed during or after a minimum of 2 cycles of 1 course of a platinum based combination therapy administered for the treatment of a metastatic disease. A history of continuation (use of a non platinum agent from initial combination) or switch (use of a different agent) maintenance therapy is permitted provided there was no progression after the initial combination. A switch of agents during treatment for the management of toxicities is also permitted provided there was no progression after the initial combination OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "  2. Participants must have progressed within 6 months of completion of a platinum-based adjuvant, neoadjuvant, or definitive chemotherapy, or concomitant chemoradiation regimen for locally advanced disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Participants with non-squamous cell NSCLC of unknown epidermal growth factor receptor (EGFR) mutation status will require testing (local laboratory, or central laboratory if local testing is not available). Participants with a tumor that harbors an activating EGFR mutation will not be eligible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Estimated life expectancy of more than 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Adequate hematological function defined by White Blood Cell (WBC) count \\>= 2.5 × 10\\^9/L with absolute neutrophil count (ANC) \\>= 1.5 × 10\\^9/L, lymphocyte count \\>=0.5 × 10\\^9/L, platelet count \\>= 100 × 10\\^9/L, and hemoglobin \\>= 9 gram per deciliter (g/dL) (may have been transfused)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Adequate hepatic function defined by a total bilirubin level less than or equal to (\\<=) 1.5 × the upper limit of normal (ULN) range and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels \\<= 2.5 × ULN for all participants",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Adequate renal function defined by an estimated creatinine clearance \\> 30 milliliter per minute (mL/min) according to the Cockcroft-Gault formula (or local institutional standard method).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Other protocol defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* In the United States only, participants with a squamous cell histology will be excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Systemic anticancer therapy administered after disease progression during or following a platinum based combination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Participants with non-squamous cell NSCLC whose disease harbors EGFR mutation(s) and/or anaplastic lymphoma kinase (ALK) rearrangement will not be eligible for this trial. Participants of unknown ALK and/or EGFR mutation status will require testing at screening (local laboratory, or central laboratory if local testing is not available)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Prior therapy with any antibody/drug targeting T cell coregulatory proteins (immune checkpoints) such as PD-1, PD L1, or cytotoxic T lymphocyte antigen-4 (CTLA-4).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Concurrent anticancer treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Major surgery for any reason, except diagnostic biopsy, within 4 weeks of randomization and/or if the participant has not fully recovered from the surgery within 4 weeks of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Participants receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of the trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* All participants with brain metastases, except those meeting the following criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "  1. Brain metastases have been treated locally, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "  2. No ongoing neurological symptoms that are related to the brain localization of the disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "  1. Participants with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "  2. Participants requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses less than or equal to (\\<=)10 milligram (mg) or equivalent prednisone per day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "  3. Administration of steroids through a route known to result in a minimal systemic exposure are acceptable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "* Previous or ongoing administration of systemic steroids for the management of an acute allergic phenomenon is acceptable as long as it is anticipated that the administration of steroids will be completed in 14 days, or that the daily dose after 14 days will be \\<=10 mg per day of equivalent prednisone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Other protocol defined exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has a histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or reactive oxygen species (ROS) 1 directed therapy is not indicated as primary therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has PD as determined by the investigator after platinum doublet chemotherapy for metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has measurable disease defined as at least 1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI), based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has provided tumor tissue for PD-L1 biomarker analysis from an archival sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has a life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 assessed within 7 days prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Male participants randomized to docetaxel are eligible to participant if they agree to refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse; or 2) must agree to follow contraceptive guidance as per study protocol unless confirmed to be azoospermic during the intervention period and for at least 180 days after the last dose of docetaxel",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Female participants must be not pregnant, not breastfeeding, and not be a woman of child-bearing potential (WOCBP). A WOCBP is eligible is she agrees to either use contraception, or be abstinent from heterosexual intercourse during the intervention period and for ≥120 days after the last dose of study intervention. If a WOCBP is randomized to docetaxel, she agrees not to donate eggs and either uses contraception or be abstinent from heterosexual intercourse during the treatment period and for ≥180 days after the last dose of docetaxel",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has known active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has received docetaxel as monotherapy or in combination with other therapies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has received previous treatment with another agent targeting the T-cell immunoreceptor with immunoglobulin \\[Ig\\] and immunoreceptor tyrosine-based inhibitory motif \\[ITIM\\] domains (TIGIT) pathway",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has received radiotherapy within 2 weeks of start of study intervention. One week washout is permitted for palliative radiation to non-CNS disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has severe hypersensitivity (≥Grade 3) to docetaxel or pembrolizumab/vibostolimab coformulation and/or any of its excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has an active autoimmune disease that has required systemic treatment in past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has interstitial lung disease, or history of pneumonitis requiring steroids for treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has known history of active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has had an allogenic tissue/solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04725188",
    "statement": "* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Patients must have histologically or cytologically confirmed advanced or metastatic:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Resistant/Refractory Small Cell Carcinoma (SCC) patients in 3rd line or beyond that have previously received platinum or patients in 2nd line with platinum-refractory or platinum-resistant disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* EGFR mutated non-small cell lung cancer (NSCLC) that has previously received a first line platinum doublet and all applicable EGFR TKIs",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Epithelial Ovarian Cancer (EOC), fallopian tube or primary peritoneal cancer and Malignant Mixed Mullerian Tumor (MMMT) of the ovary or uterus. Excludes other non-epithelial ovarian tumors and ovarian tumors with low malignant potential. Patients must have previously received a platinum based regimen for advanced/metastatic disease or have platinum resistant or refractory disease defined as relapse within 6 months. EOC - specific criteria: Patients who progress or have stable disease during first-line treatment or who relapse within 1 month are considered to be 'platinum-refractory'. Patients who respond to primary treatment and relapse within 6 months are considered 'platinum-resistant', and patients who relapse more than 6 months after completion of initial therapy are characterized as 'platinum-sensitive'. Patients who relapse 6-12 months following the end of their initial regimen are classified as 'partially sensitive'. Platinum sensitive patients may be enrolled but must have failed or declined all other lines of FDA approved therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* High-Grade Neuroendocrine Carcinoma (HGNEC), any organ of origin, including a pathology of neuroendocrine features, in patients previously been treated with chemotherapy Although neuroendocrine tumors may be classified differently based on organ of origin, in the context of this protocol they are defined as high grade on the basis of either",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "    1. Aggressive clinical behavior requiring previous treatment with chemotherapy even if histologic features such as the Ki67 index or mitotic rate corresponds with low or intermediate grade.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "    2. Histologic features: (a) Neuroendocrine tumors of lung origin are considered high grade if in any part of the tumors, there are \\>10 mitoses/2mm2 or 10 high power field (HPF). Large zones of necrosis are usually present. This includes small cell lung carcinoma and large cell neuroendocrine lung carcinoma. \\[SCLC will not enroll in the HGNEC cohort.\\] (b)Neuroendocrine tumors of gastroenteropancreatic origin are considered high grade if in any part of the tumors there are either \\>20 mitoses/2mm2 or 10 high power field (HPF) OR Ki67.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Radiographically measurable disease by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* A washout period of 3-weeks from last treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Patients must have previously received a platinum based regimen for advanced/metastatic disease and progressed or have platinum resistant or refractory disease defined as relapse within 6 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Age ≥18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Life expectancy of ≥12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* ECOG performance status 0-2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Participants must have adequate organ and marrow function as defined below both prior to administration of RRx-001 and prior to administration of platinum doublet based regimen:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Absolute neutrophil count ≥1,500/mcL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Platelets ≥100,000/mcL (non-transfused platelet count)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Hemoglobin ≥9 g/dL (transfused Hgb allowed)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Creatinine ≤1.5 x the upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Total bilirubin ≤2.0 x the upper limit of normal or \\<3.0 xULN if patient has a history of Gilbert's syndrome",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* AST (SGOT)/ALT (SGPT) ≤5 X institutional upper limit of normal if with liver metastases; ≤2.5 X ULN if no liver metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Patient must consent to the access, review and analysis of previous medical and cancer history, including tumor archival tissue (if available) and imaging data by the sponsor or a third party nominated by the sponsor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Ability to understand and sign a written informed consent document.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Note: A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been postmenopausal for at least 12 consecutive months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Receiving concurrent investigational therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Symptomatic central nervous system metastasis (e.g., patients requiring increasing doses of steroids)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* History of needing to permanently discontinue prior platinum doublet-based regimen for toxicity (e.g., cisplatin causing renal impairment, ototoxicity, or severe neuropathy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Known severe hypersensitivity to the platinum agent (i.e., carboplatin or cisplatin) or prior partner of platinum agent (i.e., etoposide for SCC and HGNEC; nab-paclitaxel, paclitaxel, or pemetrexed for NSCLC; paclitaxel, pegylated liposomal doxorubicin, docetaxel or gemcitabine for ovarian) planned for the platinum therapy period. If the patient has had prior hypersensitivity reaction to the drug partner of platinum, a patient may enroll as long as it is acceptable to treat with platinum and one of the alternative chemotherapy partner agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Any significant medical diseases or conditions, as assessed by the investigators and sponsor that would substantially increase the medical risks of participating in this study (i.e., uncontrolled diabetes, NYHA II-IV congestive heart failure, myocardial infarction within 6 months of study, severe chronic pulmonary disease or active uncontrolled infection, uncontrolled or clinically relevant pulmonary edema).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02489903",
    "statement": "* Pregnant or nursing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Subjects must be initiating first-line carboplatin/paclitaxel chemotherapy within 8 days after randomization and expected to receive at least 4 cycles of chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Small cell lung cancer (SCLC) or mixed SCLC and NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Central nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Malignancy other than NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Palliative radiotherapy for bone lesions inside the thorax",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Prior radiotherapy of bone marrow",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Known to be positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Life expectancy \\< 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Woman of child-bearing potential who is pregnant or is breast feeding or who is not consenting to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01966003",
    "statement": "* Other inclusion/exclusion criteria may apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Is of the Chinese race (i.e., Chinese descent born in China) and has a Chinese home address.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has a life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has histologically-/cytologically-confirmed, advanced unresectable NSCLC and has measurable disease based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the site.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has failed established standard medical anti-cancer therapies or has been intolerant to such therapy, or in the opinion of the investigator have been considered ineligible for any form of standard therapy on medical grounds.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has a score of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status within 3 days prior to the first dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Male participants of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study drug through 120 days after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has had chemotherapy, radioactive, or biological cancer therapy within 4 weeks prior to the first dose of study therapy pembrolizumab, or who has not recovered to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from the AEs due to cancer therapeutics administered more than 4 weeks earlier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Is expected to require any other form of antineoplastic therapy while on study (including maintenance therapy with another agent for NSCLC).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has a medical condition that requires chronic systemic steroid therapy or on any other form of immunosuppressive medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has a known history of a hematologic malignancy, primary brain tumor or sarcoma, or of another primary solid tumor, unless the participant has undergone potentially curative therapy with no evidence of that disease for 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has known central nervous system metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are stable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Had prior treatment targeting PD-1: PD-L1 axis or cytotoxic T-lymphocyte-associated protein, or was previously randomized in any pembrolizumab study. Examples of such agents include (but are not limited to): Nivolumab (BMS-936558, MDX-1106 or ONO-4538); Pidilizumab (CT-011); AMP-224; BMS-936559 (MDX-1105); MPDL3280A (RG7446); and MEDI4736.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has an active infection requiring systematic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Is positive for Human Immunodeficiency Virus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has known active Hepatitis B or C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Has received or will receive a live vaccine within 30 days prior to the first administration of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Is at the time of signing informed consent, a regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02835690",
    "statement": "* Is pregnant or breastfeeding, or expecting to conceive or father a child within the projected duration of the study, starting with the screening visit (Visit 1) through 120 days after the last dose of pembrolizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": ". Males of any race, between 35 and 55 years of age, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "2. Body mass index between 18.0 and 32.0 kg/m2, inclusive, and a total body weight between 50 and 100 kg, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "3. In good health, determined by no clinically significant findings from medical history, vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \\[eg, suspicion of Gilbert's syndrome based on total and direct bilirubin\\] is not acceptable) at screening and check-in and from the physical examination at check-in, as assessed by the investigator (or designee).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "4. No clinically significant abnormalities in 12-lead ECG determined within 28 days before dose of IMP including average PR \\> 220 ms and QT interval corrected for heart rate using Fridericia's formula \\>450 ms.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "5. No history of clinically significant dysrhythmias (long QT features on ECG, sustained bradycardia, left bundle branch block, or ventricular arrhythmia), atrial fibrillation, or history of familial long QT syndromes.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "6. Will agree to use contraception as detailed in the study protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "7. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "8. History of a minimum of 1 bowel movement per day.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": ". Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "4. Positive hepatitis panel and/or positive human immunodeficiency virus test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "   Prior/concomitant therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "5. Administration of a COVID-19 vaccine in the past 30 days prior to dosing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "6. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to check-in, unless deemed acceptable by the investigator (or designee).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "7. Use or intend to use any prescription medications/products within 14 days prior to check-in, unless deemed acceptable by the investigator (or designee).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "8. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to check-in, unless deemed acceptable by the investigator (or designee).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "9. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior to check-in, unless deemed acceptable by the investigator (or designee).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "   Prior/concurrent clinical study experience",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "10. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days prior to dosing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "11. Subjects who have participated in any clinical study involving a radiolabelled investigational product within 12 months prior to check-in.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "12. Have previously completed or withdrawn from this study or any other study investigating bemcentinib, and have previously received bemcentinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "    Diet and lifestyle",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "13. Alcohol consumption of \\> 28 units per week for males. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "14. Positive alcohol breath test result or positive urine drug screen (confirmed by repeat) at screening or check-in.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "15. History of alcoholism or drug/chemical abuse within 2 years prior to check-in.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "16. Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or positive cotinine at screening or check-in.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "17. Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages within 7 days prior to check-in.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "    Other exclusions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "18. Receipt of blood products within 2 months prior to check-in.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "19. Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or platelets from 6 weeks prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "20. Poor peripheral venous access.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "21. Subjects with exposure to significant diagnostic or therapeutic radiation (eg, serial X-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "22. Subjects who, in the opinion of the investigator (or designee), should not participate in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06469138",
    "statement": "Subjects may previously have been screened on a generic basis to determine their eligibility for inclusion in Phase 1 clinical studies conducted at the study site. If generic screening was performed within the specified study screening window, selected study-specific procedures will be repeated either at an additional screening visit or on admission to the study site on Day -1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": ". Signed informed consent form (ICF) and ability to comply with protocol requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "2. Known tumor TP53 mutation status from recent or archival sample.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "3. Histologically and/or cytologically confirmed solid tumor malignancy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "   1. Safety lead in- Advanced non-central nervous system (CNS) primary tumors that have progressed after first line treatment, who are intolerant to first line treatment, or who are unable to receive first line treatment, and for whom pembrolizumab, or pembrolizumab-based therapy is considered appropriate",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "   2. Expansion 1- Patients with a confirmed diagnosis of advanced gastric or gastroesophageal junction (GEJ) tumors that have progressed after first line treatment, who are intolerant to first line treatment, or who are unable to receive first line treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "   3. Expansion 2- Patients with a confirmed diagnosis of advanced bladder/urothelial tumors that have progressed after first line treatment, or who are intolerant to first line treatment, or who are unable to receive first line treatment with cisplatin-based chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "   4. Expansion 3- Confirmed diagnosis of advanced non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "4. Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "   1. Creatinine clearance \\> 30 mL/min",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "   2. Total serum bilirubin \\< 1.5 × upper limit of normal (ULN) unless due to Gilbert's syndrome, tumor involvement, hemolysis or considered an effect of regular blood transfusions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "   3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\< 3 × ULN, unless due to involvement by the underlying malignancy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "5. Projected life expectancy of ≥ 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "6. Age ≥ 18 years at the time of signing the ICF.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "7. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "8. In the expansion portion, measurable disease meeting the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "   1. At least 1 lesion of ≥10 mm in the longest diameter (LD) for a non-lymph node or ≥15 mm in the short-axis diameter for a lymph node that is serially measurable according to RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "   2. Lesions that have had external beam radiotherapy or loco-regional therapies such as radiofrequency ablation must show subsequent evidence of substantial size increase (ex. 20% increase in LD) to be deemed a target lesion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "9. Negative serum or urine pregnancy test prior to study treatment initiation in female subjects of childbearing potential.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "10. Women of childbearing potential and men with female partners of childbearing potential must be willing to use an effective form of contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": ". Known history of untreated human immunodeficiency virus (HIV)/HIV with a detectable viral load or active hepatitis B or active hepatitis C infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "2. Cardiac abnormalities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "3. Concomitant malignancies or previous malignancies with less than a 1-year disease-free interval at the time of signing consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "4. Pregnancy or lactation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "5. Active uncontrolled systemic infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "6. An autoimmune condition requiring ≥ 10 mg (or equivalent corticosteroid) prednisone daily, or any other systemic immunosuppressive treatment within 28 days of first dose of study therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "7. Known history of active tuberculosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "8. Current (non-infectious) pneumonitis, or a history of pneumonitis that required steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "9. A live vaccine administered within 30 days of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "10. Receipt of any investigational product within 14 days or 5 half-lives prior to study treatment initiation, whichever is shortest.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04383938",
    "statement": "11. Prior intolerance to pembrolizumab or other anti-PD-1/PD-L1 agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Histologically or cytologically confirmed diagnosis of Stage IIIb or IV NSCLC that carries an ALK rearrangement as determined locally by Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.) test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Patients must have NSCLC that has progressed at study enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Patients must have received previous treatment with alectinib for treatment of locally advanced or metastatic NSCLC. Prior therapy with crizotinib as ALK inhibitor therapy in addition to alectinib is allowed. Alectinib doesn't need to be the last therapy prior to study enrollment. No particular sequence of prior alectinib and crizotinib is required for enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Patients must be chemotherapy-naïve or have received only one line of prior cytotoxic chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Age 18 years or older at the time of informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Patients with known hypersensitivity to any of the excipients of LDK378.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Prior therapy with other ALK inhibitor investigational agents except crizotinib and alectinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Prior systemic anti-cancer (including investigational) therapy aside from alectinib, crizotinib and one regimen of previous cytotoxic chemotherapy for locally advanced or metastatic NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Patient with history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Patients with history of carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Patient with a concurrent malignancy or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02450903",
    "statement": "* Patient has clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457002",
    "statement": "* men and non-pregnant, non-breastfeeding women",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457002",
    "statement": "* 40 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457002",
    "statement": "* hospitalized with congestive heart failure or acute respiratory failure",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457002",
    "statement": "* infection (without septic shock)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457002",
    "statement": "* acute rheumatic disorder",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457002",
    "statement": "* inflammatory bowel disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457002",
    "statement": "* patients with venous thromboembolism (VTE)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457002",
    "statement": "* active bleeding or at high risk of bleeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457002",
    "statement": "* unable to take oral medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00457002",
    "statement": "* with diseases requiring ongoing treatment with anticoagulants or antiplatelets other than aspirin at a dose ≤ 165 mg/day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has measurable, metastatic NSCLC, other elderly NSCLC patients over 70 years of age who are not felt to be candidates for standard chemotherapy at the discretion of the treating physician may also be enrolled as long as they meet the criteria; these \"special consideration\" patients enrollment in the study must be approved by Dr. Reynolds or DR. Smith in Dr. Reynolds absence. Patients must have a nonsquamous histology to be eligible for this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has not received any prior chemotherapy for the current disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has an ECOG Performance status. Is 70 years of age or older.Has resolution of all acute toxic effects of radiotherapy or surgical procedures to NCI CTCAE.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* If fertile, patient (males only) has agreed to an acceptable method of birthcontrol to avoid pregnancy for the duration of the study and for a period of 2 months thereafter.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has signed the most recent Patient Informed Consent Form. Has signed a Pate int Authorization Form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has predominantly squamous NSCLC histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Had prior treatment with study drugs or other drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has a history of hypersensitivity to any component of the study drug. Has any evidence of an of antecedent hemoptysis, squamous histology, or ongoing anticoagulation or clotting diathesis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Pre-existing hemoptysis Grade 2, cavitating lesions or clear proximity or involvement of blood vessels.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has had major surgery or radiation therapy within 4 weeks of starting the study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has had NCI CTCAE (Version 3.0) Grade 3-4 hemorrhage within 4 weeks of starting the study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has a history of or known spinal cord compression, or carcinomatous meningitis, or evidence of symptomatic brain or leptomeningeal disease on screening CT or MRI scan; however, treated, stable, and asymptomatic brain metastases are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has had any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism. Has ongoing cardiac dysrhythmias of NCI CTCAE (Version 3.0) Grade 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04816214",
    "statement": "HIV participants at high risk or with history of uncontrolled opportunistic infection must also be excluded. HIV participants coinfected with hepatitis virus must also be excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Is receiving concurrent treatment on another clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Supportive care trials or non-treatment trials, (eg, QOL), are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Is receiving concurrent immunotherapy, hormonal therapy, or radiation therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Is receiving concurrent investigational therapy or has received such therapy within the past 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00864721",
    "statement": "* Is unable to comply with requirements of study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Nonsquamous Non-Small Cell Lung Cancer that was confirmed by tissue biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Stage IIIAN2 disease (T1aN2, T1bN2, T2aN2, T2bN2, and T3N2)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Tumor considered potentially resectable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Good performance status (score of 0 or 1) according to Eastern Cooperative Oncology Group scale (ECOG)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* No prior therapy for lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Measurable disease according to version 1.1 of Response Evaluation Criteria in Solid Tumors (RECIST) Criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Life expectancy of at least 6 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Organs are functioning well (bone marrow reserve, liver, kidney, lung)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Signed Informed Consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Women must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen (for example, intrauterine device, birth control pills, or barrier device) during and for 6 months after last dose of study drug; must have a negative pregnancy test within 7 days before study enrollment; and must not be breast-feeding.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Men must be surgically sterile, or compliant with a contraceptive regimen during and for 6 months after last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Be fit for surgery at the time of enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Receiving or have received an investigational drug or device within the last 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Have previously completed or withdrawn from this study or any other study investigating pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Serious concomitant systemic disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Receiving concurrent administration of any other anticancer therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Have received a recent (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Inability or unwillingness to take Pemetrexed supplementation/premedication (folic acid, vitamin B12, or corticosteroids)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01165021",
    "statement": "* Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose less than or equal to 1.3 grams per day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Histologically or cytologically documented locally advanced or metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Prior platinum-containing regimen or disease recurrence ≤ 6 months since prior platinum-based adjuvant/neoadjuvant regimen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Measurable disease as defined by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Life expectancy ≥12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Adequate hematologic and end-organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "Additional Inclusion Criteria (Part 2 Only) • Availability of tissue and known epidermal growth factor receptor (EGFR) status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Uncontrolled or symptomatic hypercalcemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Pregnancy or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Active or history of autoimmune disease or immune deficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Severe infection ≤ 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Treatment with therapeutic oral or IV antibiotics ≤ 2 weeks prior to study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Significant cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Prior allogeneic stem cell or solid organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Treatment with a live, attenuated vaccine ≤ 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Treatment with systemic immunostimulatory agents ≤ 4 weeks or 5 half-lives of the drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Treatment with systemic immunosuppressive medication ≤ 2 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "Additional Exclusion Criteria (Part 2 Only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03735121",
    "statement": "* Tested tumor programmed death-ligand-1 (PD-L1) expression status with an intention to treat the patient if positive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Newly diagnosed and confirmed Stage IIIB/IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Previously treated NSCLC with asymptomatic brain metastases (eligible for Arm M) See additional details below",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Men and women aged ≥18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Subject must be chemotherapy naive (except Arm D, K, L and M). Prior use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is acceptable. For Arms D, K, and L, subjects must be non-progressors within 42 days after completion of first-line treatment with ≥4 cycles of Platinum Doublet chemotherapy with or without Bevacizumab. See below for Arm M",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Either a formalin fixed tissue block or a minimum of 10 slides of tumor sample (archived or fresh) must be available for biomarker evaluation (a local pathologist must review for adequacy of sampling)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Prior radiotherapy must have been completed at least 2 weeks prior to study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "For Arm M:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* No more than 4 brain metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Each brain metastases ≤3 cm in size",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* No evidence of cerebral edema",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Subjects must be free of neurologic symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroids for ≥10 days prior to initiation of study treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* At least 1 measurable target brain lesion \\>0.5 cm and no larger than 3 cm in diameter and/or 2 measurable brain target lesions \\>0.3 cm",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* No prior radiation therapy, surgery, or other local therapy for target brain lesions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Must have received at least one prior systemic anticancer therapy for NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Subjects with symptomatic brain metastases, spinal cord compression, or intractable back pain due to a compressive or destructive mass",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Subjects who require emergent use of systemic steroids, emergent surgery and/or radiotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Any active or history of a known autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Subjects with previous malignancies (except non-melanoma skin cancers, in situ bladder cancer, gastric, or colon cancers or cervical cancers/dysplasia, or breast carcinoma in situ) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* History of Grade ≥2 neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01454102",
    "statement": "* Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": ". Tumor tissue specimens from the glioblastoma surgery or open biopsy (formalin-fixed, paraffin-embedded block; stereotactic biopsy not allowed) must be available for MGMT status analysis and central pathology review",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "2. Newly diagnosed histologically proven supratentorial glioblastoma (World Health Organization \\[WHO\\] Grade IV)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "3. Proven methylated MGMT gene promoter methylation status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "4. Available post-operative gadolinium-enhanced magnetic resonance imaging (Gd-MRI) performed within less than (\\<) 48 hours after surgery (in case it was not possible to obtain a Gd-MRI within \\<48 hours post surgery, a Gd-MRI is to be performed prior to randomization)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "5. Stable or decreasing dose of steroids for greater than or equal to (\\>=) 5 days prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "6. Eastern Cooperative Oncology Group performance score (ECOG PS) of 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "7. Meets 1 of the following recursive partitioning analysis (RPA) classifications: Class III (Age \\< 50 years and ECOG PS 0). Class IV (meeting one of the following criteria: a) Age \\< 50 years and ECOG PS 1 or b) Age \\>= 50 years, underwent prior partial or total tumor resection, mini mental state examination \\[MMSE\\] \\>= 27). Class V (meeting one of the following criteria: a) Age \\>= 50 years and underwent prior partial or total tumor resection, MMSE \\< 27 or b) Age \\>= 50 years and underwent prior tumor biopsy only)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "8. Other protocol defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": ". Prior chemotherapy within the last 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "2. Prior RTX of the head",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "3. Receiving concurrent investigational agents or has received an investigational agent within the past 30 days prior to the first dose of cilengitide",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "4. Prior systemic antiangiogenic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "5. Placement of Gliadel® wafer at surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "6. Inability to undergo Gd-MRI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "7. Planned surgery for other diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "8. History of recent peptic ulcer disease (endoscopically proven gastric ulcer, duodenal ulcer, or esophageal ulcer) within 6 months of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "9. History of malignancy. Subjects with curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin, or subjects who have been free of other malignancies for \\>= 5 years are eligible for this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "10. History of coagulation disorder associated with bleeding or recurrent thrombotic events",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "11. Clinically manifest myocardial insufficiency (New York Heart Association \\[NYHA\\] III, IV) or history of myocardial infarction during the past 6 months; uncontrolled arterial hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00689221",
    "statement": "12. Other protocol defined exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01588184",
    "statement": "* Participant is treated with bevacizumab at the end of the Roche/Genentech sponsored parent trial and continues to have benefit as judged by the investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01588184",
    "statement": "* Eligible for continuation of bevacizumab treatment at the end of a parent trial, according to parent trial protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01588184",
    "statement": "* Able to comply with this extension study protocol (MO25757)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01588184",
    "statement": "* Evidence of disease progression assessed according to parent trial protocol during the screening phase for this extension study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01588184",
    "statement": "* Evidence of any adverse event potentially attributable to bevacizumab, for which the local label recommends permanent discontinuation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01588184",
    "statement": "* A treatment interruption with bevacizumab of more than 42 days since the last administration of bevacizumab in the parent trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01588184",
    "statement": "* Evidence of any other disease that would put the participant at high risk for treatment-related complications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject is ≥18 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has been diagnostically imaged and is suspected of having a primary or metastatic tumour lesion ≥2.5 cm of one of the following types: high-grade glioma, including glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma; lung cancer, including small cell lung cancer and non-small cell lung cancer; H\\&N tumours, including laryngeal squamous cell carcinoma, and well-differentiated thyroid and oral cavity carcinoma; sarcoma; and melanoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject is scheduled to undergo resection or biopsy of the ≥2.5 cm target tumour as a result of routine clinical treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject is scheduled to undergo or has received standard of care diagnostic imaging work-up (following the study centre's routine procedures), e.g. CT with or without contrast, MRI with or without contrast, bone scintigraphy, X-ray, or FDG-PET.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* Female subjects need to be either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post menopausal (cessation of menses for more than 1 year), or if of childbearing potential the results of a serum pregnancy test performed within 24 hours must be negative and with the result known before administration of AH-111585 (18F) Injection. Female subjects of reproductive potential should also employ an effective method of birth control. Barrier contraceptives must be used throughout the study in both sexes.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject is able and willing to comply with study procedures, and signed and dated informed consent is obtained.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has a blood urea nitrogen value and serum creatinine value of ≤1.5 of the upper normal limit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has a platelet count of \\>75,000 x 10\\^6/L.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has a haemoglobin value of \\>9 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has a prothrombin time and an activated partial thromboplastin time and within normal limits.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has a clinically acceptable (as judged by the investigator) physical examination at screening and is capable of self-care, i.e. Eastern Cooperative Oncology Group performance status is 0 to 2, such that the subject has a high chance to complete the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has not received any anti-angiogenic agents (e.g. bevacizumab, sorafenib, sunitinib) within 10 days prior to PET imaging.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has had no open wounds within 10 days prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The chosen target tumour is not within the liver.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "Inclusion Criteria Specific for Subjects with High-grade Glioma:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject is suspected of having supratentorial malignant primary glioma (by biopsy or presenting MRI characteristics as determined by the subject's clinician) requiring further surgical resection as part of the recommended treatment plan for their newly diagnosed disease. These gliomas include glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has undergone recent biopsy of newly diagnosed high-grade glioma, has recovered from the effects of surgical biopsy, and baseline on-study MRI/CT is performed within 14 days of entry into the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject is lactating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject is being treated with heparin or coumadin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has received another investigational medicinal product (IMP) within 14 days before, or will receive an IMP within 1 week after administration of AH-111585 (18F) Injection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject was previously included in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject experienced substantial changes in their medical status before all essential study procedures (including all imaging procedures and surgical excision or biopsy) are performed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has any contraindication to any of the study procedures, products used or its constituents (e.g. X-ray contrast media).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has known hyper- or hypo-coagulation syndromes. Such coagulopathies include but are not limited to Von Willebrand disease, Protein C deficiency, Protein S deficiency, Hemophilia A/B/C, Factor-V Leiden, and Bernard-Soulier syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject is unable to lie down for 125 minutes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject suffers from claustrophobia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has known diagnosis of human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has known diagnosis of hepatitis B or C infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has known diagnosis of mental incapacitation and it affects their ability to consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00565721",
    "statement": "* The subject has been diagnosed with a primary or metastatic tumour lesion \\<2.5 cm.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00800202",
    "statement": "* adult patients, \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00800202",
    "statement": "* stage IV non-squamous non-small cell lung cancer;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00800202",
    "statement": "* asymptomatic, untreated brain metastasis;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00800202",
    "statement": "* ECOG performance status 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00800202",
    "statement": "* previous treatment for brain metastasis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00800202",
    "statement": "* history of migraine or epilepsy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00800202",
    "statement": "* previous treatment with angiogenesis inhibitors;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00800202",
    "statement": "* for cohort 2, previous first line treatment with Avastin or Tarceva;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00800202",
    "statement": "* current or recent use of aspirin (\\>325mg/day) or full-dose anticoagulants or thrombolytic agent for therapeutic purposes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02702921",
    "statement": "* Subjects with a confirmed or suspected diagnosis of stage IA to stage IIIA non-small cell lung cancer scheduled for a lobectomy (Lung Cancer Staging per American Joint Committee on Cancer,7th Edition)5;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02702921",
    "statement": "* Subjects scheduled for VATS lobectomy in accordance with their institution's Standard Of Care;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02702921",
    "statement": "* Performance status 0-1 (Eastern Cooperative Oncology Group classification);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02702921",
    "statement": "* American Society of Anesthesiologists (ASA) score \\</= 3;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02702921",
    "statement": "* No prior history of VAT or open lung surgery (on the lung in which the procedure will be performed);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02702921",
    "statement": "* Willing to give consent and comply with study-related evaluation and treatment schedule; and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02702921",
    "statement": "* At least 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02702921",
    "statement": "* Prior chemotherapy or radiation (within 30 days prior to the procedure or the duration of the subject's enrollment);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02702921",
    "statement": "* Pregnancy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02702921",
    "statement": "* Physical or psychological condition which would impair study participation; or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02702921",
    "statement": "* The subject is judged unsuitable for study participation by the Investigator for any other reason.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Histologically or cytologically confirmed metastatic and/or advanced solid tumor (Phase 1 only)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Phase 2 requires Non-small cell lung cancer (NSCLC); Small-cell lung cancer; Breast adenocarcinoma (female patients only); Squamous cell cancer of the head and neck (HNSCC); or Gastroesophageal adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Voluntary written consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Wiling to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Measurable disease (Phase 2 only)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Female patients who are pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Serious medical or psychiatric illness that could interfere with protocol completion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Receipt of more than 2 previous cytotoxic chemotherapeutic regimens (4 previous regimens for breast cancer). There is no limit on the number of prior noncytotoxic therapies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Prior treatment with Aurora A-targeted agents, including MLN8237",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Prior treatment with high-dose chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Prior allogeneic bone marrow or other organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Antineoplastic therapy, radiation therapy or any experimental therapy 21 days prior to first dose of MLN8237",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Symptomatic brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Radiotherapy to greater than 25% of bone marrow",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Myocardial infarction within 6 months of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Uncontrolled cardiovascular condition",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Major surgery within 14 days of first dose of MLN8237",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Active infection requiring systemic therapy, or other serious infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Inability to swallow oral medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Patients requiring full systemic anticoagulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* History of uncontrolled sleep apnea syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01045421",
    "statement": "* Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of MLN8237 and during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Evidence of histo or cytopathology confirmed, advanced NSCLC (with known histology) with the presence of EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* It is acceptable for subjects with the presence of the exon 20 T790M mutation together with either EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21) to be included in this study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Minimum of 12 months disease free interval between completion of neoadjuvant/adjuvant systemic therapy and recurrence of NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Adequate tissue sample must be available for central analyses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Adequate renal, hematologic, liver function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* ECOG PS of 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Radiologically measurable disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Any evidence of mixed histology that includes elements of small cell or carcinoid lung cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Any other mutation other than exon 19 deletion or L858R in exon 21, with or without the presence of the exon 20 T790M mutation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Any history of brain metastases or leptomeningeal metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Any previous anti-cancer systemic treatment of early, locally advanced, or metastatic NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Any surgery(not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Current enrollment in another therapeutic clinical study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Uncontrolled medical disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Prior malignancy and concurrent malignancy except for non melanoma skin cancer or in-situ cervical cancer with no evidence of active disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01774721",
    "statement": "* Use of narrow therapeutic index drugs that are CYP2D6 substrates from screening to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00600821",
    "statement": "* Advanced non squamous cell, lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00600821",
    "statement": "* No prior treatment for lung cancer except prior adjuvant therapy if last dose was \\>12 months prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00600821",
    "statement": "* Prior therapy for advanced lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00600821",
    "statement": "* The need for blood-thinners",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00600821",
    "statement": "* Coughing up blood",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": ". Written and signed informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "2. Male or female at least 18 years of age with documented imaging diagnosis of Stage IV unresectable, recurrent or metastatic nsNSCLC with at least one measurable lesion as defined by RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "3. Documented histologic or cytologic diagnosis of advanced nsNSCLC with negative or unknown sensitizing epidermal growth factor receptor (EGFR) mutation, and negative or unknown echinoderm microtubule-associated protein like 4 anaplastic lymphoma kinase (EML4 ALK) rearrangement.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "5. Has not received any prior systemic therapy for first-line treatment of advanced lung cancer, except adjuvant chemotherapy, and remained disease-free for at least 12 months from time of surgery, and at least 6 months from last dose of chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "6. Treated and stable brain metastasis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": ". Documented squamous NSCLC or small cell type or large cell neuroendocrine histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "2. History of significant hemoptysis, central tumors with proximity to large vessels and tumor with cavitation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "3. Received prior treatment with paclitaxel, bevacizumab or anthracycline or had known hypersensitivity to any of these components.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "4. Recent significant cardiac condition or vascular event or inadequately controlled hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "5. On anticoagulant therapy not considered stable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "6. Risk of hemorrhage in the central nervous system",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "7. Recent history of surgery, nonhealing wound, active ulcer, or untreated bone fracture.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04633564",
    "statement": "8. History of gastrointestinal fistula, perforation, or abscess.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Diagnosis of locally advanced, unresectable or metastatic cutaneous or melanoma of unknown primary AJCC Stage IIIC or IV (uveal and mucosal melanoma are excluded)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Presence of NRAS Q61 mutation in tumor tissue prior to randomization as determined by a Novartis designated central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Naïve untreated patients or patients who have progressed on or after any number of prior lines of immunotherapy for unresectable locally advanced or metastatic melanoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Evidence of at least one measurable lesion as detected by radiological or photographic methods",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Adequate bone marrow, organ function, cardiac and laboratory parameters",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Normal functioning of daily living activities",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Any untreated CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Uveal or mucosal melanoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* History of or current evidence of retinal vein occlusion (RVO) or risk factors of RVO",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Patients with washout period \\< 6 weeks from the last dose of ipilimumab or other immunotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Previous systemic chemotherapy for unresectable locally advanced or metastatic melanoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* History of Gilbert's syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Prior therapy with a MEK- inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Impaired cardiovascular function or clinically significant cardiovascular diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Uncontrolled arterial hypertension despite medical treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* HIV positive or active Hepatitis A or B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Impairment of gastrointestinal function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Patients who have undergone major surgery or radiotherapy ≤ 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Patients with neuromuscular disorders that are associated with elevated CK.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Pregnant or nursing (lactating) women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "* Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763164",
    "statement": "Other protocol-defined inclusion/exclusion criteria may apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": ". For Dose Escalation Only: any locally advanced or metastatic, histologically or cytologically proven solid tumor or NHL, relapsed after or progressing despite conventional treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "2. Life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "3. World Health Organization (WHO) performance status of 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "4. Must meet select hematological and biochemical laboratory indices",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "5. Archival tumor tissue or accessible tumor and willingness to consent to a biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "Expansion Only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "1. Any locally advanced or metastatic malignancy of the following types for which no other conventional therapy is considered appropriate:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Metastatic Colorectal Cancer (CRC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Platinum-resistant or intolerant High Grade Serious Ovarian Cancer (HGSOC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Head and Neck Squamous Cell Carcinoma (HNSCC) or squamous cell carcinoma of the anus (SCCA).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Eligibility may be further restricted by the select number of prior regimens specific to each indication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "2. Measurable disease per RECIST v1.1, or for mCRPC, evaluable disease per any of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Measurable disease per RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Increasing PSA",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Circulating tumor cell (CTC) count of 5 or more cells per 7.5 ml of blood",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "3. Tumor tissue or ctDNA evidence that subject's tumor harbors a combination of mutations which are expected to confer sensitivity to Chk1 inhibition. Eligibility will be determined by the Sponsor's review of genetic abnormalities detected in genes in the following categories:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Oncogenic drivers such as MYC, CCNE1, etc.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Key tumor suppressor genes regulating G1 cell cycle progression/arrest such as RAD50, TP53, etc. For patients with NHSCC or SCCA, positive HPV status is also considered for eligibility.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* The DDR pathway including BRCA1, BRCA2 and FANC. For patients with CRC, MMR genetic alterations and/or high microsatellite instability are also considered for eligibility.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Genetic indicators of replicative stress such as gain of function/amplification of Chk1 or ATR or other related gene.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": ". Received the following prior or current anticancer therapy:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Radiotherapy within the last 6 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Endocrine therapy during the previous 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Chemotherapy during the previous 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Immunotherapy during the previous 6 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Nitrosoureas or Mitomycin C during the previous 6 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Other Investigational Medicinal Product during the 4 weeks before treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "* Any prior treatment with a Chk1 inhibitor or prior treatment with an ATR inhibitor within 6 months prior to receiving SRA737",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "2. Other malignancy within the past 2 years, except for adequately treated tumors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "3. Ongoing toxic manifestations of previous treatments greater than NCI-CTCAE Grade 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "4. For Dose Escalation: new or progressing brain metastases. For Cohort Expansion: present or prior brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "5. High medical risk because of nonmalignant systemic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "6. Serologically positive for hepatitis B, hepatitis C or HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "7. Serious cardiac condition, left ventricular ejection fraction \\< 45% at baseline, history of cardiac ischemia within the past 6 months, or prior history of cardiac arrhythmia requiring treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "8. Prior bone marrow transplant or extensive radiotherapy to greater than 25% of bone marrow within 8 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "9. Peanut allergy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "10. QTcF\\> 450 msec in adult males and \\> 470 msec in adult females",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "11. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of SRA737",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "12. Inability to swallow capsules without chewing or crushing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "13. Is a participant or plans to participate in another interventional clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02797964",
    "statement": "14. Any other condition which in the Investigator's opinion would not make the subject a good candidate",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01674621",
    "statement": "* Postmenopausal woman, less than 85 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01674621",
    "statement": "* BMD T-score ≤-2.5 of spine or hip (femoral neck) or ≤-2.0 with previous fracture (within 5 years).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01674621",
    "statement": "* Normal physical exam, vital signs, electrocardiogram (ECG), and medical history.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01674621",
    "statement": "* Laboratory tests within the normal range, including serum calcium, Vitamin D, parathyroid hormone (PTH) (1-84), serum phosphorus, and alkaline phosphatase.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01674621",
    "statement": "* BMD T-score ≤-5.0 at the lumbar spine or hip.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01674621",
    "statement": "* History of bone disorders (for example, Paget's disease) other than postmenopausal osteoporosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01674621",
    "statement": "* Significantly impaired renal function.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01674621",
    "statement": "* History of any cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* treatment-naïve or have received no more than 3 systemic treatment regimen(s)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Positive for translocation or inversion events involving the ROS1 gene",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Negative for translocation or inversion events involving the ALK gene",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Patients with brain metastases are eligible if asymptomatic, or if treated, must be neurologically stable for at least 2 weeks and are not taking any contraindicated medications",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Any prior treatment (chemotherapy, radiation \\[except for palliative\\], or surgery) must have been completed at least 2 weeks prior to initiation of study medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* At least 1 measurable tumor lesion as per RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Female or male, 18 years of age or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* ECOG performance status 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Signed and dated informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including completion of the PRO measures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Agree to use effective contraception during the study period and for at least 90 days after completion of the study treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Current treatment on another therapeutic clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Prior therapy specifically directed against ALK or ROS1 fusion genes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function, carcinomatous meningitis, or leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* known interstitial fibrosis or interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack within 3 months prior to start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Ongoing cardiac dysrhythmias of NCI CTCAE v4.03 Grade \\>/=2, uncontrolled atrial fibrillation of any grade, or QTc \\>470 msec",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Pregnant or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Use of drugs or foods that are known potent CYP3A4 inhibitors or inducers",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Use of other anti-cancer drugs including traditional Chinese medicine on the SFDA list",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945021",
    "statement": "* Evidence of active malignancy within last 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": ". You must be at least 18 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "2. You must have been diagnosed with non-squamous non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "3. You must have had no prior systemic anticancer therapy for lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "4. You must live close enough to the study doctor to be able to visit regularly for follow up",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "5. You must have signed informed consent form indicating your willingness to take part in this study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "6. Your laboratory and medical history and tests must meet study requirements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": ". Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "2. Prior radiotherapy and surgery should be completed at least 4 weeks prior to initiation of treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "3. Serious concomitant systemic disorder (e.g., active infection including human immunodeficiency virus, or unstable cardiovascular disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "4. Prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer unless treated at least 5 years previously with no subsequent evidence of recurrence",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "5. Brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "6. Presence of clinically significant (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "7. Significant weight loss (greater than 10%), over the previous 6 weeks before study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "8. Concurrent administration of any other antitumor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "9. Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "10. Inability or unwillingness to take folic acid, dexamethasone (or equivalent) or vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "11. Pregnancy or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606021",
    "statement": "12. You are allergic to pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Patients with histologically or cytologically confirmed advanced (stage IIIB or stage IV) NSCLC who have received at least two prior lines of treatment. Patients who, in the investigators opinion, are deemed unsuitable for the standard 2nd line chemotherapy will be eligible for protocol participation. One of the prior lines must have included a platinum agent. Prior treatment with a platinum agent is not a requirement for EGFR mutant patients and patients with EML4-ALK translocations",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Patients enrolled to the fifth stratum, modified EGFR mutant, must have documented prior response to EGFR TKI as defined by CR, PR or SD for 6 months or greater unless patient has de novo resistance to EGFR TKI (e.g. exon 20 insertions.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* All patients must have at least one measurable lesion as defined by RECIST criteria. Previously irradiated lesions are not measurable unless the lesion is new or has demonstrated clear progression after radiation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* World Health Organization (WHO) performance status ≤ 2. For patients enrolled to the fifth stratum, modified EGFR mutant, World Health Organization (WHO) performance status ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Patients enrolled to the fifth stratum, modified EGFR mutant, must be willing and suitable to undergo fresh baseline biopsy prior to study treatment (unless patient had recent biopsy after EGFR TKI progression that concluded resistance to EGFR TKI.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Hematologic:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Hemoglobin (Hgb) ≥ 9 g/dl.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Platelets (plt) ≥ 100 x 109/L.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "Biochemistry:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Total calcium (corrected for serum albumin) within normal limits or correctable with supplements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Magnesium within lower normal limits or correctable with supplements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "Adequate liver function defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* AST/SGOT and ALT/SGPT ≤ 3.0 x Upper limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastasis are present.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Serum bilirubin ≤ 1.5 x ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Serum albumin \\> 2.5 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Serum creatinine ≤ 1.5 x ULN or 24 hour clearance ≥ 50 mL/min.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Patients who have received more than four lines of prior treatment. Exception: Patients enrolled to the fifth stratum, modified EGFR mutant, must not have received more than two prior lines of therapy. Chemotherapy administered as adjuvant treatment more than six months prior to study enrollment is not considered a prior line of therapy for purposes of this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Patients with a history of CNS metastasis. Note: Patients without clinical signs and symptoms of CNS involvement are not required to have MRI of the brain. Exception: Patients with treated brain metastases who are asymptomatic, who has discontinued corticosteroids, and who have been clinically stable for one month will be eligible for protocol participation. This exception is not valid for patients enrolled to the fifth stratum, modified EGFR mutant. These patients must not have CNS involvement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Prior anti-neoplastic treatment with any HSP90 or HDAC inhibitor compound.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Patients must not have received:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* any systemic anti-cancer treatment or radiotherapy within 4 weeks prior to first dose of study treatment and should have recovered to baseline or less than Grade 1 from toxicities of such therapy prior to the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* 2 weeks for palliative radiotherapy to bones, 6 weeks for nitrosoureas and mitomycin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* 4 weeks for monoclonal antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* and ≤5 half-life of the agent or active metabolites \\[if any\\] for continuous systemic anti-cancer treatment or investigational",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "* Patients who do not have either an archival tumor sample available or are unwilling to have a fresh tumor sample collected at baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01124864",
    "statement": "Other protocol-defined inclusion/exclusion criteria may apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Histological documented adenocarcinoma, locally advanced - Stage IIIB, metastatic - Stage IV or recurrent non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Activated EGFR mutation positive status (Exons 19 and 21) for treatment phase",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Life expectancy greater than or equal to (≥) 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Evidence of disease with at least one measurable disease evaluation on Response Evaluation Criteria in Solid Tumors (RECIST)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Adequate hematological , liver and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Known hypersensitivity to erlotinib or any of its excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Squamous non-small cell or small cell tumors or absence of histological report",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Neoadjuvant/adjuvant chemotherapy within 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Prior exposure to inhibitors of EGFR",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Prior chemotherapy or treatment with another systemic anti-cancer agent for the treatment of the participant's current stage of disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjögren syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Radical radiotherapy with curative intent within 28 days prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01153984",
    "statement": "* Any active non-controlled systemic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group \\[VALG\\] staging system)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* No prior systemic treatment for ES-SCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Eastern Cooperative Oncology Group performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Measurable disease, as defined by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Adequate hematologic and end organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Malignancies other than SCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* History of autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Positive test result for human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Active hepatitis B or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Severe infections at the time of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Significant cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1 (PD-1), and anti-PD-L1 therapeutic antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02763579",
    "statement": "* History of severe (or known) hypersensitivity to chimeric or humanized antibodies or fusion proteins or any component of atezolizumab formulation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Confirmed Stage IIIB/ IV non-small cell lung cancer (NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Relapsed after treatment with 1 or 2 prior chemotherapy regimens, including at least 1 platinum-based treatment. Patients may have received pemetrexed as 1 of the prior therapies. Patients may not have received investigational therapy as their only prior therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Recovered from the toxic effects of prior therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Smoked ≥ 100 cigarettes in their lifetime, whether a former or current cigarette smoker.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Adequate blood, liver and kidney function as defined by laboratory values.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Received 1-1.25 mg daily oral folic acid for at least 7 days prior to randomization and 1 mg intramuscular injection of vitamin B12 within 10 weeks prior to randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Women of childbearing potential must use medically acceptable birth control and have a negative serum pregnancy test within 14 days prior to randomization. Patients who are postmenopausal for at least 1 year (\\> 12 months since last menses) or are surgically sterilized do not require this test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Men who are not surgically sterile must use medically safe and effective birth control from the time of study randomization, and agree to continue practicing until at least 90 days after the last administration of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Accessible for repeat dosing and follow-up.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Give written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Active concurrent primary malignancy (except non-melanoma skin cancer or in situ carcinoma of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years. Patients with other prior malignancies less than 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no evidence of active or recurrent disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Use of investigational drugs, biologics, or devices within 4 weeks prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Previous exposure to pralatrexate or erlotinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Women who are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Congestive Heart Failure Class III/IV according to New York Heart Association (NYHA) Functional Classification.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Uncontrolled hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of \\<100 mm3 or detectable viral load within the past 3 months, and is receiving combination anti-retroviral therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Symptomatic central nervous system metastases or lesions for which treatment is required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Major surgery within 2 weeks of study randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Receipt of any conventional systemic chemotherapy within 4 weeks (6 weeks for nitrosoureas, mitomycin C), or radiation therapy (RT) within 2 weeks, prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Active infection or any serious underlying medical condition, which would impair the ability of the patient to receive protocol treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00606502",
    "statement": "* Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent or limit study compliance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* In Part A: has a histological or cytological diagnosis of solid tumor, progressive metastatic disease, or progressive locally advanced disease not amenable to local therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* In Part B, C, and D: has a histologically- or cytologically-confirmed diagnosis of NSCLC (Stage IIIB/IV) and are naïve to systemic therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* In Part C: has a histologically- or cytologically-confirmed diagnosis of squamous cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* In Part E: has a histologically- or cytologically-confirmed diagnosis of SCLC (ED stage) and are naïve to systemic therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* Has adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* Female participants of reproductive potential must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* Female and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to 120 days after the last dose of study therapy and for up to 180 days after the last dose of chemotherapeutic agents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* Has had cancer therapy within 2 weeks (Part E) or 4 weeks (Parts A, B, C, and D) prior to the first dose of study therapy, or not recovered from the adverse events of agents administered more than 4 weeks prior to the first dose of study therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* Part A: Chemotherapy, radiation therapy, biological therapy or kinase inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* Parts B, C, D and E: Radiation therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* For Part B: has a histological diagnosis of squamous cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* Is currently participating or has participated in a study with an investigational agent or using an investigational device within 30 days of first dose of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* Is expected to require any other form of antineoplastic therapy while on study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* Is on chronic systemic steroid therapy within two weeks prior to the first dose of trial treatment or on any other form of immunosuppressive medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* For Part C: Has pre-existing peripheral neuropathy that is ≥ Grade 2 by Common Terminology Criteria for Adverse Events version 4 criteria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01840579",
    "statement": "* Has interstitial lung disease detected by chest computed tomography (CT), or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management. Lymphangitic spread of the NSCLC is not exclusionary.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Signed, written informed consent provided prior to performing any study-specific procedures or assessments. Subject must be willing to comply with treatment and follow-up.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Subjects ≥21 years of age with a life expectancy of ≥12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* The time between initial diagnosis and the scheduled surgery date allows for the subject to receive a minimum of 2 weeks or a maximum of 6 weeks treatment with pazopanib. Note: At least 4 weeks must be available between the diagnostic biopsy and surgery to allow for 1) one-week delay following the diagnostic biopsy prior to first dose of study drug, 2) minimum of 2 weeks on study drug, and 3) minimum of 1 week wash out prior to surgery.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Histologically- or cytologically-confirmed Stage IA, IB, IIA, or IIB (to T2) NSCLC according to the International Staging System \\[Mountain, 1997\\] and must be scheduled for surgical resection.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Disease must consist of only a single lesion and must be measurable according to high-resolution CT scan-assisted volumetric measurement \\[Yankelevitz, 2000, Armato, 2004\\]. In addition to the measurable single lesion, other small indeterminate nodules may also be present",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* No approved or investigational anti-cancer therapy concurrently or in the 6 months prior to start of study drug, including surgery, tumor embolization, chemotherapy, radiation therapy, immunotherapy, hormone therapy, biologic therapy, or anti-angiogegneic therapy (e.g., inhibitors of VEGF or VEGFR).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Fresh tumor biopsy for apoptosis and relevant biomarker analyses must be obtained within 30 to 8 days of first dose of study drug and must be available for all subjects prior to start of pazopanib treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* System (Laboratory Values)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Hematologic:Absolute neutrophil count (ANC)(≥ 1.5 X 109/L), Hemoglobin (≥9 g/dL), Platelets(≥100 X 109/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Hepatic:Albumin (≥ 2.5 g/dL), Serum bilirubin(≤1.5 X upper limit of normal (ULN) unless due to Gilbert's syndrome), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (≤2.0 X ULN) Renal:Serum creatinine(≤1.5 mg/dL) OR Calculated creatinine clearance (≥30 mL/min), Urine Protein (Trace or +1 by dipstick urinalysis or \\<1.0 gram determined by 24-hour urine protein analysis.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Ability to swallow and retain oral medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* A female is eligible to enter and participate in this study if she is of:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* A hysterectomy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* A bilateral oophorectomy (ovariectomy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* A bilateral tubal ligation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Is post-menopausal:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Subjects not using hormone replacement therapy (HRT) must have experienced total cessation of menses for ≥1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone (FSH) value \\>40mIU/mL and an estradiol value \\<40pg/mL (\\<140pmol/L).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Subjects must discontinue HRT prior to study enrollment due to the potential for inhibition of cytochrome P450 enzymes that metabolize estrogens and progestins. For most forms of HRT, at least 2-4 weeks must elapse between the cessation of HRT and determination of menopausal status; length of this interval depends on the type and dosage of HRT. If a female subject is determined not to be post-menopausal, they must use adequate contraception, as defined immediately below.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Childbearing potential, including any female who has had a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception. GlaxoSmithKline (GSK)-acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* An intrauterine device with a documented failure rate of less than 1% per year",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the dosing period, and for at least 21 days after the last dose of investigational product",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide) Note: Oral contraceptives are not reliable due to potential drug-drug interactions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 15 days following the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* A male with a female partner of childbearing potential is eligible to enter and participate in the study if he uses a barrier method of contraception or abstinence during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Subjects must complete all screening assessments as outlined in the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Active malignancy or any malignancy in the 6 months prior to first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Concurrent disease or condition that would make the subject inappropriate for study participation including (1) any unresolved or unstable, serious toxicity from prior administration of another investigational drug, (2) any serious medical disorder that would interfere with the subject's safety, obtaining informed consent, or compliance with all study related procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study; minor surgical procedures such as fine needle aspiration or core biopsy within 1 week prior to beginning therapy are also excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis. Routine screening with CNS imaging studies (computed tomography \\[CT\\] or magnetic resonance imaging \\[MRI\\]) is required only if clinically indicated.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* History of hemoptysis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to beginning therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Active or uncontrolled infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Concurrent treatment with an investigational agent or participation in another clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Has taken/received prohibited medications within specified timeframes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Corrected QT interval (QTc) prolongation defined as QTc interval \\>480 msecs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* History of any one of the following cardiac conditions within the past 6 months: cardia angioplasty or stenting, myocardial infarction,or unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* History of cerebrovascular accident within the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Has Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Poorly controlled hypertension (mean systolic blood pressure (SBP) of ≥140mmHg, or mean diastolic blood pressure (DBP) of ≥ 90mmHg. Note: Initiation or adjustment of anti-hypertensive medication(s) is permitted prior to study entry. The blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 5 minutes. The mean SBP/DBP values from both BP assessments must be \\< 140/90mmHg in order for a subject to be eligible for the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* History of untreated deep venous thrombosis (DVT) within the past 6 months (e.g. calf vein thrombosis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Presence of any non-healing wound, fracture, or ulcer, or the presence of symptomatic peripheral vascular disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Receiving therapeutic warfarin or heparin as a concurrent medication. Note: prophylactic low-dose warfarin (less than or equal to 2 mg daily) is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Evidence of bleeding diathesis or coagulopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00367679",
    "statement": "* Pregnant or lactating female",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Male/female participants, who are at least 18 years of age on the day of signing informed consent with previously untreated, unresectable, pathologically confirmed NSCLC and Stage IIIA, IIIB or IIIC NSCLC by American Joint Committee on Cancer Version 8.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* No evidence of metastatic disease by whole body positron emission tomography/computed tomography (PET/ CT) scan, diagnostic quality CT scan, and brain imaging.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Have measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Have provided tumor tissue sample (core, incisional, or excisional biopsy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Have adequate pulmonary function test (PFT)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Have adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* A male participant must agree to use contraception through the end of treatment and refrain from donating sperm during this period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and if participant is a woman of childbearing potential (WOCBP), agrees to follow the contraceptive guidance as provided in the protocol through the end of treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment allocation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has small cell lung cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has had documented weight loss \\>10% in the preceding 3 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Participants whose radiation treatment plans are likely to encompass a volume of whole lung receiving \\>20 Gy in total (V20) of more than 31% of lung volume.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus or for breast cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent (programmed cell death protein 1 \\[PD-1\\] and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 \\[PD-L2\\]) or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has received a live vaccine within 30 days prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has had an allogenic tissue/solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has severe hypersensitivity (Grade 3 or higher) to pembrolizumab and/or any of its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has a known severe hypersensitivity (Grade 3 or higher) to any of the study chemotherapy agents and/or to any of their excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease that requires steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has an active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has a known history of hepatitis B (defined as hepatitis B surface antigen \\[HBsAg\\] reactive) or known active hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has a known history of active tuberculosis (TB; Bacillus tuberculosis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Has a known psychiatric or substance abuse disorder that would interfere with cooperating with the requirements of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631784",
    "statement": "* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study through the end of treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01465802",
    "statement": "* Advanced Non-Small Cell Lung Cancer (NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01465802",
    "statement": "* For Cohort I and Cohort II, advanced NSCLC patients must have received at least one prior regimen of systemic therapy which includes at least one standard chemotherapy for advanced NSCLC and who have failed (ie, progressed or intolerant due to toxicity which precludes further treatment) standard therapy for advanced or metastatic disease. To be considered intolerant to treatment, a patient must have received at least two cycles to be considered previously treated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01465802",
    "statement": "* For Cohort III, advanced NSCLC patients must not have received prior systemic treatment for their advanced disease and require a known EGFR (HER-1) mutation, HER-2 mutation or HER-2 amplification. Cohort III patients could have received prior adjuvant chemotherapy for Stage I-III disease or combined modality chemotherapy-radiation for Stage IIIA disease is allowed if treatment completed\\>12 months prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01465802",
    "statement": "* All cohorts, patients must have evidence of disease; however, measurable disease is not required to enroll.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01465802",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01465802",
    "statement": "* Estimated creatinine clearance ≥15 mL/min.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01465802",
    "statement": "* Prior treatment with an EGFR-targeted or HER-targeted agent (all cohorts).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01465802",
    "statement": "* Chemotherapy, radiotherapy, biological or investigational agents within 2 weeks of baseline disease assessments (all cohorts).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01465802",
    "statement": "* Patients with known diffuse interstitial lung disease (all cohorts).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01465802",
    "statement": "* Investigational therapy as only treatment for advanced NSCLC without administration of an approved chemotherapy for advanced NSCLC (for Cohort I and Cohort II)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "(Bolus and Infusion):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "Solid Tumor:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Histologically confirmed advanced solid tumor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* 1 to 3 prior treatment regimens",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* At least one site of radiographically measurable disease of ≥ 2 cm in the largest dimension by traditional computed tomography (CT) scanning technique or ≥ 1 cm in the largest dimension by spiral CT scanning (per Response Evaluation Criteria in Solid Tumors \\[RECIST\\] criteria); or if, in the Principal Investigator's opinion, evaluable disease can be reliably and consistently followed, the subject may be eligible upon approval by the Medical Monitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "Multiple Myeloma (MM):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Relapsed and/or refractory multiple myeloma following 2 or more prior treatment regimens.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Measurable disease as indicated by one or more of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Serum M-protein ≥ 1 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Urine M-protein ≥ 200 mg/24 hr",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Serum Free Light Chain: Involved free light chain (FLC) level ≥ 10 mg/dL provided serum FLC ratio is abnormal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "Lymphoma:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Histologically or cytologically confirmed lymphoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Patients must have had an initial diagnosis of indolent non-Hodgkin lymphoma (NHL) (including follicular, small lymphocytic, lymphoplasmacytoid, and marginal zone lymphoma), indolent disease that transformed to a more aggressive subtype, as previously described or patients may have mantle cell lymphoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Patients are required to have received prior rituximab (alone or combined with other treatment) and are considered refractory to (defined as no response, or progression within 6 months of completing therapy) or intolerant of continued rituximab.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Patients may have received up to a maximum of four prior unique chemotherapy regimens, including if not contra-indicated autologous stem-cell transplantation (ASCT).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* For patients to enroll in the expanded dose group for lymphoma, patients must have measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "Phase 2 Bolus Subjects:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "*Histologically confirmed advanced solid tumor diagnosis and:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Non-small cell lung cancer (NSCLC): Failed at least 1 prior platinum-based chemotherapy regimen but not more than 3 prior therapies for metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Small cell lung cancer (SCLC): Failed 1 to 3 prior chemotherapy regimens",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Ovarian: Failed at least 1 prior platinum-based chemotherapy regimen but not more than 4 therapies for metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Renal: Failed at least 2 prior chemotherapy regimens for metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Other solid tumor types: Failed at least 1 prior chemotherapy regimen for metastatic or relapsed disease and for which standard of care therapy is no longer effective or does not exist",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* At least one site of radiographically measurable disease of ≥ 2 cm in the largest dimension by traditional CT scanning technique or ≥ 1 cm in the largest dimension by spiral CT scanning (per RECIST criteria); or if, in the Principal Investigator's opinion, evaluable disease can be reliably and consistently followed, the subject may be eligible upon approval by the Medical Monitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "Demographic",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Males and females ≥ 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Life expectancy of more than 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "Laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Adequate hepatic function, with bilirubin 1.5 times the upper limit of normal (ULN), and alanine aminotransferase (ALT) 3 times ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Absolute neutrophil count (ANC) \\> 1000/mm³, hemoglobin ≥ 8 gm/dL for solid tumors or 7.0 gm/dL for MM, and platelet count ≥ 100,000/mm³ for solid tumors or ≥ 30,000/mm³ for MM.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Subjects should not have received platelet transfusions for at least 1 week prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Screening ANC should be independent of granulocyte- and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for ≥ 2 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Subjects may receive red blood cell (RBC) transfusions or receive supportive care with erythropoietin or darbepoetin in accordance with institutional guidelines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Calculated or measured creatinine clearance (CrCl) of ≥ 20 mL/minute calculated using the formula of Cockcroft and Gault. Subjects with calculated CrCl \\< 20 mL/min may be allowed, only with prior approval by the Medical Monitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "Ethical/Other",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Written informed consent in accordance with federal, local, and institutional guidelines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 3 days of the first dose and agree to use dual methods of contraception during the study and for 3 months following the last dose of study drug. Post-menopausal females (\\> 45 years old and without menses for \\> 1 year) and surgically sterilized females are exempt from these requirements. Male subjects must use an effective barrier method of contraception during the study and for 3 months following the last dose if sexually active with a female of childbearing potential.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Chemotherapy with approved or investigational anticancer therapeutics, including steroid therapy, within 3 weeks prior to first dose or 6 weeks for antibody therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Radiation therapy or immunotherapy within 3 weeks prior to first dose (except for antibody therapy, where 6 weeks is required); localized radiation therapy within 1 week prior to first dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Subjects with prior brain metastases are permitted, but must have completed treatment and have no evidence of active central nervous system (CNS) disease for at least 4 weeks prior to first dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* For lymphoma patients; patients with prior stem cell transplant therapy (autologous SCT within the prior 8 weeks; allogeneic SCT within the prior 16 weeks). Patients with prior allogeneic SCT should not have evidence of moderate-to-severe graft-versus-host disease (GVHD)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Evidence of CNS lymphoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Participation in an investigational therapeutic study within 3 weeks prior to first dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Prior treatment with carfilzomib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "Concurrent Conditions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Major surgery within 3 weeks prior to first dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Congestive heart failure (New York Heart Association class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction within 3 months prior to first dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to first dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Known or suspected human immunodeficiency virus (HIV) infection or subjects who are HIV seropositive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Active hepatitis A, B, or C infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Subjects with pleural effusions requiring routine thoracentesis or ascites requiring routine paracentesis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Subjects at risk\\* in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g., due to pre-existing pulmonary, cardiac, or renal impairment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* High risk for Tumor Lysis Syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "Ethical / Other",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Female subjects who are pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531284",
    "statement": "* Any clinically significant psychiatric or medical condition that in the opinion of the Investigator could interfere with protocol adherence or a subject's ability to give informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00530621",
    "statement": "* Laboratory confirmed diagnosis of NSCLC with locally advanced or metastatic disease which cannot be cured.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00530621",
    "statement": "* Participants must have disease which progressed after 1 prior systemic cytotoxic chemotherapy regimen for advanced disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00530621",
    "statement": "* At least 1 measurable lesion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00530621",
    "statement": "* Must have stopped all previous systemic therapies for cancer for at least 2 weeks prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00530621",
    "statement": "* Must be able to follow study guidelines and be able to show up for appointments.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00530621",
    "statement": "* Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00530621",
    "statement": "* Previous treatment with enzastaurin or pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00530621",
    "statement": "* Concurrent administration of any other antitumor therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00530621",
    "statement": "* Inability to swallow tablets.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00530621",
    "statement": "* Pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* Patients must be at least one year and no more than 30 years of age when registered on this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* Patients must have high risk neuroblastoma and either have tumor left after treatment started at diagnosis or have had the tumor grow back (relapsed) after getting some treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* Patients must an MIBG scan done and it must be positive for neuroblastoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* Patients must have a PBSC or bone marrow stem cell product available that meets study criteria. If they don't already have stem cells frozen away then they must be able to have a stem cell pheresis done to collect the necessary amount of stem cells for study entry and these stem cells must meet study criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* Patients must have adequate heart, lung, liver, kidney and bone marrow function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* They have had a stem cell transplant using another person as the stem cell donor. (You can still be in the study if a previous transplant used your own stem cells)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* They have other medical problems that could get much worse if they had this treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* They are on dialysis for badly working kidneys or have other kidney problems.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* They are pregnant or breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* They have tumor in the brain or spinal cord that is seen on a CT or MRI scan one month before starting treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* They had total body radiation or radiation to the entire belly.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* They have a known allergy to MIBG, iodine or SSKI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00659984",
    "statement": "* They can't cooperate with the special precautions that are needed during UltratraceTM MIBG treatment or with other safety monitoring requirements of the study..",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": ". Signed written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "2. Female or male ≥18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "3. Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "4. Body mass index \\< 20 kg/m2 with involuntary weight loss of \\>2% within 6 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "5. Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of ≤ 17 points on the 5-item Anorexia Symptom Scale and ≤ 37 points on the 12-item FAACT A/CS",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "6. Patient receiving or not receiving systemic anti-cancer treatment at the time of screening are eligible to participate. Systemic anti-cancer treatment includes first, second, third treatment line with chemotherapy/radiation therapy, immunotherapy or targeted therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   Patient not receiving systemic anti-cancer treatment is eligible if:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   1. Not planning to receive anti-cancer treatment and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   2. Planning to receive anti-cancer treatment within 14 days from randomization and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   3. Patient on palliative care treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "7. ECOG performance status 0,1 or 2 at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "8. AST (SGOT) and ALT (SGPT) ≤ 3 x ULN or if hepatic metastases are present ≤ 5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "9. Adequate renal function, defined as creatinine ≤2 ULN, or calculated creatinine clearance \\>30 ml/minute",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "10. Female patient shall be: a) of non-childbearing potential or b) of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within 24 hours prior to first dose of investigational product.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "    Notes:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "    1. Female patient of non-childbearing potential are defined as being in post-menopausal state since at least 1 year; or having documented surgical sterilization or hysterectomy at least 3 months before study participation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "    2. Reliable contraceptive measures include implants, injectables, combined oral contraceptives, intrauterine devices, vasectomized partner or complete (long term) sexual abstinence.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "11. The patient must be willing and able to comply with the protocol tests and procedures All inclusion criteria will be checked at screening visit (Visit 1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": ". Patient with other forms of lung cancer (e.g., small cell, neuroendocrine tumors)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "2. Woman who is pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "3. Reversible causes of reduced food intake, as determined by the Investigator. These causes may include but are not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   1. NCI CTCAE Grade 3 or 4 oral mucositis,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   2. NCI CTCAE Grade 3 or 4 GI disorders \\[nausea, vomiting, diarrhea, and constipation\\],",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   3. mechanical obstructions making patient unable to eat, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   4. severe depression",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "4. Patient undergoing major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization. Patient must be well recovered from acute effects of surgery prior to screening. Patient should not have plans to undergo major surgical procedures during the treatment period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "5. Patient currently taking androgenic compounds (including but not limited to testosterone, testosterone-like agents, oxandrolone, megestrol acetate, corticosteroids, olanzapine, mirtazapine (however, long-term use of mirtazapine for depression for at least four weeks prior to screening is allowed), dronabinol or marijuana (cannabis) or any other prescription medication or off-label products intended to increase appetite or treat unintentional weight loss",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "6. Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring drainage, edema or evidence of ascites",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "7. Patient with uncontrolled or significant cardiovascular disease, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   1. History of myocardial infarction within the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   2. A-V block of second or third degree (may be eligible if currently have a pacemaker)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   3. Unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   4. Congestive heart failure within the past 3 months, if defined as NYHA class III-IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   5. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW) syndrome, or torsade de pointes)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   6. Uncontrolled hypertension (blood pressure \\>150 mm Hg systolic and \\>95 mm Hg diastolic)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "   7. Heart rate \\< 50 beats per minute on pre-entry electrocardiogram and patient is symptomatic",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "8. Patient on drugs that may prolong the PR or QRS interval durations, such as any of the antiarrhythmic medications Class I (Fast sodium (Na) channel blockers)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "9. Patient unable to readily swallow oral tablets",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "10. Patient with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "11. Patient with history of gastrectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "12. Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "13. Patient with cachexia caused by other reasons, as determined by the investigator such as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "    1. Severe COPD requiring use of home O2,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "    2. New York Heart Association (NYHA) class III-IV heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "    3. AIDS",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "    4. Uncontrolled thyroid disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "14. Patient receiving strong CYP3A4 inhibitors within 14 days of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "15. Patient currently receiving tube feedings or parenteral nutrition (either total or partial).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "16. Current excessive alcohol or illicit drug use",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "17. Any condition, including the presence of laboratory abnormalities, which in the Investigator's opinion, places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "18. Enrollment in a previous study with anamorelin HCl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "19. Patient actively receiving a concurrent investigational agent, or having received an investigational agent within 28 days of Day 1 All exclusion criteria will be checked at screening visit (Visit 1).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "(For all patients unless otherwise specified)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Histologically or cytologically confirmed locally advanced (stage IIIB not amenable to definitive multi-modality therapy including surgery) or metastatic (stage IV) EGFR mutant NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Patients with controlled brain metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* ECOG performance status: Phase I part: 0, 1, or 2; Phase II part: 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Presence of at least one measurable lesion according to RECIST 1.1 per investigator assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Patients who are either Hepatitis B surface antigen (HBsAg) positive or hepatitis B virus (HBV)-DNA positive must be willing and able to take antiviral therapy 1-2 weeks prior to 1st dose of EGF816 treatment and continue on antiviral therapy for at least 4 weeks after the last dose of EGF816",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Patients must have negative hepatitis C antibody (HCV-Ab) or positive HCV-Ab but undetectable level of HCV-RNA. Note: patients with detectable HCV-RNA are not eligible for the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* For Phase I: patients must have failed no more than 3 lines of any systemic antineoplastic therapy for advanced NSCLC, including EGFR-TKI",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* For Phase II: patients must be naïve from any systemic antineoplastic therapy in the advanced setting. Patients who have failed no more than 1 cycle of systemic antineoplastic therapy in the advanced setting are allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "(For all patients unless otherwise specified)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Patients with a history or presence of interstitial lung disease (ILD) or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e. affecting activities of daily living or requiring therapeutic intervention)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Presence or history of another malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Undergone a bone marrow or solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Known history of human immunodeficiency virus (HIV) seropositivity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use at the time of study entry except for control of brain metastases, topical applications, inhaled sprays, eye drops or local injections",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Patients with clinically significant, uncontrolled heart disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Any prior therapies ≤ 4 weeks prior to the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Patients who are receiving treatment with medications that are known to be strong inhibitors or inducers of CYP3A4/5 and cannot be discontinued 1 week prior to the start of EGF816 treatment and for the duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Patients who have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of EGF816",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Patients who are receiving treatment with any enzyme-inducing anticonvulsant that cannot be discontinued at least 1 week before first dose of study treatment, and for the duration of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "* Sexually active males unless they use a condom during intercourse while taking drug and for 3 months after stopping treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02108964",
    "statement": "Other protocol-defined inclusion and exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": ". Subject with histologically or cytologically confirmed extensive-stage disease SCLC which is newly diagnosed and chemotherapy naive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "2. Phase 1 ONLY: histologically or cytologically confirmed advanced/metastatic solid tumors for which carboplatin/etoposide treatment is considered appropriate.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "3. Subject in Phase 2 only: must have measurable disease per RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "4. Subjects with ED SCLC must consent to provide available archived formalin fixed paraffin embedded (FFPE) tissue sample of SCLC lesion (primary or metastatic) for central review and biomarker analysis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "6. Subject must have adequate hematologic, renal and hepatic function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": ". Phase 1 ONLY: Subject has had any prior anti-cancer therapy other than:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "   Hormonal, non-myelosuppressive, biologic, targeted, or immune therapy (must be completed ≥ 4 weeks prior to Cycle 1 Day -2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "   One line of cytotoxic chemotherapy (must be completed ≥ 4 weeks prior to Cycle 1 Day -2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "   Adjuvant/neoadjuvant radiotherapy (must be completed ≥ 12 months prior to Cycle 1 Day -2, with field not involving \\> 10% of bone marrow reserve).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "2. Phase 2 ONLY: Subject has had any prior chemotherapy, radiotherapy, investigational anti-cancer agents or biologic therapy for the disease under study. Single non-target lesion irradiation with intent of symptom palliation is allowed if ≥ 4 weeks prior Cycle 1 Day -2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "3. Subject has current central nervous system (CNS) or leptomeningeal metastases or history of CNS or leptomeningeal metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "4. Subject has a history of seizures within 12 months of Cycle 1 Day-2 or diagnosed neurological condition placing subject at the increased risk of seizures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "5. Subject has received anti-cancer Chinese medicine or anti-cancer herbal remedies within 14 days prior to Cycle 1 Day-2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "6. Subject has had major surgery within 6 weeks prior to Cycle 1 Day-2 (subjects must have completely recovered from any previous surgery prior Cycle 1 Day-2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "7. Subject has clinically significant and uncontrolled major medical condition(s) including but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "* Uncontrolled nausea/vomiting/diarrhea;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "* Active uncontrolled infection;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "* History of hepatitis B (HBV) with surface antigen (HBsAg) positivity within 3 months prior to the date of informed consent for this study (if no test has been performed within 3 months, it must be done at screening);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "* History of hepatitis C (HCV) with HCV ribonucleic acid (RNA) positivity within 3 months prior to the date of informed consent for this study (if no test has been performed within 3 months it must be done at screening);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "* Symptomatic congestive heart failure (Yew York Heart Association \\[NYHA\\] class ≥ II);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "* Unstable angina pectoris or cardiac arrhythmia (except atrial fibrillation);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "* Psychiatric illness/social situation that would limit compliance with study requirements;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "* Any other medical condition, which in the opinion of the Investigator, places the subject at an unacceptably high risk for toxicities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289690",
    "statement": "8. The subject has a history of another active cancer within the past 3 years except cervical cancer in situ, in situ carcinoma of the bladder, squamous or basal cell carcinoma of the skin or another in situ cancer that is considered cured by the investigator (e.g., in situ prostate cancer, breast DCIS).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01025284",
    "statement": "* Have histological or cytological evidence of extensive-disease small-cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01025284",
    "statement": "* Have the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01025284",
    "statement": "* Have received at least 1 prior chemotherapy regimen with agents known to provide clinical benefit for small-cell lung cancer and be, in the opinion of the investigator, an appropriate candidate for experimental therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01025284",
    "statement": "* Have discontinued all previous therapies for cancer, including chemotherapy, biologic therapy, hormone therapy, or radiotherapy. Participants must have recovered from the acute effects of therapy (except alopecia and fatigue) before study enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01025284",
    "statement": "* Part A: Have a performance status of 0 to 2 on the Eastern Cooperative Oncology Group scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01025284",
    "statement": "* Part B: Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01025284",
    "statement": "* Have received treatment within 28 days of the first dose of LY2523355 with a drug that has not received regulatory approval for any indication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01025284",
    "statement": "* Have a mixed histological diagnosis of small-cell lung cancer and non-small-cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01025284",
    "statement": "* Have serious preexisting medical conditions that, in the opinion of the investigator, would preclude participation in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01025284",
    "statement": "* Part A: Have symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases. Participants with treated CNS metastases are eligible provided their disease is radiographically stable, asymptomatic, and corticosteroid use has been discontinued for at least 2 weeks prior to the first dose of study drug. Screening of asymptomatic participants without history of CNS metastases is not required",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01025284",
    "statement": "* Part B: Have symptomatic, untreated, or uncontrolled CNS metastases or a history of CNS metastases. Participants who have received prophylactic radiation are not excluded. Screening of asymptomatic participants without history of CNS metastases is not required",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01544179",
    "statement": "* Male or female patients aged 18 years or older (For Japan only- male or female patients aged 20 years or older)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01544179",
    "statement": "* Cytological or histological confirmation of NSCLC other than predominantly squamous cell histology with an activating EGFR TK mutation as determined locally",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01544179",
    "statement": "* Patients with documented 'acquired resistance' on first line gefitinib",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01544179",
    "statement": "* Patients suitable to start cisplatin based pemetrexed combination chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01544179",
    "statement": "* Provision of informed consent prior to any study specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01544179",
    "statement": "* Prior chemotherapy or other systemic anti-cancer treatment (excluding gefitinib). Palliative bone radiotherapy must be completed at least 2 weeks before start of study treatment with no persistent radiation toxicity).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01544179",
    "statement": "* Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01544179",
    "statement": "* Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ or completely resected intramucosal gastric cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01544179",
    "statement": "* Any evidence of severe of uncontrolled systemic disease Treatment with an investigational drug within 4 weeks before randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* Adult patients, \\>/= 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* Locally advanced (Stage IIIB), metastatic (Stage IV) or recurrent non-small cell lung cancer with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* At least one measurable lesion according to RECIST criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* European Cooperative Oncology Group (ECOG) performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* Adequate hematological, liver and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* Patients with stable cerebral metastases who have received surgical or radiotherapy will be eligible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* Previous chemotherapy or therapy against EGFR for metastatic disease (neoadjuvant or adjuvant therapy after radical surgery is allowed if finalized \\>/= 6 months before entering the study)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* History of another neoplasm except for carcinoma in situ of the cervix, adequately treated basal cell skin carcinoma, radically treated prostate carcinoma with good prognosis (Gleason \\</= 6), or another curatively treated neoplasm without evidence of disease in the last 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* Symptomatic cerebral metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* Any significant ophthalmologic abnormality",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* Use of coumarins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* Pregnant or breast-feeding women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01372384",
    "statement": "* Pre-existing parenchymal lung disease such as pulmonary fibrosis, lymphangiosis and carcinomatosis (if this is the only presence of the disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00777179",
    "statement": "* Histologic or cytologic confirmation of locally advanced or metastatic NSCLC (IIIb-IV) at the time of original diagnosis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00777179",
    "statement": "* Completion of 4 cycles of chemotherapy of gemcitabine (1,000 or 1250mg/m\\^2/day on day 1 and 8) and cisplatin (70-80mg/m\\^2/day on day 1) every 3 weeks and have shown response, Complete Response(CR), Partial Response (PR) or stable disease (SD) by RECIST.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00777179",
    "statement": "* WHO PS 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00777179",
    "statement": "* No prior radiotherapy to chest, immunotherapy or biologic therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00777179",
    "statement": "* Mixed small cell and non small-cell lung cancer history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00777179",
    "statement": "* Prior treatment with EGFR TKIs or VEGFR TKIs (prior treatment with cetuximab \\[Erbitux\\] or bevacizumab \\[Avastin\\] is not permitted.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00777179",
    "statement": "* Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00777179",
    "statement": "* Radiation therapy within 4 weeks before the start of study therapy. Major surgery within 4 weeks, or incomplete healed surgical incision before starting study therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* give voluntary, signed informed consent in accordance with institutional policies",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* be non-obese as defined as body mass index (BMI)\\< or = to 32 and weight \\<300 pounds (\\<136kg)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* have been diagnosed with Stage III or IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* be prior to first line chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* planned first line chemotherapy regimen is platinum plus paclitaxel only or platinum plus docetaxel only",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* if surgery is part of the cancer treatment, screening for this study should be conducted at least 4 weeks (28 days) after surgery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* life expectancy of \\>6 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* ECOG score \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "or= 30 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* FEMALES - age \\>or=30 years and clinically confirmed as postmenopausal.Subjects must have undergone the onset of spontaneous or surgical menopause prior to the start of this study. Spontaneous menopause is defined as the natural cessation of ovarian function as indicated by being amenorrheic for at least 12 months. If the subject has been amenorrheic for \\>or=6 months but \\<12 months they must have a serum FSH concentration of \\>or=50 mIU/mL and an estradiol concentration of \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": " 10 years prior to enrollment and no evidence of active liver disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* positive screen for anti-HCV (Hepatitis C Antibody),hepatitis A antibody IgM, or HIV",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* currently taking testosterone, oxandrolone (Oxandrin), testosterone-like agents (such as dehydroepiandrosterone (DHEA), androstenedione, and other androgenic compounds, including herbals), or antiandrogens; previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the medical monitor for this study to determine appropriate washout period)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* currently taking megestrol acetate (Megace), dronabinol (Marinol), medical marijuana (medical cannabis) or any prescription medication intended to increase appetite or treat unintentional weight loss",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* have a baseline stair climb time \\>or=30 seconds (mean of two stair climbs)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "* Have active cancer, other than NSCLC, or non-melanoma carcinoma of the skin, within the previous two years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355484",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00883779",
    "statement": "* adult patients, \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00883779",
    "statement": "* advanced (stage IIIB/IV)non-small cell lung cancer;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00883779",
    "statement": "* measurable disease;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00883779",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00883779",
    "statement": "* prior exposure to agents directed at the HER axis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00883779",
    "statement": "* prior chemotherapy or systemic anti-tumor therapy after advanced disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00883779",
    "statement": "* unstable systemic disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00883779",
    "statement": "* any other malignancy within last 5 years, except cured basal cell cancer of skin or cured cancer in situ of cervix;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00883779",
    "statement": "* brain metastasis or spinal cord compression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": ". Male or female Japanese participants aged \\>=20 years on the day of consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "2. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "3. Have histologically or cytologically confirmed stage IIIB, stage IIIC (locally advanced or recurrent and not a candidate for definitive multimodality therapy), or stage IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "4. Have documentation of ALK rearrangement that meets following criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   For the Safety Evaluation Lead-in Part and the Refractory Expansion Part, participants must meet 1 of the following 2 criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   1. Have documentation of ALK rearrangement by a positive result from the Vysis ALK Break Apart fluorescence in situ hybridization (FISH) Probe Kit, the Nichirei Histofine ALK iAEP Kit, or the Ventana ALK (D5F3) Companion Diagnostics (CDx) Assay at any time during prior disease course. The sponsor may require an adequate tissue available for central laboratory testing by the Vysis ALK Break Apart FISH test if a documented ALK rearrangement is confirmed by a positive result from the Nichirei Histofine ALK iAEP Kit \"ONLY\".",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   2. Had a documented ALK rearrangement by a different test at any time during prior disease course, and adequate tissue available for central laboratory testing by the Vysis ALK Break Apart FISH test. Central confirmation of ALK rearrangement is not required before enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   For TKI-naïve Expansion Cohort, participants must meet the following criteria Have documentation of ALK rearrangement by a positive result from Ministry of Health, Labour and Welfare (MHLW) Approved tests (e.g Vysis ALK Break Apart FISH Probe Kit, the Nichirei Histofine ALK iAEP Kit, or the Ventana ALK \\[D5F3\\] CDx Assay) prior to enrollment, and required to submit sufficient tumor tissue for central laboratory testing upon request of sponsor. Central confirmation of ALK rearrangement is not required before enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "5. The Refractory Expansion Part only: had documented progressive disease (PD) during treatment or within 30 days after discontinuation of treatment with ALK inhibitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "* Note 1: The Refractory Expansion Part consists of the Main Cohort and a Sub-cohort based on prior ALK inhibitor treatment. The Main Cohort includes participants who had previously received alectinib (as their only ALK inhibitor) or both crizotinib and alectinib (regardless the sequence of those 2 ALK inhibitors), and a total of 47 participants will be enrolled. Participants with all other sequences of up to 2 prior ALK inhibitor(s) may be included in the Sub-cohort, and the number of participants will be limited to 20.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "* Note 2: Participants who will be included in the Main Cohort of the refractory should have documented PD during treatment or within 30 days after discontinuation of treatment with alectinib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "6. Have at least 1 measurable (ie, target) lesion per RECIST version 1.1. Note: Previously irradiated lesions may not be used for target lesions, unless there is unambiguous radiological progression after radiotherapy. Brain lesions may not be used as target lesions if they were 1) previously treated with whole brain radiation therapy (WBRT) within 3 months, or 2) previously treated by stereotactic radiosurgery (SRS) or surgical resection.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "7. Recovered from toxicities related to prior anticancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 Grade =\\<1. Note: Treatment-related alopecia is allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "8. Have a life expectancy of \\>=3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "9. Have adequate organ and hematologic function, as determined by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   1. Both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\<2.5 times the upper limit of the normal range (ULN) (=\\<5×ULN is acceptable if liver metastases are present).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   2. Total serum bilirubin =\\<1.5×ULN (\\<3.0×ULN for participants with Gilbert syndrome).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   3. Serum creatinine \\<1.5×ULN. For participants with creatinine levels above or equal to 1.5×ULN, the participant is eligible if the estimated creatinine clearance using the Cockcroft-Gault formula is \\>=30 mL/minute.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   4. Serum lipase =\\<1.5×ULN and serum amylase =\\<1.5×ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   5. Absolute neutrophil count (ANC) \\>=1.5×10\\^9/Liter (L).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   6. Platelet count \\>=75×10\\^9/L.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   7. Hemoglobin \\>=9 gram (g)/ deciliter (dL).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   8. Percutaneous oxygen saturation (SpO2) \\>=94% without oxygen support. Participants who need oxygen support are excluded.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "10. Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\\<2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "11. Must meet the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "    1. Female participants who:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "* Are postmenopausal for at least 1 year before the screening visit, OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "* Are surgically sterile, OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "* If they are of childbearing potential, agree to practice 1 highly effective non-hormonal method of contraception and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "* Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant, from the time of signing the informed consent through 4 months after that last dose of study drug. (Periodic abstinence \\[eg, calendar, ovulation, symptothermal, postovulation methods\\], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "    2. Male participants, even if surgically sterilized (ie, status postvasectomy), who:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "* Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "* Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant, during the entire study treatment period and through 4 months after that last dose of study drug. (Periodic abstinence \\[eg, calendar, ovulation, symptothermal, postovulation methods\\], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "12. Have the willingness and ability to comply with scheduled visit and study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": ". Previously received the following treatments. The Refractory Expansion Part only: received any prior ALK inhibitor not specified in the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "   TKI-naïve Expansion Cohort only: received any prior TKI including but not limited to ALK inhibitor and vascular endothelial growth factor receptor (VEGFR) TKI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "2. The Refractory Expansion Part only: received more than 2 prior ALK inhibitors. Note: The Safety Evaluation Lead-in Part allows participants with any line of prior ALK inhibitor which includes treatment-naïve participants; however, ALK inhibitor-naïve participants may be enrolled after the confirmation of first 3 dose-limiting toxicity (DLT) evaluable participants to have no more than 1 DLT during Cycle 1 by investigator's judgement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "3. The Safety Evaluation Lead-in Part and the Refractory Expansion Part only: received ALK inhibitor within 7 days before the first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "4. Previously received more than 1 regimen (more than 3 regimens in the Safety Evaluation Lead-in part) of systemic anticancer therapy (other than ALK inhibitors) for locally advanced or metastatic disease. Note: A systemic anticancer therapy regimen will be counted if it is administered over at least 1 cycle. A new anticancer agent used as maintenance therapy will be counted as a new regimen unless it was previously used as initial anticancer therapy. Neoadjuvant or adjuvant systemic anticancer therapy will be counted as a prior regimen if completion of (neo) adjuvant therapy occurred \\<12 months before the first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "5. Treatment with any investigational products within 30 days or 5 half-lives of that investigational agent, whichever is longer, before the first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "6. Received chemotherapy or radiation within 14 days before the first dose of brigatinib, except stereotactic radiosurgery (SRS) or stereotactic body radiation therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "7. Received antineoplastic monoclonal antibodies within 30 days before the first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "8. Received systemic treatment with strong inhibitors or strong and moderate inducers of cytochrome P450 (CYP) 3A within 7 days before the first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "9. Had major surgery within 30 days before the first dose of brigatinib. Minor surgical procedures such as venous catheter placement or minimally invasive biopsies are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "10. Have been diagnosed with another primary malignancy other than NSCLC, except for the following adequately/definitively treated malignancies: nonmelanoma skin cancer, cervical cancer in situ, nonmetastatic prostate cancer; or participant with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "11. Have symptomatic central nervous system (CNS) metastases (parenchymal or leptomeningeal) at screening or asymptomatic disease requiring an increasing dose of corticosteroids to control symptoms within 7 days before the first dose of brigatinib. Note: If a participant has worsening neurological symptoms or signs due to CNS metastasis, the participant needs to complete local therapy and be neurologically stable (with no requirement for an increasing dose of corticosteroids or use of anticonvulsants for symptomatic control) for 7 days before the first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "12. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Participants with asymptomatic leptomeningeal disease and without cord compression are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "13. Have ongoing or history of interstitial lung disease (ILD) (including interstitial pneumonitis, pneumonitis, radiation pneumonitis, drug-related pneumonitis, organized pneumonia, and pulmonary alveolitis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "14. Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "    1. Myocardial infarction within 6 months before the first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "    2. Unstable angina within 6 months before the first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "    3. Congestive heart failure within 6 months before the first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "    4. Uncontrolled atrial arrhythmias despite appropriate medical therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "    5. History of ventricular arrhythmia, including history of ventricular tachycardia, ventricular fibrillation, or torsades de pointes. Participants with premature ventricular contractions are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "    6. Cerebrovascular accident or transient ischemic attack within 6 months before the first dose of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "15. Have uncontrolled hypertension. Participants with hypertension should be under treatment at the start of screening and demonstrate adequate control of blood pressure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "16. Have an ongoing or active infection, including, but not limited to, the requirement for intravenous antibiotics.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "17. Have a known history of human immunodeficiency virus (HIV) infection. Testing is not required in the absence of history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "18. Hepatitis B surface antigen (HBsAg) positive, detectable hepatitis B viral load, or detectable hepatitis C virus (HCV) infection viral load. Note: Participants who have positive hepatitis B core antibody (HBcAb) or hepatitis B surface antibody (HBsAb) can be enrolled but must have an undetectable hepatitis B viral load. Participants who have positive HCV antibody can be enrolled but must have an undetectable hepatitis C viral load.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "19. Have malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "20. Have a known or suspected hypersensitivity to brigatinib or its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "21. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period. Note: Female participants who are lactating will be excluded, even if they discontinue breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03410108",
    "statement": "22. Have any condition or illness that, in the opinion of the investigator, would compromise participant safety or interfere with the evaluation of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Participants capable of giving signed informed consent/assent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Male or female, aged 18 years or older at the time consent is obtained. Participants in Korea must be age 19 years or older at the time consent is obtained.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Participants with histologically or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  a) Documented disease progression based on radiographic imaging, during or after a maximum of 2 lines of systemic treatment for locally/regionally advanced recurrent, Stage IIIb/Stage IIIc/Stage IV or metastatic disease. Two components of treatment must have been received in the same line or as separate lines of therapy: i) No more than or less than 1 line of platinum-containing chemotherapy regimen, and ii) No more than or less than 1 line of Programmed cell death ligand 1 (PD\\[L\\]1) monoclonal antibody (mAb) containing regimen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  b) Participants with known BRAF molecular alterations must have had disease progression after receiving the locally available SoC treatment for the molecular alteration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  c) Participants who received prior anti-PD(L)1 therapy must fulfill the following requirements: i) Have achieved a CR, PR or SD and subsequently had disease progression (per RECIST 1.1 criteria) either on or after completing PD(L)1 therapy ii) Have not progressed or recurred within the first 12 weeks of PD(L)1 therapy, either clinically or per RECIST 1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Measurable disease, presenting with at least 1 measurable lesion per RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* A tumor tissue sample obtained at any time from the initial diagnosis of NSCLC to time of study entry is mandatory. Although a fresh tumor tissue sample obtained during screening is preferred, archival tumor specimen is acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Adequate organ function as defined in the protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* A male participant must agree to use a highly effective contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions apply:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  i) Not a woman of childbearing potential (WOCBP) or ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Life expectancy of at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Participants who received prior treatment with the following therapies (calculation is based on date of last therapy to date of first dose of study treatment):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  1. Docetaxel at any time.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  2. Any of the investigational agents being tested in the current study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  3. Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  4. Prior radiation therapy: permissible if at least one non-irradiated measurable lesion is available for assessment per RECIST version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least 2 weeks before start of study drug for radiation of any intended use is required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Received greater than (\\>)2 prior lines of therapy for NSCLC, including participants with BRAF molecular alternations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Invasive malignancy or history of invasive malignancy other than disease under study within the last 2 years, except",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Any other invasive malignancy for which the participant was definitively treated, has been disease-free for at least 2 years and in the opinion of the principal investigator and GlaxoSmithKline Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Curatively treated non-melanoma skin cancer or successfully treated in situ carcinoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Carcinomatous meningitis (regardless of clinical status) and uncontrolled or symptomatic Central nervous system (CNS) metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Major surgery less than or equal to (\\<=) 28 days of first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Autoimmune disease (current or history) or syndrome that required systemic treatment within the past 2 years. Replacement therapies which include physiological doses of corticosteroids for treatment of endocrinopathies (for example, adrenal insufficiency) are not considered systemic treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Receiving systemic steroids (\\>10 milligrams \\[mg\\]) oral prednisone or equivalent) or other immunosuppressive agents within 7 days prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Prior allogeneic/autologous bone marrow or solid organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Receipt of any live vaccine within 30 days prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Toxicity from previous anticancer treatment that includes:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  1. Greater than or equal to (\\>=) Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  2. Toxicity related to prior treatment that has not resolved to \\<= Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \\<= Grade 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* History (current and past) of idiopathic pulmonary fibrosis, pneumonitis (for past- pneumonitis exclusion only if steroids were required for treatment), interstitial lung disease, or organizing pneumonia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* History or evidence of cardiac abnormalities within the 6 months prior to enrollment which include",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  1. Serious, uncontrolled cardiac arrhythmia or clinically significant electrocardiogram abnormalities including second degree (Type II) or third degree atrioventricular block.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  2. Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting or bypass grafting.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "  3. Symptomatic pericarditis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypo-albuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Active infection requiring systemic therapy \\<=7 days prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Participants with known human immunodeficiency virus infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Participants with history of severe hypersensitivity to mAb or hypersensitivity to any of the study treatment(s) or their excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Participants requiring ongoing therapy with a medication that is a strong inhibitor or inducer of the cytochrome P 3A4 (CYP3A4) enzymes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Pregnant or lactating female participants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Participant who is currently participating in or has participated in a study of an investigational device within 4 weeks prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Participants with presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Participants with positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Participants with positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05553808",
    "statement": "* Receipt of transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony stimulating factor \\[G-CSF\\], granulocyte-macrophage colony-stimulating factor, and recombinant erythropoietin) within 14 days before the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": ". Provision informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "2. Aged at least 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "3. Histological or cytological confirmation diagnosis of NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "4. Locally advanced or metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "5. Radiological documentation of disease progression while on a previous continuous treatment with an approved EGFR TKI. In addition other lines of therapy may have been given",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Documented EGFR mutation (at any time since the initial diagnosis of NSCLC) known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "6. World Health Organisation (WHO) performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "7. At least one lesion suitable for accurate repeated measurements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "8. Females",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Child bearing potential : should not be breast feeding, use adequate contraceptive measures for female patients with child-bearing potential, OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Have evidence of non-child-bearing potential that meet one of the following criteria at screening:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Women below 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "9. Male patients should be willing to use barrier contraception ie, condoms",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": ". Treatment with any of the following (prior to first dose of study treatment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Treatment with an EGFR TKI within 8 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Any investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Previous treatment with AZD9291, or a Thr790Met (T790M) directed EGFR TKIs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Major surgery (excluding placement of vascular access) within 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Radiotherapy :",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Within 1 week if limited field of radiation for palliation of the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Within 4 weeks if receiving radiation to more than 30% of the bone marrow or with a wide field of radiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Patients currently receiving (or unable to stop use at least 1 week) medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 3A4 (CYP3A4)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Treatment with an investigational drug within five half-lives of the compound",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "2. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum-therapy related neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "3. Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "5. Any of the following cardiac criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Mean resting corrected QT interval (QTc) \\>470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derivedQTc value",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block, second degree heart block, P wave to R wave (PR) interval \\>250 msec",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long (Q-T interval) QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "6. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease 7, Inadequate bone marrow reserve or organs function as demonstrated by any of the following laboratory values:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Absolute neutrophil count \\<1.5x109/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Platelet count \\<100x109/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Hemoglobin \\<90 g/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Alanine aminotransferase \\>2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Aspartate aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Total bilirubin \\>1.5 times ULN if no liver metastases or \\>3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "* Creatinine \\>1.5 times ULN concurrent with creatinine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02529995",
    "statement": "8, Clearance \\<50 ml/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9291 9, History of hypersensitivity to active or inactive excipients of AZD9291 or drugs with a similar chemical structure or class to AZD9291 10, Women who are breast feeding 11, Involvement in the planning and conduct of the study (applies to AstraZeneca staff or staff at the study site) 12, Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Aged at least 18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Documented evidence of NSCLC (stage IIIB/IV disease)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Disease progression or recurrence after both a platinum-based chemotherapy and at least 1 additional regimen for treatment of NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* World Health Organisation (WHO) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Estimated life expectancy of more than 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Patient's tumour sample must be PD-L1 positive (≥25%of tumour cells with membrane staining (Cohort 1 and 2) or PD-L1 positive with ≥90% of tumour cells with membrane staining (Cohort 3))",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Brain metastases or spinal cord compression or unless asymptomatic, treated and stable (not requiring steroids).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Active or prior autoimmune disease or history of immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Any unresolved toxicity CTCAE \\>Grade 2 from previous anti-cancer therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \\>Grade 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02087423",
    "statement": "* Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": ".",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "Participants were included in the study if they presented either via ambulance or to a center where PCI was not performed and met all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "1. Provided written informed consent before initiation of any study related procedures. Participants randomized in the ambulance may initially have signed an abridged version.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "2. Aged ≥18 years at the time of randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "3. Had a presumed diagnosis of STE-ACS with onset of symptoms of \\>20 minutes and \\<12 hours with one or more of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "* ST segment elevation of ≥1 millimeters (mm) in ≥2 contiguous leads",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "* Presumably new left bundle branch block",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "* An infero-lateral myocardial infarction with ST segment depression of ≥1 mm in ≥2 of leads V1-3 with a positive terminal T wave",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "4. All participants would proceed with emergent angiography and primary PCI if indicated \\<2 hours after first medical contact",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": ". Any bleeding diathesis or severe hematological disease or history of intra-cerebral mass, aneurysm, arterio-venous malformation, hemorrhagic stroke, intra-cranial hemorrhage, or gastrointestinal or genitourinary bleeding within the last 2 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "2. Participants who had undergone recent surgery (including biopsy) within the last 2 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "3. Participants who were on warfarin (not applicable if International Normalized Ratio known to be \\<1.5).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "4. Participants who had received UFH, LMWH, or bivalirudin immediately before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "5. Thrombolytic therapy within the last 48 hours.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "6. Absolute contra-indications or allergy that could not be pre-medicated to iodinated contrast or to any of the study medications including aspirin or clopidogrel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "7. Contraindications to angiography, including but not limited to severe peripheral vascular disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "8. If it was known, pregnant or nursing mothers. Women of child-bearing age were asked if they were pregnant or thought that they may be pregnant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "9. If it is known, a creatinine clearance \\<30 milliliter/minute or dialysis dependent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "10. Previous enrolment in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "11. Treatment with other investigational drugs or devices within the 30 days preceding randomization or planned use of other investigational drugs or devices in this trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "12. Participants may not have been enrolled if the duration of randomized investigational medicinal product anti-thrombin infusion was likely to be \\<30 minutes from the time of onset to the commencement of angiography.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "13. Participants may not have been enrolled within a primary PCI-capable hospital (unless at the time of randomization, the catheter laboratory was not available, and the participant required transfer to another primary PCI capable hospital).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01087723",
    "statement": "14. Estimated body weight of \\>120 kg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": ". Part A (1st line, PD-X naïve NSCLC): histologically- or cytologically-confirmed diagnosis of non-small cell lung carcinoma stage IIIB not amenable to curative treatment or stage IV not amenable to EGFR/ALK based therapy, treatment naïve for systemic therapy given for advanced/metastatic disease (previous palliative radiotherapy for advanced/metastatic disease acceptable)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "   Part B (2nd line, PD-X refractory NSCLC): histologically- or cytologically-confirmed diagnosis of NSCLC after failure of first-line treatment (for metastatic disease) with at least 2 cycles of any PD-1/PD-L1 containing based therapy (e.g. nivolumab, pembrolizumab, avelumab, durvalumab, etc.) alone, or in combination with any other immunotherapeutic or chemotherapy given as part of first-line treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "   Part C (2nd line PD-X naive HNSCC): Histologically- or cytologically-confirmed recurrent disease not amenable to curative treatment with local or systemic therapy, or metastatic (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies after failure of prior platinum-based therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "2. Submission of formalin-fixed diagnostic tumor tissue",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "3. ECOG performance status 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "4. Expected survival \\> 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "Main",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": ". For part A (1st line, PD-X naïve NSCLC):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "* The NSCLC can be treated with curative intent with either surgical resection and/or chemoradiation and/or radiation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "* Has received systemic therapy for the treatment of their stage IV NSCLC. Completion of treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "* EGFR-sensitizing mutation and/or is EML4 gene/ ALK gene fusion positive (ALK translocation).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "* Lung radiation therapy that is \\>30Gy within 6 months of the first dose of trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "   For Part B (2nd line, PD-X refractory NSCLC):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "* Symptomatic ascites or pleural effusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "* \\> 1 line of chemotherapy for metastatic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "* Lung radiation therapy that is \\>30Gy within 6 months of the first dose of trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "   For Part C (2nd line PD-X naive HNSCC):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "* Disease is suitable for local therapy administered with curative intent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "* Previously treated with \\> 1 systemic regimens for recurrent and/or metastatic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "2. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) (Part A and C only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "3. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher irAE (Part B only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "4. Has received prior chemotherapy, anti-cancer monoclonal antibody, major surgery, another systemic cancer therapy or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to cycle 1 day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "   Note: Patients must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Patients with ≤Grade 2 neuropathy, alopecia and elevated transaminases in case of liver metastases may be eligible. If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "5. Known active central nervous system metastasis and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable: i.e. without evidence of progression documented by repeat imaging performed after therapy completed for CNS metastasis and with at least 4 weeks difference, clinically stable and without requirement for steroid treatment for at least 14 days prior to cycle 1 day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03625323",
    "statement": "6. Receives continuous systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days prior to cycle 1 day 1. Inhaled or topical steroids and physiological replacement doses of up to 10 mg daily prednisone equivalents are permitted in the absence of active auto-immune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00376623",
    "statement": ", who relapsed or failed prior first-line chemotherapy for advanced or metastatic disease. At least one tumour lesion must be present that can accurately be measured by magnetic resonance imaging (MRI), or computed tomography (CT) in at least one dimension (longest diameter to be recorded) as 20 mm or greater with conventional techniques or as 10 mm or greater with spiral CT scan. Life expectancy of at least three months; Eastern co-operative oncology group (ECOG) performance score of 2 or less and written informed consent which must be consistent with international conference on harmonisation good clinical practice (ICH-GCP) and local legislation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00376623",
    "statement": ", known secondary malignancy requiring therapy, brain metastases which are symptomatic or require therapy, absolute neutrophil count less than 1,500/mm3, platelet count less than 100,000/mm3, haemoglobin less than 9 mg/dl, aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal, or AST or ALT greater than 5 times the upper limit of normal in case of known liver metastases, bilirubin greater than 1.5 mg/dl, serum creatinine greater than 2.0 mg/dl, concomitant intercurrent illnesses that would limit compliance with trial requirement or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, chemo-, hormone- or immunotherapy within the past four weeks or within less than four half-life times of the previous drug prior to treatment with the trial drug (whatever is the longest period), radiotherapy within the past four weeks prior to treatment with the trial drug, men or women who are sexually active and unwilling to use a medically acceptable method of contraception during the trial, pregnancy or lactation, treatment with any other investigational drug within the past four weeks or within less than four half-life times of the investigational drug before treatment with the trial drug (whatever is the longest period), patient unable to comply with the protocol, patients who are considered eligible by the investigator for other second-line chemotherapy, radiotherapy or immunotherapy, patients who have received more than two lines of prior anti-tumour therapy for advanced or metastatic non small cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00994123",
    "statement": "* Patients with locally advanced or metastatic non-small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00994123",
    "statement": "* Patients must be \\>/= 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00994123",
    "statement": "* Patients must have adequate Performance Status (PS) as measured by ECOG and adequate end organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00994123",
    "statement": "* Patients with a recent history (within 5 years) of another malignancy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00994123",
    "statement": "* Patients who are pregnant or nursing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00994123",
    "statement": "* Patients with clinically significant heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00994123",
    "statement": "* Patients with clinically significant eye or gastrointestinal abnormalities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* M/F at least 18 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* ECOG performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Adequate bone marrow, liver, and kidney function within 2 weeks prior to first dose",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Serum potassium, calcium, magnesium, phosphorus within normal limits (may be supplemented)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Adequate birth control",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Somatostatin receptor 2 positive tumor as assessed at pre-screening or within 180 d of first drug dose using indium SPECT or gallium PET",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "Patients in Phase 1 must have a histologically or cytologically-confirmed solid tumor in 1 of the following categories:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Advanced small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of lung progressed after at least 1 line of anticancer chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Advanced low or intermediate grade gastroenteropancreatic or lung or thymus neuroendocrine tumor (NET), or NET of unknown primary, progressed after at least 1 line of anticancer therapy (unless no standard treatments available or such treatments are deemed not appropriate)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Advanced paraganglioma, pheochromocytoma, medullary thyroid carcinoma, Merkel cell carcinoma, or high grade extrapulmonary neuroendocrine carcinoma having progressed after 1 or more lines of anticancer chemotherapy (unless no standard treatments available or such treatments are deemed not appropriate)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "For patients enrolling once escalation is complete (Phase 2a), disease must be measurable per RECIST 1.1 criteria with last imaging performed within 28 days prior to first drug dose",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "In addition to the criterion listed above, Patients in Phase 2a must have a histologically- or cytologically-confirmed, advanced or metastatic solid tumor, in 1 of the following categories: disease history specified in one of the criteria listed below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Well differentiated, low or intermediate grade, gastrointestinal mid-gut (arising from the lower jejunum, ileum, appendix, cecum, and proximal colon) NET with documented disease progression within 6 months prior to start of study treatment and evidence of radiographic disease progression based on scans performed not more than 15 months apart. Patients may have received 1 or more prior lines of anticancer therapy, such as somatostatin analogues, targeted agents, or liver-directed intra-arterial therapy, but are NOT eligible if they have received prior systemic cytotoxic chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Well differentiated, low or intermediate grade, pancreatic NET with documented disease progression within 6 months prior to start of study treatment and evidence of radiographic disease progression based on scans performed not more than 15 months apart. Patients may have received 1 or more prior lines of anticancer therapy, such as somatostatin analogues, targeted agents, or liver-directed intra-arterial therapy, and up to 1 prior line of systemic cytotoxic chemotherapy, but are NOT eligible if they have received more than 1 prior line of systemic cytotoxic chemotherapy or if they have received prior peptide receptor radionuclide therapy (PRRT)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* SCLC after having received up to three prior lines of anticancer therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Treatment with anticancer therapy or investigational drug or device within 3 wk (6 wk for nitrosureas or mitomycin C) or 5 half-lives of agent, whichever is shorter, prior to first PEN-221 drug dose, and any drug-related toxicities must have recovered to grade 1 or less",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Any other malignancy known to be active or treated within 3 years of start of screening, except cervical intra-epithelial neoplasia, superficial (non-invasive) bladder cancer, and non-melanoma skin cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Cardiac criteria such as unstable angina, myocardial infarction within 6 months of screening, NY Heart Association Class 1 or 2 heart failure, QTc greater than 470 msec, congenital long Qt syndrome, symptomatic orthostatic hypotension within 6 months of screening, uncontrolled hypertension, or clinically important abnormalities in heart rhythm, conduction, morphology of resting ECG",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Stroke or transient ischemic attack within 6 months of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Peripheral neuropathy greater than grade 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Requirement for medication with strong CYP3A4 inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* History of leptomeningeal disease or spinal cord compression",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Brain metastases unless asymptomatic on a stable low dose of steroids. Patients with SCLC or LCNEC of lung only must have CT or MRI of brain during screening, and if metastases found, must have radiotherapy with 14 day washout or stereotactic radiotherapy or radio surgery with 7 day washout prior to first drug dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Major surgery within 28 days of first drug dose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Female who is pregnant or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Evidence of severe uncontrolled systemic disease, bleeding diatheses, renal or liver transplant, active infection with hepatitis B or C, or HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02936323",
    "statement": "* Hypersensitivity or anaphylactic reaction to any somatostatin analog or to maytansinoids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00308750",
    "statement": "* You must have been diagnosed with NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00308750",
    "statement": "* You must be able to visit the doctor's office weekly during the active treatment period and as needed during the study follow-up period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00308750",
    "statement": "* You must be willing and able to swallow capsules.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00308750",
    "statement": "* Your entry labs and medical tests must meet study requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00308750",
    "statement": "* You must be willing to have blood samples drawn and tissue samples obtained for gene and protein testing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00308750",
    "statement": "* You have received radiation within 2 weeks of study enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00308750",
    "statement": "* You have previously received any anti-cancer drug therapy for NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00308750",
    "statement": "* You have an active infection or other serious condition.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00308750",
    "statement": "* You take aspirin or aspirin-like medication regularly and are not able to stop taking them for a few days during each cycle of chemotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00308750",
    "statement": "* You have recently lost a significant amount of weight.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": ". Signed inform consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "2. Age \\>= 18 years and \\<= 70 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "3. Histologically or cytologically confirmed small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "4. ED-SCLC according to Veterans Administration Lung Study Group.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "5. Radiographically progression following a platinum-based standard prior chemotherapy regimen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "6. Eastern Cooperative Oncology Group performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "7. Measurable disease as defined by RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "8. Life expectancy \\>= 8 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "9. Adequate hematologic and end organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": ". Histologically or cytologically confirmed mixed non-small cell and small cell carcinoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "2. Prior exposure to therapeutic anticancer vaccines; prior exposure to any T cell co-stimulatory therapy or immune checkpoint inhibitors, including but not limited to other anti-CTLA-4, anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "3. Prior exposure to anti-VEGF or anti-VEGFR therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "4. Active brain metastasis or meningeal metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "5. Clinically significant third space effusion (e.g., uncontrolled pericardial effusion, ascites or pleural effusion by extraction or other treatment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "6. Known hypersensitivity to study drug or any of its excipients; known hypersensitivity to any antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "7. Treatment with any other investigational agent or participation in another clinical trial within 4 weeks prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03417895",
    "statement": "8. Other conditions that the investigator thinks unsuitable in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00585195",
    "statement": "* Advanced malignancies (except leukemias), histologically proven at diagnosis; Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00585195",
    "statement": "* Solid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients with non-measurable disease may enter on a case-by-case basis); not required for DDI sub-studies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00585195",
    "statement": "* Adequate blood cell counts, kidney function, liver function and Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG score of 2 may be allowed on a case-by-case basis)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00585195",
    "statement": "* Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of starting study treatment, depending on the patient cohort",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00585195",
    "statement": "* Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00585195",
    "statement": "* Active or unstable cardiac disease or heart attack within 3 months of starting study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* For Part A, the subject has histological or cytological evidence of a solid tumor; for Part B, the subject has a diagnosis of melanoma or renal cell carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* All subjects must have advanced solid tumors that have returned after treatment with established approved therapies or be intolerant of established therapies",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects enrolled in Part B or Part C must have at least 1 lesion that may qualify as a target lesion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subject can move around on their own, has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and has an estimated life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subject must have adequate hematologic reserve",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects must have adequate liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects must have adequate kidney function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy or surgery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects who have received investigational agents must wait at least 4 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Females of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and on Day 1 before the first dose is administered. A female not of childbearing potential is one who has undergone bilateral oophorectomies or who is postmenopausal, defined as \\>45 years of age and without a menstrual period for 12 consecutive months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Meets contraceptive requirements defined in the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Additional criteria may apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subject is currently pregnant or breastfeeding, or is planning to become pregnant during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects with an active infection or with a fever \\>/= 38.5 degrees C within 3 days of the first scheduled day of dosing for Cycle 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects with active or symptomatic central nervous system metastases are excluded. Subjects with central nervous system metastases are eligible for the study if the metastases have been treated by surgery and/or radiation therapy, the subject is off corticosteroids for at least 2 weeks and the subject is neurologically stable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects have a mean QT interval corrected by the Fridericia Correction formula value of \\>470 msec (in females) or \\>450 msec (in males)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects with known hypersensitivity to any components of ALKS 4230",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects who require pharmacologic doses of corticosteroids; replacement doses, topical, ophthalmologic, and inhalational steroids are permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects who developed autoimmune disorders while on prior immunotherapy, including pneumonitis, nephritis, and neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects with any other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the subject to cooperate and participate in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* The subject is known to be positive for human immunodeficiency virus (HIV), hepatitis B or C, or active tuberculosis, or has a known history of tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects with dyspnea at rest of requiring oxygen therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects active autoimmune disease requiring systemic treatment within the past 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects who received radiotherapy within the last 4 weeks before start of study treatment administration with the exception of limited field palliative radiotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects who have received systemic immunomodulatory agents within 28 days prior to C1D1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects who have received administration of a live, attenuated vaccine within 4 weeks of Cycle 1, Day1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Prior solid organ and/or non-autologous hematopoietic stem cell or bone marrow transplant recipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Subjects who have received prior IL-2 based or IL-15 based cytokine therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02799095",
    "statement": "* Additional criteria may apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01885195",
    "statement": "* Patient has a confirmed diagnosis of a select solid tumor (except for primary diagnosis of pancreatic cancer, biliary cancer, colorectal cancer, low grade serous ovarian cancer, melanoma) or hematologic malignancy (except for primary diagnosis of chronic myelomonocytic leukemia).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01885195",
    "statement": "* Patients must be pre-identified as having a tumor with a mutation in RAF, RAS, NF1 or MEK at a CLIA certified laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01885195",
    "statement": "* Patient must have received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01885195",
    "statement": "* Patient must have progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01885195",
    "statement": "* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01885195",
    "statement": "* Patient has received prior treatment with MEK162.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01885195",
    "statement": "* Patients with primary CNS tumor or CNS tumor involvement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01885195",
    "statement": "* History of retinal degenerative disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01885195",
    "statement": "* History or current evidence of central serous retinopathy (CSR) or retinal vein occlusion (RVO)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01885195",
    "statement": "* Any ophthalmopathy visible at screening that would be considered a risk factor for CSR or RVO by the ophthalmologist",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01885195",
    "statement": "* Patients who have neuromuscular disorders that are associated with elevated CK",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Presence of measurable disease per RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Laboratory and medical history parameters not within the Protocol-defined range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Receipt of anticancer medications or investigational drugs within the Protocol-defined intervals before the first administration of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Previous radiotherapy within 2 weeks of starting study therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Has not recovered to ≤ Grade 1 from toxic effects of previous therapy and/or complications from previous surgical intervention before starting study therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Receipt of a live vaccine within 30 days of planned start of study therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Subjects who have any active or inactive autoimmune disease or syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03085914",
    "statement": "* Women who are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Signed informed consent;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Age ≥18 years and able to tolerate the EBUS-TBNI procedure;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Histologically/cytologically confirmed lung cancer. Eligible subjects may include, for example: primary or recurrent non-resectable disease, locally advanced stages II and III with nodal disease, stage IV advanced disease;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* At least one lesion documented via imaging (within 4 weeks of Screening) which can be accessed using EBUS-TBNI;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Subject is not a candidate for surgery;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Has received or plans to receive SOC chemotherapy; adequate hematologic recovery must be confirmed according to the institution's SOC;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Performance Status (ECOG) 0-2 at study entry;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Life expectancy of at least 6 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Adequate marrow, liver, and renal function at study entry;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* ANC ≥ 1.5 x 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Hemoglobin ≥ 9.0 grams/dL;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Platelets ≥ 75 x 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Total bilirubin ≤ 1.5x institutional ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* AST/ ALT ≤ 2.5x institutional ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Creatinine ≤ 1.5x institutional ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Appropriate steps taken to minimize or avoid the potential for pregnancy for subjects of child-bearing potential.\\*",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Significant cardiac disease (Class III or IV per New York Heart Association guidelines);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Active bacterial, viral, or fungal infections (including active AIDS, hepatitis B or hepatitis C);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Symptomatic central nervous system (CNS) metastasis which are neurologically unstable, or CNS disease requiring increase in steroid dose (treated metastatic disease and stable steroid use are not excluded)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Known hypersensitivity to study agent;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "* Pregnant or breastfeeding women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* During dose escalation, subjects with advanced solid tumors that have progressed following at least one standard regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* During cohort expansion, subjects with advanced cancer that either have received at least one prior therapy or are treatment naive, depending on the specified tumor type",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* Subjects must have measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* Subject must consent to provide previously collected tumor tissue and a tumor biopsy during screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* At least 4 weeks since any previous treatment for cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* Must be able to swallow pills or capsules",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* Active or chronic autoimmune diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* Uncontrolled or significant cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* Chronic hepatitis: Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except for subjects with hepatocellular carcinoma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* Active central nervous system (CNS) metastases and CNS metastases as the only sites of disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "* Active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02658890",
    "statement": "Other protocol defined inclusion/exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02264990",
    "statement": "* Subject must be ≥ 18 years of age with life expectancy \\> 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02264990",
    "statement": "* Subject must have cytologically or histologically confirmed advanced or metastatic non-squamous NSCLC and are current or former smokers.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02264990",
    "statement": "* Subject must have NSCLC that is not amenable to surgical resection or radiation with curative intent at time of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02264990",
    "statement": "* Subject must have at least 1 unidimensional measurable NSCLC lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02264990",
    "statement": "* Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02264990",
    "statement": "* Subject has a known hypersensitivity to platinum compounds.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02264990",
    "statement": "* Subject has peripheral neuropathy ≥ grade 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02264990",
    "statement": "* Subject has squamous NSCLC, or an untreated known epidermal growth factor receptor (EGFR) mutation of exon 19 deletion or L858R mutation in exon 21, or a known anaplastic lymphoma kinase (ALK) gene rearrangement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02264990",
    "statement": "* Subject has received prior cytotoxic chemotherapy or chemoradiotherapy for NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": ". The participants has histologically or cytologically confirmed Non-Small Cell Lung Cancer (NSCLC)Stage IIIB with effusion. Mixed Non-Small Cell Lung Cancer (NSCLC) tumors will be categorized by the predominant cell type. Primary or metastatic site may be used for histology",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "2. For squamous cell histology or for centrally located mediastinal masses (\\< 3 cm from the carina) identified by computed tomography scan (CT) or chest x-ray, the participant must undergo a magnetic resonance imaging (MRI) of the chest or I.V. contrast CT scan within 3 weeks of randomization, to exclude major airway or blood vessel invasion (in the investigator's opinion) by cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "3. The participant has measurable disease (Tumors within a previously irradiated field will be designated as \"nontarget\" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "4. The participant's Eastern Cooperative Oncology Group (ECOG) performance status is 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "5. The participant's age at the time of study entry is ≥ 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "6. The participant has adequate hematologic function as defined by an absolute neutrophil count (ANC) ≥ 1500/μL, hemoglobin ≥ 9.5 g/dL, and a platelet count ≥ 100,000/μL obtained within 2 weeks prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "7. The participant has adequate hepatic function as defined by a total bilirubin ≤ 1.5 mg/dL, and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 × the upper limit of normal (ULN), or ≤ 5 × the ULN in the presence of known liver metastases)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "8. The participant has adequate renal function as defined by serum creatinine ≤ 1.5 × the institutional ULN. If creatinine is above the ULN, the patient's creatinine clearance (CrCl) is ≥ 60 mL/min",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "9. The participant has urinary protein ≤ 1+ on dipstick or routine urinalysis; if urine dipstick or routine analysis is ≥ 2+, a 24-hour urine for protein must demonstrate \\< 1 g of protein in 24 hours to allow participation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "10. The participant has adequate coagulation function, as defined by international normalized ratio (INR) ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 5 seconds above ULN if not receiving anticoagulation therapy. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin, have therapeutic INR, no active bleeding (defined as within 14 days randomization) and no pathological condition that carries a high risk of bleeding (eg, tumor involving major vessels or known varices)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "11. Because the teratogenicity of Olaratumab is not known, women of childbearing potential (WOCBP) and sexually active males must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to randomization and for the duration of study participation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "12. The participant has resolution to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4 (NCI-CTCAE v 4.02) of all clinically significant toxic effects of prior locoregional therapy, surgery, chemoembolization, or other anticancer therapy. The exceptions for such effects are events that pertain to the lab values found elsewhere in these inclusion criteria. (For example, criterion # 6 states that a patient with hemoglobin ≥ 9.5 g/dL is considered eligible, even though NCI-CTCAE v 4.02 defines this value as Grade 2 anemia.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "13. The participant has a life expectancy of ≥ 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "14. The participant has provided signed informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": ". The participant has untreated central nervous system (CNS) metastases. Participants are eligible if they are clinically stable, off all steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, stereotactic radiosurgery)ending at least 2 weeks prior to randomization, or after surgical resection performed at least 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "2. The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer, or of intratumor cavitation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "3. The participant received prior systemic chemotherapy or biologic therapy (eg erlotinib) for Stage IIIB/IV NSCLC outside of the adjuvant setting. Participants who received prior cytotoxic chemotherapy or biologic therapy in the adjuvant setting will not be excluded based on such therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "4. The participant has a history of another primary cancer, with the exception of a) curatively resected nonmelanomatous skin cancer b) curatively treated cervical carcinoma in situ c)other primary solid tumor treated with curative intent, no known active disease present, and no treatment administered during the last 3 years prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "5. The participant is receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemo-embolization, targeted therapy, or an investigational agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "6. The participant has an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "7. The participant has an uncontrolled thrombotic or hemorrhagic disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "8. The participant has a history of gross hemoptysis (defined as bright red blood or ≥ 1/2 teaspoon) within 2 months of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "9. The participant has a serious non-healing wound, ulcer, or bone fracture within 28 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "10. The participant has undergone major surgery within 28 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "11. The participant has received adjuvant chemotherapy 21 days prior to randomization or has participated in clinical trials of experimental agents within 28 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "12. The participant has an elective or a planned major surgery to be performed during the course of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "13. The participant has peripheral neuropathy ≥ Grade 2 NCI-CTCAE v 4.02",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "14. The participant has known human immunodeficiency virus (HIV) positivity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "15. The participant, if female, is pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "16. The participant has received previous therapy with any agent that targets platelet derived growth factor (PDGF) or platelet derived growth factor receptor (PDGFR)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "17. The participant has a known allergy to any of the treatment components",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00918203",
    "statement": "18. The participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to that of Olaratumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02448303",
    "statement": "* Men and women ≥ 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02448303",
    "statement": "* ECOG performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02448303",
    "statement": "* Histologically confirmed recurrent or metastatic NSCLC (adenocarcinoma, large cell, squamous cell, or not otherwise specified) that has either progressed during or after platinum-based chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02448303",
    "statement": "* Received at least 1 platinum-based chemotherapy regimen. Note: Subjects with EGFR mutations or ALK translocations are required to have received prior therapy with appropriate TKI; prior platinum-based chemotherapy is not required for this specific patient population",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02448303",
    "statement": "* Prior malignancy (other than lung cancer), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to \\< 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02448303",
    "statement": "* Known central nervous system metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02448303",
    "statement": "* Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02448303",
    "statement": "* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02448303",
    "statement": "* Breastfeeding or pregnant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": ". Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the Schedule of Assessments",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "2. Age ≥ 18 years on the day of signing the informed consent form (or the legal age of consent in the jurisdiction in which the study is taking place)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "3. At least 1 measurable lesion as defined by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "4. Provide archival tumor tissue (formalin-fixed paraffin-embedded block \\[FFPE\\] with tumor tissue or unstained slides), if available.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "6. Adequate hematologic and end-organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "7. Participants with inactive/asymptomatic carrier, chronic, or active hepatitis B virus (HBV) must have HBV deoxyribonucleic acid (DNA) \\< 500 IU/mL (or 2500 copies/mL) at Screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "8. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and ≥ 120 days after the last dose of study drugs and have a negative serum pregnancy test ≤ 7 days of first dose of study drugs",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "9. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of study drugs",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": ". Unacceptable toxicity on prior anti-PD-1/PD-L1 treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "2. Active leptomeningeal disease or uncontrolled brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "3. Active autoimmune diseases or history of autoimmune diseases that may relapse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "4. Any active malignancy ≤ 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "5. Any condition that required systemic treatment with either corticosteroids (\\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before first dose of study drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "6. History of interstitial lung disease, noninfectious pneumonitis or uncontrolled diseases, including pulmonary fibrosis, acute lung diseases, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "7. Severe chronic or active infections (including tuberculosis infection, etc.) requiring systemic antibacterial, antifungal or antiviral therapy, within 14 days prior to first dose of study drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "8. Known history of human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "9. Participants with active hepatitis C infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "10. Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "11. Prior allogeneic stem cell transplantation or organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "12. Hypersensitivity to tislelizumab or sitravatinib, to any ingredient in the formulation, or to any component of the container",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "13. Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic international normalized ratio (INR) monitoring within 6 months before first dose of study drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03666143",
    "statement": "14. Concurrent participation in another therapeutic clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Eastern Cooperative Oncology Group performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Histologically or cytologically confirmed, Stage IV non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Participants with no prior treatment for Stage IV non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Known PD-L1 status as determined by immunohistochemistry assay performed on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Measurable disease as defined by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Adequate hematologic and end organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "-Specific Exclusions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Active or untreated central nervous system metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "General Medical Exclusions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* History of autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Positive test for human immunodeficiency virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Active hepatitis B or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Severe infection within 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Significant cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Illness or condition that interferes with the participant's capacity to understand, follow and/or comply with study procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "Exclusion Criteria Related to Medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02366143",
    "statement": "* Prior treatment with cluster of differentiation 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1, and anti-PD-L1 therapeutic antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Histological or cytological diagnosis of Stage IV NSCLC lacking epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) translocation, and received no prior systemic chemotherapy treatment for their metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* At least one radiographically measurable lesion per RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* No history of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cervical cancer, or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Provided newly obtained formalin fixed tumor tissue from a biopsy of a tumor at the time of or AFTER the diagnosis of metastatic disease has been made AND from a site not previously irradiated",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* PD-L1 strong expressing tumor as determined by immunohistochemistry (IHC) at a central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Female participants must have a negative pregnancy test at screening if of childbearing potential or be of non-childbearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Female participants of childbearing potential and male partners with female partners of childbearing potential must agree to use 2 adequate barrier methods of contraception during the study and for 120 days after last dose of study drug and up to 180 days after last dose of chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* EGFR sensitizing mutation and/or ALK translocation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Has received systemic therapy for the treatment of their stage IV NSCLC. Completion of treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Tumor specimen is not evaluable for PD-L1 expression by the central laboratory",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Receiving systemic steroid therapy \\< 3 days prior to first dose of study drug or receiving any other form of immunosuppressive medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Expected to require any other form of systemic or localized antineoplastic therapy during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Received prior systemic cytotoxic chemotherapy, biological therapy, major surgery within 3 weeks of first dose of study drug; received thoracic radiation therapy of \\> 30 gray (Gy) within 6 months of first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-PD-L1, anti-programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member of the Tumor Necrosis Factor Receptor \\[TNFR\\] family), or anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Active autoimmune disease that has required systemic treatment in past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Allogenic tissue/solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Interstitial lung disease or pneumonitis that has required oral or IV steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Received or will receive a live vaccine within 30 days prior to first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Active infection requiring IV systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Known history of human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Known active tuberculosis, or hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Is, at the time of signing informed consent, a regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Pregnant or breastfeeding, or expecting to conceive or father children during the study and through 120 days after last dose of pembrolizumab or 180 days after last dose of SOC chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02142738",
    "statement": "* Immediate family member who is investigational site or sponsor staff directly involved with this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* For Phase 1b, must have advanced refractory solid tumors in any line of therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* For Phase 2, must have one of the following tumor types: recurrent or refractory NSCLC (any histology), or HCC with elevated alpha-fetoprotein (AFP) ≥200 nanogram/milliliter (ng/mL).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* For Phase 2 only, have had disease progression or be refractory or intolerant to 1 prior line of therapy (first line therapy) for recurrent or refractory for NSCLC or HCC and have refused currently approved second-line therapy. First line therapy is defined as therapy used to treat advanced disease. This may include multiple chemotherapeutic, targeted or immunotherapeutic agents with or without radiation therapy and/or surgery. Each subsequent line of therapy is preceded by disease progression. A switch of an agent within the same drug class (eg, cisplatinum to carboplatinum) within a regimen in order to manage toxicity does not define the start of a new line of therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* For NSCLC:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Prior lines of therapy must include a platinum-based therapy. Investigational agents used in combination with standard therapies are allowed. Participants who received platinum-based neoadjuvant or adjuvant therapy and subsequently received platinum-based therapy as first-line therapy are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Participants who have completed neo-adjuvant or adjuvant therapy with a platinum doublet and have experienced disease recurrence within 6 months of completing the platinum doublet are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Tumors with driver mutations (epidermal growth factor receptor mutation positive or anaplastic lymphoma kinase fusion oncogene positive) treated with a tyrosine kinase inhibitor or crizotinib are eligible. For participants who have progressed on a tyrosine kinase inhibitor or crizotinib or are intolerant to this targeted therapy, that participant must receive platinum-based therapy prior to enrollment in this study. Documentation of such mutations must be available and entered into the electronic case report form (eCRF).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Maintenance or switch maintenance therapy after first-line chemotherapy will be considered part of the first-line regimen and is acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "Participants who completed and progressed on a platinum-containing regimen as adjuvant, neoadjuvant, or part of a course of chemoradiation therapy given from locally advanced disease and developed recurrent (local or metastatic) disease within the 6 months before screening would be counted as having received 1 prior platinum-containing regimen and therefore would not require re-treatment with a platinum-containing regimen for Stage IIIB, IV, or recurrent disease and are eligible. However, participants must have received at least 2 cycles of a platinum doublet based chemotherapy before discontinuation for toxicity. If participants received only one cycle of a platinum doublet and discontinue due to clear progression, that regimen should be counted as a prior line of therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* For HCC:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* One prior line of therapy which must include sorafenib or participant must have progressed or been intolerant to sorafenib for participants not eligible for transarterial chemoembolization. Participants who had sorafenib for locally advanced disease or are intolerant to sorafenib are eligible. Participants may have had clinical progression only following sorafenib or local therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Must have Child-Pugh A only. Participants may have any viral status (hepatitis B, hepatitis C, or none).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Have a viral load \\<100 international units/milliliter (IU/mL).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* For hepatitis B participants, must be on a nucleoside analog reverse transcriptase inhibitor (lamivudine, telbivudine, adefovir, tenofovir, or entecavir).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Have adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Use an approved contraceptive method.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* For Phase 2 only, more than 1 prior line of therapy for their tumor type.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Have moderate or severe cardiovascular disease:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Have the presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Have documented major electrocardiogram (ECG) abnormalities which are clinically significant at the investigator's discretion (for example, symptomatic or sustained atrial or ventricular arrhythmias, second- or third-degree atrioventricular block, bundle-branch blocks, ventricular hypertrophy, or recent myocardial infarction).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Have major abnormalities documented by ECHO with Doppler:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Moderate or severe heart valve function defect including moderate or severe valve stenosis or regurgitation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Left ventricular (LV) ejection fraction \\<50%, evaluation based on the institutional lower limit of normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Have septal aneurysm or other heart aneurysm.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Any aneurysm of the major vessels.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Active infection with hepatitis B virus (HBV) (positive hepatitis B surface antigen); HCV is allowed only in HCC participants. HCC participants at risk for HBV reactivation (as defined by anti-hepatitis B core antibody positive) are only eligible in the HCC cohort.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02423343",
    "statement": "* Have evidence of interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity or active, noninfectious pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Histologically or cytologically documented small cell carcinoma of the bronchus, classified as extensive-stage disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Measurable disease or lesions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Life expectancy of \\< 12 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Current, recent, or planned participation in another experimental drug study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Ongoing or active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Active malignancy other than SCLC or superficial basal/squamous cell carcinoma within the previous 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Prior systemic therapy, radiation therapy, or surgery for SCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Inadequate bone marrow function, renal function, or hepatic function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Serum sodium of \\< 120 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Inadequately controlled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* History of hypertensive crisis or hypertensive encephalopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* New York Heart Association Class II or greater congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* History of myocardial infarction or unstable angina within 6 months prior to study enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* History of stroke or transient ischemic attack within 6 months prior to study enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Known central nervous system disease, except for brain metastases treated with whole-brain radiotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Significant vascular disease or recent peripheral arterial thrombosis within 6 months prior to study enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* History of hemoptysis within 4 weeks prior to study enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Evidence of bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of a need for a major surgical procedure during the course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Core biopsy or other minor surgical procedure, including placement of a vascular access device, within 7 days prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* History of abdominal fistula or gastrointestinal perforation within 6 months prior to study enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Serious, non-healing wound, active ulcer, or untreated bone fracture",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Known hypersensitivity to any component of bevacizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00403403",
    "statement": "* Pregnant (positive pregnancy test) or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Diagnosis of ovarian, non-small cell lung, prostate, colorectal, gastroesophageal cancer (adenocarcinoma of the esophageal cancer, stomach, or gastroesophageal junction), or squamous cell cancer of the head and neck",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Have measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines (except prostate cancer participants)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Are willing to follow study procedures for the duration of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Are willing to use an approved contraceptive method during treatment and for 3 months after discontinuation of study treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Have a serious preexisting medical condition that would preclude participation in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Are pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Have received treatment within 28 days of first dose of LY2523355 with a drug that has not received regulatory approval for any indication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Have symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Have a second active primary malignancy or a history of a second malignancy requiring cytotoxic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Have QTc interval greater than 470 millisecond (msec) or intraventricular conduction delay (IVCD) with QRS greater than 120 msec on screening electrocardiogram (ECG)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Have active symptomatic fungal, bacterial, and/or known viral infection including active human immunodeficiency virus (HIV) or viral (A, B, C) hepatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059643",
    "statement": "* Participants with pneumonia, evidence of obstructive pneumonitis, other respiratory infections, or infection from other sources are to be excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02208843",
    "statement": ". Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02208843",
    "statement": "2. Documented EGFR mutation (L858R and/or Deletion 19) with no other known EGFR mutation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02208843",
    "statement": "3. Measureable disease according to RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02208843",
    "statement": "4. Radiologically confirmed progression or recurrence of disease during or following first line therapy with a platinum-based chemotherapy regimen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02208843",
    "statement": "5. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02208843",
    "statement": "6. Adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02208843",
    "statement": ". More than one line of prior therapy for disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02208843",
    "statement": "2. Previously received less than 3 cycles of platinum-based chemotherapy due to toxicity and/or intolerance of treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02208843",
    "statement": "3. Previous treatment with any EGFR targeting Tyrosine Kinase Inhibitor (TKI) or antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02208843",
    "statement": "4. Known pre-existing interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* Histologically or cytologically confirmed diagnosis of stage IIIB or IV NSCLC that carried an ALK rearrangement, as per the FDA-approved Vysis ALK break-apart FISH assay (Abbott Molecular Inc.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* Age 18 years or older at the time of informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* Patients must have NSCLC that had progressed during or after the last chemotherapy regimen received prior to the first dose of LDK378, if chemotherapy was received",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* Patients must have been chemotherapy-naive or had received 1-3 lines of cytotoxic chemotherapy to treat their locally advanced or metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* Patients must have had a tumor tissue sample available, collected either at the time of diagnosis of NSCLC or any time since.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 2, except for patients with grade 2 nausea/vomiting and/or grade 2 diarrhea despite optimal supportive therapy who were not allowed to participate in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* Prior treatment with crizotinib, or any other ALK inhibitor investigational agent, for NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* Patients with known hypersensitivity to any of the excipients of LDK378.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* Patients with symptomatic central nervous system (CNS) metastases who were neurologically unstable or had required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* History of carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01685138",
    "statement": "* Clinically significant, uncontrolled heart disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* At least 18 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Histologically- or cytologically-confirmed diagnosis of predominantly nonsquamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* No prior systemic first-line therapy for advanced NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Able to swallow and retain oral medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Adequate organ system function (hematological, hepatic, and renal)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR childbearing potential, and agrees to use adequate contraception. A male with a female partner of childbearing potential is eligible if he uses a barrier method of contraception or abstinence during the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Active malignancy or any malignancy in the 3 years prior to first dose of study drug other than NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for asymptomatic, previously treated CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Clinically significant gastrointestinal abnormalities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Prolongation of corrected QT interval (QTc) \\> 480 msecs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* History of any one or more cardiovascular conditions within the past 6 months prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Poorly controlled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Major surgery or trauma within 28 days or any non-healing wound, fracture, or ulcer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Evidence of active bleeding or bleeding diathesis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Recent hemoptysis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Endobronchial lesions and/or lesions infiltrating major pulmonary vessels",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Serious and/or unstable pre-existing medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Use of any prohibited medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Use of an investigational agent within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Ongoing toxicity from prior anti-cancer therapy that is \\>Grade 1 and/or that is progressing in severity except alopecia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib, pemetrexed, and/or cisplatin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Inability to interrupt aspirin or other non-steroidal anti-inflammatory drugs during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Inability or unwillingness to take folic acid, vitamin B12 supplementation, or dexamethasone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Clinically significant third-space fluid collections (e.g., ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to study start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00871403",
    "statement": "* Recent or concurrent yellow fever vaccination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Histologically or cytologically documented Small cell Lung Cancer with extensive disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Patients who had received chemoradiotherapy for LS-SCLC and have experienced a treatment-free interval of at least 6 months since last chemotherapy, radiotherapy, or chemoradiotherapy cycle, can be included under investigator criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Brain metastases; must be asymptomatic or have been treated at least 2 weeks prior to study treatment and are currently receiving 10 mg/day or less of prednisone or equivalent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Patients must be considered suitable to receive a platinum-based chemotherapy regimen as 1st line treatment for ES-SCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* ECOG Performance Status of 0-2 at enrolment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* No prior exposure to immune-mediated therapy for cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Adequate hematologic and organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Life expectancy of at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Body weight \\>30 kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy (except paliative care outside of the chest).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Paraneoplastic syndrome of autoimmune nature, requiring systemic treatment or clinical symptomatology suggesting worsening of PNS",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Active infection including tuberculosis, HIV, hepatitis B anc C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Active or prior documented autoimmune or inflammatory disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04712903",
    "statement": "* Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Adult patients, \\>/= 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Histologically or cytologically documented, inoperable, locally advanced, recurrent or metastatic (Stage IIIB or Stage IV) lung adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Non-small cell lung cancer with an EGFR activating mutation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Patients must have evidence of disease, but measurable disease is not mandatory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Adequate renal and liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Prior chemotherapy or other systemic anti-cancer treatment. Neoadjuvant/adjuvant chemotherapy is allowed if completed within 6 months prior to enrolment. Prior radiochemotherapy is allowed if completed more than 6 months before start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Prior therapy with systemic anti-tumour therapy with HER1/EGFR inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Any other malignancies within 5 years, except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin carcinoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Brain metastasis or spinal cord compression not yet definitely treated with surgery and/or radiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Patients unable to take oral medication or requiring intravenous alimentation, with prior surgical procedures affecting absorption or active peptic ulcer disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Any significant ophthalmologic abnormality, especially those likely to increase the risk of corneal epithelial lesions; the use of contact lenses is not recommended during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609543",
    "statement": "* Pregnant or breast-feeding women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Male or female 16 years or older, at the time of signing the informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. If the subject is less than 18 years old, an Assent form and parental/guardian Consent form (replacing \"you will\" with \"your child will\" will be required).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Diagnosis of one of the following: Part 1 Only: NUT Midline Carcinoma based on ectopic expression of NUT protein as determined by IHC and/or detection of NUT gene translocation as determined by FISH. Subjects may be treatment naïve or have had prior therapy; SCLC, CRC, NB, TNBC, ER positive BC, CRPC, NSCLC and any other solid tumor which has been confirmed by clinical testing to be MYCN amplified (defined as a MYCN gene copy number gain of \\>=5). Subjects should have tumor progression after receiving at least one prior standard/approved chemotherapy, or where there is no approved therapy, or where standard therapy is refused. Part 2 only: NUT Midline Carcinoma as diagnosed by the Central Laboratory. Subjects may be treatment naïve or have had prior therapy. SCLC, CRPC, TNBC and ER+BC .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Subjects with solid tumors, with the exception of CRPC, must demonstrate measurable disease, per RECIST v1.1. NOTE: Subjects with NMC that do not meet the RECIST v1.1 criteria for measurable disease, but have evaluable disease may be considered for enrollment after discussion with the GSK medical monitor..",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* All prior treatment- related toxicities must be CTCAE (Version 4.0) \\<=Grade 1 (except alopecia and peripheral neuropathy) at the time of treatment allocation \\[NCI-CTCAE, 2009\\].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* ECOG Performance Status score of 0 or 2 for subjects with NMC; 0-1 for subjects with other tumor types.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Adequate organ function as follows: Hematologic system: Absolute neutrophil count (ANC), Lab values - \\>=1.5 X 10\\^9/L; Hematologic system: Hemoglobin, Lab values - \\>=9.5 grams/deciliter (g/dL) (subjects that required transfusion or growth factor need to demonstrate stable haemoglobin for 7 days of 9.5 g/ g/dL); Hematologic system: Platelets, Lab values - \\>=100 X 10\\^9/Liter \\[L\\] ); Hematologic system: Prothrombin time /International normalized ratio and partial thromboplastin time, Lab values - \\<=1.5 X upper limit of normal (ULN). Renal system: Creatinine, lab values - \\<=1.5 X ULN; or Renal system: Calculated creatinine clearance \\[calculated by Cockcroft Gault formula\\], lab values - \\>=50 milliliter (mL)/minute (min); or Renal system: 24-hour urine creatinine clearance\\>=50 mL/min; Hepatic system: total Bilirubin \\<=1.5 X ULN (isolated bilirubin \\>1.5 X ULN is acceptable if bilirubin is fractionated and direct bilirubin \\<35% or subject has a diagnosis of Gilbert's syndrome), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\>=2.5 x ULN. Cardiac system: Ejection fraction, lab values - \\>=lower limit of normal (LLN) by Echocardiogram (ECHO) (minimum of 50%); Cardiac system: Troponin ( T), lab values - \\<=ULN; Cardiac system: Potassium, lab values - \\>=LLN and \\<=ULN; Cardiac system: Magnesium, lab values - \\>=LLN. Thyroid system: thyroid stimulating hormone, lab values \\>=LLN and \\<=to ULN. Reproductive /endocrine system: testosterone \\<50 nanogram (ng)/dL (only for subject with CRPC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \\[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) greater than 40 milli international unit/mL and estradiol less than 40 pg/mL (less than 140 pmol/L) is confirmatory\\]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status prior to study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; Child-bearing potential and agrees to use one of the contraception methods (described in the protocol) for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 7 months after the last dose of study medication; Negative serum pregnancy test \\<=7 days prior to first study drug dose; Female subjects who are lactating must discontinue nursing prior to the first dose of study treatment and must refrain from nursing throughout the treatment period and for 5 half-lives of GSK525762 or at least 28 days (whichever is longer) following the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Male subjects must agree to use one of the methods of contraception specified. This method must be used from the time of the first dose of study medication until least 16 weeks after the last dose of study medication. In addition, male subjects whose partners are or become pregnant while on study medication must continue to use condoms for 7 days after stopping study medications.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Specific eligibility criteria for Part 2 CRPC expansion cohort: Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma, surgically castrated or continuously medically castrated (for \\>=8 weeks prior to pre-screening).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Specific eligibility criteria for Part 2 CRPC expansion cohort: Persistent disease with evidence of disease progression following standard therapy(ies) including prior treatment with androgen/androgen receptor directed therapy, including enzalutamide and/or abiraterone",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Specific eligibility criteria for Part 2 CRPC expansion cohort: Ongoing androgen deprivation therapy with a serum testosterone level \\<1.7 nanomoles/L or \\<50 ng/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Specific eligibility criteria for Part 2 CRPC expansion cohort: Prostate-Specific Antigen (PSA) levels \\>=2.0 ng/mL. Note: If PSA level has been obtained within 14 days of Screening, this test does not need to be repeated and the result previously obtained may be used for the Screening value.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Primary malignancy of the central nervous system or malignancies related to human immunodeficiency virus or solid organ transplant. History of known HIV. History of known Hepatitis B surface antigen or positive Hepatitis C antibody (confirmed by RIBA).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Prior treatments usage as defined: A) Use of an investigational anti-cancer drug within 14 days or 5 half-lives, whichever is longer, prior to the first dose of the investigational products:; B) A minimum of 14 days between termination of the investigational drug and administration of GSK525762; C) Any therapy related toxicities must also have resolved to Grade 1 or less. Note that an investigational drug is defined as a drug without an approved oncologic indication; D) Chemotherapy, radiotherapy, anti-neoplastic antibody or targeted therapy or immunotherapy within 14 days, major surgery within 28 days (or 42 days for prior nitrosoureas or mitomycin C) prior to the first dose of the investigational product. Anti-androgen (e.g., bicalutamide) therapies for prostate cancer must be stopped 4 weeks prior to enrollment. Second line hormone therapies such as enzalutamide, abiraterone, or orteronel should be stopped 2 weeks prior to enrollment. Subjects with prostate cancer should remain on luteinizing hormone releasing hormone (LHRH) agonists or antagonists. Subjects with prostate cancer may also remain on low-dose prednisone or prednisolone (up to 10 mg/day) and still be eligible for this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Current use of anticoagulants (e.g., warfarin, heparin) at therapeutic levels within 7 days prior to the first dose of GSK525762. Low dose (prophylactic) low molecular weight heparin (LMWH) is permitted. In addition, INR must be monitored in accordance with local institutional practices.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Current use of a prohibited medication or requires any of these medications during treatment with the investigational drugs (details will be available in the protocol). This includes excluding current medications known or suspected to be associated QT prolongation. In addition, any subject who may require a QT prolonging medication while on trial should not be enrolled.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding episodes). Any serious and/or unstable pre-existing medical (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. NOTE: Subjects previously treated for these conditions that have had stable central nervous system disease (verified with consecutive imaging studies) for \\>1 month, are asymptomatic and off corticosteroids, or are on stable dose of corticosteroids for at least 1 month prior to study Day 1 are permitted. Stability of brain metastases must be confirmed with imaging. Subject treated with gamma knife the can be enrolled 2 weeks post-procedure as long as there are no post-procedure complications/stable. In addition, subjects treated or currently taking enzyme-inducing anticonvulsant are allowed on study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Cardiac abnormalities as evidenced by any of the following: History or current \"untreated\" clinically significant uncontrolled arrhythmias; Clinically significant conduction abnormalities or arrhythmias, subjects with Bundle Branch Block; Presence of cardiac pacemaker; History or evidence of current \\>=Class II congestive heart failure as defined by New York Heart Association (NYHA); History of acute coronary syndromes (including unstable angina and myocardial infarction ), coronary angioplasty, or stenting within the past 3 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Any of the following ECG findings: Baseline QTcF interval \\>=450 millisecond (msec); Any clinically significant ECG assessments should be reviewed by the site cardiologist prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* GSK525762 is a benzodiazepine class molecule. Any serious known immediate or delayed hypersensitivity reaction(s) to GSK525762 or idiosyncrasy to drugs chemically related to the investigational drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Hemoptysis \\>1 teaspoon in 24 hours within the last 28 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* History of major gastrointestinal bleeding within the last 6 months. Any evidence of active gastrointestinal bleeding excludes the subject.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01587703",
    "statement": "* Besylate Sub-Study only: unable or unwilling to eat the FDA recommended high-fat high-calorie breakfast (two eggs fried in butter, two strips of bacon, 4 ounce \\[oz\\]) of hash brown potatoes and 8 oz of whole milk) within the recommended 30 minutes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Has histologically or cytopathologically confirmed metastatic or locally advanced stage IIIB/IV Non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Has measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Has not been previously treated with surgery (involving the thorax), radiation (unless it was for a metastatic site), or chemotherapy for NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Is 18 years of age or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Has a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Women of childbearing potential have a negative pregnancy test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Is participating in or has participated in a study with an investigational compound or device within 30 days or 5 half-lives of the start of treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Has untreated brain metastases related to their NSCLC or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Abuses drugs or alcohol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Is pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Is Human Immunodeficiency Virus (HIV) positive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Has active viral hepatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Has hearing loss",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Has poorly controlled diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00599755",
    "statement": "* Is allergic to gemcitabine, cisplatin or carboplatin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Recipients of either first- or second-line chemotherapy for advanced or metastatic lung, breast, gastrointestinal, bladder, ovarian, or prostate cancer or myeloma, selected lymphomas, or cancer of unknown origin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Able to begin study medication ≤6 weeks of starting either first- or second-line chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Expected course of chemotherapy must have been ≥ 90 days after the start of chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Per Protocol Amendment 5, patients receiving bevacizumab were eligible to participate, provided that bevacizumab was used for indications approved by local country law",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Women who are pregnant, breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* History of deep vein thrombosis or pulmonary embolism",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Active bleeding or at high risk of bleeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Metastatic brain cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Familial bleeding diathesis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Serious hemorrhage requiring hospitalization, transfusion, or surgical intervention within 4 weeks of study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Expected survival \\<6 months or an Eastern Cooperative Oncology Group performance status ≥3.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Candidates for bone marrow transplantation within the 12-week treatment period or 30-day follow-up period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Uncontrolled hypertension (systolic blood pressure \\>200 mm Hg and/or diastolic blood pressure \\>110 mm Hg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* Coagulopathy (international normalized ratio \\>1.5 or platelet count \\<100\\*10\\^9/L) if not yet receiving chemotherapy or \\<50\\*10\\^9/L if receiving chemotherapy). Platelet count must have been \\>100\\*10\\^9/L before starting study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320255",
    "statement": "* One or more of the following: alanine aminotransferase \\>3 times the upper limit of normal (ULN), total bilirubin \\>2\\*ULN, or calculated creatinine clearance \\<30 mL/min.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC), regardless of histology subtype, which failed on gefitinib for reasons other than toxicity or compliance;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Availability of a fresh or archived pre treatment tumor biopsy (excluding fine needle aspiration and cytology samples). For participants who have had at least 1 prior anticancer treatment, a biopsy obtained between failure of the most recent anticancer treatment and enrolment is mandatory;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Mesenchymal-epithelial transition diagnostic-positive (status) (MET+ status), as determined by the central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Other protocol defined inclusion criteria could apply.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "Phase II",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Locally advanced or metastatic NSCLC other than predominantly squamous histology (confirmed by either histology or cytology);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Activating mutation of the epidermal growth factor (EGFR) receptor (documented, or as determined by the central laboratory)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Acquired resistance on first-line EGFR-Tyrosine Kinase Inhibitors (EGFR-TKI) therapy including gefitinib, erlotinib, icotinib, or afatinib",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* EGFR T790M status after acquired resistance to first line EGFR-TKI therapy including gefitinib, erlotinib, icotinib, or afatinib treatment (as determined by the central laboratory, using a validated PCR test);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* T790M negative status for the randomized part",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* T790M positive status for the single-arm cohort (mainland China sites only)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Availability of a fresh or archived tumor tissue (excluding fine needle aspiration and cytology samples) obtained between documentation of acquired resistance to gefitinib, erlotinib, icotinib, or afatinib and enrollment is mandatory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* MET+ status, as determined by the central laboratory i.e. c-Met overexpression as determined by IHC (i.e., IHC 2+ or IHC 3+) and/or c-Met amplification and/or increased c-Met gene copy number (GCN), both determined by ISH;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Other protocol defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "(Phase I and II):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Estimated life expectancy less than (\\<) 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Inadequate bone marrow, liver or renal functions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Prior chemotherapy, biological therapy, radiation therapy, or other investigational anticancer therapy (not including palliative radiotherapy at focal sites) within 21 days prior to the first dose of study treatment (Phase 1b only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Prior systemic anticancer treatment with chemotherapy or other agents targeting the EGFR pathway excluding gefitinib, erlotinib, icotinib, and afatinib for advanced NSCLC (one course of chemotherapy regimen for \\[neo\\] adjuvant purpose, or one course of chemoradiation for Stage IIIa disease is allowed) (Phase 2 only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01982955",
    "statement": "* Other protocol defined exclusion criteria could apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": ". Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "2. Adults (according to each country regulations for age of majority)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "3. Locally advanced (stage IIIB) or metastatic (stage IV) EGFRm NSCLC, not amenable to curative surgery or radiotherapy, with confirmation of the presence of the T790M mutation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "4. Prior therapy with an EGFR-TKI. Patients may have also received additional lines of treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "5. World Health Organization (WHO) performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "6. Adequate bone marrow reserve and organ function as demonstrated by complete blood count, biochemistry in blood and urine at baseline (please refer to IB for guidance)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "7. ECG recording at baseline showing absence of any cardiac abnormality as per exclusion criterion #6",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "8. Female patients of childbearing potential must be using adequate contraceptive measures, must not be breast feeding, and must have a negative pregnancy test prior to start of dosing. Otherwise, they must have evidence of nonchildbearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "9. Male patients must be willing to use barrier contraception, i.e., condoms",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": ". Previous (within 6 months) or current treatment with AZD9291",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "2. Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of AZD9291) any treatment known to be potent inhibitors or inducers of cytochrome P450 (CYP) 3A4",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, active infection including hepatitis B, hepatitis C, and human immunodeficiency virus, or significantly impaired bone marrow reserve or organ function, including hepatic and renal impairment, which in the investigator's opinion would significantly alter the risk/benefit balance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "4. Patient with symptomatic central nervous system (CNS) metastases who is neurologically unstable or has required increasing doses of steroids to manage CNS symptoms within the 2 weeks prior to start AZD9291 administration;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "5. Past medical history of ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "6. Any of the following cardiac criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "   1. Mean resting corrected QT interval (QTcF) \\> 470 ms using Fredericia's formula :",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "   2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "   3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "7. Any unresolved toxicity from prior therapy CTCAE \\> grade 3 at the time of starting treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02474355",
    "statement": "8. History of hypersensitivity to excipients of AZD9291 or to drugs with a similar chemical structure or class to AZD9291",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Non-small cell lung adenocarcinoma or squamous cell carcimona",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* At least one site of measurable disease by RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Arm 5: Received at least one prior line of therapy, but no more than three prior lines of therapy, for incurable (i.e. unresectable) or metastatic NSCLC. Up to one prior line of FDA-approved checkpoint inhibitor therapy is permitted (must have received at least 4 months of treatment) --OR--",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Arm 6: Received front line immunotherapy (with or without chemotherapy) for incurable or metastatic NSCLC and did not progress clinically or radiographically per RECIST 1.1 at the most recent imaging assessment, and will begin maintenance immunotherapy with standard of care pembrolizumab ± pemetrexed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Life expectancy ≥18 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Arm 5: Disease progression at study entry --OR--",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Arm 6: Documented Stable Disease, Partial Response, Complete Response (SD/PR/CR) per RECIST 1.1 after a minimum of 9 to 12 weeks of front line immunotherapy (with or without chemotherapy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Central nervous system (CNS) metastases may be permitted but must be treated and neurologically stable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Adequate laboratory parameters",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Willing and able to comply with the protocol and sign informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Female patients who are of childbearing potential and fertile male patients must agree to use an effective form of contraception throughout study participation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Willing to provide archival or fresh tumor biopsy at Screening, and fresh tumor biopsy at Week 10 when feasible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Arm 5: Suitable for treatment with nivolumab per package insert --OR--",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Arm 6: Suitable for front line maintenance treatment with pembrolizumab ± pemetrexed per the current approved package inserts.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Arm 5: Received systemic anticancer therapy within 21 days prior to first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or concurrent illness, unrelated to the tumor, requiring active therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Any condition requiring concurrent systemic immunosuppressive therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Known immunodeficiency disorders, either primary or acquired",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Known leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Prior participation in a clinical study of viagenpumatucel-L (HS-110)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Administration of a live vaccine within 30 days prior to first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Active, known or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Significant cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02439450",
    "statement": "* Refractory to prior immunotherapy (clinical or radiographic progression after 12 weeks or less of immunotherapy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00532155",
    "statement": "* Histological/cytological proven locally advanced or metastatic non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00532155",
    "statement": "* Disease progression during or after one, and only one, prior anticancer therapy which is platinum-based for advanced or metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00532155",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00532155",
    "statement": "* Adequate renal, liver and bone marrow functions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00532155",
    "statement": "* Squamous histology/cytology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00532155",
    "statement": "* Less than 28 days elapsed from prior treatment with radiotherapy, surgery, or chemotherapy to the time of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00532155",
    "statement": "* Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to \\> 25% of bone marrow",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00532155",
    "statement": "* Prior docetaxel treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00532155",
    "statement": "* Uncontrolled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00532155",
    "statement": "The above information was not intended to contain all considerations relevant to participation in a clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Histologically-confirmed Stage IV metastatic or recurrent (Stage IV) NSCLC of squamous histology",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Availability of formalin-fixed paraffin-embedded (FFPE) block containing tumor tissue or a minimum of 15 (preferably 25) unstained tumor slides (cut within 1 week) suitable for Programmed death ligand 1 (PD-L1) expression and epidermal growth factor receptor (EGFR) expression/amplification assessments",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* At least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Adequate hematological, hepatic and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Estimated life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Can give signed informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Other protocol defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Participants whose tumor disease harbors an activating EGFR mutation or ALK rearrangement. Participants with tumors of unknown EGFR or ALK status will require testing only in never smokers",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* All participants with brain metastases with protocol defined exceptions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Previous malignant disease (other than NSCLC) within the last 5 years (except adequately treated non-melanoma skin cancers, carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or prostate) unless a complete remission without further recurrence was achieved at least 2 years prior to study entry and the participant was deemed to have been cured with no additional therapy required or anticipated to be required",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Active infection requiring systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Known history of human immunodeficiency virus or known acquired immunodeficiency syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV ribonucleic acid (RNA) if anti-HCV antibody screening test positive)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Interstitial parenchymal lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Pregnancy or lactation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Known alcohol or drug abuse as determined by the Investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* History of uncontrolled intercurrent illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Clinically significant (that is active) cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Known history of inflammatory colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Any psychiatric condition that would prohibit the understanding or rendering of informed consent or that would limit compliance with study requirements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Prior/Concomitant Therapy as described in protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Use of any investigational drug within 28 days before the start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03717155",
    "statement": "* Other protocol defined exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00768755",
    "statement": "* Histologically or cytologically confirmed diagnosis of adeno-, large cell or bronchioalveolar non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00768755",
    "statement": "* Cytologic specimens for diagnosis or for cell type classification must have been obtained from bronchial brushings or washings or from needle aspiration of a defined lesion. Sputum cytology alone will not be acceptable for diagnosis or for cell type classification.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00768755",
    "statement": "* Patients with mixed NSCLC with predominantly squamous cell carcinoma should be classified as squamous and thus do not qualify for this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00768755",
    "statement": "* Stage IIIB with malignant effusion (with cytologic confirmation of malignant pleural or pericardial effusion), Stage IV, or recurrent disease after definitive loco-regional therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00768755",
    "statement": "* Candidate for primary treatment with cisplatin and pemetrexed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00768755",
    "statement": "* Any histological/cytological evidence of predominantly squamous NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00768755",
    "statement": "* Small cell or carcinoid lung cancer patients are also ineligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00768755",
    "statement": "* NSCLC that cannot be classified as one of the eligible histologies (adenocarcinoma, large cell or bronchioalveolar).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00768755",
    "statement": "* Prior systemic therapy for Stage IIIB (with malignant effusion), Stage IV, or recurrent NSCLC. (Prior treatment with systemic therapy as adjuvant chemotherapy or in conjunction with radiotherapy for Stage II or III NSCLC is permitted if the last dose of chemotherapy was completed 12 months or more prior to randomization).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00768755",
    "statement": "* Prior treatment with a VEGF or VEGFR inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": ". Signed informed consent obtained prior to initiation of any study-specific procedures and treatment;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "2. Histologically or cytologically confirmed diagnosis of one of the following advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective, intolerable or inacceptable for the patient:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* NUT midline carcinoma (ectopic expression of NUT protein as determined by immunohistochemistry (IHC) and/or detection of BRD-NUT gene translocation as determined by fluorescence In situ hybridization \\[FISH\\]);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* Triple negative breast cancer defined according to American Society of Clinical Oncology (ASCO) recommendations (Hammond et al., 2010; Wolff et al., 2007);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* Non-small cell lung cancer harboring a rearranged ALK gene/fusion protein (FISH or IHC) or KRAS mutation (as defined by any molecular analysis);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* Castrate-resistant prostate cancer (CRPC);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* Pancreatic ductal adenocarcinoma;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "3. At least one measurable lesion as per RECIST version 1.1., except for CRPC participants who may be enrolled with objective evidence of disease as per PCWG2 criteria;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "4. Age ≥18 years at the time of informed consent;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "5. Life expectancy ≥3 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤1;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "7. Adequate bone marrow reserve, renal and liver function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* Absolute neutrophil count ≥1.5 x10\\^9/L,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* Platelet count ≥150 x10\\^9/L,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* Hemoglobin ≥9 g/dL,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* Creatinine clearance ≥30 mL/min calculated according to the Cockroft and Gault formula or Modification of Diet in Renal Disease (MDRD) formula for participants aged \\>65 years,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤3 x upper limit of normal (ULN) and total bilirubin ≤1.25 x ULN (in case of liver involvement, ALT/AST ≤5 x ULN and total bilirubin ≤2 x ULN will be allowed),",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* Serum albumin ≥2.8 g/dL,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "* International Normalized Ratio (INR) ≤1.5 x ULN or INR \\<3 for participants treated with antivitamin K;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "8. An interval of ≥3 weeks since chemotherapy (≥6 weeks for nitrosoureas or mitomycin C), immunotherapy, hormone therapy or any other anticancer therapy or surgical intervention resection, or ≥3 half-lives for monoclonal antibodies, or ≥5 half-lives for other non-cytotoxic agents (whichever is longer);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "9. CRPC participants must maintain ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue, antagonist or orchiectomy providing serum testosterone is \\<50 ng/dL (\\<1.7 nmol/L);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "10. Participants receiving bisphosphonate or denosumab therapy must be on stable doses for at least 4 weeks before initiating study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": ". Inability to swallow oral medications or presence of a gastrointestinal disorder (e.g. malabsorption) deemed to jeopardize intestinal absorption of birabresib;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "2. Persistent grade \\>1 clinically significant toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy ≤ grade 2 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.4.0 is accepted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "3. Known primary central nervous system (CNS) malignancy or CNS involvement;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "4. History of prior or concomitant malignancies (other than excised non-melanoma skin cancer or cured in situ cervical carcinoma) within 3 years of study entry;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "5. Other serious illness or medical conditions, such as active infection, unresolved bowel obstruction, or psychiatric disorders;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "6. Known human immunodeficiency virus (HIV) positivity;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "7. Participation in another clinical trial or treatment with any investigational drug within 30 days prior to study entry;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "8. Other concomitant anticancer treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "9. Concomitant therapy with strong CYP3A4 interfering drugs;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "10. Current use of anticoagulants (e.g. warfarin, heparin) at therapeutic levels within 7 days prior to the first dose of birabresib. Low-dose (prophylactic) low molecular weight heparin (LMWH) is permitted;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02259114",
    "statement": "11. Pregnant or breast-feeding participants, and men and women with childbearing potential not using effective contraception while on study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* Subjects with histologically or cytologically documented NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* Locally advanced or metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* Radiological documentation of disease progression following 1st line EGFR TKI Treatment without any further treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* Eligible to receive treatment with the selected doublet-chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* Central confirmation of T790M+ mutation status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* World Health Organization (WHO) performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* At least one lesion, not previously irradiated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* • Prior neo-adjuvant or adjuvant chemotherapy treatment within 6 months prior of starting 1st EGFR TKI treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* Treatment with more than one prior line of treatment for advanced NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* Treatment with an approved EGFR-TKI (e.g.,erlotinib, gefitinib, afatinib) within 8 days or approximately 5x half-life of the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* Any investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* Previous treatment with Osimertinib, or a 3rd generation EGFR TKI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "For subjects who cross-over to Osimertinib:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151981",
    "statement": "* At least 14 days since last dose of platinum-based doublet chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949910",
    "statement": "* Adults greater than or equal to (≥) 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949910",
    "statement": "* Histologically or cytologically documented inoperable, locally advanced, metastatic, or recurrent NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949910",
    "statement": "* Previous treatment with no more than 2 prior chemotherapy regimens",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949910",
    "statement": "* Previous systemic anti-cancer therapy with human epidermal growth factor receptor 1 (HER1)/epidermal growth factor receptor (EGFR) inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949910",
    "statement": "* Inability to take oral medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00949910",
    "statement": "* Any other malignancies within 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Eastern Cooperative Oncology Group performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Histologically or cytologically confirmed, Stage IV non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Participants with no prior treatment for Stage IV non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Previously obtained archival tumor tissue or tissue obtained from fresh biopsy at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Measurable disease, as defined by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Adequate hematologic and end organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "-Specific Exclusions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Active or untreated central nervous system metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "General Medical Exclusions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* History of autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Positive test for human immunodeficiency virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Active hepatitis B or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Severe infection within 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Significant cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Illness or condition that interferes with the participant's capacity to understand, follow and/or comply with study procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "Exclusion Criteria Related to Medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02367781",
    "statement": "* Prior treatment with cluster of differentiation 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1, and anti-PD-L1 therapeutic antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Adult patients ≥ 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Histologically documented non-small cell lung cancer (NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Locally advanced or recurrent (Stage IIIB) or metastatic (Stage IV) disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Completion of 4 cycles of an acceptable, standard, platinum-based chemotherapy doublet without progression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Patients of reproductive potential must agree to use effective contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Prior exposure to agents directed at the human epidermal growth factor receptor (HER) axis (eg, gefitinib, cetuximab, trastuzumab).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Prior treatment with any monoclonal antibody therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Any other malignancies within the previous 5 years, except for adequately treated carcinoma in situ of the cervix or squamous cell skin cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Clinically significant cardiovascular, hepatic, renal, or metabolic disease or active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Pre-existing interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01230710",
    "statement": "* Pregnant or lactating women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Phase 1: Subjects with advanced or metastatic solid tumors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Phase 1: Subjects who have disease progression after treatment with available therapies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Phase 2: Subjects with advanced or metastatic cervical cancer, gastric cancer (including stomach, esophageal, and GEJ), SCCHN, PD-1 refractory SCCHN and PD-1/PD-L1 relapsed melanoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Presence of measurable disease based on RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Laboratory and medical history parameters not within the Protocol-defined range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Prior treatment with any tumor necrosis factor super family agonist.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Has not recovered to ≤ Grade 1 from toxic effects of prior therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Active autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Known active central nervous system metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03126110",
    "statement": "* Known history of human immunodeficiency virus (HIV; HIV 1/2 antibodies).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* histologically or cytologically confirmed extensive-stage disease small cell lung carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* measurable disease as defined by the New Response Evaluation Criteria in Solid Tumors (RECIST): Revised RECIST Guideline (version 1.1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* no prior systemic chemotherapy, immunotherapy, biological, hormonal, or investigational therapy for SCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* adequate organ function, including:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* hematologic: absolute neutrophil (segmented and bands) count (ANC) greater than or equal to (≥)1.5 x 10\\^9/ liter (L), platelets ≥100 x 10\\^9/L, and hemoglobin ≥9 grams per deciliter (g/dL).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* hepatic: bilirubin less than or equal to (≤)1.5 times upper limits of normal (ULN), and alkaline phosphatase (AP), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 times ULN (AP, AST, and ALT ≤5 times ULN is acceptable if liver has tumor involvement",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* renal: calculated creatinine clearance (CrCl) ≥45 milliliters per minute (mL/min) based on the standard Cockcroft and Gault formula",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* For women: Must be surgically sterile (surgical procedure: bilateral tubal ligation), post-menopausal (at least 12 consecutive months of amenorrhea), or compliant with a medically approved contraceptive regimen (intrauterine device \\[IUD\\], birth control pills, or barrier device) during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment, and must not be breast-feeding. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* estimated life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* written informed consent prior to any study-specific procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* able and willing to learn to self-administer LY2510924, or have a caregiver who is willing to learn and able to administer LY2510924 by subcutaneous (SC) injection",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* prior treatment with carboplatin/etoposide or LY2510924",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* any concurrent administration of any other antitumor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* diagnosis of non-small cell lung cancer (NSCLC) or mixed NSCLC and small cell lung cancer (SCLC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* no prior malignancy other than SCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated 5 or more years prior to study entry with no subsequent evidence of recurrence. Participants with a history of low grade (Gleason score ≤6) localized prostate cancer will be eligible even if diagnosed less than 5 years prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the participant's ability to adhere to the study requirements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* active or ongoing infection during screening requiring the use of systemic antibiotics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease as defined by the New York Heart Association Class III or IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously- treated central nervous system (CNS) metastases, are asymptomatic, and have had no requirement for steroid medication for 1 week prior to the first dose of study drug and have completed radiation 2 weeks prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* known or suspected allergy to any agent given in association with this trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01439568",
    "statement": "* pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": ". Adult aged 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "2. Histologically confirmed SCLC with documented disease progression after at least 2 prior systemic regimens, including at least one platinum-based regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "3. DLL3-expressing SCLC based on central immunohistochemistry (IHC) assessment of banked or otherwise representative tumor tissue. Positive is defined as staining in ≥ 1% of tumor cells",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "6. Minimum life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "7. Subjects with a history of central nervous system (CNS) metastases must have documentation of stable or improved status based on brain imaging for at least 2 weeks after completion of definitive treatment and within 2 weeks prior to first dose of study drug, off or on a stable dose of corticosteroids",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "8. Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "9. Adequate hematologic and organ function as confirmed by laboratory values",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "10. Last dose of any prior therapy administered by the following time intervals before the first dose of study drug:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "* Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "* Immune-checkpoint inhibitors (i.e., anti-PD-1, anti-PD-L1, or anti-CTLA-4): 4 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "* Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or T-cell or other cell-based therapies: 4 weeks (2 weeks with documented disease progression)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "11. Females of childbearing potential must have a negative beta human chorionic gonadotropin (β-hCG) pregnancy test result within 7 days prior to the first dose of study drug. Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": ". Any significant medical condition, including any suggested by screening laboratory findings that, in the opinion of the investigator or sponsor, may place the subject at undue risk from the study, including but not necessarily limited to uncontrolled hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 6 months) or neurological disorder (e.g., seizure disorder active within 6 months)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "2. Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) Class III-IV within 6 months prior to their first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "3. Recent or ongoing serious infection, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "* Any active grade 3 or higher (per National Cancer Institute's Common Terminology Criteria for Adverse Events \\[NCI CTCAE\\] version 4.03) viral, bacterial, or fungal infection within 2 weeks of the first dose of the study drug. Routine antimicrobial prophylaxis is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "* Known seropositivity for or active infection by human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "* Active Hepatitis B (by surface antigen expression or polymerase chain reaction) or C (by polymerase chain reaction) infection or on hepatitis-related antiviral therapy within 6 months of first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "4. Women who are breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "5. Systemic therapy with corticosteroids at \\>20 mg/day prednisone or equivalent within 1 week prior to the first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "6. History of another invasive malignancy that has not been in remission for at least 3 years. Exceptions to the 3 year limit include nonmelanoma skin cancer, curatively treated localized prostate cancer, and cervical cancer in situ on biopsy or squamous intraepithelial lesion on pap smear",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02674568",
    "statement": "7. Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulation, unless undergoing retreatment with rovalpituzumab tesirine in the context of this protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402168",
    "statement": "* Men and women age 18 and older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402168",
    "statement": "* 6-36 months after kidney transplant receiving cyclosporine or tacrolimus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402168",
    "statement": "* calculated GFR ≥35 and ≤75mL/min/1.73 m²",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402168",
    "statement": "* subjects must have completed 1 year in the IM103-010ST and remained on study treatment (Long Term Extension)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402168",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402168",
    "statement": "* Significant infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402168",
    "statement": "* acute rejection within 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402168",
    "statement": "* prior graft loss due to rejection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402168",
    "statement": "* pregnancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402168",
    "statement": "* positive crossmatch",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Histologically or cytologically confirmed unresectable locally advanced or metastatic (stage IIIb or IV) Non-small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Recurrent disease (either no response to treatment or subsequent relapse after an objective response) that has progressed after first-line platinum based therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Male or female ≥ 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Anticipation of more than 3 months survival",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Adequate organ and bone marrow function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Prior Tyrosine Kinase Inhibitor (TKI) therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Anticipation of need for a major surgical procedure or radiation therapy during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Remaining influence of previous therapies such as radiotherapy, surgery, immunotherapy within 4 weeks prior to start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Treatment with anticancer medication within 4 weeks before study treatment, currently enrolled in another investigational drug study, or enrolled in another investigational drug study within 4 weeks of start of treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* History of any of the following events within 6 months prior to start of study treatment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) class ≥I Congestive Heart Failure (CHF), cerebrovascular accident or cerebral infarction, pulmonary embolism, deep vein thrombosis, or other clinically significant thromboembolic event; clinically significant pulmonary disease (eg, severe Chronic-Obstructive Pulmonary Disease (COPD) or asthma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Severe edema, ascites fluid, pericardial or pleural effusion or pericardial involvement with the tumor within 6 months prior to start of study treatment, or which require steroid therapy/ diuretic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Subjects with brain metastasis (defined as untreated, symptomatic or requiring steroids or anticonvulsant medications to control associated symptoms)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Subjects with clinically significant active infection which requires antibiotic therapy, or who are hepatitis B surface antigen (HBsAg)-, hepatitis C virus (HCV)- or human immunodeficiency virus (HIV)-positive or receiving antiretroviral therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Subjects with malabsorption syndrome, chronic diarrhea (lasting over 4 weeks), inflammatory bowel disease, or partial bowel obstruction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Diabetes mellitus requiring insulin, or a history of poor serum glucose control with the use of non-insulin diabetes medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Treatment with Thiazolidinedione(TZDs) within 4 weeks prior to start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* History of a second malignancy, with the exception of in situ cervical cancer or adequately treated basal cell or squamous cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01199068",
    "statement": "* Poorly-controlled blood pressure as judged by the Investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Documented diagnosis of unresectable Stage III or Stage IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Patients may be receiving maintenance chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Patients planning to initiate a new chemotherapy and/or radiation therapy regimen may do so only within ± 14 days of randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Patients may have completed a chemotherapy and/or radiation therapy and/or have no plan to initiate a new regimen within 12 weeks from randomization; at least 14 days must elapse from the completion of the chemotherapy and/or radiation therapy prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Involuntary weight loss of ≥5% body weight within 6 months prior to screening or a screening body mass index (BMI) \\<20 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Body mass index ≤30 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Life expectancy of \\>4 months at time of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* ECOG performance status ≤2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Adequate hepatic function, defined as AST and ALT levels ≤5 x upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Adequate renal function, defined as creatinine ≤2 x upper limit of normal, or calculated creatinine clearance \\>30 ml/minute",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Ability to understand and comply with the procedures for the HGS evaluation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* If a woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for 30 days following the last dose of study drug (an effective form of contraception is abstinence, a hormonal contraceptive, or a double-barrier method)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Must be willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Other forms of lung cancer (e.g., small cell, mesothelioma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Women who are pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Known HIV, hepatitis (B\\&C), or active tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Had major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization; patients must be well recovered from acute effects of surgery prior to screening; patients should not have plans to undergo major surgical procedures during the treatment period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Currently taking prescription medications intended to increase appetite or treat weight loss; these include, but are not limited to, testosterone, androgenic compounds, megestrol acetate, methylphenidate, and dronabinol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Inability to readily swallow oral tablets; patients with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption, or obstructive symptoms) or intractable or frequent vomiting are excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Has an active, uncontrolled infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Has uncontrolled diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Has untreated clinically relevant hypothyroidism",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Has known or symptomatic brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Receiving strong CYP3A4 inhibitors within 14 days of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Receiving tube feedings or parenteral nutrition (either total or partial); patients must have discontinued these treatments for at least 6 weeks prior to Day 1, and throughout the study duration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Other clinical diagnosis, ongoing or intercurrent illness that in the Investigator's opinion would prevent the patient's participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Has had previous exposure to Anamorelin HCl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01387269",
    "statement": "* Patients actively receiving a concurrent investigational agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Male or female patients who are ≥ 18-years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Histologically or cytologically confirmed, locally advanced or metastatic NSCLC (adenocarcinoma, bronchoalveolar, squamous cell, large cell, or mixed carcinoma) that is not amendable to surgical treatment and patient has have failed 1 or 2 different lines of chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Measureable disease and evidence of progression on the previous therapy. Progression may be clinical or radiological.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* ECOG performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Hemoglobin ≥ 10 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Absolute neutrophil count (ANC) ≥ 1500 cells/µL without growth factor support.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Platelet count ≥ 100,000 cells/µL without support.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Adequate hepatic and renal function including the following: Total bilirubin \\< 2 × ULN, AST or ALT ≤ 2.5 × ULN or ≤ 5 × ULN for patients with liver metastasis, PTT within normal limits, INR ≤ 1.5, Serum Creatinine \\<1.5 ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* At least 4 weeks post any radiotherapy or biological therapy; at least 6 weeks post nitrosoureas therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Full recovery from diagnostic or therapeutic surgery (i.e., complete wound healing) and at least 30 days have elapsed prior to initial dosing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Full recovery from the toxic effects of prior therapy (i.e., Common Toxicity Criteria \\[CTC\\] Grade 1 or less with the exception of Grade 2 alopecia).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Women of childbearing potential must have adequate pregnancy test. If postmenopausal, must be ≥ 12 months since last menses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Women of childbearing potential and men must agree to use an effective form of contraception during the study and for 60 days after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* CNS metastases by radiologic evidence or histology, unless clinically stable (must have been treated by resection or radiation) for at least 4 weeks prior to first dose of study drug. Patients may not be receiving dexamethasone for control of CSF pressure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Concurrent therapeutic anticoagulation: PTT less than or equal to 1.5 × ULN or low dose aspirin and low-weight heparin only are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* More than 2 previous lines of chemotherapy for lung cancer. This includes biologic (immunotherapy) therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* History of previous cerebrovascular accident (CVA) or history transient ischemic attack (TIA) within 6 months of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* History of prior malignancy not cured by excision. Patients with non-melanoma skin cancer or carcinoma in situ of the cervix are not excluded, but patients with other prior malignancies must have had at least 2-year disease free interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Recent history (within 6 months of screening) of unstable angina, myocardial infarction, or NYHA Class III or IV congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* History of cardiac arrhythmia requiring medical or electrical therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* QTc \\> 450 msec for males and \\> 470 msec for females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Any major surgery within 30 days or minor surgery within 10 days of study entry, or patient not recovered from surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* History of organ or bone marrow transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Known active and/or uncontrolled infection, including HIV and are not stable on antiretroviral therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Any investigational therapy within 28 days of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Pregnant or nursing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Anyone who in the judgment of the investigator cannot comply with the protocol, provide truly informed consent, or is likely to live \\< 90 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Severe or significant allergy to any chemotherapy or premedication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Clinically evident ascites (e.g., abdominal distention, bulging and/or fluid wave) or Grade 3 peripheral edema.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01380769",
    "statement": "* Any prior cancer treatment with a topoisomerase I inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": ". Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICFs and in the protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "2. Provision of signed and dated, written informed consent form prior to any mandatory study-specific procedures, sampling, and analyses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "3. Provision of signed and dated written optional genetic informed consent prior to collection of the optional sample for genetic analysis. This consent should be signed at the time of second screening. This optional sample and analyses are separate from the mandatory genetic testing consent included in ICF1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "   The following criteria must have been met at the time of surgery or at the time of the curative intent therapy (first screening):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "4. Age ≥18 years at the time of screening (ICF1);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "5. Male and/or female",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "6. Histologically confirmed NSCLC with resectable stage II-III disease who have undergone curative intent therapy (complete resection of the primary tumor ± neoadjuvant and/or adjuvant therapy) per SoC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "   Select stage IIIB (ie, T3N2 or T4N2) patients will be eligible, provided they are upstaged to T3N2 or T4N2 based on confirmed pathology after surgery. Patients who are staged as T3N2 or T4N2 prior to surgery are not eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "7. A contrast-enhanced CT/MRI scan of the chest and abdomen (including liver and adrenal glands) along with brain MRI (preferred) or brain CT with IV contrast must have been done for surgical planning prior to surgery. It is recommended that patients undergo combined FDG-PET (18F-Fluoro-deoxyglucose positron emission tomography) and CT scan (computerized tomography) within the 6 weeks prior to surgery in order to rule out detectable extrathoracic, extracranial metastasis and to assess for potential mediastinal lymph node involvement prior to surgery. If the positron emission tomography (PET) scan was not performed, or data from a PET is not available, patients may still be enrolled into the study provided appropriate imaging (CT/MRI) is performed prior to randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "8. Complete resection of the primary NSCLC is mandatory. Invasive (pre-operative or intra-operative) exploration of hilar and mediastinal lymph nodes must have been performed to confirm primary tumor nodal status (prior to or after surgery). Surgical resection of the primary NSCLC can occur by open thoracotomy or by video-assisted thoracic surgery (VATs) and resection can be achieved by segmentectomy, lobectomy, sleeve resection, bilobectomy or pneumonectomy. Patients undergoing wedge resection are not eligible for this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "   Criteria for prior systemic chemotherapy/radiotherapy:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "9. Patients should have completed (or be undergoing) curative intent therapy (surgery ± neoadjuvant and/or adjuvant therapy; adjuvant therapy can include PORT) with exceptions noted below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "   Patients who discontinue chemotherapy and/or PORT for toxicity prior to completion of all planned therapy are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "   Patients who have not received any neoadjuvant and/or adjuvant chemotherapy, and meet all other eligibility criteria, may be eligible under the following circumstances:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "* All patients who are eligible for adjuvant chemotherapy MUST be offered adjuvant chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "* The patient has declined adjuvant chemotherapy, and in the opinion of the Investigator, this is the patient's final decision after receiving appropriate information and adequate time to make the decision. The patient's refusal of adjuvant chemotherapy must be documented.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "* If in the view of the Investigator, adjuvant chemotherapy is contraindicated due to an underlying intercurrent illness/laboratory abnormality, which is not considered reversible within a reasonable timeframe for the patient to be eligible for adjuvant therapy, which must be documented.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "   Criteria assessed prior to and at the start of surveillance:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "10. Confirmation of suitable biosamples for WES and central PD-L1 testing. Resected tumor tissue and whole blood samples must be provided to the diagnostic laboratory for WES of tumor and germline DNA, respectively as soon as possible following pathology confirmation. Samples must be sent no later than 1-2 weeks after completion of adjuvant therapy or 3-5 weeks after surgery (if no adjuvant therapy is given) for development of the Sponsor-approved personalized panel for MRD detection at a central reference laboratory. Germline sequencing of whole blood is mandatory. Resected tumor tissue must also be provided for PD-L1 testing at a central reference laboratory (see inclusion criteria 15).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "11. Post-adjuvant therapy or post-surgery (if no adjuvant therapy is given) CT scan of the chest and abdomen (including liver and adrenal glands) and brain MRI \\[preferred\\] or brain CT with IV contrast should be available to confirm no evidence of metastasis. If scans were not performed post-curative intent therapy, additional scans must be done prior to start of surveillance.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "12. Consents to be accessible for q6w±3d plasma sample collection for MRD evaluation and for q12w±1w CT scans during the 96-week surveillance period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "13. The plasma sample that marks the start of surveillance must be collected 8±1 weeks after completion of adjuvant therapy (if administered) or 12±1 weeks after surgery (where adjuvant therapy is not given).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "* A patient who is determined to be MRD- based on analysis of this plasma sample (ie, MRD- at the start of surveillance) may continue in surveillance provided all other eligibility criteria are met.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "* A patient who is determined to be MRD+ based on analysis of this plasma sample (ie, MRD+ at the start of surveillance) may be eligible for immediate randomization provided all other eligibility criteria are met.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "    A patient who becomes MRD+ during surveillance is eligible to enter the second screening period and may be randomized in the study if all other eligibility criteria are met.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "    Criteria for second screening prior to randomization to treatment:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "14. CT scan of the chest and abdomen (including liver and adrenal glands) and brain MRI \\[preferred\\] or brain CT with IV contrast performed within the 28 days ± 7 days prior to randomization to confirm no evidence of RECIST 1.1-defined disease recurrence and/or metastasis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "15. Known tumor PD-L1 status determined at a central reference laboratory testing service using a validated Ventana SP263 PD-L1 immunohistochemistry (IHC) assay prior randomization. Patients with unknown PD-L1 status are not eligible for the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "16. WHO/Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "17. Complete post-operative wound healing must have occurred prior to randomization; patients must have recovered from all acute, reversible toxic effects from prior treatments (excluding alopecia) that could potentially adversely impact further administration of durvalumab/placebo according to the Investigator's judgment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "18. Must have recovered from all acute, reversible toxic effects from chemotherapy that could potentially adversely impact further administration of durvalumab or placebo according to the Investigator's judgment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "19. Adequate organ and marrow function as described in the protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "20. Must have a life expectancy of at least 12 weeks Weight",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "21. Body weight \\>30 kg Inclusion criteria assessed prior to entering the observation period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "22. No evidence of RECIST 1.1-defined disease recurrence or metastasis confirmed by CT scan of the chest and abdomen (including liver and adrenal glands) and a brain MRI (preferred) or brain CT with IV contrast.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "23. MRD- status, as determined by testing the last plasma sample collected during the 96-week surveillance period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": ". EGFR and/or ALK mutant as assessed either from the tumor biopsy taken prior to surgery or the resected tumor tissue. Testing must be performed using a wellvalidated, local regulatory-approved test. EGFR/ALK may be tested centrally if local testing is unavailable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "2. Mixed small cell and NSCLC histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "3. Require re-resection or are deemed to have unresectable NSCLC by amultidisciplinary evaluation that must include a thoracic surgeon who performs lung cancer surgery as a significant part of their practice.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "4. Baseline imaging demonstrating unequivocal evidence of RECIST 1.1-defined disease recurrence or evidence of clinical recurrence outside of imaging prior to randomization. In the event of lymphadenopathy on imaging that would lead to exclusion, histopathological confirmation of lymph node metastasis should be obtained prior to excluding a patient from the study. If pathological confirmation of lymph node metastasis is not technically feasible and imaging appearance are deemed unequivocal for relapse, the patient will be excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "   Medical conditions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "5. History of allogeneic organ or bone marrow transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "6. Non-leukocyte-depleted whole blood transfusion in 120 days of genetic sample collection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "7. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[eg, colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "   Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "   Patients with vitiligo or alopecia Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement Any chronic skin condition that does not require systemic therapy Patients without active disease in the last 5 years may be included but only after consultation with the Study Physician Patients with celiac disease controlled by diet alone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "8. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active ILD, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "9. History of another primary malignancy except for Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease Adequately treated carcinoma in-situ without evidence of disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "10. History of active primary immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "11. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B virus (HBV) (known positive HBV surface antigen (HBsAg) result), hepatitis C virus (HCV), or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "12. Known allergy or hypersensitivity to any of the IPs or any of the IP excipients Prior/concomitant therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "13. Received any IO therapy in the adjuvant setting or any prior exposure to durvalumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "14. Received any radiotherapy in the neoadjuvant setting.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "15. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "16. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "17. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "18. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "19. Current or prior use of immunosuppressive medication within 14 days before the first dose of IP. The following are exceptions to this criterion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "    Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection) Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) Prior/concurrent clinical study experience",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "20. Previous IP assignment in the present study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "21. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "22. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "    Other exclusions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "23. Female patients who are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "* Female patients who become pregnant during the study will be withdrawn from surveillance and are not eligible for randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "24. Male or female patients of reproductive potential who are not willing to employ effective birth control at the time of entry into second screening (initiated with the signing of ICF2a) until 90 days after the last dose of IP (See Appendix H).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04642469",
    "statement": "25. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932893",
    "statement": "* histologically or cytologically proven diagnosis of non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932893",
    "statement": "* positive for the ALK fusion gene (test provided by a central laboratory)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932893",
    "statement": "* must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932893",
    "statement": "* tumors must be measurable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932893",
    "statement": "* prior treatment with PF-02341066",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932893",
    "statement": "* current treatment in another clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02179671",
    "statement": "* Provision of archived tumor tissue sample and mandatory tissue biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02179671",
    "statement": "* Patients must have either histologically or cytologically documented NSCLC who present with locally advanced or metastatic stage IIIB-IV disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02179671",
    "statement": "* Life expectancy ≥12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02179671",
    "statement": "* Patients must have measurable disease and at least 1 lesion not previously irradiated",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02179671",
    "statement": "* World Health Organization (WHO) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02179671",
    "statement": "* Mixed small cell and NSCLC histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02179671",
    "statement": "* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* History of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation or an EGFR activating mutation that has had a clinical response to erlotinib, afatinib, or gefitinib in the patient being enrolled",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Occurrence or progression of BM while receiving first-line therapy (either erlotinib, afatinib, or gefitinib) for at least 14 days. Patients may have received osimertinib (or other agents inhibiting the T790M EGFR mutation) as second line therapy. If BM progression occurs after osimertinib, patient will be eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* At least one measurable BM by RECIST 1.1 criteria (≥ 10 mm in longest diameter). Target lesions must not have received stereotactic radiotherapy (SRS). If a subject had prior whole brain radiotherapy (WBRT), progression in any measurable BM lesion must have occurred at least 3 months after the end of WBRT. Subjects with asymptomatic brain metastases may have been enrolled without prior radiation therapy to the brain. Subjects with minimally symptomatic brain metastases may have been enrolled without prior radiation therapy to the brain if they do not require immediate surgical or radiation therapy in the opinion of the treating investigator and in the opinion of a radiation therapy or neurosurgical consultant",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Subjects in Cohort A may have had asymptomatic LM detected by MRI. (Subjects with symptoms or signs attributed to LM were enrolled in Cohort B whether or not they have brain metastases)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* No clinically significant progression outside of the CNS on most recent EGFR inhibitor therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* ECOG Score ≤ 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* No history of another malignancy in the 5 years prior to study entry, except treated non-melanoma skin cancer or superficial bladder cancer or carcinoma in situ of the cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and have not recurred",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Adequate organ and bone marrow functions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Serum potassium and magnesium levels above the lower limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* No coexisting medical problems of sufficient severity to limit compliance with the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Willing and able to sign written informed consent and able to comply with the study protocol for the duration of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Women of childbearing potential (i.e., menstruating women) must have had a negative urine pregnancy test (positive urine tests confirmed by serum test)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* First day of dosing with tesevatinib less than 2 weeks from the last treatment of cytotoxic chemotherapy, biological therapy, or immunotherapy, and less than 6 weeks for nitrosoureas and mitomycin C. Surgical procedures must have been performed at least 2 weeks prior to the start of study treatment. Subjects must have recovered from the reversible effects of prior lung cancer treatments, including surgery and radiation therapy (excluding alopecia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* First day of dosing with tesevatinib less than 4 weeks from the last radiotherapy of the brain or spinal cord/cauda equina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* First day of dosing with tesevatinib less than 2 weeks from treatment with another investigational agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Treatment with erlotinib must have been discontinued at least 3 days prior to first dose of tesevatinib and treatment with afatinib or other tyrosine kinase inhibitor must have been discontinued at least 3 days prior to first dose of tesevatinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Any concurrent therapy for BM other than the specified treatment in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or any drugs that are CYP3A4 inducers (including anti-epileptic agents such as phenytoin). A stable regimen (≥ 4 weeks) of antidepressants of the selective serotonin uptake inhibitor (SSRI) class was allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine, paroxetine, sertraline, and fluoxetine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Taking any drugs associated with torsades de pointes or known to moderately or severely prolong the QTc(F) interval",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Evidence of active heart disease such as myocardial infarction within the 3 months prior to study entry; symptomatic coronary insufficiency congestive heart failure; moderate or severe pulmonary dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (\\< 50 bpm), heart block (excluding first degree block, being PR interval only), or congenital long QT syndrome. Subjects with a history of atrial arrhythmias were discussed with the medical monitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Had an active infectious process",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Female subject pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign body",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Marked prolongation of QTc(F) interval at screening or baseline (QTc\\[F\\] interval \\> 470 msec) using the Fridericia method of correction for heart rate",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Gastrointestinal (GI) condition interfering with drug absorption",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Non-malignant neurological disease that would interfere with evaluation of symptoms or signs of brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "Cohort B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* History of NSCLC with EGFR mutation (either exon 19 deletion or L858R mutation) or, if previously treated, history of an activating EGFR mutation that had a clinical response to erlotinib, afatinib, or gefitinib in the subject being enrolled).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Presentation with LM at initial presentation with no prior systemic treatment, or occurrence or progression of LM while receiving first-line therapy (either erlotinib, afatinib, or gefitinib) for at least 14 days. Patients may have received osimertinib (or other agents inhibiting the T790M EGFR mutation) as second line therapy. If LM progression occurred after osimertinib, subjects were eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Presence of at least one CTCAE 4.03 symptom/sign of at least Grade 1 attributed by the investigator to LM",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Diagnosis of LM by:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "  1. Cytological evidence in cerebrospinal fluid (CSF) sample of LM due to NSCLC, and/or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "  2. Findings on gadolinium-enhanced MRI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* No clinically significant progression outside of the CNS on most recent EGFR inhibitor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Concomitant brain metastases and brain metastases previously treated with radiation therapy were allowed. (Subjects with symptoms or signs attributed to LM will be enrolled in Cohort B whether or not they have brain metastases)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* ECOG Score ≤ 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* No history of another malignancy in the 5 years prior to study entry, except treated non-melanoma skin cancer or superficial bladder cancer or carcinoma in situ of the cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and had not recurred",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Adequate organ and bone marrow functions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Serum potassium and magnesium levels above the lower limit of normal (LLN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* No coexisting medical problems of sufficient severity to limit compliance with the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Willing and able to sign written informed consent and able to comply with the study protocol for the duration of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Women of childbearing potential (i.e., menstruating women) must have had a negative urine pregnancy test (positive urine tests confirmed by serum test)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* First day of dosing with tesevatinib less than 2 weeks from the last treatment of cytotoxic chemotherapy, biological therapy, or immunotherapy, and less than 6 weeks for nitrosoureas and mitomycin C. Surgical procedures must have been performed at least 2 weeks prior to the start of study treatment. Subjects must have recovered from the reversible effects of prior lung cancer treatments, including surgery and radiation therapy (excluding alopecia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* First day of dosing with tesevatinib less than 4 weeks from the last radiotherapy of the brain or spinal cord/cauda equina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* First day of dosing with tesevatinib less than 2 weeks from treatment with another investigational agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Treatment with erlotinib must have been discontinued at least 3 days prior to first dose of tesevatinib and treatment with afatinib or other tyrosine kinase inhibitor must have been discontinued at least 3 days prior to first dose of tesevatinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Any concurrent therapy for LM other than the specified treatment in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or any drugs that are CYP3A4 inducers (including anti-epileptic agents such as phenytoin). A stable regimen (≥ 4 weeks) of antidepressants of the SSRI class was allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine, paroxetine, sertraline, and fluoxetine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Taking any drugs associated with torsades de pointes or known to moderately or severely prolong the QTc(F) interval",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Evidence of active heart disease such as myocardial infarction within the 3 months prior to study entry; symptomatic coronary insufficiency congestive heart failure; moderate or severe pulmonary dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (\\< 50 bpm), heart block (excluding first degree block, being PR interval only), or congenital long QT syndrome. Subjects with a history of atrial arrhythmias were discussed with the medical monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Has an active infectious process",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Female subject pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign body",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Marked prolongation of QTc(F) interval at screening or baseline (QTc\\[F\\] interval \\> 470 msec) using the Fridericia method of correction for heart rate",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* GI condition that would interfere with drug absorption",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Non-malignant neurological disease that would interfere with evaluation of symptoms or signs of leptomeningeal metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Contraindications to lumbar puncture:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "  1. International Normalized Ratio (INR) \\> 1.5",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "  2. Platelets \\< 50 × 10\\^9/L (Note that platelets are required to be ≥100× 10\\^9/L at screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "  3. Therapeutic anticoagulant treatment that can't be held for 24 hours. Low dose low molecular weight heparin given for deep vein thrombosis (DVT) prophylaxis was allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "  4. CNS lesions considered to be at risk for cerebral herniation, myelocompression, or conus/cauda compression",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "Cohort C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* NSCLC with EGFR activating mutation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* No prior systemic treatment for NSCLC. Treatment with systemic steroids was not considered systemic treatment for NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* No prior radiation therapy to the CNS (brain or spinal cord)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* At least one measurable BM by RECIST 1.1 criteria (≥ 10 mm in longest diameter) in a subject with asymptomatic or minimally symptomatic brain metastases who did not require immediate surgical or radiation therapy in the opinion of the treating investigator and in the opinion of a radiation therapy or neurosurgical consultant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Subjects in Cohort C may have had asymptomatic LM detected by MRI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* ECOG Score ≤ 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* No history of another malignancy in the 5 years prior to study entry, except treated non-melanoma skin cancer or superficial bladder cancer or carcinoma in situ of the cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and have not recurred",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Adequate organ and bone marrow functions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Serum potassium and magnesium levels above the LLN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* No coexisting medical problems of sufficient severity to limit compliance with the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Willing and able to sign written informed consent and able to comply with the study protocol for the duration of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Women of childbearing potential (i.e., menstruating women) must have had a negative urine pregnancy test (positive urine tests are to be confirmed by serum test)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Surgical procedures performed less than 2 weeks prior to the start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Any concurrent therapy for BM other than the specified treatment in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or any drugs that are CYP3A4 inducers (including anti-epileptic agents such as phenytoin). A stable regimen (≥ 4 weeks) of antidepressants of the SSRI class was allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine, paroxetine, sertraline, and fluoxetine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Taking any drugs associated with torsades de pointes or known to moderately or severely prolong the QTc(F) interval",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Evidence of active heart disease such as myocardial infarction within the 3 months prior to study entry; symptomatic coronary insufficiency congestive heart failure; moderate or severe pulmonary dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (\\< 50 bpm), heart block (excluding first-degree block, being PR interval only), or congenital long QT syndrome. Subjects with a history of atrial arrhythmias were discussed with the medical monitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* An active infectious process",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Female subject pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign body",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Marked prolongation of QTc(F) interval at screening or Cycle 1 Day 1 (QTc\\[F\\] interval \\> 470 msec) using the Fridericia method of correction for heart rate",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* GI condition interfering with drug absorption",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02616393",
    "statement": "* Non-malignant neurological disease that would interfere with evaluation of symptoms or signs of brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": ". pathologically confirmed diagnosis of stage IIIB or stage IV adenocarcinoma of the Lung",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "2. EGFR(Epidermal Growth Factor Receptor) mutation detected by central laboratory analysis of tumor biopsy material",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "3. Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST)1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "4. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "5. Age\\>=18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "6. life expectancy of at least three months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "7. Written informed consent that is consistent with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": ". Prior chemotherapy for relapsed and/or metastatic NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "2. Prior treatment with EGFR targeting small molecules or antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "3. Radiotherapy or surgery(other than biopsy) within 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "4. Active brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "5. Any other current malignancy or malignancy diagnosed within the past 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "6. Known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "7. Significant or recent acute gastrointestinal disorders with diarrhoea as a a major symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "8. History or presence of clinically relevant cardiovascular abnormalities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "9. Cardiac left ventricular function with resting ejection fraction of less than 50%.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "10. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "11. Absolute neutrophil count(ANC)\\<1500/mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "12. Platelet count\\<100,000/mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "13. Creatinine clearance\\<60ml/min or serum creatinine\\>1.5 times Upper Limit of Normal (ULN).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "14. Bilirubin\\>1.5 times ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "15. Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) \\> 3 times ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "16. Women of childbearing potential, or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "17. Pregnancy of breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "18. Patients unable to comply with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "19. Active hepatitis B infection, active hepatitis C infection or known HIV(Human Immunodeficiency Virus) carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "20. Known or suspected active drug or alcohol abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "21. requirement for treatment with any of the prohibited concomitant medications listed in section 4.2.2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "22. Any contraindications for therapy with gemcitabine/cisplatin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "23. Known hypersensitivity to BIBW2992 or the excipient of any of the trial drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121393",
    "statement": "24. Use of any investigational drug within 4 weeks of randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": ". Pathologically or cytologically confirmed Stage IIIB/IV non-small cell lung cancer or recurrent disease following locoregional treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "2. Either or both of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "1) A tumor which harbors an Epidermal Growth Factor Receptor (EGFR) -mutation known to be associated with drug sensitivity (i.e., G719X, exon 19 deletion, L858R, L861Q) from previous tumor biopsy or surgery. A tumor which harbors exon 20 insertion or de novo T790M mutation is eligible for the treatment in the sequential arm 2) Objective clinical benefit from treatment with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) as defined by either",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "1. Documented partial or complete response (Response Evaluation Criteria in Solid Tumors, RECIST), or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "2. Stable disease \\>=6 months as defined by RECIST in absence of radiographic progression after initiation of gefitinib or erlotinib; or stable disease/PR/CR \\>=12 weeks as defined by RECIST after initiation of BIBW 2992 3. Systemic progression of disease (RECIST v1.1) while on continuous treatment with erlotinib or gefitinib or BIBW 2992 within the last 30 days. Patients whose disease progresses only in the central nervous system (CNS) are not eligible 4. No intervening systemic therapy between cessation of gefitinib or erlotinib or BIBW 2992 and initiation of the treatment in the study 5. Adequate tumor-derived material such as fresh or archived tumor tissue or pleural fluid from malignant pleural effusion after disease progression on erlotinib/gefitinib/BIBW 2992 prior to the study entry must be made available for EGFR mutation analyses 6. Patients aged 18 years or older 7. Life expectancy of at least three (3) months 8. Eastern Cooperative Oncology Group (ECOG) performance score 0-2 9. Written informed consent that is consistent with ICH-GCP guidelines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": ". Prior treatment with EGFR targeting antibodies; prior severe infusion reaction to a monoclonal antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "2. Adverse events due to major surgery (at least 28 days after) or minor surgery not recovered to CTC grade 1 or less. Surgical wounds must be healing without clinical evidence of infection prior to study treatment to be eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "3. Radiotherapy less than two weeks prior to the start of the study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "4. Systemic chemotherapy, hormonal therapy, immunotherapy, or experimental or approved proteins/antibodies (except erlotinib/gefitinib/BIBW 2992) \\<=30 days before study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "5. Less than three days from prior treatment with gefitinib or erlotinib. Patients with adverse events related to gefitinib or erlotinib must recover to CTC AE grade 1 or less to be eligible. No need to stop BIBW 2992 before start of the study treatment for patient who progressed on BIBW 2992 from a separate clinical trial/treatment setting",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "6. Brain metastases, which are symptomatic. Patients with treated, asymptomatic brain metastases are eligible if there has been no change in brain disease status for at least four (4) weeks, no history of cerebral oedema or bleeding in the past four (4) weeks. Anticonvulsant therapy will be allowed if patient is stable on anticonvulsant treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "7. Other malignancies diagnosed within the past five (5) years (other than non melanomatous skin cancer, ductal carcinoma in situ and in situ cervical cancer)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "8. Known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "9. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohns disease, malabsorption, or Common Toxicity Criteria for Adverse Events (CTCAE) grade \\>2 diarrhea of any etiology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01090011",
    "statement": "10. Women of childbearing potential (WOCBP), or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial; pregnancy or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": ". Patients with histologically confirmed advanced solid tumours that are metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. Patients who refuse standard therapy are also eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": "   Part B only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": "2. Pathologically confirmed diagnosis of Stage IV (M1a or b) non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": "3. Documented Epidermal Growth Factor Receptor (EGFR) T790M mutation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": "4. Progression of disease on a reversible tyrosine kinase inhibitor within 30 days of starting study drug. Loss of exposure to prior EGFR TKI should not be \\>30 days; any procedural delay in confirmation of progression is to be discussed with the BI Clinical Monitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": "   Parts A and B:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": "5. Evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": "6. Age \\>/= to 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": "7. Eastern Cooperative Group (ECOG) performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": "8. Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": "9. Recovered from any previous therapy-related toxicity to \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": " 0.47 seconds as measured during screening procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01647711",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": ". Provision of signed, written and dated informed consent prior to any study specific Procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "2. Male or female aged 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "3. As per local prescribing information and in view of positive benefit-risk assessment, patient prescribed Durvalumab treatment as per independent clinical judgment of treating physician for either",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": ". Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "3. Prior exposure to any anti-PD-1 or anti-PD-L1 antibody including durvalumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "4. For NSCLC cohort only:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "   1. Mixed small cell and non-small cell lung cancer histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "   2. Any unresolved toxicity CTCAE \\>Grade 2 from the prior chemoradiation therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "   3. Patients with ≥Grade 2 pneumonitis from prior chemoradiation therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "5. Active or prior documented autoimmune disease within the past 2 years, inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), primary immunodeficiency, organ transplant that requires therapeutic immunosuppression, hypersensitivity to study drug or any excipient, leptomeningeal carcinomatosis, tuberculosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "   NOTE: Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "6. Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "7. Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of patient safety or study results.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Histologically and/or cytologically confirmed selected solid tumor types that have progressed after treatment with standard therapies or for which there are no other appropriate therapies available.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "The selected tumor types are: non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal melanoma)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* At least 1 measurable target lesion according to modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Participants must have an Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) of 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Adequate liver function as evidenced by bilirubin ≤1.5×ULN and alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤3×ULN (in the case of liver metastases ≤5×ULN). In case ALP is \\>3×ULN (in the absence of liver metastases) or \\>5×ULN (in the presence of liver metastases) AND the participant also is known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of the total ALP.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Males or females age ≥20 years at the time of informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Life expectancy of 12 weeks or more",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Prior anticancer treatment within 28 days (or 5 times the half-life time, whichever is shorter) or any investigational agent within 28 days prior to the first dose of study drugs. All toxicities related to prior treatments must be resolved to Grade ≤1 (except alopecia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Prior treatment with lenvatinib or any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, excluding cancer types such as melanoma and non-small cell lung cancer where prior treatment with one anti-PD-1, anti-PD-L1, or anti-PD-L2 agent is allowed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Participants must have recovered adequately from any complications from major surgery prior to starting therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Prolongation of QTc (Fridericia formula) interval to \\>480 milliseconds (ms)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Active infection (any infection requiring systemic treatment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Participant is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Known intolerance to either of the study drugs (or any of the excipients)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* History of organ allograft",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis, or has a history of interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Females who are breastfeeding or pregnant at Screening or Baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Females of childbearing potential.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03006887",
    "statement": "* Participants must be on a stable dose of the same oral hormonal contraceptive product for at least 4 weeks before dosing with study drug and for the duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": ". Age 18 or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "2. Eastern cooperative oncology group performance status of 0-2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "3. Life expectancy of at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "4. Measurable disease according to Response evaluation criteria in solid tumors 1.1 criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "5. Written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": ". Treatment with an investigational drug within the past 28 days prior to the start of therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "2. Persisting toxicities which are clinically significant from previous therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "3. Patients who are unwilling or unable to take folic acid and vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "4. Active brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "5. Other active malignancy diagnosed within the past 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "6. Concomitant intercurrent illnesses that would limit compliance with trial requirement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "7. Patients unable or unwilling to interrupt concomitant administration of Non-steroidal anti-inflammatory drugs (NSAIDS) as per pemetrexed prescribing information",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "8. Patients who have received prior therapy with BIBW 2992",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "9. Left ventricular function by echocardiogram or Multiple gated acquisition scan (MUGA) less than institutional lower limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "10. Absolute neutrophil count (ANC) less than 1,500/mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "11. Platelet count less than 100,000/mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "12. Hemoglobin less than 90g/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "13. Total bilirubin less than 26µmol/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "14. Alanine amino transferase (ALT) and/or aspartate amino transferase (AST) greater than 2.5 X ULN, except in case of known liver metastasis where maximum 5 X ULN is acceptable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "15. Serum creatinine level greater than 133µmol/L and/or creatinine clearance (measured or calculated) less than 45 ml/min",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "16. History or recent gastrointestinal bleeding, obstruction or perforation or malabsorption syndrome and must be able to swallow the BIBW 2992 in whole by mouth.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "17. History of interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "18. Women and men who are sexually active and unwilling to use a medically acceptable method of contraception",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "19. Pregnancy or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "20. Known or suspected active alcohol or drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "21. Patients unable to comply with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "22. Has a diagnosis of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01169675",
    "statement": "23. Any known hypersensitivity to the trial drugs or their excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "(Part 2 Only):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Histological or cytological diagnosis of locally advanced or metastatic NSCLC or urothelial carcinoma who have progressed on or were intolerant to standard of care systemic therapy, or for whom standard of care systemic therapy was refused (refusal must be documented) or unavailable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* No prior treatment with anti-PD-1 or anti-PD-L1 therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* NSCLC patients whose tumor is not known to have ALK or EGFR mutations must have progressed on or after no more than 1 prior line of platinum-containing systemic therapy or were intolerant or refused standard of care systemic therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* NSCLC patients whose tumor is known to have ALK or EGFR mutation must have received prior systemic therapies that only include 1 or more lines of ALK or EGFR targeting drugs and chemotherapy limited to 1 line of a platinum-based regimen and they must have progressed on or after both types of therapies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Urothelial carcinoma patients must have received up to 2 lines of prior systemic therapy and progressed on or after, experienced disease recurrence within 12 months of neoadjuvant or adjuvant treatment, were intolerant to, ineligible or refused platinum-containing systemic therapy. If urothelial cancer patients are treatment naïve and eligible for platinum-containing systemic therapy but are refusing platinum chemotherapy, they must also be documented to have previous PD-L1 high status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Provide archived tumor tissue sample taken within the past 2 years or provide a fresh tumor biopsy sample.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* At least one measurable lesion as defined by RECIST version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Adequate renal, liver, thyroid and bone marrow function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Performance status 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Patient is capable of receiving study treatment for at least 8 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "(Part 2 Only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Active brain or leptomeningeal metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Diagnosis of prior immunodeficiency or organ transplant requiring immunosuppressive therapy or prior allogeneic bone marrow or hematopoietic stem cell transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Patients with a condition requiring systemic treatment with either corticosteroids (\\>10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses \\>10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Patients with a history of interstitial lung disease, non-infectious pneumonitis, or active pulmonary tuberculosis. Those with active lung infections requiring treatment are also excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* History of Grade ≥3 immune mediated AE (including AST/ALT elevations that where considered drug related and cytokine release syndrome) that was considered related to prior immune modulatory therapy (eg, immune checkpoint inhibitors, co-stimulatory agents, etc.) and required immunosuppressive therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Active hepatitis B or C, HIV/AIDS.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573259",
    "statement": "* Other potentially metastatic malignancy within past 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* Males and females greater than or equal to (\\>=)18 years of age (at the time consent is obtained)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* Diagnosis of non-resectable or metastatic solid malignancy (as defined in the protocol) or NHL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* Presence of evaluable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* Adequate organ function (as defined in the protocol)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* Reproductive criteria (as defined in the protocol).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* Malignancy attributed to prior solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* Leptomeningeal disease, spinal cord compression, or brain metastases that require immediate central nervous system (CNS)-specific treatment in the opinion of the Investigator (for example \\[e.g.\\], for symptomatic disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* History of a second malignancy, excluding non-melanoma skin cell cancer within the last three years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* Evidence of severe or uncontrolled systemic diseases, or serious and/or pre-existing medical or other condition that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* Select cardiac abnormalities (as defined in the protocol)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783300",
    "statement": "* History of optic nerve neuropathy or neuritis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Histologically or cytologically confirmed carcinoma of the breast",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Locally advanced breast cancer that is not amenable to curative radiation or surgical cure and/or metastatic disease appropriate for systemic single cytotoxic chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation from Myriad Genetics or other laboratory approved by the Sponsor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* No more than 3 prior chemotherapy-inclusive regimens for locally advanced and/or metastatic disease (no limit on prior hormonal therapies or targeted anticancer therapies such as mechanistic target of rapamycin (mTOR) or CDK4/6 inhibitors, immune-oncology agents, tyrosine kinase inhibitors, or monoclonal antibodies against CTL4 or VEGF)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Prior treatment with a taxane and/or anthracycline in the neoadjuvant, adjuvant, locally advanced, or metastatic setting unless medically contraindicated",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Have measurable or non-measurable, evaluable disease by the revised response evaluation criteria in solid tumors (RECIST) v.1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* First-line locally advanced and/or metastatic breast cancer with no prior adjuvant chemotherapy unless the Investigator determines that one of the 4 cytotoxic chemotherapy agents in the control arm would otherwise be offered to the subject",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Prior treatment with a PARP inhibitor (not including iniparib)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Not a candidate for treatment with at least 1 of the treatments of protocol-specific physician's choice (ie, capecitabine, eribulin, gemcitabine, vinorelbine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Subjects who had objective disease progression while receiving platinum chemotherapy administered for locally advanced or metastatic disease; subjects who received low-dose platinum therapy administered in combination with radiation therapy are not excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Subjects who have received platinum in the adjuvant or neoadjuvant setting are eligible; however, subjects may not have relapsed within 6 months of the last dose of prior platinum therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Cytotoxic chemotherapy within 14 days before randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Radiation or anti-hormonal therapy or other targeted anticancer therapy within 14 days before randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* HER2 positive breast cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Active inflammatory breast cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Exception: Adequately treated brain metastases documented by baseline CT or MRI scan that has not progressed since previous scans and that does not require corticosteroids (except prednisone ≤ 5 mg/day or equivalent) for management of CNS symptoms. A repeat CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Subjects with leptomeningeal carcinomatosis are not permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Prior malignancy except for any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Prior BRCA-associated cancer as long as there is no current evidence of the cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Carcinoma in situ or non-melanoma skin cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* A cancer diagnosed and definitively treated ≥ 5 years before randomization with no subsequent evidence of recurrence",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Known to be human immunodeficiency virus positive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Known active hepatitis C virus, or known active hepatitis B virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945775",
    "statement": "* Known hypersensitivity to any of the components of talazoparib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": ". Subjects with Histologically or cytologically confirmed squamous cell NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "2. Subjects with stage IIIB/stage IV or recurrent disease (not suitable for definitive concurrent chemoradiotherapy) (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) after failure of first-line platinum-based therapy; Subjects who developed recurrent disease \\<6 months after platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy also could also be eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "3. At lease one measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "4. Age ≥ 18 and ≤ 75",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "5. ECOG performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "6. Life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "7. Adequate organ and bone marrow function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "   1. CBC: absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; platelet count (PLT) ≥ 100 × 109 / L; hemoglobin content (HGB) ≥ 9.0 g / dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "   2. Liver function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; serum albumin ≥ 28 g / L.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "   3. Renal function: serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate (Ccr) ≥ 40 mL / min (calculated using Cockcroft / Gault equation) Female:CrCl= (140-Age) x Weight(kg) x 0.85 72 x Serum creatinine (mg/dL) Male:CrCl= (140-Age) x Weight(kg) x 1.00 72 x Serum creatinine (mg/dL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "8. Subjects of reproductive potential must be willing to use adequate contraception during the course of the study and through 6 months after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "9. Voluntarily signed written informed consent form, willing and able to comply with scheduled visits and other requirements of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": ". EGFR mutation and ALK rearrangement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "2. Mixed adeno-squamous carcinoma or other pathological type",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "3. Prior therapy with anti-PD-1,anti-PD-L1,anti-CTLA4 antibody or docetaxel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "4. Have received following treatment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "   1. Received any investigational agent within 4 weeks of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "   2. Received any anti-tumor therapy (chemotherapy, targeted therapy, tumor immunotherapy or arterial embolization) within 3 weeks of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "   3. Received radiotherapy within 4 weeks of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "   4. Received systemic treatment with high-dose corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive drugs within 4 weeks of first dose. Inhaled or topical steroids and adrenal replacement steroid are permitted in the absence of active autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "   5. Received attenuated live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "   6. Received major surgery (such as craniotomy, thoracotomy or laparotomy) within 4 weeks of the first dose of study drugs or open wound, ulcer or fracture.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "5. Unrecovered toxicity (grade \\>1, according to NCI CTCAE 4.03) due to prior anti-tumor therapy before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "6. Subjects with active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis, Crohn's disease, autoimmune thyroiditis. Subjects with cured childhood asthma, type I diabetes mellitus and hypothyroidism only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "7. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "8. Known allergic or hypersensitive to docetaxel, any monoclonal antibody or any other components used in their preparation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "9. Hemoptysis within 4 weeks of randomization (≥ 1/2 spoon per time).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "10. Received thoracic radiotherapy \\>30Gy within 6 months or palliative radiotherapy (brain or bone metastasis) ≤30Gy within 7 days of randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "11. Symptomatic central nervous system (CNS) metastasis and/or carcinomatous meningitis. Subjects should have stable disease more than 4 weeks from first dose of study treatment, with neurological symptoms returned to NCI CTCAE 4.03 grade 0 or 1, are permitted to enroll.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "12. Subjects with a history of interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "13. Superior vena caval obstruction syndrome;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "14. Uncontrolled third space effusion, eg. ascites or pleural effusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "15. Uncontrolled concomitant disease, including but not limited to :",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "    1. Active or poorly controlled severe infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "    2. Human Immunodeficiency Virus (HIV) infection (HIV antibody positive)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "    3. Known acute or chronic active hepatitis B (HBV DNA positive) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "    4. Active tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "    5. Symptomatic congestive heart failure (New York Heart Association grade III-IV) or symptomatic, poorly controlled arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "    6. Uncontrolled hypertension (SBP ≥ 160mmHg or DBP ≥ 100mmHg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "    7. Prior arterial thromboembolism event, including myocardial infarction, unstable angina, stroke and transient ischemic attack, within 6 months of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "    8. Concomitant disease needs anticoagulant therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "    9. Uncontrolled hypercalcemia(Ca2+\\>1.5mmol/L or Ca \\>12mg/dl or corrected Serum Calcium \\>ULN),or Symptomatic hypercalcemia during diphosphonate therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "    10. Other primary malignancy, with the exception of: (radical Non-melanoma skin cancer or cured cervical in-situ carcinoma;)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "16. Subjects with other diseases or abnormal Lab test results which might increase the risk of enrollment and treatment or Interfere with the interpretation of study results could be excluded according to the judgments of investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03150875",
    "statement": "17. Women who are pregnant or nursing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02659059",
    "statement": "* Men and Women ≥ 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02659059",
    "statement": "* Diagnosed with stage IV Non-Small Cell Lung Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02659059",
    "statement": "* Diagnosed with recurrent stage IIIB non-small cell lung cancer and failed previous concurrent chemoradiation with no further curative options.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02659059",
    "statement": "* Subjects with untreated CNS metastases are excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02659059",
    "statement": "* Subjects with carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02659059",
    "statement": "* Subjects with an active, known or suspected autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02659059",
    "statement": "* Subjects with a condition requiring systemic treatment with either corticosteroids ( \\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02659059",
    "statement": "* Women who are pregnant, plan to become pregnant, and/or breastfeed during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02659059",
    "statement": "Other protocol defined inclusion/exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02613507",
    "statement": "* Disease progression experienced during or after one prior platinum containing doublet chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02613507",
    "statement": "* Stage IIIb/IV or recurrent disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02613507",
    "statement": "* Male and Female ≥ 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02613507",
    "statement": "* Measurable disease per RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02613507",
    "statement": "* Performance Status ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02613507",
    "statement": "* History of Carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02613507",
    "statement": "* Active Central nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02613507",
    "statement": "* History of auto immune diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02613507",
    "statement": "* Prior treatment with Docetaxel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02613507",
    "statement": "* Prior treatment with ipilimumab or any drug targeting T-Cell costimulation or checkpoint pathways",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has a documented new diagnosis of SCLC by histology or cytology from brushing, washing, or needle aspiration of a defined lesion. Participants who do not have histology samples (defined as core or excisional biopsy, or resections) will need to undergo a new biopsy to provide a tissue sample.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has extensive-stage disease defined as Stage IV (T any, N any, M 1a/b) by the American Joint Committee on Cancer (AJCC), Seventh Edition",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has ≥1 lesion that meets the criteria for measurable, as defined by RECIST 1.1, and is appropriate for selection as a target lesion, as determined by local site investigator/radiology assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has a life expectancy of ≥3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Female and male participants of childbearing potential must be willing to use an adequate method of contraception, starting with the first dose of study treatment through 120 days after the last dose of study treatment and up to 180 days after last dose of chemotherapeutic agents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has received prior systemic therapy for the treatment of SCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Is currently participating and receiving study treatment or has participated in a study of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment for another health-related problem",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Is expected to require any other form of antineoplastic therapy for SCLC, including radiation therapy, while on study. (Prophylactic cranial irradiation will be possible for those participants with stable disease or better at the completion of the 4 cycles of chemotherapy with or without pembrolizumab.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has known central nervous system (ie, brain and/or spinal cord) metastases and/or carcinomatous meningitis. Participants with brain metastases may participate only if they satisfy all of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has completed treatment (eg, whole brain radiation treatment \\[WBRT\\], stereotactic radiosurgery, or equivalent) ≥14 days prior to the first dose of study treatment,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has no evidence of new or enlarging brain metastases confirmed by post-treatment repeat brain imaging performed ≥3 weeks after pre-treatment brain imaging, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Is neurologically stable without the need for steroids for ≥7 days before first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has had major surgery within 3 weeks prior to receiving the first dose of study treatment or has not recovered adequately from toxicity and/or complications from an intervention prior to receiving the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has a known history of interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include early stage cancers (carcinoma in situ or Stage 1) treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has a known history of, or active, neurologic paraneoplastic syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has clinically active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, and/or abdominal carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has a history of a severe hypersensitivity reaction to treatment with another monoclonal antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Is taking chronic systemic steroids (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within 7 days prior to the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has received a live vaccine within 30 days prior to the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-programmed cell death-ligand 2 (anti-PD-L2) agent or with an agent directed to another co-inhibitory T-cell receptor (i.e., cytotoxic T-lymphocyte-associated protein 4 \\[CTLA-4\\], tumor necrosis factor receptor superfamily member 9 \\[TNFRSF9, OX-40, CD137\\]) or has previously participated in a Merck pembrolizumab (MK-3475) clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has severe hypersensitivity (Grade ≥3) to pembrolizumab and/or any of its excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has an active infection requiring systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has a known history of human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has a known history of Hepatitis B or known active Hepatitis C virus infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has a known history of active TB (Bacillus Tuberculosis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03066778",
    "statement": "* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study starting with the screening visit through 120 days after the last dose of study treatment through and up to 180 days after last dose of chemotherapeutic agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Must have recovered from all side effects of their most recent systemic or local treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Adequate hematological, renal and liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "For solid tumors only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation and that are resistant to standard therapy or for which standard or curative therapy does not exist",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "For multiple myeloma only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Confirmed diagnosis of multiple myeloma with a BRAF V600 mutation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Must have received at least one prior systemic therapy for the treatment of multiple myeloma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Treated with local radiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Must have relapsed and/or refractory multiple myeloma with measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Melanoma, papillary thyroid cancer or hematological malignancies (with the exception of multiple myeloma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Uncontrolled concurrent malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Multiple myeloma: solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Active or untreated central nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* History of or known carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Concurrent administration of any anti-cancer therapies other than those administered in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524978",
    "statement": "* Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that would, in the investigator's opinion, contraindicate participation in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02774278",
    "statement": "* Advanced NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02774278",
    "statement": "* Tumor accessible for biopsy by bronchoscopy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02774278",
    "statement": "* Disease progression following course of standard chemotherapy, or participants unwilling/unable to undergo chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02774278",
    "statement": "* Unstable systemic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02774278",
    "statement": "* Any other malignancies in the last 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02774278",
    "statement": "* Brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02774278",
    "statement": "* Previous treatment with therapy acting on the epidermal growth factor receptor (EGFR) axis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Men and women greater than or equal to 18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* A diagnosis of ovarian, lung (small cell or non-small cell) or bladder cancer requiring systemic chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Participant receiving a chemotherapy regimen given in a 21 or 28-day cycle, including 1 or more of the following agents or class of agents:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Nucleoside analog, including gemcitabine and fluorouracil;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Carboplatin or cisplatin;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Anthracycline; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Alkylating agent;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Participant experienced severe thrombocytopenia, defined as 2 platelet counts \\<50 x 109/L measured at least 24 hours apart, during the qualifying chemotherapy cycle, of their current chemotherapy regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* ECOG performance status \\<=2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Participant has experienced \\>=Grade 2 CIT other than during the current chemotherapy treatment regimen within 6 months of Screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Participant has any history of hematologic malignancies, including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic diseases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Participant has received \\>2 previous lines of chemotherapy or is receiving whole brain radiation during the study treatment period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Participant has a known medical history of genetic prothrombotic syndromes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Participant has a history of arterial or venous thrombosis within 3 months of screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Use of vitamin K antagonists;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "* Participant has previously received a thrombopoietin receptor agonist or recombinant human thrombopoietin for the treatment of CIT within 3 months of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02574078",
    "statement": "* Histologically confirmed locally advanced or stage IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02574078",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02574078",
    "statement": "* Tumor tissue sections must be available for biomarker evaluation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02574078",
    "statement": "* Untreated or active/progressing Central Nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02574078",
    "statement": "* Active, known or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02574078",
    "statement": "* Known history of testing positive for HIV or AIDS",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02574078",
    "statement": "* Active or chronic infection of hepatitis B virus or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient has radically resected NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The NSCLC is of pathological stage IA-T1b, IB, II or IIIA NSCLC The surgical technique for resection of the patient's tumor is anatomical, involving at least a segmentectomy The patient's tumor shows expression of PRAME.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient is ≥ 18 years of age at the time of first consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* Written informed consent has been obtained from the patient prior to performance of any study-specific procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient is free of disease (no residual tumor, no loco-regional recurrence, no distant metastasis), as confirmed by a post- thoracic surgery contrast-enhanced computed tomography (CT scan) of the chest, upper abdomen and by a contrast-enhanced CT scan or Magnetic Resonance Imaging (MRI) of the brain. Other examinations should be performed as clinically indicated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2 at the time of randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* Adequate bone-marrow reserve, adequate renal, hepatic and adrenal function as assessed by standard laboratory criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study product, have a negative pregnancy test and continue such precautions during all study treatment period and for 2 months after last treatment administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* Patients who the investigator believes can and will comply with the requirements of this protocol (e.g. return for active follow-up visits).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient is diagnosed with a concomitant malignancy and/or has a history of malignancy within the past five years or has had a malignancy that has been in complete remission for less than 5 years. Patients with effectively treated non - melanoma skin cancers or effectively treated carcinoma in situ of the cervix both of which in remission for less than 5 years will be eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient has received any anti-cancer specific treatment, including radiotherapy, immunotherapy, hormonal therapy, chemotherapy or neo-adjuvant chemotherapy, except for:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* Administration of adjuvant platinum-based doublet chemotherapy for the treatment of the current NSCLC allowed between surgery and randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* Treatment of previous malignancies as allowed by the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient has been diagnosed with a Potential Immune-Mediated Disease (pIMD). Patients with vitiligo are not excluded from the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient has a history of confirmed adrenal dysfunction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient requires concomitant treatment with any immunosuppressive agent, or with systemic corticosteroids prescribed for chronic treatment (more than 7 consecutive days).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient needs chronic long term oxygen therapy (LTOT). The patient has medically uncontrolled congestive heart failure or hypertension, unstable heart disease or uncontrolled arrhythmia at the time of randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient has an uncontrolled bleeding disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient has undergone splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient is known to be Human Immunodeficiency Virus (HIV)-positive.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the trial procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient has other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient has a history of allergic disease or reactions likely to be exacerbated by any component of the study investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* The patient has received any investigational or non-registered product within the 30 days preceding randomization, or planned use during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01853878",
    "statement": "* For female patients: the patient is pregnant or lactating or is planning to become pregnant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* Adult participants, \\>/= 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* Measurable disease, as defined by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* Known active or untreated central nervous system (CNS) metastases as determined by CT or MRI evaluation during screening and prior radiographic assessments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* History of autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* Active hepatitis B or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* Prior treatment with docetaxel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01903993",
    "statement": "* Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770588",
    "statement": "* Histologically or cytologically confirmed locally advanced or metastatic (stage=IIIB/IV) non-small cell lung cancer (NSCLC) before the front line chemotherapy. Note: sputum cytology alone is not acceptable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770588",
    "statement": "* Patients have completed 4 cycles of first line platinum contained doublet chemotherapy without progression or intolerable toxicity.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770588",
    "statement": "* Patients with PR or SD on study entry need to have one or more measurable lesions according to RECIST criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770588",
    "statement": "* The study treatment should be started at least 3 weeks (21 days) but no more than 6 weeks (42 days) since last dose of chemotherapy, and within 4 weeks (28 days) since last tumour assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770588",
    "statement": "* Prior exposure to monoclonal antibodies or small molecule inhibitors against EGFR receptors. (e.g. gefitinib, erlotinib, C225)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770588",
    "statement": "* Patients with previously diagnosed and treated CNS metastases or spinal cord compression may be considered if they are clinically stable and have been discontinued from steroid therapy for at least 4 weeks prior to first dose of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770588",
    "statement": "* Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770588",
    "statement": "* Known biomarker status of one or more of the following: Tumour EGFR gene copy number, tumour EGFR gene mutation status, tumour EGFR protein expression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03647488",
    "statement": "* Histologically confirmed locally advanced/metastatic (stage IIIB/IV), EGFR wild-type, ALK rearrangement negative, non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03647488",
    "statement": "* Subject had demonstrated progression following one prior platinum doublet and one prior PD-(L)1 checkpoint inhibitor (either alone or in combination, the most recent treatment regimen must have contained a PD-(L)1 checkpoint inhibitor)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03647488",
    "statement": "* Subjects must be candidates for single agent docetaxel",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03647488",
    "statement": "* Subjects must have at least one lesion evaluable by RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03647488",
    "statement": "* Prior treatment with a MET inhibitor or HGF (Hepatocyte growth factor) targeting therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03647488",
    "statement": "* Any untreated central nervous system (CNS) lesion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03647488",
    "statement": "* Use of any live vaccines against infectious diseases within 12 weeks of initiation of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03647488",
    "statement": "Other protocol-defined inclusion/exclusion criteria might apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Histologically-proven diagnosis of malignant GIST (Gastrointestinal Stromal Tumors).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Evidence of unidimensionally measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Failure of prior treatment with imatinib or intolerant to imatinib",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Male or female, 18 years of age or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Resolution of all acute toxic effects",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Anticancer treatment after last dose of imatinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Major surgery within 4 weeks or radiation therapy within 2 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Grade 3 hemorrhage within 4 weeks prior to starting the study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Diagnosis of second malignancy within the last 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* History of brain disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Cardiac disease within 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Thyroid function abnormality.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Ongoing cardiac dysrhythmias.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Uncontrolled hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Ongoing treatment with anticoagulant and CYP3A4 inhibitors and inducers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* HIV or AIDS related illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00793871",
    "statement": "* Pregnancy or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02341456",
    "statement": "* Histological or cytological confirmation of a locally advanced or metastatic solid tumour, excluding lymphoma, that failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02341456",
    "statement": "* At least 1 measureable lesion that can be accurately assessed at baseline by computerised tomography (CT) or magnetic resonance imaging (MRI) for solid tumours assessed using RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02341456",
    "statement": "* World Health Organisation performance status 0 to 1 with no deterioration over the previous 2 weeks and a minimum life expectancy of ≥12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02341456",
    "statement": "* Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days (if investigational agent does not have well characterised PK profile) or 5 × half-lives of the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02341456",
    "statement": "* Patient has had prescription or non-prescription drugs or other products (ie, grapefruit juice) known to be sensitive to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors or inducers of CYP3A4, which cannot be discontinued 2 weeks before Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study drug. Co-administration of aprepitant during this study is prohibited.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02341456",
    "statement": "* AZD1775 is an inhibitor of breast cancer resistance protein (BCRP). The use of statins including Atorvastatin which are substrates for BCRP are therefore prohibited and patients should be moved on to non-BCRP alternatives.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Participants with advanced solid tumor that is refractory to standard treatment, for which no standard treatment is available, or the participant refuses standard therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Participants must be willing to provide an archival tumor tissue block or slides for biomarker analysis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Time from prior therapy:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "  1. Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter (6 weeks for prior nitrosoureas or mitomycin C).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "  2. Radiotherapy: wide-field radiotherapy (for example, greater than \\[\\>\\] 30 percent \\[%\\] of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Participants must have recovered or stabilized from all therapy-related toxicities.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Major surgery (not including placement of vascular access device or tumor biopsies) must be completed four weeks prior to Day 1. Participants must have recovered or stabilized from the side effects prior to study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Participants must have adequate hematologic, liver and kidney function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Participants with central nervous system (CNS) disease involvement are eligible if they have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to study day 1 and they meet all of the following criteria: Residual neurological symptoms less than or equal to (\\<=) Grade 1; No dexamethasone requirement; and Follow-up magnetic resonance imaging (MRI) shows no progression of treated lesions and no new lesions appearing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Participants must be willing and able to sign the informed consent form, and to adhere to the study visit schedule and other protocol requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Women of childbearing potential and men must agree to use effective contraceptive methods while on study and for at least twelve weeks after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Women of childbearing potential must have a negative pregnancy test prior to the first dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Grade \\>1 neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Any active or chronic corneal disorder, including, but not limited to the following: Sjogren's syndrome, Fuch's corneal dystrophy (requiring treatment), history of corneal transplantation, active herpetic keratitis, and also active ocular conditions requiring ongoing treatment/monitoring such as wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, presence of papilledema, acquired monocular vision.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Serious concurrent illness, including, but not limited to the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "  1. Clinically relevant active infection including known active hepatitis B or C, Human Immunodeficiency Virus (HIV) infection, varicella-zoster virus (shingles) or cytomegalovirus infection or any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of study enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "  2. Significant cardiac disease such as recent myocardial infarction (\\<=6 months prior to Day 1), unstable angina pectoris, uncontrolled congestive heart failure (New York Heart Association \\>class II), uncontrolled hypertension (greater than or equal to \\[\\>=\\] Common Terminology Criteria for Adverse Events Version 4.03 \\[CTCAE v4.03\\] Grade 3), uncontrolled cardiac arrhythmias, severe aortic stenosis, or \\>=Grade 3 cardiac toxicity following prior chemotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "  3. History of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last six months, or alcoholic liver disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "  4. Previous clinical diagnosis of treatment-related pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Any other concomitant anti-cancer treatment such as immunotherapy, biotherapy, radiotherapy, chemotherapy, investigative therapy, or high-dose steroids; however, low dose steroids and Luteinizing Hormone Releasing Hormone (LHRH) at doses that have been stable for \\>=14 days are permitted for participants with prostate cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Known hypersensitivity to previous monoclonal antibody therapy or maytansinoids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Prior history of solid tumor malignancy within the last 3 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer (participants must have shown no evidence of active disease for 2 years prior to enrollment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Concomitant administration of folate-containing vitamins.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Participants who have received prior allogeneic or autologous bone marrow transplants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01609556",
    "statement": "* Women of childbearing potential who are pregnant or breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient must sign an informed consent document for clinical and translational research.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient must have locally advanced or metastatic nonsquamous Non-Small Cell Lung Cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient must have biological tissue available from your diagnosis tumor for detection of some biomarkers (translational research).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot be receiving nor have received any prior systemic anticancer therapy, immunotherapy, targeted therapy, or biological therapy for your lung cancer (except chemotherapy given after surgery if it has been completed more than one year before the study entry).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient is allowed to have had prior radiation therapy as long as it was not more than 25% of the bone marrow and did not include the whole pelvis. Prior radiation therapy should be completed at least 2 weeks prior to first study drug. Thoracic radiation must be completed more than 12 weeks before the study entry. You must be recovered from the toxic effects.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient must have at least 1 measurable tumor lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient must at least be able to be physically mobile, take care of yourself, and must be up and about and able to perform light activities such as light housework or office work.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Test results assessing the function of blood forming tissue, kidneys, and liver must be satisfactory.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Females must be sterile, postmenopausal or on contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Males must be on contraception or sterile (for example post-vasectomy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have symptomatic central nervous system metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have an active infection or other serious condition that your doctor thinks would make you unable to participate.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have a serious cardiac condition, such as a heart attack, angina, or heart disease within 6 months of entering the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have had a another form of cancer other than superficial basal cell and superficial squamous (skin) cell cancer, or carcinoma in situ of the cervix within the last 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have had significant neurologic or psychiatric disorders including dementia, seizures and bipolar disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have moderate or severe peripheral neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have received treatment within 30 days with any experimental drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have had a major surgery within the last 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have previously received treatment with transduction inhibitors or Epidermal Growth Factor Receptor (EGFR)-targeting therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have prior known allergic/hypersensitivity reaction to any of the components of study treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Females cannot be pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient is unable to stop taking more than 1.3 grams of aspirin on a daily basis or other aspirin like medication (non-steroidal antiinflammatory drugs: NSAIDs) for a few days during each cycle of therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient is unable or unwilling to take folic acid, injections of vitamin B12, or corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have fluid around your lungs or in your abdomen (pleural effusions or ascites) that cannot be controlled by drainage or other procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have received a yellow fever vaccination within the previous 30 days or plan to have it.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00867009",
    "statement": "* Patient cannot have known drug abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01285609",
    "statement": "* Non small cell lung cancer (NSCLC) - squamous cell",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01285609",
    "statement": "* Stage IV or recurrent NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01285609",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01285609",
    "statement": "* Brain Metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01285609",
    "statement": "* Autoimmune diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00548093",
    "statement": "* Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00548093",
    "statement": "* Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00548093",
    "statement": "* Prior treatment with no more than two chemotherapy regimens, including adjuvant or combined modality treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00548093",
    "statement": "* Measurable disease .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00548093",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00548093",
    "statement": "* Tissue available for KRAS/ EGFR testing",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00548093",
    "statement": "* Creatinine clearance \\> 40 cc/min or serum creat \\< 1.5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00548093",
    "statement": "* Chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00548093",
    "statement": "* Radiotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00548093",
    "statement": "* Biological or investigational agents within 4 weeks of baseline disease assessment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00548093",
    "statement": "* Patients who lack of tolerance of erlotinib therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": ". Voluntary written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "2. Adult patients ≥ 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "3. Histologically or cytologically confirmed diagnosis of limited or extensive stage SCLC which failed one prior platinum-containing regimen and with a chemotherapy-free interval (CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease) ≥ 30 days. Small-cell carcinoma of unknown primary site with or without neuroendocrine features confirmed in histology test(s) performed on metastatic lesion(s) are eligible, if Ki-67/MIB-1 is expressed in \\>50% of tumor cells.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "5. Adequate hematological, renal, metabolic and hepatic function within 7-10 days prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "6. At least three weeks since last prior anticancer treatment and adequate recovery from prior treatment toxicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "7. Prior radiotherapy (RT): At least four weeks since completion of whole-brain irradiation, at least two weeks since completion of prophylactic cranial irradiation, and to any other site.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "8. Evidence of non-childbearing status for women of childbearing potential (WOCBP). WOCBP must agree to use a highly effective contraceptive measure up to six weeks after treatment discontinuation. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last investigational medicinal product dose.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": ". More than one prior chemotherapy-containing line(re-challenge with the same initial regimen is not allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "2. Patients who never received platinum-containing regimen for Small-cell Lung Cancer (SCLC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "3. Prior treatment with PM01183, topotecan or anthracyclines.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "4. Limited-stage patients who are candidates for local or regional therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "5. Impending need for palliative RT or surgery for pathological fractures and/or for medullary compression within four weeks prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "6. Symptomatic or progressing or steroid requiring Central Nervous System (CNS) involvement disease at least four weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "7. Concomitant diseases/conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "   Angina, myocardial infarction, congestive heart failure or clinically significant valvular heart disease, arrhythmia, immunodeficiency (including known HIV seropositive), ongoing or treatment-requiring chronic liver disease, active infection, oxygen requirement within two weeks prior to randomization, diffuse interstitial lung disease (ILD) or pulmonary fibrosis, second invasive malignancy treated with chemotherapy and/or radiotherapy, invasive fungal infections requiring systemic treatment within 12 weeks of randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02566993",
    "statement": "8. Pregnant or breast feeding women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": ". Evidence of histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK positive NSCLC where ALK status has been previously established by the Ventana ALK (D5F3) CDx Assay (Roche Diagnostics), the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular), or the EML4 ALK Fusion Gene Detection Kit (AmoyDx).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "2. Subject should have:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "   1. (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "   2. (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib, with or without prior crizotinib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "3. Prior treatment with an ALK inhibitor must have completed 5 half lives prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "4. All Subjects must have at least 1 measurable extracranial target lesion according to RECIST v1.1 that has not been previously irradiated. CNS metastases are allowed if:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "   1. Asymptomatic: either not currently requiring corticosteroid treatment, or on a stable or decreasing dose of 10 mg QD prednisone or equivalent; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "   2. Previously diagnosed and treatment has been completed with full recovery from the acute effects of radiation therapy or surgery prior to enrollment, and if corticosteroid treatment for these metastases has been withdrawn for at least 4 weeks with neurological stability.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0, 1, or 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "6. Age 18 years (or 20 years as required by local regulation).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "7. Adequate bone marrow functions:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "   1. Absolute Neutrophil Count (ANC) 1,500/mm3 or 1.5 x 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "   2. Platelets 100,000/mm3 or 100 x 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "   3. Hemoglobin 9 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "8. Adequate pancreatic function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "   1. Serum total amylase 1.5 x upper limit of normal (ULN);\\*",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "   2. Serum lipase 1.5 x ULN. \\*if total amylase \\>1.5 x ULN, but pancreatic amylase is within the ULN, then subject may be enrolled.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "9. Adequate renal function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "   a. Serum creatinine 1.5 x ULN or estimated creatinine clearance 60 mL/min as calculated using the method standard for the institution.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "10. Adequate liver function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "    1. Total serum bilirubin 1.5 x ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "    2. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 x ULN (5.0 x ULN in case of liver metastases).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "11. Acute effects of prior radiotherapy and chemotherapy resolved to baseline severity or to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 except for AEs that in the investigator's judgment do not constitute a safety risk for the subject.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "12. Serum or urine pregnancy test (for females of childbearing potential) negative at screening. Female subjects of non childbearing potential must meet at least 1 of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "    1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause (which may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state if appropriate;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "    2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "    3. Have medically confirmed ovarian failure. All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "13. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "14. Willing and able to comply with the study scheduled visits, treatment plans, laboratory tests, and other procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "/conditions will not be included in the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "1. More than 1 prior chemotherapy regimen prior to enrollment in advanced/metastatic setting.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "   If disease recurred/relapsed within the adjuvant chemotherapy treatment or \\<=6 months after the completion of the adjuvant chemotherapy, then the adjuvant chemotherapy is considered as the first line systemic chemotherapy to the disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "2. Systemic anti cancer therapy completed within a minimum of 5 half lives of study enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "3. Prior therapy with an antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways, including, but not limited to, anti programmed cell death protein 1 (anti PD 1), anti programmed cell death protein ligand 1 (anti PD L1), anti PD L2, anti cluster of differentiation 137 (anti CD137), or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "4. Known epidermal growth factor receptor (EGFR) activating mutations; known prior therapy with EGFR TKI(s) (the prior treatment with brigatinib is allowed as an ALK TKI).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "5. Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "6. Radiation therapy within 2 weeks prior to enrollment. Palliative radiation must have been completed at least 48 hours prior to enrollment. Stereotactic or partial brain irradiation must have completed at least 2 weeks prior to enrollment. Whole brain irradiation must have completed at least 4 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "7. Spinal cord compression unless the subject has good pain control attained through therapy, and there is complete recovery of neurological function for the 4 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "8. Gastrointestinal abnormalities, including inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection or lap band; active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer disease in the past 6 months; malabsorption syndromes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "9. Known prior or suspected severe hypersensitivity to lorlatinib or any component in the formulation; known prior therapy with lorlatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "10. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "11. Clinically significant cardiovascular disease (both arterial and venous) and non vascular cardiac conditions, (active or within 3 months prior to enrollment, which may include, but not are limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "* Arterial disease such as cerebral vascular accident/stroke (including transient ischemic attack -TIA), myocardial infarction, unstable angina;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "* Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary embolism;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "* Nonvascular cardiac disease such as congestive heart failure (New York Heart Association Classification Class ≥ II), second degree or third degree atrioventricular block (unless paced) or any AV block with PR interval \\>220 msec; or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "* Ongoing cardiac dysrhythmias of CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as \\<50 bpm (unless subject is otherwise healthy such as long distance runners, etc.), machine read electrocardiogram (ECG) with QTc \\>470 msec, or congenital long QT syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "12. Subject with predisposing characteristics for acute pancreatitis according to investigator judgment, including but not limited to uncontrolled hyperglycemia, current gallstone disease, in the last month prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "13. History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "14. Evidence of active malignancy (other than NSCLC, non melanoma skin cancer, or localized and presumed cured prostate cancer or any in situ cancer which does not currently require treatment) within the last 3 years prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "15. Concurrent use of any of the following food or drugs (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days prior to the first dose of administration of lorlatinib:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "    1. Known strong CYP3A inhibitors (eg, strong CYP3A inhibitors: grapefruit juice or grapefruit/grapefruit related citrus fruits \\[eg, Seville oranges, pomelos\\], boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole, ritonavir alone and with danoprevir or elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir, troleandomycin, and voriconazole). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "    2. Known CYP3A substrates with narrow therapeutic index, such as astemizole\\*, terfenadine\\*, cisapride\\*, pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine) (\\*withdrawn from US market);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "    3. Known strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "    4. Known P glycoprotein (P gp) substrates with a narrow therapeutic index (eg, digoxin).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "16. Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator and/or the sponsor, would make the subject inappropriate for entry into this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "17. Subject who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "18. Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "19. Pregnant female participants; breastfeeding female participants; fertile male participants and female participants of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 97 days if male or 35 days if female, after the last dose of investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01196078",
    "statement": "* Adult patients, \\>=70 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01196078",
    "statement": "* Non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01196078",
    "statement": "* Naive to prior chemotherapy or specific immunotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01196078",
    "statement": "* Presence of at least 1 measurable lesion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01196078",
    "statement": "* Active non-controlled infection or disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01196078",
    "statement": "* CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01196078",
    "statement": "* Any other malignancies (other than adequately treated basal cell cancer of skin, or in situ cancer of the cervix)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Participants who provided signed written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Male or female, 18 years or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Participants with Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Participants with histologically or cytologically confirmed diagnosis of MM as defined in IMWG, 2014 criteria, and participant has undergone stem cell transplant or is considered transplant ineligible and has failed at least 3 prior lines of anti-myeloma treatments, including an anti-CD38 antibody (example \\[e.g.\\], daratumumab) alone or in combination, and is refractory to an Immunomodulatory drug (IMiD) (that is \\[i.e.\\], lenalidomide or pomalidomide), and to a proteasome inhibitor (e.g., bortezomib, ixazomib or carfilzomib).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* The participant has measurable disease with at least one of the following: Serum M-protein \\>=0.5 grams per deciliter (g/dL) (\\>=5 grams per Liter \\[g/L\\]); Urine M-protein \\>=200 milligram per 24 hours (mg/24h); Serum Free light chain (FLC) assay: Involved FLC level \\>=10 mg/dL (\\>=100 mg/Liter) and an abnormal serum FLC ratio (\\<0.26 or \\>1.65).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Participants with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: transplant was \\>100 days prior to study enrollment; no active infection(s); participants meet the remainder of the eligibility criteria outlined in the protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Participants with adequate organ system functions as defined follows: Absolute neutrophil count (ANC) \\>=1.0 X 10\\^9/L; Hemoglobin \\>=8.0 g/dL; Platelets\\>= 50 X 10\\^9/L; Total bilirubin \\<=1.5X Upper limit of normal (ULN). Isolated bilirubin \\>=1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \\<35 percent); Alanine aminotransferase (ALT) \\<=2.5X ULN; Estimated glomerular filtration rate (eGFR) \\>=30 milliliter per minute per 1.73 meter square (mL/min/m\\^2); Spot urine (albumin/creatinine ratios \\[spot urine\\]) \\<500 milligram per gram (mg/g) (56 mg per millimoles \\[mg/mmol\\]); Left ventricular ejection fraction (LVEF) (Echocardiogram)\\>=45 percent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Female participants: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and not a woman of childbearing potential (WOCBP) or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\<1% per year), preferably with low user dependency, during the intervention period and for at least 80 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Male participants: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 140 days: Refrain from donating sperm; Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or Agree to use a male condom and female partner to use an additional highly effective contraceptive method with a failure rate of \\<1% per year as when having sexual intercourse with a WOCBP who is not currently pregnant.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events \\[NCI-CTCAE\\]), version 4.03, must be \\<=Grade 1 at the time of enrollment except for alopecia and Grade 2 peripheral neuropathy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* For France only: A participant will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Systemic anti-myeloma therapy within \\<=14 days, or 5 half-lives, whichever is shorter, or plasmapheresis within 7 days prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Systemic treatment with high dose steroids (equivalent to \\>=60 mg prednisone daily for \\>=4 days) within the past 14 days if administered to treat MM or non-MM disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Symptomatic amyloidosis, active 'polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes' (POEMS) syndrome, active plasma cell leukemia at the time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Prior allogeneic stem cell transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Current corneal epithelial disease except mild punctate keratopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Use of an investigational drug within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug. Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs. Prior B-cell maturation antigen (BCMA) targeted therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Evidence of active mucosal or internal bleeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Any major surgery within the last four weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Malignancies other than disease under study are excluded, except for any other malignancy from which the participant has been disease-free for more than 2 years and, in the opinion of the principal investigators and GlaxoSmithKline Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (MM). Participants with curatively treated non-melanoma skin cancer may be enrolled.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Evidence of cardiovascular risk including any of the following: Corrected QT interval Fridericia (QTcF) interval \\>480 milliseconds (msec); Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant electrocardiogram abnormalities such as 2nd degree (Type II) or 3rd degree atrioventricular (AV) block; History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within six months of Screening; Class III or IV heart failure as defined by the New York Heart Association functional classification system (NYHA); Uncontrolled hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Pregnant or lactating female.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Active infection requiring antibiotic, antiviral, or antifungal treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Known Human Immunodeficiency Virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb at screening or within 3 months prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03525678",
    "statement": "* Positive hepatitis C antibody test result or positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": ". Pathologically confirmed: Non-small cell lung cancer (NSCLC, adenocarcinoma or squamous-cell carcinoma), Breast Cancer (HER2 positive or triple negative), Pancreatic Cancer (adenocarcinoma)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "2. Relapsed or refractory disease (Stage III or IV): NSCLC or pancreatic cancer must have failed at least 1 prior treatment. Breast cancer must have failed at least 2 prior treatments.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "3. Measurable lesion by RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "4. Adequate hematologic function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "* ANC \\>1500 cells/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "* Platelet count \\>100,000 cells/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "* HGB \\>9.0 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "5. Adequate hepatic and renal function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "* AST and ALT ≤2.5 x ULN for subjects without liver metastases and ≤3.5 x ULN for subjects with liver metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "* Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "* Creatinine ≤2.0 x ULN and Creatinine Clearance ≥40 mL/min (Cockcroft-Gault or 24-hour creatinine clearance collection)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "6. PT/INR \\<1.5 x ULN and PTT/ aPTT \\<1.5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": ". Mixed small cell and NSCLC histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "2. A history of CNS involvement except as follows: Subjects with previously treated CNS metastases that are adequately treated with whole brain radiotherapy, that are neurologically stable, and do not require corticosteroids for symptomatic management for at least 14 days prior to first dose of study drug. There must be no clear evidence of radiographically active disease for at least 90 days prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "3. Anti-tumor therapy within 21 days of study Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "4. Prior treatment with ibrutinib or other BTK inhibitor anti-CD137 or CTLA-4 antibody. The following are exceptions to this criterion: Subjects previously treated with an anti-PD1, anti-PD-L1, or anti-PD-L2 antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "5. History of allogeneic organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02403271",
    "statement": "6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Squamous Non-Small Cell Lung Cancer Disease (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Clinical Stage IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Measurable or nonmeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* No prior systematic chemotherapy, targeted therapy, surgery and chest radiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Ha resolution to Grade less than or equal to (≤) 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0, of all clinically significant toxic effects of prior therapy for other than NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Adequate-organ function defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Total bilirubin ≤1.5 x the upper limit of normal value (ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Serum creatinine ≤ 1.2 x ULN or calculated creatinine clearance (CrCL)\\>50 milliliter per minute (mL/min) (per the Cockcroft Gault formula or equivalent and/or 24-hour urine collection)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Absolute neutrophil count (ANC) greater than or equal to ≥1.5 x 10\\^3/μL(microliter)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Hemoglobin ≥10.0 g/dL(gram per deciliter)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Platelets ≥100 x 10\\^3/μL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* At least 20 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Estimated life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* A formalin-fixed, paraffin-embedded tumor tissue block or a minimum of 5 unstained slides of tumor sample prior to randomization for the evaluation of epidermal growth factor receptor (EGFR) protein expression (IHC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* If women: surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method (failure rate \\<1%) during and for 6 months after the treatment period (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method). If men: surgically sterile or compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has provided signed informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Participant has undergone major surgery within 28 days prior to enrollment or have planned major surgery, subcutaneous venous access device placement within 7 days prior to enrollment Phase 1b) or randomization (Phase 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has undergone any prior radiation therapy, except for Gamma Knife radiation and palliative radiation treatment at least 14 days have elapsed from last radiation treatment prior to enrollment (Phase 1b) or randomization (Phase 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has brain metastases that are symptomatic or require surgery, medication and radiotherapy except for stereotactic irradiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has superior vena cava syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has clinically relevant coronary artery disease or uncontrolled congestive - heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Participant has uncontrolled hypertension defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg despite standard medical management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has diabetes requiring insulin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has an angina or has experienced myocardial infarction within 6 months prior to enrollment (Phase 1b) or randomization (Phase 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has an Acquired Immunodeficiency Syndrome (AIDS)-related illness or have evidence of or test positive test results for human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has evidence of or test positive test results for hepatitis B, or hepatitis C virus antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has a known allergy and history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has significant third-space fluid retention requiring drainage",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has history of interstitial pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has an ongoing or active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has a history of significant neurological or psychiatric disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has a Grade 2 peripheral neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Pregnant (confirmed within 7 days prior to enrollment \\[Phase 1b\\] or randomization \\[Phase 2\\]), or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Has known history of drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763788",
    "statement": "* Assessed as inadequate for the study by the investigator or sub investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02509507",
    "statement": "≥ 18 years at the time of informed consent. Subjects must have histologically or cytologically confirmed disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02509507",
    "statement": "Part 1 is restricted to BC, CRC, GEC, melanoma, NSCLC, or RCC with liver metastases or HCC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02509507",
    "statement": "Part 2 Group A is restricted to advanced hormone receptor positive BC, CRC, TNBC, CSCC, and BCC with or without liver metastases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02509507",
    "statement": "* Part 2 Hormone receptor positive Breast Cancer Arm only: Histologically and/or cytologically confirmed diagnosis of estrogen receptor (ER) positive and/or progesterone receptor (PrR) positive breast cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02509507",
    "statement": "* Triple negative breast cancer: Histologically and/or cytologically confirmed diagnosis of ER negative, PrR negative, human epidermal growth factor receptor 2 (HER2)-Neu negative.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02509507",
    "statement": "Part 2 Group B is restricted to HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02509507",
    "statement": "For HCC subjects with a diagnosis of hepatitis B, they must be on antiviral therapy for at least 4 weeks prior to enrollment and hepatitis B virus (HBV) viral load by real-time polymerase chain reaction (qPCR) must be \\< 100 IU/mL. HCC subjects with past or ongoing hepatitis C infection must have completed treatment for hepatitis C at least 1 month prior to study enrollment and hepatitis C viral load must be undetectable; subjects with hepatitis B and C must fulfill the eligibility criteria for hepatitis B and hepatitis C. Subjects with unresectable locally recurrent TNBC are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02509507",
    "statement": "Non-HCC subjects must have received at least 1 prior standard of care systemic anti-cancer therapy for their locally advanced or metastatic disease. For the combination cohorts (Cohorts 5 and 6 in Part 1) and Part 2, subjects with melanoma CSCC or NSCLC do not need to have received prior therapy. In Part 1, subjects must have measurable liver tumors and liver tumors that are suitable for injection. In Part 2, subjects must have measurable disease and cutaneous, subcutaneous, lymph node, or liver tumors suitable for injection. NOTE: as of Protocol Amendment 6 \\[dated 26 October 2021\\], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study, enrollment for this study has stopped. Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1, and life expectancy should be approximately 5 months or more. Adequate hematological, renal, hepatic, and coagulation function is required. Liver function tests may be mildly abnormal but within the parameters. Child-Pugh score must be A.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02509507",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02509507",
    "statement": "-cancer therapy, with the exception of immunotherapy in the combination cohorts (Cohorts 5 and 6 in Part 1 and all subjects in Part 2). Liver tumors must not be estimated to invade approximately more than one-third of the liver. Liver tumor-directed therapy, hepatic surgery or major surgery, antibody-based therapy, or immunotherapy must not have been performed \\< 28 days, chemotherapy \\< 21 days, and targeted small molecule therapy or hormonal therapy \\< 14 days prior to enrollment. Subjects must either (1) have no central nervous system (CNS) metastasis, or carcinomatous meningitis, or (2) if CNS metastasis is present, must have stable treated cerebral metastases. Subjects must not have symptomatic auto-immune disease or be symptomatically immunosuppressed. They must not have a history of solid organ transplantation. For non-HCC, there must not be acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. For HCC with prior hepatitis B and/or C infection, HBV and/or HCV viral load by qPCR must be undetectable, and they must not have had recent treatment within 12 weeks for HBV or HCV with certain antiviral medications in Part 1 Group B cohorts 1-5 and 6a, and Part 2 Group B HCC without viral hepatitis. For all patients in Part 1 and for patients in Part 2 where intrahepatic liver injection is planned (NOTE: as of Protocol Amendment 6 \\[dated 26 October 2021\\], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study, enrollment for this study has stopped), there should be no macroscopic intravascular invasion of tumors into the main portal vein, hepatic vein, or vena cava. Subjects must not: have active herpetic skin lesions or prior complications of herpetic infection (eg, herpetic keratitis or encephalitis); require treatment with an antiherpetic drug; have received live-virus vaccination within 30 days of planned treatment start; have previous therapy with talimogene laherparepvec, oncolytic viruses, or tumor vaccine. Subjects in the combination treatment cohort must not have: a history or evidence of psychiatric, substance abuse, or any other clinically significant disorder; toxic effects of the most recent prior chemotherapy not resolved to grade 1 or less (except alopecia); or expected other cancer therapy while on study with the exception of local radiation to the site of bone or other metastasis for palliative treatment. Male subjects of reproductive potential in the combination treatment must be willing to use acceptable methods of effective contraception during treatment and through 4 months after the last dose of pembrolizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have histologically or cytologically confirmed squamous NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have stage IV disease at the time of study entry (American Joint Committee on Cancer \\[AJCC\\] Staging Manual, 7th edition).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have measurable disease at the time of study enrollment as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have tumor tissue available for biomarker analysis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have adequate organ functions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Are currently enrolled in another clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), or VEGF receptor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have received previous chemotherapy for advanced NSCLC. Participants who have received adjuvant or neoadjuvant chemotherapy are eligible if the last administration of the prior regimens occurred at least 1 year prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have undergone major surgery or received any investigational therapy in the 4 weeks prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have undergone systemic radiotherapy within 4 weeks prior to study entry, or focal radiotherapy within 2 weeks prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have a history of arterial or venous embolism within 6 months prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have clinical evidence of concomitant infectious conditions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have a known history of drug abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have a concurrent active malignancy. Participants with a history of malignancy are eligible provided the participant has been disease-free for ≥3 years, with the following exception: Participants with adequately treated basal or squamous cell carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancer that in the judgment of the investigator and Lilly clinical research physician/designee may not affect the interpretation of results (for example, prostate, bladder) are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02392507",
    "statement": "* Have discontinued investigational product or non approved use of a drug or device from a clinical trial within 30 days before the first day of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Histologically or cytologically confirmed advanced or metastatic NSCLC (Stage IIIB/C or IV per the AJCC Cancer Staging Manual, 8th Edition). Both squamous and nonsquamous NSCLC are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Radiographically measurable disease (per RECIST v1.1). Tumor lesions located in a previously irradiated area, or in an area subjected to other loco-regional therapy, are considered measurable if progression has been clearly demonstrated in the lesion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Documentation of known/likely actionable known or likely FGFR1-3 alterations.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Must have objective documented progression after at least 1 prior therapy, and must have no therapy available that is likely to provide clinical benefit. Participants who are intolerant of or decline the approved therapy are eligible only if they have no therapy available that is likely to provide clinical benefit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* ECOG performance status of 0 to 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Baseline archival tumor specimen (if less than 24 months from date of screening) or willingness to undergo a pretreatment tumor biopsy to obtain the specimen. Must be a tumor block or approximately 15 unstained slides from biopsy or resection of primary tumor or metastasis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Willingness to avoid pregnancy or fathering a child.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Prior receipt of a selective FGFR inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Receipt of anticancer medications or investigational drugs for any indication or reason within 28 days before the first dose of pemigatinib. Participants must have recovered (≤ Grade 1 as per CTCAE v5.0 or at pretreatment baseline) from AEs from previously administered therapies (excluding alopecia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Concurrent anticancer therapy (eg, chemotherapy, immunotherapy, biologic therapy, hormonal therapy, or investigational therapy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Candidate for potentially curative surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Current evidence of clinically significant corneal (including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis) or retinal disorder (including but not limited to macular/retinal degeneration, diabetic retinopathy, and retinal detachment) as confirmed by ophthalmologic examination.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Radiation therapy administered for the treatment of cancer lesions within 2 weeks before enrollment/first dose of study drug. Participants must have recovered from all radiation related toxicities, not require corticosteroids, and not have had radiation pneumonitis. Evidence of fibrosis within a radiation field from prior radiotherapy is permitted with medical monitor approval. A 1-week washout is permitted for palliative radiation to non-CNS disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Untreated brain or CNS metastases or brain or CNS metastases that have progressed (eg, evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain or CNS metastases). Participants who have previously treated and clinically stable brain or CNS metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and if they are on a stable or decreasing dose of corticosteroids for at least 1 week.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* Participants with defined laboratory values at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues (exception: commonly observed calcifications in soft tissues such as the skin, kidney tendon, or vessels due to injury, disease, or aging in the absence of systemic mineral imbalance).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05253807",
    "statement": "* History of hypovitaminosis D requiring supraphysiologic doses (eg, 50,000 UI/weekly) to replenish the deficiency. Vitamin D supplements are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Male or female subjects, age 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Subjects with histologically or cytologically confirmed NSCLC, MEL (including I/O relapsed MEL or I/O refractory MEL), CRC, SCCHN, ovarian cancer, recurrent B cell NHL or HL, or glioblastoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Presence of measurable disease by RECIST v1.1 for solid tumors or Cheson criteria for B cell NHL (including DLBCL) or HL. For subjects with glioblastoma, presence of measurable disease is not required.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Fresh baseline tumor biopsies (defined as a biopsy specimen taken since completion of the most recent prior chemotherapy regimen) are required for all cohorts except glioblastoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Laboratory and medical history parameters not within Protocol-defined range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Currently pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Subjects who have received prior immune checkpoint inhibitors or an IDO inhibitor (except select Phase 2 cohorts evaluating I/O relapsed or I/O refractory MEL). Subjects who have received experimental vaccines or other immune therapies should be discussed with the medical monitor to confirm eligibility",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Untreated central nervous system (CNS) metastases or CNS metastases that have progressed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Subjects with any active or inactive autoimmune process",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Evidence of interstitial lung disease or active, noninfectious pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Subjects with any active or inactive autoimmune process",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02327078",
    "statement": "* Ocular MEL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00661778",
    "statement": "* Adult patients, ≥ 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00661778",
    "statement": "* Stage IIIb or IV non-small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00661778",
    "statement": "* Chemotherapy-naive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00661778",
    "statement": "* Previous treatment for non-small cell lung cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00661778",
    "statement": "* Previous malignant tumor within last 5 years, except for basal cell skin cancer or preinvasive cervical cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00661778",
    "statement": "* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to start of study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00661778",
    "statement": "* Recent or current chronic treatment with aspirin (\\> 325 mg/day).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Histologically or cytologically documented unresectable stage III non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Documented stable disease or objective response, according to Response Evaluation Criteria in Solid Tumors (RECIST), after primary chemoradiotherapy (either sequential or concomitant) for unresectable stage III disease, within 4 weeks (28 days) prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Receipt of concomitant or sequential chemoradiotherapy, consisting of a minimum of two cycles of platinum-based chemotherapy and a minimum radiation dose of \\>=50 Gray (Gy). Subjects must have completed the primary thoracic chemo-radiotherapy at least four weeks (28 days) and no later than 12 weeks (84 days) prior to randomization. Subjects who received prophylactic brain irradiation as part of primary chemo-radiotherapy are eligible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Geographically accessible for ongoing follow-up, and committed to comply with the designated visits",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* An Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* A platelet count \\> 140 x 10\\^9/Liter; white blood cells (WBC) \\> 2.5 x 10\\^9/Liter and hemoglobin \\> 90 gram per liter (g/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "-Therapies:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Undergone lung cancer specific therapy (including surgery) other than primary chemo-radiotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Receipt of immunotherapy (e.g. interferons, tumor necrosis factor \\[TNF\\], interleukins, or biological response modifiers \\[granulocyte macrophage colony stimulating factor {GM-CSF}, granulocyte colony stimulating factor {G-CSF}, macrophage-colony stimulating factor {M-CSF}\\], monoclonal antibodies) within 4 weeks (28 days) prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Receipt of investigational systemic drugs (including off-label use of approved products) within 4 weeks (28 days) prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "Disease Status:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Malignant pleural effusion at initial diagnosis and/or at study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* A recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary or congenital immunodeficiencies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Any preexisting medical condition requiring chronic steroid or immunosuppressive therapy (steroids for the treatment of radiation pneumonitis are allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Known Hepatitis B and/or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "Physiological Functions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Clinically significant hepatic dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Clinically significant renal dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Clinically significant cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Splenectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Infectious process that in the opinion of the investigator could compromise the subject's ability to mount an immune response",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "Standard Safety:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Pregnant or breast-feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Known drug abuse/alcohol abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409188",
    "statement": "* Legal incapacity or limited legal capacity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Receipt of concomitant or sequential chemoradiotherapy, consisting of a minimum of two cycles of platinum-based chemotherapy and a minimum radiation dose of greater than or equal to (\\>=) 50 Gray (Gy). Participant must have completed the primary thoracic chemoradiotherapy at least 4 weeks and no later than 12 weeks prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Written informed consent given before any study-related activities are carried out.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Histologically or cytologically documented unresectable stage III NSCLC. Cancer stage must be confirmed and documented by Computed Tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Documented stable disease or objective response, according to RECIST, after primary chemoradiotherapy for unresectable stage III disease, within four weeks prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Receipt of concomitant or sequential chemoradiotherapy, consisting of a minimum of two cycles of platinum-based chemotherapy and a minimum radiation dose of \\>= 50 Gy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Eastern cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Adequate bone marrow function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Greater than or equal to 20 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Lung cancer-specific therapy (including surgery), other than primary chemoradiotherapy. Note: exploratory surgery before study entry is allowed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Immunotherapy (e.g., interferons, tumor necrosis factor \\[TNF\\], interleukins, or biological response modifiers \\[granulocyte macrophage colony stimulating factor {GM-CSF}, granulocyte colony stimulating factor {G-CSF}, macrophage-colony stimulating factor {M-CSF}\\], monoclonal antibodies) received within four weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Malignant pleural/pericardial effusion or pleural dissemination or separate tumor nodules in the same lobe at initial diagnosis and/or at study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Past or current history of neoplasm other than lung carcinoma, except for adequately treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least five years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* A recognized immunodeficiency disease including cellular immunodeficiencies, hypogamma-globulinemia, or dysgammaglobulinemia; participants who have hereditary or congenital/acquired immunodeficiencies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Any preexisting medical condition requiring chronic steroid or immunosuppressive therapy, including presence of diffuse radiation pneumonitis spreading out of the involved field",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Known Hepatitis B and/or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Clinically significant hepatic dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Clinically significant renal dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Clinically significant cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Splenectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Infectious process that, in the opinion of the investigator, could compromise the subject's ability to mount an immune response",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Pregnant or breast-feeding women. Participants whom the investigator considers may be at risk of pregnancy will have a pregnancy test performed per institutional standard. Male and female subjects who have a reproductive ability, unless using effective contraception as determined by the investigator throughout the study until at least 6 months after the last study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Known drug abuse or alcohol abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00960115",
    "statement": "* Legal incapacity or limited legal capacity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": ". Age ≥ 18 years, male or female;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "2. Histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "* Patients scheduled to receive carboplatin plus etoposide regimen: no prior systemic therapy (eg, chemotherapy or combined with immunotherapy);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "* Patients scheduled to receive topotecan regimen: previously received 1/2 lines of chemotherapy or combined immunotherapy but not topotecan.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "3. Presence of at least one radiation-naïve measurable lesion according to RECIST 1.1 criteria;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "4. Hemoglobin ≥ 90 g/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "5. Neutrophil count ≥ 1.5 × 10\\^9/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "6. Platelet count ≥ 100 × 10\\^9/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "7. Creatinine ≤ 15 mg/L or creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault formula);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "8. Total bilirubin ≤ 1.5 × upper limit of normal (ULN);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN or ≤ 5 × ULN (for patients with liver metastases);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "10. Albumin ≥ 30 g/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "11. ECOG PS score 0 - 2;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "12. Expected survival time ≥ 3 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "13. Contraception:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "    Females: All females of childbearing potential must have a negative serum pregnancy test at screening and must use reliable contraception from signing of informed consent through 3 months after the last dose; Male: Female partners of childbearing potential must use reliable contraception from signing the informed consent until 3 months after the last dose;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "14. Understand and sign informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": ". Symptomatic brain metastases requiring local radiotherapy or hormonal therapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "2. History of other malignancies, with the following exceptions: (1) clinically cured cutaneous basal cell or squamous cell tumors; (2) cured a) cervical cancer, b) prostate cancer, c) superficial bladder cancer; or (3) other solid tumors with a clinical cure time of more than 3 years;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "3. Uncontrolled ischemic heart disease or clinically significant congestive heart failure (NYHA Class III or IV);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "4. Stroke or cardiovascular or cerebrovascular event within 6 months prior to enrollment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "5. Severe active infection;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "6. Psychological or other social factors causing insufficient trial compliance;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "7. Other uncontrolled serious chronic diseases or conditions that, in the opinion of the investigator, would make participation in the trial inappropriate;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "8. Known HIV infection, active hepatitis B (defined as positive HBV DNA), and hepatitis C (positive HCV RNA);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "9. Radiation therapy within 2 weeks prior to enrollment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "10. Patients who have received cytotoxic drug therapy or investigational drug therapy within 4 weeks before enrollment, or non-cytotoxic anti-tumor drug therapy within 2 weeks;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "11. Subjects in the first part of the study should not take strong or moderate inducers of CYP3A4 concomitantly within 4 weeks before taking the study drug, and strong inhibitors of CYP3A4 concomitantly within 2 weeks before taking the study drug;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "12. Toxicity from prior anticancer therapy has not recovered to Grade 0 or 1 (except alopecia);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "13. Hypersensitivity to the study drug (Trilaciclib, etoposide, carboplatin, topotecan) or components thereof;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "14. Persons who are unable to act independently due to legal restriction or legal sense;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "15. Pregnant or lactating women;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04902885",
    "statement": "16. Not suitable for participating in this study in the investigator 's opinion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": ". Subjects with a confirmed or suspected diagnosis of stage IA to stage IIB non-small cell lung cancer scheduled for lobectomy (Lung Cancer Staging per American Joint Committee on Cancer,7th Edition)7;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "2. Subjects scheduled for VATS lobectomy in accordance with their institution's SOC;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "3. Performance status 0-1 (Eastern Cooperative Oncology Group classification);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "4. ASA score \\< 3;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "5. No prior history of VATS or open lung surgery (on the lung in which the procedure will be performed);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "6. Willing to give consent and comply with study-related evaluation and treatment schedule; and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "7. 18-75 years of age (inclusive).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": ". Active (subject currently receiving systemic treatment) bacterial infection or fungal infection;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "2. Systemic administration (intravenous or oral) of steroids, including herbal supplements that contain steroids (within 30 days prior to study procedure);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "3. Uncontrolled diabetes mellitus;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "4. End stage renal or liver disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "5. History of severe cardiovascular disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "6. FEV1% \\<50% or severe COPD;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "7. Prior chemotherapy or radiation for lung cancer;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "8. Scheduled concurrent surgical procedure other than diagnostic wedge resection followed by lobectomy (central venous access - e.g., port placement, mediastinoscopy with lymph node sampling, and VATS lymphadenectomy are allowed);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "9. Robotic-assisted procedure;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "10. Women who are pregnant or lactating at the time of screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "11. Physical or psychological condition which would impair study participation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "12. The subject is judged unsuitable for study participation by the Investigator for any other reason;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "13. Participation in any other investigational drug (within 30 days or 5 half-lives of an investigational drug) or device study; or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03056300",
    "statement": "14. Unable or unwilling to attend follow-up visits and examinations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121575",
    "statement": "* advanced non small cell lung cancer (dose escalation phase)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121575",
    "statement": "* acquired resistance to erlotinib or gefitinib (expansion phase)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121575",
    "statement": "* mandatory entrance biopsy (expansion phase)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121575",
    "statement": "* interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121575",
    "statement": "* unstable brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01121575",
    "statement": "* leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01987232",
    "statement": ". Histologically or cytologically confirmed diagnosis of extensive-stage small-cell lung cancer (ES-SCLC) with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; ES-SCLC is defined as: small-cell lung cancer (SCLC) that has spread beyond one hemithorax and regional lymph nodes on the same side (e.g., supraclavicular) to the contralateral hemithorax, lymph nodes, or more distant locations in the body",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01987232",
    "statement": "2. Subjects with asymptomatic brain metastases or other central nervous system (CNS) disease at screening/diagnosis are eligible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01987232",
    "statement": "3. Males and females ≥ 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01987232",
    "statement": "4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01987232",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01987232",
    "statement": ". Previous systemic therapy to treat small-cell lung cancer (SCLC). Subjects with recurrent or progressive limited-stage SCLC after previous systemic treatment are not eligible for study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01987232",
    "statement": "2. Whole brain or focal radiation therapy within 14 days prior to Cycle 1 Day 1 (C1D1) for Phase 1b or prior to randomization for Phase 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01987232",
    "statement": "3. Congestive heart failure (New York Heart Association \\[NYHA\\] class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction within 6 months prior to prior to C1D1 for Phase 1b or prior to randomization for Phase 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant is \\>=18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has any histologically or cytologically confirmed advanced (unresectable) or metastatic solid tumor and has PD after treatment with available therapies that are known to confer clinical benefit or who are intolerant to treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant must have an archival tumor tissue sample that is formalin-fixed and paraffin-embedded (FFPE) (blocks preferred over slides) and requested and confirmed available from offsite locations prior to dosing. The quality and quantity of the sample must be confirmed sufficient as per the Study Laboratory Manual. Participants who do not have archival tissue must agree to a new biopsy to obtain fresh tumor tissue prior to dosing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Part 1b (PK/PDy cohort): The participant must have lesions amenable for biopsy and agree to undergo biopsies for fresh tumor tissue prior to treatment, approximately 4 to 6 weeks after treatment, and, whenever possible, at the time of PD and /or end of treatment (EOT). Serial biopsies are optional for participants in Part 1a and 1c.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Female participants must have a negative serum or urine pregnancy test within 72 hours prior to the date of the first dose of study medication if of childbearing potential or be of non-childbearing potential. Non-childbearing potential is defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Participants \\>=45 years of age and has not had menses for \\>1 year.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Amenorrheic for \\<2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Post hysterectomy, bilateral oophorectomy, or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Female participants of childbearing potential (that is \\[ie\\], those who do not meet above criteria) must agree to use 2 highly effective forms of contraception with their partners, starting with the screening visit through 150 days after the last dose of study therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant must have an ECOG PS of \\<=1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has adequate hematologic and organ function, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Absolute neutrophil count (ANC) \\>=1500 per microliter (/μL).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Platelets \\>=100,000/μL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Hemoglobin (Hb) \\>=9 grams per deciliter (g/dL) or \\>=5.6 millimoles per liter (mmol/L).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Serum creatinine \\<=1.5 times upper limit of normal (× ULN) or calculated creatinine clearance (CrCL) \\>=50 milliliters per minute (mL/min) using Cockcroft-Gault equation for participants with creatinine levels \\>1.5 × institutional ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Total bilirubin \\<=1.5 × ULN and direct bilirubin \\<=1× ULN (in the event that the total bilirubin result exceeds the upper institutional limits of normal, direct bilirubin will be obtained to determine eligibility).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* AST and ALT \\<=2.5 × ULN unless liver metastases are present, in which case they must be \\<=5 × ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* INR of PT \\<=1.5 × ULN, unless participant is receiving anticoagulant therapy, then PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants; aPTT) \\<= 1.5 × ULN unless participant is receiving anticoagulant therapy, then PT or PTT is within therapeutic range of intended use of anticoagulants.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "Inclusion criteria for participants in Part 2:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant is \\>= 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has any histologically or cytologically confirmed CRC that is metastatic or not amenable to potentially curative resection (advanced), in the opinion of the Investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has a primary and/or metastatic tumor(s) that is known to be MSS, as determined locally.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant must have lesions amenable for biopsy and agree to undergo biopsies for fresh tumor tissue prior to treatment, approximately 4 to 6 weeks after, and, whenever possible, at EOT and/or the time of PD. If the participant has had a biopsy prior to entering the 28-day screening period, and within approximately 12 weeks of study treatment, that biopsy sample may be accepted as the Baseline fresh biopsy. Additionally, submission of sufficient high-quality archival tumor tissue is recommended, if available, to enable a longitudinal analysis of tumor biomarkers.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has measurable disease by RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has resolution to Grade \\<=1, per CTCAE v5.0, of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy, with the exception of peripheral neuropathy, which must have resolved to Grade \\<=2, and except where otherwise noted in the eligibility criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Female participants must have a negative serum or urine pregnancy test within 72 hours prior to the date of the first dose of study medication if of childbearing potential or be of non-childbearing potential. Non-childbearing potential is defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Participants \\>=45 years of age and has not had menses for \\>1 year.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Amenorrheic for \\<2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Post hysterectomy, bilateral oophorectomy, or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Female participants of childbearing potential (ie, those who do not meet above criteria) must agree to use 2 highly effective forms of contraception with their partners, starting with the screening visit through 150 days after the last dose of study therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has an ECOG PS of \\<=1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has adequate hematologic and organ function, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* ANC \\>=1500/μL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Platelets \\>=100,000/μL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Hb \\>=9 g/dL or \\>=5.6 mmol/L.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Serum creatinine \\<=1.5 × ULN or calculated CrCL \\>=50 mL/min using Cockcroft-Gault equation for participants with creatinine levels \\>1.5 × institutional ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Total bilirubin \\<=1.5 × ULN and direct bilirubin \\<=1× ULN (in the event that the total bilirubin result exceeds the upper institutional limits of normal, direct bilirubin will be obtained to determine eligibility).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* AST and ALT \\<=2.5 × ULN unless liver metastases are present, in which case they must be \\<=5 × ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* INR of PT \\<=1.5 × ULN, unless participant is receiving anticoagulant therapy, then PT or PTT is within therapeutic range of intended use of anticoagulants; aPTT) \\<= 1.5 × ULN unless participant is receiving anticoagulant therapy, then PT or PTT is within therapeutic range of intended use of anticoagulants.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Urinary protein is \\<=1+ on dipstick for routine urinalysis; if urine protein \\>=2+, a 24-hour urine sample must be collected and must demonstrate \\<1000 mg of protein in 24 hours to allow participation in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Baseline albumin \\>=3.0 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "Inclusion Criteria for participants in Part 2A:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant must have had at least 2, but no more than 3, prior lines of therapy in the advanced or metastatic setting. Adjuvant chemotherapy with radiographic progression \\>12 months after the last dose will not be considered a line of therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has progressed on standard therapies or withdrawn from standard treatment due to unacceptable toxicity. Previous standard treatment must include all of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Fluoropyrimidine.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Oxaliplatin: Participants treated with oxaliplatin in adjuvant setting should have progressed after 12 months of completion of adjuvant therapy or they must have been treated with oxaliplatin for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Irinotecan.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Participants whose disease is known to be RAS-wild-type must have been treated with cetuximab, panitumumab, or other epidermal growth factor receptor (EGFR) inhibitor for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Bevacizumab and/or another anti-angiogenic agent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* Previous treatment with regorafenib and/or TAS-102 are allowed in the absence of contraindications and if these agents are available to the participant according to local standards.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The time between a participants's last chemotherapy and enrollment must be \\<=8 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "Inclusion Criteria for participants in Part 2B:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has received \\<=2 prior systemic chemotherapy regimens in any setting (only 1 prior regimen for metastatic disease is permitted).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "Inclusion Criteria for participants in Part 2 Cohort B1:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has received first-line combination therapy consisting of bevacizumab or anti-EGFR antibodies with FOLFIRI and has experienced radiographic progression during or after first-line therapy. Radiographic progression \\>12 months after the last dose of adjuvant therapy will not be considered a line of therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* mFOLFOX6 therapy with bevacizumab is appropriate for the participant and is recommended by the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "Inclusion Criteria for participants in Part 2 Cohort B2:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has received first-line combination therapy consisting of bevacizumab or anti-EGFR antibodies with FOLFOX (or variant) and has experienced radiographic progression during or after first-line therapy. Radiographic progression \\>12 months after the last dose of adjuvant therapy will not be considered a line of therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* FOLFIIRI therapy with bevacizumab is appropriate for the participant and is recommended by the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has previously been treated with an anti-LAG-3 antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has known uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has a known concurrent, serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy, including human immunodeficiency virus (HIV), known active hepatitis B or hepatitis C, active infection, or active autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has a history of interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has not recovered (ie, to Grade \\<=1 or to Baseline) from radiation- and chemotherapy-induced AEs, has received transfusion of blood products (including platelets or red blood cells), or has received administration of colony stimulating factors (including granulocyte colony-stimulating factor \\[G-CSF\\], granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 3 weeks prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant is currently participating in an investigational study (therapy or device) or has participated in an investigational study within 4 weeks prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days or less than 5 times the half-life of the most recent therapy prior to the first dose of the drug, whichever is shorter.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has received wide-field (full-dose pelvic) radiotherapy within 28 days prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has experienced any arterial thrombotic or arterial thromboembolic events, including, but not limited to myocardial infarction, transient ischemic attack, or cerebrovascular accident, within 12 months prior to first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has received a prior autologous or allogeneic organ or transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has undergone major surgery within 28 days or subcutaneous venous access device placement within 7 days prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has had a serious non-healing wound, ulcer, or bone fracture within 28 days prior to first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has an elective or planned major surgery to be performed during the course of the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has a history of inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) in the 12 months prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has an acute or subacute bowel obstruction, abdominal fistula, or history of chronic diarrhea which is considered clinically significant, in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has experienced a Grade \\>=3 bleeding event within 3 months prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has either peptic ulcer disease associated with a bleeding event or known active diverticulitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has not recovered (Grade \\>=1) from AEs and/or complications from any major surgery prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has received a vaccine within 7 days of the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has known hypersensitivity to TSR-033, dostarlimab (Part 1c and Part 2), or associated excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "Exclusion Criteria for participants in Part 1:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant's prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-LAG-3 agent that resulted in permanent discontinuation due to an AE.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "Exclusion Criteria for participants in Part 2:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has been previously treated with an anti-PD-1 or anti-PD-L1 antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "Exclusion Criteria for participants in Part 2B:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has known dihydropyrimidine dehydrogenase deficiency.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant experienced an arterial thrombotic/thromboembolic event, Grade 4 hypertension, Grade 4 proteinuria, a Grade 3-4 bleeding event, or bowel perforation during first-line therapy with a bevacizumab-containing regimen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant has known hypersensitivity to bevacizumab, mFOLFOLX6 (Cohort B1) or FOLFIRI (Cohort B2), or associated excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03250832",
    "statement": "* The participant experienced PD within 12 months of last dose of adjuvant therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Healthy participants of non-child bearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Body weight between 50 to 100 kilogram (kg)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Body mass index (BMI) between 18.5 and 29.9 kilogram per meter square (kg/m\\^2)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* A male participant must agree to use and to have his female partner of childbearing potential to use highly effective method of contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Participant must have given written informed consent before any study-related activities",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* All values for hematology, coagulation, and biochemistry tests of blood and urinalysis are within the normal range. Minor (solitary) non-clinically relevant deviation(s) are allowed as judged by the Investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Other protocol defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Participation in a clinical study within 60 days prior to first drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Whole blood donation or loss of \\> 450 milliliter (mL) within 60 days prior to first drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Any surgical or medical condition, or any other significant disease that could interfere with the study objectives, conduct, or evaluation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Supine systolic blood pressure (SBP) greater than (\\>) 140 millimeter of mercury (mmHg) or less than (\\<) 90 mmHg, diastolic blood pressure (DBP) \\> 90 or \\< 50 mmHg, and pulse rate \\> 90 or \\<50 beats per minute (bpm) at Screening and at admission on Day-1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* 12-Lead electrocardiograms (ECG) showing a corrected QT interval per Fridericia's formula (QTcF) \\> 450 milliseconds (ms), PR \\> 215 ms, or QRS \\> 120 ms (at Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Creatinine clearance estimated glomerular filtration rate (eGFR) \\< 90 milliliter per minute (mL/min) (at Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Participants with gall bladder removal or other relevant surgery of gastrointestinal tract",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* History of any malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* History of epilepsy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Participants who in the Investigator's judgment were perceived as having an increased risk of bleeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Positive screen for alcohol or drugs of abuse (at Screening and Day -1)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), and human immunodeficiency virus 1 and 2 antibodies (HIV1/HIV2 antibodies) (at Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Excessive consumption of xanthine-containing food or beverages before study drug administration until collection of last pharmacokinetic (PK) sample in each period (at Screening and Day -1)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Receipt of any prescription or nonprescription medication within 14 days or 5 half-lives, before study drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Smoker or former smoker who stopped smoking less than 6 months before the time of the Screening Visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Intake of grapefruit, Seville orange, cranberry or juices of these 3 fruits, or St. John's Wort, from 14 days prior to Day -1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Inability to communicate or cooperate with the Investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Other factors, which in the opinion of the Investigator may interfere with study conduct (at Screening and Day -1 of first Period only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Legal incapacity or limited legal capacity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Participants kept in detention",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03492437",
    "statement": "* Other protocol defined exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00441337",
    "statement": "* Relapsed/refractory non-small cell lung cancer, colorectal adenocarcinoma, malignant melanoma, renal (clear) cell carcinoma, or hormone-refractory prostate adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00441337",
    "statement": "* Prior treatment must have been completed at least 4 weeks prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00441337",
    "statement": "* No untreated primary or metastatic brain or meningeal tumors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00441337",
    "statement": "* ECOG PS 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00441337",
    "statement": "* Meet all screening laboratory values",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00441337",
    "statement": "* History of severe hypersensitivity reactions to other monoclonal antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00441337",
    "statement": "* Active autoimmune disease or a documented history of autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00441337",
    "statement": "* Prior therapy with an anti-PD-1 or anti-CTLA-4 antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00441337",
    "statement": "* Active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00441337",
    "statement": "* Concurrent medical condition requiring the use of immunosuppressive medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01451632",
    "statement": "* No standard options remaining",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01451632",
    "statement": "* Adequate liver and kidney functions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01451632",
    "statement": "* 18 years of age or above",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01451632",
    "statement": "* History of any secondary active cancer in the last 3 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01451632",
    "statement": "* Pregnant or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01451632",
    "statement": "* History of severe allergic reactions or contraindications to cetuximab or irinotecan",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Aged at least 18 years. Patients from Japan aged at least 20 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Histological or cytological confirmation diagnosis of Non Small Cell Lung Cancer (NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI e.g. gefitinib or erlotinib (with the exception of 1st line expansion cohort). In addition other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Patients (with the exception of 1st line expansion cohort) must fulfil one of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Confirmation that the tumour harbours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Must have experienced clinical benefit from EGFR TKI, according to the Jackman criteria (Jackman et al 2010) followed by systemic objective progression (RECIST or WHO) while on continuous treatment with EGFR TKI.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Previous treatment with a single-agent EGFR TKI (e.g. gefitinib or erlotinib).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Females should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to start of dosing or evidence of non-child bearing potential.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Male patients should be willing to use barrier contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* For 1st Line expansion cohort ONLY, confirmation that the tumour is EGFRm+ve and have had no prior therapy for their advanced disease (for 1st line patients biopsy will be at time of diagnosis of advanced disease).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* For dose expansion and extension cohorts, patients must also have confirmation of tumour T790M mutation status (confirmed positive or negative) from a biopsy sample taken after disease progression on the most recent treatment regimen (irrespective of whether this is EGFR TKI or chemotherapy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "Prior to entry a result from the central analysis of the patient's T790M mutation status must be obtained.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* World Health Organisation (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Treatment with an EGFR TKI (erlotinib or gefitinib) within 8 days (approximately 5x half-life) of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from the treatment of advanced NSCLC from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* AZD9291 in the present study (ie, dosing with AZD9291 previously initiated in this study).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01802632",
    "statement": "* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "* General and Demographics",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  1. Age ≥ 18 years of age at the time of signing the Informed Consent Form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  2. Understand and voluntarily provide written consent to the Informed Consent Form prior to conducting any study related assessments/procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  3. Able to adhere to the study visit schedule and other protocol requirements. Disease Specific",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  4. Histologically or cytologically confirmed Stage IIIB or IV Non-Small Cell Lung Cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  5. Radiographically documented measurable disease at study entry per response evaluation criteria in solid tumours ( RECIST) v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  6. No prior anti-cancer therapy for the treatment of metastatic disease at the time of signing the ICF. Adjuvant treatment is permitted providing cytotoxic chemotherapy was completed 12 months prior to signing the ICF and without disease recurrence.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  7. Absolute neutrophil count (ANC) ≥ 1500 cells/mm3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  8. Platelets ≥ 100,000 cells/mm3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  9. Hemoglobin (Hgb) ≥ 9 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  10. Aspartate transaminase (AST/serum glutamic oxaloacetic transaminase \\[SGOT\\]), alanine transaminase (ALT/serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 2.5 × upper limit of normal range (ULN) or ≤ 5.0 × ULN if liver metastases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  11. Total bilirubin ≤ 1.5 × ULN except in cases of Gilbert's disease and liver metastases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  12. Serum creatinine ≤ 1.5 x ULN, or calculated creatinine clearance ≥ 40 mL/min (if renal impairment is suspected 24-hour urine collection for measurement is required).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  13. Eastern Cooperative Oncology Group Performance Status 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  14. Females of childbearing potential \\[defined as a sexually mature woman who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months)\\] must:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "      1. Have a negative pregnancy test Beta Human Chorionic Gonaditrophin(ß-hCG) as verified by the study doctor within 72 hours prior to starting study therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "      2. You must commit to complete abstinence from heterosexual contact, or agree to use medical doctor-approved contraception throughout the study without interruption; while receiving study medication or for a longer period if required by local regulations.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "         Male subjects must:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "      3. practice true abstinence\\* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 6 months following study drug discontinuation, even if he has undergone a successful vasectomy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "* The presence of any of the following will exclude a subject from enrollment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  1. Evidence of active brain metastases, including leptomeningeal involvement (prior evidence of brain metastasis are permitted only if treated and stable and off therapy for at least 21days prior to signing ICF). MRI of the brain (or CT scan w/contrast) is preferred for diagnosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  2. History of leptomeningeal disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  3. Only evidence of disease is non-measurable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  4. Pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per Criteria for Adverse Events (CTCAE) v4.0).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  5. Subject has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting investigational product (IP), and/or from whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  6. Venous thromboembolism within 1 month prior to signing ICF.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  7. Current congestive heart failure (New York Heart Association Class II-IV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  8. History of the following within 6 months prior to first administration of investigational product: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant ECG abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  9. Subject has a known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  10. Subject has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  11. History of interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or pulmonary hypersensitivity pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  12. Treatment with any investigational product within 28 days prior to signing the ICF.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  13. History of or suspected allergy to nab-paclitaxel, carboplatin and human albumin or any other platinum-based therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  14. Currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  15. Any other clinically significant medical condition, psychiatric illness, and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol or which, in the views of investigator, preclude combination chemotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  16. Subject has any other malignancy within 5 years prior to signing the ICF. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (Tumor, node and metastasis (TNM) stage of T1a or T1b). All treatment should have been completed 6 months prior to signing ICF.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  17. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  18. Any medical condition that confounds the ability to interpret data from the study. This includes subjects with known psychiatric disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  19. Pregnant or breast-feeding females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289456",
    "statement": "  20. Subjects with an ECOG PS other than 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Participants greater than or equals to (\\>=) 18 years of age inclusive at the time of signing the informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Participants who have histologically confirmed diagnosis of Stage IV NSCLC:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "  1. Participants in Cohort A, B, and C must not have received prior systemic therapy treatment for their Stage IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "  2. Participants who had disease progression on previous treatment with Programmed death-ligand 1 (PD- L1) inhibitors in combination with platinum-based chemotherapy are enrolled in Cohort D, as long as therapy was completed at least 28 days of the first study intervention.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Have measurable disease based on Response evaluation criteria in solid tumors (RECIST) 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Have a life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Availability of archived tumor material (less than \\[\\<\\] 6 months old) adequate for biomarker analysis is mandatory at Screening, central laboratory confirmation is required. Fresh biopsies should be collected if archived tumor material is not available",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study entry and date of first dose",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* The participant's tumor harbors an epidermal growth factor receptor (EGFR) sensitizing (activating) mutation,ROS1 rearrangement, or BRAF V600E mutation or anaplastic lymphoma kinase (ALK) positive, if targeted therapy is locally approved",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Mixed small cell with NSCLC cancer histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Has received major surgery within 4 weeks prior to the first dose of study intervention; received thoracic radiation therapy (RT) of \\> 30 gray (Gy) within 6 months prior to the first dose of study intervention",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Previous malignant disease (other than the target malignancy to be investigated in this study) within the last 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 2 weeks after the end of the RT and, have no evidence of new or enlarging brain metastases evaluated by imaging, preferably brain magnetic resonance imaging (MRI)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Known severe hypersensitivity to study intervention or any components in their formulations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* For participants in Cohort A, B and C: Has received prior systemic therapy for Stage IV NSCLC, including anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03840915",
    "statement": "* Unable to tolerate computed tomography (CT) or MRI in the opinion of the Investigator and/or allergy to contrast material.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Histologically or cytologically confirmed non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Documented progression of disease (locally recurrent or metastatic) per investigator assessment following first-line treatment with 4-6 cycles of Bevacizumab plus a platinum doublet-containing chemotherapy regimen and a minimum of 2 cycles of Bevacizumab (monotherapy) maintenance treatment prior to first progression of disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* No treatment interruption of Bevacizumab treatment greater than 2 consecutive cycles (42 days) between the start of first-line treatment to start of Cycle 1 of second line treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Randomization within 4 weeks of progression of disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* At least one unidimensionally measurable lesion meeting RECIST v1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Participants with adequate hematological, liver, and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Female participants must not be pregnant or breast-feeding. Female participants of childbearing potential and fertile male participants must agree to use a highly effective contraceptive during the trial and for a period of at least 6 months following the last administration of trial drug(s)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Epidermal growth factor receptor (EGFR)-mutation-positive disease according to local laboratory testing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* History of hemoptysis greater than or equal to (\\>/=) grade 2 within 3 months of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding and active gastrointestinal bleeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Major cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Treatment with any other investigational agent within 28 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Known hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs foreseen",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01351415",
    "statement": "* Malignancy other than NSCLC within 5 years prior to randomization and evidence of any other disease that contraindicates the use of an investigational or SOC drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": ". Patient willing and able to sign the informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "2. Patients age ≥18 years at signing the informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "3. Life expectancy \\> 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "4. Histologically confirmed diagnosis of advanced or metastatic solid tumors, disease should have progressed following at least one line of therapy and no other standard therapy with proven clinical benefit is available or recommended based on the investigator's individual risk-benefit assessment for the patient.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "5. Patients with secondary metastasis to the central nervous system (CNS) are eligible if they have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to trial day 1 and they meet all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "   1. Residual neurological symptoms ≤Grade 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "   2. No glucocorticoids requirement or patients may be receiving low doses of glucocorticoids providing the dose has been stable for at least 2 weeks prior to starting the trial medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "   3. Follow-up imaging studies show no progression of treated lesions and no new lesions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "6. Evaluable disease; measurable on imaging as assessed by RECIST version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "7. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "8. Absolute neutrophil count (ANC) (polymorphonuclear cells \\[PMN\\] plus bands) \\>1,000/ μL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "9. Platelets ≥100,000 μL. Platelet transfusions within the 14 days before Day 1 of Cycle 1 is prohibited.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "10. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 3 upper limit of normal (ULN). In cases with liver involvement ALT/ AST ≤ 5× ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "11. Total bilirubin ≤1.5 mg/dL unless elevated due to known Gilbert's syndrome.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "12. Creatinine ≤1.5 ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "13. Serum potassium and magnesium at least at the lowest limit of normal (LLN), before every IMP administration. If it is below the LLN, supplementation is permissible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "14. Female study participants of child-bearing potential and their partners, and male study participants who intend to be sexually active with a woman of child-bearing potential, must be willing to use at least two (2) highly effective forms of contraception. This should start from the time of study enrollment and continue throughout IMP administration. For female study participants of child-bearing potential this must continue using contraception for at least six (6) months after the last administration of the IMP. Female study participants should be willing to have a pregnancy test performed at screening, ≤ 1 day prior to day 1 of each IMP administration and at study treatment discontinuation. Male study participants who are sexually active with a woman of child-bearing potential should also use a condom during treatment and for at least ninety (90) days after the last administration of IMP. Vasectomized males are considered fertile; therefore, vasectomized partners and patients must be willing to use a secondary method of effective birth control. Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the trial treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": ". All eligible patients were treated with Tinostamustine employing sequential enrollment (i.e. as they qualify for participation). In the first phase of the trial (Phase 1), the dose received for each eligible patient was dependent on the requirements of the dose escalation scheme at the time the patient was enrolled. In the second phase of the trial (Phase 2), all patients were treated with the Tinostamustine at 80 mg/m2 administered over 1 hour on Day 1 and 15 of each 4-week treatment cycle.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "General Inclusion Criteria for Phase 1 and Phase 2 portions of Study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "1. Patient willing and able to sign the informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "2. Patients age ≥18 years at signing the informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "3. Life expectancy \\> 3 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "4. Histologically confirmed diagnosis of advanced or metastatic solid tumors, disease should have progressed following at least one line of therapy and no other standard therapy with proven clinical benefit is available or recommended based on the investigator's individual risk-benefit assessment for the patient.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "5. Patients with secondary metastasis to the central nervous system (CNS) are eligible if they have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to trial day 1 and they meet all of the following criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "   1. Residual neurological symptoms ≤Grade 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "   2. No glucocorticoids requirement or patients may be receiving low doses of glucocorticoids providing the dose has been stable for at least 2 weeks prior to starting the trial medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "   3. Follow-up imaging studies show no progression of treated lesions and no new lesions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "6. Evaluable disease; measurable on imaging as assessed by RECIST version 1.1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "7. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "8. Absolute neutrophil count (ANC) (polymorphonuclear cells \\[PMN\\] plus bands) \\>1,000/ μL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "9. Platelets ≥100,000 μL. Platelet transfusions within the 14 days before Day 1 of Cycle 1 is prohibited.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "10. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 3 upper limit of normal (ULN). In cases with liver involvement ALT/ AST ≤ 5× ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "11. Total bilirubin ≤1.5 mg/dL unless elevated due to known Gilbert's syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "12. Creatinine ≤1.5 ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "13. Serum potassium and magnesium at least at the lowest limit of normal (LLN), before every IMP administration. If it is below the LLN, supplementation is permissible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "14. Female study participants of child-bearing potential and their partners, and male study participants who intend to be sexually active with a woman of child-bearing potential, must be willing to use at least two (2) highly effective forms of contraception. This should start from the time of study enrollment and continue throughout IMP administration. For female study participants of child-bearing potential this must continue using contraception for at least six (6) months after the last administration of the IMP. Female study participants should be willing to have a pregnancy test performed at screening, ≤ 1 day prior to day 1 of each IMP administration and at study treatment discontinuation. Male study participants who are sexually active with a woman of child-bearing potential should also use a condom during treatment and for at least ninety (90) days after the last administration of IMP. Vasectomized males are considered fertile; therefore, vasectomized partners and patients must be willing to use a secondary method of effective birth control. Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the trial treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "Exclusion Criteria Phase 1 and Phase 2 portions of Study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "To be eligible to participate in the trial, a patient cannot meet any of the following exclusion criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "1. Patients with primary central nervous system (CNS) cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "2. Patients with QTc interval (Fridericia's formula) \\>450 msec.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "3. Patients who are on treatment with drugs known to prolong the QT/QTc interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "4. Patients who are being treated with Valproic Acid for any of its indication (epilepsy, mood disorder).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "5. Any serious medical condition that interferes with adherence to trial procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "6. Prior history of solid tumor malignancy diagnosed within the last three (3) years of study enrollment excluding adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer, in situ breast cancer, in situ prostate cancer (patients must have shown no evidence of active disease for 2 years prior to enrollment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "7. Pregnant or breast feeding females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "8. New York Heart Association (NYHA) stage III/IV congestive heart failure, arrhythmias not adequately controlled, or other significant co-morbidities \\[e.g. active infection requiring systemic therapy, history of human immunodeficiency virus (HIV) infection, or active Hepatitis B or Hepatitis C\\].",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "9. Use of other investigational agents within 28 days prior to the first dose of study drug, provided the patient has recovered from any related toxicities ≥Grade 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "10. Steroid treatment within seven (7) days prior to trial treatment. Patients that require intermittent use of bronchodilators, topical steroids or local steroid injections will not be excluded from the study. Patients who have been stabilized to 10 mg Prednisolone orally (PO) once daily (QD) (or equivalent), daily (or less) at least seven (7) days prior to IMP administration are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "Phase 2:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "Patients must meet the cohort-specific inclusion/exclusion criteria in addition to the general inclusion/exclusion criteria for Phase 1 and Phase 2 study listed above.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "Cohort 1: Relapsed/Refractory small cell lung cancer (SCLC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "1. Histologically or cytologically confirmed limited or extensive disease stage of SCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "2. Must have received at least 1 line of prior combination chemotherapy or biological therapy and no other standard therapy with proven clinical benefit is available or recommended based on the investigator's individual risk-benefit assessment for the patient.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "3. At least 28 days should have elapsed since prior treatment as long as the patient has recovered from any related toxicities to ≤ Grade 1 (or ≤ Grade 2 for any symptomatic neuropathy or endocrinopathies).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "4. Prior radiotherapy is acceptable provided the patient has recovered from any radiotherapy related acute toxicities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "5. The disease should be progressing during or relapsing after the previous treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "6. Presence of measurable disease as defined by RECIST version 1.1. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "Cohort 2: Relapsed/Refractory Soft Tissue Sarcoma (STS)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "1. Histologically confirmed diagnosis of advanced, unresectable, or metastatic soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy excluding: neuroblastoma, GIST, embryonal rhabdomyosarcoma, Kaposi sarcoma, chondrosarcoma, osteosarcoma or Ewing's sarcoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "2. Must have received at least one prior line prior line chemotherapy or biological therapy regimen and no other standard therapy with proven clinical benefit is available or recommended based on the investigator's individual risk-benefit assessment for the patient. At least twenty-eight (28) days should have elapsed since prior chemotherapy, as long as the patient recovered from any related toxicities to ≤ Grade 1 (or ≤Grade 2 for any symptomatic neuropathy or endocrinopathies).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "3. The disease should be progressing during or relapsing after the previous treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "4. Presence of measurable disease as defined by RECIST version 1.1. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "Cohort 3: Relapsed/Refractory Triple Negative Breast Cancer (TNBC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "1. Histologically or cytologically confirmed locally advanced or metastatic Triple Negative Breast Cancer. Proven human epidermal growth factor receptor 2 (HER2) negative by immunohistochemistry (INH) or in situ hybridization (ISH) per per American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "2. Must have received at least one (1) line of chemotherapy or biological therapy and no other standard therapy with proven clinical benefit was available or recommended based on the Investigator's individual risk-benefit assessment for the subject.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "3. At least three (3) weeks should have elapsed since prior chemotherapy as long as the subject recovered from acute toxicity of previous therapies to ≤ Grade 1 (or ≤ Grade 2 for any symptomatic neuropathy or endocrinopathies).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "4. Prior radiotherapy was acceptable provided it was administered at least four (4) weeks (two (2) weeks for palliative, limited field radiation therapy) prior to starting treatment on this study and the subject recovered from any radiotherapy related acute toxicities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "5. The disease had to be progressing during or relapsing after the previous treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "6. Presence of measurable disease as defined by RECIST version 1.1. Tumour lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, were usually not considered measurable unless there had been demonstrated progression in the lesion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "Cohort 4: Patient Population: Relapsed/Refractory Ovarian Cancer (OC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "1. Histologically or cytologically confirmed advanced ovarian cancer: epithelial ovarian cancer, including primary peritoneal cancer or fallopian tube cancer (excluding borderline ovarian cancer, MMMT) of high grade serous histology, or high grade endometrioid cancer, that is resistant or refractory to platinum therapy and no other standard therapy with proven clinical benefit is available or recommended based on the investigator's individual risk-benefit assessment for the patient. Clear cell carcinomas are excluded. Patients with primary platinum refractory disease (failure to respond to initial platinum treatment or relapse within four (4) weeks) and patients with primary platinum resistant disease (progression within six (6) months of completing first line platinum-based therapy) are excluded from the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "2. At least twenty eight (28) days should have elapsed since prior chemotherapy as long as the patient recovered from acute toxicity of previous therapies to ≤ Grade 1 (or ≤ Grade 2 for any symptomatic neuropathy or endocrinopathies).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "3. The disease should be progressing during or relapsing after the previous treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "4. Presence of measurable disease as defined by RECIST version 1.1. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "Cohort 5: Relapsed/Refractory Endometrial Cancer (EC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "1. Histologically or cytologically confirmed locally advanced or metastatic endometrial cancer (excluding leiomyosarcoma and carcinosarcoma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "2. Must have received at least one (1) line of chemotherapy and no other standard therapy with proven clinical benefit is available or recommended based on the investigator's individual risk-benefit assessment for the patient. At least three (3) weeks should have elapsed since prior chemotherapy or 5 half-lives, whichever is shorter, as long as the patient recovered from acute toxicity of previous therapies to ≤ Grade 1 (or ≤ Grade 2 for any symptomatic neuropathy or endocrinopathies).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "3. Prior radiotherapy is acceptable provided it was administered at least four(4) weeks (two (2) weeks for palliative, limited field radiation therapy) prior to starting treatment on this trial and recovered from any radiotherapy related acute toxicities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "4. The disease should be progressing/relapsed during or after the previous treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03345485",
    "statement": "5. Presence of measurable disease as defined by RECIST version 1.1. Tumour lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, were usually not considered measurable unless there had been demonstrated progression in the lesion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00269152",
    "statement": "* Histologically proven non-small cell lung cancer stage Ib, IIa or IIb",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00269152",
    "statement": "* Must have complete tumor resection by pneumonectomy or lobectomy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00269152",
    "statement": "* Must have been surgically proven to be N2 negative",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00269152",
    "statement": "* Serious concomitant systemic disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00269152",
    "statement": "* Post-operative complications or other surgery related conditions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00269152",
    "statement": "* A prior malignancy other than NSCLC unless that malignancy was diagnosed and treated at least 5 years ago",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04078152",
    "statement": ". Patient must be 18 years or older, at the time of signing the ICF. For subjects aged \\< 20 years and enrolled in Japan, a written ICF should be obtained from the subject and his or her legally acceptable representative.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04078152",
    "statement": "2. Patient received durvalumab monotherapy and/or durvalumab containing combination in an AstraZeneca/MedImmune-sponsored parent clinical study that is approved for enrollment into this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04078152",
    "statement": "3. Patients who received durvalumab in combination with any other approved or investigational anticancer agents in the parent clinical study must have completed or discontinued all other anticancer therapy (beyond durvalumab regimen).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04078152",
    "statement": "4. Patient must be willing and able to provide written informed consent and to comply with scheduled visits and other study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04078152",
    "statement": ". Currently receiving treatment in another interventional study other than the parent clinical study or, for retreatment patients, received treatment during the follow up period with an agent other than durvalumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04078152",
    "statement": "2. Any concurrent chemotherapy, IP, biologic or hormonal therapy for cancer treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04078152",
    "statement": "3. Experienced an immune-mediated or non-immune-mediated toxicity that led to permanent discontinuation of durvalumab in parent clinical study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04078152",
    "statement": "4. Diagnosis of a new primary malignancy since enrollment into the parent clinical study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01996332",
    "statement": "* adult patients \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01996332",
    "statement": "* locally advanced or metastatic NSCLC (Stage IIIB or IV);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01996332",
    "statement": "* not a candidate for curative surgery or radical chemotherapy;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01996332",
    "statement": "* no brain metastases, or clinically stable metastases for \\>=2 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01996332",
    "statement": "* radiotherapy over the previous 2 weeks;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01996332",
    "statement": "* weight loss \\>10% in the previous 6 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Individuals able to understand and give written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Histologically or cytologically confirmed epithelial cancer of one of the following types:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Gastric adenocarcinoma (GC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Esophageal cancer (EC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Hepatocellular carcinoma (HCC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Non-small-cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Small-cell lung cancer (SCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Epithelial ovarian cancer (EOC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Cervical Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Endometrial Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Triple-negative breast cancer (TNBC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Non-triple-negative breast cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Papillary thyroid cancer (excludes follicular, medullary, Hurthle cell, and anaplastic thyroid cancer)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Glioblastoma multiforme (GBM)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Hormone-refractory prostate cancer (HRPC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Head and neck cancers- squamous cell (SCCHN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Renal cell cancer (clear cell) (RCC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Urothelial cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Stage IV (metastatic) disease (except for individuals with GBM).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Refractory to or relapsed after at least one prior standard therapeutic regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Adequate performance status (ECOG 0 or 1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Expected survival ≥ 6 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Measurable disease by CT or MRI.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* At least 2 weeks beyond treatment (chemotherapy, investigational drugs including small molecular inhibitors, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities to Grade 1 or less (except alopecia).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* At least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids \\< 20 mg prednisone or equivalent daily are permitted).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Adequate hematology without ongoing transfusional support (hemoglobin \\> 9 g/dL, absolute neutrophil count (ANC) \\> 1,500 per mm\\^3, platelets \\> 100,000 per mm\\^3).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Adequate renal and hepatic function (creatinine ≤ 2.0 x institutional upper limit of normal (IULN), bilirubin ≤ 1.5 IULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x IULN or 5 x IULN if know liver metastases).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Otherwise, all toxicity at study entry ≤ Grade 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Women who are pregnant or lactating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Women of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Individuals with Gilbert's disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Individuals with brain metastases can be enrolled only if treated, non-progressive brain metastases and off high-dose steroids (\\> 20 mg prednisone or equivalent) for at least 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Presence of bulky disease (defined as any single mass \\> 7 cm in its greatest dimension). Individuals with a mass over 7 cm, but otherwise eligible, may be considered for enrollment after discussion and approval with the medical monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Individuals with active ≥ grade 2 anorexia, nausea or vomiting, and/or signs of intestinal obstruction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Individuals with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while individuals with other prior malignancies must have had at least a 3-year disease-free interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Individuals known to be HIV positive, hepatitis B positive, or hepatitis C positive.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Known history of unstable angina, MI, or CHF present within 6 months or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Known history of clinically significant active COPD, or other moderate-to-severe chronic respiratory illness present within 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Prior history of clinically significant bleeding, intestinal obstruction, or GI perforation within 6 months of initiation of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Infection requiring intravenous antibiotic use within 1 week.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* History of an anaphylactic reaction to irinotecan or ≥ Grade 3 GI toxicity to prior irinotecan,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01631552",
    "statement": "* Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Stage IIIB or Stage IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Stable disease or a clinical response following first-line treatment, consisting of either chemotherapy alone or chemotherapy and radiotherapy. Subjects must have completed the first-line treatment at least 3 weeks prior to study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of greater than or equal to (\\>=) 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Ability to understand and willingness to sign a written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Other protocol-defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Received immunotherapy within 4 weeks prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Received immunosuppressive drugs within 3 weeks prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Subjects with known brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Autoimmune disease or immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Clinically significant hepatic, renal or cardiac dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Subjects with clinically significant active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Pregnant or breast feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157209",
    "statement": "* Other protocol-defined exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00961415",
    "statement": "* adults \\>/=18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00961415",
    "statement": "* inoperable, locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00961415",
    "statement": "* at least 1 measurable lesion meeting RECIST criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00961415",
    "statement": "* ECOG performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00961415",
    "statement": "* adequate hematological, liver and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00961415",
    "statement": "* prior chemotherapy or treatment with another systemic anti-cancer agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00961415",
    "statement": "* malignancies other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00961415",
    "statement": "* evidence of tumor invading major blood vessels",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00961415",
    "statement": "* current or recent use of aspirin (\\>325mg/day) or full-dose anticoagulants or thrombolytic agents for therapeutic purposes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00961415",
    "statement": "* history of haemoptysis \\>/=grade 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00961415",
    "statement": "* clinically significant cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has one of the selected solid tumors with no distant metastases, and is more than 8 weeks from completion of definitive therapy with intention to cure. Selected Solid Tumors: Stage I to III non-small cell lung carcinoma (NSCLC); Stage III breast cancer; Stage IIB or III melanoma; Stage II or III upper gastrointestinal tract carcinoma (e.g., esophagus, stomach, gallbladder, pancreas); Stage III colon carcinoma; Stage II, III, or IV (M0 only) renal cell carcinoma; Stage II, III, or IV (M0 only) bladder carcinoma; clinically-localized prostate carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Female participant of childbearing potential has a negative serum pregnancy test within 3 days of study enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has known hypersensitivity to any component of study vaccine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has a history of clinically significant cardiac conditions, including cardiac arrhythmias which have not been controlled within the last 3 months, unstable angina, myocardial infarction (within the last 3 months), or New York Heart Association (NYHA) Class III or IV congestive heart failure. Participant must have no clinically significant electrocardiogram (ECG) abnormalities and not have a pacemaker or cardioverter/defibrillator implanted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has undergone splenectomy or has any history of autoimmune disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has received immunosuppressive treatment within 1 month prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has known acquired, inherited, or idiopathic thrombocytopenia, platelet dysfunction or coagulopathy that would contraindicate IM injections.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has an acute infection requiring intravenous antibiotic, antiviral or antifungal agents within 2 weeks of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant is pregnant or breastfeeding, or expecting to conceive at any time during the study or within 1 year after receiving the last vaccination.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant is known to be Human Immunodeficiency Virus (HIV)-seropositive.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has known history of Hepatitis B or C or active Hepatitis A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has been vaccinated for any disease or for prophylaxis within 1 month prior to the first vaccination.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* The participant has been diagnosed with Systemic Lupus Erythematosus (SLE)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "Inclusion Criteria Part B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant must have completed their respective vaccination Treatment Group regimen for Part A of this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant must have completed a ≥12 week safety observation period prior to receiving their first V934-EP boost.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "Exclusion Criteria Part B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has new or metastatic tumor lesions since enrollment in Part A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has developed any significant cardiac conditions since enrollment in Part A including cardiac arrhythmias which have not been controlled within the last 3 months, unstable angina, myocardial infarction (within the last 3 months), or NYHA Class III or IV congestive heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has undergone a splenectomy, or has developed any autoimmune disorders, since enrollment in Part A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has received immunosuppressive treatment within 1 month prior to enrollment in Part B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has developed any acquired, inherited, or idiopathic thrombocytopenia, platelet dysfunction or coagulopathy that would contraindicate IM injections",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00753415",
    "statement": "* Participant has an acute infection requiring intravenous antibiotic, antiviral or antifungal agents within 2 weeks of entry to Part B.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Diagnosis during dose escalation (Phase 1) - Pathologically documented, definitively diagnosed non-resectable advanced solid tumor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* All participants treated at doses \\> 120 mg per day must have MTC, or a RET-altered solid tumor per local assessment of tumor tissue and/or blood.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Diagnosis during dose expansion (Phase 2) - All participants (with the exception of participants with MTC enrolled in Groups 3, 4, and 9) must have an oncogenic RET-rearrangement/fusion or mutation (excluding synonymous, frameshift, and nonsense mutations) solid tumor, as determined by local or central testing of tumor or circulating tumor nucleic acid in blood; as detailed below.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Group 1 - participants must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET fusion previously treated with a platinum-based chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Group 2 - participants must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET fusion not previously treated with a platinum-based chemotherapy, including those who have not had any systemic therapy. Prior platinum chemotherapy in the neoadjuvant and adjuvant setting is permitted if the last dose of platinum was 4 months or more before the first dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Group 3 - participants must have pathologically documented, definitively diagnosed advanced MTC that had progressed within 14 months prior to the Screening Visit and was previously treated with cabozantinib and/or vandetanib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Group 4 - participants must have pathologically documented, definitively diagnosed advanced MTC that had progressed within 14 months prior to the Screening Visit and was not previously treated with cabozantinib and/or vandetanib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Group 5 - participants must have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET fusion, have previously received standard of care (SOC) appropriate for their tumor type (unless there is no accepted standard therapy for the tumor type or the Investigator has determined that treatment with standard therapy is not appropriate), and must not have been eligible for any of the other groups.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Group 6 - participants must have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET fusion or mutation that was previously treated with a selective tyrosine kinase inhibitor (TKI) that inhibits RET",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Group 7 - participants must have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET mutation previously treated with SOC appropriate for the tumor type and not eligible for any of the other groups",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Group 8 - participants must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET fusion that was previously treated with a platinum based chemotherapy (China only).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Group 9 - participants must have pathologically documented, definitively diagnosed advanced MTC that had progressed within 14 months prior to the Screening Visit, and was not previously treated with systemic therapy (except prior cytotoxic chemotherapy is allowed) for advanced or metastatic disease (China only).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Participants must have non-resectable disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Dose expansion (Phase 2): Participants in all groups (except Group 7) must have measurable disease per RECIST v1.1 (or RANO, criteria if appropriate for tumor type).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Participants agrees to provide tumor tissue (archived, if available or a fresh biopsy) for RET status confirmation and is willing to consider an on-treatment tumor biopsy, if considered safe and medically feasible by the treating Investigator. For Phase 2, Group 6, participants are required to undergo a pretreatment biopsy to define baseline RET status in tumor tissue.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Participants has Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Participant's cancer has a known primary driver alteration other than RET. For example, NSCLC with a targetable mutation in EGFR, ALK, ROS1 or BRAF; colorectal with an oncogenic KRAS, NRAS, or BRAF mutation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Participants had any of the following within 14 days prior to the first dose of study drug:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "  1. Platelet count \\< 75 × 10\\^9/L.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "  2. Absolute neutrophil count \\< 1.0 × 10\\^9/L.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "  3. Hemoglobin \\< 9.0 g/dL (red blood cell transfusion and erythropoietin may be used to reach at least 9.0 g/dL, but must have been administered at least 2 weeks prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "  4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3 × the upper limit of normal (ULN) if no hepatic metastases are present; \\> 5 × ULN if hepatic metastases are present.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "  5. Total bilirubin \\> 1.5 × ULN; \\> 3 × ULN with direct bilirubin \\> 1.5 × ULN in presence of Gilbert's disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "  6. Estimated (Cockcroft-Gault formula) or measured creatinine clearance \\< 40 mL/min.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "  7. Total serum phosphorus \\> 5.5 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* QT interval corrected using Fridericia's formula (QTcF) \\> 470 msec or history of prolonged QT syndrome or Torsades de pointes, or familial history of prolonged QT syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Clinically significant, uncontrolled, cardiovascular disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Central nervous system (CNS) metastases or a primary CNS tumor that is associated with progressive neurological symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Clinically symptomatic interstitial lung disease or interstitial pneumonitis including radiation pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Participants in Groups 1-5 and 7 (Phase 2) previously treated with a selective RET inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Participant had a major surgical procedure within 14 days of the first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Participant had a history of another primary malignancy that had been diagnosed or required therapy within the a year prior to the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "* Pregnant or breastfeeding female participants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00496470",
    "statement": "* \\>=40 years of age, diagnosed COPD with symptoms \\>=2 years, pre-bronchodilatory FEV1 \\<=50% of PN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00496470",
    "statement": "* Current respiratory tract disorder other than COPD, history of asthma or rhinitis, significant or unstable cardiovascular disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) that is PD-L1 positive per central laboratory review",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* At least one measurable lesion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Radiographic progression of NSCLC after treatment with a platinum-containing doublet for Stage IIIB/IV or recurrent disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Scale 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Systemic cytotoxic chemotherapy, biological therapy, or major surgery within 3 weeks of the first dose of trial treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Systemic steroid therapy within 3 days prior to the first dose of trial treatment or any other form of immunosuppressive medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Expected to require any other form of systemic or localized antineoplastic therapy while on trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* History of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Active central nervous system (CNS) metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Active autoimmune disease or documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Concurrent or past history of interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02007070",
    "statement": "* Pregnant or breast-feeding, or expecting to conceive or father children within the projected duration of the study, starting with screening visit through 120 days after the last dose of pembrolizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02604342",
    "statement": "* Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive. ALK positivity must have been determined by a validated fluorescence in situ hybridization (FISH) test (recommended probe, Vysis ALK Break-Apart Probe) or a validated immunohistochemistry (IHC) test (recommended antibody, clone D5F3)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02604342",
    "statement": "* Participant had received two prior systemic lines of therapy, which must have included one line of platinum-based chemotherapy and one line of crizotinib",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02604342",
    "statement": "* Prior CNS or leptomeningeal metastases allowed if asymptomatic",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02604342",
    "statement": "* Participants with symptomatic CNS metastases for whom radiotherapy is not an option will be allowed to participate in this study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02604342",
    "statement": "* Measurable disease by RECIST Version 1.1 prior to the administration of study treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02604342",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02604342",
    "statement": "* For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02604342",
    "statement": "* Participants with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal \\[GI\\] cancer by endoscopic resection or in situ carcinoma of the cervix)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02604342",
    "statement": "* Participants who have received any previous ALK inhibitor other than crizotinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02604342",
    "statement": "* Any GI disorder that may affect absorption of oral medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00172042",
    "statement": "* Histologically or cytologically confirmed Non-small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00172042",
    "statement": "* Newly Diagnosed, Stage IIIA and Stage IIIB excluding patients with pleural effusion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00172042",
    "statement": "* Patients must have received primary treatment for their disease and had no progression",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00172042",
    "statement": "* Diagnosed with NSCLC longer than 6 months ago",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00172042",
    "statement": "* Treatment with other bisphosphonates in past 12 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00172042",
    "statement": "* Presence of metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00172042",
    "statement": "Other protocol-defined inclusion and exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* Male or female subjects aged ≥18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably including the presence of neuroendocrine features by immunohistochemistry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* At least 1 target lesion that is unirradiated and measurable by RECIST, Version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* Prior chemotherapy for extensive-stage SCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* Known history of stroke or cerebrovascular accident within 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* Other uncontrolled serious chronic disease or conditions that in the investigator's opinion could affect compliance or follow-up in the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02499770",
    "statement": "* Receipt of any investigational medication within 4 weeks prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Male or female participants at least 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Histological or cytological proven advanced (unresectable) or metastatic NSCLC as defined as stage IIIB (positive supraclavicular lymph nodes) not amenable to definitive chemoradiotherapy or stage IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Adequate organ function, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "  1. Absolute neutrophil count (ANC) \\>= 1500 per microliter (/µL).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "  2. Platelets \\>= 100,000/µL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "  3. Hemoglobin \\>= 9 grams per deciliter (g/dL) or \\>= 5.6 millimoles per liter (mmol/L).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "  4. Serum creatinine \\<= 1.5 times upper limit of normal (ULN) or creatinine clearance \\>= 50 milliliters per minute (mL/min) (as calculated using the Cockcroft Gault equation or measured using 24-hour urine creatinine clearance) for participants with creatinine levels \\> 1.5 times institutional ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "  5. Total bilirubin \\<= 1.5 times ULN except in participants with Gilbert's syndrome. Participants with Gilbert's syndrome may enroll if direct bilirubin \\<= 1.5 times ULN of the direct bilirubin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "  6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\<= 2.5 times ULN unless liver metastases are present, in which case they must be \\<= 5 times ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participant must have recovered to Grade 1 toxicity from prior cancer therapy (a participant with Grade 2 neuropathy or Grade 2 alopecia is an exception to this criterion and may qualify for this study).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participant agrees to submit formalin fixed paraffin embedded (FFPE) tumor tissue specimen, which may have been collected at any time prior to screening. If no archival FFPE tumor tissue is available, participant agrees to undergo a tumor tissue biopsy before Cycle 1/Day 1. (For Cohort 3 only: if diagnosis was made by cytology and archival tissue is not available, participant will not need to provide tumor tissue).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participants is able to take oral medications.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Female participant meets the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "  a) Female participant (of childbearing potential) is not breastfeeding, has a negative serum pregnancy test within 72 hours prior to taking study drug, and agrees to abstain from activities that could result in pregnancy from enrollment through 180 days after the last dose of study treatment or is of nonchildbearing potential; or b) Female participant is of nonchildbearing potential, other than medical reasons, defined as follows: i) \\>=45 years of age and has not had menses for \\> 1 year. ii) Amenorrheic for \\< 2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone (FSH) value in the postmenopausal range upon screening evaluation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "iii) Post hysterectomy, bilateral oophorectomy, or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the participant must be willing to use 2 highly effective contraception methods throughout the study, starting with the screening visit through 180 days after the last dose of study therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Male participant agrees to use an adequate method of contraception and not donate sperm starting with the first dose of study therapy through 120 days after the last dose of study therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participant is able to understand the study procedures and agree to participate in the study by providing written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "Cohort Specific Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Cohorts 1 and 1A (combination of niraparib and PD-1 inhibitor): participants must have tumors with high PD-L1 expression (TPS \\>= 50%) per local assessment; with no known Epidermal Growth Factor Receptor (EGFR)-sensitizing mutation and/or ROS -1 or anaplastic lymphoma kinase (ALK) translocation, and no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment for metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Cohorts 2 and 2A (combination of niraparib and PD-1 inhibitor): participants must have tumors with PD-L1 expression (TPS between 1% and 49%) per local assessment, with no known EGFR-sensitizing mutation and/or ROS-1 or ALK translocation, and no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment for metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Cohort 3 (single agent niraparib): participants must have metastatic squamous non-small cell lung cancer (sqNSCLC) and have progressed after both prior platinum-based chemotherapy and prior PD-1 or PD-L1 inhibitor treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": ", 1A , 2 and 2A:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participant has received systemic therapy for the treatment of advanced stage NSCLC. Completion of treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Known hypersensitivity to the components of niraparib, pembrolizumab, TSR-042 (Dostarlimab), or their excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Known EGFR (exon 19 and 21) mutations, ALK translocations, and/or ROS-1 translocations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participant has a history or current condition (such as transfusion-dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the participant's participation for the full duration of the study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Known diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participant is immunocompromised, in the opinion of the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Current participation in a treatment study or past participation in a study of an investigational agent within 4 weeks before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Symptomatic uncontrolled brain or leptomeningeal metastases. (To be considered \"controlled,\" central nervous system \\[CNS\\] disease must have undergone treatment \\[example, radiation or chemotherapy\\] at least 1 month prior to study entry. The participant must not have any new or progressive signs or symptoms related to the CNS disease and must be taking \\<= 10 mg of prednisone or equivalent per day or no steroids.) Participants who have untreated brain metastases and who are not symptomatic may enroll if the Investigator feels that treatment of these metastases is not indicated. A scan to confirm the absence of brain metastases is not required. Participants with spinal cord compression may be considered if they have received definitive treatment for this and evidence of clinically SD for 28 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Active autoimmune disease that required systemic treatment in the past 2 years (with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (examples, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Major surgery within 3 weeks of starting the study or participant has not recovered from any effects of any major surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Other active concomitant malignancy that warrants systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, uncontrolled hypertension, active uncontrolled coagulopathy or any psychiatric disorder that prohibits obtaining informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Known history of interstitial lung disease, drug-related pneumonitis, or radiation pneumonitis requiring steroid treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participant is pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and for 180 days (for pregnancy or conception) or 30 days (for breastfeeding) after the last dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Male participant is expecting to donate sperm or father children while receiving study drug or for 120 days after the last dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Known active hepatic disease (known hepatic cirrhosis, hepatitis B surface antigen-positive status, or suspected active hepatitis C infection).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Prior treatment with a known poly adenosine diphosphate-ribose (ADP-ribose) polymerase (PARP) inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participant received a live vaccine within 30 days of planned start of study therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "Exclusion criteria for Cohort 3:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Platinum-treated participant who progressed while on or within less than 8 weeks from the last day of platinum administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Known hypersensitivity to the components of niraparib or excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participant has a history or current condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the participant's participation for the full duration of the study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Known diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Current participation in a treatment study or past participation in a study of an investigational agent within 4 weeks before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Symptomatic uncontrolled brain or leptomeningeal metastases. (To be considered \"controlled,\" CNS disease must have undergone treatment \\[example, radiation or chemotherapy\\] at least 1 month prior to study entry. The participant must not have any new or progressive signs or symptoms related to the CNS disease and must be taking \\<= 10 mg of prednisone or equivalent per day or no steroids.) Participants who have untreated brain metastases and who are not symptomatic may enroll if the investigator feels that treatment of these metastases is not indicated. A scan to confirm the absence of brain metastases is not required. Participants with spinal cord compression may be considered if they have received definitive treatment for this and evidence of clinically SD for 28 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Major surgery within 3 weeks of starting the study or participant has not recovered from any effects of any major surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Other active concomitant malignancy that warrants systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, uncontrolled hypertension, active uncontrolled coagulopathy, or any psychiatric disorder that prohibits obtaining informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Known history of interstitial lung disease, drug-related pneumonitis, or radiation pneumonitis requiring steroid treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participant is pregnant, breastfeeding, or expecting to conceive children, while receiving study treatment and for 180 days (for pregnancy or conception) or 30 days (for breastfeeding) after the last dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Male participant is expecting to donate sperm or father children while receiving study drug or for 120 days after the last dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Participant is immunocompromised, in the opinion of the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Known active hepatic disease (known hepatic cirrhosis, hepatitis B surface antigen-positive status, or suspected active hepatitis C infection).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Prior treatment with a known PARP inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03308942",
    "statement": "* Known history of MDS or AML.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04148937",
    "statement": "* Participants must have certain types of cancer such as breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and ovarian cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04148937",
    "statement": "* Participants must have stopped other forms of treatment for the cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04148937",
    "statement": "* In the expansion cohorts participants must be able and willing to provide a sample of the tumor before beginning treatment and a sample during the treatment. For certain tumor types, the result of a test on the tumor sample may exclude the participant from the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04148937",
    "statement": "* Participants must not be pregnant, and must agree to use birth control",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04148937",
    "statement": "* Participants must have progressed through or be intolerant to therapies with known clinical benefit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04148937",
    "statement": "* Participants must not have a current untreated tuberculosis, lung disease, heart disease, uncontrolled HIV, autoimmune disease, active hepatitis B or C virus infection or using corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04148937",
    "statement": "* Participant must not have cancer that has spread to the brain",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04148937",
    "statement": "* Participant must not have received a vaccine within the last 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04148937",
    "statement": "* Participant must not have had bowel obstruction within the last 6 months, or intestinal surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04148937",
    "statement": "* Participant must not have an infection that is currently being treated",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Men or women ≥18 years, follow local regulatory requirements if the legal age of the consent for study participation is \\>18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Pathologically documented metastatic NSCLC with a known activating HER2 mutation. Note: A HER2 mutation documented only from a liquid biopsy samples cannot be used for enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Had previous treatment including platinum therapy in the metastatic/locally advanced setting and not amenable to curative surgery or radiation. Participant must have progressed during or after the last treatment regimen or discontinued because of unacceptable toxicity.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Presence of at least 1 measurable lesion confirmed by the blinded Independent Central Review based on RECIST version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Willing and able to provide an archival tumor tissue sample. A fresh biopsy is required if an archival tumor tissue sample cannot be supplied. Resection and core needle biopsy are acceptable. Fine needle aspirates or cell block are not acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Eastern Cooperative Oncology Group performance status 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Left ventricular ejection fraction ≥ 50% within 28 days before randomization Resection and core needle biopsy are acceptable - Adequate organ function as specified in protocol within 14 days before randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Adequate treatment washout period before randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Participants of reproductive/childbearing potential agree to use a highly effective form of contraception (or avoid intercourse) during study period and up to 7 months (females) and 4 months (males) after last study dose",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Males should not freeze or donate sperm throughout the study period up to at least 4 months after last study dose; females should not donate or retrieve ova for their own use throughout the study period and up to at least 7 months after last study dose",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Life expectancy 3 months or more",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Known driver mutation in the epidermal growth factor receptor (EGFR), BRAF, or MET exon 14 gene or a known anaplastic lymphoma kinase (ALK), ROS1, RET, or NTRK fusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Medical history of myocardial infarction within 6 months before randomization, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV). Participants with troponin levels above upper limit of normal at screening (as defined by the manufacturer) and without any myocardial infarction (MI)-related symptoms should have a cardiologic consultation before randomization to rule out MI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Corrected QT interval (QTcF) prolongation \\> 470 msec (females) or \\>450 msec (males) based on average of the triplicate12-lead electrocardiogram at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* History of non-infectious interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* History of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* History of severe hypersensitivity reactions to other monoclonal antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the participant's participation in the clinical study or evaluation of the clinical study results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Known human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Known active, clinically relevant liver disease (eg, active hepatitis B, or active hepatitis C) such as those with serologic evidence of viral infection within 28 days of Cycle 1, Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Pregnant, breastfeeding, or planning to become pregnant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Otherwise considered inappropriate for the study by the Investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (eg. pulmonary emboli within three months of the study randomization, severe asthma, severe COPD, restrictive lung disease, pleural effusion, etc.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Any autoimmune, connective tissue or inflammatory disorders (e.g., Rheumatoid arthritis, Sjogren's, sarcoidosis etc.) where there is documented, or a suspicion of pulmonary involvement at the time of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Prior complete pneumonectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04644237",
    "statement": "* Had prior treatment with any agent, including an antibody drug conjugate (ADC), containing a chemotherapeutic agent targeting topoisomerase I",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Histologically or cytologically confirmed diagnosis of Stage IV non-squamous NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Documentation of tumor activating EGFR mutation, specifically either DEL19 or L858R.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Investigator-determined radiographic disease progression per RECIST 1.1 after treatment with an EGFR TKI therapy: a) Participants previously treated with 1st or 2nd generation EGFR TKI (e.g. erlotinib/afatinib/gefitinib) are required to have confirmed documented absence of EGFR T790M mutation; b) Participants with confirmed acquired T790M mutation after 1st or 2nd generation EGFR TKI (e.g. erlotinib/afatinib/gefitinib) are required to have osimertinib TKI treatment failure prior to enrollment; c) Participants previously failed osimertinib TKI treatment as 1st line therapy are eligible regardless of their EGFR T790M mutation status. Note: TKI washout period for all participants is 1 week or 2 half-lives after last treatment dose, whichever is longer. TKI washout should be completed prior to first dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Provided archival tumor tissue sample or newly obtained (no anti-neoplastic therapy since biopsy) core or excisional biopsy of a tumor lesion not previously irradiated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study treatment but before randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Male participants must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and up to 180 days after last dose of chemotherapeutic agents.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Female participants must not be pregnant, not breastfeeding, and must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and up to 180 days after the last dose of chemotherapeutic agents.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Predominantly squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the participant is ineligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein-4 \\[CTLA-4\\], OX-40, CD137).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Received prior systemic cytotoxic chemotherapy or investigational agent(s), excluding EGFR TKIs, for metastatic NSCLC. \\[Notes: 1) Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic NSCLC. 2) If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. 3) Prior exposure to traditional medicine(s) is allowed as long as therapy was discontinued at least 4 weeks prior to the first dose of study treatment.\\]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Received prior radiotherapy within 2 weeks of start of study treatment or has received lung radiation therapy of \\>30 Gray (Gy) within 6 months before the first dose of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Received a live vaccine within 30 days prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Known additional malignancy that is progressing or has required active treatment within the past 5 years. (Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Known active untreated CNS metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Known sensitivity to any component of cisplatin, carboplatin, or pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Active autoimmune disease that has required systemic treatment in past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* History of (non-infectious) pneumonitis that required steroids or has current pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Known history of human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Known history of Hepatitis B or known active Hepatitis C virus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Known history of active tuberculosis (TB; Bacillus tuberculosis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03515837",
    "statement": "* Pregnant, breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and up to 180 days after the last dose of chemotherapeutic agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients must have a histologically or cytologically confirmed diagnosis of non-small cell lung cancer with at least one site of measurable disease by the RECIST criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients must have failed prior platinum-containing doublet chemotherapy. Patients who have received single agent chemotherapy with or without a subsequent taxane containing regimen may be enrolled after discussion with Sponsor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients must be ≥ 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients must have a performance score of 0 or 1 using the ECOG performance scale.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients must have a life expectancy of ≥ 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients must have adequate renal function as evidenced by a serum creatinine ≤ 2.0 mg/dL or a calculated creatinine clearance ≥ 40 mL/min per the Cockcroft and Gault formula.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients must have adequate hepatic function as evidenced by bilirubin ≤1.5 mg/dL and alkaline phosphatase, AST and ALT ≤ 3 times upper limit of normal, unless there is evidence of liver metastases, in which case the alkaline phosphatase, AST and ALT must be ≤ 5 times upper limit of normal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients must have adequate bone marrow function as evidenced by absolute neutrophil counts (ANC) ≥ 1.5 X 10\\^9/L, hemoglobin ≥ 10.0 g/dL (a hemoglobin \\< 10.0 g/dL would be acceptable if it can be corrected by growth factor or transfusion), and platelet count ≥ 100 X 10\\^9/L.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients must be willing and able to comply with the protocol guidelines for the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients must be willing and able to complete the Lung Cancer Symptom Scale (LCSS) instrument.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* The biopsy specimen (paraffin block or at least 10 unstained slides) must be available from either the initial diagnosis or any subsequent diagnostic or surgical procedure of patients participating in the pharmacogenomics sub-study only. However, no additional biopsies are obligatory for participation in this study except those required for confirmation of the diagnosis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients with pre-existing peripheral neuropathy \\> Grade 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients who require therapeutic doses of warfarin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients who have not recovered from any chemotherapy, radiation or other therapy related toxicity deemed to be clinically significant at study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients with active symptomatic brain metastases. Patients with central nervous system (CNS) metastases are considered eligible if they have had adequately treated brain metastases, i.e. have completed treatment (tapered off steroids) at least four weeks before starting treatment with E7389. Patients who have no evidence that the metastases are symptomatic or actively growing (no evidence of midline shift on CT scan or MRI) may be enrolled without initiation of local therapy for the CNS metastases. In this case, a repeat scan must be performed within four weeks of the original scan to ensure that disease progression is not occurring. It is not the intention of this study to treat patients with active brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients who have a positive history for HIV, active hepatitis B or active hepatitis C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients with other significant medical, or psychiatric disorders that, in the opinion of the investigator, will exclude the patient from the study for compliance or safety reasons",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients who have received investigational drugs, including immunotherapy, gene therapy, hormone therapy (except megestrol acetate for appetite stimulation), or other biological therapy; conventional chemotherapy or radiation therapy (except for palliation, defined as less than 10% of the bone marrow reserve and less than 20 Gy), within three weeks of E7839 enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients who have received non-cytotoxics (eg, gefitinib, erlotinib) within one week of E7389 enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients who have not recovered from major surgery within three weeks of E7389 enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients with severe/uncontrolled intercurrent illness/infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients with significant cardiovascular impairment (history of congestive heart failure\\>NYHA grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients with organ allografts",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients with hypersensitivity to halichondrin B and/or halichondrin B-related compounds",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients who participated in a prior E7389 clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Patients with second malignancy within the past 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Women who are pregnant or breast-feeding; woman of childbearing potential with a positive pregnancy test at screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Perimenopausal women must be amenorrheic for at least 12 months or using adequate contraception to be considered of non-childbearing potential.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00100932",
    "statement": "* Fertile men who are not willing to use contraception or fertile men with a female partner who is not willing to use contraception",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Age ≥18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* For RMC-4630 + Cobimetinib only - Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anti-cancer treatments including approved drugs for oncogenic drivers in their tumor type.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* For RMC-4630 + Osimertinib only - Locally advanced or metastatic EGFR mutant NSCLC not amenable to curative surgery or radiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* For RMC-4630 + Cobimetinib only - Participants must have one of the following genotypic aberrations: KRAS mutations and amplifications, BRAF Class 3 mutations, or NF1 LOF mutations",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* For RMC-4630 + Osimertinib only - Evidence of radiological documentation of progression with osimertinib monotherapy or an osimertinib containing regimen. Participants should not be considered a current candidate for 1st generation EGFR TKI's by the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of ≤1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Adequate hematological, hepatic, and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Capable of giving signed informed consent form (ICF). Willing and able to compile with study requirements and restrictions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Life expectancy \\>12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Female of childbearing potential and males with partners of childbearing potential must comply with effective contraception criteria .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Primary central nervous system (CNS) tumors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Known or suspected leptomeningeal or brain metastases or spinal cord compression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* For RMC-4630 + osimertinib arm only - Known or suspected Small cell, squamous, or pleomorphic lung transformations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Clinically significant cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Active, clinically signiﬁcant interstitial lung disease or pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* History or current evidence of retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or RVO",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Known HIV infection or active/chronic hepatitis B or C infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Any other unstable or clinically signiﬁcant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03989115",
    "statement": "* Females who are pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00718315",
    "statement": "* adult patients, \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00718315",
    "statement": "* locally advanced or metastatic non-small cell lung cancer (stage IIIB/IV);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00718315",
    "statement": "* eligible to start treatment with Tarceva, or receiving Tarceva for \\<=5 days.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00718315",
    "statement": "* presence of skin rash or other signs of skin toxicity;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00718315",
    "statement": "* treatment with any systemic or intranasal antibiotic within 7 days before randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00718315",
    "statement": "* treatment with other topical formulation within 14 days before randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00718315",
    "statement": "* other anticancer therapy in addition to Tarceva.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has Stage IV NSCLC (American Joint Committee on Cancer \\[AJCC 8th edition\\])",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has measurable disease based on RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has tumor tissue that demonstrates programmed cell death-ligand 1 (PD-L1) expression in ≥1% of tumor cells (Tumor Proportion Score \\[TPS\\] ≥1%) as assessed by immunohistochemistry (IHC) 22C3 pharmDx assay (Dako North America, Inc.) at a central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has a life expectancy of ≥3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study treatment but before randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Male participants must agree to the following during the treatment period and for ≥7 days after the last dose of lenvatinib/matching placebo: 1) Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR 2) Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Female participants are eligible to participate if not pregnant or breastfeeding, and ≥1 of the following applies: 1) Is not a woman of child-bearing potential (WOCBP), OR 2) Is a WOCBP and is using a highly effective contraceptive method that has a low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle during the treatment period and for ≥120 days post pembrolizumab or ≥30 days post lenvatinib/matching placebo, whichever occurs last",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week before randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has known untreated central nervous system metastases and/or carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has active hemoptysis (at least 0.5 teaspoon of bright red blood) within 2 weeks prior to the first dose of study intervention",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has radiographic evidence of intratumoral cavitations, encasement, or invasion of a major blood vessel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for ≥3 years since initiation of that therapy. (Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has had an allogeneic tissue/solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has a known history of human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has a history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has a known history of hepatitis B or known active hepatitis C virus infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has a history of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral study drug absorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has significant cardiovascular impairment within 12 months of the first dose of study treatment, such as a history of congestive heart failure greater than New York Heart Association Class II, unstable angina, myocardial infarction, cerebrovascular accident/stroke, or cardiac arrhythmia associated with hemodynamic instability",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has not recovered adequately from any toxicity and/or complications from major surgery before starting study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has a known history of active tuberculosis (TB)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has an active infection requiring systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has previously had a severe hypersensitivity reaction to treatment with a monoclonal antibody or has a known sensitivity or intolerance to any component of lenvatinib or pembrolizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 \\[CTLA-4\\], Tumor necrosis factor receptor superfamily, member 4 \\[OX 40\\], tumor necrosis factor receptor superfamily member 9 \\[CD137\\]) or has received lenvatinib as monotherapy or in combination with anti- programmed cell death protein (anti-PD-1) agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has received radiotherapy within 14 days before the first dose of study treatment or received lung radiation therapy of \\>30 Gray (Gy) within 6 months before the first dose of study treatment. (Note: Participants must have recovered from all radiation-related toxicities to ≤Grade 1, not require corticosteroids, and not have had radiation pneumonitis.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within 7 days before the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Is receiving systemic steroid therapy (doses \\>10 mg daily of prednisone equivalent) within 7 days before the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has received a live or attenuated vaccine within 30 days before the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has had major surgery within 3 weeks prior to first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03829332",
    "statement": "* Has pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363415",
    "statement": "* Clinical diagnosis of extensive stage small cell lung cancer (SCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363415",
    "statement": "* Capable of self-care but may be unable to carry out any work activities.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363415",
    "statement": "* No prior anticancer therapy for SCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363415",
    "statement": "* have previously participated in a study involving pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00363415",
    "statement": "* have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03090737",
    "statement": "* Non small cell lung cancer (Squamous or non-squamous)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03090737",
    "statement": "* At least one prior anti-cancer therapy that did not work",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03090737",
    "statement": "* ECOG Performance Scale 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03090737",
    "statement": "* Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03090737",
    "statement": "* Active, known or suspected autoimmune disease or infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03090737",
    "statement": "* Prior immuno-oncology therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03090737",
    "statement": "* Corticosteroids within 2 weeks of study drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03090737",
    "statement": "Other protocol defined inclusion/exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* Documented diagnosis of non-small cell lung, pancreatic, colorectal, prostate, breast or ovarian cancer which, in the treating oncologist's assessment, is considered advanced.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* Anorexia as defined by a score of ≤5 in the Cancer-Related Cachexia Symptom Assessment Appetite 7-day recall scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* Meets any of the following criteria at Randomization:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* Not currently receiving antineoplastic therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* On standard of care systemic antineoplastic therapy or treatment without curative intent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* Signed informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* Current active reversible causes of decreased food intake.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* Current, severe gastrointestinal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* Participants with known symptomatic brain metastases requiring steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* Active uncontrolled bacterial, fungal, or viral infection, including HBV, HCV, HIV or participants with known AIDS-related illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* inadequate renal or liver function.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04803305",
    "statement": "* Women who are pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Histological or cytological confirmed small cell lung cancer (SCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Performance Status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Measurable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Known or suspected brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Small cell cancer not lung in origin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Significant or acute medical illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Uncontrolled or significant cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* ≥ Grade 2 peripheral neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Concomitant malignancies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* HIV related disease or known or suspected HIV+",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Hepatitis B or C infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* ECG abnormalities as defined by the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "* Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related compounds, including fucosyl-GM1 vaccine and Nivolumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02247349",
    "statement": "Other protocol defined inclusion/exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00147537",
    "statement": "* Diagnosis of advanced/metastatic lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00147537",
    "statement": "* Previous treatment with chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00147537",
    "statement": "* Uncontrolled diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00147537",
    "statement": "* History/active cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Histologically or cytologically documented, unresectable, locally advanced or metastatic solid tumor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Must have available archived tumor tissue (formalin-fixed paraffin-embedded) \\[FFPE\\].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* 18 years of age or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) or increased CA-125 (ovarian cancer) or PSA (prostate cancer) and/or CA 19-9 (pancreatic cancer).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Have adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Able to take oral medications.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Willing and able to provide informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Sexually active patients must be willing to use an acceptable method of contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Females of childbearing potential must have a negative serum pregnancy test at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Willing and able to comply with all study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "Part 2 Dose Expansion Tumor Types:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Breast and ovarian cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 4 prior regimens for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Prostate or pancreatic cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 2 prior regimens for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Small cell lung cancer (SCLC) patients who have received no more than one prior regimen for SCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Ewing's sarcoma patients who have received no more than 3 prior regimens for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Part 2 Expansion: Prior treatment with a PARP inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Has history of central nervous system (CNS) metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "  \\* Exception: In patients with SCLC, history of adequately treated brain metastasis who do not require corticosteroids for management of CNS symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Has had major surgery within 28 days before Cycle 1, Day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Has active peptic ulcer disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Active gastrointestinal tract disease with malabsorption syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01286987",
    "statement": "* Pregnant or breastfeeding at screening or planning to become pregnant (in each case, either oneself or one's partner) at any time during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": ". Participation in another clinical study with an IP during the last 14 days (or a longer period depending on the defined characteristics of the agents used).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "2. Treatment with any of the following: Treatment with an EGFR TKI w/in 8 days or approximately 5x half-life, whichever is the longer, of the first dose of study treatment; Any cytotoxic chemotherapy, investigational agents or other anticancer drugs w/in 14 days of the first dose of study treatment; Major surgery (excluding placement of vascular access) within 4 weeks of the first dose; Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation which must be completed within 4 weeks of the first dose of study treatment; Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inhibitors of CYP2C8 and of CYP3A4 (at least 1 week prior) and potent inducers of CYP3A4 (at least 3 week prior). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer/inhibitory effects on CYP3A4, CYP2C8, and/ or CYP1A2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "3. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of the IP until the end of Part A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "4. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum therapy related neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "5. Patients unable to fast for up to 14 hours.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "6. Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "7. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus. Screening for chronic conditions is not required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "8. Patients with type I diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "9. Patients unable to swallow orally administered medication or patients with gastrointestinal disorders or significant gastrointestinal resection likely to interfere with the absorption of AZD9291.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "10. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "11. Women who are breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "12. Patients with a known hypersensitivity to AZD9291",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "13. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: Absolute neutrophil count (ANC) \\<1.5 x 109/L; Platelet count \\<100 x 109/L; Haemoglobin \\<90 g/L; ALT \\>2.5 x the institutional ULN if no demonstrable liver metastases or \\>5 x institutional ULN in the presence of liver metastases; AST \\>2.5 x institutional ULN if no demonstrable liver metastases or \\>5 x institutional ULN in the presence of liver metastases; Total bilirubin \\>1.5 x institutional ULN if no liver metastases or \\>3 x institutional ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases; Creatinine \\>1.5 x institutional ULN concurrent with creatinine clearance \\<50 mL/min (measured or calculated by Cockcroft-Gault formula); confirmation of creatinine clearance is only required when creatinine is \\>1.5 x institutional ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "14. Any of the following cardiac criteria: Mean resting corrected QT interval corrected for heart rate using Fridericia's correction factor (QTcF) \\>470 msec obtained from 3 ECGs; Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block, second degree heart block, PR interval \\>250 msec; Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02163733",
    "statement": "15. For optional genetic research: Previous allogenic bone marrow transplant or non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Aged at least 18 years. Japan patients aged at least 20 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Locally advanced/metastatic NSCLC, not amenable to curative surgery or radiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Confirmation from a previous archival sample that the tumour harbours an EGFR mutation known to be associated with EGFR TKI sensitivity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI. Additional other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Patients must have central lab confirmation of tumour T790M status from a biopsy taken after disease progression on the most recent treatment regimen. Only patients with T790M+ will be included in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* At least one lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have short axis ≥ 15mm) with computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for accurate repeated measurements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* World Health Organisation (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Females of child-bearing potential using contraception; negative pregnancy test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Treatment with an EGFR-TKI within 5x half-life of study entry; any cytotoxic chemotherapy, investigational agents or other anticancer drugs within 14 days of study entry; current treatment with potent inhibitors/inducers of cytochrome P450 3A4 (CYP3A4); previous treatment with AZD9291 (or other agents specifically targeted against EGFR T790M mutation positive NSCLC); Prior neo-adjuvant or adjuvant chemotherapy treatment within 6 months of starting 1st EGFR TKI treatment; prior exposure to immune-mediated therapy including, but not limited to, other anti cytotoxic T-lymphocyte-associated antigen 4 (anti CTLA-4), anti- programmed cell death 1 (anti-PD-1), anti- programmed cell death ligand 1 (anti-PD-L1), and anti-programmed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines; radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks; major surgery within 4 weeks;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Current or prior use of immunosuppressive medication within 14 days before the first dose of MEDI4736 (excluding intranasal, inhaled, topical steroids, or local steroid injections)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Unresolved toxicities from prior therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* History of active primary immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Unstable brain metastases or spinal cord compression",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Severe/uncontrolled systemic diseases, including uncontrolled hypertension, renal transplant, bleeding diatheses or infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Ophthalmological conditions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Refractory nausea/vomiting, chronic gastrointestinal diseases or bowel resection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Past history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* History of another primary malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* History of organ transplant that requires use of immunosuppressive medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Known history of tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Receipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02454933",
    "statement": "* Inadequate bone marrow reserve or organ function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Histologically or cytologically documented diagnosis of Stage IIIB not amenable to radical treatment or Stage IV NSCLC (pathological characterization must determine the non-squamous or squamous histological subtype as well as adenocarcinoma subtype classification)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* HER2 status of IHC 2+ or 3+ as determined by a Sponsor-designated central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Prior treatment with at least one regimen of platinum-based (cisplatin or carboplatin) chemotherapy in the locally advanced or metastatic setting/recurrent NSCLC with documented disease progression by investigator assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Participants with a known anaplastic lymphoma kinase (ALK) fusion oncogene (must be documented in the participant's chart) must have also experienced disease progression or intolerance with a first-line ALK Tyrosine Kinase Inhibitor (TKI) approved for the treatment of ALK fusion oncogene NSCLC (for example, crizotinib). Disease progression or intolerance must be documented",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Participants with a known mutation in the epidermal growth factor receptor (EGFR) gene (must be documented in the participant's chart) must have also experienced disease progression or intolerance with an EGFR TKI approved for the treatment of EGFR-mutant NSCLC (for example, gefitinib, erlotinib, afatinib). Disease progression or intolerance must be documented",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Measurable disease determined as per the RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Life expectancy of at least (\\>/=) 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Left ventricular ejection fraction (LVEF) \\>/= 50 percent (%) by either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Use of highly effective contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "-Related Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Any approved anti-cancer therapy less than or equal to (\\",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": ") 7 days prior to the first study treatment on D1C1 (The baseline computed tomography \\[CT\\] scan must be completed after discontinuation of TKIs); (2) Hormone-replacement therapy or oral contraceptives; (3) Anti-emetics, Granulocyte-colony stimulating factor (GCS-F), and prophylactic antibiotics according to local standards",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Investigational therapy participation in another clinical study with therapeutic intent \\",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "/=14 days since the last fraction of radiotherapy have elapsed before the first study treatment on Day 1 as long as a sufficient number of target lesions remain to allow for measurable disease as per RECIST v1.1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Participants who have untreated brain metastases or are symptomatic; participants with treated brain metastases must have discontinued corticosteroid therapy and not have any neurological symptoms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* History of intolerance (including Grade 3 or 4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins or any excipient of the product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* History of exposure to the following cumulative doses of anthracyclines: Doxorubicin or liposomal doxorubicin \\> 500 milligram per meter-square (mg/m\\^2); Epirubicin \\> 900 mg/m\\^2; Mitoxantrone \\> 120 mg/m\\^2. If another anthracycline, or more than one anthracycline, has been used, the cumulative dose must not exceed the equivalent of 500 mg/m\\^2 doxorubicin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Peripheral neuropathy of Grade \\>/= 3 per the National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v. 4.0)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those mentioned above",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "Cardiopulmonary Function Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Severe dyspnea at rest due to complications of advanced malignancy or requiring current continuous oxygen therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Clinical history of active hemoptysis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Evidence of active pneumonitis during screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Current unstable ventricular arrhythmia requiring treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* History of symptomatic congestive heart failure (CHF) New York Heart Association (NYHA) classes II-IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* History of myocardial infarction or unstable angina within 6 months of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* History of a decrease in LVEF to \\<50%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "General Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Major surgical procedure or significant traumatic injury within 28 days before enrollment or anticipation of the need for major surgery during the course of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Current pregnancy or lactation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02289833",
    "statement": "* Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Written informed consent;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Newly diagnosed histologically or cytologically confirmed NSCLC excluding squamous NSCLC (mixed cancer types should be classified according to the prevalent cell type);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* IIIb or IV stage of NSCLC (TNM classification version 6);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Age ≥ 18 years and age ≤ 75 years (both inclusive);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2, (not declining within 2 weeks prior to the first dose of investigational product);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Life expectancy - 12 weeks or more from the moment of randomization;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Presence of at least 1 measurable tumour with a size not less than 1 cm (revealed with CT slice thickness not more than 5 mm), as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria (specifically, no ascites, pleural, or pericardial effusions, osteoblastic bone metastases, or carcinomatous lymphangitis of the lung as only lesion;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Patients should be able to follow the Protocol procedures (according to Investigator's assessment);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Patients must implement reliable contraceptive measures during all the study treatment, starting 4 weeks prior to the administration of the first dose of investigational product until 6 months after the last dose of investigational product. This requirement does not apply to participants who have undergone surgical sterilization, or patients who are postmenopausal (documented) for the past 2 years. Reliable contraceptive measures include two methods of contraception, including one barrier method",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Squamous NSCLC;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Proven coagulopathy, clinically significant hemorrhage in the past including nasal hemorrhage;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* absolute neutrophil count \\<1500/mm3;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Platelets \\<100 000/mm3;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Hemoglobin \\< 90 g/L;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Creatinine level ≥1.5 mg/dL;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Bilirubin level ≥1.5 × upper limit of normal (ULN);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Aspartate-aminotransferase(AST) and alanine-aminotransferase (ALT) levels ≥2.5 × ULN (≥5 × ULN for patients with liver metastases);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Alkaline phosphatase level ≥5 × ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Current therapeutic anticoagulation treatment, aspirin (more than 325 mg/day), nonsteroidal anti-inflammatory drugs, antiplatelet agents or protracted treatment with these drugs less than 1 month before entering the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medical correction methods (low salt diet, physical exercise);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Any previous anticancer therapy (chemotherapy, radiation therapy , surgery etc.) of metastatic NSCLC;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Radiation or hormone therapy within 21 days prior to randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Major surgery 28 days before inclusion into the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Previous antiangiogenic therapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Hypersensitivity to taxanes, platinum agents, recombinant murine proteins, contrast agents, premedication agents specified by Protocol (dexamethasone, diphenhydramine, ranitidine) or excipients of investigational products;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* NSCLC metastases in central nervous system excluding metastases non-progressing without glucocorticosteroids within 4 weeks before inclusion into the trial;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Cardiovascular system pathology (CHF stage III-IV according to New York Heart Association (NYHA) classification);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Pregnancy or lactation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Conditions limiting patient's adherence to Protocol requirements (dementia, neurologic or psychiatric disorders, drug addiction, alcoholism and others);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Simultaneous participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Any other concomitant cancer revealed within 5 years prior to screening, except curatively treated intraductal carcinoma in situ, curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Acute or active chronic infections;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Hepatitis C virus, hepatitis B virus, HIV, or syphilis infections;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01763645",
    "statement": "* Obstacles in intravenous administration of study drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Histologically or cytologically confirmed solid tumors that are refractory to standard therapy or for which no standard therapy exist",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Age ≥ 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* ECOG Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* LVEF (measured by Echocardiogram) \\> 50%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* No gastrointestinal bleeding within 1 year of study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Adequate organ and marrow function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Hemoglobin ≥ 10g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Absolute Neutrophil Count ≥ 1500/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Platelet Count ≥ 100,000/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* AST \\& ALT ≤ 2.5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Bilirubin ≤ 1.5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Cr Cl ≥ 50 mL/min (as determined by the Cockcroft-Gault equation or by 24-hour urine collection)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Prior therapy against VEGF or VEGFRs including, but not limited to bevacizumab, sunitinib, sorafenib, pazopanib, motesanib (AMG706), or cediranib (AZD2171), is permitted so long as the agent does not have any known activity against DLL4 and the last dose received s at least 6 weeks prior to first dose of MEDI0639.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Life expectancy ≥ 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Females of childbearing potential must be surgically sterile, have a sterile male partner, be premenarchal or at least 2 years postmenopausal, practice abstinence or otherwise must use 2 effective methods of contraception from the time of initiation of investigational product.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Males, unless surgically sterile, must use 2 effective methods of contraception with a female partner and must agree to continue using such contraception for 90 days after the last dose of MEDI0639",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Concurrent enrollment in another investigational clinical study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Receipt of any investigational anticancer therapy within 4 weeks prior to the first dose of MEDI0639 or in the case of monoclonal antibodies, 6 weeks prior to the first dose of MEDI0639",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Concurrent or previous treatment with inhibitors of DLL4",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Known bleeding diathesis, esophageal varices, or angioplasty",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Pulmonary hemorrhage or gross hemoptysis within 12 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Known arterial or venous thrombosis or pulmonary embolism within 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Concurrent use of systemic low molecular weight heparin or low dose warfarin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Presence of brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Cerebrovascular accident or transient ischemic attack within 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Cardiovascular events, such as myocardial infarction, unstable/severe angina, coronary/peripheral artery bypass graft, unstable cardiac arrhythmia requiring medication, congestive heart failure (NYHA \\> class II), within 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Tumors with squamous cell histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Major surgical procedure within 90 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Pregnancy or lactation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01577745",
    "statement": "* Known HIV positive or Hepatitis A, B, or C infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has histologically or cytologically confirmed nonsquamous (adenocarcinoma/large cell or other) non small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has Stage IV disease at the time of study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Measurable or nonmeasurable disease (as defined by the Response Evaluation Criteria in Solid Tumors RECIST 1.0) at the time of study entry (participants with only truly nonmeasurable disease are not eligible)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has resolution to Grade ≤ 1 of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has an Eastern Cooperative Oncology Group performance status score of 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has adequate hepatic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has adequate renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has adequate hematologic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* If female, is surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method during and for 6 months after the treatment period (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method). If male, the participants surgically sterile or compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Female participants of childbearing potential must have a negative serum",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has squamous non small cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the Epidermal Growth Factor Hormone (EGFR), vascular endothelial growth factor (VEGF), or VEGF receptor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Received previous chemotherapy for advanced NSCLC (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 1 year prior to randomization)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Undergone major surgery or received any investigational therapy in the 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Undergone chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants. Participants who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has superior vena cava syndrome contraindicating hydration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has current clinically-relevant coronary artery disease or uncontrolled congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has experienced myocardial infarction within 6 months prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has an ongoing or active infection (requiring antibiotics), including active tuberculosis or known infection with the human immunodeficiency virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder, potentially precluding protocol compliance",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has Grade ≥ 2 peripheral neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has significant third space fluid retention, requiring repeated drainage",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has any other serious uncontrolled medical disorders or psychological conditions that would, in the opinion of the investigator, limit the participant's ability to complete the study or sign an informed consent document The participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of IMC-11F8, or any other contraindication to one of the administered treatments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Is pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has a known history of drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00982111",
    "statement": "* Has a concurrent active malignancy other than adequately-treated basal cell carcinoma of the skin or preinvasive carcinoma of the cervix. A participant with previous history of malignancy other than NSCLC is eligible, provided that he/she has been free of disease for ≥ 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00518011",
    "statement": "* adult patients, \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00518011",
    "statement": "* non-small cell lung cancer, stage IIIb (with effusion) or stage IV with measurable disease ;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00518011",
    "statement": "* ECOG PS 2;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00518011",
    "statement": "* adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00518011",
    "statement": "* prior chemotherapy or systemic anti-tumor therapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00518011",
    "statement": "* hypersensitivity to erlotinib;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00518011",
    "statement": "* any condition contraindicating the use of the study medication and/or impairing the interpretation of results and/or leading to treatment-related complications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02668393",
    "statement": "*Patients with histologically/ cytologically confirmed locally advanced (Stage IIIB) or metastatic (Stage IV) lung adeno carcinoma after failure of first line platinum - based chemotherapy (patients with non-target lesion only are eligible).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02668393",
    "statement": "First line chemotherapy may include continuation or switch maintenance therapy. One prior adjuvant and/or neoadjuvant chemotherapy line is accepted. Prior immunotherapy is allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02668393",
    "statement": "* ECOG inferior or equal to 1 at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02668393",
    "statement": "* Further inclusion criteria apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02668393",
    "statement": "* Patients who have received more than one prior line of chemotherapy (i.e. second or third line chemotherapy) for advanced or metastatic NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02668393",
    "statement": "* Patients known to be positive for activating Epidermal Growth Factor Receptor (EGFR) mutation or patients known to be positive for ALK translocation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02668393",
    "statement": "* Further exclusion criteria apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094261",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02094261",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Signed informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Histologically or cytologically confirmed NSCLC except for squamous cell carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Treated brain metastases without evidence of progression or hemorrhage after treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Appropriateness for first- or second-line systemic therapy for advanced NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Age ≥ 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* For women of childbearing potential and sexually active males, use of an accepted and effective method of contraception (e.g., hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Brain biopsy/neurosurgical procedure performed within 3 months prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Progressive neurologic symptoms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Active malignancy other than lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Current, recent, or planned participation in an experimental drug study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Prior treatment with an investigational or marketed agent that acts by anti-angiogenesis mechanisms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Gross hemoptysis within 3 months prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Inadequately controlled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Unstable angina or New York Heart Association Grade II or greater congestive heart failure (CHF)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Myocardial infarction within 6 months prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Stroke within 6 months prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Active symptomatic peripheral vascular disease within 6 months prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* History of significant vascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Evidence of bleeding diathesis or coagulopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Known hypersensitivity to any components of bevacizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Inadequate organ function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Serious non-healing wound, ulcer, or bone fracture",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Urine protein/creatinine (UPC) ratio of ≥ 1.0",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Pregnancy or lactation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Known evidence of disseminated intravascular coagulation (DIC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Active infection or fever \\> 38.5°C within 3 days prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312728",
    "statement": "* Any other medical condition (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": ". Age ≥ 18 years of age at the time of signing the Informed Consent Form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "2. Understand and voluntarily provide written consent to the Informed Consent Form prior to conducting any study related assessments/procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "3. Able to adhere to the study visit schedule and other protocol requirements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "   Disease Specific",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "4. Histologically or cytologically confirmed Stage IIIB or IV squamous cell Non Small Cell Lung Cancer at study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "5. No other current active malignancy requiring anticancer therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "6. Radiographically documented measurable disease at study entry (as defined by the Response Evaluation Criteria In Solid Tumors \\[RECIST\\] v1.1 criteria).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "7. No prior chemotherapy for the treatment of metastatic disease at study entry. Adjuvant chemotherapy is permitted providing cytotoxic chemotherapy was completed 12 months prior to starting the study and without disease recurrence.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "8. Absolute neutrophil count ≥ 1500 cells/mm\\^3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "9. Platelets ≥ 100,000 cells/mm\\^3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "10. Hemoglobin ≥ 9 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "11. Aspartate transaminase/serum glutamic oxaloacetic transaminase, alanine transaminase/serum glutamic pyruvic transaminase ≤ 2.5 × upper limit of normal range or ≤ 5.0 × upper limit of normal range if liver metastases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "12. Total bilirubin ≤ 1.5 × upper limit of normal range except in cases of Gilbert's disease and liver metastases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "13. Creatinine ≤ 1.5 mg/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "14. Expected survival of \\> 12 weeks for the Induction part of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "15. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "16. For Maintenance part of the study, subjects must have received at least one dose of nab-paclitaxel in each of the 4 cycles during Induction",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "    Pregnancy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "17. Females of childbearing potential \\[defined as a sexually mature woman who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)\\] must:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "    1. agree to take a pregnancy test prior to starting study medication and throughout the study participation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "    2. commit to complete abstinence from heterosexual contact, or agree to use medical doctor-approved contraception throughout the study without interruption, and while receiving study medication or for a longer period if required by local regulations.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "18. Male subjects must:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "    c. agree to complete abstinence from heterosexual contact or use a condom during sexual contact with a female of child bearing potential while receiving study medication and within 6 months after last dose of study medication, even if he has undergone a successful vasectomy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "19. Females must abstain from breastfeeding during study participation and 3 months after IP discontinuation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "(except if specified at study entry only):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "1. Evidence of active brain metastases, including leptomeningeal involvement (prior evidence of brain metastasis are permitted only if treated and stable and off therapy for ≥ 4 weeks prior to first dose of study drug).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "2. Only evidence of disease is non-measurable at study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "3. Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology Criteria for Adverse Events v4.0).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "4. Venous thromboembolism within 6 months prior to signing Informed Consent Form.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "5. Current congestive heart failure (New York Heart Association class II-IV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "6. History of the following within 6 months prior to first administration of a study drug: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant electrocardiogram (ECG) abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "7. Treatment with any investigational product within 28 days prior to signing Informed Consent Form.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "8. History of allergy or hypersensitivity to nab-paclitaxel or carboplatin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "9. Currently enrolled in any other clinical protocol or investigational trial that involved administration of experimental therapy and/or therapeutic devices.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "10. Any other clinically significant medical condition and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "11. Subject has any other malignancy within 5 years prior to randomization. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (TNM stage of T1a or T1b) - all treatments that should have been completed 6 months prior to signing informed consent form (ICF).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "12. Subject has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting investigational product (IP), and/or from whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02027428",
    "statement": "13. Pregnant and nursing females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": ". Diagnosis of advanced stage NSCLC squamous histology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "2. Platinum-based doublet chemotherapy as 1st line treatment of Stage IIIB/IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "3. Eligible to receive 2nd line therapy in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "4. Measurable disease according to RECIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "5. Adequate Performance Status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "6. Availability of tumour tissue material for correlative studies. Archived tumour tissue is acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "7. Adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "8. Age = 18 years and above.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "9. Written informed consent that is consistent with International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": ". Prior treatment with Epidermal Growth Factor Receptor (EGFR) directed small molecules or antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "2. Radiotherapy within 4 weeks prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "3. Active brain metastases .",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "4. Any other current malignancy or malignancy diagnosed within the past three (3) years (other than basal-cell carcinoma of the skin, in situ cervical cancer, in situ prostate cancer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "5. Known pre-existing interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "6. Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "7. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "8. Women of child-bearing potential and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "9. Female patients of childbearing potential (see Section 4.2.3.3) who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "   1. are nursing or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "   2. are pregnant or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "   3. are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "10. Active hepatitis B infection (defined as presence of Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "11. Known or suspected active drug or alcohol abuse in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "12. Any contraindications for therapy with afatinib or erlotinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "13. Known hypersensitivity to erlotinib, afatinib or the excipients of any of the trial drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "14. Major surgery within 4 weeks of starting study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "15. Prior participation in an afatinib clinical study, even if not assigned to afatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "16. Use of any investigational drug within 4 weeks of randomisation (unless a longer time period is required by local regulations or by the guidelines for the investigational product).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01523587",
    "statement": "17. Patients without Progression of their lung cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Age \\> 18 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Stage IIIB (with cytologically confirmed malignant pleural or pericardial effusion) or Stage IV histological or cytological confirmation of NSCLC of non-squamous cell carcinoma subtype. (thoracentesis or pericardiocentesis is not necessary if a biopsy of the original tumor is available to confirm diagnosis of NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Patients with at least one measurable lesion. Lesions must be measured by CT-scan or MRI (Magnetic resonance imaging) according to Response Evaluation Criteria in Solid Tumors (RECIST, see Appendix 10.3)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Life expectancy of at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Hemoglobin \\>/= 9.0 g/dl (\\>/= 5.6 mmol/l)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Absolute neutrophil count (ANC) \\>/= 1,500/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Platelet count \\>/= 100,000/µl",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Total bilirubin \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "/= 70ml/min",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to performing any study specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Excluded medical conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Cardiac disease: Congestive heart failure \\> class II NYHA (New York Heart Association). Patients must not have unstable angina (anginal symptoms at rest) or active coronary artery disease (CAD), or myocardial infarction within the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Cardiac arrhythmias requiring anti-arrhythmic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Uncontrolled hypertension defined as systolic blood pressure \\> 150 mmHg or diastolic pressure \\> 90 mmHg, despite optimal medical management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* History of HIV (Human immunodeficiency virus) infection or chronic hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Active clinically serious infections (\\> grade 2 NCI-CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 3.0)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Known brain metastasis. Patients with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* History of organ allograft",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Patients with evidence or history of bleeding diathesis or coagulopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Patients undergoing renal dialysis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Cancer other than NSCLC within 5 years prior to start of study treatment EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors \\[Ta (Noninvasive tumor), Tis (Carcinoma in situ) \\& T1 (Tumor invades lamina propria)\\]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Uncontrolled hypertension defined as systolic blood pressure \\> 150 mmHg or diastolic pressure \\> 90 mmHg, despite optimal medical management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Pulmonary hemorrhage/bleeding event \\> Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Any other hemorrhage/bleeding event \\> CTCAE Grade 3 within 4 weeks of first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Serious, non-healing wound, ulcer, or bone fracture",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Uncorrected dehydration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate birth control measures during the course of the trial. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Known or suspected allergy to the investigational agent or any agent given in association with this trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Patients unable to swallow oral medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Any malabsorption condition",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Patients with a hearing impairment (FOR GERMANY ONLY)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* NSCLC patients with squamous cell carcinoma diagnosis documented either by cytology or biopsy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Excluded therapies and medications, previous and concomitant:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Any prior systemic anticancer therapy including cytotoxic therapy, targeted agents, experimental therapy, adjuvant, or neo-adjuvant therapy for NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Concomitant use of nephrotoxic drugs, ototoxic drugs, anticonvulsant, anti-gout treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed as described in the Prior and Concomitant Therapy section)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Radiotherapy during study or within 4 weeks of start of study drug. (Palliative radiotherapy will be allowed as described in the Prior and Concomitant Therapy section) (FOR FRANCE ONLY)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug (bronchoscopy is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00449033",
    "statement": "* Granulocyte colony stimulating factor (GCSF) or Granulocyte macrophage colony stimulating factor (GMCSF), within 3 weeks of study entry (these growth factors may be used during the study thereafter).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02544633",
    "statement": "* Diagnosis of non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02544633",
    "statement": "* Metastatic or locally advanced disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02544633",
    "statement": "* Prior platinum chemotherapy or immunotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02544633",
    "statement": "* Test result showing genetic change in MET tumor gene",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02544633",
    "statement": "* At least one tumor that can be measured on a radiographic scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02544633",
    "statement": "* Prior treatment with inhibitor of MET or HGF",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02544633",
    "statement": "* Prior positive test for EGFR mutation or ALK gene rearrangement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02544633",
    "statement": "* Uncontrolled tumor in the brain",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00404924",
    "statement": "* Patients with Non-small cell lung cancer for which the standard cancer treatments of surgery, chemotherapy, radiation or other anticancer drugs are no longer appropriate treatments for you.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00404924",
    "statement": "* Patients who have had standard cancer treatments of surgery, chemotherapy or other systemic anti-cancer therapy within 4 weeks before start of study therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00404924",
    "statement": "* Three or more prior chemotherapy regimens.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00404924",
    "statement": "* Significant cardiovascular events.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Histologically or cytologically confirmed NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Advanced NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Measurable disease (as defined by Response Evaluation Criteria in Solid Tumors \\[RECIST 1.0\\])",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status is ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Age ≥ 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Adequate hematologic function = an absolute neutrophil count (ANC) ≥ 1500/μL, hemoglobin ≥ 9 g/dL, and a platelet count ≥ 100,000/microliter (μL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Adequate hepatic function = a total bilirubin ≤ 1.5 mg/dL transaminases and alkaline phosphatase ≤ 5 x the upper limit of normal (ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Adequate renal function serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance (CrCl) \\> 60 mL/minute, and urine dipstick for protein \\< 1+ (ie, either 0 or trace)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Adequate coagulation function, INR ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 5 seconds above ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Adequate contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Signed informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Untreated CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Prior bevacizumab therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Radiologically documented evidence of major blood vessel invasion or encasement by cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Prior systemic chemotherapy for Stage IIIB/IV NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Prior systemic chemotherapy or radiation therapy for Stage I-IIIA NSCLC \\< 1 year prior",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Any concurrent malignancy other than basal cell skin cancer, or carcinoma in situ of the cervix",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Uncontrolled thrombotic or hemorrhagic disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Poorly-controlled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Chronic daily treatment with aspirin (\\> 325 mg/day) or other known inhibitors of platelet function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* History of gross hemoptysis (defined as bright red blood or ≥ 1/2 teaspoon)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Serious non-healing wound, ulcer, or bone fracture",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Undergone major surgery or subcutaneous venous access device placement. Post-operative bleeding complications or wound complications from a surgical procedures performed in the last 2 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Elective or a planned major surgery to be performed during the course of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Peripheral neuropathy ≥ Grade 2 (National Cancer Institute Common Toxicity Criteria for Adverse Events, Version 3.0 \\[NCI-CTCAE v 3.0\\])",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* If female, is pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Radiographic evidence of intratumor cavitation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00735696",
    "statement": "* Grade 3-4 gastrointestinal bleeding within 3 months prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Life expectancy \\>3 months assessed during Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic, and that is refractory to standard therapy or for which no standard therapy is available or accessible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* If female and of childbearing potential: a negative pregnancy test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Male or female: either not of childbearing potential or agreeing to use a medically effective method of contraception as per institutional standards during the trial and for 4 months after the last dose of trial drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Part 1 ONLY: Tumor documented to be KRAS WT by local assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Part 2 ONLY:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Measurable disease according to RECIST v1.1 that has been confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks prior to Cycle 1/Day 1 (C1/D1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Basket Cohort ONLY:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Tumor documented to be KRAS WT by local assessment according to institutional standards. If KRAS WT is not previously documented and if archival tissue is not available for pretrial assessment, patient must be willing to undergo a tumor biopsy to confirm eligibility.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Confirmed MET-amplification by local assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* No prior therapy with MET-targeting agents (except a subset of patients having received prior therapy with a MET-targeting TKI).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Willingness to undergo a pre- and post-dosing biopsy (maximum of 2 biopsies) from primary or metastatic tumor site(s) considered safely accessible for biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* NSCLC MET-Amplified Cohort ONLY:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Documented NSCLC meeting disease criteria as defined per protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Documented MET-amplification.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* May have received prior therapy with MET-targeting and/or EGFR-targeting agents (antibodies or TKIs).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Willingness to undergo a pre-dosing biopsy (mandatory unless a recent tumor biopsy is available), and potentially a biopsy at the End of Cycle 2 (EOC2) (optional), from a primary or metastatic tumor site considered safely accessible for biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* NSCLC METex14del Cohort ONLY:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Documented NSCLC meeting disease criteria as defined per protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Documented METex14del (tumors need not be MET-amplified).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* May have received prior therapy with MET-targeting and/or EGFR-targeting agents (antibodies or TKIs).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Willingness to undergo a pre-dosing biopsy (mandatory unless a recent tumor biopsy is available), and potentially a biopsy at the EOC2 (optional), from a primary or metastatic tumor site considered safely accessible for biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Any antineoplastic agent for the primary malignancy (standard or investigational) without delayed toxicity within 4 weeks or 5 plasma half-lives, whichever is shortest, prior to C1/D1, except nitrosoureas and mitomycin C within 6 weeks prior to C1/D1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Immunosuppressive or systemic hormonal therapy within 2 weeks prior to C1/D1, with exceptions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Use of hematopoietic growth factors within 2 weeks prior to C1/D1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Active second malignancy or history of another malignancy within the last 3 years, with exceptions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Central nervous system (CNS) malignancy including primary malignancies of the CNS and known, untreated CNS or leptomeningeal metastases, or spinal cord compression; patients with any of these not controlled by prior surgery or radiotherapy, or symptoms suggesting CNS involvement for which treatment is required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Inadequate recovery from an acute toxicity associated with any prior antineoplastic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Major surgical procedure within 4 weeks prior to C1/D1 or inadequate recovery from any prior surgical procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 1 month prior to C1/D1, unless adequately treated and stable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Active uncontrolled bleeding or a known bleeding diathesis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Significant cardiovascular disease or condition.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Abnormal hematologic, renal or hepatic function.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Part 2 ONLY:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Radiotherapy against target lesions within 4 weeks prior to C1/D1, unless there is documented progression of the lesion following the radiotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Basket Cohort ONLY:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Prior therapy with MET-inhibiting agents (exceptions will be a subset of patients that will be entered to the Basket Cohort after having received prior therapy with a MET-targeting TKI).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Prior therapy with antibody to hepatocyte growth factor (HGF).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Basket Cohort and NSCLC MET-Amplified Cohort ONLY:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02648724",
    "statement": "* Tumor status demonstrating MET-polysomy in the absence of MET-amplification, as specified per protocol. Patients in the NSCLC METex14del Cohort with polysomy are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": ". Age≥18 years old, male or female, signed Informed Consent Form (ICF).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "3. Histologically or cytologically confirmed ES-SCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "4. No prior systemic treatment for ES-SCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "5. Adequate hematologic and end organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": ". Active leptomeningeal disease or uncontrolled, untreated brain metastasis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "2. Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "3. Was administered a live vaccine ≤ 4 weeks before randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "4. Active autoimmune diseases or history of autoimmune diseases that may relapse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "5. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "6. With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "7. Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to randomization, including but not limited to tuberculosis infection;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "8. Participant with untreated hepatitis B virus (HBV)/hepatitis C virus (HCV), or a known history of HIV infection;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "9. Participants with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized at the time of randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "10. Clinically significant pericardial effusion, or Clinically uncontrolled pleural effusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04005716",
    "statement": "NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "* Patients diagnosed with lung cancer who have not responded to prior therapy or have become worse.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "* Patients who have overall good general conditions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "* Patients who have at least one lesion that can be accurately assessed by imaging.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "* Patients who have appropriate renal conditions confirmed by test results for taking part in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "* Evidence of non-childbearing status for women of childbearing potential, or postmenopausal status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "* Patients with brain metastases or spinal cord compression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "* Patients with significant abnormal ECG findings.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "* Patients with evidence of severe or uncontrolled systemic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "* The main organ functional test values for bone marrow, kidney, and liver, etc., do not meet the standards.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "* Patients with known hypersensitivity to docetaxel or products containing polysorbate 80.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "Only for monotherapy cohort eligibility criteria Patients with advanced solid malignancies refractory to standard treatment or for which no standard therapy exists irrespective of the stage and previous treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01605916",
    "statement": "Patients with histologically or cytologically confirmed advanced solid malignancies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556322",
    "statement": "* adult patients \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556322",
    "statement": "* histologically documented, locally advanced or recurrent or metastatic NSCLC;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556322",
    "statement": "* measurable disease;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556322",
    "statement": "* disease progression during 1-4 cycles of platinum-based chemotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556322",
    "statement": "* any other malignancies within the last 5 years;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00556322",
    "statement": "* unstable systemic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Written informed consent provided prior to any screening procedure",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Male or female, greater than (\\>) 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Demonstrated PD on or after first-line chemotherapy for Stage IIIB/IV disease. The first-line therapy must consist of platinum-based regimens in combination with taxanes, gemcitabine or vinorelbine. Stage IIIB/IV participants must have measurable disease (tumor) without clinically significant pleural effusion unless the pleural effusion can be effectively drained prior to admission into the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* A chemotherapy-free interval of at least 3 weeks between the end of first-line chemotherapy and start of study treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* At least 1 measurable lesion according to the modified World Health Organization (WHO) criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Archived tissue or cytologic sample available for the determination of epidermal growth factor receptor (EGFR) expression",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Eastern cooperative oncology group (ECOG) performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Life expectancy \\>12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Adequate baseline organ functions, defined as: Serum creatinine less than or equal to (≤)1.5\\*upper limit of normal (ULN). In case of borderline values for serum creatinine, creatinine clearance must be greater than or equal to (≥) 45 millimeters per minute (mL/min); Total bilirubin \\<1.5\\*ULN; Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5\\*ULN (participants with liver metastases should have ALT/AST \\<5\\*ULN.); Absolute neutrophil count ≥1500per cubic millimeter(mm\\^3); Platelet count ≥100000/mm\\^3; Hemoglobin level ≥10 grams per deciliter",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* If procreative potential (male or female), willingness to use effective contraceptive methods for the duration of treatment and continuing for 2 months after the last dose. Participants of procreative potential are defined as any fertile male, or any female who has experienced menarche and who is not postmenopausal (defined as age-related amenorrhea ≥12 months) or who has not undergone successful surgical sterilization (hysterectomy or bilateral oophorectomy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Radiotherapy or major surgery within 30 days prior to the start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Prior treatment with an EGFR-directed therapy or with EGFR signal transduction inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Prior treatment with pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Pregnant (confirmed by beta-human chorionic gonadotropin \\[β-HCG\\]) or lactating female",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Weight loss \\>10% within 12 weeks prior to the start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Documented or symptomatic brain metastases or leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Myocardial infarction within 6 months prior to the start of study treatment, uncontrolled congestive heart failure, or any current New York Heart Association Grade III or IV cardiovascular disorder despite treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Presence of a Grade ≥2 preexisting skin disorder (except for alopecia)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Previous diagnosis of autoimmune disease with significant organ involvement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Concurrent malignancies or invasive carcinomas diagnosed within the past 5 years, except for adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Any significant disease that, in the Investigator's opinion, should exclude the participant from the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* History of significant neurologic or psychiatric disorder (for example, dementia, seizures, or bipolar disorder)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* History of drug abuse within 6 months prior to the start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Known conditions that require concurrent treatment with a nonpermitted drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Presence of a contraindication to the study treatment(s) according to the current Investigator's Brochure (IB) for matuzumab and the labeling for pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Known hypersensitivity to the study treatment or any of its components",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00111839",
    "statement": "* Participation in another clinical study within 30 days prior to the start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Subjects with Stage IIIB or IV NSCLC (any histology) at the time of study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Subjects with histologically or cytologically confirmed diagnosis of NSCLC that is:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "  1. EGFR wt status (for exon 19 deletions and exon 21 L858R substitution mutations)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "  2. and ALK rearrangement-negative",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "  3. and MET-mutation and/or amplification status (as defined in the protocol).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* For Cohorts 1a, 1b, 2, 3, 4 subjects must have failed one or two prior lines of systemic therapy for advanced disease (stage IIIB or IV NSCLC). For Cohort 6, subjects must have failed one prior line of systemic therapy for advanced disease (stage IIIB or IV NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* For Cohorts 5a, 5b, and 7, subjects must not have received any systemic therapy for advanced disease (stage IIIB or IV NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Subjects with at least one measurable lesion as defined by RECIST 1.1. A previously irradiated site lesion may only be counted as a target lesion if there was clear sign of progression since the irradiation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Subjects who recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (Common Terminology Criteria for Adverse Events \\[CTCAE\\] v 4.03). Subjects with any grade of alopecia were allowed to enter the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Subjects with adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Prior treatment with crizotinib, or any other MET or HGF inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Characterized EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 mutations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Characterized ALK-positive rearrangement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Clinically significant, uncontrolled heart diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting capmatinib or subjects who had not recovered from radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy ≤ 2 weeks prior to starting capmatinib or subjects who had not recovered from radiotherapy-related toxicities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Palliative radiotherapy for bone lesions ≤ 2 weeks prior to starting capmatinib was allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Receiving treatment with strong inducers of CYP3A4 and/or any enzyme-inducing anticonvulsant and could not be discontinued ≥ 1 week prior to the start of treatment with capmatinib and for the duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Receiving treatment with unstable or increasing doses of corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of capmatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Applicable to Cohorts 1-4 and Cohort 6 only: previous anticancer and investigational agents within 4 weeks or ≤ 5 × half-life of the agent (whichever was longer) before first dose of- capmatinib. If previous treatment was a monoclonal antibody, then the treatment must have been discontinued ≥ 4 weeks before first dose of capmatinib. If previous treatment was an oral targeted agent, then the treatment must have been discontinued ≥ 5 × half-life of the agent before the first dose of capmatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Pregnant or nursing (lactating) women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 7 days after stopping treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Sexually active males unless they used a condom during intercourse while taking drug and for 7 days after stopping treatment and should not father a child in this period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "* Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": ". Provide a signed and dated informed consent form (ICF).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "2. Chinese male or female with age ≥18 years old at the time of the informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "3. Documented histology- and/or cytology-confirmed metastatic melanoma or non-small cell lung cancer (NSCLC) (i.e. adenocarcinoma, large cell carcinoma, squamous cell carcinoma).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "4. Presence of B-RAF Proto-oncogene, Serine/threonine Kinase V600E Mutant (BRAF V600E) mutation as determined by a local laboratory with a National Medical Products Administration (NMPA) approved BRAF test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "5. BRAF inhibitor treatment-naïve participants and having failed the previous therapy(ies) for metastatic disease or are not eligible to standard therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "6. At least one tumor lesion as per investigator assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, which has neither been irradiated nor biopsied during the screening period. The irradiated lesion is acceptable only if it is proven as disease progression deemed measurable prior to study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "7. Life expectancy ≥3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "8. Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "9. Adequate hematologic function at screening and baseline",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "10. Adequate hepatic function at screening and baseline",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "11. Adequate renal function at screening and baseline",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "12. Able to comply with the study protocol as per investigator assessment including oral drug intake, complying scheduled visits, treatment plan, laboratory tests and other study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "13. Women are either postmenopausal for at least 1 year, or are surgically sterile for at least 6 weeks, or women of childbearing potential (WOCBP) must agree to take appropriate precautions to avoid pregnancy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "14. Men must agree not to father child until 90 days after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": ". Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to encorafenib, or its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "2. For metastatic NSCLC: documented anaplastic lymphoma kinase (ALK) fusion oncogene, ROS1 (c-ros oncogene 1) rearrangement or epidermal growth factor receptor (EGFR) sensitizing or driver mutation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "3. Receipt of anticancer medications or investigational drugs within intervals before the first administration of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "4. Symptomatic brain metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "5. Leptomeningeal disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "6. Participant has not recovered to ≤Grade 1 from toxic effects of prior therapy and/or complications from prior surgical treatment before starting study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "7. Current use of prohibited medication ≤1 week prior to start of the study treatment and/or concomitantly.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "8. Impairment of gastrointestinal function or disease which may significantly alter the absorption of oral study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "9. Impaired cardiovascular function or clinically significant cardiovascular diseases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "10. Participants with active Hepatitis B virus (HBV) or Hepatitis C virus (HCV) or any other severe viral active infection (e.g. severe acute respiratory syndrome coronavirus 2 \\[SARS-CoV-2\\] infection).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "11. Evidence of active, non-infectious pneumonitis, history of interstitial lung disease that required oral or intravenous glucocorticoid steroids for management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "12. Known history of a positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). Testing for HIV must be performed at sites where mandated locally.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "13. Participants who have had major surgery (e.g. inpatient procedure with regional or general anesthesia) within 6 weeks prior to start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "14. Previous or concurrent malignancy within 2 years of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "    Except:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "    1. Bowen's disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "    2. Cured basal cell or squamous cell skin cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "    3. Gleason 6 prostate cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "    4. Treated in-situ carcinoma of cervix.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "15. Participant's conditions that contraindicates the use of study treatment and may affect interpretation of results or that may render the participant at high risk from treatment complications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "16. Pregnant (confirmed by positive serum beta-human Chorionic Gonadotropin (ß-HCG) test), lactating or breast-feeding women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "17. Is a family member of the Investigator or any associate, colleague, and employee assisting in the conduct of the study (secretary, nurse, technician).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05003622",
    "statement": "18. Is in a position likely to represent a conflict of interest.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Signed written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Histologically or cytologically confirmed diagnosis: Arm A and B- stage IV recurrent metastatic squamous NSCLC with Fibroblast growth factor receptor 1 (FGFR1) gene amplification by central laboratory testing. Arm C- recurrent after local therapy or unresectable MPM with measurable lesions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "For specific arms the following requirements:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "Arm A: Subjects who have received no prior therapy for Stage IIIB or Stage IV or recurrent metastatic disease. Note, to avoid any undue delay of initiating systemic chemotherapy for these subjects with newly diagnosed metastatic disease, it is allowed to initiate the first cycle of chemotherapy while eligibility for the study is still being determined, as long as the first dose of GSK3052230 is given no later than Cycle 2 Day 1 of chemotherapy. In addition, subjects with Stage IIIB or Stage IV disease and recurrence after previous NSCLC that has been treated with surgery and adjuvant chemotherapy or a radio- chemotherapy regimen with curative intent are eligible, provided 6 months has passed since this treatment ended.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "Arm B: Subjects who have documented tumor progression (based on radiological imaging) or intolerability after receiving at least one prior line of platinum containing combination chemotherapy for Stage IIIB or Stage IV or recurrent metastatic disease. Note: Prior treatment should not include docetaxel but may have included paclitaxel.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "Arm C: Subjects who have received no prior systemic therapy for MPM.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Availability of archival tumor tissue required for assessment of deregulated FGF pathway signalling, but not limited to, FGFR1 amplification or FGF2 or FGFR1 expression. If archival tissue is not available, a fresh biopsy is required. In Arms A and B, subjects will be prospectively screened for FGFR1 gene amplification using a Fluorescence in situ hybridization (FISH) assay for the dose expansion and the MTD/MFD cohorts only. For inclusion in this study, based on the central laboratory testing, FGFR1 gene amplification must meet one of the following criteria: a ratio of FGFR1/CEN 8 of \\>=2; or average number of FGFR1 signals per tumor nucleus of \\>=6; or the percentage of tumor nuclei containing \\>=5 FGFR1 signals is \\>=50%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "In Arm C, FGF2 expression by IHC will be evaluated retrospectively in tissue samples by a central laboratory and is not a requirement for study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Measurable disease per RECIST version 1.1 (Arm A and B) and modified RECIST for Arm C.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Male or female \\>=18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception, from 14 days prior to the first dose of study treatment, throughout the study, and for 6 months following the last dose of chemotherapy or 4 weeks after the last dose of GSK3052230, whichever is latest. .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception for at least 2 weeks prior to administration of the first dose of study treatment and for at least 6 months after the last dose of chemotherapy to allow for clearance of any altered sperm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 for Arm A and C subjects and 0-2 for Arm B.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Must have adequate organ function as defined by the following baseline values: Absolute neutrophil count \\>=1.5 x 10\\^9/Liter, Hemoglobin \\>=9 gram (g)/decilitre(dL), Platelets \\>=100 x 10\\^9/L, Partial thromboplastin time (PTT) \\<=1.25 x upper limit of normal (ULN), Albumin \\>=2.5 g/dL, Serum total bilirubin \\<=1.25 times ULN (for Arm B: \\<=ULN ), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) \\<=2.5 times ULN (for Arm B: \\<=1.5 times ULN), Serum Creatinine \\<=1.5 x ULN, Or Measured or Calculated Creatinine Clearance \\>=45 mL/min (Arm A or B), \\>=65 mL/min (Arm C), Left ventricular ejection fraction \\>=50% by ECHO.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* For Arms A and C: Treatment with any FGFR inhibitor. For Arm B: Treatment with any anti-cancer therapy (for biological anti-cancer therapies see criteria below) during the preceding 4 weeks or within 4 half-lives of the therapy, whichever is longer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Receipt of any biological therapy within 6 weeks of the first dose of GSK3052230",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 (NCI CTCAE version 4.03) Grade 2 or higher from previous anti-cancer therapy, except alopecia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Active malignancy other than the cancer under study. Subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Presence of uncontrolled infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Prior major surgery or trauma within 28 days before first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Presence of any non-healing wound, fracture, or ulcer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Any prohibited medication(s) as described in protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Conditions likely to increase the potential for abdominal perforation or fistula formation, including but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "Luminal intestinal cancers or bulky abdominal disease. Presence or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease or intra-abdominal abscess within the six months prior to the first dose of GSK3052230.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "Other risk factors for perforation, such as acute diverticulitis, obstruction or previous abdominal or pelvic radiation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Symptomatic leptomeningeal or brain metastases or spinal cord compression Note: Subjects previously treated for these conditions are eligible if they meet both of the criteria below: (1) have had stable CNS disease for at least 4 weeks after local therapy as assessed by imaging (contrast enhanced magnetic resonance imaging \\[MRI\\] or computed tomography \\[CT\\]) prior to Day 1, and (2) are asymptomatic and off corticosteroids, or are on stable dose of corticosteroids for at least 4 weeks prior to Day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drugs (GSK3052230, docetaxel, paclitaxel, carboplatin, pemetrexed, cisplatin) and or their excipients that contraindicate their participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Known human immunodeficiency virus-positive serology, acquired immunodeficiency syndrome (AIDS), or an AIDS-related illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Prior organ or allogeneic stem cell transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* The following cardiac abnormalities:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "Corrected QT (QTc) interval \\>=480 millisecond. History of acute coronary syndromes (including unstable angina) within the past 24 weeks Coronary angioplasty or stenting within the past 24 weeks. Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "Abnormal cardiac valve morphology (\\>= Grade 2) documented by echocardiogram (subjects with Grade 1 abnormalities \\[i.e., mild regurgitation/stenosis\\] can be entered on study).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "History of known arrhythmias (except sinus arrhythmia and atrial fibrillation that is controlled) within the past 24 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Presence or history of hemoptysis (\\>1/2 teaspoon of red blood) 2 weeks prior to the first dose of GSK3052230",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per investigator's assessment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* Pregnant, lactating or actively breast feeding females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01868022",
    "statement": "* French subjects: The French subject has participated in any study using an investigational study treatment(s) during the previous 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Pathologically confirmed Stage IIIB NSCLC with malignant pleural effusion, or Stage IV disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Measurable disease on CT scan (by the Response Evaluation Criteria in Solid Tumors \\[RECIST\\] criteria)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 (which means able to independently care for self and to perform light work) .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Adequate blood counts",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Adequate liver and kidney function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Subjects or their legal representatives must be able to read, understand and provide written informed consent to participate in the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Predominant Squamous Cell NSCLC histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* History of treatment for NSCLC with chemotherapy, biological therapy, immunotherapy (surgery or radiation therapy are accepted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Brain (CNS) metastasis by head CT scan or MRI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Subjects with history of prior malignancy except for curatively treated basal cell carcinoma of the skin; cervical intra-epithelial neoplasia; or localized prostate cancer with a current prostate specific antigen (PSA) of \\< 4.0 mg/dL. Subjects with other curatively treated malignancies who have no evidence of metastatic disease and \\>2 year disease free interval may be entered after discussion with the Medical Monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* History of bleeding disorders, particularly coughing up ≥ ½ teaspoon bright red blood during the last 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Certain cardiac disorders such as recent myocardial infarction (MI), severe congestive heart failure, certain types of abnormal cardiac rhythm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Uncontrolled high blood pressure despite medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Uncontrolled, clinically significant active infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Known HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "* Known hypersensitivity to any of the components of CA4P, paclitaxel, carboplatin, bevacizumab, or radiologic contrast dyes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00653939",
    "statement": "Details of the above and additional inclusion and exclusion criteria can be discussed with an investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Female aged \\>/= 18 years with a diagnosis of LAM",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Pulmonary function abnormalities as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* FEV1 of ≤ 80% of the predicted value following administration of a standard dose of a short acting β2-agonist (\\*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* FEV1 \\< 90% of the predicted value of bronchodilator following administration of a standard dose of a short acting β2-agonist (\\*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) and DLco (uncorrected) \\<80% predicted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Female patients including those of childbearing potential will be included in this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Negative pregnancy test at screening and baseline",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* FEV1\\<50% of predicted post-bronchodilator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Change in FVC (ml) \\> ± 15% of screening value at baseline visit (not less than 14d after screening visit).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Use of any medicine containing estrogen in the 4 months prior to the screening visit and for the duration of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Significant hematologic, renal, hepatic laboratory abnormality or amylase \\> 1.5x the upper limit of the normal range at the screening or baseline visits",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Fasting blood glucose \\> 126mg/dl or random blood glucose \\>200mg/dl at screening and/or baseline",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Recent surgery (involving entry into a body cavity or requiring sutures) within 2 months of the screening visit or any evidence of unhealed surgical wound.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Uncontrolled hyperlipidemia (defined as persistent elevation of total cholesterol or triglycerides \\>6.5nM/L) or a history of clinical atherosclerotic disease including heart attack, angina, peripheral vascular disease or stroke.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Previous organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Inability to give informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "* Inability to perform pulmonary function or 6 minute walk tests and imaging assessments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01059318",
    "statement": "Other protocol-defined inclusion/exclusion criteria may apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* presence of Epidermal Growth Factor Receptor (EGFR) mutations in tumor biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* male or female patients age 18 years or older (For India only, male or female patients age \\>=18 years and \\<=75 years)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* adequate organ function, defined as all of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "  1. Absolute Neutrophil Count (ANC) \\> 1500/mm3. (ANC \\>1000/mm3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the sponsor).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "  2. Platelet count \\>75,000/mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "  3. Serum creatinine \\< 1.5 times of the upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "  4. Total Bilirubin \\< 1.5 times upper limit of (institutional) normal (Patients with Gilbert's syndrome total bilirubin must be \\<4 times institutional upper limit of normal).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "  5. Aspartate Amino Transferase (AST) and Alanine Amino Transferase (ALT) \\< three times the upper limit of (institutional) normal (ULN) (if related to liver metastases \\< five times ULN). 5) Eastern Cooperative Oncology Group (ECOG) score between 0 - 2 6) written informed consent by patient or guardian prior to admission into the trial that is consistent with International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP) guidelines and local law.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* prior treatment with an EGFR tyrosine kinase inhibitor (TKI)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* use of anti-cancer treatment within 2 weeks prior to start of trial treatment (continued use of anti-androgens and / or gonadorelin analogues for treatment of prostate cancer permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* radiotherapy within 4 weeks prior to drug administration except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "  1. palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "  2. single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* major surgery within 4 weeks from day 1 of first dose of afatinib. At least 7 days should have elapsed since minor surgical procedure including placement of an access device or fine needle aspiration and at least 14 days for diagnostic or palliative video-assisted thoracoscopic surgery (VATS).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* known hypersensitivity to afatinib or any of its excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* history or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of \\>3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to starting trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* Women of Child-Bearing Potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use medically acceptable method of contraception during the trial entry and for at least 4 weeks after treatment has ended. Adequate methods of contraception and Women of Child-Bearing Potential. Perimenopausal women must be amenorrhoeic for at least 24 months to be considered for non-childbearing potential.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* childbearing potential (see Section 4.2.3) who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "  1. are nursing or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "  2. are pregnant or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "  3. are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* history of or co-existing condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of safety for the trial drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* previous or concomitant malignancies at other sites, except effectively treated nonmelanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* requiring treatment with any of the prohibited concomitant medications listed, that cannot be stopped for the duration of trial participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* presence of poorly controlled gastrointestinal disorders that could affect the absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis, malabsorption, or CTC grade =2 diarrhoea of any aetiology) based on investigator assessment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* Known active hepatitis B infection (defined as presence of Hepatitis B (HepB) sAg and/or HepB DNA), active Hepatitis C (HEP C) infection (defined as presence of Hep C RNA) and/or known Human Immunodeficiency Virus (HIV) carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* meningeal carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01953913",
    "statement": "* symptomatic brain metastases (patients with brain metastases, who were previously treated, are eligible provided they have asymptomatic brain metastasis for at least 4 weeks on stable doses of medication)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01250119",
    "statement": "* Adult patients, \\>/= 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01250119",
    "statement": "* Locally advanced or metastatic (stage IIIB/IV) non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01250119",
    "statement": "* ECOG performance status 0-3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01250119",
    "statement": "* Treatment phase: histologically confirmed EGFR exon 19 deletion or exon 21 mutation in the diagnostic phase of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01250119",
    "statement": "* Adequate haematological, liver and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01250119",
    "statement": "* Female patients must be postmenopausal, surgically sterile, or agree to use a barrier method of contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01250119",
    "statement": "* Male patients must be surgically sterile or agree to use a barrier method of contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01250119",
    "statement": "* Previous treatment for NSCLC with chemotherapy or therapy against EGFR, either with antibody or small molecule (tyrosine kinase inhibitor)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01250119",
    "statement": "* Symptomatic cerebral metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01250119",
    "statement": "* Pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01250119",
    "statement": "* Any other concomitant anti-cancer therapy (until disease progression and discontinuation of Tarceva therapy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": ". Participants must have histologically or cytologically confirmed advanced or metastatic tumors (unresectable), have had progression or intolerability since last standard anti-tumor treatment, or have no standard treatment or have refused standard therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "2. Participants must be able to provide archival tumor tissues (paraffin blocks or at least 10 unstained tumor specimen slides).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "3. Participants must have at least one measurable lesion as defined per RECIST criterion version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "4. Participant must have adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "5. Females are eligible to participate in the study if they are:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "   a) Non-childbearing potential (that is, physiologically incapable of becoming pregnant) who:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "* Has had hysterectomy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "* Has had bilateral oophorectomy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "* Has had bilateral tubal ligation or are post-menopausal (total cessation of menses for ≥1 year) b) Childbearing potential:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "* Must be willing to use a highly effective method of birth control for the duration of the study, and for at least 120 days after the last dose of tislelizumab, and have a negative urine or serum pregnancy test within 7 days of the first dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "6. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": ". History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "2. Prior malignancy active within the previous 2 years except for the tumor under investigation in this trial, cured or locally curable cancers, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "3. Prior therapies targeting PD-1 or PD-L1. Active brain or leptomeningeal metastases. Participants with brain metastases are permitted if they are asymptomatic, for example, diagnosed incidentally by brain imaging, or participants with previously treated brain metastases that are asymptomatic at screening, radiographically stable and not requiring steroid medications for at least 4 weeks prior to the first administration of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "4. Participants with active autoimmune diseases or history of autoimmune diseases or immunodeficiency that may relapse should be excluded. Participants with following diseases are allowed to be enrolled for further screening: type I diabetes, hypothyroidism managed with hormone replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis or alopecia), or diseases not expected to recur in the absence of external triggering factors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "5. Participants should be excluded if they have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "6. With uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "7. Use of any live or attenuated vaccines within 4 weeks (28 days) prior to initiation of study therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "8. Major surgical procedure (Grade 3 or 4) within the past 4 weeks (28 days) prior to study drug administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "9. Prior allogeneic or solid organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04068519",
    "statement": "NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Signed written informed consent;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Histologically or cytologically confirmed non-small cell cancer of the lung (NSCLC) stage IV (accordingto AJCC Staging 7th Edition);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* For Cohorts A and B, documented tumor progression (based on radiological imaging) after receiving at least one prior approved platinum-based chemotherapy regimen for advanced stage/metastatic NSCLC. An alternate chemotherapeutic agent/regimen is an acceptable substitute in the event that the subject was intolerant to, or ineligible to receive platinum based chemotherapy. Subjects enrolled in Cohort B cannot have more than 3 prior systemic treatments for advanced stage/metastatic NSCLC (neoadjuvant and adjuvant therapies are not counted in number of prior regimens and maintenance therapy is not counted as a separate regimen). Subjects in Cohort C will be required to have not received prior systemic anti-cancer therapies for metastatic disease (i.e., dabrafenib/trametinib will be 1st line treatment for metastatic disease);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Measurable disease according to Response Evaluation Criteria in Solid Tumors \\[RECIST 1.1\\];",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* At least 18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Anticipated life expectancy of at least three months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Presence of a BRAF V600E mutation in lung cancer tissue. Mutation must be locally confirmed in a CLIA-certified laboratory (or equivalent). An adequate amount of tumor tissue (archived tumor tissue, or fresh biopsy if archived tissue is not available) must be available at the time of enrolment for central validation of BRAF mutation;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Able to swallow and retain oral medication;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Women of childbearing potential must have a negative serum pregnancy test within 14 days before the first dose of study treatment and agree to use effective contraception during the study; NOTE: Oral contraceptives are not reliable due to potential drug-drug interaction with dabrafenib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Must have adequate organ function as defined by the following baseline values:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "Absolute neutrophil count (ANC) \\>/=1.5x10\\^9/L Hemoglobin \\>/=9 g/dL Platelets \\>/=100x10\\^9/L Prothrombin time /International normalized ratio (INR) and partial thromboplastin time \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "1.5 mg/dL, calculate creatinine clearance using standard Cockcroft and Gault; creatinine clearance must be \\> 50 mL/min); creatinine clearance should be \\>/= 50 mL/min Left ventricular ejection fraction \\>/= institutional lower limit of normal ECHO",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Previously tested for presence of EGFR and ALK mutations in lung cancer tissue confirmed in a CLIA-certified laboratory (or equivalent). Subjects with EGFR or ALK mutation are eligible if they have previously received EGFR or ALK inhibitor(s) respectively.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Previous treatment with a BRAF inhibitor (including but not limited to dabrafenib, vemurafenib, LGX818, and XL281/BMS-908662) or MEK inhibitor (including but not limited to trametinib, AZD6244, and RDEA119) prior to start of study treatment (Note: Prior treatment with dabrafenib is allowed for crossover subjects in Cohort A);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Anti-Cancer therapy including chemotherapy, radiation-therapy, immunotherapy, biologic therapy or major surgery within 14 days prior to start of study treatment (Note: Dabrafenib monotherapy within 14 days prior to starting combination therapy is allowed for crossover subjects in Cohort A);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Use of any investigational anti-cancer drug within 14 days or 5-half-lives (minimum 14 days), prior to start of study medication (Note: Dabrafenib monotherapy within 14 days prior to starting combination therapy is allowed for crossover subjects in Cohort A);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Current use of a prohibited medication or expected to require any of these medications during treatment with study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.0) Grade 2 or higher from previous anti-cancer therapy, except alopecia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK medical monitor for guidance to enrol the subject;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Known Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection. Subjects with laboratory evidence of cleared HBV and HCV infection may be enrolled;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* History of another malignancy \\< 3 years prior to starting study treatment or any malignancy with confirmed activating RAS-mutation; Exceptions: Subjects with any of the following malignancies within 3 years (does not include malignancies with confirmed activating RAS-mutation) are eligible: (a) a history of completely resected skin cancer, (b) successfully treated in situ carcinoma, (c) chronic lymphocytic lymphoma (CLL) in stable remission, or (d) indolent prostate cancer (definition: clinical stage T1 or T2a, Gleason score \\<= 6, and prostate specific antigen \\[PSA\\] \\< 10 ng/mL) requiring no or only anti-hormonal therapy with histologically confirmed tumour lesions that can be clearly differentiated from lung cancer target and non-target lesions are eligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Subjects with brain metastases are excluded if their brain metastases are:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Symptomatic OR",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Treated (surgery, radiation therapy) but not clinically and radiographically stable 3 weeks after local therapy(as assessed by contrast enhanced magnetic resonance imaging \\[MRI\\] or computed tomography \\[CT\\]), OR",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Asymptomatic and untreated but \\>1 cm in the longest dimension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* A history or evidence of cardiovascular risk including any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "Corrected QT (QTc) interval \\>=480 msecs History of acute coronary syndromes (including myocardial infarction or unstable angina) within 6 months prior to first dose of study treatment Coronary angioplasty, or stenting within the past 24 weeks; A history or evidence of current Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) guidelines; Treatment refractory hypertension defined as a blood pressure of systolic \\>140 mmHg and/or diastolic \\>90 mmHg which cannot be controlled by antihypertensive therapy; Abnormal cardiac valve morphology ( \\>=Grade 2) documented by echocardiogram (subjects with Grade 1 abnormalities \\[i.e., mild regurgitation/stenosis\\] can be entered on study). Subjects with moderate valvular thickening should not be entered on study; Patients with intra-cardiac defibrillators A history or evidence of current clinically significant uncontrolled arrhythmias; Exception: Subjects with atrial fibrillation controlled for \\> 30 days prior to randomization are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "Uncontrolled medical conditions (i.e., diabetes mellitus, hypertension, etc.), psychological, familial, sociological, or geographical conditions that interfere with the subject's safety or obtaining informed consent or do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Pregnant, or actively breastfeeding females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* Additional Exclusion Criteria for dabrafenib and trametinib combination therapy (Cohort B and C as well as subjects that crossover from monotherapy to combination therapy):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* History of interstitial lung disease or pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01336634",
    "statement": "* A history or current evidence of retinal vein occlusion (RVO).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175017",
    "statement": ". Male or female ≥ 20 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175017",
    "statement": "2. Histologically or cytologically confirmed non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175017",
    "statement": "3. Diagnosis of NSCLC in stage IIIB/IV unsuited to radical radiotherapy according to UICC-TNM classification (7th edition) or recurrent NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175017",
    "statement": "4. Has at least one measurable lesion, as defined by the RECIST guideline (version 1.1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175017",
    "statement": ". Current or prior severe hypersensitivity to another antibody product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175017",
    "statement": "2. Multiple primary cancers",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": ". For the dose escalation part: Patients with selected, relapsed or refractory solid tumors who have failed available standard therapy or who are not candidates for standard therapy. For the expansion part: Patients with advanced and/or metastatic solid tumors who are not candidates for standard therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "2. Patients must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "3. For the expansion patients must provide a tumor tissue sample from archival tissue or fresh biopsy at enrolment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "4. Age ≥ 18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "5. Acceptable renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "6. Acceptable liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "7. Acceptable hematological status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "9. Life expectancy of at least three months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "10. Patients, both females and males, of childbearing/reproductive potential must agree to use adequate contraception while included in the trial and for six months after the last infusion of HuMax-AXL-ADC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "11. Patients must provide a signed informed consent form before any trial relates activities are carried out.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": ". Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for at least 4 weeks prior to first IMP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "2. Have clinically significant cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "3. Known congestive heart failure and/ or a known decreased cardiac ejection fraction of \\< 45%. A baseline QT interval as corrected by Fridericia's formula (QTcF) \\> 480 msec, a complete left bundle branch block (defined as a QRS interval ≥ 120 msec in left bundle branch block form) or an incomplete left bundle branch block.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "4. Uncontrolled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "5. Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support 3 weeks prior to first IMP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "6. Have received a cumulative dose of corticosteroid \\> 150 mg prednisone (or equivalent doses of corticosteroids) within two weeks before the first Investigational Medicinal Product (IMP) administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "7. History of ≥ grade 3 allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "8. Major surgery within four weeks before first IMP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "9. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, brain metastases or stroke.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "10. Any anticancer therapy including; small molecules, immunotherapy, chemotherapy monoclonal antibodies or any other experimental drug within five half-lives but maximum four weeks before first infusion. Accepted exceptions are bisphosphonates, denosumab and gonadotropin-releasing hormone agonist or antagonist.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "11. Prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "12. Radiotherapy within 14 days prior to first IMP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "13. Known past or current malignancy other than inclusion diagnosis, except for:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "* Cervical carcinoma of Stage 1B or less.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "* Non-invasive basal cell or squamous cell skin carcinoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "* Non-invasive, superficial bladder cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "* Prostate cancer with a current prostate specific antigen (PSA) level \\< 0.1 ng/mL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "* Breast cancer in BRCA1 or BRCA2 positive ovarian cancer patients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "* Any curable cancer with a complete response (CR) of \\> 2 years duration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "14. Melanoma patients with an lactate dehydrogenase (LDH) ≥ 3 x upper limit normal (ULN).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "15. Ongoing significant, uncontrolled medical condition including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "    o Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "16. Grade 2 or higher peripheral neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "17. Clinically significant active viral, bacterial or fungal infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "18. Known human immunodeficiency virus seropositivity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "19. Known positive serology for hepatitis B (unless due to vaccination or passive immunization due to immunoglobulin therapy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "20. Known positive serology for hepatitis C (unless due to immunoglobulin therapy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "21. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the trial or evaluation of the trial result",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "22. History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of IMP",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "23. Body weight \\< 40 kg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "24. Women who are pregnant or breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "25. Pulmonary hemorrhage or hemoptysis \\> 2.5 ml blood within 6 weeks unless cause has been addressed and is medically resolved.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02988817",
    "statement": "26. History of acute pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Metastatic disease or locally advanced, unresectable disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Has histopathologically confirmed gastric or GEJ adenocarcinoma with documented disease progression after 0-2 prior lines of systemic therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Has histopathologically confirmed nonsquamous or squamous NSCLC with documented disease progression after 0-3 prior lines of systemic therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Has histopathologically confirmed transitional cell carcinoma of the urothelium (bladder, urethra, or renal pelvis) with documented disease progression after 1-3 prior lines of systemic therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Has histologically confirmed biliary tract adenocarcinoma with documented progression after 1-2 prior lines of systemic therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Availability of tumor tissue for biomarker analysis from a newly obtained core or excisional biopsy or willing to undergo a tumor biopsy. For first line NSCLC participants only, PD-L1 expression should be 1% or higher.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Has adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Have an anticipated life expectancy of ≥3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Have known brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Has received ≥3 lines of prior systemic therapy for gastric or GEJ adenocarcinoma and BTC or ≥4 lines for NSCLC or urothelial cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Has active autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Known human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Known active hepatitis B or hepatitis C infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Has received any previous systemic therapy targeting vascular endothelial growth factor (VEGF) or VEGF receptor, or programmed death (PD) 1 or PD-ligand 1/2 signaling pathways.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Have received a live vaccine within 30 days prior to enrollment. Seasonal flu vaccines that do not contain live virus are permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02443324",
    "statement": "* Have an elective or a planned major surgery during the course of the trial or has undergone major surgery within 28 days prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832117",
    "statement": "* Men and women age ≥ 18",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832117",
    "statement": "Exclusion:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832117",
    "statement": "* More than 2 prior chemotherapy containing regimens for metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832117",
    "statement": "* No prior exposure to cisplatin or ixabepilone",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832117",
    "statement": "Expansion Phase Subjects: Advanced Non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832117",
    "statement": "* Men and women age ≥ 18",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832117",
    "statement": "Exclusion:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832117",
    "statement": "* No prior chemotherapy-containing regimen for metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832117",
    "statement": "* No prior exposure to cisplatin or ixabepilone",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832117",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01203917",
    "statement": "* Locally advanced or metastatic non-small cell lung cancer (i.e. cancer that has spread from where it started) which is EGFR mutation positive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01203917",
    "statement": "* Caucasian female or male patients aged 18 years or over",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01203917",
    "statement": "* Measurable disease, i.e. at least one lesion, not previously irradiated, as ≥ 10 mm in the longest diameter (≥ 15 mm in short axis for lymph node )",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01203917",
    "statement": "* Prior adjuvant chemotherapy or other systemic anti-cancer treatment less than 6 month, or palliative radiotherapy less than 4 weeks prior to start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01203917",
    "statement": "* Brain metastases or spinal cord compression, unless treated and stable without steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01203917",
    "statement": "* Any clinically significant illness, which will jeopardize the patients' safety and their participation in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": ". Signed informed consent form (ICF) and able to comply with study requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": "2. At least 1 measurable lesion as defined by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": "3. Tumor tissue (archival tumor tissues as formalin-fixed paraffin-embedded blocks or approximately 15 unstained slides) for central laboratory assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": "4. Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to (\\<=) 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": "5. Histologically or cytologically confirmed, advanced or metastatic, unresectable adenocarcinoma of gastric or esophagogastric junction or colon or rectum, and histologically or cytologically confirmed, locally advanced (Stage IIIB) not amenable to curative surgery or radiotherapy, or metastatic (Stage IV) NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": ". Had at screening any central nervous system metastasis and/or leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": "2. Prior therapy targeting CTLA-4, PD-1, PD-L1 or programmed cell death protein ligand-2 (PD-L2) or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": "3. Prior treatment with VEGFR-TKI or anti-VEGFR antibody (eg, ramucirumab)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": "4. Received more than 1 line of systemic treatment for advanced or metastatic, unresectable adenocarcinoma of gastric or esophagogastric junction, or more than 2 lines of systemic treatment for advanced or metastatic, unresectable adenocarcinoma of the colon or rectum, or prior systemic therapy for advanced or metastatic NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": "5. Active autoimmune diseases or history of autoimmune diseases that may relapse, or history of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716634",
    "statement": "NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "-in Cohort",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "6. Has received previous systemic therapy for unresectable NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "7. Has exhausted existing licensed therapies, or is unsuitable for treatment with existing licensed therapies for NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "8. Known EGFR mutation status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "9. Either:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "   1. Has received ≥ 6 weeks historical treatment with erlotinib. Erlotinib treatment must be re started ≥ 1 week before the first dose of bemcentinib (Cycle 1, Day 1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "      Or:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "   2. Is currently receiving erlotinib treatment for NSCLC and will have received ≥ 6 weeks treatment at the time of the first dose of bemcentinib (Cycle 1, Day 1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "10. Erlotinib-related toxicities being well-controlled and \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "2.5 mL blood within 6 weeks of consent unless cause has been addressed and is medically resolved.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "6. Congestive cardiac failure of \\>Class II severity according to the New York Heart Association (NYHA) defined as symptomatic at less than ordinary levels of activity.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "7. Unstable cardiac disease, including unstable angina or unstable hypertension, as defined by the need for change in medication for lack of disease control within 3 months of consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "8. History or presence of sustained bradycardia (≤ 60 bpm) or history of symptomatic bradycardia, left bundle branch block, cardiac pacemaker or significant atrial tachyarrhythmias, as defined by the need for treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "   tachyarrhythmias, as defined by the need for treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "9. Current treatment with agents that may prolong QT interval and may cause Torsade de Points which cannot be discontinued at least 2 weeks prior to treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "10. Known family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "11. Previous history of ≥ Grade 3 drug-induced QTc prolongation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "12. Screening 12-lead triplicate electrocardiogram (ECG) with an average measurable interval utilizing Fridericia's correction (QTcF) \\>450 ms.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "13. Inadequate liver function as demonstrated by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "* Serum bilirubin ≥ 1.5 times the upper limit of normal range (ULN); or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.5 times the ULN (up to 5 times the ULN in the presence of liver metastases).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "14. Inability to tolerate oral medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "15. Impaired coagulation as evidenced by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "    1. International normalized ratio (INR) \\>1.5 times ULN (or equivalent); or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "    2. Activated partial thromboplastin time (aPTT) \\>1.5 times ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "16. Existing gastrointestinal disease affecting drug absorption, such as celiac disease or Crohn's disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "17. Previous bowel resection that may impair study drug absorption.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "18. Impaired renal function as demonstrated by creatinine clearance of ≤ 50 mL/min determined by Cockcroft Gault formula.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "19. Absolute neutrophil count \\<1.5 x 109/L, hemoglobin \\<9.0 g/dL, platelet count \\<100 x 109/L in the absence of blood product support.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "20. Any evidence of severe or uncontrolled systemic conditions (e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the participant to participate in the study or which could jeopardize compliance with the protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "21. Treatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "22. Active, uncontrolled central nervous system (CNS) disease; (previously treated CNS metastases that are asymptomatic and do not require steroid treatment are allowed). Note: Participants with known CNS metastases who have completed radiotherapy at least 2 weeks prior to bemcentinib treatment are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "23. Known active infection with human immunodeficiency virus (HIV), hepatitis B or C viruses (screening not required):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "* Participants who have a history of hepatitis B infection are eligible provided they are hepatitis B surface antigen negative.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "* Participants who have a history of hepatitis C infection are eligible provided they have no evidence of hepatitis C ribonucleic acid using a quantitative polymerase chain reaction assay at least 6 months after completing treatment for hepatitis C infection.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "24. Major surgery requiring general anesthesia within 28 days prior to the start of bemcentinib, excluding biopsies and procedures for insertion of central venous access devices.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "25. Treatment with cytotoxic chemotherapy, within the 3 weeks prior to the first dose of bemcentinib (Cycle 1, Day 1) with the exception of treatment with other EGFR inhibitors which must be completed 1 week prior to commencing treatment with bemcentinib. There is no requirement to discontinue ongoing treatment with erlotinib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "26. Treatment with other non-cytotoxic agents for NSCLC in the 10 days or 4 half-lives, prior to the first dose of bemcentinib (Cycle 1, Day 1) whichever is shorter.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "27. Prior biological therapies in the 4 weeks or 5 half-lives, whichever is shorter before the first dose of bemcentinib (Cycle 1, Day 1). Note prior treatment with an alternative EGFR inhibitor and/or programmed cell death protein 1 (PD-1) blockade is permitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02424617",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": ". Participation in another study with an IP during the last 14 days (or a longer period depending on the defined characteristics of the agents used).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "2. Treatment with any of the following: Treatment with an EGFR TKI (eg, erlotinib or gefitinib) within 8 days or approx. 5 x half-life, whichever is the longer, of the first dose of study treatment; any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of the first dose; major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment; radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation which must be completed within 4 weeks of the first dose; patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inhibitors of CYP3A4 (at least 1 week prior) and potent inducers of CYP3A4 (at least 3 week prior). All patients must avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer/inhibitory effects on CYP3A4.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "3. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "4. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of the IP until the final PK sample collection on Day 32 of Part A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "5. Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the PI's opinion makes it undesirable for the patient to participate in the study or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C, and HIV. Screening for chronic conditions not required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "7. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: ANC \\<1.5 x 10\\^9/L; platelet count \\<100 x 10\\^9/L; haemoglobin \\<90 g/L; ALT \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases; Aspartate aminotransferase (AST) \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases; total bilirubin \\>1.5 times ULN if no liver metastases or \\>3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases; creatinine \\>1.5 times ULN concurrent with creatinine clearance \\<50 ml/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "8. Any of the following cardiac criteria: mean resting corrected QT interval corrected for heart rate using Fridericia's correction factor (QTcF) \\>470 msec obtained from 3 ECGs; any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block, second degree heart block, PR interval \\>250 msec; any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under age of 40 or any concomitant medication known to prolong the QT interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "9. Patients unable to swallow oral medication or patients with GI disorders or significant GI resection likely to interfere with the absorption of AZD9291.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "10. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "11. Women who are breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "12. Patients with a known hypersensitivity to AZD9291, simvastatin, or any of the excipients of the products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "13. Concomitant medication contraindicated for use with simvastatin due to drug interaction associated with increased risk of rhabdomyolysis (including, but not limited to): itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors (eg, nelfinavir), nefazodone, cyclosporine, danazol, gemfibrozil, amiodarone, amlodipine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "14. 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA)-reductase inhibitors, such as lovastatin and simvastatin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197234",
    "statement": "15. For optional genetic research: Previous allogenic bone marrow transplant or non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00192036",
    "statement": "* Inoperable non small cell lung cancer Stage III",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00192036",
    "statement": "* Adequate hematological parameters",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00192036",
    "statement": "* Adequate Lung function reserve",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00192036",
    "statement": "* Previous chemotherapy and thoracic radiation for non small cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00192036",
    "statement": "* Presence of distant metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "(applicable to all arms)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Adults with histologically or cytologically documented ED SCLC who have demonstrated progressive disease either during first-line platinum-based chemotherapy (platinum refractory) or within 90 days of completing platinum based-chemotherapy (platinum resistant) and have not received further treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Brain metastases must be asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* At least 1 lesion, not previously irradiated, that can be accurately measured at baseline (per RECIST v 1.1 guidelines)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Life expectancy of at least 8 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* WHO/ ECOG PS of 0-1 at enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "Inclusion criteria (Arm A specific)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Body weight \\>30 kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* No prior exposure to immune mediated therapy, excluding therapeutic anticancer vaccines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "Inclusion criteria (Arm B specific) • Able and willing to swallow oral medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "Inclusion criteria (Arm C specific)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Able and willing to swallow oral medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "(applicable to all arms):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Participation in another clinical study, major surgery, radiation therapy within 28 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Any condition that, in the opinion of the Investigator, would interfere with the evaluation of the IP or interpretation of patient safety or study results.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* History of another primary malignancy, leptomeningeal carcinomatosis or spinal cord compression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "Exclusion criteria (Arm A specific)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Active autoimmune disease, including a paraneoplastic syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Active or prior documented autoimmune or inflammatory disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Any unresolved toxicity (CTCAE Grade \\>2) from previous anticancer therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Active infection including tuberculosis, HIV, Hepatitis B or C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "Exclusion criteria (Arm B specific)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Prior exposure to any WEE1 inhibitors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Products known to be sensitive to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors/inducers of CYP3A4. Co-administration of rosuvastatin, atorvastatin, simvastatin and lovastatin, aprepitant or fosaprepitant or any herbal preparations. Grapefruit and Seville oranges should be avoided while taking AZD1775.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Any known hypersensitivity or contraindication to IP or CBDP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* QTcF \\> 470 msec or congenital long QT syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Any current or within 6 months cardiac diseases NYHA ≥ Class 2: unstable angina pectoris, congestive heart failure, acute MI, conduction abnormality not controlled with pacemaker or medication, significant ventricular or supraventricular arrhythmias.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* A recent history of Torsades de pointes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "Exclusion criteria (Arm C specific)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Cytotoxic chemotherapy within 21 days of Cycle 1 Day 1 is not permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Previous treatment with a PARP inhibitor (including olaparib) or ATR inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Concomitant use of known strong CYP3A inhibitors and moderate CYP3A inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Concomitant use of known strong and moderate CYP3A inducers",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Persisting (\\> 4 weeks) severe pancytopenia due to previous therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Cardiac dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Refractory nausea and vomitting, chronic gastrointenstinal diseases or previous significant bowel resection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Patients with uncontrolled seizures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02937818",
    "statement": "* Intenstinal obstruction or CTCAE grade 3 or grade 4 GI bleeding within 4 weeks before dosing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01077713",
    "statement": "* adult patients, \\>=70 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01077713",
    "statement": "* inoperable, locally advanced, metastatic non-squamous non-small cell lung cancer;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01077713",
    "statement": "* \\>=1 measurable lesion;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01077713",
    "statement": "* ECOG performance status 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01077713",
    "statement": "* neoadjuvant/adjuvant chemotherapy within 6 months prior to enrollment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01077713",
    "statement": "* radical radiotherapy with curative intent within 28 days prior to enrollment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01077713",
    "statement": "* history of \\>=grade 2 hemoptysis in 3 months prior to enrollment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01077713",
    "statement": "* evidence of CNS metastases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01077713",
    "statement": "* current or recent (within 10 days of first dose of Avastin)use of aspirin (\\>325 mg/day)or full dose anticoagulants or thrombolytic agents for therapeutic purposes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Patients must have histologically or cytologically confirmed Stage IIIB or IV (American Joint Committee on Cancer, 7th edition; AJCC 7) non-small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Patients must have measurable disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Patients must have not have received any prior therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) for the treatment of stage IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Age ≥ 18 years at time of study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* ECOG performance status of 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Life expectancy of greater than 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Tissue available (archived or fresh tumor biopsy) for the PD-L1 assay.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Patients must have normal organ and marrow function as defined below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9/L (\\> 1500 per mm\\^3)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Hemoglobin ≥ 9.0 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Platelet count ≥ 100 x 10\\^9/L (\\>100,000 per mm\\^3)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* AST (SGOT)/ALT (SGPT) ≤ 2.5 x ULN unless liver metastases are present, in which case it must be ≤ 5x ULN Serum creatinine CL\\>40 mL/min by the Cockcroft-Gault formula",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Female subjects must either be of non-reproductive potential OR must have a negative serum pregnancy test upon study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* The effects of durvalumab on the developing human fetus are unknown. For this reason and because immunomodulatory agents are potentially teratogenic, sexually active women of child-bearing potential and men must agree to use adequate contraception (2 methods of effective contraception from screening) from screening, for the duration of study participation, and for at least 90 days following the last infusion of durvalumab.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Involvement in the planning and/or conduct of the study; previous enrollment in the present study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Participation in another clinical study with an investigational product for cancer during the last 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids in excess of prednisone 10 mg/d or equivalent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Sensitizing mutations in EGFR or rearrangements in ALK or ROS1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Mean QT interval corrected for heart rate (QTc) ≥ 470 ms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids . Patients may be on systemic corticosteroids provided the dose does not exceed prednisone 10 mg/d or equivalent for 1 week prior to study drug administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* History of primary immunodeficiency.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* History of allogeneic organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Uncontrolled intercurrent illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Known history of previous clinical diagnosis of tuberculosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* History of leptomeningeal carcinomatosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Subjects with uncontrolled seizures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Pregnant women; breastfeeding should be discontinued.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02879617",
    "statement": "* Prior history of radiation pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Documented EGFR mutation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Documented c-MET dysregulation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Prior clinical benefit on EGFR inhibitors and then subsequent progression",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "*≥ 18 year old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Life expectancy of ≥ 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* ECOG performance status ≤ 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Unable to swallow tables once or twice daily",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Previous treatment with c-MET inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Any unresolved toxicity from previous anticancer therapy greater than grade 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* History of cystic fibrosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* History of acute or chronic pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Unable to undergo MRI or CT scans",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Known history of HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Undergone a bone marrow or solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Clinically significant wound or lung tumor lesions with increased likelihood of bleeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01610336",
    "statement": "* Pregnant or nursing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00609518",
    "statement": "* Histologic or cytologic diagnosis of non-small cell lung cancer (NSCLC) with locally advanced or metastatic disease (Stage IIIA, IIIB or IV)that is of non-squamous histology",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00609518",
    "statement": "* Patients must have failed only one prior chemotherapy regime and must be considered eligible for further chemotherapy following progression of their disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00609518",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00609518",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00609518",
    "statement": "* Concurrent administration of any other anti-tumor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00609518",
    "statement": "* Other co-existing malignancies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00609518",
    "statement": "* Pregnancy or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00609518",
    "statement": "* Serious concomitant disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00609518",
    "statement": "* Inability or unwillingness to take folic acid or vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": ". Has histologically- or pathologically-confirmed recurrent/metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "2. If has adenocarcinoma, required to have previously been tested for anaplastic lymphoma kinase (ALK) rearrangements and epidermal growth factor receptor (EGFR) mutations, with results available for collection in this study, and, if positive, has been treated with prior epidermal growth factor receptor (EGFR) or ALK therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "3. Received at least 1 chemotherapeutic regimen in the advanced/metastatic setting and experienced documented, unequivocal progressive disease by either RECIST 1.1 or clinical assessment. Additional requirements related to prior treatments applied and may have been dependent on mutational status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "4. Participants with NSCLC enrolled in Cohort 1 of the Expansion Phase should not have been previously treated with a PD-1/PD-L1-blocking antibody.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "   Participants in Expansion Phase, Cohorts 2 (NSCLC) and 3 (Melanoma):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "5. Previously treated with a PD-1/PD-L1-blocking antibody and experienced documented, unequivocal radiographic progression of disease by irRECIST, or similar criteria during or within 12 weeks after last dose of such treatment. Participants must have received at least 6 weeks of PD-1/PD-L1 therapy for Cohort 2 and at least 8 weeks of PD-1/PD-L1 therapy for Cohort 3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "   Participants with Melanoma:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "6. In addition to having been previously treated with a PD-1/PD-L1-blocking antibody, has a histologically- or cytologically-confirmed diagnosis of unresectable or metastatic melanoma and experienced unequivocal progressive disease during treatment with a Serine/threonine-protein kinase B-Raf (BRAF) inhibitor if BRAF V600 mutation-positive. Treatment with BRAF inhibitor may occur after treatment with the checkpoint inhibitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "   Participants in Expansion Phase, Cohort 4 (CRC):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "7. Received at least 1 chemotherapeutic regimen in the advanced/metastatic setting and experienced documented, unequivocal progressive disease by either RECIST 1.1 or clinical assessment. Must have documented mismatch repair-proficient colon cancer as determined by either immunohistochemistry for mismatch repair proteins or polymerase chain reaction (PCR)-based functional microsatellite instability. Participants with CRC enrolled in Cohort 4 should not have been previously treated with a PD-1/PD-L1-blocking antibody (that is, pembrolizumab, nivolumab, MEDI4736, or GNE PDL1 \\[MPDL3280A\\]).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "   All Participants:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "8. Aged 18 years or older on the day written informed consent is given.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "9. If has brain metastases, must have stable neurologic status following local therapy for at least 4 weeks without the use of steroids or on stable or decreasing dose of ≤10 milligrams (mg) daily prednisone (or equivalent), and must be without neurologic dysfunction that would confound the evaluation of neurologic and other AEs.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "10. Evidence of locally recurrent or metastatic disease based on imaging studies within 28 days before the first study drug dose:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "* At least 1 measurable lesion ≥20 mm by conventional techniques or ≥10 mm by spiral computed tomography (CT) scan or magnetic resonance imaging (MRI), with the last imaging performed within 28 days before the first study drug dose. If there is only 1 measurable lesion and it is located in previously irradiated field, it must have demonstrated unequivocal progression according to RECIST, version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "11. If receiving radiation therapy, has a 2-week washout period following completion of the treatment prior to receiving the first study drug dose and continues to have at least 1 measurable lesion, per above criterion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "12. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "13. Has acceptable renal and hepatic function and stable hematologic and coagulation status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "14. Female participants must not be pregnant. If a participants is of childbearing potential, the participant must agree to use effective contraception, as defined in the protocol, during the study and for 120 days after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "15. If male, agrees to use an adequate method of contraception starting from the first dose of study drug through 120 days after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "16. Experienced resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If participant underwent major surgery or radiation therapy of \\>30 gray (Gy), they must have recovered from the toxicity and/or complications from the intervention.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "17. Willing to have fresh tumor samples collected during screening and at other time points designated as mandatory, per the Schedule of Study Assessments.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "18. Able to understand and give written informed consent and comply with study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": ". Diagnosis of immunodeficiency or receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "2. Active autoimmune disease that has required systemic treatment in past 2 years (that is, with disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (for example, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "3. History of interstitial lung disease (ILD).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "4. Allergy to benzamide or inactive components of entinostat.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "5. History of allergies to any active or inactive ingredients of pembrolizumab or severe hypersensitivity (≥Grade 3) to pembrolizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "6. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator, including, but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "* Myocardial infarction or arterial thromboembolic events within 6 months prior to baseline or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease, or a QTc interval \\> 470 milliseconds (msec).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "* Uncontrolled heart failure or hypertension, uncontrolled diabetes mellitus, or uncontrolled systemic infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "* Another known additional malignancy that is progressing or requires active treatment (excluding adequately treated basal cell carcinoma, squamous cell of the skin, cervical intraepithelial neoplasia \\[CIN\\]/cervical carcinoma in situ or melanoma in situ, or ductal carinoma in situ of the breast). Prior history of other cancer is allowed, as long as there is no active disease within the prior 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "* Active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "   Note: Participants with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging \\[using the identical imaging modality for each assessment, either MRI or CT scan\\] for at least 4 weeks prior to the first dose of study drug and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 2 weeks prior to the first dose of study drug or are on stable or decreasing dose of ≤10 mg daily prednisone (or equivalent). This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "7. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "8. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "9. Received a live virus vaccination within 30 days of the first dose of treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "10. Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to baseline or who has not recovered (that is, ≤Grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "11. Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study baseline or who has not recovered (that is, ≤Grade 1 or at baseline) from AEs due to a previously administered agent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "    Note: Participants with ≤Grade 2 neuropathy or ≤Grade 2 alopecia are an exception to this criterion and may qualify for the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "    Note: If participant underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "12. Received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte-colony stimulating factor \\[G-CSF\\], granulocyte macrophage-colony stimulating factor \\[GM-CSF\\], or recombinant erythropoietin) within 4 weeks prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "13. Currently receiving treatment with any other agent listed on the prohibited medication list such as valproic acid, or other systemic cancer agents within 14 days of the first dose of treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "14. If female, is pregnant, breastfeeding, or expecting to conceive, or if male, expect to father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "15. Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "16. Known active hepatitis B (for example, hepatitis B surface antigen-reactive) or hepatitis C (for example, hepatitis C virus ribonucleic acid \\[qualitative\\]).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "17. For CRC expansion cohort, no prior history of malignant bowel obstruction requiring hospitalization in the 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02437136",
    "statement": "18. For the CRC expansion cohort, history of uncontrolled ascites, defined as symptomatic ascites and/or repeated paracenteses for symptom control in the past 3 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": ". Target Population",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Subjects with histologically-or cytologically-documented NSCLC \\[squamous (SQ) or nonsquamous (NSQ)\\] who present with Stage IIIB/Stage IV disease (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection or definitive chemoradiotherapy for locally advanced disease)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Subjects must have experienced disease progression or recurrence during or after at least one systemic therapy for advanced or metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Each subsequent line of therapy must be preceded by disease progression. A switch of an agent within a regimen in order to manage toxicity does not define the start of a new line of therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Maintenance therapy following platinum doublet-based chemotherapy is not considered as a separate regimen of therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Subjects who received platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy given for locally advanced disease, and developed recurrent (local or metastatic) disease within 6 months of completing therapy are eligible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Subjects with recurrent disease \\>6 months after platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy given for locally advanced disease, who also subsequently progressed during or after a platinum doublet-based regimen given to treat the recurrence are eligible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Subjects with non-squamous histology must be tested for Epithelial Growth Factor Receptor (EGFR) mutations (including, but not limited to, deletions in exon 19 and exon 21 \\[L858R\\] substitution) and Anaplastic Lymphoma Kinase (ALK) rearrangement if tests have not been previously performed. Subjects with progressive disease during or after EGFR or ALK tyrosine kinase inhibitor (TKI) regimens are eligible. Subjects are eligible if genetic test results are indeterminate or if no tumor tissue is available or accessible for testing as long as they have received one prior systemic therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Experimental therapies when given as separate regimen are considered as separate line of therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria (radiographic tumor assessment performed within 28 days of first dose of study drug) or clinically apparent disease that the investigator can follow for response per RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Eastern Cooperative Oncology Arm (ECOG) performance status (PS)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* PS 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* PS 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": ". Target Disease Exceptions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Subjects with active central nervous system (CNS) metastases are excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Subjects with carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "2. Medical History and Concurrent Diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Subjects with a history of interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Subjects with active, known or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Subject whom participated in either arm of the following clinical trials CA209-017, CA209-057, CA209-026, and CA184-104 or received prior treatment with anti-programmed death 1 (PD-1) or anti-programmed death-ligand 1 (PDL1) experimental agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "3. Prohibited Treatments and/or Restricted Therapies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Ongoing or planned administration of anti-cancer therapies other than those specified in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02066636",
    "statement": "* Use of corticosteroids or other immunosuppressive medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Patients must have either:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "  1. completed the base trial and have shown a clinical benefit of SD or better and have never met any withdrawal criteria as defined in the tisotumab vedotin base protocol, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "  2. not completed treatment as defined in the base protocol for reasons that are not considered critical and unmanageable for the safety of the patient (as evaluated by the investigator and/or the sponsor) and the patient clearly showed response of PR or better.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Patients must not have experienced radiographic disease progression or clinical signs of symptoms of instability requiring urgent intervention.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Patients must not have received any other anti-cancer treatment (including surgery, radiation or systemic chemotherapy) since the base trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Acceptable renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Acceptable liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Acceptable hematological status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* A negative serum pregnancy test (if female and aged between 18-55 years old).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for six months after the last infusion of tisotumab vedotin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "  1. Adequate contraception for women is defined as hormonal birth control or an intrauterine device (safe hormonal contraceptives include contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release). In countries where two highly effective methods of contraception are required this will be an inclusion criterion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "  2. Male patients must be willing to use a latex condom during any sexual contact with females of childbearing potential during and for six months after the last infusion of tisotumab vedotin, even after having undergone a successful vasectomy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "  3. In order to be considered as sterilized or infertile, a patient must have undergone surgical sterilization (vasectomy/bilateral tubectomy; hysterectomy and bilateral ovariectomy) or be postmenopausal (12 months or more with no period prior to enrolment).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Following receipt of verbal and written information about the trial, patients must provide signed informed consent before any trial-related activity is carried out.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Acceptable coagulation status as defined in the applicable base protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "  1. GEN701: Acceptable coagulation status: International normalized ratio (INR) ≤ 1.2 (without anticoagulant therapy), and activated partial thromboplastin time (aPTT) ≤ 1.25 ULN; patients on stable doses of therapeutic anti-coagulative treatment for ≥ 8 weeks (e.g., warfarin) must have an INR \\< 3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "  2. GEN702: Acceptable coagulation status defined as: INR ≤ 1.2 (without anticoagulant therapy), and aPTT ≤ ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Presence of CTCAE (Common Terminology Criteria for Adverse Events) grade ≥ 2 peripheral neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Clinically significant active viral, bacterial or fungal infection requiring:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "  1. Intravenous treatment with anti-infective therapy that has been administered less than two weeks prior to first dose in this trial, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "  2. Oral treatment with anti-infective therapy that has been administered less than one week prior to first dose in this trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "  3. Prophylactic anti-infective therapy, which is given without clinical symptoms is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Ongoing acute or chronic inflammatory skin disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03245736",
    "statement": "* Women who are breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01998919",
    "statement": "* adult patients, \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01998919",
    "statement": "* histologically documented advanced or recurrent stage IIIB or IV non-small cell lung cancer;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01998919",
    "statement": "* measurable disease;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01998919",
    "statement": "* no previous chemotherapy for non-small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01998919",
    "statement": "* unstable systemic disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01998919",
    "statement": "* any other malignancies in the last 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Subjects with NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Demonstrating average weight loss of 5% within 2 months prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Heart rate of 72 bpm or greater",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Negative pregnancy test (female patients of child bearing age)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Able to give informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Able to be administered medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Able to take food and defined nutritional support",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Have not been on beta-blockers for a minimum of 1 week prior to administration of the medication screening dose",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Have not undergone surgery for at least 2 weeks prior to entry into trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Have not been on chemotherapy, immunotherapy, biologic therapy, radio therapy, and experimental therapy for a minimum of two weeks prior to medication screening dose and during their participation in this trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* An expected survival for a minimum of 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Contraindication to nonsteroidal antiinflammatory drugs (NSAIDs) and beta blockers",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Blood pressure less than 100/65",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Weight loss of 15% within 2 months prior to recruitment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Hypersensitivity reaction to the active components in VT-122",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* History of myocardial infraction within the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Congestive heart failure (as determined by symptoms and ECG)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* A-V block of second or third degree",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Uncontrolled diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Unable to be assessed for grip strength",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* A positive pregnancy test",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Chronic infection or sepsis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* History of bleeding disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Patients with peripheral edema",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Patients on digoxin or other chronotropic drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Patients with evidence of severe dehydration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527319",
    "statement": "* Patients with evidence of ascites",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "* Histologic or cytologic confirmation of advanced (metastatic and/or unresectable) solid tumors of one of the following tumor types:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "  1. Metastatic squamous or non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "  2. RCC, advanced or metastatic",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "  3. Melanoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "  4. HCC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "  5. CRC, metastatic (MSI-H or dMMR)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "  6. In Part B, other solid tumor types may be considered at the discretion of the Medical Monitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "  7. In Part E, Metastatic urothelial carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "* Measurable disease as per RECIST version 1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "* ECOG performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "* Active brain metastases or leptomeningeal metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "* Ocular melanoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "* Active, known, or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03656718",
    "statement": "Other protocol defined inclusion/exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": ".",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "2. Subject has a histologically confirmed diagnosis of one of the following unresectable locally advanced or metastatic malignancies: melanoma, non-small cell lung cancer (squamous, adeno, or adeno-squamous), urothelial cancer, squamous cell carcinoma of the head and neck, squamous cell cervical cancer, gastric or gastro-esophageal junction adenocarcinoma, squamous cell carcinoma of the anal canal, squamous cell carcinoma of the skin, renal cell cancer, Hodgkin's lymphoma, and microsatellite instability high (MSI-H) or mismatch repair deficient (MMRD) solid tumors excluding CNS malignancies. MSI and MMRD testing results as per institution is acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Head and neck cancers: Subjects must have primary tumor locations in the oropharynx, oral cavity, hypopharynx, or larynx. Primary tumor sites of nasopharynx, maxillary sinus, paranasal, and unknown primary are excluded.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Non-small cell lung cancers: Subjects with a known EGFR sensitizing (activating) mutation or an ALK fusion are excluded.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "3. Subject must have received, been intolerant to, or is ineligible for standard therapy (per local guidelines and approvals) or have a malignancy for which there is no approved therapy considered standard of care.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "4. Age 18 years and older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "5. Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "6. Has measurable disease by iRECIST (solid tumors) or RECIL 2017 (lymphoma). Refer to Appendix Sections 16.6 and 16.7 for details on criteria of measurable disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "7. Has life expectancy of greater than 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "8. Laboratory values must meet the following criteria. Laboratory parameter Threshold value",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Absolute lymphocyte count (ALC) ≥ 0.8 x 109/liter (L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Platelet count ≥ 50 x 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "   Laboratory parameter Threshold value",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Hemoglobin (Hgb) \\> 9.0 g/dL with no blood transfusions for at least 5 days prior to D1 of investigational product (IP; SL-279252)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/min (modified Cockcroft-Gault)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* ALT/AST ≤ 3 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Total bilirubin ≤ 1.5 x ULN; subjects with isolated indirect hyperbilirubinemia are permitted if direct bilirubin ratio is \\<35% and total bilirubin is ≤ 3.0 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) ≥ lower limit of normal (LLN) per institutional threshold. If LLN is not defined for a given institution, then ejection fraction must be ≥50 %.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "9. Females of child bearing potential (FCBP) must have a negative serum or urine pregnancy test within 72 hours of D1 of IP. NOTE: FCBP unless they are surgically sterile (i.e., have undergone a complete hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy or bilateral salpingectomy), have a congenital or acquired condition that prevents childbearing or are naturally postmenopausal for at least 12 consecutive months (see Appendix Section 16.2 for additional details). Documentation of postmenopausal status must be provided. FCBP should use an acceptable method of contraception (see Appendix Section 16.2) to avoid pregnancy during treatment and for 30 days (which exceeds 5 half-lives) after the last dose of IP. FCBP must start using acceptable contraception at least 14 days prior to D1 of IP.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "10. Male subjects with female partners must have azoospermia from a prior vasectomy or underlying medical condition or agree to use an acceptable method of contraception during treatment and for 30 days (which exceeds 5 half-lives) after last dose of SL-279252 (see Appendix Section 16.2). Male subjects of reproductive potential must start using acceptable contraception at least 14 days prior to D1 of treatment with SL-279252 as per Appendix Section 16.2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "11. All AEs resulting from prior anti-cancer immunotherapy have resolved (NOTE: exceptions include alopecia, vitiligo, and endocrinopathies adequately treated with hormone replacement).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Subjects that were discontinued from prior PD-1/L1 therapy due to immune-related adverse events are not eligible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "12. Recovery from toxicities from prior anti-cancer treatments including surgery, radiotherapy, chemotherapy or any other anti-cancer therapy to baseline or ≤ Grade 1. (NOTE: Low-grade toxicities (e.g., alopecia, ≤ Grade 2 lymphopenia, ≤ Grade 2 hypomagnesemia, ≤ Grade 2 neuropathy) may be allowed at the discretion of the investigator if considered clinically insignificant. Please consult the Sponsor Medical Monitor to discuss these cases).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": ". Has received more than two prior checkpoint inhibitor containing treatment regimens (regimen refers to either monotherapy or combination immunotherapies) or has had prior treatment with an OX40 agonist.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Prior PD-1/L1 therapy is not required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "2. Refractory to last PD-1/L1 inhibitor-based therapy which is defined as disease progression within 3 months of treatment initiation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Subjects must have had clinical benefit (stable disease or response) to last PD-1/L1 inhibitor-based therapy for at least three months to be eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "3. Any anti-cancer therapy within the time intervals noted below prior to first dose (D1) of SL-279252.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "   Therapy Washout period Chemotherapy 3 weeks Hormonal therapy 3 weeks PD-1/L1 inhibitor and other immunotherapies not otherwise specified 3 weeks Tumor vaccine 4 weeks Cell-based therapy 8 weeks Other mAbs or biologic therapies 3 weeks Major surgery 2 weeks Radiation (except palliative intent which does not require washout) 2 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "4. Concurrent chemotherapy, immunotherapy, biologic or hormonal therapy is prohibited. Concurrent use of hormones for non-cancer related conditions is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "5. Use of corticosteroids or other immunosuppressive medication, current or within 14 days of D1 of IP with the following exceptions (i.e., the following are allowed during treatment with or within14 days of D1 of IP):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Topical, intranasal, inhaled, ocular, intraarticular corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Physiological doses of replacement steroid (e.g., for adrenal insufficiency) provided ≤ 10 mg/day of prednisone or equivalent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Steroid premedication for hypersensitivity reactions (HSRs; e.g., reaction to IV contrast)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "6. Receipt of live attenuated vaccine within 28 days of D1 of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "7. Active or documented history of autoimmune disease (autoimmune disease does not refer to irAEs; for irAEs see inclusion criteria #11). Exceptions include Type I diabetes, vitiligo, alopecia areata or hypo/hyperthyroidism.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "8. Active pneumonitis (i.e. drug-induced, idiopathic pulmonary fibrosis, radiation-induced, etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "9. Ongoing or active infection (e.g., no systemic antimicrobial therapy for treatment of infection within 5 days of D1 of IP).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "10. Symptomatic peptic ulcer disease or gastritis, active diverticulitis, other serious gastrointestinal (GI) disease associated with diarrhea within 6 months of D1 of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "11. Clinically significant or uncontrolled cardiac disease including any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Myocarditis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Unstable angina within 6 months from D1 of IP",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Acute myocardial infarction within 6 months from D1 of IP",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Uncontrolled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* New York Heart Association (NYHA) Class II, III or IV congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* Clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, second- or third- degree atrioventricular block without a pacemaker, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia requiring therapy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "12. Untreated central nervous system (CNS) or leptomeningeal metastases. Subjects with treated CNS metastases must have completed definitive treatment (radiotherapy and/or surgery) \\> 2 weeks prior to D1 of IP and no longer require steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "13. Women who are breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "14. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or compromised ability to provide written informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "15. Another malignancy that requires active therapy and that in the opinion of the investigator and Sponsor would interfere with monitoring of radiologic assessments of response to IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "16. Has undergone allogeneic stem cell transplantation or organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "17. Known history or positive test for human immunodeficiency virus, or positive test for hepatitis B (positive for hepatitis B surface antigen \\[HBsAg\\]) or hepatitis C virus (\\[HCV\\]; if HCV antibody (Ab) test is positive check for HCV ribonucleic acid \\[RNA\\]).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03894618",
    "statement": "* (NOTE: Hepatitis B virus (HBV): Subjects who are hepatitis B core antibody \\[HBcAb\\] positive, but HBsAg negative are eligible for enrollment. HCV: Subjects who are HCV Ab positive, but HCV RNA negative are eligible for enrollment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00380718",
    "statement": "* Histologic or cytologic diagnosis non-small cell lung cancer (NSCLC) (Stage IIIB or IV)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00380718",
    "statement": "* Patients' NSCLC must have progressed following one chemotherapy regimen for palliative therapy with or without subsequent targeted biological therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00380718",
    "statement": "* Disease status must be that of measureable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00380718",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00380718",
    "statement": "* Concurrent administration of any other tumor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00380718",
    "statement": "* Pregnancy or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00380718",
    "statement": "* Serious concomitant disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00380718",
    "statement": "* Inability or unwillingness to take folic acid or vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior lines, or recurrent advanced NSCLC having received 3 or fewer prior lines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Performance Status of 0, 1, or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Adequate bone marrow, kidney, and liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "Q2W",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* OVCA pts excluded with any of the following: non-epithelial, including malignant mixed mullerian tumors, unresolved bowel obstruction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Brain metastases requiring steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Active and clinically significant bacterial, fungal, or viral infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "Q3W Inclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Performance Status of 0 or 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Adequate bone marrow, kidney, and liver function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Part 2 includes ovarian cancer, target expressing triple negative breast cancer and non small cell lung cancer patients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "Q3W Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* OVCA pts excluded with any of the following: non-epithelial, including malignant mixed mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease, unresolved bowel obstruction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Brain metastases requiring steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02222922",
    "statement": "* Active and clinically significant bacterial, fungal, or viral infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191139",
    "statement": "* histologic or cytologic proof of single primary non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191139",
    "statement": "* No prior chemotherapy or radiation therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191139",
    "statement": "* no prior malignancy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191139",
    "statement": "* pregnancy or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191139",
    "statement": "* serious concomitant systemic disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00191139",
    "statement": "* unintentional weight loss greater than 10%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has one of the following histologically- or cytologically-confirmed advanced/metastatic solid tumors: NSCLC, CRPC, or MSS CRC, by pathology report and has received, or been intolerant to, or has been ineligible for all treatment known to confer clinical benefit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has Stage III or Stage IV disease that is not surgically resectable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has measurable disease by RECIST 1.1 criteria as assessed by the local site investigator/radiology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has supplied tumor tissue from either a newly obtained biopsy or an archival specimen for biomarker analysis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Male participants must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Female participants must agree to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Demonstrates adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "Non-small Cell Lung Cancer (NSCLC) Participants",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has histologically or cytologically confirmed diagnosis of Stage IV metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has progressed on treatment with an anti-Programmed Death-Ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies. PD-L1 treatment progression is defined by meeting all of the following criteria: a) Has received ≥2 doses of an approved anti-PD-L1 mAb; b) Has demonstrated disease progression after anti-PD-L1 as defined by RECIST 1.1; c) Progressive disease has been documented within 12 weeks from the last dose of anti-PD-L1 mAb.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "Castration Resistant Prostate Cancer (CRPC) Participants",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has histologically- or cytologically-confirmed adenocarcinoma of the prostate. Components of small cell prostate cancer are permitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has prostate cancer progression on the most recent treatment, as determined by the investigator, by means of one of the following: a) Prostate-Specific Antigen (PSA) progression using local laboratory values as defined by a minimum of 2 rising PSA levels with an interval of ≥1 week between each assessment where the PSA value at screening should be ≥2 ng/mL; b) Radiographic disease progression in soft tissue based on RECIST 1.1 criteria with or without PSA progression; c) Radiographic disease progression in bone defined as the appearance of 2 or more new bone lesions on bone scan with or without PSA progression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has progressed on at least one second generation anti-androgen therapy (e.g., enzalutamide, abiraterone).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has ongoing androgen deprivation with serum testosterone \\<50 ng/dL (\\<2.0 nM).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "Microsatellite Stable Colorectal Cancer (MSS-CRC) Participants",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has a histologically proven locally advanced unresectable or metastatic (Stage IV) CRC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has locally confirmed (MSS) CRC; participants with microsatellite instability-high (MSI-H) or microsatellite unstable CRC are not eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has been previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging, clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has had a severe hypersensitivity reaction to treatment with any mAb or components of the study treatment(s).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has an active autoimmune disease that has required systemic treatment in the past 2 years except vitiligo or resolved childhood asthma/atopy. Participants who have previously been permanently discontinued from PD-(L)1 therapy due to immune related side effects are not eligible for this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has an active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has symptomatic ascites or pleural effusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has interstitial lung disease that required oral or intravenous glucocorticoids to assist with management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years. Note: Participants who have had a stem cell transplant \\>5 years ago are eligible as long as there are no symptoms of graft-versus-host disease (GVHD).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has a known history of human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has a known history of Hepatitis B or known active Hepatitis C virus infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has a history or current evidence of a gastrointestinal condition (e.g. inflammatory bowel disease, Crohn's disease, ulcerative colitis) or impaired liver function or diseases that in the opinion of the Investigator may significantly alter the absorption or metabolism of oral medications; any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, make administration of the study drugs hazardous, or make it difficult to monitor AEs such that it is not in the best interest of the participant to participate, in the opinion of the treating Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Is pregnant or expecting to conceive or father children within the projected duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has undergone major surgery and has not recovered adequately from any toxicity and/or complications from the intervention prior to starting study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has CRPC or MSS CRC and has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has been treated with an agent directed to another stimulatory or co-inhibitory Tcell receptor (e.g. cytotoxic T-lymphocyte protein 4 \\[CTLA-4\\], tumor necrosis factor receptor superfamily, member 4 \\[OX 40\\], tumor necrosis factor receptor superfamily member 9 \\[CD137\\]).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has received prior systemic anti-cancer therapy including investigational agents or has used an investigational device within 28 days prior to the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has received prior radiotherapy (not to target lesions) within 2 weeks of start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Is expected to require any other form of antineoplastic therapy while on study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy in excess of replacement doses (prednisone ≤10 mg/day is acceptable), or on any other form of immunosuppressive medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has received a live-virus vaccine within 30 days prior to first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03473925",
    "statement": "* Has been previously treated with a chemokine receptor 2 (CXCR2) inhibitor (e.g. AZD5069, reparixin, danirixin, LY3041658 Ab, HuMax-IL8, etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01183858",
    "statement": "* Adult patients aged ≥18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01183858",
    "statement": "* inoperable, locally advanced (stage IIIB/IV) with supraclavicular lymph node metastases or malignant pleural or pericardial effusion) or metastatic (stage IV) non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01183858",
    "statement": "* Disease must be characterized according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01183858",
    "statement": "* Patients have received one prior platinum-based chemotherapy regimen for advanced NSCLC, but must have recovered from any treatment-related toxicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01183858",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01183858",
    "statement": "* Life expectancy ≥12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01183858",
    "statement": "* Current cigarette smoker (having smoked \\>100 cigarettes in entire lifetime and currently smoking on average ≥1 cigarette per day), not intending to stop during the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01183858",
    "statement": "* Prior antibody or small molecule therapy against Epidermal growth factor receptor (EGFR)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01183858",
    "statement": "* Radiotherapy within 28 days prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01183858",
    "statement": "* Received more than one line of chemotherapy for locally advanced/metastatic NSCLC (first-line maintenance chemotherapy after first-line platinum-based chemotherapy is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has a histologically or cytologically confirmed diagnosis of stage IV (M1a or M1b-American Joint Committee on Cancer \\[AJCC\\] 7th edition) squamous NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has not received prior systemic treatment for metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has provided tumor tissue from locations not radiated prior to biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has a life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* If female of childbearing potential, is willing to use an adequate method of contraception for the course of the study through 180 days after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* If male with a female partner(s) of child-bearing potential, must agree to use an adequate method of contraception starting with the first dose of study drug through 95 days after the last dose of study drug. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has non-squamous histology NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Before the first dose of study drug: a) Has received prior systemic cytotoxic chemotherapy for metastatic disease; b) Has received other targeted or biological antineoplastic therapy (e.g., erlotinib, crizotinib, cetuximab) for metastatic disease; c) Has had major surgery (\\<3 weeks prior to first dose).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Received radiation therapy to the lung that is \\> 30 Gy within 6 months of the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Completed palliative radiotherapy within 7 days of the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Is expected to require any other form of antineoplastic therapy while on study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has received a live-virus vaccination within 30 days of planned treatment start.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has a known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has pre-existing peripheral neuropathy that is ≥ Grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) version 4 criteria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has a known sensitivity to any component of carboplatin or paclitaxel or nab-paclitaxel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has active autoimmune disease that has required systemic treatment in past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Is on chronic systemic steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Had prior treatment with any other anti-programmed cell death 1 (anti-PD-1), or programmed cell death ligand 1 (PD-L1) or PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors or mechanisms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has participated in any other pembrolizumab trial and has been treated with pembrolizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has an active infection requiring therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has known history of Human Immunodeficiency Virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has known active Hepatitis B or C. Active Hepatitis B.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Is, at the time of providing documented informed consent, a regular user (including \"recreational use\") of any illicit drugs or has a recent history (within the last year) of substance abuse (including alcohol).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02775435",
    "statement": "* Has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* No prior treatment for Stage IV non-squamous or squamous NSCLC. Participant known to have a sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) fusion oncogene are excluded from the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Tumor PD-L1 expression as determined by immunohistochemistry (IHC) assay of archival tumor tissue or tissue obtained at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Adequate hematologic and end-organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Known sensitizing mutation in the EGFR gene or ALK fusion oncogene",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Active or untreated central nervous system (CNS) metastases as determined by Computed Tomography (CT) or magnetic resonance imaging (MRI) evaluation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* History of autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Positive test for Human Immunodeficiency Virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Active hepatitis B or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, anti PD1, and anti-PD-L1 therapeutic antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Severe infection within 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02409342",
    "statement": "* Significant history of cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": ". Locally advanced or metastatic solid tumors who meet 1 of the following 4 criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "* With locally advanced or metastatic ALK-positive NSCLC who have progressed on or are intolerant to treatment with at least 1 other ALK inhibitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "* With ALK-positive nonlung solid tumors that are locally advanced or metastatic and for whom no standard, nonexperimental therapy is available.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "* With locally advanced or metastatic ROS1-positive NSCLC who have progressed on crizotinib therapy or are intolerant to crizotinib, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "* With ROS1-positive nonlung solid tumors that are locally advanced or metastatic and for whom no standard, nonexperimental therapy is available.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "2. Eastern cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "3. Have at least 1 target lesion per response evaluation criteria in solid tumors (RECIST) version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "4. Have recovered from toxicities related to prior anticancer therapy to National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) version 4.03 Grade less than or equal to (\\<=) 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "5. Suitable venous access for study-required blood sampling (that is, including PK and laboratory safety tests).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": ". Systemic treatment with strong or moderate cytochrome P450 3A (CYP3A) inhibitors or inducers within 14 days before enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "2. Prior therapy with brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "3. Received prior ALK-inhibitor therapy within 7 days before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "4. Treatment with any investigational systemic anticancer agents within 14 days or 5 half-lives, whichever is longer, before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "5. Received chemotherapy or radiation therapy within 14 days before the first dose of study drug, except for stereotactic radiosurgery (SRS) or stereotactic body radiation therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "6. Received antineoplastic monoclonal antibodies within 30 days before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "7. Had major surgery within 30 days before the first dose of study drug. Minor surgical procedures, such as catheter placement or minimally invasive biopsies, are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03420742",
    "statement": "8. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with leptomeningeal disease and without cord compression are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": ". Pathologically confirmed stage IIIB/IV adenocarcinoma in non-small cell lung cancer\\[NSCLC\\]",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "2. Progressive disease following a second-line cytotoxic chemotherapy including at least one platinum-containing regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "3. A known wild-type EGFR status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "4. Patients 18 years of age or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": ". More than two prior cytotoxic chemotherapy treatment regimens for relapsed or metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "2. Prior treatment with EGFR targeting small molecules or antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "3. Radiotherapy or surgery within 4 weeks prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "4. Active brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "5. Known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "6. History or presence of clinically relevant cardiovascular abnormalities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "7. Cardiac left ventricular function with resting ejection fraction of less than 50%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "8. Absolute neutrophil count\\[ANC\\] \\< 1,500/mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "9. Platelet count \\<100,000/mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "10. Creatinine clearance\\<60ml/min or serum creatinine \\>1.5 times upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "11. Women of childbearing potential, or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01003899",
    "statement": "12. Pregnancy or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "\\>=18 years with histologically or cytologically confirmed advanced nonsquamous non-small cell lung cancer (nsNSCLC). Mixed tumors should be categorized according to the predominant histology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "Note: NSCLC should be predominantly nonsquamous. Recurrent or metastatic disease (Stage IV) with an indication for therapy with paclitaxel + carboplatin + Avastin®.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "Patients harboring tumors with unknown or without activating epidermal growth factor receptor (EGFR) / anaplastic lymphoma receptor tyrosine kinase (ALK) mutation maybe included provided chemotherapy is standard of care. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on independent central review.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "Adequate hepatic, renal, and bone marrow function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "Life expectancy \\> 6 months based on clinical judgment. Further inclusion criteria apply.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "(VEGF) or VEGF receptors, including Avastin®.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "Prior systemic therapy for metastatic disease. Prior systemic anticancer therapy or radiotherapy for locally advanced nsNSCLC if completed \\<12 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "Previous malignancy other than NSCLC in the last 5 years except for basal cell cancer of the skin or pre-invasive cancer of the cervix.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "Symptomatic brain metastasis. Diagnosis of small cell carcinoma of the lung, squamous cell carcinoma of the lung, NSCLC not specified (NS) or NSCLC not otherwise specified(NOS).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "Any unresolved toxicity \\> Common Toxicity Criteria Grade 1 (except alopecia) from previous anticancer therapy (including radiotherapy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02272413",
    "statement": "History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding. Thrombotic or hemorrhagic event =\\< 6 months prior to Screening. Further exclusion criteria apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Participants must have histologically confirmed B-cell CLL, including small lymphocytic lymphoma (SLL), DLBCL, MCL, or FL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* B-cell NHL: a) Have previous confirmation of B-cell NHL b) Participants with DLBCL or MCL, must have relapsed or refractory disease after at least one prior regimen containing rituximab, either alone or in combination, and be ineligible for any available standard line of therapy known to be life-prolonging or life-saving c) Participants with FL, must have relapsed or refractory disease after at least two prior regimens, one of which included rituximab, either alone or in combination, and be ineligible for any available standard line of therapy known to be life-prolonging or life-saving d) Have measurable disease (at least one lesion greater than or equal to (≥) 20 millimeter (mm) in one dimension or ≥ 15 mm in two dimensions as measured by conventional or high resolution \\[spiral\\] computed tomography e) Not be a candidate for a hematopoietic stem cell (HSC) or bone marrow transplant",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* B-cell CLL: a) Have previous confirmation of B-cell CLL with a characteristic immunophenotype by flow cytometry b) Have relapsed or refractory disease after at least 2 prior lines of treatment, at least 1 of which must have contained rituximab and be ineligible for any available standard line of therapy known to be life-prolonging or life-saving c) Not be a candidate for an HSC or BM transplant d) Have symptomatic disease that requires treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Karnofsky Performance Status ≥ 70",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Life expectancy of ≥ 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Toxicities from previous cancer therapies must have recovered to Grade less than (\\<) 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Adequate hematological function defined as: a) Hemoglobin ≥ 9 g/dL b) Absolute neutrophil count ≥ 1500/mm\\^3 c) Platelet count ≥ 75,000/mm\\^3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Prothrombin time-International Normalized Ratio/Partial thromboplastin time less than or equal to (≤) 1.5 × upper limit of normal (ULN), or for participants on anticoagulation therapy, status within therapeutic range",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Women of non-child-bearing potential or using effective contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Male participants with partners of child-bearing potential must be surgically sterile or use a contraceptive method",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Any available standard line of therapy known to be life-prolonging or life-saving",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic, or hormonal therapy for treatment of cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* For CLL participants only, rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* History of allergy or reaction to any component of the CAT-8015",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Receipt of any chemotherapy or small molecule targeted therapy or any biological- or immunological-based therapies for leukemia or lymphoma within 6 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Prior radiation therapy will not be excluded, providing the volume of bone marrow treated is less than 25 percent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Any history of prior pseudomonas-exotoxin immunotoxin administration including CAT-8015, CAT-3888, or LMB-2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* History of other invasive malignancy within 5 years, with some exceptions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Evidence of significant active infection requiring antimicrobial, antifungal, antiparasitic or antiviral therapy or for which other supportive care is given",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Autologous stem cell transplantation within 6 months prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Allogenic stem cell transplantation or any other organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* HIV-positive or AIDS, Hepatitis B or hepatitis C infection as defined by seropositive for hepatitis B (HBsAg) or hepatitis C and elevated liver transaminases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Use of immunosuppressive medication other than steroids within 7 days, use of systemic steroids within 7 days before the first dose of CAT-8015 (inhaled and topical corticosteroids are permitted). Participants may take replacement doses of steroids (defined as ≤ 30 mg/day hydrocortisone or the equivalent) if on a stable dose for at least 2 weeks prior to the first dose of CAT-8015",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Documented current central nervous system involvement by leukemia or lymphoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Pregnancy or lactation, other severe, concurrent diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01030536",
    "statement": "* Concurrent enrollment in another clinical study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": ". Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV who have failed treatment with erlotinib (Tarceva) or gefitinib (Iressa).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "2. Patients should have received and failed at least one line of cytotoxic chemotherapy including a platinum-based regimen in patients eligible for platinum-based therapy and pemetrexed in pemetrexed eligible patients (unless pemetrexed is not considered a regulatory or clinical standard of care e.g. no label indication, no availability or no coverage by 3rd party payer(s)) for advanced or metastatic disease and have progressive disease following at least 12 weeks of treatment with erlotinib or gefitinib",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "3. Patients pretreated with taxane-based chemotherapy for advanced or metastatic disease must have experienced stable disease, partial or complete response as best response",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "4. Eastern Cooperative Oncology Group performance Score 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "5. Patients with at least one tumor lesion that can accurately be measured by magnetic resonance imaging (MRI), or computed tomography (CT) in at least one dimension with longest diameter to be recorded as 10 mm but no less than double the slice thickness according to RESIST 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "6. Male and female patients no less than 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "7. Life expectancy of at least three (3) months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "8. Written informed consent that is consistent with ICH-GCP guidelines. Part B 1) Clinical benefit (disease stabilization or antitumor response) of 12 weeks duration in Part A of the trial determined on the second tumour assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "2.) Patients should have progressed in Part A according to RECIST 1.1 3.) New informed consent, including consent to biomarker sampling, must be signed before patients enter Part B of the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": ". Previous treatment with BIBW 2992",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "2. Chemo-, hormone- (other than megestrol acetate, steroids required for maintenance non-cancer therapy or as premedication before chemotherapy) or immunotherapy within the past 4 weeks; except for TKI pretreatment (2 weeks only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "3. Active/symptomatic brain metastases including leptomeningeal disease. Patients with a history of treated brain metastasis must have a stable or normal brain MRT/CT scan at screening and be at least 4 weeks post-radiation or surgery for brain metastasis. Dexamethasone therapy will be allowed if administered as a stable dose for at least one month before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "4. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's disease, mal-absorption, or CTCAE Grade \\>2 diarrhea of any etiology at baseline",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "5. Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the Investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "6. Other malignancies diagnosed within the past five (5) years (other than non-melanomatous skin cancer and in situ cervical cancer)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "7. Radiotherapy within the past 2 weeks prior to treatment with the trial drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "8. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New york Heart Association (NYHA) functional classification of 3, unstable angina, or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to entering the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "9. Cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram .",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "10. Prior treatment with anthracyclines with a cumulative dose of doxorubicin (or equivalent) at or greater than 400 mg/m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "11. Absolute neutrophil count (ANC) at or less than 1500 / mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "12. Platelet count at or less than 100,000 / mm3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "13. Bilirubin at or greater than 1.5 mg / dL (\\>26 mol / L, SI unit equivalent)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "14. Aspartate amino transferase (AST) or alanine amino transferase (ALT) at or greater than three times the upper limit of normal (if related to liver metastases at or greater than five times the upper limit of normal)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "15. Serum creatinine at or greater 1.5 times the upper normal limit or calculated/measured creatinine clearance at or less than 45 mL/min",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "16. Women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "17. Pregnancy or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "18. Patients unable to comply with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "19. Patients with any serious active infection including known human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "20. Known or suspected active drug or alcohol abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "21. Pre-existing or current Interstitial lung disease (ILD) 22.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "22. Peripheral polyneuropathy of \\> Grade 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01085136",
    "statement": "23. Requirement for treatment with any of the pohibited concomitant medication listed in section 4.2.2.1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Age = 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Life expectancy of at least 12 weeks at the pre-treatment evaluation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Patients with metastatic, measurable, histologically or cytologically documented NSCLC (includes squamous, large cell or adenocarcinoma). In case of unique metastatic site, histological confirmation is required in order to ensure proper diagnosis prior to study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Patients must have progressive non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* No more than 2 prior systemic agent or regimen at least 28 days prior to study entry. (Prior therapy with gefitinib is allowed but not mandatory)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Patients must be considered appropriate for systemic anti-cancer therapy by the Investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Patients with at least one uni-dimensional measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Adequate bone marrow, liver and renal function, as assessed by the following laboratory:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Hemoglobin = 9.0 g/dl",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Absolute granulocytes = 1.5 x 10E9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Platelet count = 100 x 10E9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Total bilirubin \\< 1.5 x the upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\< 2.5 x upper limit of normal (\\< 5 x upper limit of normal for patients with liver involvement of their cancer)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* prothrombin time (PT) or International Normalized Ratio (INR) and partial thromboplastin time (PTT) \\< 1.5 x upper limit of normal (except in patients who are on warfarin or heparin. Patients who receive anti-coagulation treatment with an agent such as warfarin or heparin, prophylactically or therapeutically, will be allowed to participate. For patients on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre dose, as defined by the local standard of care)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Serum creatinine = 2.0 x upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Amylase and lipase \\< 1.5 x the upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Cardiac arrhythmia requiring anti-arrhythmics (excluding beta-blockers or digoxin), symptomatic coronary artery disease (CAD) or ischemia (myocardial infarction (MI) within the last 6 months) or congestive heart failure (CHF) \\> New York Heart Association (NYHA) Class II",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Uncontrolled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Complete renal shut-down requiring hemo- or peritoneal dialysis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Mixed histologies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Active clinically serious infections (\\> grade 2 on the National Cancer Institute \\[NCI\\] Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Known history of HIV infection or chronic hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Known metastatic brain or meningeal tumors, unless the patient is \\> 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. A head CT or MRI must be conducted to rule out brain metastasis or meningeal tumors. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable, provided that the dose is stable for one month prior to and following screening radiographic studies)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* History of seizure disorder requiring medication (such as steroids or anti-epileptics)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* History of organ allograft and bone marrow transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumors \\[Ta, Tis \\& T1\\] or other malignancies curatively treated \\> 3 years prior to entry)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Patients with clinically significant bleeding (e.g., gastrointestinal bleeding) within the past month prior to study entry are ineligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures (e.g. cervical cap, condom, and diaphragm) during the course of the trial. Oral birth control methods alone will not be considered adequate on this study, because of the potential pharmacokinetic interaction between BAY 43-9006 and oral contraceptives",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Substance abuse, medical, psychological or social conditions that, in the judgment of the investigator, is likely to interfere with the patients participation in the study or evaluation of the study results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Known allergy to the investigational agent or any agent given in association with this trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Any condition that is unstable or could jeopardize the safety of the patient and its compliance in the study, in the investigator's judgment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Anti cancer chemotherapy, immunotherapy, vaccines or investigational therapy during the study or within 4 weeks of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Radiotherapy during the study or within 4 weeks of study entry. Patients must have recovered from radiation-induced toxicity. However, palliative is allowed for local pain control.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00101413",
    "statement": "* Any surgical procedure within 4 weeks prior to the start of study drug. Autologous and/or allogenic including mini-allogenic bone marrow transplant or stem cell rescue. Use of biologic response modifiers, such as Granulocyte-Colony Stimulating Factor (G-CSF) or Granulocyte macrophage colony-stimulating factor (GM-CSF), during or within 3 weeks of study entry. G-CSF and other hematopoietic growth factors may only be used in the management of acute toxicity, when medically indicated, or at the discretion of the investigator. Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study. Use of St. John's Wort. Use of rifampicin. Prior use of Raf-Kinase inhibitors, MAPK/ERK kinase (MEK) or Farnesyl Transferase Inhibitors. Prior use of Bevacizumab and all other drugs that target vascular endothelial growth factor (VEGF)/ vascular endothelial growth factor receptor (VEGFR). Use of any investigational drug therapy outside of this during or within 4 weeks of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* At least 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Able to understand and provide an informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Life expectancy \\>12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Histopathologically or cytologically confirmed small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Evaluable disease as defined by RECIST Version 1.1 guidelines (patients with non measurable lesions only are eligible).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Radiologically confirmed progression on or after first-line platinum based chemotherapy (carboplatin or cisplatin), or chemo-radiation including platinum-based chemotherapy for treatment of limited or extensive stage Small Cell Lung Cancer (SCLC). In addition to platinum-based regimen, one line of immunotherapy as monotherapy or in combination, in first or in second line setting is allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Recovered from the effects of any prior chemotherapy, surgery, radiotherapy or other anti-neoplastic therapy (recovered to Grade 1 or better, with the exception of alopecia, peripheral neuropathy, or ototoxicity).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Adequate bone marrow reserves",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Adequate hepatic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Adequate renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Electrocardiogram during the Screening period without any clinically significant findings, per investigator's assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Patients with certain types of asymptomatic CNS metastases that meet ALL the following criteria are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "  1. Patients with asymptomatic CNS metastases prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "  2. Prior radiation for CNS metastatic disease is completed ≥4 weeks prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "  3. CNS metastases that are stable or have decreased according to the post radiation follow-up scan that is conducted at least 4 weeks after completion of radiation treatment for CNS lesion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "  4. Patients have discontinued corticosteroids or are on stable low-dose steroids (prednisone or equivalent 10 mg daily or less) for at least 1 week after completion of radiation for CNS lesion prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Any medical or social condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Pregnant or breast feeding;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Patients with large cell neuroendocrine lung carcinoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Patients who have received prior topoisomerase I inhibitor treatment, retreatment with platinum-based regimen, antibody-drug conjugates or molecular targeted agents, more than one line of immunotherapy, or any other additional regimen of prior cytotoxic chemotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Patients with the symptomatic Central Nervous System (CNS) metastasis and/or who have developed new or progressive brain metastasis within 3 months following prophylactic and/or therapeutic cranial radiation (whole brain stereotactic radiation).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Patients with carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Unable to discontinue the use of strong CYP3A4 or UGT1A1 inhibitors at least 1 week or strong CYP3A4 inducers at least 2 weeks prior to receiving the first dose of irinotecan liposome injection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Have a previous or concurrent cancer that is distinct in primary (non-pulmonary) site or SCLC histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is less, prior to the first scheduled day of dosing in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Severe cardiovascular and pulmonary diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* New York Heart Association Class III or IV congestive heart failure, ventricular arrhythmias, or uncontrolled blood pressure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Known hypersensitivity to any of the components of irinotecan liposome injection, other liposomal products, or topotecan.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03088813",
    "statement": "* Clinically significant gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea \\> grade 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00452413",
    "statement": ". Phase 1: Any incurable solid malignancy, with no more than 3 prior systemic treatment regimens.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00452413",
    "statement": "   Phase 2: Histologic diagnosis of advanced NSCLC, Stage IIIB with malignant pleural effusion or Stage IV per American Joint Committee on Cancer Staging Criteria for NSCLC. Participants must have failed 1 or 2 prior systemic treatment regimen(s).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00452413",
    "statement": "2. Performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00452413",
    "statement": "3. Prior chemotherapy must be completed at least 2 weeks prior to study enrollment, and the participant must have recovered from acute toxic effects (except alopecia) prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00452413",
    "statement": "4. Prior radiotherapy is allowed to \\<25% of the bone marrow. Prior radiotherapy must be completed at least 2 weeks before study enrollment, and the participant must have recovered from acute toxic effects (except alopecia) prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00452413",
    "statement": "5. Non-measurable or measurable disease as defined by Response Evaluation Criteria in Solid Tumors \\[RECIST, version (v) 1.0\\].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00452413",
    "statement": ". Are unable to swallow tablets.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00452413",
    "statement": "2. Unable to discontinue use of carbamazepine, phenobarbital, and phenytoin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00452413",
    "statement": "3. Have previously been treated with an epidermal growth factor receptor (EGFR) inhibitor, including erlotinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00452413",
    "statement": "4. Are receiving concurrent administration of any other antitumor therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00452413",
    "statement": "5. Have received treatment within the last 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Diagnosis of metastatic Stage IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* At least 1 measurable extra-central nervous system (CNS) lesion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Documented radiographic progression while on continuous treatment with erlotinib monotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Objective clinical benefit from erlotinib treatment as defined by either documented partial or complete response or stable disease ≥6 months or, if most recent erlotinib treatment has been initiated based on documented epidermal growth factor receptor mutation (EGFRmt) status, at least 12 weeks stable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Determined to be MET diagnostic positive (+)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Availability of a tumor sample post-erlotinib progression",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Have adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Have previously been treated with LY2875358 or any other MET-targeting experimental therapeutic",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Have a serious concomitant systemic disorder or significant cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Have interstitial pneumonia or interstitial fibrosis of the lung or have pleural effusion, pericardial fluids or ascites, requiring drainage every other week or more frequently",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Have a history of another malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and without evidence of recurrence for at least 3 years prior to the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Have major surgery less than 2 weeks prior initiation of study treatment therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01900652",
    "statement": "* Have symptomatic CNS metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Signed and dated written informed consent prior to any trial-specific procedure",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Male or female subjects age greater than or equal to (\\>=) 18 years with R/M SCCHN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Histologically confirmed R/M SCCHN, documented in the medical record",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* History of progressing disease on a first-line cytotoxic chemotherapy regimen for R/M SCCHN, such as 5-fluorouracil (FU) plus cisplatin, or taxanes. (A history of chemotherapy or radiotherapy for localized disease was not considered a first-line regimen)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* The subject is suited for systemic therapy in the opinion of the Investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* At least one radiographically documented lesion measurable according to response evaluation criteria in solid tumors (RECIST) 1.0. All target lesions are to be measurable (that is, the lesion must be adequately measurable in at least one dimension; longest diameter to be recorded as \\>= 2 centimeter (cm) by conventional techniques or \\>= 1 centimeter (cm) by spiral computed tomography \\[CT\\] scan). Target lesions are to be selected from the required protocol imaging. If the sole site of measurable disease is in a prior radiation field, there has to be unequivocal evidence of progression at \\>= 8 weeks since the completion of radiation or a positive biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Eastern cooperative oncology group performance status (ECOG PS) of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* If female, either post-menopausal, surgically sterile, or having a negative urine or serum pregnancy test (beta-human chorionic gonadotropin \\[beta-HCG\\]) at screening and practicing medically accepted contraception. If male, practicing contraception if the risk of conception exists. For relevant subjects, the duration of contraception should be 1 week prior to the start of therapy through 4 weeks after receipt of trial therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Recovered from previous toxicities of prior cytotoxic regimen to common terminology criteria of adverse events (CTCAE) Grade 1 (with the exception of alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Hemoglobin \\>= 9 gram per deciliter (g/dL) without transfusion support; no transfusion within 7 days prior to screening)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Neutrophils \\>= 1.5 \\* 10\\^9 per liter",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Platelets \\>= 100 \\* 10\\^9 per liter",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Prothrombin time/partial thromboplastin time (PT/PTT) less than or equal to (=\\<) 1.5 times the upper limit of normal (ULN) for the site, unless there is therapeutic anti-coagulation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Serum creatinine =\\< 1.5 times the ULN for the site",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\< 3 times the ULN for the site",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Be willing and able to comply with the protocol procedures for the duration of the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* History of prior exposure to cetuximab or panitumumab or any other approved or investigational anti-epidermal growth factor receptor (EGFR) agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Undifferentiated nasopharyngeal carcinoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Chemotherapy, radiotherapy or any investigational agents within 4 weeks prior to first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Major surgical or planned procedure within 30 days prior to first dose of trial medication (isolated biopsies are not considered major surgical procedures)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Active malignancy other than SCCHN, non-metastatic basal cell or squamous cell carcinoma of the skin, or second primary SCCHN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Impaired cardiac function (for example, left ventricular ejection fraction less than \\[\\<\\] 45 percent defined by echocardiograph or other study), history of uncontrolled serious arrhythmia, unstable angina pectoris, congestive heart failure (new york heart association \\[NYHA\\] Grade III and IV), myocardial infarction within the last 12 months prior to trial entry, or signs of pericardial effusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Hypertension uncontrolled by standard pharmacologic therapies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* History of diagnosed interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Subject requires systemic anti-coagulation (example, warfarin greater than \\[\\>\\] 10 milligram per day \\[mg/day\\])",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Pregnancy or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Legal incapacity or limited legal capacity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Significant medical or psychiatric disease which makes the trial inappropriate in the Investigator's opinion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Any brain metastasis and/or leptomeningeal disease (known or suspected)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Significant pre-existing immune deficiency, such as infection of human immuno-deficiency virus (HIV) (documented or known)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Clinically significant ongoing infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Known hypersensitivity to the trial treatments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer from such disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01040832",
    "statement": "* Other significant disease that in the Investigator's opinion would exclude the subject from the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00322452",
    "statement": "* Locally advanced Stage IIIB not amenable to local therapy or Stage IV (metastatic) NSCLC with adenocarcinoma histology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00322452",
    "statement": "* Never smokers or light ex-smokers.(ceased smoking at least 15 years before Day 1 of study treatment and 10 pack-years or fewer)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00322452",
    "statement": "* Had prior chemotherapy, biological (including targeted therapies such as EGFR and vascular epidermal growth factor (VEGF) inhibitors) or immunological therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00322452",
    "statement": "* Pre-existing idiopathic pulmonary fibrosis evidence by CT scan at baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has histologically or cytologically confirmed, nonsquamous (adenocarcinoma/large cell or other) NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has Stage IV disease at the time of study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* Participants with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least 14 days prior to randomization, or after surgical resection performed at least 28 days prior to randomization. The participant may have no evidence of Grade 1 (or greater) Central Nervous System (CNS) hemorrhage based on pretreatment scans(performed within 21 days before randomization).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has measurable or nonmeasurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 guidelines.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* If prior adjuvant or neoadjuvant chemotherapy, the last dose of adjuvant or neoadjuvant treatment was administered at least 6 months prior to randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has adequate bone marrow reserve, and renal and hepatic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has fasting serum glucose less than or equal to 125 mg/dL, and hemoglobin A1C less than or equal to 6%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* Females with reproductive potential: Must have a negative serum or urine pregnancy test within 7 days prior to the first dose of any study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for 6 months following the last dose of any study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has the ability to understand and the willingness to sign a written informed consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* Previous radiation therapy is allowed to less than 25% of the bone marrow, but should have been limited and must not have included whole pelvis radiation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has archived tumor tissue available for analysis (can be either primary tumor or metastases).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has an estimated life expectancy of at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* Participants who have squamous histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant's tumor fully or partially contains Small Cell Lung Cancer (SCLC).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has leptomeningeal disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant is currently or has previously received chemotherapy for advanced (Stage IV) NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has a history of treatment with other agents targeting the Insulin-like or Epidermal Growth factor receptors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* Participants who have received prior Pemetrexed treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The patient has a known allergy/history of hypersensitivity reaction to any of the treatment components.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has diabetes mellitus as defined by being treated with glucose lowering medications in the past 3 months prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics, symptomatic congestive heart failure, uncontrolled hypertension, clinically significant cardiac arrhythmia,or psychiatric/social situations that would limit compliance with study requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has undergone major surgery within 28 days prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has received a prior autologous or allogeneic organ or tissue transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant is pregnant or lactating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has a history of another primary cancer, with the exception of the following: curatively resected nonmelanomatous skin cancer, curatively treated carcinoma in situ, or other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has superior vena cava syndrome contraindicating hydration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has current clinically-relevant coronary artery disease (New York Heart Association III or IV) or uncontrolled congestive heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has any Grade 2 (or greater) peripheral neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant is unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose less than or equal to 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant is unwilling or unable to take premedications (folic acid, vitamin B12, or corticosteroids) required by the pemetrexed label.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01232452",
    "statement": "* The participant has received a recent (within 30 days of enrollment) or is receiving concurrent yellow fever vaccination.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02279732",
    "statement": "* Subjects with NSCLC of predominantly squamous histology documented by histology or cytology from brushing, washing or needle aspiration of a defined lesion but not from sputum cytology alone",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02279732",
    "statement": "* Stage IV or Recurrent NSCLC (per the 7th International Association for the Study of Lung Cancer (IASLC) classification)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02279732",
    "statement": "* At least 1 measurable tumor lesion, as defined by mWHO criteria, that is not located in a previously irradiated area",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02279732",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02279732",
    "statement": "* Brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02279732",
    "statement": "* Malignant pleural effusion that is recurrent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02279732",
    "statement": "* Documented history of severe autoimmune or immune mediated symptomatic disease that required prolonged (more than 2 months) systemic immunosuppressive (ie, steroids) treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject must have cytologically or histologically confirmed non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject must have brain metastases demonstrated on a magnetic resonance imaging (MRI) brain scan.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject must be eligible for treatment with WBRT",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject must have had adequate hematologic, renal, and hepatic function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject is diagnosed with brain metastases greater than 28 days prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject received any prior form of cranial radiation and/or neurosurgery for their brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject's last dose of anti-cancer therapy or investigational therapy was less than or equal to 7 days prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject has a Karnofsky Performance Score of less than 70",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject has significant dyspnea requiring supplemental oxygen therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject has liver metastases (restaging is not required for known liver metastases)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject has more than 2 sites (organ systems) of metastases from non-small cell lung cancer with the exception of intra-cranial sites of metastases from non-small cell lung cancer, thoracic sites of metastases from non-small cell lung cancer and bone metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject has leptomeningeal metastases or subarachnoid spread of tumor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject has unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject has a known seizure disorder that is uncontrolled, or has seizures occurring greater than or equal to 3 times a week over the past month. Subjects presenting with symptoms of seizures from the brain metastases are eligible; however he/she should receive adequate anti-seizure medication prior to study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject is pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject has previously been treated with a poly-(ADP-ribose)-polymerase inhibitor as an investigational agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject has clinically significant and uncontrolled major medical condition(s)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01657799",
    "statement": "* Subject has a history of another active cancer within the past 5 years except: cervical cancer in situ, in situ carcinoma of the bladder, basal or squamous cell carcinoma of the skin or other cancer in situ that is considered cured",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": ". Histological or cytological confirmation of NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "2. Stage II, III, or IV NSCLC for whom radiation therapy of 60 Gy and concurrent weekly paclitaxel/carboplatin is recommended",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "3. Up to three small (≤ 3 cm each) lung oligometastases will be allowed and/or one oligometastasis at any other site in the body",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "4. Eastern Cooperative Oncology Group Performance Scale (ECOG PS) of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "5. Forced expiratory volume at one second (FEV1): best value obtained pre- or post-bronchodilator must be ≥ 1.0 liters/second or \\> 50% predicted value",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "6. Adequate bone marrow reserve",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "7. Adequate hepatic reserve",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "8. Adequate renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "9. Female subjects of childbearing potential must have a negative pregnancy test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "10. Female subjects of childbearing potential and male subjects with female sexual partners of childbearing potential must agree to use an effective method of contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "11. Ability to read and provide written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": ". Weight loss greater than 10% in prior 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "2. Prior malignancy in which they received any thoracic radiotherapy unless the treating physician considers it unlikely to impact the clinical outcome of the patient",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "3. Patients with concurrent invasive malignancy other than non-melanoma skin cancer or cervical intraepithelial neoplasia unless the treating physician considers it unlikely to impact the clinical outcome of the patient",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "4. An active infection or with a fever ≥ 38.5°C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "5. Poorly controlled intercurrent illnesses",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "6. Patients with a prior thoracotomy within 1 week of study registration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "7. Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "8. Patients with any of the following are not eligible:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "* Previous history of Corrected QT Interval (QTc ) prolongation resulting from medication that required discontinuation of that medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "* Congenital long QT syndrome, or 1st degree relative with unexplained sudden death under 40 years of age;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "* Presence of left bundle branch block (LBBB);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "* QTc with Fridericia's correction that is unmeasurable, or ≥ 480 msec on screening ECG. The average QTc from the screening ECG (completed in triplicate) must be \\< 480 msec in order for the patient to be eligible for the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "* Subjects taking any concomitant medication that may cause QTc prolongation, induce Torsades de Pointes are not eligible if QTc ≥ 460 msec.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "9. Patients must not have had a clinically significant cardiac event within 6 months before entry; or the presence of any other uncontrolled cardiovascular conditions that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "10. Patients with a history of arrhythmia or asymptomatic sustained ventricular tachycardia are not eligible. Patients with atrial fibrillation with well-controlled ventricular rate on medication, are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "11. Psychiatric conditions, social situations or substance abuse that precludes the ability of the subject to cooperate with the requirements of the trial and protocol therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "12. Grade 2 or higher peripheral neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "13. Known history of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), hepatitis B or C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "14. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02567799",
    "statement": "15. Women who are breastfeeding are not eligible for this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Pathologic confirmation of metastatic, unresectable, or locally-advanced NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Disease progression during or following one prior platinum-based chemotherapy regimen for advanced disease (stage IIIB or IV).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Bidimensionally measurable disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Karnofsky performance status score of 60 to 100 at study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* The participant has tumor tissue available for immunohistochemical determination of epidermal growth factor (EGFR) expression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least 4 weeks must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational agent, or prior radiation therapy (palliative radiation therapy is allowed).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Accessible for treatment and follow-up. Participants enrolled in this trial must be treated at the participating center.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Women of childbearing potential (WOCBP) and fertile men with partners of childbearing potential must be using an adequate method of contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* WOCBP must have a negative serum or urine pregnancy test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Women who are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* A serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Symptomatic or uncontrolled metastases in the brain. Participants receiving a glucocorticoid for brain metastases will be excluded, but those receiving anticonvulsants will be eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Uncontrolled pleural effusion or ascites.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Peripheral neuropathy greater than grade 2, as assessed by the National Cancer Institutes-Common Toxicity Criteria Adverse Events (NCI-CTCAE), Version 3.0.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Any concurrent malignancy other than basal cell skin cancer, or carcinoma in situ of the cervix. Patients with a previous malignancy, but without evidence of disease for greater than or equal 3 years will be allowed to enter the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* More than one prior chemotherapy regimen for advanced disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Inadequate hematologic function defined by an absolute neutrophil count (ANC) \\<1,500/mm3, a platelet count \\<100,000/mm3, and a hemoglobin level \\<9 g/dL. Red blood cell transfusions are not permitted within 7 days of receiving cetuximab, docetaxel, or pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Inadequate hepatic function, defined by a total bilirubin level \\>1.5 times the upper limit of normal (ULN), aspartate transaminase (AST) and alanine aminotransferase (ALT) levels \\>2.5 times the ULN (greater than or equal to 5 times the ULN if known liver metastases), and an alkaline phosphatase level \\>5.0 times the ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Inadequate renal function defined by a serum creatinine level \\>1.5 times the ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Prior treatment with cetuximab, or any other epidermal growth factor receptor inhibitors, including tyrosine kinase inhibitors, such as gefitinib or erlotinib. Participants must not have received prior chimerized or murine monoclonal antibody therapy. Prior treatment with other monoclonal antibodies targeting receptors other than the EGFR is permitted \\>30 days prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Prior treatment with docetaxel or pemetrexed therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Inability or unwillingness to take folic acid or vitamin B12 supplementation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Inability or unwillingness to interrupt nonsteroidal anti-inflammatory drugs (NSAIDs) for a 5-day period (8-day period for long-acting agents such as piroxicam). Aspirin will be permitted during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Patients (including prisoners) who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious disease) illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00095199",
    "statement": "* Prior treatment with an experimental drug or medical device within 30 days of randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409006",
    "statement": "* Histologic or cytologic diagnosis non-small cell lung cancer (NSCLC) (Stage IIIB or IV)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409006",
    "statement": "* Have not received any prior chemotherapy, molecular therapy, immunotherapy, biological therapy, or radiotherapy. Exception: palliative radiotherapy that is completed at least 4 weeks prior to study enrolment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409006",
    "statement": "* Have 'never smoked' (defined as having smoked \\<100 cigarettes during his/her lifetime)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409006",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409006",
    "statement": "* Concurrent administration of any other tumor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409006",
    "statement": "* Other co-existing malignancies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409006",
    "statement": "* Pregnancy or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409006",
    "statement": "* Serious concomitant disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00409006",
    "statement": "* Inability or unwillingness to take folic acid or vitamin B12 supplementation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00423449",
    "statement": "* Patient must have a histologically-confirmed metastatic or locally advanced non-small cell lung cancer that has not been previously treated with systemic chemotherapy or has received non-platinum and non-gemcitabine based neoadjuvant or adjuvant chemotherapy if the last dose was at least 6 months prior to study enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00423449",
    "statement": "* Patient who has had chemotherapy, radiotherapy, or biological therapy prior to entering the study, except for adjuvant or neoadjuvant chemotherapy, as allowed for treatment of a tumor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* At least one measurable cancerous lesion in the brain from primary non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Must have received previous chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Must be 18 years of age of greater",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Must be Easter Cooperative Oncology Group (ECOG) Performance Status 0, 1, 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* At least 2 weeks must have elapsed since any surgery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* At least 4 weeks must have elapsed since any radiation to a non-CNS site",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Must have adequate bone marrow, renal, and live capacities",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Women must be of non-childbearing potential or practice adequate birth control",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Males must practice adequate methods of birth control",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Must sign written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Previous whole brain radiation therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Prior treatment with topotecan",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Investigational agent within 30 days or 5 half-live",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Concomitant therapy with inhibitors of breast cancer resistance protein (BCRP) or P-glycoprotein such as erlotinib or gefitinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Primary or secondary immunodeficiencies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Gastrointestinal conditions that affect GI absorption or motility",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Uncontrolled emesis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Brain metastasis at time of initial diagnosis of NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* History of other malignancy except in situ carcinoma of cervix; nonmelanomatous skin cancer, low grade prostate cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Pregnant or intending to become pregnant or intending to father a baby",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00390806",
    "statement": "* Any severe concurrent medical condition that could affect compliance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* Histologically confirmed diagnosis of advanced NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* Have not received prior systemic therapy treatment for their advanced/Stage four NSCLC. Completion of treatment with cytotoxic chemotherapy, biological therapy, and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease. Confirmation of resolution of toxic effects of previous neoadjuvant/adjuvant chemotherapy therapy to Grade less than or equal to 1. For radiation toxicity or prior major surgeries, participants should have recovered from side effects and/or complications",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* Have measurable disease based on RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* Have a life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* Availability of tumor tissue (less than 6 months old) before the first dose is mandatory to determine PD-L1 expression level prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* PD-L1 high status as determined by central testing",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* Other protocol defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* Participants with nonsquamous NSCLC histologies whose tumor harbors any of the following molecular alterations and targeted therapy is locally approved: epidermal growth factor receptor (EGFR) sensitizing (activating) mutation, anaplastic lymphoma kinase (ALK) translocation, ROS1 rearrangement, or BRAF V600E mutation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* Has received major surgery within 4 weeks prior to the first dose of study intervention; received thoracic radiation therapy of greater than 30 units of gray (Gy) within 6 months prior to the first dose of study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* Known severe hypersensitivity to investigational products (M7824 or pembrolizumab), or any components in their formulations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* Previous malignant disease (other than the target malignancy to be investigated in this study) within the last 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03631706",
    "statement": "* Other protocol defined exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02364999",
    "statement": "* Male and female patients age at least 18 years of age, or age of consent in the region.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02364999",
    "statement": "* Newly diagnosed Stage IIIB or IV non-small cell lung cancer (according to Revised International System for Staging Lung Cancer criteria of 2010) or recurrent non-small cell lung cancer (NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02364999",
    "statement": "* Histologically or cytologically confirmed diagnosis of predominately non-squamous NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02364999",
    "statement": "* Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin based on local standard of care, for the treatment of advanced or metastatic non-squamous NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02364999",
    "statement": "* Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02364999",
    "statement": "* Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation that is likely to bleed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02364999",
    "statement": "* Known sensitizing EGFR mutations (for example, deletion 19 or L858R) or EML4-ALK translocation positive mutations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02364999",
    "statement": "* Prior systemic therapy for NSCLC; prior neoadjuvant or adjuvant therapy is allowed if surgical resection for primary disease was performed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03117049",
    "statement": "* Subjects with histologically- or cytologically-confirmed non-squamous non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03117049",
    "statement": "* Subjects who received a diagnosis of stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation according to the UICC-TNM Classification (7th edition) with no prior systemic anticancer therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03117049",
    "statement": "* Subjects with at least one measurable lesion by radiographic tumor assessments per RECIST 1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03117049",
    "statement": "* Subjects who are able to provide tumor tissue specimens.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03117049",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03117049",
    "statement": "* Subjects with known EGFR mutations, including deletions in exon 19 and exon 21 (L858R) substitution mutations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03117049",
    "statement": "* Subjects with known ALK translocations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03117049",
    "statement": "* Complication or history of severe hypersensitivity reactions to antibody products or platinum-containing compounds",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03117049",
    "statement": "* Subjects with autoimmune disease or known chronic or recurrent autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03117049",
    "statement": "* Subjects with multiple cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": ". At least ≥ 18 years of age (male or female) at the time of signing the informed consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "2. ECOG performance status of 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "3. Patients with:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "   Phase 2 only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Advanced or metastatic NSCLC failing platinum-based therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "   Phase 3 only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Advanced or metastatic breast cancer, who have failed \\< 5 prior lines of chemotherapy (Note that study treatment may be the first chemotherapy treatment for advanced or metastatic cancer)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* locally advanced or metastatic NSCLC after platinum therapy failure",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* HRPC (Note that study treatment may be the first chemotherapy treatment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "4. Pathology confirmation of cancer is required.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "5. Patients with ≥ 1 of the following risk factors, at the initiation of docetaxel chemotherapy, that would require neutropenia prophylaxis per National Comprehensive Cancer Network (NCCN) guidelines (version 2, 2016):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Prior chemotherapy or radiation treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Bone marrow involvement by tumor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Surgery and/or open wounds within 4 weeks of first administration of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Age \\> 65 years of age and receiving full chemotherapy dose intensity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "6. Life expectancy of 3 months or more.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "7. The following laboratory results assessed within 14 days prior to study drug administration:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Hemoglobin \\>/= 9 g/dL independent of transfusion or growth factor support",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Absolute neutrophil count (ANC) \\>/= 1.5 x 10\\*\\*9/L independent of growth factor support",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Serum total bilirubin \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": " 2.5 x ULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Serum creatinine \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": " 1 year prior to first dose of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "4. Phase 3 only: Received \\>/= 5 lines of cytotoxic chemotherapy for advanced or metastatic breast cancer (adjuvant chemotherapy will count as one line of chemotherapy, and any hormonal or biological, non conjugate therapy \\[e.g., trastuzumab\\] will not count as a line of therapy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "5. Current use of strong cytochrome P450 (CYP) 3A4 inhibitors, within 3 days of the first administration of study drug, and 7 days after treatment with taxanes OR requires use of strong CYP3A4 inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "6. Received an investigational agent or tumor vaccine within 2 weeks before the first dose of study drug; patients must have recovered from toxicity of prior treatment and have no \\> Grade 1 CTCAE (v4.03) treatment emergent AEs.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "7. Receiving any concurrent anticancer therapies (except continued hormonal treatment).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "8. Received a prior bone marrow or stem cell transplant.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "9. Has a co-existing active infection or received systemic anti-infective treatment within 72 hours before the first dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "10. Prior radiation therapy within the 4 weeks before the first dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "11. Prior use of pegfilgrastim or filgrastim within 4 weeks before the first dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "12. Presence of any serious or uncontrolled illness including, but not limited to: uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, uncontrolled arterial thrombosis, symptomatic pulmonary embolism, or psychiatric illness that would limit compliance with study requirements, or any other conditions that would preclude the patient from study treatment as per the discretion of the Investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "13. Significant cardiovascular history:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* History of myocardial infarction or ischemic heart disease within 1 year (within a window of up to 18 days less than 1 year) before first study drug administration;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Uncontrolled arrhythmia;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* History of congenital QT prolongation;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Electrocardiogram (ECG) findings consistent with active ischemic heart disease;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* New York Heart Association Class III or IV cardiac disease;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "* Uncontrolled hypertension: blood pressure consistently \\>150 mm Hg systolic and \\> 100 mm Hg diastolic in spite of antihypertensive medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "14. History of hemorrhagic diarrhea, inflammatory bowel disease, or active uncontrolled peptic ulcer disease. (Concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable). History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "15. Any other malignancy requiring active therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "16. Known human immunodeficiency virus (HIV) seropositivity.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "17. Active Hepatitis B virus (HBV) infection which requires antiviral treatment. Patients with detectable Hepatitis B surface Antigen (HBsAg) may be eligible provided the patient has a negative viral load. Patients with a positive HBsAg must have a negative viral load before each chemotherapy administration. Hepatitis B surface antibody (anti HBs) without detectable HBsAg does NOT exclude patients from the study. Hepatitis C infection (Hepatitis C antibody reactive) which requires treatment also excludes patients from the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "18. Female subject who is pregnant or lactating.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "19. Unwilling or unable to comply with procedures required in this protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03102606",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Histologically or cytologically confirmed advanced (Stage IV) or recurrent non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Eligible participants of reproductive potential must agree to use adequate contraceptive methods during the study period and for at least 6 months after the last dose of study therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Negative pregnancy test for women of childbearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Males or females, aged 18 years or above",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant's primary NSCLC tumor has an activating Epidermal Growth Factor Receptor (EGFR) mutation, as determined by any validated method",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant consents to provide a tissue sample for prestudy EGFR mutation testing and the tumor tissue sample is available for detection of EGFR expression and other markers for centralized testing by Lilly",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant has measurable disease at the time of study entry, documented by computed tomography (CT) scan or magnetic resonance imaging (MRI), as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant has not had any prior systemic chemotherapy, immunotherapy, or biological therapy (for example, targeted therapy, such as erlotinib or gefitinib) for Stage IV or recurrent non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant has adequate organ function, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* White blood cell count ≥3 x 10\\^9/liter (L); absolute neutrophil count (segmented and bands) ≥1.5 x 10\\^9/L; platelet count ≥100 x 10\\^9/L; hemoglobin ≥9.0 gram per deciliter (g/dL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Total bilirubin ≤1.5 times the upper limit of the normal (ULN) range; and alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 times ULN (or ≤5 times ULN if the liver has tumor involvement)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Calculated creatinine clearance ≥45 milliliter per minute (mL/min)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant is able to take folic acid, vitamin B12, and dexamethasone, according to the protocol's requirements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Provision of informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Prior radiation therapy is allowed to \\<25% of the bone marrow; however, prior radiation to the whole pelvis not allowed. Prior radiation therapy must be completed at least 2 weeks prior to first study-drug administration. Participants must have recovered from the acute toxic effects prior to first study-drug administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant has received prior chemotherapy for advanced and/or metastatic disease, or adjuvant/neoadjuvant treatment with pemetrexed or an EGFR-tyrosine Kinase inhibitor (TKI)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant's tumor contains predominantly small cell lung cancer or squamous NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant is receiving concurrent treatment with any other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, biological or targeted therapy, or radiotherapy (palliative irradiation of bone lesions is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant has untreated central nervous system (CNS) metastases Participants with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, stereotactic radiosurgery) ending at least 2 weeks before enrollment, or after surgical resection performed at least 28 days before enrollment. No evidence of Grade ≥1 CNS hemorrhage based on pretreatment MRI or Intravenous (IV) contrast CT scan (performed within 21 days before randomization).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant has undergone radiotherapy within 28 days before enrollment (localized radiotherapy for pain relief allowed, provided 25% or less of their total bone marrow had been irradiated)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant has clinically relevant congestive heart failure (New York Heart Association \\[NYHA\\] II-IV) or symptomatic or poorly controlled cardiac arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant has a serious illness or medical condition that would compromise their safety or impair their ability to comply with the protocol's requirements, including, but not limited to, the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Active or uncontrolled clinically serious infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Previous or concurrent malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and without evidence of recurrence for at least 5 years prior to the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Uncontrolled metabolic disorders or other nonmalignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the participant ineligible for entry into this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant has significant third space fluid retention, and is not amenable for required repeated drainage",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Known allergy or hypersensitivity reaction to any of the treatment components",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Are unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 grams per day, for at least 2 days (5 days for long-acting agents \\[for example, piroxicam\\]) before, during, and for at least 2 days after administration of pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Concomitant use of cytochrome P450 (CYP)3A4 inducers or CYP3A4 inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Participants under therapy with warfarin or coumarin derivatives who are unable to switch to low molecular weight heparin, unless regular monitoring of changes in prothrombin time (PT) (PT/international normalized ratio \\[INR\\]) will be applicable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Any known significant ophthalmologic abnormalities of the surface of the eye. The use of contact lenses is not recommended during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study Participants participating in surveys or observational studies are eligible to participate in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant has previously received treatment with gefitinib, erlotinib or pemetrexed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Any evidence of clinically active interstitial lung disease. Asymptomatic participants with chronic, stable, radiographic changes are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* Have preexisting idiopathic pulmonary fibrosis as evidenced by computed tomography (CT) scan/x-ray at baseline; have or had any disease of acute lung injury, idiopathic pulmonary fibrosis, pulmonary pneumonia, or pneumoconiosis evident on an x-ray; have or had any disease of radiation pneumonia or drug-induced pneumonia, which requires treatment with corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01469000",
    "statement": "* The participant is pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants must have Stage IIIA or IIIIB NSCLC of the non-squamous type",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants must have measureable tumor lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines or disease that can be evaluated on computerized tomography (CT) scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants must be physically mobile, take care of themselves and must be up and about and able to perform light activities, such as light housework or office work",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants must be 18 years of age or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants must have lost no more than 10% of their body weight in the previous 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Women must be sterile, postmenopausal, or on contraception, and men must be sterile or on contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants' test results assessing the function of their blood forming tissue, kidneys, liver, and lungs must be satisfactory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants with Stage IIIB NSCLC who have supraclavicular nodal involvement may be entered into this study. However, participants with cervical nodes are not permitted. The upper border of supraclavicular nodes must not extend above the upper border of the lateral end of the clavicle, extended medially.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants cannot have other on-going (uncontrolled) illnesses, including active infections, recent heart problems, or psychiatric illnesses",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants who are unable to take vitamins (including injections of vitamin B12) or oral cortisone medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants who have had a heart attack (myocardial infarction) or other cardiac issues within 6 months of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants who have received other investigational drugs within the last 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants who are unable to stop taking more than 1.3 grams of aspirin on a daily basis or non-steroidal anti-inflammatory agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants who have diseases considered for surgical treatment as part of their care plan, such as Pancoast or superior sulcus tumors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants who had prior thoracic radiation. However, other prior radiotherapy is allowed. Participants must have recovered from the toxic effects of the treatment prior to study enrollment. Participants may not have received whole pelvis radiation or radiation to more than 25% of their bone marrow. Prior radiotherapy must have been completed at least 30 days prior to study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants who have a radiation treatment plan that would expose more than 35% of the volume of their lung to 20 gray (Gy) or more of radiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00686959",
    "statement": "* Participants who have concurrent cancer from another primary site requiring treatment of any kind within the past 5 years. Exemptions to this will be permitted on a case-by-case basis after prior approval by the Sponsor physician or designate if the investigator believes the participant's risk of recurrence and death is very low. Curatively treated nonmelanoma skin cancer or in situ carcinoma of any origin is allowed. Participants with recurrence of a previously resected lung cancer or who have a second primary lung cancer are ineligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00529100",
    "statement": "* Patient must be at least 18 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00529100",
    "statement": "* Patient must have been diagnosed with non-small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00529100",
    "statement": "* Patient must be able to visit the doctor's office once a week.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00529100",
    "statement": "* Patient must have adequate blood, liver, lungs and kidney function within the requirements of this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00529100",
    "statement": "* Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00529100",
    "statement": "* Patient has previously had chemotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00529100",
    "statement": "* Patient has previously had thoracic radiation therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00529100",
    "statement": "* Patient has received treatment within the last 30 days with a drug that has not received approval by Health Canada for any indication at the time of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00529100",
    "statement": "* Female patient is pregnant or breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00529100",
    "statement": "* Patient is unsuitable to participate in the study in the opinion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00529100",
    "statement": "* Patient is unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Adult patients greater than or equal to 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Histological confirmation of non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Locally advanced or metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Failure of at least one prior regimen of standard chemotherapy for locally advanced or metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Life expectancy of more than or equal to 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Baseline Left Ventricular Ejection Fraction (LVEF) of greater than or equal to 50%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* A negative pregnancy test one week prior to treatment and willingness to use contraception among women of childbearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Availability of histological Formalin-Fixed, Paraffin-Embedded (FFPE) tumor tissue",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Prior chemotherapy, radiotherapy or immunotherapy within 4 weeks of study Day -8",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Prior treatment with any agent which targets growth factors or their receptors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Patients who have not recovered from the acute reversible effects of chemotherapy and radiotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* History of clinically significant cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* History or evidence of central nervous system metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Treatment with any investigational drug within 28 days of the start of the study (day -8)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02507375",
    "statement": "* Prior cumulative doxorubicin dose of more than 360 mg/m2 or the equivalent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Phase 1 portion:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Participants with a cytologic or histologic diagnosis of nonsquamous NSCLC that is classified as Stage IV according to the 7th edition of the American Joint Committee on Cancer (AJCC) classification and for whom the combination of pemetrexed and cisplatin is deemed to be appropriate",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Participants with histologic or cytologic diagnosis of malignant mesothelioma that is unresectable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Participants with histologic or cytologic diagnoses of advanced or metastatic solid tumors who are not candidates for any standard therapy and for whom the combination with pemetrexed and cisplatin is deemed to be appropriate",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Phase 2 portion:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have a histological diagnosis of NSCLC other than predominantly squamous cell histology that is classified as Stage IV according to the 7th edition of the AJCC classification",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Eligible for a first line of palliative treatment with a platinum doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have archived or fresh tumor tissue (not cytology)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Phase 1 participants can have measurable or nonmeasurable disease. Phase 2 participants must have at least 1 measurable lesion according to Investigational New Drug (Response Evaluation Criteria in Solid Tumors \\[RECIST\\], v1.1) definitions. Tumor lesions located in a previously irradiated area can be considered measurable if they are new or if have shown unequivocal progression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have a performance status ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have adequate hematologic, hepatic, and renal organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Prior radiation therapy for treatment of cancer is allowed to \\<25% of the bone marrow, and participants must have recovered from the acute toxic effects of their treatment prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks before study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* For women: Must be surgically sterile, postmenopausal, or compliant with a highly reliable contraceptive method (failure rate \\<1%) during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment and must not be breast-feeding. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have serious preexisting medical conditions or serious concomitant systemic disorders that would compromise the safety of the participant or his/her ability to complete the study, at the discretion of the investigator (for example, unstable angina pectoris or uncontrolled diabetes mellitus). Special attention should be paid to kidney and heart conditions that may be worsened with cisplatin treatment or hydration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have central nervous system (CNS) metastases (unless the participant has completed successful local therapy for CNS metastases and has been off corticosteroids for at least 4 weeks before starting study therapy). A screening computed tomography scan or magnetic resonance imaging before enrollment in the absence of a clinical suspicion of brain metastases is not required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have current active infection that would, in the opinion of the investigator, compromise the participant's ability to tolerate therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have known allergy to pemetrexed, cisplatin, LY2603618, or any ingredient of pemetrexed, cisplatin, or LY2603618",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have clinically significant (by physical exam) third-space fluid collections; for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Participants taking non-steroidal anti-inflammatory drugs who cannot interrupt the treatment appropriately according to the guidelines",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have received a recent yellow-fever vaccination (within 28 days of enrollment) or are receiving concurrent yellow-fever vaccination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Phase 1 portion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have received more than 2 previous lines of chemotherapy for the advanced/metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01139775",
    "statement": "* Have received more than 6 cycles of therapy containing an alkylating agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00372775",
    "statement": "* Patients with radiologically proven brain metastases secondary to non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00372775",
    "statement": "* Received previous whole brain radiation therapy and none, 1 or 2 prior systemic therapy for the treatment of advanced/metastatic non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00372775",
    "statement": "* Patients with brainstem lesions, spinal cord compression. carcinomatous meningitis, or leptomeningeal disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00372775",
    "statement": "* Brain metastases \\>4 cm in any linear direction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00372775",
    "statement": "* Intracranial or intratumoral hemorrhage",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* a histologic or cytologic diagnosis of advanced non-small cell lung cancer (NSCLC) \\[Stage IV from the American Joint Committee on Cancer Staging Criteria (AJCC) staging system, version 7.0, including both M1a and M1b\\], other than predominantly squamous cell histology, that is not amenable to curative therapy. Participants may not have received any prior systemic chemotherapy, immunotherapy, targeted therapy, or biological therapy, including adjuvant therapy, for any stage of NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* prior radiation therapy is allowed to \\< 25% of the bone marrow; however, prior radiation to the whole pelvis not allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* good performance status.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* estimated life expectancy of at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* known central nervous system (CNS) disease, other than treated brain metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* major surgical procedure, open biopsy, open pleurodesis, or significant traumatic injury within 28 days prior to study or have an anticipated need for major surgery during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* core biopsy or other minor surgical procedure, excluding placement of vascular access device, closed pleurodesis, thoracentesis, and mediastinoscopy, within 7 days prior to study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* history of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* currently receiving ongoing treatment with full-dose warfarin or equivalent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* significant vascular disease within 6 months prior to Day 1 of Cycle 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* evidence of bleeding diathesis or coagulopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the participant's ability to adhere to the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* serious cardiac condition, such as myocardial infarction, angina, or heart disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* inadequately controlled hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* any prior history of hypertensive crisis or hypertensive encephalopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* serious, nonhealing wound, active ulcer, or untreated bone fracture.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* another active malignancy, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within the last 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* previously received treatment with paclitaxel, carboplatin, pemetrexed, or bevacizumab (prior intravitreal administration of bevacizumab does not preclude study participation).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* pregnant or breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* history of stroke or transient ischemic attack within 6 months prior to study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* known sensitivity to any component of paclitaxel, carboplatin, pemetrexed, or bevacizumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* history of hemoptysis within 3 months prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* unwilling to take folic acid or vitamin B12 supplementation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00948675",
    "statement": "* clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage. Participants with M1a disease with pleural effusions are eligible if the effusions can be adequately controlled.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01721759",
    "statement": "* Men and women ≥18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01721759",
    "statement": "* Patients with histologically or cytologically documented squamous cell nonsmall-cell lung cancer who present with Stage IIIB/Stage IV disease (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemoradiation for locally advanced disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01721759",
    "statement": "* Eastern Cooperative Oncology Group Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01721759",
    "statement": "* Disease progression or recurrence after both a platinum doublet-based chemotherapy regimen and at least 1 additional systemic therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01721759",
    "statement": "* Measurable disease by computed tomography scan/magnetic resonance imaging as per Response Evaluation Criteria in Solid Tumors, volume 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01721759",
    "statement": "* Untreated central nervous system (CNS) metastases. Metastases have been treated and patients neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment. In addition, patients must have stopped taking corticosteroids or be taking a stable or decreasing dose of ≤10 mg prednisone daily (or equivalent)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01721759",
    "statement": "* Carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01721759",
    "statement": "* Active known or suspected autoimmune disease or interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01721759",
    "statement": "* Prior treatment on either arm of study CA209-017 or CA184-104",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01721759",
    "statement": "* Prior therapy with anti-Programmed death-1 (anti-PD-1), anti-Programmed cell death ligand 1 (anti-PD-L1), anti-Programmed cell death ligand 2 (anti-PD-L2), anti-CD137, or anti-Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01721759",
    "statement": "* A condition requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days of first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Female or male patients age \\> 18 years-old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 at study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Histologically confirmed non-squamous NSCLC (adenocarcinoma, large cell carcinoma, undifferentiated carcinoma or other)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Stage IIIB-IV cancer or delayed relapse of any stage not amenable to surgery or radiotherapy with curative intent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* PD-L1 expression by immunohistochemistry in \\< 50% of tumor cells",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Patients must be chemotherapy-naïve for the advanced stage of the disease. Previous neoadjuvant and/or adjuvant chemotherapy is allowed for patients who successfully underwent complete radical surgery and if last treatment was administered more than 12 months prior to the start of the study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* At least one measurable lesion by CT scan based on RECIST 1.1 performed within 28 days prior to start of study treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Adequate hematological, hepatic, and renal functions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 72 hours prior to the start of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug plus 30 days for a total of 5 months posttreatment completion. Highly effective contraception are defined in the protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 90 days for a total of 7 months post-treatment completion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "Principal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Patients having central nervous system (CNS) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Patients with pericardial effusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Prior exposure to cancer immunotherapy including cancer vaccines, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cytotoxic T-Lymphocyte antigen- 4 antibody or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)- rearrangements leading to eligibility for tyrosine kinase inhibitor (TKI) treatment (tests mandatory)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Prior history of other malignancy except basal cell carcinoma of the skin, cervical intra epithelial neoplasia, and other cancer curatively treated with no evidence of disease for at least 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Patients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of start of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Patients with an active, known or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Patient with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Patients with grade ≥ 2 neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Signs or symptoms of infection within 14 days prior to start of study treatment or active infection requiring systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Positive serology for HIV or hepatitis C virus (HCV); presence in the serum of the antigens hepatitis B (HBs) at baseline",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Patient with any underlying medical condition that the treating physician considers might be aggravated by treatment or which is not controlled (e.g., elevated troponin or creatinine, uncontrolled diabetes)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* History of cardiovascular conditions within 12 months of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Left ventricular ejection fraction less than the Lower Limit of Normal as assessed by echocardiography (or multigated acquisition (MUGA) scan)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Patient with major surgery or radiotherapy within 3 weeks prior to the start of the study treatment. However, prior surgery or radiation therapy aimed at local palliation or attempted local disease control (except in case of thoracic radiotherapy) is permitted but has to be completed 2 weeks before treatment start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Pregnant or nursing (lactating) women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Patients with an organ allograft",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Any known allergy to eggs, gentamicin or history of allergy or hypersensitivity to study drug components",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03353675",
    "statement": "* Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": ". Age ≥ 18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "2. Signed Informed Consent Form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "3. Histologically confirmed locally advanced or metastatic (Stage IIIB or IV) NSCLC of either squamous or non-squamous histology types with disease progression during or following treatment with at least one platinum-containing regimen, but no more than 2 lines of systemic therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "4. Participants must be able to provide fresh or archival tumor tissues for central assessment of PD-L1 expression in tumor cells. Participants with non-squamous histology must provide evidence of not harboring sensitizing epidermal growth factor (EGFR) mutation tested by a histology-based method.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "6. Adequate hematologic and end-organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "7. Expected life span \\> 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "8. Willing to be compliance with birth control requirement during pre-specified study participating period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": ". Prior therapies of docetaxel or treatment targeting programmed cell death protein 1 (PD-1), PD-L1 or cytotoxic T-lymphocyte associated protein 4 (CTLA-4).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "2. Harboring EGFR sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "3. Unresolved side effects of Grade 2 and above from prior anti-cancer therapies, except for adverse events (AEs) not constituting a likely safety risk (e.g. alopecia, rash, pigmentation, specific lab abnormalities).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "4. History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "5. History of interstitial lung disease, non-infectious pneumonitis or participants with significantly impaired pulmonary function, or who require supplemental oxygen at baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "6. With uncontrollable pleural effusion, pericardial effusion, or clinically significant ascites requiring interventional treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "7. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "8. Severe chronic or active infection requiring systemic treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "9. Known human immunodeficiency virus (HIV) infection, participants with untreated chronic hepatitis B, active vaccination treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "10. Insufficient cardiac functions and other underlying unfavorable cardiovascular conditions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "11. Prior allogeneic stem cell transplantation or organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "12. Active autoimmune diseases or history of autoimmune diseases that may relapse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "13. With conditions requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone or equivalent) or other immunosuppressive medications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "14. With severe underlying medical conditions (including laboratory abnormalities) or alcohol or drug abuse that may affect the explanation of drug toxicity or AEs or result in impaired compliance with study conduct.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03358875",
    "statement": "NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "(Visit 1) and at Start of Study Treatment (Visit 2):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Provision of informed consent prior to any study specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Histologically or cytologically confirmed NSCLC with an activating sensitising EGFR TK mutation as it was determined before starting the first gefitinib treatment by using a well-validated and robust methodology: adenocarcinoma, including Bronchoalveolar Carcinoma (BAC), squamous cell carcinoma, large cell carcinoma, adenosquamous carcinoma or undifferentiated carcinoma or not-otherwise specified NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Female or male patients aged 18 years or over with Locally advanced or metastatic stage IIIB/IV disease, not suitable for therapy of curative intent or stage IV (metastatic) disease, eligible for gefitinib re-challenge treatment for NSCLC who have already received gefitinib with a documented complete (CR) or partial response (PR) or stable disease (SD) \\>12 weeks as the best response to their 1st gefitinib treatment and progressing during or after a subsequent anti-cancer therapy (excluding EGFR-TKIs) treatment, including but not limited to doublet platinum based chemotherapy or docetaxel monotherapy or pemetrexed monotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Measurable disease defined as at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with spiral CT or MRI and which is suitable for accurate repeated measurements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* WHO / ECOG / Zubrod performance status 0-2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Known severe hypersensitivity to gefitinib or any of the excipients of the product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Prior EGFR TKIs except gefitinib followed by subsequent anti-cancer treatment (including chemotherapy and excluding EGFR-TKIs).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "Previous adjuvant chemotherapy is allowed. Prior surgery or radiotherapy must be completed more than 6 months before start of study treatment. Palliative radiotherapy must be completed at least 4 weeks before start of study treatment with no persistent radiation toxicity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Progression disease or stable disease (SD) \\<12 weeks as best response to the 1st line treatment with gefitinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Not progressing during or after the last anti-cancer treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Considered to require radiotherapy to the lung at the time of study entry or in the near future",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Pre-existing idiopathic pulmonary fibrosis evidenced by CT scan at baseline",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Insufficient lung function as determined by either clinical examination or an arterial oxygen tension (PaO2) of \\< 70 Torr",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Known or suspected brain metastases or spinal cord compression, unless treated with surgery and/or radiation and stable without steroid treatment for at least 4 weeks prior to the first dose of study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Concomitant use of known CYP 3A4 inducers such as phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Pregnancy or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* As judged by the investigator, any evidence of severe or uncontrolled systemic disease (eg, unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01530334",
    "statement": "* Life expectancy of less than 12 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531934",
    "statement": "* adult patients, 18-75 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531934",
    "statement": "* confirmed non-small cell lung cancer;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531934",
    "statement": "* failure after first line chemotherapy for advanced disease, and scheduled for second line therapy with Tarceva.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531934",
    "statement": "* rash of any etiology at study entry;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531934",
    "statement": "* history of significant heart disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531934",
    "statement": "* any other malignancies (other than adequately treated squamous cell skin cancer, or in situ cancer of the cervix);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00531934",
    "statement": "* history of allergic reactions to tetracyclines.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": ". Patients with pathologic confirmation of NSCLC Stage III-B (with pleural effusion) or Stage IV adenocarcinoma who have failed at least one but not more than two lines of cytotoxic chemotherapy (including adjuvant chemotherapy). One of the chemotherapy regimens must have been platinum-based.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "2. Progressive disease following at least 12 weeks of treatment with erlotinib (Tarceva®) or gefitinib (Iressa®)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "3. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance Score 0, 1 or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "4. Patients with at least one tumor lesion that can accurately be measured by magnetic resonance imaging (MRI), or computed tomography (CT) in at least one dimension with longest diameter to be recorded as \\>20 mm using conventional techniques or \\>10 mm with spiral CT scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "5. Male and female patients age \\>18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "6. Life expectancy of at least three (3) months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "7. Written informed consent that is consistent with ICH-GCP guidelines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": ". Use of erlotinib (Tarceva®) or gefitinib (Iressa®) within 14 days of treatment Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "2. Chemo-, hormone- (other than megestrol acetate or steroids required for maintenance non-cancer therapy) or immunotherapy within the past 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "3. Active brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "4. Significant or recent acute gastrointestinal disorders with diarrhea",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "5. Patients who have any other life-threatening illness or organ system dysfunction,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "6. Other malignancies diagnosed within the past five (5) years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "7. Radiotherapy within the past 2 weeks prior to treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "8. History of clinically significant or uncontrolled cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "9. Adequate ANC and platelet count",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "10. Adequate liver and kidney function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00656136",
    "statement": "11. Patients with any serious active infection including known HIV, active hepatitis B or active hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02923349",
    "statement": "* Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02923349",
    "statement": "* Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. There is no limit to the number of prior treatment regimens.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02923349",
    "statement": "* Part 1: Subjects with advanced or metastatic solid tumors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02923349",
    "statement": "* Part 2: Subjects with advanced or metastatic adenocarcinoma of the endometrium, ovarian cancer, renal cell carcinoma, melanoma, and non-small cell lung cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02923349",
    "statement": "* Presence of measureable disease based on RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02923349",
    "statement": "* Eastern Cooperative Oncology Group performance status 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02923349",
    "statement": "* Laboratory and medical history parameters not within the protocol-defined range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02923349",
    "statement": "* Receipt of anticancer medications or investigational drugs within the protocol-defined intervals before the first administration of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02923349",
    "statement": "* Has not recovered to ≤ Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02923349",
    "statement": "* Receipt of a live vaccine within 30 days of planned start of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02923349",
    "statement": "* Active autoimmune disease that required systemic treatment in the past.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Patients must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Patients must have had progressive disease on, after, or refused, appropriate approved therapy for their tumor type.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Patients must have histologically or cytologically confirmed solid tumor that is locally recurrent or metastatic and has progressed following standard treatment or is not appropriate for standard treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Understand and sign an Institutional review board/Independent ethics committee (IRB/IEC)-approved informed consent form (ICF) prior to any study-specific evaluation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Willing and able to comply with all study procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Current or history of clinically significant muscle disorders (e.g., myositis), recent unresolved muscle injury, or any condition known to elevate serum creatine kinase (CK) levels",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Decreased cardiac function with New York Heart Association (NYHA) \\> Class 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Uncontrolled or significant heart disorder such as unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Significant abnormalities on electrocardiogram (ECG) at screening. Fridericia's correction formula for QT interval (QTcF) \\> 450 msec for males or \\> 470 msec for females at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* History of anti-drug antibodies, severe allergic, anaphylactic, or other infusion-related reaction to a previous biologic agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Positive test for latent tuberculosis (TB) at screening (Quantiferon test) or evidence of active TB",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Patients with abnormal serum chemistry values, which in the opinion of the Investigator is considered to be clinically significant, will be excluded from the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Any uncontrolled medical condition or psychiatric disorder which, in the opinion of the Investigator, would pose a risk to patient safety or interfere with study participation or interpretation of individual patient results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Current unresolved infection or history of chronic, active, clinically significant infection (viral, bacterial, fungal, or other) which, in the opinion of the Investigator, would preclude the patient from exposure to a biologic agent or pose a risk to patient safety",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02526017",
    "statement": "* Prior exposure to any colony stimulating factor 1 receptor (CSF1R) pathway inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Histologically confirmed diagnosis of Malignant Pleural Mesothelioma (MPM) or Non-Small Cell Lung Cancer (NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Measurable disease as defined by the modified Response Evaluation Criteria in Solid Tumors (mRECIST) for MPM or the RECIST 1.1 for NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* ≥ 20 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Provision of written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* For male or female patient of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 30 days after the last protocol treatment dose.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Hemoglobin (Hb) ≥ 9.0 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Neutrophils ≥ 1500/μL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Platelets ≥ 100,000/μL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5-fold the upper limit of normal range (ULN) \\[≤ 5-fold ULN with any liver metastasis\\].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Total bilirubin ≤ 1.5-fold ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Creatinine clearance (estimated value) ≥ 60 mL/min.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Life expectancy ≥ 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Females of childbearing potential have a negative urine pregnancy test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "Phase 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Histologically confirmed diagnosis of MPM.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Treatment naïve and not indicated for resection.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Measurable disease as defined by the modified RECIST.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* ≥ 20 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Provision of written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* For male or female patient of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 30 days after the last protocol treatment dose.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* ECOG Performance Status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Hb ≥ 9.0 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Neutrophils ≥ 1500/μL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Platelets ≥ 100,000/μL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* AST and ALT ≤ 2.5-fold ULN \\[≤ 5-fold ULN for patients with any liver metastasis\\].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Total bilirubin ≤ 1.5-fold ULN.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Creatinine clearance (estimated value) \\> 60 mL/min.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Life expectancy ≥ 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Females of childbearing potential have a negative urine pregnancy test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "Both Phase 1 and 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Prior anti-cancer chemotherapy and radiotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Prior hormonal therapy, immunotherapy, thermotherapy, operation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Any brain metastasis requiring treatment or symptomatic.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Active multiple primary cancers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Crohn's disease, ulcerative colitis, small intestine resection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Abnormal ECGs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Prior myocardial infarction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Current use of antiarrhythmic medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Uncontrolled concurrent diseases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Known severe hypersensitivity to pemetrexed, cisplatin or other drugs containing platinum.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Women who are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Received other investigational drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Unable or unwilling to swallow BBI608 capsules daily.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Prior treatment with BBI608.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02347917",
    "statement": "* Ineligible for participation in the study in the opinion of the Investigators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": ". Diagnosis of CF based on conclusively abnormal sweat test (sweat chloride \\>35 milliequivalents \\[mEq\\]/liter).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "2. Abnormal nasal epithelial TEPD total chloride conductance (a more electrically negative value than 5 mV for Δchloride-free+isoproterenol).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "3. Presence of a mutation in both alleles.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "4. Documentation that a blood sample has been drawn for reconfirmation of the presence of a nonsense mutation in the CFTR gene.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "5. Age ≥6 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "6. Body weight ≥25 kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "7. FEV1 ≥40% of predicted for age, gender, and height.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "8. Oxygen saturation ≥92% on room air.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "9. Willingness of male and female participants, if not surgically sterile, to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration and follow-up periods.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "10. Negative pregnancy test (for females of childbearing potential).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "11. Willingness and ability to comply with scheduled visits, drug administration plan, study procedures (including TEPD measurements, clinical laboratory tests, pulmonary function tests, and PK sampling), and study restrictions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "12. Ability to provide written informed consent and/or assent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "13. Evidence of signed and dated informed consent document (by the participant or a legal guardian) indicating that the participant and/or the legal guardian has been informed of all pertinent aspects of the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": ". Prior exposure to ataluren.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "2. Prior or ongoing medical condition (for example, concomitant illness, alcoholism, drug abuse, psychiatric condition), medical history, physical findings, ECG findings, or laboratory abnormality that, in the Investigator's opinion, could adversely affect the safety of the participant, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "3. Ongoing acute illness including acute upper or lower respiratory infections within 2 weeks before start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "4. History of major complications of lung disease (including recent massive hemoptysis or pneumothorax) within 2 months prior to start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "5. Abnormalities on screening chest x-ray suggesting clinically significant active pulmonary disease other than CF, or new, significant abnormalities such as atelectasis or pleural effusion which may be indicative of clinically significant active pulmonary involvement secondary to CF.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "6. Positive hepatitis B surface antigen, hepatitis C antibody test, or human immunodeficiency virus (HIV) test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "7. Hemoglobin \\<10 grams/deciliter (g/dL).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "8. Serum albumin \\<2.5 g/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "9. Abnormal liver function (serum total bilirubin \\> the upper limit of normal, or serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) \\>2.0 times the upper limit of normal).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "10. Abnormal renal function (serum creatinine \\>1.5 times upper limit of normal).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "11. Pregnancy or breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "12. History of solid organ or hematological transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "13. Exposure to another investigational drug within 14 days prior to start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "14. Ongoing participation in any other therapeutic clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "15. Ongoing use of thiazolidinedione peroxisome proliferator-activated receptor gamma (PPAR γ) agonists, for example, rosiglitazone (Avandia® or equivalent) or pioglitazone (Actos® or equivalent).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "16. Change in intranasal medications (including use of corticosteroids, cromolyn, ipratropium bromide, phenylephrine, or oxymetazoline) within 14 days prior to start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "17. Change in treatment with systemic or inhaled corticosteroids within 14 days prior to start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "18. Use of or requirement for inhaled gentamicin or amikacin within 14 days prior to start of study treatment or during study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00458341",
    "statement": "19. Requirement for systemic aminoglycoside antibiotics within 14 days prior to start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Histologically confirmed non-small-cell lung adenocarcinoma that is locally advanced or metastatic",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Prior treatment with at least 2 cancer drug regimens in the advanced disease setting",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Platinum- and erlotinib-resistant disease defined by relapse or progression during or after treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Measurable disease by RECIST criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* ECOG Performance status less than or equal to 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Resolution of any toxic effects of prior therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Adequate organ and bone marrow function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Female patients must be post-menopausal, surgically sterile or using effective contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Willing and able to comply with study procedures and sign informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Diagnosis of squamous-cell lung cancer or any second malignancy within the last 5 years (except for adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Prior treatment with a VEGF or VEGF receptor inhibitor with the exception of bevacizumab (Avastin-TM)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Anticipation of a need for major surgical procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Treatment with chemotherapy, radiotherapy, surgery, blood products, or an investigational agent within 3 weeks (6 weeks for nitrosoureas, mitomycin C, immunotherapy, or cytokine therapy) of study enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Uncontrolled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Any severe or acute medical or psychiatric problem within the past 6 months requiring further investigation or that may cause undue risk for the patient's safety",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* History of brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Active infection or on antiretroviral therapy for HIV disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "* Pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00284141",
    "statement": "The above information is not intended to contain all considerations relevant to potential participation in a clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976741",
    "statement": "* For dose escalation: Participants with any type of solid tumor (all comer) were eligible for dose escalation and dose expansion at MTD in Part 1; Participants enrolled for dose expansion (MTD expansion cohort \"all comer\") were stratified according to high fibroblast growth factor receptor (FGFR) expression levels / FGFR mutation using archival or fresh tumor biopsy material",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976741",
    "statement": "* For expansion cohorts: Participants were eligible for Part 2 only if they have histological or cytological confirmed squamous non-small cell lung cancer (sqNSCLC), lung adenocarcinoma, head and neck cancer or bladder cancer (BC). All participants in Part 2 were stratified according to high FGFR expression levels FGFR mutation using archival or fresh tumor biopsy specimen. BC participants with low overall FGFR expression levels could be included if activating FGFR3 (FGFR tyrosine kinases 3) mutations were confirmed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976741",
    "statement": "* Participants must have measurable disease (Response evaluation criteria in solid tumors (RECIST 1.1))",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976741",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976741",
    "statement": "* Bone marrow, liver and renal functions as assessed by adequate laboratory methods to be conducted within 7 days prior to starting study Treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976741",
    "statement": "* Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m\\^2 according to the modified diet in renal disease (MDRD) abbreviated formula",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976741",
    "statement": "* Previous treatment with anti-FGFR directed therapies (e.g. receptor tyrosine kinase inhibitors or FGFR-specific antibodies)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976741",
    "statement": "* Concomitant therapies that cannot be discontinued or switched to a different medication prior to study entry that are known to increase serum phosphate levels are not permitted within 4 weeks prior to start of study treatment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976741",
    "statement": "* Anticancer chemotherapy or immunotherapy during the study or within 5-halflives prior to start of study treatment. Mitomycin C, nitrosoureas or monoclonal antibodies with anticancer activity (e.g. bevacizumab or cetuximab etc.) should not be given within 6 weeks before starting to receive study treatment or within 6 weeks of pre-treatment biopsy for biomarker (p-ERK1/2) studies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": ". For multiple myeloma, must have symptomatic myeloma as defined by the International Myeloma Working Group inclusive of measurable serum and/or urine monoclonal protein (M-protein) or for those without elevations they must have measurable increased concentrations of free light chains",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "Part B: Patients with previously treated, histologically confirmed advanced NSCLC with progressive disease requiring therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "Parts A and B:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Refractory or intolerant to all standard/approved therapy(ies)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Patients with solid tumors must have one or more metastatic tumors measurable on computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Radiation for symptomatic lesions outside the central nervous system (CNS) must have been completed at least 2 week prior to study enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Treated brain metastases will be allowed, if they are asymptomatic. Patients must be off corticosteroids for at least 2 week prior to study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Ambulatory patients greater than or equal to (≥) 30 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Females with child bearing potential must have a negative serum pregnancy test within 7 days of study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Acceptable liver function, renal function, hematologic status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Urinalysis - No clinically significant abnormalities",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Acceptable coagulation status:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Prothrombin Time/Partial Thromboplastin Time (PT/PTT) ≤ 1.2 x upper limit of normal (ULN) (unless receiving anticoagulation therapy - eligibility based upon INR)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* International Normalization Ratio (INR) ≤ 1.6 (unless receiving anticoagulant therapy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Receiving warfarin; INR ≤ 3.0 and no active bleeding",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* For men and women of child-producing potential, the use of effective contraceptive methods during the study and for women 18 months following the last dose of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Available for the study duration and willing to follow procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Serum calcium:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Solid tumors only: within normal limits",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Multiple myeloma: ≤ 11.5 milligrams per deciliter (mg/dL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* History of osteonecrosis of the hip or evidence of structural bone abnormalities in the proximal femur on magnetic resonance imaging (MRI) scan considered clinically significant or may impact the interpretation of the scan. Degenerative changes of the hip joint are not exclusionary",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Unable to tolerate the confinement/noise of an MRI scanner or have any contraindication for MRI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* New York Heart Association Class 3 or 4, cardiac disease, myocardial infarction, unstable arrhythmia, or evidence of ischemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Have Fridericia-corrected QT interval (QTcF) \\> 470 millisecond (msec) (female) or \\> 450 (male), or history of congenital long QT syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Active, uncontrolled bacterial, viral, or fungal infections",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Pregnant or nursing women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Radiation therapy, surgery, or chemotherapy, within 1 month prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Previously treated with an anti-Dickkopf-related protein 1 (DKK-1) therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Significant allergy to a biological pharmaceutical therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* History of major organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Had an autologous or allogenic bone marrow transplant, current acute leukemia, colon, prostate, breast or small cell lung cancer, osteoblastic lesions, concomitant disease known to influence calcium metabolism including hyperparathyroidism, hyperthyroidism and/or Paget's disease of bone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Unwillingness / inability to comply with procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Serious nonmalignant disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Receiving other investigational agent or have received other investigational agent within last 30 days or 5 half-lives, whichever is longer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01457417",
    "statement": "* Receiving lithium chloride (LiCl)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Written informed consent must have been obtained prior to any screening procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Phase I part: Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1 (refer to Appendix 1), who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Phase II part: Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have progressed following their last prior therapy, and fit into one of the following groups:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Group 1a and 1b: NSCLC:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "Patients with NSCLC must have had disease recurrence or progression during or after no more than one prior systemic chemotherapy regimen (platinum doublet-based) for advanced or metastatic disease. Prior maintenance therapy is allowed (e.g. pemetrexed, erlotinib, bevacizumab).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "Only patients with EGFR mutation-negative tumor are eligible (defined as negative for exon 19 deletions and for the L858R mutation in EGFR at a minimum; however, if more extensive EGFR mutation testing has been performed, the tumor must not harbor any known activating EGFR mutations in Exons 18-21 in order to be considered EGFR mutation-negative). All patients must be tested for EGFR mutational status and, for ALK translocation status if no mutation is detected in EGFR. Patients with ALK translocation-positive NSCLC must have had disease progression following treatment with a corresponding inhibitor and no more than one systemic chemotherapy regimen (platinum doublet-based), in any sequence.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Group 2: Melanoma:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "All patients must have been tested for BRAF mutations. Patients with V600 mutation positive melanoma must have clinical or radiological evidence of disease progression during or after treatment with a BRAF inhibitor alone or in combination with other agents.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Group 3: Triple negatice breast cancer.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Group 4: Anaplastic thyroid cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Patients are not required to have received or progressed on a prior therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Patients must not be at short term risk for life threatening complications (such as airway compromise or bleeding from locoregional or metastatic disease).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Chemoradiation and/or surgery should be considered prior to study entry for those patients with locally advanced disease if those therapies are considered to be in the best interest of the patient.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* ECOG Performance Status ≤ 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy. Patient must be willing to undergo a new tumor biopsy at baseline or at molecular pre-screening if applicable, and during therapy on this study. For patients in the phase II part of the study, exceptions may be granted after documented discussion with Novartis. After a sufficient number of paired biopsies are collected, the decision may be taken to stop the collection of biopsies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* History of severe hypersensitivity reactions to other mAbs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Active infection requiring systemic antibiotic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* HIV infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Active HBV or HCV infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Patients with ocular melanoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, 4 weeks washout period. For patients receiving anticancer immunotherapies such as CTLA-4 antagonists, 6 weeks is indicated as the washout period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Prior PD-1- or PD-L1-directed therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Patients requiring chronic treatment with systemic steroid therapy, other than replacement-dose steroids in the setting of adrenal insufficiency. Topical, inhaled, nasal and ophthalmic steroids are not prohibited.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Patients receiving systemic treatment with any immunosuppressive medication (other than steroids as described above).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Use of any vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02404441",
    "statement": "* Presence of ≥ CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ≥ CTCAE grade 3) due to prior cancer therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00265317",
    "statement": "* Patients with locally advanced/metastatic non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00265317",
    "statement": "* Prior treatment with no more than 2 chemotherapy regimens including a platinum-based regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00265317",
    "statement": "* Prior treatment with any receptor tyrosine kinase inhibitors, Vascular endothelial growth factor (VEGF) inhibitors or other angiogenic inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00265317",
    "statement": "* History of or known brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients must have a histologically confirmed diagnosis of lowgrade non-Hodgkin's B-cell lymphoma. The following low-grade histologies are included: small lymphocytic (with or without plasmacytoid differentiation); follicular, small cleaved; follicular, mixed small cleaved and follicular large cell (less than 50% large cell component); and monocytoid B-cell lymphoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients must have evidence that their tumor tissue expresses the CD20 antigen. Immunoperoxidase stains of paraffin-embedded tissue showing positive reactivity with L26 antibody or immunoperoxidase stains of frozen tissue showing positive reactivity with Anti-B1 Antibody (Coulter Clone®) or similar commercially available CD20 antibody (\\>50% of tumor cells are positive) or evidence of CD20 positivity by flow cytometry (\\>50% of tumor cells are positive) are acceptable evidence of CD20 positivity. Testing of tumor tissue from any time in the course of the patient's disease is acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients must have Ann Arbor stage III or IV extent of disease after complete staging.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients must not have had any previous treatment for low-grade lymphoma including chemotherapy or radiation. They may be newly diagnosed or observed without treatment after diagnosis. Symptomatic and asymptomatic patients will be eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients must have a performance status of at least 60% on the Karnofsky Scale and an anticipated survival of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients must have an absolute neutrophil count (ANC) \\>1500 cells/mm3 and a platelet count \\>100,000 cells/mm3 within 14 days of study entry. These blood counts must be sustained without support of hematopoietic cytokines or transfusion of blood products.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients must have adequate renal function (defined as serum creatinine \\<1.5 x upper limit of normal \\[ULN\\]) and hepatic function (defined as total bilirubin \\<1.5 x ULN and aspartate transaminase \\[AST\\] \\<5 x ULN) within 14 days of study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients must have bi-dimensionally measurable disease. At least one lesion must be ≥2 x 2 cm (by computed tomography \\[CT\\] scan).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients must be at least 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients must give written informed consent and sign an IRB- approved informed consent form prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients with more than an average of 25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens as assessed microscopically within 42 days of study entry. Bilateral posterior iliac crest core biopsies are required if the percentage of intratrabecular space involved exceeds 10% on a unilateral biopsy. The mean of bilateral biopsies must be no more than 25%.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients with evidence of active infection requiring intravenous (IV) antibiotics at the time of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients with New York Heart Association class III or IV heart disease or other serious illness that would preclude evaluation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients with active obstructive hydronephrosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients with prior malignancy other than lymphoma, except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients with known HIV infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients with known brain or leptomeningeal metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients who are pregnant or nursing. Patients of childbearing potential must undergo a pregnancy test within 7 days of study entry and radiolabeled antibody is not to be administered until a negative result is obtained. Males and females must agree to use effective contraception for 6 months following the radioimmunotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients with previous allergic reactions to iodine. This does not include reacting to IV iodine-containing contrast materials.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients who were previously given any monoclonal or polyclonal antibodies of any non-human species for either diagnostic or therapeutic purposes. This includes engineered chimeric and humanized antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00996996",
    "statement": "* Patients who are concurrently receiving either approved or nonapproved (through another protocol) anti-cancer drugs or biologics.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04075396",
    "statement": "* Females should agree to use adequate contraceptive measure, should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of following criteria at screening; Post-menopausal defined as aged more than 50 years and ameorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments; Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation; Women under 50 years old would be considered postmenopausal if they have been ameorrhoeic for at least 12 months following cessation of exogenous hormonal treatment, and have serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in postmenopausal range for the institution",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04075396",
    "statement": "* Male participants who have not undergone a vasectomy must agree to use barrier contraception that is, condoms, and refrain from donating sperm until 3 months after last drug is taken",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04075396",
    "statement": "* During the study, and for 3 months after receiving the last dose of study drug, female participants must agree not to donate eggs (ova, oocytes) and male participants must agree not to donate sperm for the purposes of assisted reproduction",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04075396",
    "statement": "* In Part D: Participants outside Korea with histologically or cytologically (that is, using pleural effusion, ascites) confirmed Non-Small Cell Lung Cancer (NSCLC) with previously diagnosed epidermal growth factor receptor single activating mutation positive (EGFRm+), and who have had progressive disease on prior epidermal growth factor receptor- Tyrosine kinase inhibitor (EGFR-TKI) therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04075396",
    "statement": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04075396",
    "statement": "* An unapproved investigational product from another clinical study within 30 days of the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04075396",
    "statement": "* Treatment with an EGFR TKIs (example: erlotinib or gefitinib) within 8 days or approximately 5x half-life, whichever is the longer, of the first dose of study treatment or other investigational products within approved indication of marketed product (if sufficient wash-out time has not occurred due to schedule or PK properties, an alternative appropriate wash-out time based on known duration of time to reversibility of drug related adverse events could be agreed upon by sponsor and the Investigator)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04075396",
    "statement": "* Any cytotoxic chemotherapy or other anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen within 14 days of the first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04075396",
    "statement": "* Symptomatic spinal cord compression (if steroid treatment is not required within at least 2 weeks prior to the start of the study treatment then the participant may be enrolled)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04075396",
    "statement": "* Brain metastases with symptomatic and/or requiring emergency treatment (example; Steroid for at least 2 weeks prior to start of study treatment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02317016",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02317016",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": ". Subjects with a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "2. Locally advanced and/or metastatic non-small cell lung cancer (NSCLC) (Stage IIIB/IV).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "3. Subjects with at least one measurable tumor lesion by Response Evaluation Criteria In Solid Tumors (RECIST).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "4. Subjects with Performance Status (PS) 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "5. Subjects with adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": ". Subjects who have ever received the following therapy for non-small cell lung cancer (NSCLC):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "   1. Chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "   2. Biological or immunotherapies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "   3. Surgery for primary focus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "   4. The radiation therapy for primary focus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "2. Subjects with the severe complications or disease history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "3. Subjects with brain metastasis accompanying clinical symptoms or requiring treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "4. Subjects with simultaneous or metachronous cancers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "5. Subjects who cannot take oral medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832819",
    "statement": "6. Subjects who are using drugs that strongly inhibit or induce cytochrome P450 (CYP) 3A4.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject with advanced solid tumors for which there is no approved therapy:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Advanced solid tumor with diagnosed alteration in one or more of the following genes (PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 and/or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* A histologically or cytologically confirmed diagnosis of one of the following solid tumors: pancreatic, thyroid, colorectal, non-small cell lung, endometrial, renal, breast, ovarian carcinoma and melanoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject with archived tumor tissue available for transfer to the Sponsor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject enrolled at lower dose level cohorts and MTD expansion cohorts must have tumor available for biopsy and agree to pre-treatment and on-treatment tumor biopsies",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject has measurable or evaluable disease by response evaluation criteria in solid tumors (RECIST) v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject is aged greater than or equal to (\\>=) 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subjects enrolled in disease specific expansion cohorts must fulfill all the inclusion/",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Relapsed or refractory Kirsten rat sarcoma viral oncogene homolog (KRAS) or neuroblastoma RAS viral oncogene homolog (NRAS) mutated metastatic non-small cell lung cancer (NSCLC) with no approved therapies, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Relapsed or refractory metastatic triple negative breast cancer defined as estrogen, progesterone and HER2 negative carcinoma of the breast with no approved therapies, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Relapsed or refractory metastatic colorectal cancer (CRC) with dual KRAS and PIK3CA mutation with no approved therapies, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* BRAF V600E/K mutated unresectable or metastatic melanoma after progression on B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Other protocol-defined inclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject has been previously treated with a PI3K inhibitor or a MEK inhibitor and taken off treatment due to treatment related adverse events",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject has received:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any other anti-cancer therapy within 28 days of trial drug treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Any investigational agent within 28 days of trial drug treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Extensive prior radiotherapy on more than 30% bone marrow reserves, or prior bone marrow/stem cell transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject has not recovered from toxicity due to prior therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject has poor organ and marrow function as defined in the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject has a history of central nervous system metastases, unless subject has been previously treated for CNS metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject has a history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject has a history of recent major surgery or trauma within the last 28 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Subject has participated in another clinical trial within the past 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01390818",
    "statement": "* Other protocol-defined exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": ". Subject and/or their legally authorized representative must be capable of understanding the investigational nature, potential risks, and benefits of the study. The subject and/or their legally authorized representative must sign a written informed consent;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "2. Subject is ≥18 years of age upon signing the Informed Consent Form;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "3. Subject has histologically or cytologically confirmed stage IV (metastatic) squamous or non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Part A only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "     ▪ Subject has received, and then progressed or been intolerant to up to 3 lines of prior therapy in the metastatic setting, including approved chemotherapy, targeted therapy, immunotherapy and antibody therapy, if eligible. Subjects who have received \\>3 lines of prior therapy may be eligible for Part A, upon discussion with and approval by the Sponsor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Subjects will be eligible for Part A irrespective of PD-L1 expression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Subjects will be eligible for Part A irrespective of EGFR or ALK mutation status. However, subjects with an EGFR sensitizing mutation or ALK translocation must have received and then progressed or been intolerant to at least 1 prior line of approved targeted therapy to be eligible for Part A.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Part B only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Subject is undergoing treatment with pembrolizumab monotherapy for metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Subject's most recent tumor assessment is consistent with PD according to RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* The Investigator has determined that PD should be confirmed within 4-8 weeks, and pembrolizumab treatment will continue pending PD confirmation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Subject is willing to undergo a confirmatory scan 4-8 weeks from the prior scan that indicated progression on pembrolizumab",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* There is no evidence of rapid disease progression or clinical deterioration in the subject that would preclude continuation of pembrolizumab treatment pending confirmation of PD.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Part C only:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Subject has received no prior systemic treatment in the metastatic setting. Subjects previously treated with adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the diagnosis of metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Subject has provided a formalin-fixed tumor sample from a biopsy of a tumor lesion either at the time of or after the diagnosis of metastatic disease AND from a site not previously irradiated, to assess for PD-L1 status. Biopsies obtained PRIOR to the administration of any systemic therapy to treat the subject's tumor (such as neoadjuvant/adjuvant therapy) will not be permitted for analysis. The tissue sample must be received by the central laboratory vendor prior to enrollment. Fine needle aspirates, Endobronchial Ultrasound (EBUS) or cell blocks are not acceptable. Needle or excisional biopsies, or resected tissue is required. If the tumor specimen is not evaluable for PD-L1 expression by the central laboratory, an additional tumor specimen may be submitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Subject's tumor has PD-L1 expression of ≥50%, as determined by immunohistochemistry (IHC) at a central laboratory.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "* Subject's tumor does not harbour an EGFR sensitizing (activating) mutation or ALK translocation. EGFR sensitizing mutations are mutations that are amenable to treatment with TKIs (e.g., erlotinib, gefitinib, afatanib, osimertinib). ALK translocations are amendable to treatment with TKIs such as crizotinib, alectinib and ceritinib. Investigators must produce the source documentation of the EGFR mutation and ALK translocation status in all subjects with non-squamous histology AND for subjects in whom testing is clinically indicated. If either an EGFR sensitizing mutation or ALK translocation is detected, additional information regarding the mutation status of the other molecule is not required. If the clinical site is unable to provide the source documentation, EGFR and ALK testing should be performed per institutional standard of care.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "4. Subject has measurable disease for response assessment as defined by RECIST v1.1 by the Investigator;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 (see Appendix 11);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "6. Subject has a life expectancy of at least 3 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "7. Subject has recovered to Grade ≤1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03 (NCI-CTCAE v4.03) of all clinically significant toxic effects of prior anti-cancer chemotherapy, immunotherapy, radiotherapy or surgery before entering this study, except for alopecia;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "8. Subject has no major existing comorbidities or medical conditions that would preclude therapy in the opinion of the Investigator;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "9. Subject has adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "10. A female subject is eligible to participate if she is not pregnant (see Appendix 5), not breastfeeding, and at least one of the following conditions applies:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "    1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 5 OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "    2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 5 during the treatment period and for at least 120 days after the final dose of study treatment;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "11. A female subject of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study treatment and throughout the study as defined in the SoA. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "12. A male subject is eligible if he agrees to follow the contraceptive guidance in Appendix 5 during the treatment period and for at least 120 days after the final dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": ". Subject has an ongoing different primary malignancy. Exceptions include treated basal cell carcinoma of the skin or squamous cell carcinoma of the skin;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "2. Subject has an active autoimmune disease requiring systemic treatment within the past 3 months, a documented history of clinically severe autoimmune disease, or a disorder that requires systemic corticosteroids or immunosuppressive agents. Subjects with vitiligo, psoriasis, alopecia or resolved childhood asthma/atopy not requiring systemic treatment would be an exception to this rule. Subjects with hypothyroidism who are stable on hormone replacement (\\>10 mg daily prednisone equivalent) or Sjögren's syndrome will not be excluded from the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "3. Subject has a diagnosis of primary immunodeficiency, is dependent on or has received systemic corticosteroid therapy (\\>10 mg daily prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior to the first dose of study treatment. Inhaled or topical corticosteroids, and adrenal replacement corticosteroid doses \\>10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "4. Subject has neuropathy (sensory or motor) ≥Grade 3 per CTCAE v4.03;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "5. Subject has had an allogeneic tissue/solid organ transplant;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "6. Subject has interstitial lung disease (ILD) OR has had a history of pneumonitis that has required oral or IV steroids;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "7. Subject has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (no new or enlarging brain metastases) by imaging for at least 2 weeks following treatment, and clinically stable with no symptoms due to CNS metastasis, and are not using corticosteroids for at least 14 days prior to the start of study treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "8. Subject has a concurrent unstable or uncontrolled medical condition (e.g., active uncontrolled systemic infection, unstable angina, congestive heart failure, uncontrolled diabetes) or other chronic disease, which in the opinion of the Investigator could compromise the subject or the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "9. Subject has a known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibodies);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "10. Subject has a known active hepatitis B (e.g., HBsAg reactive) or hepatitis C infection (e.g., HCV RNA \\[qualitative\\] is detected) or tuberculosis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "11. Subject has an active infection requiring systemic therapy or is dependent on or currently receiving antibiotics that cannot be discontinued before dosing. (Note: Subjects who discontinue an antibiotic prior to dosing must wait at least 5 half-lives after the last dose of antibiotic before receiving any study treatment);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "12. Subject has known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "13. Subject has an implanted medical device that poses a high risk for bacterial colonization and/or that cannot be easily removed (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopedic screws, metal plates, bone grafts, or other exogenous implants). NOTE: More common devices and prosthetics that include arterial and venous stents, dental and breast implants and venous access devices (e.g., Port-a-Cath or Mediport) are permitted. Sponsor must be contacted prior to consenting any subject who has any other device or implant;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "14. Subject is pregnant or breastfeeding, or plans to become pregnant or to father children, from the Screening visit through at least 120 days after the final dose of study treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "15. Subject has a contraindication (e.g., sensitivity/allergy) to trimethoprim/ sulfamethoxazole and ampicillin;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "16. Subject has a contraindication to non-steroidal anti-inflammatory drugs (NSAIDs);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "17. Subject has a known allergy to any component of the study formulation(s);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "18. Subject has a history of listeriosis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "19. Subject has any other serious or uncontrolled physical or mental condition/disease that, as judged by the Investigator, could place the subject at higher risk derived from their participation in the study, could confound results of the study, or would be likely to prevent compliance with the requirements of the study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "20. Subject has received chemotherapy and/or radiation therapy (except palliative radiation therapy for disease-related pain) within 2 weeks of the first dose of study treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "21. Subject has received monoclonal antibody or other biologic therapy within 5 half-lives or 28 days prior to the first dose of study treatment, whichever is shorter. An exception to this exclusion criterion will be pembrolizumab monotherapy for subjects enrolled in Part B;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "22. Subject has received prior treatment with an Lm-based immunotherapy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "23. Subject is receiving or plans to receive future treatment with PI3K or TNFα inhibitors;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "24. Subject has received a live vaccine within 30 days prior to the first dose of study treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "25. Subject has not recovered to baseline from AEs, with the exception of alopecia, due to previously administered agent(s);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "26. Subject has had major surgery within 6 weeks prior to the initiation of study treatment. NOTE:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "    All surgical complications must have recovered to baseline or Grade ≤1 prior to the initiation of study therapy. Sponsor must be consulted prior to enrolling subjects on the study who recently had a major surgery or have a new artificial implant, and/or devices;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "27. Subject is currently participating in or has participated in a study of an investigational agent(s) within 4 weeks of the first dose of study treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "28. Subject is or has an immediate family member (spouse or children) who, as investigational site or sponsor staff, is directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific subject;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "    Exclusion Criteria for Part C only",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "29. In Part C, subject has received systemic therapy for the treatment of their metastatic NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "    Completion of treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "30. In Part C, subject has an EGFR sensitizing mutation and/or an ALK translocation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "31. In Part C, baseline tumor specimen is not evaluable for PD-L1 expression by the central laboratory. If an additional tumor specimen is submitted AND evaluable for PD-L1 expression, the subject will be eligible to participate if PD-L1 expression is assessed as ≥50% by the central laboratory;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "32. In Part C, subject has received prior systemic chemotherapy, biological therapy, OR major surgery within 6 weeks of the first dose of study treatment; received thoracic radiation therapy of \\>30 Gy within 6 months of first dose of study treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03847519",
    "statement": "33. In Part C, subject has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti- CD137, or anti-CTLA-4 antibody, or any other antibody or drug that specifically targets T cell co-stimulation or immune checkpoint pathways.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": ". Subject is ≥ 18 years of age at the time of signing the informed consent form ().",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "4. Subject must have aggressive B-cell NHL according to \"the 2016 revision of the WHO classification of lymphoid neoplasms\", histologically confirmed at last relapse by the treating institution, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   1. Diffuse large B-cell lymphoma (DLBCL) Not otherwise specified (NOS) including transformed indolent Non-Hodgkin lymphoma (NHL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   2. Follicular lymphoma Grade 3B",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   3. T cell/histiocyte-rich large B-cell lymphoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   4. Epstein-Barr virus (EBV) positive DLBCL, NOS",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   5. Primary mediastinal (thymic) large B-cell lymphoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   6. High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple-hit lymphoma)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "5. Subjects disease must have relapsed or be refractory to at least 2 prior lines of therapy. Previous therapy must have included a CD20-targeted agent and an anthracycline.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "6. Subject must have",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   1. Positron emission tomography (PET)-positive (Deauville score 4 or 5) and computed tomography (CT) measurable disease as per Lugano Classification",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   2. Sum of product of perpendicular diameters (SPD) of up to 6 index lesions ≥ 25 cm2 by CT scan (not applicable to Arm A or B or subjects with Richter's transformation)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "7. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "8. Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "9. Subjects must agree to not donate blood, organs, sperm or semen, and egg cells for usage in other individuals",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "10. Participants must agree to use effective contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": ". Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study based on investigator´s judgment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study based on investigator´s judgment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "3. Subject has any condition that confounds the ability to interpret data from the study based on investigator´s judgment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "4. Subjects with prior history of malignancies, other than aggressive R/R NHL, unless the subject has been free of the disease for ≥ 2 years with the exception of the following non-invasive malignancies:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   1. Basal cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   2. Squamous cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   3. Carcinoma in situ of the cervix",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   4. Carcinoma in situ of the breast",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   5. Incidental histologic finding of prostate cancer (T1a or T1b using the TNM \\[tumor, nodes, metastasis\\] clinical staging system) or prostate cancer that is curative.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   6. Other completely resected stage 1 solid tumor with low risk for recurrence",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "5. Prior treatment with any prior gene therap y product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "6. Prior treatment with any adoptive T cell therapy; prior hematopoietic stem cell transplant (HSCT) is allowed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "7. Allogeneic HSCT within 90 days of leukapheresis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "8. Prior treatment with the combination agent from the assigned arm:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   1. Anti PD-1 or PD-L1 (Arm A and E)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   2. CC-122 (Arm B)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   3. CC-220 (Arm C)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   4. Prior treatment with ibrutinib is not exclusionary for subjects on any study arm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   5. Anti LAG-3 targeted agent (Arm E)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "   6. CC-99282 (Arm F)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "9. Presence of acute or chronic graft-versus-host disease (GVHD)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "10. Presence of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "    1. Active hepatitis B or active hepatitis C infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "    2. History of or active human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "11. Uncontrolled bacterial, viral or fungal infection at the time of leukapheresis, lymphodepleting chemotherapy or JCAR017 infusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "12. Any history of myocarditis (Arm E); history of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease (all arms)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "13. History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "14. Subjects with active CNS or cerebrospinal fluid (CSF) involvement by malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "15. Pregnant or nursing (lactating) women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "16. Subjects with active auto immune disorders/processes or active neurological or inflammatory disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "17. For subjects to receive oral combination therapy (Arms B, C, D or F): History of a gastrointestinal (GI) condition or procedure that in the opinion of the investigator may affect oral drug absorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "18. Progressive tumor invasion of venous or arterial vessels.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310619",
    "statement": "19. Deep venous thrombosis (DVT)/pulmonary embolism (PE) not managed on a stable regimen of anticoagulation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": ". Male or female patient aged 18 years or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "2. Histologic or cytologically confirmed Stage 3B, IV (according to American Joint Committee on Cancer (tumor staging)) or recurrent non small cell lung cancer (Non-Small Cell Lung Carcinoma) (non squamous histologies)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "3. Relapsing course or failure of one first line chemotherapy (in the case of recurrent disease one additional prior regimen is allowed for adjuvant, neoadjuvant or neoadjuvant plus adjuvant therapy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "4. At least one target tumor lesion that has not been irradiated within the past three months and that can accurately be measured by magnetic resonance imaging (Magnetic Resonance Imaging) or computed tomography (X-Ray Computed Tomography) in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral X-Ray Computed Tomography.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "5. Life expectancy of at least three months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "6. Eastern Cooperative Oncology Group (Electrocorticogram) score of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "7. Patient has given written informed consent which must be consistent with the International Conference on Harmonization, Good Clinical Practice (ICH-GCP) and local legislation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": ". Previous therapy with other vascular endothelial growth factor (endothelial growth factor A, vascular) inhibitors (other than bevacizumab) or pemetrexed for treatment of Non-Small Cell Lung Carcinoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "2. treatment - ActInformationManagementReason with other investigational drugs or treatment in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "3. Chemotherapy, hormone therapy, immunotherapy with monoclonal antibodies, treatment with tyrosine kinase inhibitors, or radiotherapy (except for treatment of extremities) within the past four weeks prior to treatment with the trial drug, i.e., the minimum time elapsed since the last anticancer therapy and the first administration of BIBF 1120 must be four weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "4. Inability to stop intake of Analgesics and non-steroidal anti-inflammatory drugs (non steroidal anti inflammatory drugs) for several days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "5. Active brain metastases (e.g. stable for \\<4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants). Dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomisation)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "6. Radiographic evidence of cavitary or necrotic tumors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "7. Centrally located tumors with radiographic evidence (X-Ray Computed Tomography or Magnetic Resonance Imaging) of local invasion of major blood vessels",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "8. History of clinically significant haemoptysis within the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "9. Therapeutic anticoagulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "10. History of major thrombotic or clinically relevant major bleeding event in the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "11. Significant cardiovascular diseases (i.e., hypertension not controlled by medical therapy, unstable angina, history of myocardial infarction within the past 6 months,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "12. Inadequate kidney, liver, blood clotting function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "13. Inadequate blood count",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "14. Significant weight loss (\\> 10 %) within the past 6 weeks prior to treatment in the present trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "15. Current peripheral neuropathy greater than or equal to National Cancer Institute common terminology criteria for adverse events (National Cancer Institute common terminology criteria for adverse events) Second grade in elementary school except due to trauma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "16. Pre-existing ascites (abdominal fluid collection) and/or clinically significant pleural effusion ( fluid collection between the lung and chest wall)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "17. Major injuries and/or surgery within the past ten days prior to start of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "18. Incomplete wound healing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00806819",
    "statement": "19. Active or chronic hepatitis C and/or B infection Additional exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00451906",
    "statement": "* adult patients, \\>=18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00451906",
    "statement": "* histologically or cytologically documented inoperable, locally advanced ( stage III), metastatic (stage IV) or recurrent Non-Small Cell Lung Carcinoma other than squamous cell (tumors of mixed histology should be categorized by the predominant cell type);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00451906",
    "statement": "* ECOG performance status status 0-2;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00451906",
    "statement": "* life expectancy \\>= 12weeks;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00451906",
    "statement": "* adequate renal, liver and hematological function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00451906",
    "statement": "* mixed, non-small and small cell tumors, or mixed Adenosquamous carcinoma with a predominant squamous component;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00451906",
    "statement": "* hemoptysis (\\>=1/2 teaspoon of bright red blood) in previous 3 months;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00451906",
    "statement": "* evidence of tumor invading major blood vessels on imaging;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00451906",
    "statement": "* evidence of Central nervous system (CNS) metastases (tumor staging), even if previously treated.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00451906",
    "statement": "* major surgery (including open biopsy), significant traumatic injury within 28 days prior to enrolment, or anticipation of need for major surgery during study treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00451906",
    "statement": "* prior chemotherapy for stage IIIb/IV disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has a histologically or cytologically confirmed diagnosis of metastatic squamous or nonsquamous Non-Small Cell Lung Carcinoma (Non-Small Cell Lung Carcinoma) -Stage level 4: Metastasis stage M1a, M1b TNM Finding, M1C.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has progressive disease (ITMIG MRECIST Progressive Disease) on treatment with one prior anti-programmed cell death 1 (ITMIG MRECIST Progressive Disease-1)/programmed cell death ligand 1 (ITMIG MRECIST Progressive Disease-L1) monoclonal antibody (Monoclonal Antibody [EPC]) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Retreatments with the same anti-CD274 wt Allele/CD274 wt Allele Monoclonal Antibody [EPC] is acceptable in the overall course of treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has ITMIG MRECIST Progressive Disease during/after platinum doublet chemotherapy for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has confirmation that Soluble ErbB-1-, anaplastic lymphoma kinase-, or ROS1 protein, human-directed therapy is not indicated as primary therapy (documentation of absence of tumor-activating Soluble ErbB-1 mutations \\[eg, DEL19 or L858R\\], and absence of anaplastic lymphoma kinase and ROS1 protein, human gene rearrangements OR presence of a K-ras mutation).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has submitted pre-study imaging that confirmed evidence of ITMIG MRECIST Progressive Disease following initiation of an anti-ITMIG MRECIST Progressive Disease-1/ITMIG MRECIST Progressive Disease-L1 inhibitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has at least 1 measurable lesion by computerized tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (Response Evaluation Criteria in Solid Tumors) 1.1, as determined by the local site assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has provided tumor tissue for CD274 wt Allele biomarker analysis from an archival sample (defined as: from initial diagnosis of Non-Small Cell Lung Carcinoma and prior to receiving immunotherapy \\[antiPD-1/CD274 wt Allele\\], from the primary lesion or a metastatic lesion).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has provided prior to allocation tissue from a newly obtained formalin-fixed sample from a new biopsy (defined as: after completion of immunotherapy \\[anti-PD-1/CD274 wt Allele\\] and before receiving a randomization number), of a tumor lesion not previously irradiated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has Eastern Cooperative Oncology Group (Electrocorticogram) performance status of 0 or 1 within 7 days before the first dose of study intervention but before randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has a life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Male participants receiving pembrolizumab ± lenvatinib or lenvatinib must agree to refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse; or 2) follow contraceptive guidance during the treatment period or 7 days after the last dose of lenvatinib. Male participants receiving docetaxel agree to adhere to the same conditions during the treatment period and for ≥90 days after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Female participants must not be pregnant, not be breastfeeding, and not be a woman of child-bearing potential (WOCBP). If a WOCBP, agrees to not donate eggs and either use contraception, or be abstinent from heterosexual intercourse during the treatment period and for ≥120 days after the last dose of pembrolizumab or 30 days after the last dose of lenvatinib, whichever occurs last. If a WOCBP receiving docetaxel, agrees to adhere to the same conditions during the treatment period and for ≥30 days after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has adequately controlled blood pressure (bleomycin/cisplatin protocol) with or without antihypertensive medications, defined as bleomycin/cisplatin protocol ≤150/90 mm Hg and no change in antihypertensive medications within 1 week before randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* If participant received major surgery or radiation therapy of \\>30 Gy, they have recovered from the toxicity and/or complications from the intervention.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has received docetaxel as monotherapy or in combination with other therapies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has received lenvatinib as monotherapy or in combination with an anti-PD-1/CD274 wt Allele Monoclonal Antibody [EPC].",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has received: 1) radiotherapy within 2 weeks before the first dose of study treatment; or 2) lung radiation therapy \\>30 Gy within 6 months before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has received a live vaccine within 30 days before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has clinically significant hemoptysis or tumor bleeding within 2 weeks before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has radiographic evidence of intratumoral cavitation, encasement, or invasion of a major blood vessel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has clinically significant cardiovascular impairment within 12 months of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has a history of a gastrointestinal condition or procedure that may affect oral absorption of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has a pre-existing ≥grade 3 education level gastrointestinal or non-gastrointestinal fistula.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Is currently participating in a clinical trial and receiving study therapy or participated in a study of an investigational agent within 4 weeks of the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of disease recurrence for 3 years since initiation of that therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has known active central nervous system metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has severe hypersensitivity to pembrolizumab and/or any of its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has a sensitivity to any of the excipients contained in lenvatinib and/or docetaxel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has an active autoimmune disease that has required systemic treatment in the past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has a history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has an active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has a known history of human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has a known history of hepatitis B reactive or known active hepatitis C virus infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has active tuberculosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through at least 120 days after the last dose of pembrolizumab or lenvatinib, or 90 days (male participants) or 30 days (for female participants) after the last dose of docetaxel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03976375",
    "statement": "* Has had an allogeneic tissue/solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00745875",
    "statement": "* Histologic or cytologically confirmed locally advanced or metastatic Non-Small Cell Lung Carcinoma on entry into study suitable for pemetrexed therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00745875",
    "statement": "* Patients that meet one of the following criteria: - progressed following one prior platinum-based chemotherapy regimen for locally advanced or metastatic disease; -progressed within 6 months of adjuvant platinum-based chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00745875",
    "statement": "* Life expectancy of \\> 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00745875",
    "statement": "* Prior treatment with pemetrexed in the last 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00745875",
    "statement": "* Prior therapy with an ET receptor antagonist",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00745875",
    "statement": "* Any recent surgery, unhealed surgical incision, severe concomitant medical condition (eg, unstable cardiac, hepatic or renal disease) or significant laboratory finding which makes it undesirable for the patient to participate",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has histologically or cytologically confirmed, Stage IIIb - IV Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has a tumor measurable according to Response Evaluation Criteria in Solid Specimen Source Codes - tumors (Response Evaluation Criteria in Solid Tumors)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has adequate hematologic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has adequate hepatic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has adequate renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has uncontrolled brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has received previous chemotherapy for Non-Small Cell Lung Carcinoma (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 6 months prior to randomization)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Receiving any other investigational agent(s)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has a history of treatment with other agents targeting the insulin-like growth factor (Somatomedins) or the epidermal growth factor (EGF gene) receptor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has a known allergy / history of hypersensitivity reaction to any of the treatment components",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has poorly controlled diabetes mellitus. Participants with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range \\[fasting glucose \\<160 milligrams per deciliter (mg/dL) or below the upper limit of normal (ULN) and hemoglobin A1C≤ 7%\\] and that they are on a stable dietary or therapeutic regimen for this condition",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has an uncontrolled intercurrent illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Patient currently pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has a history of another primary cancer, with the exception of: a) curatively resected nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has superior vena cava syndrome contraindicating hydration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has current clinically-relevant coronary artery disease (New York Heart Association III or IV) or uncontrolled congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has any National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 3.0 Grade ≥2 peripheral neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870870",
    "statement": "* Has significant third space fluid retention, requiring repeated drainage",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": ".",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "1. Able to understand and comply with study procedures, understand the risks involved in the study, and provide written informed consent before any study-specific procedure is performed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "2. Men or women 18 years of age or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "3. Participants with histologically or cytologically confirmed advanced solid tumors that are metastatic or unresectable, who are refractory or have relapsed after treatment with available therapies or for whom standard life-prolonging measures or approved therapies are not available. In Phase 1 (qualifier value) Part B and in the Phase 2 portion of the protocol, participants must also have documented gene alterations in the MAPK pathway as detailed in the protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "4. In Phase 1 Part B of the protocol, participants must have disease lesions that are amenable to biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "5. In the Phase 2 portion of the protocol, participants must have measurable disease according to RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "6. ECOG performance status 0 to 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "7. Acceptable organ function as evidenced by the following laboratory data:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   1. Aspartate aminotransferase measurement (Aspartate aminotransferase measurement) and alanine aminotransferase ≤2×upper limit of normal (Upper Limit of Normal) or ≤3 Upper Limit of Normal in the presence of liver metastases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   2. Serum total bilirubin measurement ≤1.5×Upper Limit of Normal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   3. Absolute neutrophil count (Absolute neutrophil count) ≥1500 cells/mm3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   4. Finding of platelet count ≥100,000 cells/mm3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   5. Calculated creatinine clearance (by the standard Cockcroft Gault formula) of ≥50 mL/min or glomerular filtration rate of ≥50 mL/min.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "8. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group \\[CTFG\\]; see protocol for details) must not be pregnant or breastfeeding and must have a negative pregnancy test within 24 hours before the first dose of study treatment. While receiving study treatment and for at least 5 half-lives of ASTX029 or metabolite plus 30 days after completing treatment, women of child-bearing potential must agree to practice highly effective contraceptive measures (as described in the protocol) and must refrain from donating eggs (ova, oocytes) for the purpose of reproduction.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "9. Men with female partners of child-bearing potential (according to recommendations of the S-(2-chloro-1,1,2-trifluoroethyl)glutathione; see protocol for details) must agree to, during the treatment period and for at least 5 half-lives of ASTX029 or metabolite plus 90 days after completing treatment, practice highly effective contraceptive measures (as described in the protocol), not to father a child, and to refrain from donating sperm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": ". Hypersensitivity to ASTX029 or excipients of the drug product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "2. Poor medical risk in the investigator's opinion because of systemic diseases in addition to the cancer under study, for example, uncontrolled infections.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "3. Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise participants safety or the integrity of study outcomes or interfere with the absorption or metabolism of ASTX029.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "4. Prior anticancer treatments or therapies within the indicated time window prior to first dose of study treatment (ASTX029), as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   1. Cytotoxic Chemotherapy or radiotherapy within 3 weeks prior. Palliative Radiation Therapy to a single lesion within 2 weeks prior. Any encountered treatment-related toxicities (excepting alopecia) not stabilized or resolved to ≤Grade 1 (qualifier value).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   2. Monoclonal Antibodies within 4 weeks prior. Any encountered treatment-related toxicities not stabilized or resolved to ≤Grade 1 (qualifier value).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   3. Molecularly targeted drug or investigational drugs, without the potential for delayed toxicity, within 4 weeks of the first dose of study treatment or 5 half-lives (minimum 14 days), whichever is shorter. Any encountered treatment-related toxicities (excepting alopecia) not stabilized or resolved to ≤Grade 1 (qualifier value).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "5. Prior treatment with extracellular signal-regulated kinase (ERK) inhibitors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "6. History of, or at risk for, cardiac disease, as evidenced by 1 or more of the following conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   1. Abnormal left ventricular ejection fraction (LVEF (procedure); \\<50%) on echocardiogram (Extension for Community Healthcare Outcomes) or multiple-gated acquisition (Multiple gated acquisition scanning) scan.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   2. Congestive heart failure of ≥Grade 3 severity according to New York Heart Association Functional Classification defined as patients with marked limitation of activity and who are comfortable only at rest.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   3. Unstable cardiac disease including unstable angina or hypertension as defined by the need for overnight hospital admission within the last 3 months (90 days).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   4. History or evidence of long QT interval corrected for heart rate (Corrected QT Interval), ventricular arrhythmias including ventricular bigeminy, complete left bundle branch block, clinically significant bradyarrhythmias such as sick sinus syndrome, second- and third-degree atrioventricular (AV) block, presence of cardiac pacemaker or defibrillator, or other significant arrhythmias.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "   5. Special screening finding Electrocardiography, 12-Lead (Electrocardiography) with measurable 12-lead ECG QTc interval of ≥470 msec. (Fridericia's formula should be used to calculate the 12-lead ECG QTc interval throughout the study.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "7. Known history of human immunodeficiency virus (HIV) infection or seropositive results consistent with active hepatitis B virus (hepatitis B virus) or active hepatitis C virus (Hepatitis C-Like Viruses) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "8. Known brain metastases, unless previously treated and stable for at least 3 months with or without steroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "9. Known significant mental illness or other conditions, such as active alcohol or other substance abuse that, in the opinion of the investigator, predispose the participant to high risk of noncompliance with the protocol treatment or assessments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "10. History or current evidence/risk of retinal vein occlusion (Retinal Vein Occlusion) or central serous retinopathy (Review, Continued Stay) including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "    1. Presence of predisposing factors to Retinal Vein Occlusion or Review, Continued Stay (eg, uncontrolled glaucoma or ocular hypertension, uncontrolled diabetes mellitus) or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "    2. Visible retinal pathology as assessed by ophthalmic examination at screening that is considered a risk factor for Retinal Vein Occlusion or Review, Continued Stay such as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "* Evidence of optic disc cupping or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "* Evidence of new visual field defects on automated perimetry or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03520075",
    "statement": "* Physiologic Intraocular Pressure \\>21 mmHg as measured by tonography.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": ". Phase 1b: Histologic and/or cytologically confirmed metastatic selected solid tumor types that have progressed after treatment with approved therapies or for which there are no standard effective therapies available. If nivolumab or pembrolizumab is an approved therapy for the participant's tumor type, but the participant has not been treated with it, the Investigator may enroll the participant in this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "   Phase 2: Histologic and/or cytologically confirmed metastatic selected solid tumor types with 0-2 prior lines of systemic therapy. If previously treated, participant has progressed after previous treatment. For the non-small cell lung cancer (Non-Small Cell Lung Carcinoma) and melanoma cohorts, participants must have progressed on or after prior treatment with one anti-programmed cell death protein 1 (anti-PD-1), anti-PD-1 ligand 1 (anti-PD-L1), or anti-PD-1 ligand 2 (anti-PD-L2) agent. For the renal cell carcinoma (Waist-Hip Ratio) cohort, participants must have progressed on treatment with an anti- programmed death receptor-1 /programmed death receptor-ligand 1 monoclonal antibody (anti-PD-1/PD-L1 mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies, the regimen with an anti-PD-1/PD-L1 mAb must be the most recent therapy. Selected tumor types of both phases: Non-Small Cell Lung Carcinoma, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal melanoma)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "2. Life expectancy of 12 weeks or more",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "3. Phase 2: Measurable disease meeting the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "   1. At least 1 lesion of greater than or equal to 10 mm in the longest diameter for a non-lymph node or greater than or equal to 15 mm in the short-axis diameter for a lymph node that is serially measurable according to Immune-related Response Evaluation Criteria In Solid Tumors (Immune-related Response Evaluation Criteria In Solid Tumors) using computerized tomography/magnetic resonance imaging (X-Ray Computed Tomography/Magnetic Resonance Imaging)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "   2. Lesion that have had external beam radiotherapy (External Beam Radiation Therapy) or loco-regional therapies such as radiofrequency (RF) ablation must show subsequent evidence of substantial size increase to be deemed a target lesion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "4. Participants must have an Eastern Cooperative Oncology Group (Electrocorticogram) Performance Status of 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "5. Adequately controlled blood pressure (bleomycin/cisplatin protocol) with or without antihypertensive medications, defined as bleomycin/cisplatin protocol less than or equal to 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Cycle 1 Day 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "6. Adequate renal function defined as creatinine less than or equal to 1.5\\*Upper Limit of Normal (upper limit of normal) or calculated creatinine clearance greater than or equal to 40 mL/min per the Cockcroft and Gault formula with creatinine levels greater than 1.5\\*Upper Limit of Normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "7. Adequate bone marrow function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "   1. Absolute neutrophil count (Absolute neutrophil count) greater than or equal to 1500/mm3 (greater than or equal to 1.5 X 103/uL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "   2. Blood Platelets greater than or equal to 100,000/mm3 (greater than or equal to 100 X 109/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "   3. Hemoglobin finding greater than or equal to 9.0 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "8. Adequate blood coagulation function as evidenced by an International Normalized Ratio (Integrated Neuromusculoskeletal Release) less than or equal to 1.5",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "9. Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the ULN and alkaline phosphatase (SLPI protein, human), alanine aminotransferase (Antibiotic Lock Therapy), and aspartate aminotransferase (Aspartate aminotransferase measurement) less than or equal to 3\\*ULN (in the case of liver metastases less than or equal to 5\\*ULN). In case SLPI protein, human is greater than 3 X ULN (in the absence of liver metastases) or greater than 5 X ULN (in the presence of liver metastases) AND the participant also is known to have bone metastases, the liver specific SLPI protein, human must be separated from the total and used to assess the liver function instead of the total SLPI protein, human",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "10. Males or females age greater than or equal to 18 years at the time of informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "11. Participants with known brain metastases will be eligible if they have completed the primary brain therapy (such as whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection) and if they have remained clinically stable, asymptomatic and off of steroids for at least 28 days before starting study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "12. All females must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin \\[β-hCG\\]) at the Special screening finding Visit and the BaseLine dental cement Visit. A pregnancy test needs to be performed within 72 hours of the first dose of study drug. Females of childbearing potential must agree to use a highly effective method of contraception for the entire study period and for 120 days after study discontinuation, ie",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "* total abstinence (if it is their preferred and usual lifestyle)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "* an intrauterine device (Intrauterine Devices) or hormone-releasing system (International Unit)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "* a Contraceptive implant",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "* an oral contraceptive\\*\\* (with additional barrier method) OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "* have a vasectomized partner with confirmed azoospermia.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "    NOTES:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "* All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "* Must be on a stable dose of the same oral hormonal contraceptive product for at least 4 weeks before dosing with study drug and for the duration of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "13. Male participants who are partners of women of childbearing potential must use a condom + spermicide and their female partners if of childbearing potential must use a highly effective method of contraception (see methods described in Inclusion Criterion #12) beginning at least 1 menstrual cycle prior to starting study drug(s), throughout the entire study period, and for 120 days after the last dose of study drug, unless the male participants are totally sexually abstinent or have undergone a successful vasectomy with confirmed azoospermia or unless the female partners have been sterilized surgically or are otherwise proven sterile.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "14. Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "15. Archival tumor tissue or a newly obtained biopsy must be available prior to the first dose of study drug for biomarker analysis. In the case archival tissue cannot be provided, participants with inaccessible tumors for biopsy specimens can be enrolled without a biopsy upon consultation and agreement by the sponsor Note: In case of submitting unstained cut slides, freshly cut slides should be submitted to the testing laboratory within 14 days from when the slides are cut.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": ". Prior anticancer treatment within 28 days (or 5 times the half-life time, whichever is shorter) or any investigational agent within 30 days prior to the first dose of study drugs. All acute toxicities related to prior treatments must be resolved to School Grade less than or equal to 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "2. Participants must have recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "3. Participants having greater than 1+ proteinuria on urinalysis will undergo 24-h urine collection for quantitative assessment of proteinuria. Participants with urine protein greater than or equal to 1 g/24-hour will be ineligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "4. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "5. New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "6. Prolongation of corrected QT (Corrected QT Interval) interval to greater than 480 msec",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "7. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "8. Active infection (any infection requiring systemic treatment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "9. Participant is known to be positive for HIV (HIV), hepatitis B surface antigen vaccine, or hepatitis C virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "10. Serious nonhealing wound, ulcer, or bone fracture",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "11. Known intolerance to either of the study drugs (or any of the excipients)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "12. History of organ allograft (Participant has had an allogenic tissue/solid organ transplant)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "13. Biologic response modifiers (eg, granulocyte colony-stimulating factor) within 4 weeks before study entry. Chronic erythropoietin therapy is permitted provided that no dose adjustments were made within 2 months before first dose of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "14. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "15. Females who are pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "16. Excluding the primary tumor leading to enrollment in this study, any other active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the bladder or cervix) within the past 24 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "17. Prior treatment with lenvatinib or any PDCD1 wt Allele, anti-PD-L1, or anti-PD-L2 agent, excluding melanoma and Non-Small Cell Lung Carcinoma where prior treatment with one PDCD1 wt Allele, anti-PD-L1, or anti-PD-L2 agent is allowed, and excluding Waist-Hip Ratio where prior treatment with one regimen containing an anti-PDCD1 wt Allele/PD-L1 mAb is required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "18. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. The use of physiologic doses of corticosteroids (up to 7.5mg/d of prednisone or equivalent) may be approved after consultation with the sponsor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "19. No active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Hormone replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "20. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02501096",
    "statement": "21. Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* At least 18 years old with histologically- or cytologically-confirmed diagnosis of adenocarcinoma Stage level 4 Non-Small Cell Lung Carcinoma with a positive mutational status for the K-ras Oncogene, NRAS protein, human, BRAF gene, or MAP2K1 gene gene.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Documented tumor progression after receiving at least one, but not more than one, prior approved platinum-containing chemotherapy regimen for advanced stage/metastatic Non-Small Cell Lung Carcinoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Measurable Disease per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (Electrocorticogram) scale.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Life expectancy of at least three months in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Women of childbearing potential must have a negative serum pregnancy test within 14 days of randomization to study treatment and agree to use effective contraception. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from the time of randomization to study medication until at least four weeks after the last dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Adequate baseline organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* History of another malignancy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Any serious and/or unstable pre-existing medical disorder, psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Treatment with a BRAF or Mitogen-Activated Protein Kinase Kinase Inhibitor or docetaxel as monotherapy or as part of a combination regimen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Anti-cancer therapy (including chemotherapy and radiation therapy) within the last three weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* History or current evidence / risk of retinal vein occlusion or central serous retinopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Any current or history of tumor manifestation in the Central Nervous System.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* History or evidence of cardiovascular risk, including QTcB \\>=480 msec, uncontrolled arrhythmias, acute coronary syndrome, coronary angioplasty, or stenting within 6 months prior to randomization, \\>=Class II congestive heart failure, treatment refractory hypertension, intra-cardiac defibrillators or permanent pacemakers or cardiac metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01362296",
    "statement": "* Known HIV, hepatitis B virus (hepatitis B virus), or hepatitis C virus (Victim, pedestrian in vehicular AND/OR traffic accident (finding)) infection (with the exception of chronic or cleared hepatitis B virus and HCV infection).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Dosage level 1 participants with histologically proven advanced solid tumors, for which no effective standard therapy exists, or standard therapy has failed or cannot be tolerated",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Dose level 1 participants with ECOG performance status (ECOG performance status) less than or equal to (\\<=) 1 and Karnofsky Performance Status greater than or equal to (\\>=) 70 percent (%)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Dose level 2 and main part participants with ECOG performance status \\<= 2 and Karnofsky Performance Status \\>= 60%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Dose level 2 and main part participants with histologically confirmed Small cell carcinoma of lung",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Dose level 2 and main part participants with radiologically confirmed progression after first-line or chemoradiation platinum-based treatment (carboplatin or cisplatin), with or without immunotherapy, for treatment of limited or extensive stage SCLC, with a Platinum-free interval (PFI) less than (\\<) 90 days. The PFI is measured by the elapsed time from the last day of the regimen of a platinum-based treatment until the first day of documented disease progression",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Dose level 2 and main part participants with measurable disease according to Response Evaluation Criteria in Solid Tumors (Response Evaluation Criteria in Solid Tumors) Version 1.1 (Response Evaluation Criteria in Solid Tumorsv1.1) at Special screening finding. Evidence of measurable disease must be confirmed by the insulin-responsive compartment prior to start of treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Specimen Source Codes - tumor tissue provision: archival (collected within 12 months before date of informed consent form \\[ICF\\]) signature for Special screening finding) or fresh biopsy specimen, if medically feasible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Have adequate hematologic and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Other protocol defined inclusion criteria could apply",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Clinically relevant (that is \\[i.e.\\], active), uncontrolled intercurrent illness including, but not limited to, severe active infection including, severe acute respiratory syndrome coronavirus-2 infection/coronavirus disease 2019, immune deficiencies, uncontrolled diabetes, uncontrolled arterial hypertension, symptomatic congestive heart failure (New York Heart Association Classification greater than or equal to \\[\\>=\\] Class III), unstable angina pectoris, myocardial infarction, uncontrolled cardiac arrhythmia, cerebral vascular accident/stroke. Calculated corrected QT interval (QTc) average (using the Fridericia correction calculation) of greater than \\[\\>\\] 450 millisecond (msec) for males and \\> 470 msec for females. Any psychiatric illness/social situations that would limit compliance with study requirements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Unstable brain metastases; however, participants with known brain metastases may be enrolled in this clinical study if they are clinically stable (without evidence of progression by imaging for at least 2 weeks prior to the first study intervention dose and any neurologic symptoms have returned to baseline), have no evidence of new brain metastases, and are on a stable or decreasing dose of steroids for at least 14 days prior to study intervention Participants with carcinomatous meningitis are excluded regardless of clinical stability. Screening central nervous system imaging is not mandatory",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Prior malignant disease within the last 3 years. Exceptions include fully resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ cervical cancer, fully resected ductal carcinoma in situ of the breast, superficial or noninvasive bladder cancer, and Stage 1A, Grade I endometrioid endometrial cancer with no myometrial invasion, that has undergone curative therapy. Participants with other localized malignancies treated with curative intent need to be discussed with the Medical Monitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Participants not recovered from adverse events (TLE5 gene) Grade \\> 1 from prior anticancer therapies, including surgeries. Exception: Grade 2 TLE5 gene not constituting a safety risk (for example \\[e.g.\\], alopecia), based on the Investigator's judgment; must consult with the medical Monitor prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768296",
    "statement": "* Other protocol defined exclusion criteria could apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has histologically or cytologically confirmed squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has Stage IV disease at the time of study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Measurable or nonmeasurable disease at the time of study entry as defined by the Response Evaluation Criteria in Solid Tumors (Response Evaluation Criteria in Solid Tumors) (participants with only truly nonmeasurable disease are not eligible)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has resolution to School Grade ≤ 1 of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has adequate hepatic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has adequate renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has adequate hematologic function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* If female, is surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method (failure rate \\< 1%) during and for 6 months after the treatment period (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* If male, the participant is surgically sterile or compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Woman participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has archived tumor tissue available for analysis of Soluble ErbB-1 and K-ras Oncogene mutation status (by Polymerase Chain Reaction) and Soluble ErbB-1 gene copy number (by SH3PXD2A wt Allele); minimum of four slides, paraffin-embedded tissue, required",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has nonsquamous NSCLC (adenocarcinoma/large cell or other)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the Soluble ErbB-1, vascular endothelial growth factor (endothelial growth factor A, vascular), or endothelial growth factor A, vascular receptor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has received previous chemotherapy for advanced Non-Small Cell Lung Carcinoma (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 1 year prior to randomization)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has undergone major surgery or received any investigational therapy in the 4 weeks prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has undergone chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants. Participants who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has superior vena cava syndrome contraindicating hydration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has current clinically-relevant coronary artery disease or uncontrolled congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has experienced myocardial infarction within 6 months prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has an ongoing or active infection (requiring antibiotics), including active tuberculosis or known infection with the human immunodeficiency virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has any National Cancer Institute - National Cancer Institute common terminology criteria for adverse events (National Cancer Institute common terminology criteria for adverse events) Version 3.0 Grade ≥ 2 peripheral neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has significant third space fluid retention, requiring repeated drainage",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has any other serious uncontrolled medical disorders or psychological conditions that would, in the opinion of the investigator, limit the participant's ability to complete the study or sign an informed consent document",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab (IMC-11F8), or any other contraindication to one of the administered treatments",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Is pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has a known history of drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00981058",
    "statement": "* Has a concurrent active malignancy other than adequately-treated basal cell carcinoma of the skin or preinvasive carcinoma of the cervix. A participant with previous history of malignancy other than Non-Small Cell Lung Carcinoma is eligible, provided that he/she has been free of disease for ≥ 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Adult participants, \\>/= 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Stage level 4 or recurrent non-small cell lung cancer (Non-Small Cell Lung Carcinoma)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Presence of mutation(s) in exon 18 through exon 21 of epidermal growth factor receptor (Soluble ErbB-1), (except EGFR NP_005219.2:p.T790M single mutation only)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Measurable Disease (at least one lesion \\>= 10 mm in longest diameter)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Adequate hematological, renal and liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Patients with EGFR NP_005219.2:p.T790M single mutation only",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Prior exposure to agents directed at the human epidermal receptor (Herero language) axis, e.g. erlotinib, gefitinib, cetuximab, trastuzumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Prior chemotherapy or systemic anti-cancer therapy for advanced NSCLC disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Symptomatic or uncontrolled central nervous system (Clinical Nurse Specialists) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal or squamous cell carcinoma of the skin, or surgically treated localized prostate cancer, or surgically treated ductal cell carcinoma in situ of the breast",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Any significant ophthalmologic abnormality",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Pre-existing parenchymal lung disease such as pulmonary fibrosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01310036",
    "statement": "* Use of coumarins (for anti-coagulation therapy the use of low molecular weight heparin is recommended instead)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "-",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "* Inclusion Criteria: -",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  1. Age ≥ 70 years at the time of signing the Informed Consent Form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  2. Understand and voluntarily provide written informed consent prior to the conduct of any study related assessments/procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  3. Able to adhere to the study visit schedule and other protocol requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  4. Histologic or cytologically confirmed locally advanced or metastatic non small cell lung cancer who are not candidates for curative surgery or radiation therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  5. No other current active malignancy requiring anticancer therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  6. Radiographically documented measurable disease per RECIST v 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  7. No prior chemotherapy for the treatment of metastatic disease. Chemotherapy, Adjuvant is permitted providing that cytotoxic chemotherapy was completed 12 months prior to signing the informed consent form (ICF) and without disease recurrence. Participans with previously known epidermal growth factor receptor mutation or anaplastic lymphoma kinase gene translocation must have failed or had intolerance to one treatment with epidermal growth factor receptor tyrosine kinase inhibitor or anaplastic lymphoma kinase inhibitor therapy, respectively.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  8. Absolute neutrophil count ≥ 1500 cells/cubic millimetre.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  9. Platelets ≥ 100,000 cells/cubic millimetre.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  10. Hemoglobin finding ≥ 9 grams/decilitre.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  11. SGOT - Glutamate oxaloacetate transaminase/serum glutamic oxaloacetic transaminase/ alanine transaminase/serum glutamic pyruvic transaminase ≤ 2.5 × upper limit of normal range or ≤ 5.0 × upper limit of normal range if liver metastases.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  12. Total bilirubin metabolic function ≤ 1.5 millilitre/decilitre (unless there is a known history of Gilbert Disease).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  13. Creatinine clearance \\> 40 millilitre/minute calculated using Cockcroft-Gault equation (if renal impairment is suspected 24 hour urine collection for measurement is required).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  14. ECOG performance status 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  15. Females who (1) have undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have been naturally postmenopausal for at least 24 consecutive months (ie, has not had menses at any time during the preceding 24 consecutive months).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  16. Male subjects must: Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following study drug discontinuation, even if he has undergone a successful vasectomy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "* 1. Evidence of active brain metastases, including leptomeningeal involvement (prior evidence of brain metastasis are permitted only if treated and stable and off therapy for ≥ 4 weeks prior to signing Informed Consent form. Magnetic Resonance Imaging of the brain (or X-Ray Computed Tomography w/contrast) is preferred for diagnosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  2. History of leptomeningeal disease. 3. Only evidence of disease is non measurable. 4. Preexisting peripheral neuropathy of Second grade in elementary school, 3, or 4 (per Common Terminology Criteria for Adverse Events v4.0).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  5. Participant has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting investigational product, and/or from whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  6. Venous Thromboembolism within 1 month prior to signing informed consent form.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  7. Current congestive heart failure (New York Heart Association Class II-IV). 8. History of the following within 6 months prior to first administration of a study drug: a myocardial infarction, severe/unstable angina pectoris,coronary/peripheral artery bypass graft, New York Heart Association Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant Electrocardiogram abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  9. Participant has a known infection with hepatitis B or C, or history of human immunodeficiency virus infection, or participant is receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  10. Participant has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  11.History of interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or pulmonary hypersensitivity pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  12. treatment - ActInformationManagementReason with any investigational product within 28 days prior to signing the informed consent form.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  13. History of allergy or hypersensitivity to nab-paclitaxel or carboplatin. 14. Currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices. 15. Any other clinically significant medical condition, psychiatric illness, and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol or which, in the views of investigator, preclude combination chemotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  16. Participant has any other malignancy within 5 years prior to randomization. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer Specimen Source Codes - tumor, lymph nodes, metastatic qualifier (TNM stage of Tumor stage T1a or T1b TNM Finding). All treatment of which should have been completed 6 months prior to signing Consent Forms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  17. Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  18. Any medical condition that confounds the ability to interpret data from the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02151149",
    "statement": "  19. Females who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": ". Male or female patient greater than or equal to 18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "2. Histologic or cytologically confirmed nonsquamous NSCLC stage IIIB with malignant pleural effusion or stage IV disease not amenable to curative therapy. Patients with history of stage III disease that have relapsed after chemo- and radiotherapy are also eligible;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "3. Have at least 1 site of measurable disease by the Response Evaluation Criteria in Solid Tumors version 1.1 (Response Evaluation Criteria in Solid Tumors) criteria;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "4. Have failed 1 prior platinum-doublet containing chemotherapy regimen for stage IIIB with malignant pleural effusion or stage IV nonsquamous NSCLC. One additional cytotoxic regimen is allowed for neoadjuvant, adjuvant, or neoadjuvant plus adjuvant therapy for Phase II patients. For patients enrolled in the Phase Ib portion, a maximum of three total prior regimens is allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "   Definition of a Chemotherapy Regimen: Any platinum-doublet containing chemotherapy, that may also include biological or targeted agents, and/or humanized antibodies, given concomitantly, sequentially, or both, is considered 1 regimen. If, due to toxicity, the dosing of 1 or more of the components must be reduced, or 1 or more of the components of the regimen must be omitted, or 1 of the components must be replaced with another similar drug, the changed version of the original regimen is not considered a new regimen. However, if a new component, dissimilar to any of the original components, is added to the regimen, the new combination is considered a new regimen. If the treatment is interrupted for surgery or radiotherapy, and then continues with an unchanged schedule and components, that treatment is considered as one regimen despite the interruption.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "5. Life expectancy of greater than 3 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "6. Eastern Cooperative Oncology Group (Electrocorticogram) Performance Status (phosphatidylserine) less than 1;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "7. Patients must have adequate renal function as evidenced by calculated creatinine clearance greater than 45 mL/min per the Cockcroft and Gault formula;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "8. Patients receiving daily treatment with non-steroidal anti-inflammatory agents (Analgesics and non-steroidal anti-inflammatory drugs) are eligible. Patients with creatinine clearance 45-79 ml/min must be able to interrupt Analgesics and non-steroidal anti-inflammatory drugs 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "9. Patients must have adequate bone marrow function as evidenced by absolute neutrophil count (Absolute neutrophil count) greater than 1.5 x 10\\^9/L, hemoglobin greater than 9.0 g/dL (a hemoglobin less than 9.0 g/dL at Screening is acceptable if it is corrected to greater than 9 g/dL by growth factor or transfusion prior to first dose), and platelet count greater than 100 x 10\\^9/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "10. Patients must have adequate liver function as evidenced by bilirubin less than 1.5 times the upper limit of the normal range (ULN), and alkaline phosphatase, alanine aminotransferase (Antibiotic Lock Therapy) and aspartate aminotransferase (Aspartate aminotransferase measurement) less than 3 x ULN (in the case of liver metastases, less than 5 x ULN). If there are bone metastases, liver-specific alkaline phosphatase may be separated from the total and used to assess liver function instead of total alkaline phosphatase;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "11. Male or female patients of child-producing potential must agree to use double barrier contraception, oral contraceptives, or avoidance of pregnancy measures during the study and for 90 days after the last day of treatment;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "12. Females of childbearing potential must have a negative serum pregnancy test;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "13. Females may not be breastfeeding; and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "14. Ability to understand and willingness to sign a written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": ". Prior treatment with pemetrexed, epothilone, ixabepilone, patupilone, halichondrin B or halichondrin B-like compounds;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "2. Received chemotherapy, targeted therapy, radiotherapy, surgery, or immunotherapy within the 30 days prior to commencing study treatment or have not recovered from all treatment-related toxicities to Grade less than 1, except for alopecia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "3. History of other malignancies except: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated, a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (3) other curatively treated solid tumor with no evidence of disease for greater than 5 years;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "4. Presence of brain metastases, unless the patient has received adequate treatment at least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids for at least 4 weeks prior to randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "5. Received treatment in another clinical study within the 30 days prior to commencing study treatment or patients who have not recovered from side effects of an investigational drug to Grade less than 1, except for alopecia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "6. Are currently receiving any other treatment, including palliative radiotherapy for the tumor aside from control of symptoms;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "7. National Cancer Institute common terminology criteria for adverse events (CTC) greater than grade 3 education level peripheral neuropathy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "8. Require therapeutic doses of vitamin K antagonists;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "9. Uncontrolled pleural effusions, ascites, or other third space fluid collections;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "10. Uncontrolled diabetes mellitus Type 1 or 2; Significant cardiovascular impairment (history of congestive heart failure greater than New York Heart Association (NYHA) Grade II, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "11. Patients with organ allografts requiring immunosuppression;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "12. Known positive human immunodeficiency virus (HIV), known hepatitis B surface antigen, or hepatitis C positive;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01126736",
    "statement": "13. Hypersensitivity to halichondrin B and/or halichondrin B chemical derivative; or Have any medical condition that would interfere with the conduct of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* For all Parts: The participant must have stage IV non-small cell lung cancer (Non-Small Cell Lung Carcinoma).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* For Part A (abemaciclib + pemetrexed): Non-squamous subtypes only. The participant must have received at least one but no more than three prior therapies for advanced/metastatic Non-Small Cell Lung Carcinoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* For Part B (abemaciclib + gemcitabine): Any subtype. The participant must have received at least one but not more than three prior therapies for advanced/metastatic Non-Small Cell Lung Carcinoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* For Part C (abemaciclib + ramucirumab): Any subtype. The participant must have received at least two but not more than three prior therapies for advanced/metastatic Non-Small Cell Lung Carcinoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* For Part D (abemaciclib + LY3023414): Any subtype. The participant must have received at least two, but not more than three prior therapies for advanced/metastatic Non-Small Cell Lung Carcinoma. The participant must not have received prior treatment with any phosphoinositide 3-kinase (1-phosphatidylinositol-3-kinase activity) or mammalian target of rapamycin (MTOR gene) inhibitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* For Part E (abemaciclib + pembrolizumab): Any subtype. The participant must have received at least one but no more than three prior therapies for advanced/metastatic Non-Small Cell Lung Carcinoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Have either measureable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (Response Evaluation Criteria in Solid Tumors).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Have adequate organ function including:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Hematologic: Absolute neutrophil count (Absolute neutrophil count) 1.5 x 109/liter (L), platelets 100 x 109/L, and hemoglobin 8 gram/deciliter (g/dL).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Hepatic: blood bilirubin level test 1.5 times upper limits of normal (ULN), alanine aminotransferase (Antibiotic Lock Therapy) and aspartate transaminase (Aspartate aminotransferase measurement) 3.0 times ULN. For participants with tumor involvement of the liver, Aspartate aminotransferase measurement and Antibiotic Lock Therapy equaling ≤5.0 times ULN are acceptable. Alkaline Phosphatase ≤5.0 times ULN for participants with tumor involvement of the bone is acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Kidney: Creatinine measurement, serum (procedure) 1.5 times Upper Limit of Normal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Have a performance status ≤1 on the Eastern Cooperative Oncology Group (Electrocorticogram) scale.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (treatment related toxicity resolved to baseline) except for residual alopecia.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Ache and female participants of reproductive potential must agree to use medically approved contraceptive precautions during the trial and 3 to 4 months (as appropriate) following last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Have an estimated life expectancy of ≥12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Are able to swallow oral medications.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Have a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: Participants with controlled atrial fibrillation for \\>30 days prior to study treatment are eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Parts A, B, D and E: Have central nervous system (Clinical Nurse Specialists) metastasis with development of associated neurological changes 14 days prior to receiving study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix or breast), unless in complete remission with no therapy for a minimum of 3 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 3 to 4 months after the last dose of trial treatment (as appropriate).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus \\[HIV\\] antibodies, hepatitis B surface antigen \\[Hepatitis B Antigen Vaccine\\], or hepatitis C antibodies). Screening is not required for enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Parts A, B, C, and E: Have 12-lead Electrocardiography QTc interval of \\> 470 millisecond (msec) on screening electrocardiogram (Electrocardiography). Part D participants have 12-lead Electrocardiography QTc interval of \\>450msec on screening Electrocardiography.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* History or evidence of cardiovascular risk including any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within 6 months prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* History or evidence of current ≥Class II congestive heart failure as defined by New York Heart Association.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Treatment refractory hypertension defined as a blood pressure of systolic \\>140 millimeter of mercury (mmHg) and/or diastolic \\>90 mmHg which cannot be controlled by antihypertensive therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Participants with intracardiac defibrillators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* History or evidence of CNS disorder. Radiographic screening of all participants without history of CNS metastases is required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Radiographically documented evidence of major vessel invasion or encasement by cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Uncontrolled thromboembolic or hemorrhagic disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Participants receiving daily treatment with aspirin \\>325mg/day or other known inhibitors of platelet function.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* History of gross hemoptysis within 2 months of study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Evidence of nonhealing wounds, ulcers, or bone fractures within 28 days prior to study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Undergone major surgery within 28 days prior to first dose of study drug or have subcutaneous venous access device placement within 7 days prior to first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Participants with a type 2 diabetes mellitus are eligible if adequate control of blood glucose level is obtained by oral anti-diabetic agents as documented by hemoglobin A1c (Glucohemoglobin measurement) \\<7%.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* History or evidence of cardiovascular risk including any of the following -- History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within 6 months prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Received prior monoclonal antibody (Monoclonal Antibody [EPC]) within 4 weeks prior to study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Has active autoimmune disease that has required treatment in the past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079636",
    "statement": "* Has history of interstitial lung disease or pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Signed Informed Consent Form(s)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* At least 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Advanced histologically or cytologically confirmed predominant squamous Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Subjects with treated brain metastases are eligible if there is no evidence of progression or hemorrhage after treatment of the brain metastasis/metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Prior treatment for CNS disorder as deemed appropriate by the treating physician",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* ECOG performance status 0, 1, or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Measurable or evaluable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Use of an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study (for women of childbearing potential and sexually active men)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Prior chemotherapy for metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Chemotherapy, Adjuvant or prior combined modality therapy (chemotherapy plus radiotherapy) if \\< 6 months has elapsed from completion of treatment to Day 1, Cycle 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Extrathoracic metastases as the only sites of disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Active malignancy other than lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Current, recent, or planned participation in another experimental drug study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Did not receive therapy or drug for brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Presence of intrathoracic lesion(s) with any cavitation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Gross hemoptysis within 3 months prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* In the opinion of the investigator or local radiologist, evidence of tumor that is extending into the lumen of a major blood vessel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Inadequately controlled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Angina, Unstable or NYHA Grade II or greater Congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Myocardial infarction:Find:Pt:^Patient:Ord within 6 months prior to Day 1, Cycle 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Stroke (heart beat) within 6 months prior to Day 1, Cycle 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Active symptomatic peripheral vascular disease within 6 months prior to Day 1, Cycle 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* History of significant vascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Evidence of bleeding diathesis or coagulopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Current, ongoing treatment with full-dose warfarin or its equivalent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Current or recent use of aspirin (\\>325 mg/day)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Known hypersensitivity to any components of bevacizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Serious, non-healing wound, ulcer, or bone fracture",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* UPC ratio ≥ 1.0",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, Cycle 1, or anticipation of need for major surgical procedure during the course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Pregnancy or lactation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Inadequate organ function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00318136",
    "statement": "* Any other medical conditions (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a subject's ability to provide informed consent, cooperate, or participate in the study, or to interfere with the interpretation of the results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02040870",
    "statement": "* Histologic or cytologically confirmed diagnosis of Non-Small Cell Lung Carcinoma that carries an ALK Gene Rearrangement defined as positive using the United States Food and Drug Administration approved Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.) test and scoring algorithm (including positivity criteria) or positive as assessed by the CUnited States Food and Drug Administration approved immunohistochemistry (Immunohistochemistry) test (Ventana Medical Systems, Inc)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02040870",
    "statement": "* Age 18 years or older at the time of informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02040870",
    "statement": "* Patients must have stage IIIB or IV Non-Small Cell Lung Carcinoma at the time of study entry and have had progressive disease during or after crizotinib treatment whether or not previously treated with cytotoxic chemotherapy. If treated with chemotherapy, maximum 2 lines are allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02040870",
    "statement": "* Patients with known hypersensitivity to any of the excipients of LDK378",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02040870",
    "statement": "* Patients with symptomatic central nervous system (Clinical Nurse Specialists) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage Clinical Nurse Specialists symptoms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02040870",
    "statement": "* History of carcinomatous meningitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02040870",
    "statement": "* Presence or history of a malignant disease other than Non-Small Cell Lung Carcinoma that has been diagnosed and/or required therapy within the past 3 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02040870",
    "statement": "* clinically significant, uncontrolled heart disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients must have Stage 3B or 4 Non-Small Cell Lung Carcinoma of the non- squamous type",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients must at least be able to be physically mobile, take care of yourself and be able to perform light activities such as light housework or office work",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients must not have had previous chemotherapy treatment for lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients must not have had radiotherapy in the last 30 days",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients must have measureable tumor lesions according to the Response Evaluation Criteria in Solid Specimen Source Codes - tumors (Response Evaluation Criteria in Solid Tumors) guidelines or disease that can be evaluated on computed tomography (X-Ray Computed Tomography) scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients' test results assessing the function of their blood forming tissue, kidneys, liver and lungs are satisfactory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Women must be sterile, postmenopausal or on contraception and men must be sterile or on contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients cannot have received other investigational drugs within the last 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients cannot have any serious, uncontrolled medical condition that might compromise their ability to take part in the study safely",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients cannot have a current second primary malignant tumor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients cannot be having current treatment with any other anti-tumor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients cannot have had a yellow fever vaccination within 30 days of enrolment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients who are unable to take vitamins (including injections of vitamin B12) or oral cortisone medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients who are unable to stop taking more than 1.3 grams of aspirin on a daily basis or non-steroidal anti-inflammatory agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00887549",
    "statement": "* Patients who are pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": ". Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the International Classification of Functioning, Disability and Health and in this protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "2. Provision of signed and dated, written International Classification of Functioning, Disability and Health prior to any mandatory study specific procedures, sampling, and analyses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "3. Provision of signed and dated written genetic informed consent prior to collection of sample for genetic analysis (optional).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "4. 18 years or older at the time of signing the ICF.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "5. Histologic- or cytologically-documented Non-Small Cell Lung Carcinoma with locally-advanced, unresectable Stage level 3 disease (according to the IASLC Staging Manual Version 8 \\[IASLC 2016\\]). Positron-Emission Tomography (Pet Animal)/X-Ray Computed Tomography, Magnetic Resonance Imaging of the brain, and endobronchial ultrasound with biopsy are highly encouraged at diagnosis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "6. Receipt of SCRT1 gene which must have been completed within 42 days prior to first IP dose administration in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   1. The platinum-based chemotherapy regimen must contain cisplatin or carboplatin and 1 of the following agents: etoposide, vinblastine, vinorelbine, a taxane (paclitaxel or docetaxel), or pemetrexed, according to the local standard of care (SoC) regimens. Platinum-based chemotherapy containing cisplatin or carboplatin and gemcitabine is permitted under certain conditions - refer to bullet point 6(b).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   2. Patients must have received at least 2 cycles of platinum-based chemotherapy before radiation therapy. The interval between administration of the last dose of chemotherapy regimen and start of radiation therapy must be no more than 6 weeks. Consolidation Chemotherapy after radiation is not permitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   (i) If the patient's platinum-based chemotherapy contained gemcitabine, no overlap between chemotherapy and radiation therapy is permitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   (ii) If the patient's platinum-based chemotherapy contained any of the agents listed in (a) other than gemcitabine, an overlap of 1 cycle of chemotherapy and radiation therapy is acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   (c) Patients must have received a total dose of radiation of 60 Gray Units ±10% (54 Gray Units to 66 Gray Units). Sites are encouraged to adhere to mean organ radiation dosing as follows: (i) Mean lung dose \\<20 Gray Units and/or V20 \\<35%; (ii) Mean oesophagus \\<34 Gray Units; (iii) Chest>Heart V45 \\<35% or V30 \\<30%. Note: Sites should be aware of the recent RTOG 0617 Study data demonstrating that doses higher than 60 Gray Units may be associated with greater toxicity and worse efficacy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   (d) Patients with World Health Organization/ECOG PS 2 or chronic lung disease (pulmonary emphysema or chronic obstructive pulmonary disease) must have received a V20 \\<25%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "7. Patients must not have progressed following platinum-based SCRT1 gene, as per Investigator assessed RECIST 1.1 criteria. . In order to assess disease progression, the baseline imaging (X-Ray Computed Tomography/Magnetic Resonance Imaging) used for Special screening finding purposes should be compared against the most recently performed scan that allows physician assessment as per RECIST 1.1 criteria. If an intermediate scan taken between chemotherapy and radiotherapy is available and that scan is suitable for physician assessment as per RECIST 1.1 criteria, then this scan should be used.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   1. Patients with measurable disease and/or non-measurable and/or no evidence of disease (No Evidence of Disease) assessed at baseline by X-Ray Computed Tomography/Magnetic Resonance Imaging will be entered in this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   2. Prior irradiated lesions may be considered measurable and selected as TLs provided they fulfil the other criteria for measurability.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "8. Must have a life expectancy of at least 12 weeks at enrolment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "9. WHO/ECOG performance status ≤2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "10. Adequate organ and marrow function at enrolment as defined below. These parameters should be achieved without augmentation by growth factors, transfusions, or infusions within 14 days of screening unless required for Sense of Coherence:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    1. Haemoglobin ≥9.0 g/dL;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    2. Absolute neutrophil count \\>1.0 × 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    3. Platelet count \\>75 × 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    4. Serum bilirubin measurement ≤1.5 × upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert Disease, who will be allowed in consultation with their physician.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    5. Alanine Transaminase (Antibiotic Lock Therapy) and aspartate aminotransferase (Aspartate aminotransferase measurement) ≤2.5 × Upper Limit of Normal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    6. Measured creatinine clearance \\>40 mL/min or calculated creatinine clearance \\>40 mL/min as determined by Cockcroft-Gault (using actual body weight) (Cockcroft and Gault 1976).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "Males:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "Creatinine clearance (mL/min) = Weight (kg) × (140 Age) 72 × Creatinine measurement, serum (procedure) (mg/dL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "Females:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "Creatinine clearance (mL/min) = Weight (kg) × (140 Age) × 0.85 72 × serum creatinine (mg/dL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "11 Body Weight \\>30 kg at enrolment and first IP dose administration. 12 Ache or female. 13 Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "1. Women \\<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "2. Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": ". Patients with locally-advanced Non-Small Cell Lung Carcinoma whose disease has progressed following platinum based SCRT1 gene.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "2. Patients who have disease considered for surgical treatment as part of their care plan, such as Pancoast Syndrome or superior sulcus tumours.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "3. Mixed small-cell lung cancer and Non-Small Cell Lung Carcinoma histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "4. History of allogeneic organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "5. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[eg, colitis or Crohn Disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Granulomatosis with polyangiitis \\[granulomatosis with polyangiitis, Graves Disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   1. Patients with vitiligo or alopecia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   2. Patients with hypothyroidism (eg, following Hashimoto Disease) stable on hormone replacement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   3. Any chronic skin condition that does not require systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   4. Patients without active disease in the last 5 years at enrolment may be included but only after consultation with the Study Physician.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   5. Patients with celiac disease controlled by diet alone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "6. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, Lung Diseases, Interstitial, serious chronic GI conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring TLE5 gene, or compromise the ability of the patient to give written informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "7. History of another primary malignancy except for:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   1. Malignant Neoplasms treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "   3. Adequately treated carcinoma in situ without evidence of disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "8. History of leptomeningeal carcinomatosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "9. History of active primary immunodeficiency.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "10. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (known positive hepatitis B surface antigen \\[Hepatitis B Antigen Vaccine\\] result), hepatitis C virus (Hepatitis C-Like Viruses), or human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies). Patients with a past or resolved hepatitis B virus (hepatitis B virus) infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of Hepatitis B Antigen Vaccine) are eligible. Patients positive for hepatitis C antibody are eligible only if polymerase chain reaction is negative for Hepatitis C-Like Viruses ribonucleic acid (RNA).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "11. Any unresolved toxicity of NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    1. Patients with Grade ≥2 neuropathy or Grade ≥2 lymphopenia will be evaluated on a case-by-case basis after consultation with the Study Physician.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab (MEDI4736) may be included only after consultation with the Study Physician.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "12. Known allergy or hypersensitivity to durvalumab (MEDI4736) or any of the IP excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "13. Patients who have received Concurrent Chemoradiotherapy for locally-advanced Non-Small Cell Lung Carcinoma, or who received SCALR wt Allele1 gene with at least 2 concomitant CALR wt Allele cycles. Prior surgical resection (ie, Stage level 1 or II) is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    Note: Patients whose platinum-based chemotherapy contained gemcitabine and who received SCRT1 gene with at least 1 concomitant CRT cycle are excluded from this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "14. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "15. Major surgical procedure (as defined by the Research Personnel) within 28 days prior to the first dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    Note: Local surgery of isolated lesions for palliative intent is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "16. Prior exposure to immune-mediated therapy, including but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "17. Current or prior use of immunosuppressive medication within 14 days before the first dose of IP. The following are exceptions to this criterion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    1. Intranasal approach, inhaled, topical steroids, or local steroid injections (eg, intra articular injection);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "    3. Steroids as premedication for hypersensitivity reactions (eg, X-Ray Computed Tomography premedication).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "18. Previous IP assignment in the present study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "19. Concurrent enrolment in another clinical study, unless it is an observational (noninterventional) clinical study or the follow-up period of an interventional study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "20. Participation in another clinical study with an Immunoprecipitation during the 4 weeks prior to the first Immunoprecipitation dose administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "21. Prior randomisation or treatment in a previous durvalumab (MEDI4736) ± tremelimumab clinical study regardless of treatment arm assignment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "22. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "23. Judgment by the Investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "24. Genetic research study (optional):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "Exclusion criteria for participation in the optional (DNA) genetic research component of the study include:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "1. Previous allogeneic bone marrow transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03693300",
    "statement": "2. Non-leukocyte-depleted whole blood transfusion in 120 days of genetic sample collection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "; Arm 2: Patients with Triple-Negative Breast Cancer Finding and one or two prior cytotoxic therapies in the metastatic setting.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Arm A: castrate resistant prostate cancer, advanced breast cancer, or non-small cell lunch cancer that are candidates for treatment with a docetaxel-based combination.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Arm B: Urothelial transitional cell cancer, triple negative breast cancer, ovarian cancer or non small cell lunch cancer that are candidates for a cisplatin-based combination.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Arm C: HER2-positive carcinoma of breast refractory to prior herceptin or lapatinib, her2+ esophagal-gastric cancer, head and neck squamous cell cancer, or non small cell lunch cancer that are candidates for treatment with a dacomitinib-based combination.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not available.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Eastern Cooperative Oncology Group \\[Electrocorticogram\\] performance must be 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Adequate bone marrow, renal and liver function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Prior therapy for cisplatin Combination Expansion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Prior platinum (carboplatin or cisplatin) in either the adjuvant or metastatic setting;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Prior radiation to \\>25% bone marrow as estimated by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Patients with known symptomatic brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Chemotherapy, radiotherapy, biologics or investigational agent within 4 weeks of the lead-in dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* major surgery within 4 weeks of the baseline disease assessments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* \\>2 prior regimens containing cytotoxic chemotherapy in the metastatic setting.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Active bacterial, fungal or viral infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01920061",
    "statement": "* Uncontrolled or significant cardiovascular disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02164461",
    "statement": "* Participants with histologically-confirmed, persistent, metastatic or recurrent squamous or non-squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix with documented disease progression (disease not amenable to surgery or standard radiotherapy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02164461",
    "statement": "* Participants who have received no more than 1 prior cytotoxic treatment regimen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02164461",
    "statement": "* Participant may have received ≤2 prior regimens for the treatment of their metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02164461",
    "statement": "* Participant is able to provide written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02164461",
    "statement": "* Participant must have an Eastern Cooperative Oncology Group (Electrocorticogram) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02164461",
    "statement": "* In the opinion of the investigator, participant has rapidly progressing disease, OR has life expectancy of less than 6 months, OR would be unable to receive at least one cycle of therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02164461",
    "statement": "* Participant has received chemotherapy and/or radiation therapy (except palliative radiation therapy for disease-related pain) within ≤2 weeks of first axalimogene filolisbac infusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02164461",
    "statement": "* Participant has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02164461",
    "statement": "* Has a contraindication to administration of trimethoprim/sulfamethoxazole or ampicillin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02164461",
    "statement": "* Has implanted medical device(s) that pose a high risk for colonization and/or cannot be easily removed (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopedic screw(s), metal plate(s), bone graft(s), or other exogenous implant(s). NOTE: More common devices and prosthetics which include arterial and venous stents, dental and breast implants, and venous access devices (e.g., Port-A-Cath (treatment) or Mediport) are permitted. Sponsor must be contacted prior to consenting any participant who has any other device and/or implant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* Histologic or cytologically confirmed, immunotherapy naïve or PDCD1 wt Allele/CD274 wt Allele pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment. Subjects may be treatment naive or could have received one prior platinum based chemotherapy for non-small cell lung cancer and subjects with a documented activating mutation (e.g., Soluble ErbB-1, anaplastic lymphoma kinase, Rosa) must also have received the appropriate therapy and progressed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* Histologic or cytologically confirmed unresectable or metastatic melanoma that progressed during treatment with an anti-PD-1/PD-L1 therapy and had confirmation of PD\\>=4 weeks later. Subjects with Activating BRAF Mutation could have also received a B-Raf inhibitor (disposition) and/or Mitogen-Activated Protein Kinase Kinase Inhibitor regimen prior to anti-PD-1/PD-L1 therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* Measurable Disease by RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* ECOG performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* Adequate bone marrow, liver and kidney function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* Pregnancy test negative for women of child bearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* Agreement to use effective methods of contraception per the protocol requirements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* Previous exposure to any immunomodulatory agents (e.g., anti- CD40, anti-PD-1/CD274 wt Allele, anti-CTLA-4, IDO inhibitors) except PD-1/CD274 wt Allele targeting agents in the subsets of patients that must have previous treatment with anti-PD-1/CD274 wt Allele therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* Neoplasms, Second Primary (solid or hematologic) within the past 3 years except locally curable cancers that have been apparently cured",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* Active, known, clinically serious infections within the 14 days prior to first dose of investigational product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* Use of systemic corticosteroids or other systemic immunosuppressive drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* Active, known or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* History of interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03123783",
    "statement": "* History of life-threatening toxicity related to prior anti-PD-1/CD274 wt Allele treatment for subjects with metastatic melanoma or Non-Small Cell Lung Carcinoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Signed written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Cytologically or histologically confirmed Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Clinical or radiographic progression during or after first-line chemotherapy or chemoradiotherapy for Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Consent to provide archival tissue for analysis is required for participation in this study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status of 0, 1, or 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Age ≥ 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Use of an acceptable means of contraception for men and women of childbearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* International Normalized Ratio (Integrated Neuromusculoskeletal Release) no greater than 1.3 and an Partial thromboplastin time, activated (procedure) no greater than the upper limits of normal within 28 days prior to enrollment for patients not on low-molecular-weight heparin or fondaparinux",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Squamous cell carcinoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Prior treatment with an investigational or marketed inhibitor of the Epidermal Growth Factor Receptor (Soluble ErbB-1) pathway or anti-angiogenesis agent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Systemic Chemotherapy, radiotherapy, or investigational treatment within 28 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Local palliative radiotherapy within 14 days prior to randomization or persistent adverse effects from radiotherapy that have not resolved to Second grade in elementary school or less following completion of treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Whole brain radiation therapy or stereotactic radiosurgery for brain metastases within 4 weeks of Day 0",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Science of neurosurgery for brain metastases within 24 weeks of Day 0",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Biopsy brain within 12 weeks of Day 0",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Current use of dexamethasone for treatment associated with brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* History of gross hemoptysis within 3 months prior to randomization unless definitively treated with surgery or radiation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* History of any of the following within 6 months prior to Day 0: serious systemic disease, uncontrolled hypertension, unstable angina, New York Heart Association (NYHA) Grade 2 or greater Congestive Heart Failure (CHF), unstable symptomatic arrhythmia requiring medication, clinically significant peripheral vascular disease, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Evidence of bleeding diathesis or coagulopathy or other serious or acute internal bleeding within 6 months prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Central Nervous System (Clinical Nurse Specialists) bleeding; history or clinical evidence of Clinical Nurse Specialists stroke (hemorrhagic or thrombotic) within the last 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Progressive neurologic symptoms in patients with a history of brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Full-dose anticoagulation with warfarin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Chronic daily use of aspirin or other full-dose nonsteroidal anti-inflammatory drugs (Analgesics and non-steroidal anti-inflammatory drugs) with anti-platelet activity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* In-patient surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Minor Surgical Procedures, fine needle aspirations or core biopsy within 7 days prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Anticipation of need for a major surgical procedure during the course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Serious, non-healing wound, ulcer, or bone fracture",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Inability to take oral medication or requirement for intravenous (Intravenous) alimentation or total parenteral nutrition with lipids, or prior surgical procedures affecting absorption",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Pregnancy or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Presence of another invasive cancer within 5 years prior to randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00130728",
    "statement": "* Evidence of confusion or disorientation, or history of major psychiatric illness that may impair the patient's understanding of the Consent Forms or their ability to comply with study requirements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": ". All participants must have tumor tissue available for analysis. If sufficient tissue is not available, participants must undergo a biopsy to obtain adequate samples. For participants in expansion cohorts 2, 3 and 5, for whom failure of prior therapy is specified (crizotinib for cohorts 2 and 5, one epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for cohort 3), tumor tissue must be available following failure of the prior therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "2. Must have measurable disease by Response Evaluation Criteria in Solid Tumors (Response Evaluation Criteria in Solid Tumors).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "3. Male or female participants ≥ 18 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "4. Eastern Cooperative Oncology Group (Electrocorticogram) performance status 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "5. Minimum life expectancy of 3 months or more.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "6. Adequate renal and hepatic function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "7. Adequate bone marrow function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "8. Normal QT interval feature (observable entity) on screening electrocardiogram (Electrocardiography) evaluation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "9. For females of childbearing potential, a negative pregnancy test must be documented prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "10. Female participants who are of childbearing potential and fertile male participants must agree to use an effective form of contraception with their sexual partners throughout study participation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "11. Signed and dated informed consent indicating that the participant has been informed of all pertinent aspects of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "12. Willingness and ability to comply with scheduled visits and study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "Cohort-specific Eligibility Criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "PART 1: Dose Escalation Phase:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "1. Histologic confirmed advanced malignancies. All histologies except leukemia;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "2. Unresponsive to Treatment to available therapies or for whom no standard or available curative treatments exist;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "3. Specimen Source Codes - tumor tissue available for analysis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "PART 2: Expansion cohorts (5 additional cohorts):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "1. Expansion cohort 1: Non-Small Cell Lung Carcinoma (Non-Small Cell Lung Carcinoma) participants whose tumors exhibit anaplastic lymphoma kinase (anaplastic lymphoma kinase) rearrangements and who have not been treated with previous anaplastic lymphoma kinase inhibitors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "i. Histologic or cytologically confirmed Non-Small Cell Lung Carcinoma; ii. Tumor tissue sample available for analysis (see General Eligibility Criterion 1; iii. History of ALK Gene Rearrangement by fluorescence in situ hybridization (SH3PXD2A wt Allele); iv. No prior ALK inhibitor therapy; 2. Expansion cohort 2: Non-Small Cell Lung Carcinoma participants whose tumors exhibit ALK Gene Rearrangements and who are resistant to crizotinib: i. Histologic or cytologically confirmed Non-Small Cell Lung Carcinoma; ii. Tumor tissue sample available for analysis (see General Eligibility Criterion 1); iii. History of ALK Gene Rearrangement by SH3PXD2A wt Allele; iv. Resistant to crizotinib (and have not received any other prior ALK inhibitor therapy); 3. Expansion cohort 3: Non-Small Cell Lung Carcinoma participants whose tumors exhibit an epidermal growth factor receptor EGFR-T790M mutation and who are resistant to 1 prior EGFR TKI: i. Histologic or cytologically confirmed Non-Small Cell Lung Carcinoma ii. Previous treatment with only 1 EGFR TKI for which the last administration was within 30 days of the initiation of brigatinib; iii. Documented evidence of an EGFR-T790M mutation following disease progression on the most recent EGFR TKI therapy; iv. No intervening systemic therapy between cessation of the EGFR TKI and initiating brigatinib; v. Tumor tissue sample available for analysis (see General Eligibility Criterion 1). 4. Expansion cohort 4: Participants with any cancers with abnormalities in ALK or other brigatinib targets. Examples include, but are not limited to, anaplastic large cell lymphoma (Ki-1+ Anaplastic Large Cell Lymphoma), diffuse large-cell lymphoma (Diffuse Large B-Cell Lymphoma), inflammatory myofibroblastic tumors (intramanchette transport), and other cancers with ALK abnormalities, or tumors with ROS1 fusions: i. Histologic confirmed lymphomas and other cancers, with the exception of leukemias; ii. Tumor tissue sample available for analysis (see General Eligibility Criterion 1). 5. Expansion Cohort 5: Non-Small Cell Lung Carcinoma participants whose tumors exhibit ALK Gene Rearrangements and who have active, measurable brain metastases: i. Histologic or cytologically confirmed Non-Small Cell Lung Carcinoma: ii. Tumor tissue sample available for analysis (see General Eligibility Criterion 1); iii. History of ALK Gene Rearrangement by SH3PXD2A wt Allele; iv. Either crizotinib naive or resistant; v. Have at least one measurable brain lesion (≥ 10 mm by contrast enhanced, T1 weighted magnetic resonance imaging \\[cMagnetic Resonance Imaging\\]). Previously treated brain lesions by stereotactic radiosurgery (SMS gene) or surgical resection should not be included as a target or non-target lesion; vi. Previously untreated brain metastases with radiologically documented new or progressing brain lesions. Unequivocal progression of previously treated lesions (non-SMS gene and non-surgically treated lesions) at least 3 months after the last treatment; vii. Neurologically stable. Participants must be on a stable or deceasing dose of corticosteroids and/or have no requirement for anticonvulsants for 5 days prior to the baseline Magnetic Resonance Imaging and for 5 days prior to initiating brigatinib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": ". Received an investigational agent ≤ 14 days prior to initiating brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "2. Received systemic anticancer therapy (including monoclonal antibodies and irreversible TKIs such as afatinib or dacomitinib) or radiation therapy ≤ 14 days prior to initiating brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "   a. Except for a reversible TKI (ie, erlotinib or gefitinib) or crizotinib, which are allowed up to 72 hours prior to initiating brigatinib, provided that the participant is free of treatment-related toxicity that might confound the safety evaluation of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "3. Received any prior agents targeted against anaplastic lymphoma kinase, with the exception of crizotinib, or received more than 1 prior Soluble ErbB-1 Protein-tyrosine kinase inhibitor (disposition).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "   a. Re-challenge with the same Protein-tyrosine kinase inhibitor (disposition) is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "4. major surgery within 28 days prior to initiating brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "5. Metastatic malignant neoplasm to brain that are neurologically unstable or require anticonvulsants or an increasing dose of corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "   1. Participants with previously treated brain metastases without evidence of disease or recurrence are allowed for cohorts 1-4.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "   2. Participants with evaluable but non-measurable, active brain lesions who otherwise meet the criteria for cohort 5 for CNS disorder can be enrolled in other cohorts.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "6. Significant uncontrolled or active cardiovascular disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "7. Uncontrolled hypertension (diastolic blood pressure \\[BP\\] \\> 100 mm Hg; systolic \\> 150 mm Hg).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "8. Prolonged QT interval, or being treated with medications known to cause Torsades de Pointes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "9. History or presence of pulmonary interstitial disease or drug-related pneumonitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "10. Ongoing or active infection. The requirement for intravenous (Intravenous) antibiotics is considered active infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "11. Known history of human immunodeficiency virus (HIV). Testing is not required in the absence of history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "12. Patient currently pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "13. Malabsorption Syndrome or other gastrointestinal illness that could affect oral absorption of brigatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "14. Any condition or illness that, in the opinion of the Investigator, would compromise participant safety or interfere with the evaluation of the safety of the drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01449461",
    "statement": "15. Meningeal Carcinomatosis and spinal cord compression. In the case of suspected meningeal involvement, a negative lumbar puncture prior to study entry is required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02125461",
    "statement": ". Age at least 18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02125461",
    "statement": "2. Documented evidence of Non-Small Cell Lung Carcinoma (locally advanced, Unresectable, Stage level 3)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02125461",
    "statement": "3. Patients must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02125461",
    "statement": "4. World Health Organisation (World Health Organization) Performance Status of 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02125461",
    "statement": "5. Estimated life expectancy of more than 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02125461",
    "statement": ". Prior exposure to any anti-PD-1 or anti-PD-L1 Immunoglobulin complex location, circulating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02125461",
    "statement": "2. Active or prior autoimmune disease or history of immunodeficiency.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02125461",
    "statement": "3. Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02125461",
    "statement": "4. Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02125461",
    "statement": "5. Any unresolved toxicity National Cancer Institute common terminology criteria for adverse events \\>Second grade in elementary school from the prior chemoradiation therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02125461",
    "statement": "6. Active or prior documented inflammatory bowel disease (eg, Crohn Disease, ulcerative colitis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": ". Participation in another clinical study with an Immunoprecipitation during the last 14 days (or a longer period depending on the defined characteristics of the agents used).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "2. Treatment with any of the following: Treatment with an Epidermal growth factor receptor inhibitor w/in 8 days or approximately 5x half-life, whichever is the longer, of the first dose of study treatment; Any cytotoxic chemotherapy, investigational agents or other anticancer drugs w/in 14 days of the first dose of study treatment; major surgery (excluding placement of vascular access) within 4 weeks of the first dose; Radiation therapy (procedure) with a limited field of radiation for palliation within 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation which must be completed within 4 weeks of the first dose of study treatment; Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inhibitors of CYP2C8 protein, human and of CYP3A4 gene (at least 1 week prior) and potent inducers of CYP3A4 gene (at least 3 week prior). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer/inhibitory effects on CYP3A4 gene, CYP2C8 protein, human, and/ or CYP1A2 gene.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "3. Any unresolved toxicities from prior therapy greater than Mild Adverse Event at the time of starting study treatment with the exception of alopecia and Second grade in elementary school, prior platinum-therapy related neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "4. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of the IP until the end of Part A.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "5. Compression of spinal cord or brain metastases unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "7. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: Absolute neutrophil count \\<1.5 x 10\\^9/L; Finding of platelet count \\<100 x 10\\^9/L; Hemoglobin measurement \\<90 g/L; Antibiotic Lock Therapy \\>2.5 x the institutional ULN if no demonstrable liver metastases or \\>5 x institutional ULN in the presence of liver metastases; Aspartate aminotransferase measurement \\>2.5 x institutional ULN if no demonstrable liver metastases or \\>5 x institutional ULN in the presence of liver metastases; Total bilirubin metabolic function \\>1.5 x institutional ULN if no liver metastases or \\>3 x institutional ULN in the presence of documented Gilbert Disease or liver metastases; Creatinine measurement \\>1.5 x institutional ULN concurrent with creatinine clearance \\<50 mL/min (measured or calculated by Cockcroft-Gault formula); confirmation of creatinine clearance is only required when creatinine is \\>1.5 x institutional ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "8. Any of the following cardiac criteria: Mean resting corrected QT interval feature (observable entity) corrected for heart rate using Fridericia's correction factor (QTcF) \\>450 msec obtained from 3 Electrocardiographys; Any clinically important abnormalities in rhythm, conduction or morphology of resting Electrocardiography eg, complete left bundle branch block, third degree heart block, second degree heart block, Finding of electrocardiogram PR interval \\>250 msec; Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval feature (observable entity).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "9. Patients unable to swallow oral medication or patients with Gastrointestinal Diseases or significant GI resection likely to interfere with the absorption of AZD9291.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "10. Past medical history of interstitial lung disease (Lung Diseases, Interstitial), drug-induced Lung Diseases, Interstitial, radiation pneumonitis which required steroid treatment, or any evidence of clinically active Lung Diseases, Interstitial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "11. Women who are breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "12. Patients with a known hypersensitivity to AZD9291 or itranconazole or any of their excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "12. Concomitant medication contraindicated for use with itraconazole (including, but not limited to): cisapride, oral midazolam, nisoldipine, pimozide, quinidine, dofetilide, triazolam, levacetylmethadol (levomethadyl), 3-hydroxy-3-methylglutaryl-coenzyme A (3-hydroxy-3-methylglutaryl-coenzyme A)- reductase inhibitors metabolized by CYP3A4 gene, such as lovastatin and simvastatin, ergot alkaloids metabolized by CYP3A4 gene, such as dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02157883",
    "statement": "13. For optional genetic research: Previous allogenic bone marrow transplant or non-leukocyte depleted whole blood transfusion within 120 days of sample collection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": ". Subjects must have a cytological or histological confirmed diagnosis of adenocarcinoma of the lung.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "2. Subject must be known to be RET Positive (known KIF5B-RET translocation, or other confirmed RET translocations (e.g., CCDC6-RET)) or have an available tumor sample for local or central testing obtained prior to consent (Screen 1). Subjects whose samples need to be submitted for central laboratory testing must be current non-smokers and not known to have mutation in Soluble ErbB-1, K-ras Oncogene, or anaplastic lymphoma kinase.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "3. Subjects may have received up to three prior systemic anticancer treatment regimens for adenocarcinoma of the lung (including adjuvant therapies and tyrosine-kinase inhibitors \\[TKI\\]), unless discussed with the sponsor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "4. Subjects must have a clinically indicated need for systemic chemotherapy for adenocarcinoma of the lung based on the investigator's assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "5. Presence of measurable disease meeting the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "   1. At least one lesion of at least 1.0 cm in the long-axis diameter for a non-lymph node or at least 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) using either computerized tomography (X-Ray Computed Tomography) or magnetic resonance imaging (Magnetic Resonance Imaging). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of at least 1.5 cm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "   2. Lesion previously treated with radiotherapy or locoregional therapy must show radiographic evidence of disease progression to be deemed a target lesion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "6. Subjects with known brain metastases who have completed whole brain radiotherapy, stereotactic radiosurgery, or complete surgical resection will be eligible if they have remained clinically stable, asymptomatic and off of steroids for 28 days.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "7. Adequate bone marrow function, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "   1. Absolute neutrophil count (Absolute neutrophil count) greater than or equal to 1.5 x 10\\^9/L (greater than or equal to 1500/mm\\^3)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "   2. Hemoglobin finding (Hemoglobin) greater than or equal 8.5 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "   3. Platelet count greater than or equal 75 x 10\\^9/L (greater than or equal 75,000/mm\\^3)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "8. Adequate liver function, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "   1. blood bilirubin level test less than or equal 1.5 x upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert Disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "   2. Alanine Transaminase (Antibiotic Lock Therapy), aspartate aminotransferase (Aspartate aminotransferase measurement), and alkaline phosphatase (SLPI protein, human) less than or equal 3 x ULN (less than or equal 5 x ULN if subject has liver metastases). If alkaline phosphatase is greater than 3 x ULN (in absence of liver metastases) or greater than 5 x ULN (in presence of liver metastases) AND the subject also is known to have bone metastases, the liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of total alkaline phosphatase.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "9. Adequate renal function, defined as calculated creatinine clearance greater than 40 mL/min per the Cockcroft and Gault formula.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "10. Adequately controlled blood pressure (bleomycin/cisplatin protocol) with or without antihypertensive medications, defined as bleomycin/cisplatin protocol less than 150/90 mmHg at screening and no change in antihypertensive medications within 1 week before Cycle 1/Day 1 (C1D1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "11. Eastern Cooperative Oncology Group (Electrocorticogram)-Performance Status (phosphatidylserine) of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "12. Survival expectation of 12 weeks or longer after starting study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "13. Males or females aged at least 18 years (or any age greater than 18 years as determined by country legislation) at the time of informed consent (Screen 1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "14. Females must not be breast-feeding or pregnant at Special screening finding or BaseLine dental cement (as documented by a negative beta-human chorionic gonadotropin \\[B-hCG\\] test with a minimum sensitivity of 25 IU/L or equivalent units of B-hCG). A separate baseline assessment is required if a negative Special screening finding pregnancy test was obtained more than 72 hours before the first dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "15. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with surgery at least one month before dosing).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "16. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (e.g., total abstinence, an intrauterine device, a double-barrier method \\[such as condom plus diaphragm with spermicide\\], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the subject must agree to use a double barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "17. Male subjects must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed during the study period and for 30 days after study drug discontinuation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "18. Provide written informed consent (Screen 1 and Screen 2)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "19. Willing and able to comply with all aspects of the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": ". Subjects who have received any anticancer therapy (including surgery, locoregional, biological, immunotherapy, hormonal, or radiotherapy) within 21 days before the first dose of study drug (28 days for investigational therapies).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "2. Metastatic Malignant Neoplasm to the Leptomeninges or brain metastases except as for Inclusion Criterion #6.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "3. Subjects who have not recovered from toxicities as a result of prior anticancer therapy to less than Grade 2 severity per the National Cancer Institute common terminology criteria for adverse events (CTCAE) v4.0, except alopecia and infertility.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "4. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "5. Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "6. Active malignancy (except for adenocarcinoma of the lung or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 24months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "7. major surgery within 3 weeks before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "8. Hemorrhage or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic international normalized ratio (Integrated Neuromusculoskeletal Release) monitoring. (Treatment with low molecular weight heparin is allowed.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "9. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "10. Active infection (any infection requiring treatment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "11. Symptomatic central nervous system (Clinical Nurse Specialists) disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "12. Subjects having greater than 1+ proteinuria on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Subjects with urine protein greater than or equal to 1 g/24-hour will be ineligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "13. Any medical or other condition that in the opinion of the investigator(s) would preclude the subject's participation in a clinical study or would preclude them from completing the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01877083",
    "statement": "14. Scheduled for surgery during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* ≥ 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Histologic or cytologically confirmed stage IIIB not amenable to surgery or curative intent or stage IV Non-Small Cell Lung Carcinoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Disease Progression or recurrence following treatment after last chemotherapy or chemoradiation regimen (completed within the previous 12 months) documented by radiographic assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Measurable Disease by Response Evaluation Criteria for Solid Tumors v1.1 (RECIST v1.1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Adequate bone marrow, renal, and hepatic function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Prothrombin time (procedure) and partial thromboplastin time ≤1.5 x upper limit of normal (Upper Limit of Normal).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Availability of recent (before treatment start) or archival tumor specimens (Phase 2 participants only).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* For female participants, must be postmenopausal, surgically sterile, or must use maximally effective birth control during the period of therapy, and must be willing to use effective contraception up to 6 months after the last dose of study drug and had a negative urine or serum pregnancy test before entry into the study if female participants were of childbearing potential.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* For male participants, must be surgically sterile or willing to use a double barrier contraception method upon enrollment, during the course of the study, and for 6 months following the last investigational drug dose",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Left ventricular ejection fraction (LVEF (procedure)) \\< 45%.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Prior epidermal growth factor receptor (Soluble ErbB-1)-targeted regimen, anti-HER2, anti-HER3, or anti-HER4 therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* More than 2 prior chemotherapy regimens for Non-Small Cell Lung Carcinoma (Phase 2 participants only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* History of other malignancies, except adequately treated nonmelanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* History of corneal disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* History of interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Clinically active brain metastases, defined as untreated symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Participants with treated brain metastases that were no longer symptomatic and required no treatment with steroids could be included in the study if they had recovered from the acute toxic effect of radiotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Uncontrolled hypertension (diastolic \\> 100 mmHg or systolic \\> 140 mmHg).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Clinically significant electrocardiogram changes that obscured the ability to assess the respiratory rate, pulse rate, QT, Corrected QT Interval, and QRS intervals.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Ascites or pleural effusion requiring chronic medical intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Myocardial infarction:Find:Pt:^Patient:Ord within 1 year before enrollment, symptomatic congestive heart failure (New York Heart Association \\> Class II), unstable angina, or unstable cardiac arrhythmia requiring medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Treatment with anticancer therapy, antibody based therapy, retinoid therapy, or hormonal therapy within 4 weeks before study treatment or treatment with nitrosoureas or mitomycin C within 6 weeks before study drug treatment or treatment with small molecule tyrosine kinase inhibitors (TKIs) within 2 weeks before study drug treatment. Prior and concurrent use of hormone replacement therapy was permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Therapeutic radiation or major surgery within 4 weeks before study treatment or palliative radiation therapy within 2 weeks before study drug treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Participated in clinical drug trials within 4 weeks (2 weeks for small molecule TKIs) before study drug treatment. Current participation in other investigational procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* History of hypersensitivity to any of the study drugs or to any excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Concurrent use of Cytochrome P-450 CYP3A4 Inducers or inhibitors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01211483",
    "statement": "* Any known pre-existing condition including substance abuse that could interfere with participant's participation in and completion of the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Histologically-confirmed advanced solid tumor, Lymphoma, Non-Hodgkin or multiple myeloma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Patients have not tolerated or progressed on standard therapy, and no further standard therapy is available",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Archival and screening tumor biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status 0-1 (solid tumors), 0-2 (hematologic malignancy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Prior systemic cancer-directed treatments or investigational drugs within 4 weeks or 5 half lives, whichever is shorter, prior to starting study drug or who have not recovered from side effects of such therapy. Subjects must have recovered from any effects of recent radiotherapy that might confound the safety evaluation of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Symptomatic brain metastases (prior Rx and stable metastases are OK)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Acute or chronic liver or renal disease or pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* rectal discharge diarrhea (physical finding) ≥ Grade 2, impaired GI absorption",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Disorder of cardiac function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Diabetes requiring Rx, glucose \\>126 mg/dL, Glucohemoglobin measurement ≥6.5%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Peripheral Neuropathy ≥ Second grade in elementary school",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Pulmonary Fibrosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Known HIV Infections",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Known chronic hepatitis B or C virus (hepatitis B virus/Hepatitis C-Like Viruses) infection, unless comorbidity in subjects with Hollings Cancer Center",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Patient currently pregnant, inadequate contraception",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01177397",
    "statement": "* Most concurrent second malignancies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* give voluntary, signed informed consent in accordance with institutional policies",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* be non-obese as defined as body mass index (Body mass index)\\< or = 32 and weight \\< 300 pounds (\\< 136 kg)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* have been diagnosed with Stage level 3 or IV Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* be prior to first line chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* planned first line chemotherapy regimen is platinum plus gemcitabine only or platinum plus vinorelbine only or platinum plus pemetrexed only",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* if surgery is part of the cancer treatment, screening for this study should be conducted at least 4 weeks (28 days) after surgery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* life expectancy of \\> 6 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* ECOG performance status \\< or = 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* serum creatinine \\< or = 2.0 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* MALES - age \\> or = 30 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* - FEMALES - age \\>or=30 years and clinically confirmed as postmenopausal.Subjects must have undergone the onset of spontaneous or surgical menopause prior to the start of this study. Spontaneous menopause is defined as the natural cessation of ovarian function as indicated by being amenorrheic for at least 12 months. If the subject has been amenorrheic for \\>or=6 months but \\<12 months they must have a serum FSH concentration of \\>or=50 mIU/mL and an estradiol concentration of \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": " 10 years prior to enrollment and no evidence of active liver disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* currently taking testosterone, oxandrolone (Oxandrin), testosterone-like agents (such as dehydroepiandrosterone (prasterone), androstenedione, and other androgenic compounds including herbals), or antiandrogens; previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the medical monitor for this study to determine appropriate washout period)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* currently taking megestrol acetate (Megace), dronabinol (Marinol), medical marijuana (medical cannabis) or any prescription medication intended to increase appetite or treat unintentional weight loss",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* have a baseline stair climb time \\>or=30 seconds (mean of two stair climbs)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "* have active cancer, other than Non-Small Cell Lung Carcinoma or non-melanoma carcinoma of the skin, within the previous two years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01355497",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00148798",
    "statement": "* Diagnosis:Imp:Pt:^Patient:Nom of histologically or cytologically confirmed Non-Small Cell Lung Carcinoma, stage IIIb with documented malignant pleural effusion or stage IV",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00148798",
    "statement": "* Immunohistochemical evidence of Soluble ErbB-1 expression on tumor tissue",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00148798",
    "statement": "* Presence of at least 1 bi-dimensionally measurable index lesion, whereby index lesions must not lie in an irradiated area",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00148798",
    "statement": "* Previous exposure to monoclonal antibodies, signal transduction inhibitors or EGFR-targeting therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00148798",
    "statement": "* Previous chemotherapy for Non-Small Cell Lung Carcinoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00148798",
    "statement": "* Documented or symptomatic brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00148798",
    "statement": "* Superior Vena Cava Syndrome contra-indicating hydration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00148798",
    "statement": "* Previous malignancy in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00264498",
    "statement": "* Advanced Non Small cell Lung Cell Lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00264498",
    "statement": "* Never received chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00264498",
    "statement": "* Up and about 50% of waking hours",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00264498",
    "statement": "* Spread of lung cancer to the brain",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00264498",
    "statement": "* Low level of white blood cells",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00264498",
    "statement": "* Radiation therapy (procedure) within 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00264498",
    "statement": "Patients were entered to this study, initiated in 2004, before the significance of predictive factors such as smoking history, adenocarcinoma histology and mutation status was described.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": ". Age 18-75 years old, male or female, signed informed consent form",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "2. Advanced NSCLC diagnosed by pathological or clinical physicians",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "3. Eastern Cooperative Oncology Group (Electrocorticogram) performance score ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "4. Participants must have ≥ 1 measurable lesion as defined per RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "5. Participants must have no prior systemic chemotherapy for advanced or metastatic Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "6. Life expectancy ≥ 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "7. Participants must have adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "8. Ache/female is willing to use a highly effective method of birth control",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": ". Diagnosed with Non-Small Cell Lung Carcinoma but with Epidermal Growth Factor Receptor (Soluble ErbB-1)-sensitizing mutation or anaplastic lymphoma kinase (anaplastic lymphoma kinase) gene translocation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "2. Received any approved systemic anticancer therapy within 28 days prior to the initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "3. Received prior treatment with HER1 Antagonists or ALK inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "4. Received prior therapies targeting programmed cell death protein-1 (PDCD1 wt Allele) or programmed cell death protein ligand-1 (CD274 wt Allele)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "5. With history of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "6. Clinically significant pericardial effusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "7. Severe infection, active leptomeningeal disease or uncontrolled, untreated brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "8. Any major surgical procedure ≤ 28 days before randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "9. HIV (HIV) Communicable Diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "10. Participants with untreated hepatitis B or C virus (hepatitis B virus/Hepatitis C-Like Viruses)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "11. Active autoimmune diseases or history of autoimmune diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "12. History of allergic reactions to chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03663205",
    "statement": "NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* Histologic or cytologically confirmed head and neck cancer (MMP8 wt Allele) or unresectable stage IIIb or IV non-small cell lung cancer (Non-Small Cell Lung Carcinoma)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* At least one lesion able to be used for tumor biopsy and to be measured by FDG-PET Scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* Considered suitable for treatment of Non-Small Cell Lung Carcinoma with no prior biological or immunological therapy for disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* Or considered suitable for treatment for metastatic or recurrent MMP8 wt Allele with no prior biological or immunological therapy for disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* Non-Small Cell Lung Carcinoma: Have received more than 2 previous chemotherapy regimens or have received the last chemotherapy or radiotherapy within 28 days of first dose of AZD2171",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* MMP8 wt Allele: Previous chemotherapy or radiotherapy if received 28 days of first dose of AZD2171",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* Untreatable, unstable brain or meningeal metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* Abnormal liver and kidney blood chemistries",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* History of poorly controlled hypertension with resting blood pressure of \\>150/100",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* Recent (\\< 14 days) major surgery or a surgical incision not fully healed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* Diabetes patients with type I insulin dependent diabetes or poorly controlled type II",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* Significant hemorrhage or hemoptysis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00243347",
    "statement": "* Presence of necrotic/hemorrhagic tumor or metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": ". Male or female participants ≥ 18 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "2. Have a pathologically (histology or cytology) confirmed diagnosis of Small cell carcinoma of lung.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "3. Have received and progressed after a platinum-based standard chemotherapy regimen for first line treatment of Small cell carcinoma of lung, either limited stage (LS) or extensive stage (ES).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "4. Have measurable disease within ≤ 2 weeks before randomization. Clear radiographic evidence of disease progression after initial therapy should have been documented.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "5. Eastern Cooperative Oncology Group (Electrocorticogram) Performance Status (phosphatidylserine) of 0 or 1 (phosphatidylserine 0-1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "6. Participants with treated brain metastases (surgery, whole or stereotactic brain radiation) are allowed provided the lesions have been stable for at least 2 weeks and the participant is off steroids or is on a stable dose of steroids. Participants should be without neurologic dysfunction that would confound the evaluation of neurological and/or other TLE5 gene.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": ". Any prior therapy for second-line treatment of Small cell carcinoma of lung.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "2. Participants who relapsed ≥ 180 days after their response to first-line treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "3. Prior treatment with an AURKA protein, human specific-targeted or pan-Aurora-targeted agent, including Alisertib, or any other investigational agent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "4. Prior treatment with paclitaxel or any other taxane agent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "5. Known hypersensitivity to Cremophor® EL, paclitaxel, or its components.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "6. Any comorbid condition or unresolved toxicity that would preclude administration of alisertib or weekly paclitaxel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "7. Prior history of ≥ Grade 2 neurotoxicity that is not resolved to ≤ Grade 1 (qualifier value).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "8. Participants with symptomatic and/or progressive brain metastases or with carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "9. Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of alisertib and during study conduct. Major prohibited enzyme inducers include: phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, and St. John's wort extract.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "10. Inability to Swallow Saliva alisertib or other orally administered medications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "11. Requirement for administration of proton pump inhibitor (Prepulse Inhibition), Histamine H2 Antagonists, or pancreatic enzymes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "12. Diagnosis with or treated for another malignancy within 2 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "13. Other severe acute or chronic medical or psychiatric condition(s) per protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "14. History of myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, any ongoing cardiac arrhythmias of Grade \\> 2, thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg, pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "15. Known history of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "16. Operative Surgical Procedures within 3 weeks (or 2 weeks for a minor surgery) before study enrollment and not fully recovered to baseline or to a stable clinical status.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02038647",
    "statement": "17. Participants who are pregnant, lactating, or do not agree to use effective methods of contraception during the study treatment period through 6 months after the last dose of study drug per protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312377",
    "statement": ".",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312377",
    "statement": "* I have a confirmed diagnosis of locally advanced or metastatic non small cell lung cancer (Stage 3B - IV)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312377",
    "statement": "* I have had 1st line anti-cancer therapy. Previous treatment with Avastin (bevacizumab) in first line NSCLC is allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312377",
    "statement": ".",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312377",
    "statement": "* I do not have non small cell lung cancer (Non-Small Cell Lung Carcinoma)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312377",
    "statement": "* I have received treatment with docetaxel (Taxotere). Prior treatment with paclitaxel is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312377",
    "statement": "* I have received 2nd line anti-cancer therapy (For example, patients with previous 2nd line non small cell lung cancer (Non-Small Cell Lung Carcinoma) treatment with Tarceva (erlotinib, OSI-744), Alimta (pemetrexed) are not eligible)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312377",
    "statement": "* I have been treated with VEGFR-tyrosine kinase inhibitors (Protein-tyrosine kinase inhibitor (disposition)) (sunitinib, sorafenib, other VEGF Protein-tyrosine kinase inhibitor (disposition)). Previous treatment with Avastin (bevacizumab) in 1st line non small cell lung cancer is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312377",
    "statement": "* I have a history of uncontrolled irregular heartbeat",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00312377",
    "statement": "* I have a history of high blood pressure which has not been controlled with medication If you are unsure of the meaning of the inclusion and exclusion criteria above, please contact the call center number for help.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* ECOG performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "Inclusion Criteria for Participant with Early-stage Non-Small Cell Lung Carcinoma:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Participants must have a complete resection of a histologically or cytologically confirmed Stage level 2, IIIA, and selected IIIB (T3-N2) Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* PD-L1 expression CD55 wt Allele ≥ 1% or Tumor Proportion Score ≥ 1%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Participants must have completed adjuvant chemotherapy at least 4 weeks and up to 12 weeks prior to randomization and must be adequately recovered from chemotherapy. For participants in the adjuvant setting, neoadjuvant chemotherapy or chemoradiotherapy is acceptable provided that participants also received adjuvant chemotherapy as per protocol's requirement.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "Inclusion Criteria for Participants with Metastatic non-small cell lung cancer:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Histologic or cytologically confirmed, Stage level 4 non-squamous or squamous Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Life expectancy ≥ 18 weeks in the opinion of the investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* PD-L1 expression CD55 wt Allele ≥ 50% or TPS ≥ 50% or CD55 wt Allele3 or IC3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* No prior systemic treatment for Stage level 4 non-squamous or squamous Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Participants who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from randomization since the last chemotherapy, radiotherapy, or chemoradiotherapy cycle.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* History of malignancy within 5 years prior to initiation of study treatment, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Uncontrolled tumor-related pain",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Participants known to have a sensitizing mutation in the EGFR gene or an ALK fusion oncogene",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* History of leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Uncontrolled or symptomatic hypercalcemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Active or history of autoimmune disease or immune deficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* History of idiopathic pulmonary fibrosis, organizing pneumonia), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (X-Ray Computed Tomography) scan",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "Exclusion Criteria for Participants with Metastatic non-small cell lung cancer:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05171777",
    "statement": "* Symptomatic, untreated, or actively progressing central nervous system (Clinical Nurse Specialists) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": ". Involvement in the planning and/or conduct of the study (applies to both AstraZeneca and Quintiles staff).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "2. Previous enrollment in the present study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "3. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the healthy volunteer at risk because of participation in the study, or influence the results or the healthy volunteer's ability to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "4. History or presence of gastrointestinal, hepatic, or renal disease or surgical procedure or any other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "5. Any clinically significant abnormalities in physical examination, vital signs (supine blood pressure \\>140 mmHg systolic, \\>90 mmHg diastolic, or pulse rate ≤35 or ≥100 beats per minute), or clinical laboratory assessment as judged by the Research Personnel.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "6. Acute illness, surgical procedures, or trauma from within 2 weeks before enrollment until first administration of investigational product (IP).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "7. Voluntary Workers who have received live or live-attenuated vaccine in the 2 weeks prior to dosing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "8. Volunteers with active malignancy or neoplastic disease in the previous 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "9. A suspected/manifested infection according to International Airline Transportation Association (IATA) Categories A and B infectious substances.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "10. Positive results on screening tests for serum hepatitis B surface antigen (Hepatitis B Antigen Vaccine), hepatitis C antibody, or human immunodeficiency virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "11. Any clinically important abnormalities in rhythm, conduction, or morphology of resting Electrocardiography, as judged by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "12. Known or suspected history of significant drug abuse as judged by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "13. Positive screen for drugs of abuse or cotinine (nicotine level above 400 ng/mL) at screening or positive screen for alcohol, drugs of abuse, or cotinine on admission in Period 1 or Period 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "14. History of alcohol abuse or excessive intake of alcohol, defined as regular weekly intake of greater than 21 units of alcohol in men (Note: 1 unit=25 mL spirits, 125 mL wine, or 250 mL beer or lager).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "15. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Research Personnel, or history of hypersensitivity to AZD9291, its excipients, or drugs with a similar chemical structure or class.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "16. History of hypersensitivity to omeprazole, its excipients, or drugs with a similar chemical structure or class.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "17. Use of any prescribed or nonprescribed medication, including drugs with hepatic enzyme-altering properties, such as Hypericum perforatum, antacids, analgesics, herbal remedies, vitamins, and minerals during the 4 weeks (or longer depending on the medication's half-life) prior to the first administration of AZD9291 is not permitted. Occasional use of paracetamol (acetaminophen) and nonsteroidal nasal decongestant is permitted at the discretion of the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "18. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "19. Whole blood unit collection within 1 month of screening or any blood donation/blood loss greater than 500 mL during the 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "20. Use of another new chemical entity (defined as a compound which has not been approved for marketing) or participation in any other clinical study (including methodology studies where no drugs were given) within 3 months of the first administration of IP in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "21. Current smokers or those who have smoked or used nicotine products within the previous 3 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02224053",
    "statement": "22. Planned inpatient surgery, dental procedure, or hospitalisation during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* Male and female subjects with Stage 3B (with malignant pleural effusion or if no pleural effusion is present subjects who are not candidates for combined modality therapy), Stage level 4, or recurrent non-squamous, non-small-cell lung carcinoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* The subject must be aged 18 years or above.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* The subject must have ECOG performance status of 0 or 1 and a life expectancy of at least three months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* Subjects will have measurable disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* The subject must be able to understand the information provided to them and to give written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* Female subjects must be either postmenopausal, surgically sterilized, or using a method of contraception judged reliable by the Investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* Male subjects must be using a method of contraception judged reliable by the Investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* Subjects with squamous cell lung carcinoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* Subjects with lung lesions located centrally in the chest that involve major blood vessels.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix. Subjects with previous malignancies are eligible provided that they have been disease free for five years or more.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* Presence of additional major chronic disease such as hepatic or renal dysfunction, cardiac dysfunction, peripheral vascular disease, evidence of a myocardial infarction within six months of Screening visit, tuberculosis or epilepsy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* Subjects known to be infected with hepatitis B or C virus or HIV-1 or 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00152477",
    "statement": "* Any evidence of serious active infection (ie requiring an iv antibiotic or antiviral agent).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": ". Patients must have advanced malignant solid tumours that are metastatic or unresectable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "2. At least one measurable or evaluable (non-measurable) lesion per RECIST 1.1 Part B only",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "3. Patients must have:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "   1. measurable disease per RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "   2. diagnosis of one of the following",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "* Advanced Non-Small Cell Lung Cancer -Squamous Histology (NSCLC-SQ) with no more than 2 lines of chemotherapy for advanced/metastatic disease ( prior EGFR directed treatment is permitted) or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "* Recurrent/metastatic qualifier Squamous cell carcinoma of Head and neck structure (R/M SCCHN) no more than 2 lines of chemotherapy for advanced disease and no more than 1 line of prior cetuximab permitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "   or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "* Other malignant solid tumours except sarcomas (for metastatic colorectal cancer, only wild type KRAS are permitted) Part A and B",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "4. Age 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "5. Written informed consent that is consistent with ICH-GCP guidelines and local law.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "6. Histologic/Cytologic confirmed diagnosis of malignant solid tumours (exclusion of sarcomas)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "7. advanced disease for whom standard treatment is ineffective or no longer effective",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "8. Recovered from previous therapy related AE to \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "50% or within institutional values",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "* Absolute neutrophil count (Absolute neutrophil count) \\>1500/ mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "* Platelet count \\>75.000/ mm3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "* Estimated creatinine clearance \\> 45ml/ min",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "* Total bilirubin metabolic function\\<1.5 times upper limit of institutional normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "* Aspartate Transaminase (Aspartate aminotransferase measurement) or alanine amino transferase (Antibiotic Lock Therapy) \\<3 x upper limit of institutional normal (ULN) (if related to liver metastases\\< 5xULN)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": ". Chemotherapy, biological therapy or investigational agents within 4 weeks prior to the start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "2. Hormonal anti-cancer treatment within 2 weeks prior to the start of study treatment (continued use of anti-androgens and/or gonadorelin analogues \\[gonadorelin\\] is permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "3. Radiation therapy (procedure) within 4 weeks prior to the start of study treatment, except as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "   1. Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to study treatment, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "   2. Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "4. major surgery (as judged by the investigator) within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "5. Known hypersensitivity to afatinib or the excipients of any of the trial drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "6. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association Classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction:Find:Pt:^Patient:Ord within 6 months prior start treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "7. Female patients of childbearing potential who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "   1. are nursing or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "   2. are pregnant or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "   3. are not using an acceptable method of birth control or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "8. Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "9. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "10. Requiring treatment with any of the prohibited concomitant medications listed in the protocol that can not be stopped for the duration of trial participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "11. Known pre-existing interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "12. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn Disease, ulcerative colitis, chronic diarrhea, malabsorption)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "13. Active hepatitis B infection (defined as presence of Hepatitis B Antigen Vaccine and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hepatitis C Virus RNA Measurement) and/or known HIV carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "14. Prior participation in an afatinib clinical study, even if not assigned to afatinib treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "15. Meningeal Carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "16. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids or have been on stable dose of corticosteroids for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "17. Any SPC listed contra-indications for cetuximab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02020577",
    "statement": "18. Use of alcohol or drugs incompatible with patient participation in the study in the investigator's opinion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": ". Provision of informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "2. Male or female ≥18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "3. Histologic or cytologic confirmed diagnosis of small cell lung cancer, either limited or extensive disease at initial presentation is allowed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "4. Evidence of progressive disease during or following 1 or 2 prior chemotherapy regimens",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "* At least 1 prior regimen must have contained a platinum salt",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "* 'Adjuvant therapy' will constitute a prior treatment regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "* No more than 2 prior regimens are allowed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "5. Measurable disease (only for the phase II portion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "6. Eastern Cooperative Oncology Group (Electrocorticogram) Performance Status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "7. A minimum life expectancy of 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "8. Adequate bone marrow, hepatic and renal function as evidenced by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "* Absolute neutrophil count (Absolute neutrophil count) ≥ 1.5 x 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "* Platelet count ≥ 100 x 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "* Hemoglobin finding ≥ 9.0 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "* Serum bilirubin measurement \\< 1.5 x Upper Limit of Normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "* Aspartate aminotransferase measurement (Aspartate aminotransferase measurement)/Alanine transferase (Antibiotic Lock Therapy) (SGOT - Glutamate oxaloacetate transaminase/Serum Alanine Transaminase Test) \\< 2.5 x ULN for the reference laboratory or \\< 5 x ULN in the presence of liver metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "* Creatinine measurement, serum (procedure) \\< 1.5 x Upper Limit of Normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "9. No 'active' Central nervous system (CNS) metastases (tumor staging). Prior Central nervous system (CNS) metastases (tumor staging) are allowed, provided adequate palliative therapy has been administered and CNS disorder control has been established prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "* A brain MRI scan, ≤ 28 days from day 1, is required",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "10. Woman patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures and who have a negative serum pregnancy test within 1 week prior to initial study treatment. (See Appendix B)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "11. Male patients willing to use adequate contraceptive. (See Appendix B)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "12. At least 21 days must have elapsed prior to day 1 cycle 1, from chemotherapy, radiotherapy, immunotherapy or following major surgery and any surgical incision should be completely healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 for \"limited palliative radiotherapy\", defined as a course of therapy encompassing \\< 25% total bone marrow volume and not exceeding 30 Gy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "13. At least 14 days must have elapsed for chemotherapy regimens, biologic, and targeted therapy given continuously or on a weekly basis with limited potential for delayed toxicity.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": ". Patients who are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "2. Active involvement of the Central Nervous System (Clinical Nurse Specialists).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "3. Uncontrolled infection or systemic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "4. Clinically significant cardiac disease not well controlled with medication (e.g., congestive heart failure, symptomatic coronary artery disease e.g. angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "5. Chemotherapy regimens within the last 21 days (or within 6 weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens, biologic, and targeted therapy given continuously or on a weekly basis with limited potential for delayed toxicity within the last 14 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "6. No concurrent systemic chemotherapy or anticancer biologic therapy is allowed. Note: Patients on hormonal treatment for breast cancer or prostate cancer may continue on treatment and enter into study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "7. Known hypersensitivity to any components of SC16LD6.5 study drug product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "8. Patients with known human immunodeficiency virus (HIV) or hepatitis B surface antigen vaccine or C (active, previously treated or both), a history of solid organ or bone marrow transplantation would generally be considered to have met exclusion criteria, however exceptions may be considered on a case-by-case basis by the medical monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "9. Mental disorders or social or geographic situation that would preclude study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "10. QT interval feature (observable entity) measurement corrected by Fridericia's formula (QTcF) interval of \\>450 msec (males) or \\>470 msec (females)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01450761",
    "statement": "* Extensive-Stage Disease Small cell carcinoma of lung (ED-SCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01450761",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01450761",
    "statement": "* Prior systemic therapy for lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01450761",
    "statement": "* Symptomatic Central Nervous System (Clinical Nurse Specialists) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01450761",
    "statement": "* History of autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Male or female aged 18 or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Diagnosis with histologically confirmed solid tumor located in the peripheral lung",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Not candidate for curative surgery, is unfit for surgery, or does not wish to undergo curative surgery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* May be candidate for, have failed, or does not wish to undergo radiation therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* The tumor is ≤ 3 cm in size and clearly observable in computerized tomography (X-Ray Computed Tomography)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Able to sign an informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Diagnostic of small cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Solid Neoplasm located in central lung",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Presence of concurrent non-solid malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Abnormal blood results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Received chemotherapy/immunotherapy in the last 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Specimen Source Codes - tumor invades a major blood vessel",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Porphyria (disorder) or known hypersensitivity to Photofrin® or porphyrin-like compounds or to any of its excipients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Planned surgical procedure within the next 90 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Coexisting ophthalmic disease likely to require slit-lamp examination within the next 90 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* acute or chronic medical or psychological illnesses that prevent endoscopy procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Patient currently pregnant or intend to become pregnant, breastfeeding or intend to breastfeed during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Received 1-phenyl-3,3-dimethyltriazene during the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Severe impairment of your kidney or liver function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02916745",
    "statement": "* Participates or intends to participate in another drug study (other than observational studies) during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": ". Age 18-75 years old, male or female, and signed informed consent form (International Classification of Functioning, Disability and Health)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "2. Advanced NSCLC diagnosed by pathological or clinical physicians",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "3. Eastern Cooperative Oncology Group (Electrocorticogram) Performance Status (phosphatidylserine) ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "4. Participants must have ≥ 1 measurable lesion as defined per Response Evaluation Criteria in Solid Tumors (Response Evaluation Criteria in Solid Tumors) v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "5. Must be treatment-naive for locally advanced or metastatic squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "6. Life expectancy ≥ 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "7. Participants must have adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "8. Male/Female is willing to use a highly effective method of birth control",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "Key",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": ". Diagnosed with Non-Small Cell Lung Carcinoma but with epidermal growth factor receptors (Soluble ErbB-1)-sensitizing mutation or anaplastic lymphoma kinase (anaplastic lymphoma kinase) gene translocation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "2. Received any approved systemic anticancer therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "3. Received prior treatment with HER1 Antagonists or ALK inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "4. Received prior therapies targeting programmed death 1 (PDCD1 wt Allele) or programmed death ligand 1 (CD274 wt Allele)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "5. With history of interstitial lung disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "6. Clinically significant pericardial effusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "7. Severe infection, active leptomeningeal disease or uncontrolled, untreated brain metastasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "8. Any major surgical procedure before randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "9. HIV Infections",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "10. Untreated hepatitis B virus (hepatitis B virus)/hepatitis C virus (Hepatitis C-Like Viruses)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "11. Active autoimmune diseases or history of autoimmune diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "12. History of allergic reactions to chemotherapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03594747",
    "statement": "NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Participant has provided informed consent/assent prior to initiation of any study specific activities/procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Age greater than or equal to 18 years old at the same time of signing the informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Participants with histologically or cytologically confirmed Small cell carcinoma of lung (Small cell carcinoma of lung) who progressed or recurred following at least 1 platinum-based regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) 0 to 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Participants with treated brain metastases are eligible provided they meet defined criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Adequate organ function as defined in protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* History of other malignancy within the past 2 years with exceptions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* major surgery within 28 days of first dose of tarlatamab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Did not receive therapy or drug for or symptomatic brain metastases and leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Prior anti-cancer therapy, including anti-PD1 or anti-PDL1 antibody therapy: at least 28 days must have elapsed between any prior anti-cancer therapy and the first planned dose of tarlatamab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "Exceptions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Participants who received prior chemotherapy must have completed at least 14 days before the first dose of tarlatamab and all treatment-related toxicity resolved to grade ≤ 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Participants who received prior palliative radiotherapy must have completed at least 7 days before the first dose of tarlatamab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Participants who received prior tarlatamab therapy or prior delta-like ligand 3 (DLL3 gene) x cluster of differentiation 3 (CD3 Antigens) bispecific therapy are not eligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Participants who experienced recurrent grade 2 pneumonitis or severe or life-threatening immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* History of any immune-related colitis. Infectious colitis is allowed if evidence of adequate treatment and clinical recovery exists and at least 3 months interval observed since diagnosis of colitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Participants with evidence of interstitial lung disease or active, non-infectious pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of tarlatamab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* History of solid organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* History of hypophysitis or pituitary dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04885998",
    "statement": "* Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on study. Participants with Diabetes Mellitus, Insulin-Dependent, vitiligo, psoriasis, hypo- or hyper-thyroid disease not requiring immunosuppressive treatment are permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197247",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02197247",
    "statement": "Not Found",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Pathologic diagnosis of Non-Small Cell Lung Carcinoma and current stage IIIB (with pleural effusion) or IV, not curable with conventional therapy. For Arm C, less than or equal to 20 pack-years smoking history and current non smoker. A pack year = number of packs of cigarettes smoked per day x years smoked.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Progression following at least 12 weeks of treatment with Tarceva or gefitinib. (Arms A and B only)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Electrocorticogram (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2 (not declining within past 2 weeks).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Specimen Source Codes - tumor sample available and adequate for analysis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* At least one measurable target lesion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Adequate cardiac, kidney, and liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Adequate blood counts",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* More than 3 prior cytotoxic chemotherapy treatments for relapsed or metastatic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Significant cardiac disease or dysfunction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Prior treatment with anthracyclines with cumulative dose of \\>400 mg/m\\^2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Active central nervous system metastases, as indicated by clinical symptoms and/or progressive growth.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Use of Tarceva or gefitinib within 14 days of treatment day 1 (Arms A and B only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* major surgery, chemotherapy, radiotherapy, investigational drugs, or other cancer therapy within 3 weeks of treatment day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Inability or unwillingness to swallow HKI-272 capsules.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00266877",
    "statement": "* Patient currently pregnant or breastfeeding women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Patients with a histologically or cytologically proven diagnosis of Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Unresectable (locally advanced) stage IIIa or IIIb disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Initial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Life expectancy greater than or equal to 6 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Estimated weight loss less than or equal to 10% in the 3 months before study randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Measurable Disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* 18 years of age or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status of 0 - 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Hemoglobin finding (Hemoglobin concentration) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Absolute neutrophil count (Absolute neutrophil count) greater than or equal to 1.5 x 10\\^9/L without growth factor use in the 2 weeks before study randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Platelet count greater than or equal to 100 x 10\\^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Serum bilirubin measurement less than or equal to 1.5 x institutional upper limit of normal (Upper Limit of Normal)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Creatinine measurement, serum (procedure) less than or equal to 2.0 mg/dL (Note: Patients with a serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Females of childbearing potential: negative serum or urine pregnancy test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Patient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Patients with reproductive capability must agree to practice adequate contraception methods.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Neoplasm Metastasis (MRLN gene)/stage 4 NSCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Pleural or pericardial effusion greater than 100 ml in volume as documented by appropriate imaging (positron emission tomography \\[Pet Animal\\], computed tomography \\[X-Ray Computed Tomography\\] scan or ultrasound). If an effusion greater than 100 ml is documented by cytology to be free from malignancy and the investigator feels the patient is capable of receiving chemo/radiotherapy for their primary disease/ Non-Small Cell Lung Carcinoma, the investigator should discuss the patient with the study physician at Amgen. Effusions smaller than 100 ml would be acceptable, unless the investigator suspects that the effusion is malignant, in which case the effusions should be evaluated by cytology. Sponsor approval must be obtained before patient is randomized.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Plan to remove the tumor surgically before completing the protocol chemo/radiotherapy course",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Shielding of any part of the esophagus during radiotherapy (including posterior spinal cord shielding)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Prior chemotherapy, radiotherapy, or surgery for Non-Small Cell Lung Carcinoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Prior invasive malignancy during the past 3 years other than non-melanomatous skin cancer. Note: Patients with prior surgically-cured malignancies \\[eg, stage I breast cancer or prostate cancer, in-situ carcinoma of the cervix, etc\\] are not excluded; however, sponsor approval must be obtained before patient is randomized.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Presence or history of dysphagia or conditions predisposing to dysphagia (eg, uncontrolled gastroesophageal reflux disease \\[Gastroesophageal reflux disease\\], dyspepsia, etc)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* History of pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Four weeks or less since completion of treatment using an investigational product/device in another clinical study or presence of any unresolved toxicity from previous treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Previous treatment on this study or with a fibroblast growth factor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Known to be sero-positive for HIV (HIV), hepatitis C virus (Hepatitis C-Like Viruses), or hepatitis B virus (hepatitis B virus)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Pregnant or breastfeeding women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Known sensitivity to Escherichia coli derived products",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Compromised ability of the patient to give written informed consent and/or to comply with study procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Refusal to sign an informed consent form to participate in this study, and sign the hospital information release form, if applicable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Unwilling or unable to complete the patient reported outcome (proline) questionnaires",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00094861",
    "statement": "* Psychological, social, familial, or geographical reasons that would prevent regular follow-up",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "Not Found",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": ". Previous IP assignment in the present study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "2. Medical contraindication to etoposide-platinum (carboplatin or cisplatin)-based chemotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "3. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "4. Received prior systemic therapy for ES-SCLC. Patients who have received prior chemoradiotherapy for limited-stage SCLC must have been treated with curative intent and experienced a treatment-free interval of at least 6 months since last chemotherapy, radiotherapy, or chemoradiotherapy cycle from diagnosis of ES-SCLC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "5. Any condition that, in the opinion of the treating physician, would interfere with evaluation of the study drug or interpretation of patient safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "6. Planned consolidation chest radiation therapy. Radiation therapy (procedure) outside of the chest for palliative care (ie, bone metastasis) is allowed but must be completed before first dose of the study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "7. Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "8. History of allogeneic organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "9. Has a paraneoplastic syndrome (Single Nucleotide Polymorphism) of autoimmune nature, requiring systemic treatment (systemic steroids or immunosuppressive agents) or has a clinical symptomatology suggesting worsening of Single Nucleotide Polymorphism.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "10. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[eg, colitis or Crohn Disease\\], diverticulitis with the exception of diverticulosis, systemic lupus erythematosus, sarcoidosis syndrome, or Granulomatosis with polyangiitis \\[granulomatosis with polyangiitis, Graves Disease, rheumatoid arthritis, hypophysitis, and uveitis, etc\\]). The following are exceptions to this criterion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "* Patients with vitiligo or alopecia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "* Patients with hypothyroidism (eg, following Hashimoto Disease) and stable on hormone replacement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "* Any chronic skin condition that does not require systemic therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "* Patients without active disease in the last 5 years may be included but only after consultation with the Study Physician",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "* Patients with celiac disease controlled by diet alone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "11. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring TLE5 gene or compromise the ability of the patient to give written informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "12. History of active primary immunodeficiency.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "13. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (known positive HBV surface antigen \\[Hepatitis B Antigen Vaccine\\] result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of Hepatitis B Antigen Vaccine) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "14. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "* Intranasal approach, inhaled, topical steroids or local steroid injections (eg, intra articular",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "* injection).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "* Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "* Steroids as premedication for hypersensitivity reactions (eg, X-Ray Computed Tomography premedication). Premedication with steroids for chemotherapy is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "15. Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04449861",
    "statement": "16. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from Special screening finding to 90 days after the last dose of durvalumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": ". Adult male or female participants aged \\>=20 years (Japan) or \\>=18 years (United States).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "2. Eastern Cooperative Oncology Group (Electrocorticogram) performance status of 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "3. Has pathologically confirmed metastatic pancreatic adenocarcinoma that has progressed after, at least, a first line of standard systemic chemotherapy for the metastatic disease, OR participants with pathologically confirmed metastatic adenocarcinoma of the colon or rectum who have progressed to at least 2 lines of standard systemic chemotherapy for the metastatic disease, OR participants with pathologically confirmed locally advanced or metastatic sqEC that has progressed after at least a first line of standard systemic therapy for metastatic disease. First-line participants can be enrolled if a platinum doublet is contraindicated or refused by the participants, OR pathologically confirmed locally advanced or metastatic sqNSCLC that has progressed after at least 2 lines of standard systemic therapy for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "4. For the Western safety cohort only: participants with locally advanced or metastatic solid tumor for whom no standard treatment with an established survival benefit is available or if the participant refuses other standard therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "5. For disease-specific cohort participants: measurable disease per RECIST v. 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "6. Left ventricular ejection fraction greater than (\\>) 50% as measured by Extension for Community Healthcare Outcomes or Multiple gated acquisition scanning within 4 weeks before receiving the first dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "7. Recovering from to Grade 1 (qualifier value) or baseline from all toxic effects of previous therapy (except alopecia or neuropathy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "8. Suitable venous access for the study-required blood sampling.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "9. For the Western safety cohort only: willingness to undergo serial skin tissue biopsies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "10. For disease-specific cohort participants: Must have an archival (banked) tumor sample or agree to have a new (fresh) tumor biopsy during the screening period. If a new tumor sample is needed, the disease should be accessible for a nonsignificant risk biopsy procedure (those occurring outside the brain, lung/mediastinum, and pancreas, or obtained with endoscopic procedures not extending beyond the stomach or bowel). For participants in the Western safety cohort, this biopsy is optional.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": ". Participants who require continuous use of proton pump inhibitors (Proton Pump Inhibitors) or histamine-2 (H2) receptor antagonists and participants who are taking Proton Pump Inhibitors within 5 days before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "2. Treatment with clinically significant enzyme inducers, such as phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, or St. John's wort extract within 14 days before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "3. Treatment with any systemic anticancer treatment (including investigational products) within 30 days or 5 half-lives, whichever is shorter, before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "4. History of any of the following within the last 3 months before administration of the first dose of study drug:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "* Ischemic myocardial event including angina requiring therapy and artery revascularization procedures, myocardial infarction, and unstable symptomatic ischemic heart disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "* Ischemic cerebrovascular event, including transient ischemic attack and artery, revascularization procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "* Significant, uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation, or ventricular tachycardia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "* New York Heart Association Class III to IV heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "* Any other cardiac condition that, in the opinion of the investigator, could pose an additional risk for participation in the study (example, pericardial effusion or restrictive cardiomyopathy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "* Baseline prolongation of the QT interval corrected for heart rate (HR) using Fridericia's formula \\[QT interval corrected for heart rate using Fridericia's formula (QTcF); example, repeated demonstration of QTcF interval \\>480 millisecond (ms), history of congenital long QT syndrome, or torsades de pointes\\].",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "5. Hypertensive disease that is unstable or not controlled by medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "6. History of uncontrolled brain metastasis unless:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "* Previously treated with surgery, whole-brain radiation, or stereotactic radiosurgery, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "* RECIL Global Stable Disease in Skin (Global Stable Disease in Skin) for \\>=30 days, without steroid use (or stable steroid dose established for \\>=14 days before the first dose of TAK-931).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "7. Known history of human immunodeficiency virus infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "8. Known hepatitis B virus (hepatitis B virus) surface antigen seropositive or detectable hepatitis C virus (Hepatitis C-Like Viruses) infection viral load. Note: Participants who have positive hepatitis B virus core antibody or hepatitis B virus surface antigen antibody can be enrolled but must have an undetectable hepatitis B virus viral load.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "9. Prior treatment with radiation therapy involving \\>=25% of the hematopoietically active bone marrow within 3 months before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "10. Participants with known microsatellite instability-high (High-Frequency Microsatellite Instability) genotype or known wild type tumor protein 53 (TP53 gene) per local testing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "11. Western Safety Cohort Only: Participants with Japanese heredity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Histologic or cytologically confirmed unresectable malignancy defined as one of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Cohort 1: Relapsing course and/or refractory metastatic melanoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Uveal/ocular melanoma is excluded",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Must have progressed on treatment with an anti-PD-(L)1 Monoclonal Antibody [EPC]. PD-(L)1 treatment progression is defined as meeting all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Has received at least 2 doses of an approved anti-PD-(L)1 mAb",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Has demonstrated disease progression after PD-(L)1 as defined by Response Evaluation Criteria in Solid Tumors Version 1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* RECIL PD has been documented within 12 weeks from the last dose of anti- PD-(L)1 mAb",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Last dose of anti-PD-(L)1 must have been within 90 days prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Participants with a targetable BRAF mutation must have been treated with, been intolerant of, or declined treatment with BRAF/MEK targeted therapy prior to study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Cohort 2: Metastatic Uveal Melanoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Must not have received prior treatment for advanced or metastatic disease except for prior adjuvant/neoadjuvant immunotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* No prior liver-directed therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Cohort 3: metastatic qualifier PD-(L)1-naive melanoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Uveal/ocular melanoma is excluded",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Must not have received prior treatment for advanced or metastatic disease except for prior adjuvant/neoadjuvant immunotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* For participants with a targetable BRAF mutation, prior BRAF/MEK targeted therapy is allowed if completed 4 weeks prior to first dose of study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Cohorts 4 and 5: Non-squamous NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Participants must have stage IV disease per AJCC 8th edition",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* No known driver mutations/alterations mutation for which targeted therapy is available",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Must have non-squamous histology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* No prior therapy for metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* No prior treatment with anti-PD-(L)1 or Programmed Death Ligand 2 Protein agent or an antibody targeting other immuno-regulatory receptors or mechanisms",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Able to provide archival tumor tissue from locations not radiated prior to biopsy. If archival tumor sample is not available a fresh baseline biopsy is required.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) Performance Status score of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Measurable Disease per RECIST v1.1 at baseline",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* History of another malignancy within 3 years of first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Active central nervous system (Clinical Nurse Specialists) metastases and/or carcinomatous meningitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Previous exposure to CD40-targeted therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Currently on chronic systemic steroids in excess of physiologic replacement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* Has had an allogeneic tissue/solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04993677",
    "statement": "* History of autoimmune disease that has required systemic treatment in the past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Signed written informed consent to participate in clinical study of tivantinib",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Male or female participants of the age defined in the original protocol they were enrolled.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status (phosphatidylserine) ≤3 (or ≤2 for tivantinib-naive participants)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Adequate bone marrow function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Absolute neutrophil count (Absolute neutrophil count) ≥1.5 x 10\\^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Hemoglobin finding ≥8.0 Gram per Deciliter (or ≥ 9.0 Gram per Deciliter for tivantinib-naïve participants)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Enrollment within 14 days of the completion of End of Treatment Visit of the original study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Participants, who participated in previous ARQ 197 studies that have reached their designated end-dates, who did not meet discontinuation criteria in their original study, and who may, in the opinion of the Investigator and the Sponsor, benefit from treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Women of childbearing potential must have a negative pregnancy test performed within 14 days of the start of study drug. Both men and women enrolled in this study must agree to use adequate birth control measures while on study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Known or suspected allergy to ARQ 197",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Substance Abuse Problems, medical, psychological or social conditions that may interfere with the participant's participation in the study or evaluation of the study results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Any condition that is unstable or which could jeopardize the safety of the participant and his/her compliance in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* A serious uncontrolled medical disorder/condition that in the opinion of the Research Personnel would impair the ability of the participant to receive protocol therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* Requirement to receive other concurrent chemotherapy (excluding combination therapy defined in original protocol), immunotherapy, radiotherapy, or any other investigational drug while on study. Palliative Radiation Therapy is allowed provided that:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* in the opinion of the Investigator, the participant does not have progressive disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* the radiation field does not encompass a target lesion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01178411",
    "statement": "* no more than 10% of the participant's bone marrow is irradiated",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Histologic or cytologically confirmed metastatic Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Documented radiographic disease progression during or following treatment with platinum-containing chemotherapy and anti-PD-L1/PD-1 antibody, administered concurrently or sequentially for metastatic NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Measurable Disease per RECIST v1.1 outside Clinical Nurse Specialists as assessed by investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Known CD274 wt Allele status or availability of tumor tissue for central CD274 wt Allele testing",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* ECOG performance status score of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Recovery - healing process to baseline or School Grade \\<=1 NCI CTCAE v5.0 from toxicities related to any prior treatments, unless adverse events are clinically nonsignificant and/or stable on supportive therapy in the opinion of the investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Adequate hematologic and end-organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Negative HIV screen at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Negative hepatitis B surface antigen (Hepatitis B Antigen Vaccine) test at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Negative total hepatitis B core antibody (Antibody to hepatitis B core antigen) test at screening, or positive total Antibody to hepatitis B core antigen test followed by a negative hepatitis B virus (hepatitis B virus) DNA test at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Negative hepatitis C virus (Hepatitis C-Like Viruses) antibody test at screening, or positive Hepatitis C-Like Viruses antibody test followed by a negative Hepatitis C-Like Viruses RNA test at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Prior therapy with the following agents for Non-Small Cell Lung Carcinoma: cabozantinib, docetaxel, Combination of an anti-PD-L1/PDCD1 wt Allele antibody concurrently with a Recombinant Vascular Endothelial Growth Factor (endothelial growth factor A, vascular)R targeting Protein-tyrosine kinase inhibitor (disposition) (Protein-tyrosine kinase inhibitor (disposition))",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Treatment with investigational therapy within 28 days prior to initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Documentation of known sensitizing mutation in the EGFR gene or ALK fusion oncogene",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Patients with known ROS1 rearrangements, BRAF V600E mutations, or other actionable oncogenes with approved therapies if available",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Symptomatic, untreated, or actively progressing Central nervous system (CNS) metastases (tumor staging)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* History of leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Uncontrolled tumor-related pain",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (more frequently than once monthly)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Severe hepatic impairment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Uncontrolled or symptomatic hypercalcemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Any other active malignancy at the time of initiation of study treatment or diagnosis of another malignancy within 3 years prior to initiation of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, incidental prostate cancer, or carcinoma in situ of the prostate, cervix, or breast",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Stroke (heart beat), transient ischemic attack, myocardial infarction or other symptomatic ischemic events within 6 months of initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Significant vascular disease within 6 months of initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Active tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion on the investigator, could impact patient safety",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* treatment - ActInformationManagementReason with therapeutic oral or Intravenous antibiotics within 2 weeks prior to initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Current treatment with anti-viral therapy for hepatitis B virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Major surgical procedure, other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Patient currently pregnant or lactating females, or intention of becoming pregnant during the treatment with atezolizumab in combination with cabozantinib in the experimental arm or during the treatment with docetaxel in the control arm, or within 5 months after the final dose of atezolizumab and/or 4 months after the final dose of cabozantinib, whichever is later.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Ongoing School Grade \\>= 2 sensory or motor neuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, granulomatosis with polyangiitis, Sjogren's Syndrome, Guillain-Barre Syndrome, or multiple sclerosis with the following exceptions: Patients with a history of autoimmune-mediated hypothyroidism who are on thyroid replacement hormone are eligible for the study. Patients with controlled Diabetes Mellitus, Insulin-Dependent are eligible for the study. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only are eligible for the study provided all of following conditions are met: Rash must cover \\< 10% of body surface area.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Pharmacologically uncompensated, symptomatic hypothyroidism",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (X-Ray Computed Tomography) scan",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Prior allogeneic stem cell or solid organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Administration occupational activities of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions: Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication are eligible for the study after Medical Monitor confirmation has been obtained. Patients who received mineralocorticoids, inhaled or low-dose systemic corticosteroids for ARCN1 gene or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Known hypersensitivity to Chinese Hamster Ovary Cell products or to any component of the atezolizumab formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Known allergy or hypersensitivity to any component of the cabozantinib formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* History of severe hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Concomitant anticoagulation with coumarin agents, direct thrombin inhibitor dabigatran, direct factor Xa inhibitor betrixaban, or platelet inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* History of risk factors for torsades de pointes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Corrected QT interval feature (observable entity) corrected through use of Fridericia's formula (QTcF) \\> 480 ms per Electrocardiography within 14 days before initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Uncontrolled hypertension defined as systolic blood pressure \\> 150 mm Hg or diastolic BP \\> 90 mm Hg despite optimal antihypertensive treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Neoplasms invading the Gastrointestinal tract structure, active peptic ulcer disease, acute pancreatitis, acute obstruction of the pancreatic or biliary duct, appendicitis, cholangitis, cholecystitis, diverticulitis, gastric outlet obstruction, or inflammatory bowel disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* abdominal fistula, bowel obstruction, Gastrointestinal perforation, or intra-abdominal abscess within 6 months before initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Known cavitating pulmonary lesion(s) or known endobronchial disease manifestation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Lesion invading major pulmonary blood vessels",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Clinically significant hematuria, hematemesis, hemoptysis of \\> 0.5 teaspoon (2.5 mL) of red blood, coagulopathy, or other history of significant bleeding within 3 months before initiation of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Serious non-healing wound/ulcer/bone fracture",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Malabsorption Syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption are also excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Requirement for hemodialysis or peritoneal dialysis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04471428",
    "statement": "* Inability to Swallow Saliva tablets",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Histologic or cytologically documented, locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Evaluable Disease or disease measurable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Life expectancy \\> or = 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Adequate hematologic and end organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* For female patients of childbearing potential and male patients with partners of childbearing potential, use of an effective form of contraception with continued use for study duration and up to 3 months or more following discontinuation of treatment drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* fluorodeoxyglucose F18 positron emission tomography (FDG-Positron Emission Tomography) avid disease on baseline scan",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "For enrollment in part 2, patients must meet all of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Measurable Disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* No more than four prior systemic therapies for locally advanced or metastatic cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* History of prior significant toxicity from another Mitogen-Activated Protein Kinase Kinase Inhibitor or ERK Inhibitor requiring discontinuation of treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Evidence of visible retinal pathology as assessed by ophthalmologic examination that is considered a risk factor for retinal vein thrombosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* History of glaucoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Physiologic Intraocular Pressure \\> 21 mmHg as measured by tonometry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Predisposing factors to retinal vein occlusion (Retinal Vein Occlusion)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* History of Retinal Vein Occlusion, Neurosensory retinal detachment, or neovascular macular degeneration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Hypersensitivity or hypersensitivity to components of the cobimetinib or GDC-0994 formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Palliative Radiation Therapy within 2 weeks prior to first dose of study-drug treatment in Cycle 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Therapies, Investigational within 4 weeks prior to first dose of study-drug treatment in Cycle 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Major surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study-drug treatment in Cycle 1, or anticipation of the need for major surgery during the course of study treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Anti-cancer therapy within 28 days prior to the first dose of study-drug treatment in Cycle 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Current severe, uncontrolled systemic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* History of clinically significant cardiac dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* History of myocardial infarction within 6 months prior to the first dose of study-drug treatment in Cycle 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* History of congenital long QT syndrome or Corrected QT Interval \\> 470 msec",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* LVEF (procedure)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* History of malabsorption or other condition that would interfere with enteral absorption",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Clinically significant history of liver disease, current alcohol abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C virus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Any condition requiring warfarin or thrombolytic anticoagulants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Active autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Uncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive weeks prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Pregnancy, lactation, or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02457793",
    "statement": "* No other history of or ongoing malignancy that would potentially interfere with the interpretation of the Pharmacodynamics (ITMIG MRECIST Progressive Disease) or efficacy assays",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02998528",
    "statement": "* Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02998528",
    "statement": "* Lung function capacity capable of tolerating the proposed lung surgery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02998528",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) Performance Status of 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02998528",
    "statement": "* Available tissue of primary lung tumor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02998528",
    "statement": "* Presence of locally advanced, inoperable or metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02998528",
    "statement": "* Participants with active, known or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02998528",
    "statement": "* Prior treatment with any drug that targets T-Lymphocyte co-stimulations pathways (such as checkpoint inhibitors)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02998528",
    "statement": "Other protocol defined inclusion/exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03329911",
    "statement": ". Stage level 4 Non-Small Cell Lung Carcinoma or recurrent disease (any Stage at initial diagnosis) no longer amenable to curative surgery or local therapy (histologically or cytologically confirmed).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03329911",
    "statement": "2. No prior systemic therapy for metastatic disease. Prior systemic therapy and/or radiotherapy for locally advanced disease is permitted if completed ≥ 6 months prior to randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03329911",
    "statement": "3. Neoplasms without activating Soluble ErbB-1 or ALK mutation. Patients with unknown mutation status or known activating Soluble ErbB-1 or ALK mutation may be included provided the corresponding targeted agent is not available and chemotherapy is the standard of care of the study center.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03329911",
    "statement": "4. At least one measurable target lesion according to RECIST 1.1 (Appendix 13.4) as confirmed by KCNJ5 protein, human; bone only and brain-only metastases are not allowed. Lesions previously treated with radiotherapy are non-target lesion.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03329911",
    "statement": "5. ECOG performance status of 0 or 1 and life expectancy \\> 3 months based on Investigator's judgment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03329911",
    "statement": ". Diagnosis of Small cell carcinoma of lung, mixed predominant Squamous cell carcinoma of lung, Non-Small Cell Lung Carcinoma not otherwise specified.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03329911",
    "statement": "2. Tumour cavitation, tumor invading into large blood vessels or close to large vessels with an increased risk of bleeding, according to Investigator's judgment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03329911",
    "statement": "3. Prior therapy with monoclonal antibodies or small molecule inhibitors against endothelial growth factor A, vascular or endothelial growth factor A, vascularR, including Avastin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03329911",
    "statement": "4. Prior systemic therapy for metastatic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03329911",
    "statement": "5. Prior systemic anticancer therapy, or radiotherapy for locally advanced nsNSCLC if completed \\< 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03329911",
    "statement": "6. Previous malignancy other than Non-Small Cell Lung Carcinoma in the last 5 years except for basal cell cancer of the skin or pre invasive cancer of the cervix.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Locally advanced or metastatic non-small cell lung cancer (stage IIIB or IV by American Joint Committee on Cancer \\[American Joint Committee on Cancer (tumor staging)\\])",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Documented ALK Gene Rearrangement based on United States Food and Drug Administration (United States Food and Drug Administration)-approved test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Prior treatment with crizotinib and progression according to response evaluation criteria in solid tumors version 1.1 (Response Evaluation Criteria in Solid Tumors Version 1.1) criteria. Participants had to have a minimum 1-week wash-out period between the last dose of crizotinib and the first dose of study treatment. Participants can either be chemotherapy-naïve or have received at least one line of platinum-based chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Adequate hematologic, hepatic, and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Participants with brain or leptomeningeal metastases are allowed if protocol defined criteria are met",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Measurable Disease according to RECIST v1.1 prior to administration of first dose of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Receipt of any other ALK inhibitors in addition to crizotinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Receipt of any prior cytotoxic chemotherapy for Anaplastic lymphoma kinase fusion oncogene positive non-small cell lung cancer within 4 weeks prior to the first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Participants who received crizotinib or any other tyrosine kinase inhibitors need to have a minimum 1-week washout period before the first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Active or uncontrolled infectious diseases requiring treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* National Cancer Institute National Cancer Institute common terminology criteria for adverse events version 4.03 (NCI CTCAE v4.03) grade 3 education level or higher toxicities due to prior therapy that have not shown improvement and are considered to interfere with current study medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* History of organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Co-administration of anti-cancer therapies other than those administered in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Baseline corrected Q-T interval (Corrected QT Interval) greater than (\\>) 470 milliseconds, or baseline symptomatic bradycardia (less than 45 heart beats per minute)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Pregnant or breastfeeding women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Known HIV (HIV) positivity or Acquired Immunodeficiency Syndrome (Acquired Immunodeficiency Syndrome)-related illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* History of hypersensitivity to any of the additives in the alectinib formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01801111",
    "statement": "* Any clinically significant concomitant disease or condition that could interfere with, or for which treatment might interfere with, the conduct of the study, or absorption of oral medications, or that would, in the opinion of the principal investigator, pose an unacceptable risk to the participant in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Histologic or cytologically confirmed locally advanced or metastatic stage IIIB or stage IV Non-Small Cell Lung Carcinoma receiving 21-day cycles of gemcitabine/carboplatin or gemcitabine/cisplatin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Life expectancy ≥ 12 weeks at the time of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Thrombocytopenia as evidenced by a platelet count ≤ 50 x 10\\^9/L during the qualifying cycle of chemotherapy, OR platelet count \\< 100 x 10\\^9/L on Day 22 of the qualifying cycle (for eligibility inclusion: ability to receive the same dose of chemotherapy on study), this criteria ensures that the patient must be dose delayed for platelet recovery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Ability to receive the same dose and schedule of chemotherapy during the first on-study treatment cycle as was given in the qualifying cycle (except Day 8 gemcitabine)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Absolute neutrophil count (Absolute neutrophil count) ≥ 1,000/µL, hemoglobin ≥ 9.5 g/dL, and platelet count ≥ 100 x 10 \\^9/L on Day 1 of the first on study chemotherapy treatment cycle",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status of 0 to 2 at the time of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Adequate Liver function; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\< 3.0 x upper limit of normal (ULN) (except for patients with a confirmed diagnosis of Gilbert Disease)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Adequate renal function; serum creatinine \\< 1.5 x Upper Limit of Normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Receipt of \\> 1 prior systemic chemotherapy regimen",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Septicemia, disseminated coagulation or any other condition (i.e. immune \\[idiopathic\\] thrombocytopenic purpura \\[Inosine Triphosphate\\], thrombotic thrombocytopenic purpura \\[Purpura, Thrombotic Thrombocytopenic\\], hemolytic uremic syndrome \\[Hemolytic-Uremic Syndrome\\]) that may exacerbate thrombocytopenia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* History of unstable angina, congestive heart failure, uncontrolled hypertension (diastolic \\> 100 mmHg), uncontrolled cardiac arrhythmia, or recent (within 1 year of screening ) myocardial infarction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 1 year of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* History of pulmonary embolism or other venous thrombosis within 1 year of screening (except for catheter-related clots)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Use of any nitrosourea or mitomycin-C within 6 weeks of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Have received any thrombopoietic growth factor or related substance",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Have received granulocyte macrophage colony stimulating factor (CSF2 protein, human) within the last 4 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Have received any experimental therapy within 4 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Have ever received a bone marrow or peripheral blood stem cell infusion (within 1 year of screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00413283",
    "statement": "* Known hypersensitivity to any recombinant Escherichia coli-derived product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have a diagnosis of Non-Small Cell Lung Carcinoma with at least 1 measurable lesion assessable using standard techniques by the Response Evaluation Criteria in Solid Tumors Version 1.1 (Response Evaluation Criteria in Solid Tumors Version 1.1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have T790M-positive status using a test validated and performed locally after disease progression on Soluble ErbB-1 tyrosine kinase inhibitor (Protein-tyrosine kinase inhibitor (disposition)) treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have ECOG performance status (ECOG performance status) of 0 or 1 at the time of enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have serum albumin that is ≥25 grams per liter at the time of enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have adequate organ function, with all screening labs performed within 7 days of treatment initiation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have a life expectancy of ≥3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have resolution, except where otherwise stated in the inclusion criteria, of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 by National Cancer Institute National Cancer Institute common terminology criteria for adverse events (National Cancer Institute common terminology criteria for adverse events) Version 4.0.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Previous treatment with an EGFR monoclonal antibody (except for past treatment for squamous cell carcinoma of head and neck or metastatic colorectal cancer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Previous treatment with osimertinib or third generation EGFR TKIs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Participants with symptomatic or growing brain metastases less than 4 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* History of drug-induced interstitial lung disease (Lung Diseases, Interstitial), Lung Diseases, Interstitial, or radiation pneumonitis requiring treatment with steroid prior to study enrollment, or any evidence of clinically active Lung Diseases, Interstitial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment. Participants with a history of gross hemoptysis (defined as bright red blood of ≥1/2 teaspoon) within 2 months prior to enrollment are excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have experienced any arterial thrombotic event or arterial thromboembolic event, including myocardial infarction, unstable angina (history or evidence of current clinically relevant coronary artery disease of current ≥Class III as defined by Canadian Cardiovascular Society Angina Grading Scale or congestive heart failure of current ≥Class III as defined by the New York Heart Association), cerebrovascular accident, or transient ischemic attack, within 6 months prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have a history of deep vein thrombosis, pulmonary embolism, or any other significant venous thromboembolism (venous catheter thrombosis or superficial venous thrombosis not considered \"significant\") during the 3 months prior to study enrollment. Participants with venous thromboembolism occurring 3 to 6 months prior to study enrollment are allowed, if being treated with low molecular weight heparin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have a history of gastrointestinal perforation and/or fistula within 6 months prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (hemicolectomy or extensive small intestine resection with chronic diarrhea), Crohn Disease, ulcerative colitis, or chronic diarrhea.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have uncontrolled hypertension, as defined in CTCAE Version 4.0, prior to initiating study treatment, despite antihypertensive intervention. CTCAE Version 4.0 defines uncontrolled hypertension as Grade \\>2 hypertension; clinically, the participant continues to experience elevated blood pressure (systolic \\>160 millimeters of mercury \\[mmHg\\] and/or diastolic \\>100 mmHg) despite medications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Are receiving chronic therapy with any of the following medications within 7 days prior to enrollment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Anti-Inflammatory Agents, Non-Steroidal (Analgesics and non-steroidal anti-inflammatory drugs; such as indomethacin, ibuprofen, naproxen, or similar agents).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* other anti-platelet agents (such as clopidogrel, ticlopidine, dipyridamole, or anagrelide).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have radiologically documented evidence of major blood vessel invasion or encasement by cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have radiographic evidence of pulmonary intratumor cavitation, regardless of tumor histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Are receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or targeted therapy or radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have abnormal cardiac findings.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "* Have undergone chest irradiation within 2 weeks prior to study drug administration, have not recovered from all radiation-related toxicities, or requires corticosteroids. A 2-week washout is permitted for focal palliative radiation to non-central nervous system disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "- For Parts 1-4:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Histologically confirmed diagnosis of a locally advanced (not amenable to curative therapy such as surgical resection) or metastatic solid tumors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Life expectancy \\> 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Patients must not have received prior interleukin-2 (Interleukin-2) therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Measurable Disease per RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Patients with stable brain metastases under certain criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Fresh and archival tumor tissue available Tumor specific inclusion criteria may apply.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "- For Parts 1-4:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Use of an investigational agent or an investigational device within 28 days before administration of first dose of NKTR--214",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Females who are pregnant or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Participants who have an active autoimmune disease requiring systemic treatment within the past 3 months or have a documented history of clinically severe autoimmune disease that requires systemic steroids or immunosuppressive agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* History of organ transplant that requires use of immune suppressive agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Active malignancy not related to the current diagnosed malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "* Participants who have had \\< 28 days since the last chemotherapy, biological therapy, or \\< 14 days from approved tyrosine kinase inhibitor (Protein-tyrosine kinase inhibitor (disposition)) therapy, or systemic or inhaled steroid therapy at doses greater than 10mg of prednisone Specimen Source Codes - tumor specific exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02983045",
    "statement": "Other protocol defined inclusion/exclusion criteria may apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": ". Patients ≥ 18 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "2. Patients with an Eastern Cooperative Oncology Group (Electrocorticogram) Performance Status score of 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "3. Patients with a life expectancy of ≥ three months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "4. Patients with adequate renal function as evidenced by serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance ≥ 40 mL/min per the Cockcroft and Gault formula.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "5. Patients with adequate bone marrow function as evidenced by absolute neutrophil count (Absolute neutrophil count) ≥ 1.5 × 10\\^9/L, hemoglobin ≥ 10.0 g/dL (this may have been corrected by transfusion or growth factors) and platelet count ≥ 100 × 10\\^9/L.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "6. Patients with adequate liver function as evidenced by bilirubin ≤ 1.5 mg/dL and alkaline phosphatase (SLPI protein, human), alanine transaminase (Antibiotic Lock Therapy) and aspartate aminotransferase (Aspartate aminotransferase measurement) ≤ 3 times the upper limits of normal (ULN) (in the case of liver metastases ≤ 5 x ULN), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase. to assess the liver function instead of the total alkaline phosphatase.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "7. Patients willing and able to comply with the study protocol for the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "8. Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "For patients in the dose finding phase, the following additional inclusion criteria must be fulfilled:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "1. Patients with pathologically diagnosed, histologically or cytologically confirmed advanced solid tumor, that has progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "2. Patients with disease progression despite standard therapy or have disease for which no standard therapy exists.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "3. Patients with ≤ Second grade in elementary school chemotherapy or radiation-related toxicities except alopecia.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "For Non-Small Cell Lung Carcinoma patients at the Metatropic dwarfism, the following additional inclusion criteria must be fulfilled:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "1. Patients with pathologically diagnosed, histologically or cytologically confirmed advanced NSCLC (Stage 3B or IV) with measurable disease, not amenable to surgical or radiation treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "2. Patients with no prior chemotherapy for Non-Small Cell Lung Carcinoma including neoadjuvant or adjuvant treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": ". Patients are excluded if they have received any of the following within three weeks prior to first study treatment: investigational drugs, immunotherapy, gene therapy, hormone therapy (except leuprolide, and megestrol acetate for appetite stimulation), other biological therapy, chemotherapy or radiation. Patients with major surgery without full recovery or major surgery within 3 weeks prior to first study treatment are also excluded. Patients must have recovered from any previous major therapy-related toxicity (grade 3 education level or 4) to \\< Second grade in elementary school at study entry (except for neuropathy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "2. Patients who have received radiation ≤ 3 weeks prior to study enrollment, whose marrow exposure has exceeded 30% or who have not recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "3. Patients who have received prior high dose chemotherapy with hematopoietic stem cell rescue or stem cell or bone marrow transplant in the past two years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "4. Patients with pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "5. Patients with active symptomatic brain metastases. Patients with central nervous system (Clinical Nurse Specialists) metastases are considered eligible if they have had adequately treated brain metastases, ie, have completed treatment (tapered off steroids) at least four weeks before starting treatment with E 7389. Patients who have no evidence that the metastases are symptomatic or actively growing (no evidence of midline shift on computed tomography scan or magnetic resonance imaging) may be enrolled without initiation of local therapy for the Clinical Nurse Specialists metastases. In this case, a repeat scan must be performed within four weeks of the original scan to ensure that disease progression is not occurring. It is not the intention of this study to treat patients with active brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "6. Patients with meningeal carcinomatosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "7. Patients who require therapeutic anti-coagulant therapy with warfarin or related compounds.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "8. Women who are pregnant or breast-feeding. Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the investigator (e.g., using 2 forms of contraception including a barrier method). Perimenopausal state women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "9. Fertile men who are not willing to use contraception or fertile men with a female partner who is not willing to use contraception.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "10. Patients with severe/uncontrolled intercurrent illness or infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "11. Patients with significant cardiovascular impairment (history of congestive heart failure \\> New York Heart Association Grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "12. Patients with organ allografts.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "13. Patients who have a history of positive testing for HIV and/or have active hepatitis B or active hepatitis C at study entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "14. Patients with pre-existing neuropathy \\> Second grade in elementary school.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "15. Patients with a hypersensitivity to halichondrin B and/or to a halichondrin B chemical derivative.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "16. Patients who participated in a prior E 7389 clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "17. Patients with other significant disease or disorders that, in the investigator's opinion, would exclude the patient from the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "For Non-Small Cell Lung Carcinoma patients at the Metatropic dwarfism, the following additional exclusion criterion must be fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00268905",
    "statement": "1. Patients who have had a prior malignancy, other than carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated ≥ five years previously with no subsequent evidence of recurrence.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": ". Patients aged 20 years or older at the date of informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": "2. Patients with body surface area (serum albumin, bovine)\\<1.5 m2 at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": "3. Patients with histologically/cytologically confirmed locally advanced or metastatic adenocarcinoma subtype non-small cell lung cancer (Non-Small Cell Lung Carcinoma) after failure of first line platinum-based chemotherapy (patients with non-target lesion only are eligible) First line chemotherapy may include continuation or switch maintenance therapy. One prior adjuvant and/or neoadjuvant chemotherapy is accepted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": "4. Patients who have life expectancy of at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": "5. Patients who are Eastern Cooperative Oncology Group (Electrocorticogram) performance status (phosphatidylserine) of 0 or 1 at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": "6. Patients obtained written informed consent in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP)and Japanese GCP",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": ". Patients who have received more than one prior line of chemotherapy (i.e., second or third line chemotherapy) for advanced or metastatic Non-Small Cell Lung Carcinoma (Prior monotherapies with an epidermal growth factor receptor tyrosine kinase inhibitors \\[EGFR-TKI\\]) or anaplastic lymphoma kinase (ALK) inhibitor can be allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": "2. Patients who have received previous therapy with other vascular endothelial growth factor (endothelial growth factor A, vascular) or vascular endothelial growth factor receptor (endothelial growth factor A, vascularR) inhibitors (other than bevacizumab) for the treatment of Non-Small Cell Lung Carcinoma at any time",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": "3. Patients who have received following treatments within 4 weeks prior to start of study therapy 1) Other investigational drugs 2) Chemo-, hormone-, immunotherapy, or monoclonal antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": "4. Patients who have received molecular target therapy including EGFR TKIs and ALK inhibitors within 2 weeks prior to start of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": "5. Patents who have received radiotherapy within the past 3 months (in the case of limited -field \\[e.g. brain or bone metastasis\\] radiotherapy with palliative intent), within 2 weeks) prior to start of study therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": "6. Patients who not recovered clinically relevant therapy related toxicities from previous chemotherapy and/or radiotherapy (=CTCAE grade 2 Adverse Event from previous treatment) at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02300298",
    "statement": "further exclusion criteria may be applied",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* Histologically confirmed, locally advanced, not amenable to curative therapy, or metastatic Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* ALK-rearrangement confirmed by the United States Food and Drug Administration (United States Food and Drug Administration) approved test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* Non-Small Cell Lung Carcinoma that has failed crizotinib treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* Measurable Disease as defined by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status less than or equal to (\\<=) 2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* Adequate hematologic, hepatic and renal function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* Prior therapy with ALK Inhibitor other than crizotinib",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* Head>Brain or leptomeningeal metastases that are symptomatic and/or requiring treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* History of serious cardiac dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* History of or current active infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* Clinically significant gastrointestinal abnormality that would affect absorption of the drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871805",
    "statement": "* Patient currently pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": ". Pathologically confirmed diagnosis of Stage 3B or Stage level 4 adenocarcinoma of the lung, with EGFR mutations-positive status, who are not eligible to receive surgery or chemoradiotherapy. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology, and is a suitable candidate for EGFR-TKI monotherapy, in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "2. Patients must have Epidermal Growth Factor Receptor (Soluble ErbB-1) mutation-positive status according to the institutional standard of care.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "3. Patient received no more than one (1) prior chemotherapy for locally advanced or metastatic adenocarcinoma of the lung.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "4. Male or female patients Age 18 years and older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "5. Eastern Cooperative Oncology Group (Electrocorticogram) performance status 0 or 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "6. Adequate organ function, defined as all of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "* Left ventricular ejection fraction (LVEF (procedure)) of above 50% or within institution normal values",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "* Absolute neutrophil count (Absolute neutrophil count) above 1500 / mm3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "* Platelet count above 75,000 / mm3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "* Estimated creatinine clearance more than 45ml / min.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "* Total bilirubin metabolic function less than 1.5 times upper limit of (institutional/central) normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "* Aspartate Transaminase (Aspartate aminotransferase measurement) or alanine amino transferase (Antibiotic Lock Therapy) less than three times the upper limit of (institutional/central) normal (Upper Limit of Normal) (if related to liver metastases less than five times Upper Limit of Normal).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "7. Recovering from from any previous therapy related toxicity to Grade 0 or 1 at study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "8. Able and willing to follow diarrhea management guidelines provided under this study and to complete rectal discharge diarrhea (physical finding) Management Worksheet as instructed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": ". Chemotherapy, biological therapy or investigational agents within four weeks prior to the start of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "2. Prior treatment with Soluble ErbB-1 directed small molecules or antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "3. Hormonal treatment within 2 weeks prior to start of study treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "4. major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "5. Known hypersensitivity to afatinib or the excipients of any of the trial drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "6. History or presence of clinically relevant cardiovascular abnormalities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "7. Any history of or concomitant condition that, in the opinion of the Research Personnel, would compromise the patient¿s ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "8. Previous or concomitant invasive malignancies at other sites.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "9. Known pre-existing interstitial lung disease (Lung Diseases, Interstitial).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "10. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "14. Active hepatitis B infection, active hepatitis C infection and/or known HIV carrier, who are determined by the investigator as not a suitable candidate to receive EGFR-TKI treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01814553",
    "statement": "15. Patients with meningeal carcinomatosis. 16. Patients with brain or subdural metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402051",
    "statement": "* Cytologically and/or histologically confirmed Non-Small Cell Lung Carcinoma Stage 3B or IV",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402051",
    "statement": "* No previous systemic chemotherapy for this cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402051",
    "statement": "* At least one uni-dimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors (Response Evaluation Criteria in Solid Tumors) criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402051",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) Performance Status of 0 or 1 and adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402051",
    "statement": "* Prior radiation therapy allowed but limited to \\<25% of the patient's bone marrow",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402051",
    "statement": "* Serious concomitant systemic disorder or active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402051",
    "statement": "* Mild to moderate renal insufficiency, but unable to interrupt salicylates or other nonsteroidal anti-inflammatory drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402051",
    "statement": "* Symptomatic central nervous system (Clinical Nurse Specialists) metastases requiring concurrent corticosteroid therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00402051",
    "statement": "* Presence of clinically significant third-space fluid collections",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Histologic or cytologically confirmed diagnosis of metastatic Non-Small Cell Lung Carcinoma according to the 7th edition of the AJCC Cancer Staging Manual. In addition, the Non-Small Cell Lung Carcinoma must harbor an ALK Gene Rearrangement, as assessed using the United States Food and Drug Administration approved Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.) test and scoring algorithm (including positivity criteria). If documentation of ALK Gene Rearrangement as described above was not locally available, a test to confirm ALK Gene Rearrangement was to be performed by a Novartis designated central laboratory. Patients had to wait for the central laboratory result of the ALK Gene Rearrangement status before initiating treatment with ceritinib",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* At least one extracranial measurable lesion as defined by RECIST 1.1. A previously irradiated site lesion could only be counted as a target lesion if there was clear sign of progression since the irradiation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patients could or could not have neurological symptoms but must have been able to swallow and retain oral medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patients had to be neurologically stable within at least 1 week prior to the first dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patients could have received prior chemotherapy, crizotinib (other ALK inhibitors were not allowed), biologic therapy or other investigational agents.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03). Patients with any grade of alopecia were allowed to enter the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patient had life expectancy ≥ 6 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patient had a WHO performance status 0-2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "Patients in Arm 1 to 4 had to also meet the following inclusion criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patients had to have active brain metastases from Non-Small Cell Lung Carcinoma, confirmed by Gadolinium-enhanced magnetic resonance imaging without concomitant leptomeningeal carcinomatosis. Dose of steroids had to be stable for 5 days before the baseline brain MRI.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "Patients in Arm 5 had to also meet the following inclusion criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patients must have been diagnosed with leptomeningeal carcinomatosis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patients who needed whole brain radiation to control the brain metastases. Patients were not eligible unless treated brain lesions were progressive or new brain lesions were observed since the post whole brain radiation therapy Magnetic Resonance Imaging.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Planning of any brain local treatment (including but not limited to surgery, stereotactic radiosurgery, whole brain radiation, intrathecal chemotherapy) following the administration of the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patient with a concurrent malignancy or history of a malignant disease other than Non-Small Cell Lung Carcinoma that had been diagnosed and/or required therapy within the past 3 years. Exceptions to this exclusion included the following: completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patient had impairment of GI function or GI disease that could significantly alter the absorption of ceritinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patient was receiving unstable or increasing doses of corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02336451",
    "statement": "* Patient had other severe, acute, or chronic medical conditions including uncontrolled diabetes mellitus or psychiatric conditions or laboratory abnormalities that in the opinion of the investigator could increase the risk associated with study participation, or that could interfere with the interpretation of study results.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01204697",
    "statement": "* male patients, \\>/=18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01204697",
    "statement": "* former smoker (smoked \\>/= 100 cigarettes in his lifetime and quit \\>12 months before enrollment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01204697",
    "statement": "* locally advanced (stage IIIb), metastatic (stage IV) or recurrent squamous non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01204697",
    "statement": "* prior platinum-based therapy for advanced NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01204697",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01204697",
    "statement": "* uncontrolled symptomatic central nervous system (Clinical Nurse Specialists) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01204697",
    "statement": "* prior therapy against epidermal growth factor receptor (Soluble ErbB-1)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01204697",
    "statement": "* \\>1 prior chemotherapy for advanced/metastatic Non-Small Cell Lung Carcinoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01204697",
    "statement": "* radiotherapy \\<28 days prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01204697",
    "statement": "* history of melanoma at any time, or another malignancy in the last 5 years except for carcinoma in situ of the cervix, basal or squamous cell carcinoma of the skin, or surgically cured malignant neoplasias with a disease-free interval of \\>5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01204697",
    "statement": "* not fully treated eye inflammation or infection, or predisposing conditions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": ". Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "2. Age 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "3. Body weight ≥ 35 kg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "4. Subjects must have histologically or cytologically documented Non-Small Cell Lung Carcinoma who present with locally advanced, unresectable, Stage III disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "5. Subjects must have completed, without progressing, definitive Concurrent Chemoradiotherapy within 42 days prior to being randomized into the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "6. Provision of tumor tissue sample, when available, from original diagnosis obtained before initiation of chemoradiotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "7. Life expectancy ≥ 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "8. Eastern Cooperative Oncology Group (Electrocorticogram) Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "9. Subjects must have at least one previously irradiated tumor lesion that can be measured by RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "Main",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": ". Mixed small cell and non-small cell lung cancer histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "3. Prior exposure to any anti-PD1, anti-PD-L1, or anti-CTLA4 antibody for treatment of Non-Small Cell Lung Carcinoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "4. Subjects with history of ≥ Grade 2 pneumonitis from prior chemoradiation therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "5. Subjects with a history of venous thrombosis within the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "6. Subjects with history of myocardial infarction, transient ischemic attack, or stroke in the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "7. Congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "8. Active or prior documented autoimmune or inflammatory disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "9. History of active primary immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "10. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "11. History of allogenic organ transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "12. QTcF interval ≥ 470 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "13. History of another primary malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "14. Concurrent enrollment in another clinical study \\[concurrent enrollment in an observational (non-interventional) clinical study or during the follow-up period of an interventional study is permitted\\]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03822351",
    "statement": "15. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Histologic or cytologically confirmed diagnosis of Stage level 4 (American Joint Committee on Cancer \\[American Joint Committee on Cancer (tumor staging)\\], version 8 or current version) nonsquamous Non-Small Cell Lung Carcinoma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Confirmation that Epidermal Growth Factor Receptor (Soluble ErbB-1), anaplastic lymphoma kinase gene (anaplastic lymphoma kinase), or ROS1 protein, human Receptor Tyrosine Kinase (ROS1 protein, human)-directed therapy is not indicated as primary treatment (documentation of absence of tumor-activating Soluble ErbB-1 mutations AND absence of anaplastic lymphoma kinase and ROS1 protein, human gene rearrangements OR presence of a Kirsten Rat Sarcoma (K-ras Oncogene) gene mutation).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Have measurable disease based on RECIST 1.1. Note: Lesion that appear measurable, but are situated in a previously irradiated area, can be considered measurable (eligible for selection as target lesions) if they have shown documented growth since the completion of radiation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Provided an evaluable archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion (that was not previously irradiated) for central CD274 wt Allele testing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Life expectancy of at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status of 0 or 1 within 7 days prior to the first dose of study intervention but before randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Male participants must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and/or lenvatinib/matching placebo and up to 180 days after the last dose of chemotherapeutic agents. A male participant must also agree to the following: 1) abstinence from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, OR 2) agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant, unless confirmed to be azoospermic (vasectomized or secondary to medical cause). Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: 1) not a WOCBP OR 2) a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days after the last dose of study intervention.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Adequately controlled blood pressure (bleomycin/cisplatin protocol) with or without antihypertensive medications, defined as bleomycin/cisplatin protocol ≤150/90 mm Hg and no change in antihypertensive medications within 1 week prior to randomization. Note: Participants must not have a history of uncontrolled or poorly-controlled hypertension, defined as \\>150/90 mm Hg for \\>4 weeks despite standard medical management.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Known untreated central nervous system (Clinical Nurse Specialists) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, clinically stable, and have not required steroids for at least 14 days prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Radiographic evidence of major blood vessel invasion/infiltration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy. Note: The time requirement also does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Hormone replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Diagnosis:Imp:Pt:^Patient:Nom of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Has had allogeneic tissue/solid organ transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Known history of human immunodeficiency virus (HIV) infection. HIV screen is not required unless mandated by the local health authority.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Known history of hepatitis B surface antigen vaccine or active hepatitis C virus. No testing for hepatitis B surface antigen vaccine or hepatitis C virus is required unless mandated by the local health authority.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* History of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral drug absorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Active hemoptysis (at least 0.5 teaspoon of bright red blood) within 2 weeks prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Significant cardiovascular impairment within 12 months prior to the first dose of study intervention, including history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction, cerebrovascular accident (CVA)/stroke, or cardiac arrhythmia associated with hemodynamic instability.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Known history of active tuberculosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Active infection requiring systemic therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Has not recovered adequately from any toxicity and/or complication from major surgery prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Previously had a severe hypersensitivity reaction to treatment with a monoclonal antibody or has a known sensitivity to any component of lenvatinib or pembrolizumab, or as applicable, carboplatin, cisplatin, or pemetrexed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Patient currently pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and/or lenvatinib/matching placebo and up to 180 days after last dose of chemotherapeutic agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic NSCLC.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Received prior treatment with pembrolizumab or any other anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent, with lenvatinib or any other receptor tyrosine kinase inhibitor (RTKi), or with an agent directed to another stimulatory or co-inhibitory T cell receptor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Received radiotherapy within 14 days prior to the first dose of study intervention or received lung radiation therapy of \\>30 Gy within 6 months prior to the first dose of study intervention. Note: Participants must have recovered from all radiation-related toxicities to Grade ≤1, not required corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Received systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Received a live vaccine within 30 days prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study intervention.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Has a prolongation of QTc interval (calculated using Fridericia's formula) of \\>480 msec",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Left ventricular ejection fraction (LVEF (procedure)) below the institutional (or local laboratory) normal range as determined by multigated acquisition scan (Multiple gated acquisition scanning) or echocardiogram (Extension for Community Healthcare Outcomes).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04716933",
    "statement": "* Has preexisting ≥grade 3 education level gastrointestinal or non-gastrointestinal fistula.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01360554",
    "statement": "* Evidence of pathologically confirmed, advanced NSCLC (with known histology).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01360554",
    "statement": "* Prior treatment with at least one and no more than two systemic therapy regimens (at least one must be standard chemotherapy for advanced NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01360554",
    "statement": "* Adequate tissue sample must be submitted prior to randomization for tumor biomarker analyses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01360554",
    "statement": "* Adequate renal, hematologic, liver function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01360554",
    "statement": "* ECOG performance status of 0-2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01360554",
    "statement": "* Radiologically measurable disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01360554",
    "statement": "* Small cell histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01360554",
    "statement": "* Symptomatic brain mets or known leptomeningeal mets.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01360554",
    "statement": "* Prior therapy with agent known or proposed to be active by action on Soluble ErbB-1 tyrosine kinase or other HER family proteins.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01360554",
    "statement": "* Uncontrolled medical disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": ". Signed written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "2. Female or male ≥18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "3. Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (American Joint Committee on Cancer (tumor staging)) Stage level 3 or IV Non-Small Cell Lung Carcinoma. Stage level 3 patient must have unresectable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "4. Body mass index \\< 20 kg/m2 with involuntary weight loss of \\>2% within 6 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "5. Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of ≤ 17 points on the 5-item Anorexia Symptom Scale and ≤ 37 points on the 12-item FAACT Questionnaire A/CS",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "6. Patient receiving or not receiving systemic anti-cancer treatment at the time of screening are eligible to participate. Systemic anti-cancer treatment includes first, second, third treatment line with chemotherapy/radiation therapy, immunotherapy or targeted therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   Patient not receiving systemic anti-cancer treatment is eligible if:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   1. Not planning to receive anti-cancer treatment and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   2. Planning to receive anti-cancer treatment within 14 days from randomization and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   3. Patient on palliative care treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "7. ECOG performance status 0,1 or 2 at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "8. Aspartate aminotransferase measurement (SGOT - Glutamate oxaloacetate transaminase) and Antibiotic Lock Therapy (Serum Alanine Transaminase Test) ≤ 3 x ULN or if hepatic metastases are present ≤ 5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "9. Adequate renal function, defined as creatinine ≤2 ULN, or calculated creatinine clearance \\>30 ml/minute",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "10. Woman patient shall be: a) of non-childbearing potential or b) of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within 24 hours prior to first dose of investigational product.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "    Notes:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "    1. Woman patient of non-childbearing potential are defined as being in post-menopausal state since at least 1 year; or having documented surgical sterilization or hysterectomy at least 3 months before study participation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "    2. Reliable contraceptive measures include implants, injectables, combined oral contraceptives, intrauterine devices, vasectomized partner or complete (long term) sexual abstinence.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "11. The patient must be willing and able to comply with the protocol tests and procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "All inclusion criteria were to be checked at screening visit (Visit 1). Inclusion criterion #10 was to be re-checked and verified at Day 1 (Visit 2).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": ". Patient with other forms of lung cancer (e.g., small cell, neuroendocrine tumors)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "2. Woman who is pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "3. Reversible causes of reduced food intake, as determined by the Investigator. These causes may include but are not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   1. NCI CTCAE grade 3 education level or 4 oral mucositis,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   2. NCI CTCAE grade 3 education level or 4 Gastrointestinal Diseases \\[nausea, vomiting, diarrhea, and constipation\\],",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   3. mechanical obstructions making patient unable to eat, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   4. Severe depression",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "4. Report source - Patient undergoing major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization. Report source - Patient must be well recovered from acute effects of surgery prior to screening. Report source - Patient should not have plans to undergo major surgical procedures during the treatment period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "5. Patient currently taking androgenic compounds including but not limited to testosterone, testosterone-like agents, oxandrolone; megestrol acetate; corticosteroids; olanzapine, mirtazapine (however, long-term use of mirtazapine for depression for at least four weeks prior to screening is allowed); dronabinol; marijuana (cannabis); or any other prescription medication or off-label products intended to increase appetite or treat unintentional weight loss",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "6. Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring drainage, edema or evidence of ascites",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "7. Patient with uncontrolled or significant cardiovascular disease, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   1. History of myocardial infarction within the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   2. Atrioventricular Block of second or third degree (may be eligible if currently have a pacemaker)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   3. Angina, Unstable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   4. Congestive heart failure within the past 3 months, if defined as NYHA class III-IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   5. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White Syndrome, or torsade de pointes)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   6. Uncontrolled hypertension (Blood Pressure \\>150 mm Hg systolic and \\>95 mm Hg diastolic)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "   7. Heart rate:NRat:Pt:XXX:Qn \\< 50 beats per minute on pre-entry electrocardiogram and patient is symptomatic",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "8. Patient on drugs that may prolong the PR or electrocardiogram: QRS interval durations, such as any of the antiarrhythmic medications Class 1 (Fast sodium (Na) channel blockers)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "9. Report source - Patient unable to readily swallow oral tablets",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "10. Patient with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "11. Patient with history of gastrectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "12. Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "13. Report source - Patient with cachexia caused by other reasons, as determined by the investigator such as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "    1. Severe COPD requiring use of home oxygen,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "    2. New York Heart Association (New York Heart Association Classification) class III-IV heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "    3. Acquired Immunodeficiency Syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "    4. Uncontrolled thyroid disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "14. Patient receiving strong Cytochrome P-450 CYP3A4 Inhibitors within 14 days of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "15. Patient currently receiving tube feedings or parenteral nutrition (either total or partial).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "16. Current excessive alcohol or illicit drug use",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "17. Any condition, including the presence of laboratory abnormalities, which in the Investigator's opinion, places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "18. Enrollment in a previous study with anamorelin HCl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "19. Report source - Patient actively receiving a concurrent investigational agent, or having received an investigational agent within 28 days of Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "All exclusion criteria were to be checked at screening visit (Visit 1). Exclusion Criteria #3, 5, 6, 7g, and 9 were to be re-checked and verified before study drug administration (Visit 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553254",
    "statement": "* Advanced NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553254",
    "statement": "* Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib or gefitinib",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553254",
    "statement": "* Prior treatment with no more than two chemotherapy regimens, including adjuvant treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553254",
    "statement": "* Measurable Disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553254",
    "statement": "* Chemotherapy, radiotherapy, biological or investigational agents within 4 weeks of baseline disease assessment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553254",
    "statement": "* Patients who lack of tolerance of erlotinib therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553254",
    "statement": "* Patients with known brain Metastatic malignant neoplasm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553254",
    "statement": "* Patients with demonstrated history of or presence of interstitial lung disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Signed informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Specimen Source Codes - tumor accessible to biopsy and willingness to undergo tumor biopsy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Age \\>= 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Recurrent, histologically documented Non-Small Cell Lung Carcinoma, i.e., squamous cell, adeno-, or large cell anaplastic carcinoma. A cytologic diagnosis is acceptable (i.e. fine-needle aspiration or pleural fluid cytology).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Measurable Disease with at least one lesion that can be accurately measured in at least one dimension (bilateral dimensions should be recorded). Each lesion must be \\>= 20 mm when measured by conventional techniques, including palpation, plain Roentgen Rays, X-Ray Computed Tomography, and Magnetic Resonance Imaging, or \\>= 10 mm when measured by spiral X-Ray Computed Tomography.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Progression of disease during, or after completion of, at least one prior chemotherapy regimen, which should have contained either a platinum, a taxane or a vinca alkaloid (e.g. vinorelbine). There is no upper limit on the number of prior chemotherapy regimens each subject may have received.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Recovery - healing process from reversible acute effects of prior chemotherapy regimens or radiotherapy to NCI-CTC Grade \\<= 1 (excluding alopecia)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* ECOG performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Use of an effective means of contraception for men, or for women of childbearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Absolute neutrophil count \\>= 1500/mL, platelet count of \\>= 75,000/mL and hemoglobin \\>= 9 g/dL (hemoglobin may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors; darbepoetin \\[Aranesp\\] is permitted)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Serum bilirubin measurement \\<= 1.5 x the upper limit of normal (ULN) and alkaline phosphatase, Aspartate aminotransferase measurement, and Antibiotic Lock Therapy \\<= 2.5 x ULN (Antibiotic Lock Therapy, Aspartate aminotransferase measurement, and alkaline phosphatase \\<= 5 x ULN for subjects with liver metastases)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Creatinine measurement, serum (procedure) \\<= 1.5 x Upper Limit of Normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Internalized normalized ratio (Integrated Neuromusculoskeletal Release) \\< 1.5 and activated partial thromboplastin time (Partial thromboplastin time, activated (procedure)) \\< 1.5 ULN (except for subjects receiving warfarin)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Prior treatment with any HER pathway inhibitors (e.g., Herceptin \\[trastuzumab\\], gefitinib \\[gefitinib\\], Tarceva \\[erlotinib hydrochloride\\], IMC C225, CI1033, TAK165",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* treatment - ActInformationManagementReason with other experimental anti-cancer agents within 4 weeks prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Histologic documented bronchioalveolar carcinoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* History or clinical or radiographic evidence of central nervous system or brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Ejection fraction, determined by Extension for Community Healthcare Outcomes, \\<50%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Uncontrolled hypercalcemia (\\> 11.5 mg/dL)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Prior exposure of \\> 360 mg/m2 doxorubicin or liposomal doxorubicin, \\> 120 mg/m2 mitoxantrone, or \\> 90 mg/m2 idarubicin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Ongoing corticosteroid treatment, except for subjects who are on stable doses of \\< 20 mg of prednisone daily (or equivalent), or for subjects who are taking corticosteroids for non-malignant conditions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* History of other malignancies within 5 years of Day 1 except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, or basal or squamous cell skin cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* History of serious systemic disease, uncontrolled hypertension (diastolic blood pressure \\> 100 mmHg on two consecutive occasions), unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation, paroxysmal supraventricular tachycardia, or controlled hypertension are eligible)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Ongoing liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Active infection requiring IV antibiotics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Known human immunodeficiency virus infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Pregnancy or lactation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* major surgery or significant traumatic injury within 3 weeks prior to Day 1, with the exception of tumor biopsy for the purposes of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Inability to comply with study and follow-up procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00063154",
    "statement": "* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02041533",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) Performance Status (phosphatidylserine) ≤ 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02041533",
    "statement": "* Histologically confirmed Stage level 4, or Recurrent Non-Small Cell Lung Carcinoma with no prior systemic anticancer therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02041533",
    "statement": "* Measurable disease by computed tomography (X-Ray Computed Tomography) or magnetic resonance imaging (Magnetic Resonance Imaging) per response evaluation criteria in solid tumors version (Response Evaluation Criteria in Solid Tumors) 1.1 criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02041533",
    "statement": "* CD274 wt Allele+ on immunohistochemistry testing performed by central lab",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02041533",
    "statement": "* Men and women, ages ≥ 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02041533",
    "statement": "* Known epidermal growth factor receptor (Soluble ErbB-1) mutations which are sensitive to available targeted inhibitor therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02041533",
    "statement": "* Known anaplastic lymphoma kinase (anaplastic lymphoma kinase) translocations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02041533",
    "statement": "* Untreated central nervous system (Clinical Nurse Specialists) metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02041533",
    "statement": "* Previous malignancies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02041533",
    "statement": "* Active, known or suspected autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00364351",
    "statement": "* Confirmed locally advanced or metastatic Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00364351",
    "statement": "* Failure of at least one but not more than two prior chemotherapy regimens",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00364351",
    "statement": "* Prior treatment with erlotinib (Tarceva), gefitinib (gefitinib), sunitinib (Sutent), sorafenib (Nexavar)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00364351",
    "statement": "* Chemotherapy or other type of anti cancer therapy within 4 weeks of study start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Histologic or cytologically confirmed Stage IIIB-IVB Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* For participants who have received prior neo-adjuvant/adjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease: a treatment-free interval of at least 6 months prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Participants with any programmed death-ligand 1 (CD274 wt Allele) test result by immunohistochemistry (Immunohistochemistry) are eligible for the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Participants without a CD274 wt Allele test result are eligible for the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Measurable Disease per RECIST v1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Adequate hematologic and end-organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods among women of childbearing potential",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Prior treatment with immunotherapy for any stage Non-Small Cell Lung Carcinoma, including early-stage (neoadjuvant or adjuvant) disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Participants with epidermal growth factor receptor (Soluble ErbB-1) sensitizing mutations and anaplastic lymphoma kinase (anaplastic lymphoma kinase) rearrangements",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Active central nervous system (Clinical Nurse Specialists) metastases requiring treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Compression of spinal cord not definitively treated or not clinically stable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Leptomeningeal Neoplasms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Uncontrolled tumor-related pain",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Uncontrolled pleural, pericardial effusions, or ascites requiring recurrent drainage procedures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Uncontrolled or symptomatic hypercalcemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Malignant Neoplasms other than Non-Small Cell Lung Carcinoma within 5 years prior to enrollment, except for those curatively treated with negligible risk of metastasis or death",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Patient currently pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* History of autoimmune disease, significant pulmonary disease, or significant cardiovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Positive human immunodeficiency virus (HIV) or hepatitis B or C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Active tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Severe infection or major surgery within 4 weeks, or oral or IV antibiotics treatment within 2 weeks prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Prior treatment with or hypersensitivity to study drug or related compounds",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Prior allogeneic bone marrow or solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Administration occupational activities of a live, attenuated vaccine within 4 weeks prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* treatment - ActInformationManagementReason with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02848651",
    "statement": "* Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": ". Evidence of histologically or cytologically confirmed diagnosis of metastatic Non-Small Cell Lung Carcinoma with Soluble ErbB-1 activating mutations as detected by an appropriate test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "2. No prior treatment with systemic therapy and Soluble ErbB-1/Other Protein-tyrosine kinase inhibitor (disposition) (Protein-tyrosine kinase inhibitor (disposition)) for metastatic NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "3. Participants with asymptomatic Central Nervous System (Clinical Nurse Specialists) metastases (including participants controlled with stable or decreasing steroid use within the last 2 weeks prior to study entry) will be eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "4. Age \\>=18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "5. ECOG performance status of 0-2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "6. Adequate . hematologic, renal, liver function: Absolute neutrophil count \\>= 1000/mm3; Blood Platelets\\>=50000/mm3; Hemoglobin \\>=8 g/dL; est. Creatinine clearance \\>=30 mL/min; Serum total bilirubin measurement \\<1.5 × ULN; Aspartate aminotransferase measurement,Antibiotic Lock Therapy \\<=2.5 × ULN; (\\<=5.0 × ULN, if liver metastases).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "7. acute effects of any prior therapy resolved to baseline severity or to National Cancer Institute common terminology criteria for adverse events (National Cancer Institute common terminology criteria for adverse events) Grade \\<1 except for TLE5 gene that in the investigator's judgment do not constitute a safety risk for the participant.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "8. Cell Culture Serum or urine pregnancy test (for females of childbearing potential) negative at Special screening finding.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": ". Any evidence of mixed histology that includes elements of small cell or carcinoid lung cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "2. Any other mutation other than exon 19 deletion or L858R in exon 21, with or without the presence of the exon 20 T790M mutation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "3. Radiation therapy (procedure) (except palliative to relieve bone pain) within 2 weeks of study entry. Prior irradiation to \\>25% of the bone marrow.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "4. major surgery within 4 weeks prior to first dose of dacomitinib. Minor Surgical Procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "5. Known prior or suspected severe hypersensitivity to dacomitinib or any component of its formulation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "6. History or known presence of interstitial fibrosis, interstitial lung disease, pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and pulmonary fibrosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "7. Other severe acute or chronic medical or psychiatric condition, that may interfere with the interpretation of study results and, would make the participant inappropriate for entry into this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "8. Evidence of active malignancy (other than current Non-Small Cell Lung Carcinoma) within the last 3 years prior to first dose of dacomitinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "9. Breastfeeding female participants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04511533",
    "statement": "10. Patient currently pregnant female participants; male participants able to father children and female participants of childbearing potential who are unwilling or unable to use contraception method per protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932451",
    "statement": "* histologically or cytologically proven diagnosis of non-small cell lung cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932451",
    "statement": "* positive for the ALK fusion gene (test provided by either a central laboratory. Local laboratory may be used for certain cases)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932451",
    "statement": "* may have received pemetrexed or docetaxel from previous Phase 3 trial (A8081007) and discontinued treatment due to Response Evaluation Criterion in Solid Tumors (Response Evaluation Criteria in Solid Tumors)-defined progression. or, once the primary endpoint of Study A8081007 has been analyzed and the results made available, at any time without Response Evaluation Criteria in Solid Tumors-defined progression.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932451",
    "statement": "* Neoplasms can be measurable or non measurable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932451",
    "statement": "* prior treatment with PF-02341066",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932451",
    "statement": "* received no prior systemic treatment, chemotherapy or Epidermal growth factor receptor inhibitor, for advanced non-small cell lung cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00932451",
    "statement": "* current enrollment in another therapeutic clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Adults greater than or equal to (≥) 18 years of age, or legal age of consent if greater than 18",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Advanced phase or recurrent (Stage 3B) or metastatic (Stage level 4) Non-Small Cell Lung Carcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Completion of 4 cycles of platinum-based chemotherapy without progression (end of last chemotherapy cycle less than or equal to \\[≤\\] 28 days prior to randomization)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Eastern Cooperative Oncology Group (Electrocorticogram) performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Prior exposure to agents directed at human epidermal growth factor receptor (Herero language) axis (e.g. erlotinib, gefitinib, cetuximab)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Participants whose tumors harbor an EGFR-activating mutation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Prior chemotherapy or therapy with systemic anti-neoplastic therapy for advanced disease before Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Use of pemetrexed in maintenance setting (pemetrexed allowed during the chemotherapy run-in)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Participants who have undergone complete tumor resection after responding to the platinum-based chemotherapy during the Screening phase",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Any other malignancies within 5 years, except for curatively resected carcinoma in situ of the cervix, basal or squamous cell skin cancer, ductal carcinoma in situ, or organ-confined prostate cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Central Nervous System (Clinical Nurse Specialists) metastases or spinal cord compression that has not been definitely treated with surgery and/or radiation, or treated Clinical Nurse Specialists metastases or spinal cord compression without stable disease for ≥2 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* HIV (HIV), hepatitis B, or hepatitis C infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01328951",
    "statement": "* Any inflammatory changes of the surface of the eye",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03853551",
    "statement": ". Patient of either gender and ≥18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03853551",
    "statement": "2. Patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an appropriate test, who have progressed on or after EGFR TKI therapy by an independent clinical judgment of treating physician based on locally approved prescribing information",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03853551",
    "statement": "3. Each patient must sign an informed consent form (International Classification of Functioning, Disability and Health)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03853551",
    "statement": ". Patient with either the history of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03853551",
    "statement": "2. Pregnant and/or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03853551",
    "statement": "3. Patients participating in any current or future interventional trial will not be enrolled in the current study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* Confirmed stage IV or recurrent EGFR mutated NSCLC with disease progression on one or two prior lines of treatment with EGFR TKIs (allowed TKIs must be approved by the local health authority, including but not limited to erlotinib, gefitinib, afatinib, dacomitinib and osimertinib). In osimertinib treated subjects, T790 testing is not required.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* No evidence of exon 20 EGFR NP_005219.2:p.T790M mutation obtained at progression on prior first- or second-generation EGFR TKI therapy. For participants who were treated with osimertinib, EGFR NP_005219.2:p.T790M testing is not required.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* Measurable Disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (Response Evaluation Criteria in Solid Tumors Version 1.1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* Available tumor sample for Programmed death-ligand 1 (CD274 wt Allele) immunohistochemical (IHC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* Participants are eligible if central nervous system (Clinical Nurse Specialists) metastases are considered to be adequately controlled/treated before or during the screening period and participants are neurologically returned to baseline (except for residual signs or symptoms related to the Clinical Nurse Specialists treatment) for at least 2 weeks prior to randomization. In addition, participants must be either off corticosteroids, or on a stable or decreasing dose of ≤10 mg daily prednisone (or equivalent) for at least 2 weeks prior to randomization). Participants with asymptomatic Clinical Nurse Specialists metastasis are eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* Eastern Cooperative Group (Electrocorticogram) Performance Status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* Life expectancy is at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* Known EGFR mutation, EGFR NP_005219.2:p.T790M positive who failed 1L first- or second-generation TKI should receive osimertinib first as the Standard of Care (Sense of Coherence). These participants are only eligible if they fail osimertinib as 2L.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* who have progressed within 3 months of the first dose of 1L or 2L Epidermal growth factor receptor inhibitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* Meningeal Carcinomatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* Active, known or suspected autoimmune disease are excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* ALK Gene Translocation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* Known Small cell carcinoma of lung transformation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-Lymphocyte co-stimulation or checkpoint pathways",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02864251",
    "statement": "Other protocol defined inclusion/exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01287754",
    "statement": "* Adult patients, \\>/=18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01287754",
    "statement": "* Locally advanced or metastatic (stage III/IV) non-small cell lung cancer with EGFR mutations",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01287754",
    "statement": "* Measurable Disease according to RECIST criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01287754",
    "statement": "* ECOG performance status 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01287754",
    "statement": "* Adequate haematological, renal and liver function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01287754",
    "statement": "* Previous chemotherapy or therapy against Soluble ErbB-1 for metastatic disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01287754",
    "statement": "* History of another malignancy, except for in situ carcinoma of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01287754",
    "statement": "* Symptomatic cerebral metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01287754",
    "statement": "* Pre-existing parenchymal lung disease such as pulmonary fibrosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01287754",
    "statement": "* Simultaneous use of coumarins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Humoral hypercalcemia of malignancy (disorder) (Health maintenance) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (Corrected serum calcium measurement) \\> 12.5 mg/dL (3.1 millimoles /L) at screening by local laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Last Intravenous bisphosphonate treatment must be \\>/= to 7 days and \\",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "/=18 years)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Adequate organ function as defined by the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* serum aspartate aminotransferase (Aspartate aminotransferase measurement) \\</= 5 x upper limit of normal (Upper Limit of Normal)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* serum alanine aminotransferase (Antibiotic Lock Therapy) \\</= 5 x upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* serum total bilirubin \\</= 2 x upper limit of normal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Evidence of benign hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, milk alkali syndrome, sarcoidosis, or other granulomatous disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Receiving dialysis for renal failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of the screening CSC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* treatment - ActInformationManagementReason with cinacalcet within 4 weeks prior to the date of the screening CSC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Thirty days or less since receiving an investigational product (other than denosumab) or device (ie, does not have marketing authorization; thalidomide use is allowed) in another clinical study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Female subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Woman subject of childbearing potential is not willing to use 2 highly effective methods of contraception during treatment and for 7 months after the end of treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Subject will not be available for follow-up assessment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00896454",
    "statement": "* Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04816214",
    "statement": "Hemoglobin (Hgb) > 9 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04248829",
    "statement": "Hemoglobin (Hgb) > 9 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03037385",
    "statement": "Patient requires treatment with a prohibited medication or herbal remedy (as specified in Appendix 2) that cannot be discontinued at least 2 weeks before the start of study drug administration.",
    "type": "Exclusion",
    "tags": {}
  }
]